Orthogonal Protein Heterodimers

Abstract

Disclosed herein are designed heterodimer proteins, monomeric polypeptides capable of forming heterodimer proteins, protein scaffolds including such polypeptides, and methods for using the heterodimer proteins and subunit polypeptides for designing logic gates.

Description

CROSS REFERENCE

[0001] This application claims priority to U.S. Provisional Patent Application Serial Nos. 62/755,264 filed Nov. 2, 2018 and 62/904,800 filed Sep. 24, 2019, each incorporated by reference herein in their entirety.

BACKGROUND

[0003] Heterodimeric interaction specificity between two DNA strands, and between protein and DNA, is often achieved by varying side chains or bases coming off the protein or DNA backbone--for example, the bases participating in Watson-Crick base pairing in the double helix, or the side chains of protein contacting DNA in TALEN-DNA complexes. This modularity enables the generation of an essentially unlimited number of orthogonal DNA-DNA and protein-DNA heterodimers. In contrast, protein-protein interaction specificity is often achieved through backbone shape complementarity, which is less modular and hence harder to generalize.

SUMMARY

[0004] In one aspect, the disclosure provides designed heterodimer proteins, comprising:

[0005] (a) a monomer A polypeptide, wherein the monomer A polypeptide is a non-naturally occurring polypeptide comprising 1-5 alpha helices connected by amino acid linkers; and

[0006] (b) a monomer B polypeptide, wherein the monomer B polypeptide is a non-naturally occurring polypeptide comprising 1-5 alpha helices connected by amino acid linkers,

[0007] wherein monomer A and monomer B non-covalently interact to form the designed heterodimer protein. In one embodiment,

[0008] (i) monomer A comprises a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of an odd-numbered SEQ ID NO selected from the group consisting of selected from the group SEQ ID NOS: 1-290; and

[0009] (ii) monomer B comprises a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of an even-numbered SEQ ID NO selected from the group consisting of selected from the group SEQ ID NOS: 1-290, wherein the even-numbered SEQ ID NO is the binding partner of the odd-numbered SEQ ID NO. in step (i).

[0010] In another aspect, the disclosure provides non-naturally occurring polypeptide comprising a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-290.

[0011] In another aspect, the disclosure provides non-naturally occurring polypeptide comprising a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-290, 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494.

[0012] In another aspect, the disclosure provides proteins comprising 2, 3, 4, or more non-naturally occurring polypeptides having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-290, wherein the 2, 3, 4, or more naturally occurring polypeptides are covalently linked. In one embodiment, each of the 2, 3, 4, or more non-naturally occurring polypeptides are different. In another embodiment, each of the 2, 3, 4, or more non-naturally occurring polypeptides are present in a fusion protein.

[0013] In another aspect, the disclosure provides proteins comprising 2, 3, 4, or more non-naturally occurring polypeptides having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-290, 1-290, 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494 wherein the 2, 3, 4, or more naturally occurring polypeptides are covalently linked. In one embodiment, each of the 2, 3, 4, or more non-naturally occurring polypeptides are different. In another embodiment, each of the 2, 3, 4, or more non-naturally occurring polypeptides are present in a fusion protein. In each of these aspects, amino acid changes from the reference amino acid sequence may be conservative amino acid substitutions. In another embodiment, at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of amino acid residues at defined interface positions are invariant compared to the reference amino acid sequence.

[0014] In another aspect, the disclosure provides protein scaffolds, comprising

[0015] a) a first designed component comprised of any number of monomer A polypeptides and/or monomer B polypeptides, each from different heterodimers, connected into a single component by amino acid linkers.

[0016] b) a second designed component, comprising corresponding monomers for each monomer A and/or monomer B in the first designed component one;

[0017] wherein the first and second designed components interact to form the protein scaffold, and wherein each monomer A only interacts in the scaffold with its monomer B mate.

[0018] In another aspect, the disclosure provides methods of forming the designed heterodimer protein of any embodiment of the disclosure, comprising:

[0019] a) providing two of the monomers as unlinked monomers;

[0020] b) providing the other two monomers as linked monomers;

[0021] whereby the unlinked monomers associate with their respective monomer of the same heterodimer, and not with any of the other monomers.

[0022] In another aspect, the disclosure provides designed heterodimer proteins, comprising:

[0023] a) asymmetric buried hydrogen bond networks incorporated into regularly repeating backbone structures; and

[0024] b) helix hairpin helix monomers wherein the supercoil phases of the helices are fixed at 0, 90, 180, or 270 degrees and the supercoil twist (.omega.0) and helical twist (.omega.1) are held constant for either a two layer left handed super coil (.omega.0=-2.85 and .omega.1=102.85), or a 5 layer untwisted bundle (.omega.0=0 and .omega.1=100)

[0025] In another aspect, the disclosure provides fusion proteins comprising a polypeptide of the formula X-B-Z, wherein:

[0026] (a) the X domain is a non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices, wherein the X domain is capable of non-covalently binding to a first target;

[0027] (b) the Z domain is a non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices, wherein the Z domain is capable of non-covalently binding to either (i) a second target that differs from the first target, or (ii) a different non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices; and

[0028] (c) the B domain is an amino acid linker;

[0029] wherein a combined number of alpha helices from the X domain and the Z domain is 4, 5, or 6; and wherein the X domain and the Z domain interact at a binding interface, wherein the binding interface comprises a hydrogen bond network in which at least one side chain in each alpha helix hydrogen of the X domain bonds with a side chain in an alpha helix in the Z domain, and wherein the binding interface comprises a plurality of hydrophobic residues.

[0030] In another aspect, the disclosure provides kits or compositions, comprising at least two fusion proteins comprising the formula X-B-Z, wherein

[0031] the B domain in each fusion protein is independently a polypeptide linker;

[0032] the X domain in each fusion protein comprises a first non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices;

[0033] the Z domain in each fusion protein comprises a second non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices, wherein a combined number of alpha helices from the X domain and the Z domain in each individual fusion protein is 4, 5, or 6; wherein the X domain and the Z domain interact at a binding interface, wherein the binding interface comprises a hydrogen bond network in which at least one side chain in each X domain alpha helix bonds with a side chain in an alpha helix in the Z domain; wherein

[0034] the X domain in a first fusion protein is capable of non-covalently binding to a first target;

[0035] the Z domain in a second fusion protein is capable of non-covalently binding to a second target; and

[0036] the X domains and Z domains in each individual fusion protein that are not capable of non-covalently binding to the first target or the second target are capable of non-covalently binding to an X or a Z domain of a different fusion protein in the plurality of fusion proteins.

[0037] In one embodiment of the fusion proteins, kits, or compositions, each X domain and each Z domain comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to a polypeptide comprising the amino acid sequence selected from SEQ ID NO:1-290, with the proviso that the X domain and the Z domain do not do not form a heterodimer (a-b) pair. In another embodiment at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of amino acid residues at defined interface positions of each X domain and each Z domain are invariant compared to the reference amino acid sequence.

[0038] In one aspect, the disclosure provides methods, comprising:

[0039] (i) contacting a fusion protein according to any embodiment of the disclosure with a biological sample under conditions to promote non-covalent binding of the fusion protein with first target and second target present in the sample, and

[0040] (ii) detecting non-covalent binding of the one or more fusion proteins to the first target and/or the second target in the biological sample.

[0041] In one embodiment, the method comprises detecting cooperative non-covalently binding of the one or more fusion proteins to the first target and the second target in the biological sample. In another embodiment, the method comprises detecting non-covalent binding of the one or more fusion proteins to the first target or the second target in the biological sample.

[0042] In another aspect, the disclosure provides methods for target detection, comprising

[0043] (a) contacting a biological sample with at least two fusion proteins, wherein each of the at least two fusion proteins comprises the formula X-B-Z, wherein

[0044] each B is independently a polypeptide linker;

[0045] each X domain comprises a first non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices;

[0046] each Z domain comprises a second non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices, wherein a combined number of alpha helices from the X domain and the Z domain in each individual fusion protein is 4, 5, or 6; wherein the X domain and the Z domain interact at a binding interface, wherein the binding interface comprises a hydrogen bond network in which at least one side chain in each X domain alpha helix bonds with a side chain in an alpha helix in the Z domain; wherein

[0047] the X domain in a first fusion protein is capable of non-covalently binding to a first target;

[0048] the Z domain in a second fusion protein is capable of non-covalently binding to a second target; and

[0049] the X domains and Z domains in each individual fusion protein that are not capable of non-covalently binding to the first target or the second target are capable of non-covalently binding to an X or a Z domain of a different fusion protein in the plurality of fusion proteins;

[0050] (b) detecting non-covalent binding of the two or more fusion proteins to the first target and/or the second target in the biological sample.

[0051] In one aspect, the disclosure provides compositions comprising

[0052] (a) a first polypeptide comprising 2 alpha helices, wherein the first polypeptide is capable of non-covalently binding a first target; and

[0053] (b) a second polypeptide comprising 2 alpha helices, wherein the first polypeptide is capable of non-covalently binding to the second polypeptide, and wherein the second polypeptide is capable of non-covalently binding a second target that differs from the first target; wherein: [0054] (i) a binding affinity of the first polypeptide for the first target is approximately equal to a binding affinity of the second polypeptide for the second target; and [0055] (ii) the binding affinity of the first polypeptide for the first target and the binding affinity of the second polypeptide for the second target are greater than the binding affinity of the first target and the second target for each other.

[0056] In one aspect, the disclosure provides compositions comprising

[0057] (a) a first polypeptide comprising 2 alpha helices, wherein the first polypeptide is capable of non-covalently binding a first target; and

[0058] (b) a second polypeptide comprising 2 alpha helices, wherein the first polypeptide is capable of non-covalently binding to the second polypeptide, and wherein the second polypeptide is capable of non-covalently binding a second target that differs from the first target; wherein: [0059] (i) a binding affinity of the first polypeptide for the second polypeptide is greater than a binding affinity of the second polypeptide for the second target; [0060] (ii) a binding affinity of the first polypeptide for the first target is approximately equal to a binding affinity of the second polypeptide for the second target; and [0061] (iii) the binding affinity of the first polypeptide for the first target and the binding affinity of the second polypeptide for the second target are greater than the binding affinity of the first target and the second target for each other.

[0062] In another aspect, the disclosure provides compositions comprising

[0063] (a) a first polypeptide comprising 4 alpha helices, wherein the first polypeptide is capable of non-covalently binding a first target; and

[0064] (b) a second polypeptide comprising 4 alpha helices, wherein the second polypeptide is capable of non-covalently binding a second target that differs from the first target; wherein: [0065] (i) a binding affinity of the first target for the second target is greater than a binding affinity of the first polypeptide for the first target; [0066] (ii) a binding affinity of the first polypeptide for the first target is approximately equal to a binding affinity of the second polypeptide for the second target; and [0067] (iii) the sum of the binding affinity of (A) the first polypeptide for the first target and (B) the binding affinity of the second polypeptide for the second target, is greater than the binding affinity of the first target and the second target.

[0068] In various embodiments for each composition of the disclosure, the composition may further comprise the first target and the second target, and the first target and/or the second target further may comprise one or more effector polypeptide domains. In one embodiment, the first polypeptide and/or the second polypeptide comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 1-290, or the group consisting of SEQ ID NOS:1-290, 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494. In another embodiment, the first target and/or the second target each comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 1-290, or the group consisting of SEQ ID NOS:1-290, 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494, with the proviso that the first target forms a heterodimer (a-b) pair with the first polypeptide, and the second target forms a heterodimer (a-b) pair with the second polypeptide. In another embodiment, the compositions are contacted with a biological sample and binding is detected, such as detecting an output signal caused by actions of effector polypeptides upon binding.

[0069] The disclosure also provides nucleic acids encoding the polypeptides, proteins, and fusion proteins of the disclosure; expression vectors comprising the nucleic acids operatively linked to a promoter; and host cells comprising the nucleic acids, expression vectors, and/or polypeptides, proteins, fusion proteins, scaffolds, and designed heterodimer pairs of the disclosure.

DESCRIPTION OF THE FIGURES

[0070] FIGS. 1A to 1H shows modular heterodimer design. FIG. 1A shows individual helix generation: the helical phase (.DELTA..PHI..sub.1), supercoil radius (R) and offset along the Z-axis (Z offset) were exhaustively sampled; a total of 11 free parameters since there is no z offset for the first helix. FIG. 1B shows top-down view of the parallel twisted backbone. FIG. 1C shows representative hydrogen bond networks identified using HBNET.TM.. FIG. 1D shows matches of multiple HBNET.TM. containing heptads to a single full length backbone. FIG. 1E shows addition of loops to connect the 4 helices into two helix hairpins. FIGS. 1F, 1G, and 1H show SEC trace, CD spectra and (inset) temperature melt, and SAXS (black, experimental SAXS data; red, spectra computed from the designed backbones) profile of the design DHD37_ABXB. Experiments were performed once.

[0071] FIGS. 2A to 2F show structural characterization of designed heterodimers. FIGS. 2A-2D show crystal structures superimposed on design models with monomers; cross-sections on backbones (left) indicate locations of designed hydrogen-bond networks (middle panels). Solid and dashed boxes compare networks in design model and crystal structure. Black boxes compare overall hydrophobic packing. FIG. 2A shows DHD_131, 2.4 .ANG. resolution with 1.0 .ANG. C.alpha. RMSD. FIG. 2B shows DHD37_1:234, 3.3 .ANG. resolution with 1.4 .ANG. RMSD. FIG. 2C shows DHD_127, 1.8 .ANG. resolution with 1.7 .ANG. RMSD. FIG. 2D shows DHD_15, 3.4 .ANG. resolution with 0.9 .ANG. RMSD; hydrogen bond networks were not well resolved. FIGS. 2E-2F show DHD_39 and DHD_120 backbones and designed hydrogen bond networks. Experimental SAXS data (black) are similar to spectra computed from the designed backbones.

[0072] FIGS. 3A to 3C shows new functionality from DHD combinations. FIG. 3A shows induced dimerizer formed from "b" component of DHD13_XAAA fused to "b" component of DHD37_ABXB with an intervening flexible linker. The "a" components of the two heterodimers are brought into close proximity by the heterodimerizer. FIG. 3B shows Y2H data on 4 induced dimerization systems. For each pair of bars: left, without heterodimerizer fusion; right, with heterodimerizer fusion. Dashed line indicates background growth with unfused AD and DBD. Data are mean.+-.s.d. from 3 biological repeats. FIG. 3C shows 9_a, 13_XAAA_a and 37_ABXB_a were covalently linked to form a scaffold, recruiting 9_b (hexahistidine tagged), 13_XAAA_b and 37_ABXB_b.

[0073] FIGS. 4A to 4C show all-against-all orthogonality assessment. FIG. 4A shows Y2H for 21 heterodimers show heterodimer formation with little homodimer formation. First letter at bottom indicates monomer fused to AD, second letter, to DBD. FIG. 4B shows Y2H all by all testing of 9 pairs of heterodimers, colors indicate growth. Boxes indicate designed cognate heterodimer pairs, dashed black box indicates a set of 6 orthogonal heterodimers. FIG. 4C shows Off-target binding of DHD15_a and DHD13_XAAA_b, in the absence (left) or presence (right) of DHD15_b and DHD13_XAAA_a. Data are mean.+-.s.d. Red dashed line indicates background growth with unfused AD and DBD.

[0074] FIGS. 5A to 5B show example HBNets resulting from the systematic search. FIG. 5A shows overlay of 50 backbones with different Crick parameters for each helix. FIG. 5B shows example hydrogen bond networks from the systematic search, each involving at least 4 residues and contacting all 4 helices.

[0075] FIGS. 6A to 6C show thermal and chemical denaturation of DHDs. FIGS. 6A and 6B show CD spectra for thermal denaturation of DHD_15 and DHD_20, respectively. Top, wavelength scan at 25.degree. C., 75.degree. C., 95.degree. C., and final 25.degree. C. Designs were alpha helical and stable up to 95.degree. C. Bottom, CD temperature melts, monitoring absorption at 222 nm as temperature was increased from 25.degree. C. to 95.degree. C. FIG. 6C shows GdnHCl denaturation of DHD_127 by CD monitoring absorption at 222 nm. All CD experiments were performed once.

[0076] FIG. 7A to 7B show backbone and hydrogen bond network permutations. FIG. 7A shows on a 2+2 backbone (left), two loops were designed to connect the 4 helices into a single monomer in 2 different ways (middle), after which 4 different cut points were introduced to generate 4 possible backbone permuted heterodimers of a single helix and a three helix bundle (3+1 heterodimers, right). For example, 2:134 refers to a heterodimer where the original helix 2 is a single helix, and helices 1, 3, and 4 were connected into a 3 helix bundle. FIG. 7B shows hydrogen bond network permutation. Each unique network was assigned a letter (Networks "A" and "B" in this case), and with the hydrophobic packing assigned X. The backbone on the left reads "ABXB", with its first heptad accommodates network "A", its second and fourth heptad accommodate network "B", and its third heptad accommodates hydrophobic packing only.

[0077] FIGS. 8A to 8H show crystal structure of the domain swapped DHD_15 and biophysical characterization of higher order oligomers. FIG. 8A shows crystal structure of DHD_15 at pH 6.5, with 2.25 .ANG. resolution. FIG. 8B shows superposition of design models in color onto both halves of the crystal structure in white, with backbone RMSD of 1.83 .ANG.. FIGS. 8C to 8F show SEC traces of the induced dimerization DHD_9-13 fusion, DHD_15-37 fusion, DHD_13-37 fusion, and the scaffolding complex in FIG. 3C (the peak at around 15 mL corresponds to the fully assembled complex, followed by a peak representing excess of individual components). FIG. 8G shows CD thermal melt curves for the scaffolding complex in FIG. 3C. Wavelength scan was performed at 25.degree. C., 75.degree. C., 95.degree. C., and final 25.degree. C. Design was alpha helical and stable up to 95.degree. C. FIG. 8H, CD chemical denaturation profile of the scaffolding complex in FIG. 3C. 2 (FIG. 8C to 8F) or 1 (FIG. 8G to 8H) biologically independent repeats were performed.

[0078] FIGS. 9A to 9G show Y2H all-against-all assay of 16 DHDs. FIG. 9A shows Y2H assay with cell growth on agar plates containing 100 mM 3-AT, lacking tryptophan, leucine and histidine. Plates were imaged at Day 5. White, no growth on agar plates; grey, weak growth forming non-circular colonies; black, strong growth. FIG. 9B shows Y2H result by growing yeast culture in liquid media containing 100 mM 3-AT, lacking tryptophan, leucine and histidine. OD 600 values were measured at Day 2 to evaluate cell growth. FIG. 9C shows an additional set of DHDs tested by Y2H showing improved orthogonality. FIG. 9D shows distribution of OD 600 values for non-cognate interactions in FIG. 9B, the majority of cells grew to OD 600 values less than 0.4, indicating weak interactions for non-cognate binding. FIG. 9E shows more buried bulky polar residues strongly correlates with design success. f, Successful designs tend to have bigger polar interface surface area. FIG. 9G shows designs with better hydrophobic packing (as reported by the ROSETTA.TM. filter value Average Degree on Ile, Leu and Val residues) tend to have a higher chance of being constitutive heterodimers. Two (FIGS. 9A to 9C) independent experiments were performed.

[0079] FIG. 10 shows hydrogen bond network sequence motifs of the set of 6 orthogonal pairs in Y2H experiments. Letters patches mark the location of hydrogen bond network forming residues on the backbones, and indicate residue identities.

[0080] FIGS. 11A to 11H show cooperativity of CIPHR logic gates. FIG. 11A shows backbone structure of A:A' heterodimer building block, with hydrogen bond network detail in inset. Bottom right, condensed representation used throughout figures. FIG. 11B shows thermodynamic cycle describing the induced dimerization system. FIG. 11C shows simulation of the induced dimerization system under thermodynamic equilibrium. A and B' monomers were held constant while titrating in various initial amounts of the A'-B dimerizer proteins. If binding is not cooperative (small c), the final amount of trimeric complexes decreases when the dimerizer protein is in excess. FIG. 11D shows equilibrium denaturation experiments monitored by CD for designs with 6- and 12-amino acid (AA) linkers. Circles represent experimental data, and lines are fits to the 3-state unimolecular unfolding model. Design models are shown on the side. FIG. 11E shows experimental SAXS profile of 1'-2' with a 6-residue linker (in black), fitted to the calculated profile of 1:1' heterodimer. FIG. 11F shows an induced dimerization system using a 6-residue linker. FIG. 11G shows a two-input AND gate schematic. FIG. 11H shows a three-input AND gate.

[0081] FIGS. 12A to 12G show CIPHR two input logic gates. FIG. 12A shows CIPHR gates are built from DHDs (top) with monomers or covalently connected monomers as inputs (left); some gates utilize only the designed cognate interactions (left side of middle panel), while others take advantage of observed inter and intramolecular binding affinity hierarchies (right side of middle panel). FIGS. 12B and 12C show two-input AND (12B) and OR (12C) CIPHR logic gates based on orthogonal DHD interactions. FIGS. 12D to 12G show NOT (12D), NOR (12E), XNOR (12F), and NAND (12G) CIPHR logic gates made from multispecific and competitive protein binding. For each gate, black dots represent individual Y2H growth measurement corrected over background growth, with their average values shown in bars. * indicates no yeast growth over background. 0s and 1s in the middle and right blocks represent different input states and expected outputs, respectively.

[0082] FIGS. 13A to 13E show three-input CIPHR logic gates. FIG. 13A shows schematic of a three-input AND gate. FIG. 13B shows schematic of a three-input OR gate. FIG. 13C shows Y2H results confirmed activation of the 3-input OR gate with either of the inputs. FIG. 13D shows schematic of a DNF gate. FIG. 13E shows Y2H results confirmed proper activation of the gate. For each gate, black dots represent individual measurements corrected over background growth, with their average values shown in bars.

[0083] FIG. 14A shows molecular implementation of the cooperative induced dimerization system, binding only occurs when all three components are present. FIG. 14B shows size exclusion chromatography profiles of 1'-2' variants with 0, 2, 6, 12, and 24 amino acids in the flexible linker connecting 1' and 2.

[0084] FIGS. 15A and 15B show binding affinity gradient from individual Y2H experiments. FIG. 15A shows the 8:8' heterodimer binds more tightly than the homodimers of its monomers. FIG. 15B shows binding affinity gradient among the monomers of 1:1', 9:9', and 10:10' pairs.

[0085] FIG. 16 shows exemplary heterodimer proteins comprising combinations of monomer A and monomer B.

DETAILED DESCRIPTION

[0086] All references cited are herein incorporated by reference in their entirety. Within this application, unless otherwise stated, the techniques utilized may be found in any of several well-known references such as: Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), Gene Expression Technology (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press, San Diego, Calif.), "Guide to Protein Purification" in Methods in Enzymology (M. P. Deutshcer, ed., (1990) Academic Press, Inc.); PCR Protocols: A Guide to Methods and Applications (Innis, et al. 1990. Academic Press, San Diego, Calif.), Culture of Animal Cells: A Manual of Basic Technique, 2.sup.nd Ed. (R. I. Freshney. 1987. Liss, Inc. New York, N.Y.), Gene Transfer and Expression Protocols, pp. 109-128, ed. E. J. Murray, The Humana Press Inc., Clifton, N.J.), and the Ambion 1998 Catalog (Ambion, Austin, Tex.).

[0087] As used herein, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise.

[0088] As used herein, the amino acid residues are abbreviated as follows: alanine (Ala; A), asparagine (Asn; N), aspartic acid (Asp; D), arginine (Arg; R), cysteine (Cys; C), glutamic acid (Glu; E), glutamine (Gln; Q), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V).

[0089] All embodiments of any aspect of the disclosure can be used in combination, unless the context clearly dictates otherwise.

[0090] Unless the context clearly requires otherwise, throughout the description and the claims, the words `comprise`, `comprising`, and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to". Words using the singular or plural number also include the plural and singular number, respectively. Additionally, the words "herein," "above," and "below" and words of similar import, when used in this application, shall refer to this application as a whole and not to any particular portions of the application.

[0091] It is understood that wherever aspects are described herein with the language "comprising," otherwise analogous aspects described in terms of "consisting of" and/or "consisting essentially of" are also provided.

[0092] The term "interface residue" or "interface position", as used herein, means amino acid residues or positions that are interacting between at least two monomers in heterodimer, heterotrimer, heterotetramer, etc. The interaction comprises a hydrogen bond network in which at least a hydrogen from an alpha helix in the first monomer binds to a side chain in an alpha helix in the second monomer. In some aspects, the interaction comprises at least one hydrogen bond, at least two hydrogen bonds, at least three hydrogen bonds, at least four hydrogen bonds, at least five hydrogen bonds, at least six hydrogen bonds, at least seven hydrogen bonds, at least eight hydrogen bonds, at least nine hydrogen bonds, and at least ten hydrogen bonds. In some aspects, the interface residue comprises hydrophobic residues.

[0093] The description of embodiments of the disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. While the specific embodiments of, and examples for, the disclosure are described herein for illustrative purposes, various equivalent modifications are possible within the scope of the disclosure, as those skilled in the relevant art will recognize.

[0094] In a first aspect the disclosure provide designed heterodimer proteins, comprising:

[0095] (a) a monomer A polypeptide, wherein the monomer A polypeptide is a non-naturally occurring polypeptide comprising 1-5 alpha helices connected by amino acid linkers; and

[0096] (b) a monomer B polypeptide, wherein the monomer B polypeptide is a non-naturally occurring polypeptide comprising 1-5 alpha helices connected by amino acid linkers,

[0097] wherein monomer A and monomer B non-covalently interact to form the designed heterodimer protein.

[0098] The disclosure provides designed heterodimer proteins according to this aspect formed by the non-covalent interaction of two different alpha-helix-containing polypeptides (monomer A and monomer B).

[0099] By doubling the interaction surface area of protein coiled coils with an additional helix, and incorporating modular hydrogen bond networks, a wide range of heterodimeric interaction specificities can be achieved, as described herein. Millions of helical backbones with varying degrees of supercoiling around a central axis were generated and searched for those accommodating extensive hydrogen bond networks, followed by connecting the helices with short loops and designing the remainder of the sequence. As disclosed in the examples that follow, designs expressed in E coli exclusively formed heterodimers, and crystal structures of exemplary designs fit the computational models and confirmed the designed hydrogen bond networks. Following mixing of independently expressed and purified heterodimer designs, the vast majority of the interactions observed by native mass spectrometry were between the designed cognate pairs. The large sets of orthogonal polypeptide heterodimers disclosed herein can be used, for example, to generate synthetic protein logic gates, transcriptional networks and other synthetic biology applications.

[0100] Heterodimers are generally more useful than homodimers in bioengineering because of their ability to bring together two different entities (often fusion proteins). A long standing challenge in the field has been to come up with a set of orthogonally interacting protein heterodimers--monomers that selectively form cognate pairs and in the meantime avoid binding to other non-cognate monomers. Disclosed herein include such sets of orthogonal heterodimers, which can be programmably expanded into an even bigger set. The ability to bring together two different fusion proteins via genetically fused heterodimers allowed the design of protein-based logic gates, as also disclosed herein.

[0101] In one embodiment, monomer A and monomer B have their interaction specificity determined by at least one designed hydrogen bond network at the interface between monomer A and monomer B. In some aspects, (i) monomer A comprises 1 helix, and monomer B comprises 1 helix; (ii) monomer A comprises 1 helix and monomer B comprises 2 helices; (iii) monomer A comprises 1 helix and monomer B comprises 3 helices, (iv) monomer A comprises 1 helix and monomer B comprises 4 helices; or (v) monomer A comprises 1 helix and monomer B comprises 5 helices. In some aspects, (i) monomer A comprises 2 helices, and monomer B comprises 1 helix; (ii) monomer A comprises 2 helices and monomer B comprises 2 helices; (iii) monomer A comprises 2 helices and monomer B comprises 3 helices, (iv) monomer A comprises 2 helices and monomer B comprises 4 helices; or (v) monomer A comprises 2 helices and monomer B comprises 5 helices. In some aspects, (i) monomer A comprises 3 helices, and monomer B comprises 1 helix; (ii) monomer A comprises 3 helices and monomer B comprises 2 helices; (iii) monomer A comprises 3 helices and monomer B comprises 3 helices, (iv) monomer A comprises 3 helices and monomer B comprises 4 helices; or (v) monomer A comprises 3 helices and monomer B comprises 5 helices. In some aspects, (i) monomer A comprises 4 helices, and monomer B comprises 1 helix; (ii) monomer A comprises 4 helices and monomer B comprises 2 helices; (iii) monomer A comprises 4 helices and monomer B comprises 3 helices, (iv) monomer A comprises 4 helices and monomer B comprises 4 helices; or (v) monomer A comprises 4 helices and monomer B comprises 5 helices. In some aspects, (i) monomer A comprises 5 helices, and monomer B comprises 1 helix; (ii) monomer A comprises 5 helices and monomer B comprises 2 helices; (iii) monomer A comprises 5 helices and monomer B comprises 3 helices, (iv) monomer A comprises 5 helices and monomer B comprises 4 helices; or (v) monomer A comprises 5 helices and monomer B comprises 5 helices.

[0102] Any suitable amino acid linkers can be used to separate the alpha helices in each monomer. The length and amino acid content may vary based on an intended use, and can be determined by one of skill in the art based on the teachings herein. The polypeptide monomers may include any other useful sequences, including detectable tags and purification tags. In one non-limiting embodiment, at least one of monomer A and monomer B comprises a hexahistidine tag.

[0103] In another embodiment, the disclosure provides heterodimers, comprising:

[0104] (a) a monomer A polypeptide, wherein the monomer A polypeptide is a non-naturally occurring polypeptide comprising 1-5 alpha helices, wherein adjacent alpha helices may optionally be connected by an amino acid linker; and

[0105] (b) a monomer B polypeptide, wherein the monomer B polypeptide is a non-naturally occurring polypeptide comprising 1-5 alpha helices, wherein adjacent alpha helices may optionally be connected by an amino acid linker;

[0106] wherein the monomer A polypeptide and the monomer B polypeptide non-covalently interact to form the designed heterodimer protein.

[0107] In one embodiment, the monomer A polypeptide and the monomer B polypeptide have their interaction specificity determined by at least one hydrogen bond network at the interface between the monomer A polypeptide and the monomer B polypeptide. In another embodiment,

[0108] (i) the monomer A polypeptide comprises 2 alpha helices, and the monomer B polypeptide comprises 3 alpha helices;

[0109] (ii) the monomer A polypeptide comprises 3 alpha helices and the monomer B polypeptide comprises 3 alpha helices;

[0110] (iii) the monomer A polypeptide comprises 3 alpha helices and the monomer B polypeptide comprises 4 alpha helices,

[0111] (iv) the monomer A polypeptide comprises 4 alpha helices and the monomer B polypeptide 3 alpha helices;

[0112] (v) the monomer A polypeptide comprises 4 alpha helices and the monomer B polypeptide comprises 4 alpha helices;

[0113] (vi) the monomer A polypeptide comprises 5 alpha helices and the monomer B polypeptide comprises 4 alpha helices;

[0114] (vii) the monomer A polypeptide comprises 4 alpha helices and the monomer B polypeptide comprises 5 alpha helices;

[0115] (viii) the monomer A polypeptide comprises 5 alpha helices and the monomer B polypeptide comprises 5 alpha helices;

[0116] (ix) the monomer A polypeptide comprises 2 alpha helices and the monomer B polypeptide comprises 2 alpha helices; or

[0117] (x) the monomer A polypeptide comprises 3 alpha helices and the monomer B polypeptide comprises 2 alpha helices.

[0118] In one embodiment of any of the above embodiments,

[0119] (i) monomer A comprises a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of an odd-numbered SEQ ID NO selected from the group consisting of selected from the group SEQ ID NOS: 1-290; and

[0120] (ii) monomer B comprises a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of an even-numbered SEQ ID NO selected from the group consisting of selected from the group SEQ ID NOS: 1-290, wherein the even-numbered SEQ ID NO is the binding partner of the odd-numbered SEQ ID NO. in step (i).

[0121] The amino acid sequences of SEQ ID NOS:1-290 are provided in Table 1A. The "binding partners" are sequentially numbered (and similarly named) as shown in the Table. For example, SEQ ID NO:1 (DHD9 A) and SEQ ID NO:2 (DHD9 B) are binding partners, so that if monomer A comprises the polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of SEQ ID NO:1, then monomer B comprises the polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of SEQ ID NO:2. Similarly, SEQ ID NOS:3-4 are binding partners, SEQ ID NO:5-6 are binding partners . . . SEQ ID NOS:289-290 are binding partners. Those of skill in the art will clearly understand what is meant by binding partner based on the teachings herein.

TABLE-US-00001 TABLE 1A Design Oligomerization name State Chain Design sequence DHD9 Heterodimer a GSPKEEARELIRKQKELIKEQKKLIKEAKQKSDSRDAERIWKRSREINRES KKINKRIKELIKS SEQ ID NO: 1 DHD9 Heterodimer b PKKEAEELAEESEELHDRSEKLHERAEQSSNSEEARKILEDIERISERIEE ISDRIERLLRS SEQ ID NO: 2 DHD13_XAAA Heterodimer a GTKEDILERQRKIIERAQEIHRRQQEILEELERIIRKPGSSEEAMKRMLKL LEESLRLLKELLELSEESAQLLYEQR SEQ ID NO: 3 DHD13_XAAA Heterodimer b GTEKRLLEEAERAHREQKEIIKKAQELHRRLEEIVRQSGSSEEAKKEAKKI LEEIRELSKRSLELLREILYLSQEQKGSLVPR SEQ ID NO: 4 DHD13_XAXA Heterodimer a TKEDILERQRKIIERAQEIIRRQQEILEELERIIRKPGSSEEAMKRMLKLL EESLRLLKELLELLEESAQLLYEQR SEQ ID NO: 5 DHD13_XAXA Heterodimer b GSTEKRLLEEAERAHREAKEIIKKAQELHRRLEEIVRQSGSSEEAKKEAKK ILEEIRELSKRLLELLREILYLSQEQK SEQ ID NO: 6 DHD13_XAAX Heterodimer a TKEDILERARKIIERAQEIHRRQQEILEELERIIRKPGSSEEAMKRMLKLL EESLRLLKELLELSEELAQLLYEQR SEQ ID NO: 7 DHD13_XAAX Heterodimer b GSTEKRLLEEAERAIREQKEIIKKAQELHRRLEEIVRQSGSSEEAKKEAKK ILEEIRELSKRSLELLREILYLLQEQK SEQ ID NO: 8 DHD13_2:341 Heterodimer a TKEDILERQRKIIERAQEIHRRQQEILEELEYIIR SEQ ID NO: 9 DHD13_2:341 Heterodimer b MSEEAMKRMLKLLEESLRLLKELLELSEESAQLLYEQRKANNGSETEKRLL EEAERAHREQKEIIKKAQELHRRLEEIVRQSGSSEEAKKEAKKILEEIREL SKRSLELLREILYLSQEQK SEQ ID NO: 10 DHD13_AAAA Heterodimer a MTKEDILERQRKIIERAQEIHRRQQEILKEQEKIIRKPGSSEEAMKRSLKL IEESLRLLKELLELSEESAQLLYEQR SEQ ID NO: 11 DHD13_AAAA Heterodimer b GTEKRLLEEAERAHREQKEIIKKAQELHKELTKIHQQSGSSEEAKKRALKI SQEIRELSKRSLELLREILYLSQEQK SEQ ID NO: 12 DHD13_BAAA Heterodimer a TKEDILERQRKIIERAQEIHRRQQEILKRSEEIIRKPGSSEEALETLRELQ EESLRLLKELLELSEESAQLLYEQR SEQ ID NO: 13 DHD13_BAAA Heterodimer b GSTEKRLLEEAERAHREQKEIIKKAQELHRRTEEIIRQSGSSEEAKDELRR IQEEIRELSKRSLELLREILYLSQEQK SEQ ID NO: 14 DHD13_4:123 Heterodimer a TTKRYLEEAERAHREQKEIIKKAQELHRRLEEIVRQ SEQ ID NO: 15 DHD13_4:123 Heterodimer b GSSEEAKKEAKKILEEIRELSKRSLELLREILYLSQQVNDVDEKALERQRK IIERAQEIHRRQQEILEELERIIRKPGSSEEAMKRMLKLLEESLRLLKELL ELSEESAQLLYEAR SEQ ID NO: 16 DHD13_1:234 Heterodimer a EAMKRMLKLLEESLRLLKELLELSEESAQLLYEAR SEQ ID NO: 17 DHD13_1:234 Heterodimer b TTKRYLEEAERAHREQKEIIKKAQELHRRLEEIVRQSGSSEEAKKEAKKIL EEIRELSKRSLELLREILYLSQQVNDVDEKALERQRKIIERAQEIHRRQQE ILEELERIIRKPGS SEQ ID NO: 18 DHD15 Heterodimer a TREELLRENIELAKEHIEIMREILELLQKMEELLEKARGADEDVAKTIKEL LRRLKEIIERNQRIAKEHEYIARERS SEQ ID NO: 19 DHD15 Heterodimer b GTERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLKKARGADEKVLDELRK IIERIRELLDRSRKIHERSEEIAYKEE SEQ ID NO: 20 DHD20 Heterodimer a GDRQELIRRNIELLKEHIKILEEISQLIEELSELLDKSSSEEVVKRYKKIL ERYKQLLRKSQEIHKESSEIAKKES SEQ ID NO: 21 DHD20 Heterodimer b GDEQKLIERSQRMQKESLELLKEIIKILDTIEKLLDKPDSEELLDTIKKLH DTLKKIHDRNKKLLKEHEEILRQRSGSLVPR SEQ ID NO: 22 DHD21 Heterodimer a DKEEEYKRLLDEIKEILKESKEVLKDSKRVLEDIKRKVPDDDLVKLLEKHV RLLEEHVKLLEQLIREAEKSSK SEQ ID NO: 23 DHD21 Heterodimer b QGSSAEELLKKIKESEKKIRDSLRKIKEIIKKSRKEGVDDKQLDLIRKVVE SHRDLLRLHRDLLRLLREETS SEQ ID NO: 24 DHD25 Heterodimer a DIDESIKEVEKLLEEVEQSLQKLDDSLKKLLEKVNQDPDVDDSVRKIVKRH VEILKRHEEVLKRLIEVVKEHTKTVK SEQ ID NO: 25 DHD25 Heterodimer b GSDREEVHKEIVKLIREIIKIHKKILKIHEKIKNGEIDPSEILKLSEEIKK LTDTIIKIIEDLEQLTRDLRR SEQ ID NO: 26 DHD27 Heterodimer a DRKEIVKRHQKVVELLKESSKLLRESSKLLQRLLDKTGDENLQKAVDDQDK AIKRQETAIRKSQEASKKLD SEQ ID NO: 27 DHD27 Heterodimer b DNSEEIKKVAKTSREVAEYSERVAKENDKVVKTLEEGKIDESELLRLLEES IKIFDTALKLHEEAYKLHQDLVRKVS SEQ ID NO: 28 DHD30 Heterodimer a DESEAASVAIESVQILVESVKLLEESVRILLDAVKKNGVEDLLRVAQRWEK LVDEWLKVVKRWLDNVRDIQR SEQ ID NO: 29 DHD30 Heterodimer b GSDKAEEVEKSVRKIEESIKKIRKSIKKAEDAVQLLKEGKIDAKDFLRIVR EDLEVVKEDVEIVKEDVENVREFSS SEQ ID NO: 30 DHD33 Heterodimer a SDKEVSDKLLKASKKLLKVSEELLEVVRRLLKALKDDELIKKIADLLRKII DKDKKFIRTSEEIVKESR SEQ ID NO: 31 DHD33 Heterodimer b GSDLKEVLKTVEEAVKEIIKSSEELLQISRKILEISRVGVDEHEYISAIRE YLKALEKHIQILKKFIEILKELIRAVS SEQ ID NO: 32 DHD34_XAAXA Heterodimer a SKEEIDKIVKKHKKKIEEHKKKVDELKKLVEEHDKRVSQDKDDKVKKLSEE VKKIIKRLEEVSKRLEEVSKKLLKVISDKR SEQ ID NO: 33 DHD34_XAAXA Heterodimer b GSNDEELKKILETLDRILKKLDKILTRLIEVLKKSEDPNLDDKDYTELVKQ FIELIKKYEEVVKEYEEVVRQLIRLFS SEQ ID NO: 34 DHD34_XAXXA Heterodimer a SKEEIDKIVKKHKKKIEELKKLVDELKKLVEEHDKRVSQDKDDKVKKLSEE VKKIIKRVEEVAKRLEEVSKKLLKVISDKR SEQ ID NO: 35 DHD34_XAXXA Heterodimer b GSNDEELKKILETLDRILKKLEKILTRLIEVLKKSEDPNLDDKDYTELVKQ FIELIKKFEEVIKEYEEVVRQLIRLFS SEQ ID NO: 36 DHD34_XAAAA Heterodimer a SKEEIDKIVKKHKKKIEEHKKKVDEHKKLVEEHDKRVSQDKDDKVKKLSEE LKKISKRLEEVSKRLEEVSKKLLKVISDKR SEQ ID NO: 37 DHD34_XAAAA Heterodimer b GSNDEELKKILETLDRILKKLDKILTRLDEVLKKSEDPNLDDKDYTELVKQ YIELVKKYEEVVKEYEEVVRQLIRLFS SEQ ID NO: 38 DHD36 Heterodimer a DHSRKLKEILDRLRKHVKRLKEHLDELRDLVRQVPEDKLLEHVVKLSDKIL QISERAVREFTKSVDKDS SEQ ID NO: 39 DHD36 Heterodimer b GSDKKDELERILDEIRRLIERLDEILSRLNKLLELLKHGVPNAKEVVKDYI RLLKEYLELVKEFLKLVKRHADLVS SEQ ID NO: 40 DHD37_ABXB Heterodimer a DSDEHLKKLKTFLENLRRHLDRLDKHIKQLRDILSENPEDERVKDVIDLSE RSVRIVKTVIKIFEDSVRKKE SEQ ID NO: 41 DHD37_ABXB Heterodimer b GSDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVE LLKRHEKAVKELLEIAKTHAKKVE SEQ ID NO: 42 DHD37_BBBB Heterodimer a MDEEDHLKKLKTHLEKLERHLKLLEDHAKKLEDILKERPEDSAVKESIDEL RRSIELVRESIEIFRQSVEEEE SEQ ID NO: 43 DHD37_BBBB Heterodimer b GDVKELTKILDTLTKILETATKVIKDATKLLEEHRKSDKPDPRLIETHKKL VEEHETLVRQHKELAEEHLKRTR SEQ ID NO: 44 DHD37_XBXB Heterodimer a DSDEHLKKLKTFLENLRRELDRLDKLLKELRDILSENPEDERVKDVIDELE RVIRIVKTVIKIFEDSVRKKE SEQ ID NO: 45 DHD37_XBXB Heterodimer b GSDDKELDKLLDTLEKILQTATKIIDDLNKVLEKLRRSERKDPKVIETVVE LLKRHEKAVKELLEIAKTHAKKVE SEQ ID NO: 46 DHD37_AXXB Heterodimer a DSDEHLKKLKTFLENLRRLEDLLDKHIKQLRDILSENPEDERVKDVIDLSE RVVRTVKTVIKIFEDSVRKKE SEQ ID NO: 47 DHD37_AXXB Heterodimer b GSDDKELDKLLDTLEKILQTATKVVDDANKLLEKLRRSERKDPKVVETYVE LLKRLEKLIKELLEIAKTHAKKVE SEQ ID NO: 48 DHD37_3:124 Heterodimer a DSDEHLKKLKTFLENLRRHLDRLDKHIKQLRDILSEN SEQ ID NO: 49 DHD37_3:124 Heterodimer b EDERVKDVIDLSERSVRIVKTVIKIFEDSVRKLEKTKPDSKTAKELDKLLD TLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKEL LEIAKTHAKKVE SEQ ID NO: 50 DHD37_1:234 Heterodimer a DSDEHLYKLKTFLENLRRHLDRLDKHIKQLRDILSENPEDERVKDAIDLSE RSVRIVKTVIKIFEDSVRKKEKRPIDKRDDKELDKLLDTLEKILQTATKII DDANKLLEYLRR SEQ ID NO: 51 DHD37_1:234 Heterodimer b GDPKVVETYVELLKRHEKAVKELLEIAKTHAKKVE SEQ ID NO: 52 DHD37_AXBB Heterodimer a DSDEHLDRLDKHLKKLKTFLENLRRHIKQLRDILSENPEDERVKDVIDLSK TVIKIFEDSVRKKERSVRIVE SEQ ID NO: 53 DHD37_AXBB Heterodimer b GSDDKEATKIIDDLDKLLDTLEKILQTANKLLEKLRRSERKDPKVVETYVK AVKELLEIAKTHAELLKRHEKKVE SEQ ID NO: 54 DHD37_XBBA Heterodimer a DSDEHIKQLRDHLDRLDKHLKKLKTFLENLRRILSENPEDERVKTVIKIFE DSVRKKERSVRIVKDVIDLSE SEQ ID NO: 55 DHD37_XBBA Heterodimer b GSDDKEANKLLEKATKIIDDLDKLLDTLEKILQTLRRSERKDPKAVKELLE IAKTHAELLKRHEKVVETYVKKVE SEQ ID NO: 56 DHD39 Heterodimer a DHSRKLEEILDRLRKHVKRLLEHLRELLSLVKENPEDKDLVEVLELSLAIL RRSLEAVEAFLKSVTKKDPDDEDLRRKADEIRKEVEEIKKSLAEVEKEIYK LK SEQ ID NO: 57 DHD39 Heterodimer b GSSADDVLEDILKIIRELIEILDQILSLLNQLLKLLRHGVPNAKKVVEKYK EILELYLQLVSLFLKIVKTHADAVSGKIDKKAEEEIKKEEEKIKEKLRQAK DILKKLQEEIDKTR SEQ ID NO: 58 DHD40 Heterodimer a DRDAHLYKLLTFLEQLVRHLDRLVKHITQLRDIVKKDPEDERAVDVIRQSV RSLEIVITVLKIFVDSVSDAARSKEAEKIVRKIRKEIDEIRQKLREIDKEV KKTTS SEQ ID NO: 59 DHD40 Heterodimer b GSNDKVLDKILDILDRILRLATRVIDLANKLLQVKKKSTHKDPRIVETYKE LLKIHETAVRLLLELADLHRRLKSKDEEANKRVETELDRIRKKVKDIEDKV RKLEDKVRKTAS SEQ ID NO: 60 DHD43 Heterodimer a NDLSKEVLKKLEKSVEELLRRVQKSVKEAQKRGLLSDELVDRHLKILNQLV KRHLELLQEVIKRSDKK SEQ ID NO: 61 DHD43 Heterodimer b GSDEAVKRVVEKSLKILDEVIKKSLDILRELIELQIRHAKDDESVIRASKS ALKDAIEALKKSLDEIKKALKRSADEG SEQ ID NO: 62 DHD65 Heterodimer a SSEEVVKVHEKVVKLHKEILELLKKIIKIHETAARDPDDKDSIKKLSDEIK KIVKRIEDISDQAKRESSDAQRKQS SEQ ID NO: 63 DHD65 Heterodimer b DKEEESKELLKKLKEILKRSEELLEESKELLKLAKNGEIDESELADADRKL NKKHEKLVQDIQDLLREHERQDR SEQ ID NO: 64 DHD70 Heterodimer a DEKKKIDKIVKETEDLLQKSEKLLQQSKEAVKRIRSQVKENEIVDRLLRIS EELLKISRRLVEISRRIASTLS SEQ ID NO: 65 DHD70 Heterodimer b GSSKEEVIRLLKENVRLIKENLELLTRNLKLITDLVRGSNGSEEKIKTLKE LLKEYRELLKRYRKLVEDYKRLVDKHD SEQ ID NO: 66 DHD88 Heterodimer a EIQELIKSSRRIIEESKELIKESEEVLRRIKEILDRIRNGVDNQEDLLREI LKLLTKNLKIIQRNLKLLQDNAEILKRLVS SEQ ID NO: 67 DHD88 Heterodimer b GSYIEDVIKKILDVSRELIKLSRTIIKISEEINKQLQQGRDTKDLVKKYDE IIKKYTRIVQHYTELIKELQKLLS SEQ ID NO: 68

DHD89 Heterodimer a SPTEEAIQLSQRVIELSKRVIELSKEILKLLKRVLDLLPDLDKNEEKRLDD YDKELKEYDKELKKYEKRLKDLAS SEQ ID NO: 69 DHD89 Heterodimer b GSEEEEILKIQKELLRIQSEILDKQKKILDTLRSNGAVTEEVRSILEKVER LSEEAKELSKEAKELTKEVSKLIS SEQ ID NO: 70 DHD90 Heterodimer a SPLKELNNQLLRLLRELVKVSKKIVDLSKTIIEVLKHTDLDPRLLDSLEKS QQELDKSQKELDKVVKELTKVNKKLQ SEQ ID NO: 71 DHD90 Heterodimer b GSPLEDLVRKYDELVKTYEKLVEEFKKAVDKYDKAVKKAPVSKEATDSLDL IRKVLELLDRNLKLIKENAKLIKELLK SEQ ID NO: 72 DHD91 Heterodimer a SPTRENEKVIKENEKVISDNERVLEEVVKVVETATDRKEIQDAVDEVRKSV DKLRDSVRKLEESVRTLD SEQ ID NO: 73 DHD91 Heterodimer b GSPIKDISKRLLEISKRLVEISDRIVELLQRIADSKDPNKDLQKEVKDVLE EYKRLVREYREVVKEYEKVVS SEQ ID NO: 74 DHD92 Heterodimer a DEDEHVKQLIKNADLLRKHAELLKELVKLFQEIASQIPDDRVAKKVTDVVD RIDKILKQTEKLVRRTKQILDYSR SEQ ID NO: 75 DHD92 Heterodimer b GSNLEELVKLLKEVLEMHERLLRIHEDLVEAHKSNASDKESERKLKKSDKD IKESLKKIKSIIDQVRYIQS SEQ ID NO: 76 DHD93 Heterodimer a PVEDIIEESLRLLEESLKLLNRILKLLEDSLRKLPRSEEWRQRLDEFRKKL EDWKEELERWIEDVRYKKT SEQ ID NO: 77 DHD93 Heterodimer b GSDEDYESREIIDEIRKLLDRSKKIVHRSQRLVERVKSTPLSEDQEDLIRR HEETINRHRELVKELEKVLEDHERHIR SEQ ID NO: 78 DHD94 Heterodimer a PEEDSRRVLERFVRVSREVLKVLEEFLRVSEELLREADRDRDRRLEEYERQ VDELREEIRRYKEEVDKFDKEVKYYKK SEQ ID NO: 79 DHD94 Heterodimer b GSPEKDENRKLLDKVRKLVEKSRRLVEELRKLVDQSTKNGLIDEKALRKQQ EVLRKVEEVLEKQERVLRELEEISYRVI SEQ ID NO: 80 DHD94_3:214 Heterodimer a GSPERDENRKLLDKVRKLVEKSRRLVEELRKLVDQSTKN SEQ ID NO: 81 DHD94_3:214 Heterodimer b GSDEKALRKQQEVLRKVEEVLEKQERVLRELEEISYRVITRGEDHKAEEDS RRVLERFVRVSREVLKVLEEFLRVSEELLREADRDRDRRLEEYERQVDELR EEIRRYKEEVDKFDKEVKYYKK SEQ ID NO: 82 DHD94_2:143 Heterodimer a GSDRRLEEYERQVDELREEIRRYKEEVDKFDKEVKYYKK SEQ ID NO: 83 DHD94_2:143 Heterodimer b GSPERDENRKLLDKVRKLVEKSRRLVEELRKLVDQSTKNGLIDEKALRKQQ EVLRKVEEVLEKQERVLRELEEISYRVITRGEDHKAEEDSRRVLERFVRVS REVLKVLEEFLRVSEELLREADR SEQ ID NO: 84 DHD95 Heterodimer a DLSEESKKFVEKVKKLEKESRELEKQVKKIEEDSRSVENDVQKEFLELLKR LLDIQKKVVEVLREVVKVQQYVDS SEQ ID NO: 85 DHD95 Heterodimer b GSDSEYESRQVLRELDTVLKDSHTVLEALRQVIRDSQDVVSKSDEESRRVI DDLEKVIQDSKKVLDDIKRLIDKSKSIKS SEQ ID NO: 86 DHD96 Heterodimer a NEDELLKLLTENLKLLDENLKLLRENLSLLRQANNITDKNRIREIVKQSKE IVKQSREILKQSKEIVERIKYIVS SEQ ID NO: 87 DHD96 Heterodimer b GSSLYELTQRYEKLVQQYEELVKDYRRLVKKLEKLKRDNKPDKRLLKEIVD VIKKSVEIIDRSLKLLEESIKILEETD SEQ ID NO: 88 DHD97 Heterodimer a SQERSLEILKRILDVLKESLEILKESLSILRQLASRIKNPNRKIEEILKES DKIIKESDKVLKEIEEVIRYSS SEQ ID NO: 89 DHD97 Heterodimer b GSDIEYESKEILELIKELLKLSRELLKESRRALELVRKSRDDSIVEEVIQV HKKVLDIHKEVLKIVRKVVEVHRRVKS SEQ ID NO: 90 DHD98 Heterodimer a SKKDESTKLERLAEKIDEITKRIEELVKDVKRKSSEGVDKDQQQKIDEVFQ KLLDLQREILEILDRILKVQQYILD SEQ ID NO: 91 DHD98 Heterodimer b GSDLEYLNRRLLQLIKTLIDLNRHLLKLIDKLKKLNSREGDEEKIKEESKQ IQEQFKEIVERSKEIIKQIKEIIKRSQ SEQ ID NO: 92 DHD99 Heterodimer a DFERSSRRLEKVVEDLRRSSDRLREVIDELRKSADEKDEDEDLRRARKEHR DLIEELKRALEKQEEIIKHLQELVYRQL SEQ ID NO: 93 DHD99 Heterodimer b GSEESEEVRKVVERIKKISRELEEVVKELDRVSKEFDRHGETDEIVREHER IVEKLEEIVKKHTKIVEELAEIVYKQQ SEQ ID NO: 94 DHD100 Heterodimer a SDDDSVRVLDEIVKILDESVKLLKESLKLLDDFLRTKPDDHLKEVVKESKK VVEQSKKVLDRIKKIIYESK SEQ ID NO: 95 DHD100 Heterodimer b GSDLLYLSKELLKLVRELLKLSRELVELSRRLVNSTHKSPELVKKYDKLVK KYQDLLKKLADVADEYLRQRS SEQ ID NO: 96 DHD101 Heterodimer a DEKDYHRRLIEHLEDLVRRHEELIKRQKKVVEELERRGLDERLRRVVDRFR RSSERWEEVIERFRQVVDKLRKSVE SEQ ID NO: 97 DHD101 Heterodimer b GSDAYDLDRIVKEHRRLVEEQRELVEELEKLVRRQEDHRVDKKESHEILER LERIIRRSTRILTELEKLTDEFERRTR SEQ ID NO: 98 DHD102 Heterodimer a DERYRAREHIRRVEEHTKRLRHILKRLREHEEKLRRELKPGDEITESVDRF KKIVDQFEESIKKFETVSEELRKSDS SEQ ID NO: 99 DHD102 Heterodimer b GSDRQRILDRLDKILEKLDDILKKLKDILETLSKDDVSDRRHKDLVEKFRE LVDTHHKLVERYRELVYQNR SEQ ID NO: 100 DHD102_1:243 Heterodimer a GSDEITESVDRFKKIVDQFEESIKKFETVSEELRKSIS SEQ ID NO: 101 DHD102_1:243 Heterodimer b GSDPQRAADRLDKILEKLDDILKKLKDILETLSKDDVKDRRAKDLVEKFRE LVDTHHKLVERYRELVYTATAGSDLARELIRRVEEHTKRLRHILKRLREHE EKLRR SEQ ID NO: 102 DHD103 Heterodimer a NADDQLATSIKKLEDSIDQLIKIVRKFEESVKKLQKHGVDQHHVEILRKIV EIFRQHIEKLKKHLEKLRYTSS SEQ ID NO: 103 DHD103 Heterodimer b GSDKEYLVTEHEKLVREHEKIVSEIEKLVKKHEAGVDESELEEILKKVEKL LRKLDEILEQLTQLLRKTE SEQ ID NO: 104 DHD103_1:423 Heterodimer a GSDQHVVEILRKIVEIFRQHIEKLKKHLEKLRYTSS SEQ ID NO: 105 DHD103_1:423 Heterodimer b GSDAEYLVTEHEKLVREHEKIVSEIEKLVKKHEKGVDESELEEILKKVEKL LRKLDEILEQLTQLLRKAEKHIDKHSKAADQLATSIKKLEDSIDQLIKIVR KFEESVKKLQKH SEQ ID NO: 106 DHD104 Heterodimer a DEDDDIRRVLDESRRVLEHSRRVLKRSEEVLEKASRKKEKDTEEIEKHLKR LREHAKKLEKHRRELDDFLYKEI SEQ ID NO: 107 DHD104 Heterodimer b GSRDKYLLERLNDILKKLDEIVDKLSDILKRLKDVRHDDRLQELVERYKEI VKEYKRIVEEYEKLVREFEEQQR SEQ ID NO: 108 DHD105 Heterodimer a DRDYEDKEFKKIIKELEDVQEELKKLQEKIKRFSSELEEPNELLKEQLKVN EEQLEVNKKILKILRDQLKQNE SEQ ID NO: 109 DHD105 Heterodimer b GSDAEYKVRESVKRSKESVKHSEDVVDKLNKSVKLSESGHSDAEKASRELV KLVREVVELSREVIKLSEKVLRVIS SEQ ID NO: 110 DHD106 Heterodimer a DLQYKQEKLIRHFDRVVREWDKLVRKFSKVLEKQKHESKDKELEEASRRVD ELIKRLREQLKRSKEILRRLKELSRKSS SEQ ID NO: 111 DHD106 Heterodimer b GSDWEELLRRLEKVLQEYEEIVKELIDLIERLIKVSEDKSKDASEYKKLVT ELEKLISKLEEISKKLEELVKEYEYKTE SEQ ID NO: 112 DHD107 Heterodimer a DAKDELEKSLQEIEESLKELKKLLEELDKSLRELTSQGRNKKLEEHIKKVQ KFIELVKKYIKAVQDYLKEVRYDNS SEQ ID NO: 113 DHD107 Heterodimer b GSDKERAARATEEMVKLTKKLLKAVEDLVRDVRRLLKEGLISEKHARIAET ILEVFKKHAKIIKKHVDIVKYDES SEQ ID NO: 114 DHD108 Heterodimer a GSPLKERLLEIQRDLDRVLEEVVERLLRIQERLDSVVERKPPDVHEEYKYI VDEIREIVERVVREYEEIVKRIDEEVR SEQ ID NO: 115 DHD108 Heterodimer b GSEEDERIRYDLDRIRKDVRRKLEEIRQRVRELEKKLRDAGHRRDEKELLR ELIETSKDILRLVEELLKKIIDKSEDLLRKTE SEQ ID NO: 116 DHD109 Heterodimer a GSDEEDYINENVEKDVRDIEDDVRRINERIRELLEKIRTEEVLQRVLEEHH ELVERVLRKLVEILRKHEEENR SEQ ID NO: 117 DHD109 Heterodimer b GSDEEEYYKEKLHKLLREIEELLKHYRELVRRLEELVKRGELDKDTAAHIL ERLSELLERIIRRVAHTLRRLSEERR SEQ ID NO: 118 DHD110 Heterodimer a GSDEDEISYDSKRRVEEIVRQAREKSEKSRKDIEDVAEVLRKGDVSEKEVV DELVKVLEEQVKVLREAVERLREVLKKQVDDVR SEQ ID NO: 119 DHD110 Heterodimer b GSDIVELVDHLLKRSLKLLEELAELVRRLLEKSTELLKRRTEEHKEEVVEE SEYMVRELEERLRRVVDESEKLVRDADKHIR SEQ ID NO: 120 DHD111 Heterodimer a GSKEKDIVKTLVDLLRENLETLERLIEEVVRLLKENVDVRDEGRDDKDSER ILRDIKRRIDEAAKESREIIERIEKEVEYRSR SEQ ID NO: 121 DHD111 Heterodimer b GSPEVDVLRRIVREILKASEELLRLLRKLIDEALKLSERKRDSQEYREVVD RVKKELERLLDEYRKLVEELKEKLRYDTR SEQ ID NO: 122 DHD112 Heterodimer a GSDKRYESEKLKRRLDEAVEKVREVVERVERESDRVLEEVRRRRESKEVVD KVIEDNDKALEDVLRVVDEVAKVVRDVVRENTR SEQ ID NO: 123 DHD112 Heterodimer b GSPREYHSKDILRKVDEILERIRRHADRVKKKSERLKRENVDVNEHSKDVK RVIRELLELVKELLRLAKKHSDDQQE SEQ ID NO: 124 DHD113 Heterodimer a GSDEDEILYHSERLLQKLKKELDDLKEKSRELLEELKKEDPDDRLIERIIR LHDEVLKDLDEVLKNILEVHREVLERLR SEQ ID NO: 125 DHD113 Heterodimer b DKLDRLLKIHEEALRRAEELIKRLLDIHRRALDLARRGELDDYLLKESERE LREIIRRAREELKESRDRLEEISR SEQ ID NO: 126 DHD114 Heterodimer a GSPKEELIRRVLEEVKRLNEKLLEIIRRAAELVKRANDELPETEKLREIDR ELEKKLKEIEDELRRIDKELDDALYEIED SEQ ID NO: 127 DHD114 Heterodimer b GSPKLDKLRELLERNLEKLREILEEVLKILRTNLERVREDIRDEDVLQEYE RLIRKAEEDLRRVLKEYDDLLKKLVYELR SEQ ID NO: 128 DHD115 Heterodimer a GSKEDESVKRAEEIVRTLLKLLEDSLREAERSLRDIKNGEDEHNLRRISEK LEELSKRITETIERLLRELQYTSR SEQ ID NO: 129 DHD115 Heterodimer b GSPNQELLDRVRKILEDLLRLNEELVRLNKELLKRALEMRRKNRDSEEVLE RLAEEYRKRLEEYRRELEKLLEELEETIYRYKR SEQ ID NO: 130 DHD116 Heterodimer a GSDESEEAQHEVEKVLDDIRRLSEHLQKRLEEVLEEVYELRREGSDRTEVV ELLKEVIREIVRVNREALERLLRVVEEAVKRNE SEQ ID NO: 131 DHD116 Heterodimer b GSDEEELVETVKRIQKEILDRLTELAKLLVEIQREIKKLKDEGEDDKELKR LSDELEEKVRQVVEEIKRLSDELEETVEYVSR SEQ ID NO: 132 DHD117 Heterodimer a GSDEEEEVVRRAEELVKEHEELIERVIRTHEELVYKLEDQGADKKLVDVLK RVVEESERVAREIVKVSRELIRLLEEASR SEQ ID NO: 133 DHD117 Heterodimer b GSSKEEILKELEDLQRRLIEELKKLQERVVELLEELIKRLRDRGRDDKHLK RLVKEVRRLSEEVLRSIKEVSDRVRYQLR SEQ ID NO: 134 DHD118 Heterodimer a GSDKEEESEYLLRDLVRLLEKVKEKIEEVNREVEKLLKKVKDGRLDRREVL REILRLNRELAEIIKEVVDRIRHVVERSER SEQ ID NO: 135 DHD118 Heterodimer b GSDLHEVVYETKELLKRIEEVVEELRKKSEDIIRKAERGEISEDELKRLQE EIAREAKKLLDEIKRVLERHLEQTL SEQ ID NO: 136 DHD119 Heterodimer a GSPVEEIIKEVVKRVIEVQEKVLRIISHAVKRVVEVQKKYDPGSEESNRVV EEVKKTIEDAIRESDEVVDEVVKRIQYTVR SEQ ID NO: 137 DHD119 Heterodimer b GSPEQEIADRILTEIRESQKELERLARKILKLLDESQEKAKRGRLSEEESD ELLERIKKELDELLERSKELLKKIEYELR SEQ ID NO: 138 DHD120 Heterodimer a GSDEDKEANRVLDEVLKTVRDLLETANEVLKEVLYRLKRTDDQEKVVRTLT EVLKEHLKLVEEIVRILDKVLKEHLETEK SEQ ID NO: 139 DHD120 Heterodimer b GSPEDDVLRRLEEVSEKILRVAEDVARQLREVSEKITQGKVDRKEWEEDIK RLKRELEELLREWKEEIERLTYELR SEQ ID NO: 140 DHD121 Heterodimer a GSRREEVVKRIRELLKRNKELIDRIRELLEENEYLDKDARDKDVLRRSVEL LEELVRILEESVELAKEIIKLLREVVE SEQ ID NO: 141 DHD121 Heterodimer b GSDEKEDNRRLQHKIERILEKNEDLQRKLEEILELLERGEADEEKIDRLRK AVEDYRRVVEEIKEDVKRHKYTVR SEQ ID NO: 142 DHD122 Heterodimer a GSDEKEEAKKASEESVRTVERILEELLKASEESVELLRRGEDAKDVVERSK EALKRVKELLDEVVKRSDEILKYIHN SEQ ID NO: 143 DHD122 Heterodimer b GSDEKKLINEVVETQKRLIKEAAKRLSEVVRHQTELIRELREKNVDDKDVE KLLKESLDLAEEIVRRIKELLDESKKLVEYVSN SEQ ID NO: 144 DHD123 Heterodimer a GSPDMDEVKRVLDELIEIQEEILREIKRVLEKLIKIQEDNGSEYESREVVR EIVEIARKLVERSRRVVKKITETLQ SEQ ID NO: 145 DHD123 Heterodimer b GSDERYATREIVERIERIAREILKRTEEIVREVREVLSRDVDQEEVVRRLA DLLRESVELVQHLVRRVEELLQESVERKK SEQ ID NO: 146 DHD124 Heterodimer a GSPEREALREVLEDLKRVTDRLRELVERVLEELKKVTDHVDSERILRESRR VLKELKDIIEEILRESEKVLEKLKYTED SEQ ID NO: 147 DHD124 Heterodimer b GSPAREILEEVVKKHLEVVEDAARILEEIIREHEKAVREDRDKKELEEISR DLLRKAREALKKVKDISDDLSREIEYVAS SEQ ID NO: 148 DHD125 Heterodimer a GSPVEEAIKKVIDDLRDVQRKIRELVEELIRLLEEVQRDNDKRESEYVVER VEEILRRITETSREVVRKAVEDLS SEQ ID NO: 149

DHD125 Heterodimer b GSDSDEKAEYLLKEMERVVRESDEVVKKILRDLEEVLERLRRGEISEDDVT EILKELAERHIRAIEELVRRLRELLERHKR SEQ ID NO: 150 DHD126 Heterodimer a GSPVEEVLKELSEVNERVRDIAREIIERLSEVNEEVKETDDEDELKKISKK VVDEVEDLLRKILEVSEEVVRRVEYHDR SEQ ID NO: 151 DHD126 Heterodimer b GSPKEDILREVLRRHKEIVREIVRLVREAVETHLELVKRNSDDRDAQDVIR KLEEDLERLVRHAQEVIEEIFYRLH SEQ ID NO: 152 DHD127 Heterodimer a GSPRSYLLKELADLSQHLVRLLERLVRESERVVEVLERGEVDEEELKRLED LHRELEKAVREVRETHREIRERSR SEQ ID NO: 153 DHD127 Heterodimer b GSDREYIIKDILDSQEHLLRLIEELLETQKELLEILKRRPDSVERVRELVR RSKEIADEIRRQSDRNVRLLEEVSK SEQ ID NO: 154 DHD128 Heterodimer a GSDEKDEIRHVIESVERLIEDIKRLLKTLRELAHDDSDKKTVKEVLDRVKE MIERHRRELEEHRKELERAEYEVR SEQ ID NO: 155 DHD128 Heterodimer b GSESEDRIKELLKRHIELVERHEELLHEIKKLIDLEEKDDKDREEAVKRID DAIKESEEMLEESKEILEEIEYLNR SEQ ID NO: 156 DHD129 Heterodimer a GSSLEDSVRLNDEVVKVVERVVRLNQEVVRLIKHATDVEDEETVKYVLERV REVLDESREVLKRVHELLEESERRLE SEQ ID NO: 157 DHD129 Heterodimer b GSHEKDIVYKVEDLVRKSDRIAERAREIVKRSRDIMREIRKDKDNKKLSDD LLKVTRDLQRVVDELEELSRELLRVAEESRK SEQ ID NO: 158 DHD130 Heterodimer a GSPELDEVKKLIDELKKSVERLEESIREVKESIKKLRKGDIDAEENIKLLK ENIKIVRENIKIIKEIIDVVQYVLR SEQ ID NO: 159 DHD130 Heterodimer b GSDEEEIEELLRELEKLLKKSEEALEESKKLIDESEELLRRDRLDKEKHVR ASEEHVKLSEEHLRISREIVKILEKAVYSTR SEQ ID NO: 160 DHD131 Heterodimer a GSDESDRIRKIVEESDEIVKESRKLAERARELIKESEDKRVSEERNERLLE ELLRILDENAELLKRNLELLKEVLYRTR SEQ ID NO: 161 DHD131 Heterodimer b GSDEDDELERLLREYHRVLREYEKLLEELRRLYEEYKRGEVSEEESDRILR EIKEILDKSERLWDLSEEVWRTLLYQAE SEQ ID NO: 162 DHD132 Heterodimer a GSDKKDASRRAIRVLHEFVRVSEEVLEVLRKSVESLKRLDVDEKIKRTHDR IEEELRRWKRELEELIERLREWEYHQD SEQ ID NO: 163 DHD132 Heterodimer b GSDDEEEDKRLLEEVKRSLDTDERILEKLRHSLERQLEDVDKDEDSRRVLR ELDEITKRSREVVKRLRKLAYESK SEQ ID NO: 164 DHD133 Heterodimer a GSDKEYKLDRILRRLDELIKQLSRILEEIERLVDELEREPLDDKEVQDVIE RIVELIDEHLELLKEYIKLLEEYIKTTK SEQ ID NO: 165 DHD133 Heterodimer b GSPSKEYQEKSAERQKELLHEYEKLVRHLRELVEKLQRRELDKEEVLRRLV EILERLKDLHKKIEDAHRKNEEAHKENK SEQ ID NO: 166 DHD134 Heterodimer a GSRDRKISEELIKALEDHIRMLEELIRAIEEHIKLAERGVDEKELRESLEE LKKIVDELEKSLEELRKLAERYKYETR SEQ ID NO: 167 DHD134 Heterodimer b GSPKEESVEELKRVIDKHEEILRELKRVLEEHERVSHDEDENELRRSLERL KHILDRLHESLKELHELLKKNEYTER SEQ ID NO: 168 DHD135 Heterodimer a GSDHEYWVKIVERILRVMEKHAEIVKKHLEIVERVVREGPSEDLRRKLKES LREIEESLRELKELLDELDELSEKTR SEQ ID NO: 169 DHD135 Heterodimer b GSDEEYVTRSQRRLKRLLEEYIKVVEEHARLVERNERDDKELKRSIDELDK LTKELLELVKRYKELVDKTET SEQ ID NO: 170 DHD136 Heterodimer a GSDKEEIVKLQDEVIKTLERHLDILRKHIDLLEKLKDHLSEELKERVDRSI KKLEESIKRLERIIEELQELAEYSL SEQ ID NO: 171 DHD136 Heterodimer b GSREEELKESAEELERSVRELKKEADKYKEEVDRLHYRGKVDKDWVRVVEK LIKLVEEHLELIREHLELLKEERR SEQ ID NO: 172 DHD137 Heterodimer a GSDMEYELKKSAEELRKSLEELKRILDELHKSLRELRRHGDDEEYVQTVEE LRKELEEHAKKLEEHLKELERVAT SEQ ID NO: 173 DHD137 Heterodimer b PEYELKKSVDDLKRDVDRLVEEVEEVFELSKERLREDRKHLELVEEMVRLI EKHLELIKEHLKLADDHVR SEQ ID NO: 174 DHD138 Heterodimer a GSREKDESKELNDEYKKLLEEYERLLRRSEELVKRAKGPRDEKELKRILEE NEDILRRTKEILERTKEISEEQKYRRR SEQ ID NO: 175 DHD138 Heterodimer b GSDKDERQERLNEESDKSNEESERSNRESEELNRRARGPNDEKELQEILDR HLELLERNQRLLDENKEILRESQYLND SEQ ID NO: 176 DHD139 Heterodimer a GSENKYILKEILKLLRENLKLLHDILRLLDENLEELEKHGAKDLDDYRRKI EEIRKKVEDYREKIEEIEKKVERDR SEQ ID NO: 177 DHD139 Heterodimer b GSESEYTQEEILELLKESIKLLREILRLLEESEELWRRENTKSERSEEIKE RAKEAIKRSEEILERVKRLSDHSR SEQ ID NO: 178 DHD140 Heterodimer a GSDEEEANYVSDKAVKIAEDVQELLKELLELSEVVRRGEVDEDEYDRVLRK LQEVMKEYEEVLKEYEEVSRKHE SEQ ID NO: 179 DHD140 Heterodimer b GSPEKYLIKTQEELLRRHAEILEDLIRKVERQVDLRRKVDERDEDLKRELE RSLRELERLVRESSRLVEEIRELSKEIKR SEQ ID NO: 180 DHD141 Heterodimer a GSDEEYELERISRESKELLERYKRLLREYQELLKELRHVKDLDRAVKIIHE LMRVSKELVEISHRLLELHERLVRRRK SEQ ID NO: 181 DHD141 Heterodimer b GSEKEYIEKLSRKIEEDIRRSEERAKDSERLVRRLEELAKRKRLDLDDVLR VAEENLEILEDNLRILEEILKEQDKSNR SEQ ID NO: 182 DHD142 Heterodimer a GSPHEEVVELHERVMEISERAVELIQRIIDIIRRIREDDKDIEKLVKTIRD LVREYEELHRELEEIDEEIYKKSE SEQ ID NO: 183 DHD142 Heterodimer b GSDHEDVVRLHEDLVRKQEDARRVLEEIVRLAEEIVEVIKKDEKDKDRVTR LVEEIEKLVEEYKKKVDEMRKISDEIKYRSR SEQ ID NO: 184 DHD143 Heterodimer a GSRAREVVKRAKRIIEEWQKILEEWRRILEEWRRLLEDERVDDRDNERIIR ENERVIRENEKIIRDVIRLLEELLYERR SEQ ID NO: 185 DHD143 Heterodimer b GSREDEELEEEIDRIRQMVEEYEELVKEYEELTEKYKQGKVDKEESKKIIE KSERLLDLSQDAVRKVKEIIRRILYTNR SEQ ID NO: 186 DHD144 Heterodimer a GSPKEEIVKLHDESAELHRRSVEVADEILKMHERSKDVDDERESRELSKEI ERLIREVEEVSKRIKRLSEEVEYLVR SEQ ID NO: 187 DHD144 Heterodimer b GSPLEEILKIQRRINKIQDDINKILHEILRMQEKLNRSSDKDEVEESLRRI RELIKRIKDLSKEIEDLSREVKYRTT SEQ ID NO: 188 DHD145 Heterodimer a GSPEDEHVYVVREIYEVLREHAEVLEENREVIERLLEAKKRGDKSEELVKE LKKSIDKLKEISRKLEEIVKELEKVSEKLK SEQ ID NO: 189 DHD145 Heterodimer b GSDEDETSYRILELLREIVRASRELIRLSEELLEVARRDDKDETVLETLIR EYKELLDRYRRLIEELTRLVEEYEERSR SEQ ID NO: 190 DHD146 Heterodimer a GSTQEEINRIQHEVLRIQEEIDEILRDIVEKLKAISRGELDHEVVKDVEDK VREALEKSEELLDKSRKVEYKSE SEQ ID NO: 191 DHD146 Heterodimer b GSDEEELNRELLEKSKRLVDINRDIIRTAQELIEMLKDSKDGRVDEDTKRE LRDKLRKLEEKLERVREELRKYEELLRYVQR SEQ ID NO: 192 DHD147 Heterodimer a GSDEKDRVYEILKEVQRLVKEYRDISKEIEDLVKHYEHITDDEAQEVSKEL IDKSLRASEIVRELIRLIKELLDELE SEQ ID NO: 193 DHD147 Heterodimer b GSDEEDVLYHLRELLEELKRVSDDYERLVREIKETSERKDRDTKENKDMLD ELVKAHREQEKLLERLVRLLEELFERKR SEQ ID NO: 194 DHD1 Heterodimer a PREQAIRISEEIIRISKKIIEILERTRSSTAREAMKWAKDSIRLAEESKYL LDK SEQ ID NO: 195 DHD1 Heterodimer b IEDDVKKIQDSTKKAQKETIEALERSTSSTARKQMEEQKEQIRLQKEAMYL LKK SEQ ID NO: 196 DHD2 Heterodimer a SREEIAKLQEEVIKLQRRVIELQKEVIELQRRAKELTSSYTKEILEIQRRI EEIQREIEEIQKRIEEIQEEIQRRT SEQ ID NO: 197 DHD2 Heterodimer b SDEEIKRLSEEVIQLSRRVIKMSREAIKLSREVQKLTPSYQKRIKEIADRS IELARESIEIAKRSEKIAEESQRRT SEQ ID NO: 198 DHD3 Heterodimer a PAKDEALKMANESLELAKKSARLIQESSSKEILERIEKIQRRIAELQDRIA YLIKK SEQ ID NO: 199 DHD3 Heterodimer b PAKDEALRMIDESRELIKKSNELIQRSSSKEILERILEIQRKIAELQKRIQ YLLKS SEQ ID NO: 200 DHD4 Heterodimer a TDEARYRSERIVKEAKRLLDEARRRSEKIVREAKQRSNSEDAKRIMEENLR ESEEAARRLREIIRRNLEESRETG SEQ ID NO: 201 DHD4 Heterodimer b TREALEYQRKMAEEIEDLLREALRRQEEMVREAKQRSLSEEFKRIMERILE EQERVMRLAKEALERILEEQKRTG SEQ ID NO: 202 DHD5 Heterodimer a SERTKREAKRSQEEILREAKEAMRRAKESQDHRQNRDGSNSEDLERLSQEQ KRELEEVERRLKELAREQKYKLEDS SEQ ID NO: 203 DHD5 Heterodimer b SEDLKRILKEITERELKLMQDLMEILKKITEDENNLDSNNSEDLKRSIEKA RRILDEALRKLEESARRAKYIQEDN SEQ ID NO: 204 DHD6 Heterodimer a TEDEIRESLKWLDEVLQELREIARESNEVLERNRQKSRSDKLREDIERYKK RMEEARKKLDDQLNKYKKRMDENRS SEQ ID NO: 205 DHD6 Heterodimer b TEEELKESKKFAEDLARSARRALKESKRVLEEISQASRSKKLEEIVRRYKE QVKRWQDEWDERAREYRKRMKENRS SEQ ID NO: 206 DHD7 Heterodimer a TKTEEIERLAREIKKLSEKVERLAQEIEELSRRVKEENSTDRELKEANREI ERAIREIEKANKRMEEALRRMKYNG SEQ ID NO: 207 DHD7 Heterodimer b TKTEEHERLAREISKLADEHRKLAKIIEELARRIKEENLTDDELREAIRKI EDALRKNKEALKIMKEAAERNRYNT SEQ ID NO: 208 DHD8 Heterodimer a TKKEESRELARESEELARESEKLARKSLELARRAESSGSEEEKRRIIDENR KIIERNREIIERNKEIIEYNKELIS SEQ ID NO: 209 DHD8 Heterodimer b TKDEESLELNRESEELNRKSEELNRKSKELNDRAESSNSEEEEKEILREHK EILREHLEILRRHKEILRRHKYLTS SEQ ID NO: 210 DHD16 Heterodimer a TREELLRENIELAKEHIEIMREILELLQKMEELLERQSSEDILEELRKIIE RIRELLDRSRKIHERSEEIAYKEE SEQ ID NO: 211 DHD16 Heterodimer b SEDIAREIKELLRRLKEIIERNQRIAKEHEYIARERKKLDPSNEKERKLLE RSRRLQEESKRLLDEMAEIMRRIKKLLD SEQ ID NO: 212 DHD18 Heterodimer a DRQKLIEENIKLLDKHIKILEEILRLLKKDIDLLKKSSSEEVLEELKKIHR RIDKLLDESKKIHKRSSEIVKKRS SEQ ID NO: 213 DHD18 Heterodimer b DEQKLIETSQRLQEKSERLLEKFEQILREASDLYRKPDSEELLRRVEKLLR ELEKLIRENQDLARKHEKILRDQS SEQ ID NO: 214 DHD19 Heterodimer a DRQELIRENIELLKKHIKIVKEIQKLIETFIELLKKSSSEEILRRLKKILK RIEKLYRESQEIHKRSEEIAKKRQ SEQ ID NO: 215 DHD19 Heterodimer b DEERLIDKSRELQKESEELLKELLKIFKRIEELLEKPDSEELIREIKKLLE TLSEIHKRNEKLARTHEEILRQQS SEQ ID NO: 216 DHD22 Heterodimer a STRDVQREIAKAFKKMADVQKKLAEEIKRHVKNVEKKNKDNDEYRKIATEL LKKATESQKKLKELLDRIRKSDS SEQ ID NO: 217 DHD22 Heterodimer b DKDDRSTSLLKRVEKLIDESDRIIDKFTTLIELSRNGKIDDDQYKKELKEI LELLKKYDKHVKEVEELLKRLNS SEQ ID NO: 218 DHD23 Heterodimer a SKRKALEVSERVVRISEKVVRVLDESSDLLKKSYDDSDKFAELIDRHEEKI KKWKKLIKEWLEIIQRHKS SEQ ID NO: 219 DHD23 Heterodimer b SAEEFVKLSEEAVKRSKEILDIVRKQVKLVKAGVDKHEITDSLRKSEKLIE EHKELIKTHRDLLRREN SEQ ID NO: 220 DHD24 Heterodimer a SSTEILKRFKRALRESEKIVKHSRRVLKIIREVLKQKPTQAVHDLVRIIET QVKALEEQLKVLKRIVEALERQS SEQ ID NO: 221 DHD24 Heterodimer b DKQKEIKDILEKTRRIAEESRKIAEKFDEIIKRSTEGKIDESLTKELEELV KEVIKLSEDDARTSDDLVRKES SEQ ID NO: 222 DHD26 Heterodimer a DEDESIKLTRKSIEETRKSLKIIKEVVELIREVLKHIKDLDKEIFERIDKI LDKYKKQVDTYDEILKEYEKKQR SEQ ID NO: 223 DHD26 Heterodimer b SELDEQKELIKKQEKLIEEQQRLLSKIRRMFKERVKDQELLREIQKVLKRS QEIVETSKKILDRSDKTTE SEQ ID NO: 224 DHD28 Heterodimer a DQKEINTRIVEKLERIFKKSKEIVRQSERVISTIEKKTEDERELDLLRRHV KIVREHLKLLEELLKIIKEVQKESE SEQ ID NO: 225 DHD28 Heterodimer b DTEELVKRLNELLKELSKLVKEFIKILETYRKDQTKDTSKISERVDRILKT YEDLLQKYKEILEKIEKQLS SEQ ID NO: 226 DHD29 Heterodimer a DYARLIDQAVEVTREVVEVNVTVARVNDKFAKHLGDEELRRVSEHLKEVSK DLQEVAKKSKDAARQVK SEQ ID NO: 227 DHD29 Heterodimer b DVSKVAEEYLQISKTLVDISRTLLEISERLVRLVRTVADDRSEVKKAIEDS IEVLKTSEEVVRQIKRASDKLVKAIS SEQ ID NO: 228 DHD31 Heterodimer a DAKEIQRRVVEIQTEVVKLQKKAVDIIRKIIEAFNNSNIDQSLLEAAKEIV KEIDKLEKLTESLLEESKKLLKRSS SEQ ID NO: 229 DHD31 Heterodimer b SAEEVVKLAKIFLELLRESIKLLKRSVDLLRKSSDPSLDKSEAEKVSREIE KVSDTSLKLSKKALDVVKRALKVAS SEQ ID NO: 230 DHD32 Heterodimer a DEKDAARKARKVSEEAKEASKKIEKALEESKRILNTLKQKKDEQEVKVIKE HEDVLRQIEKIQKQVLEIQKEVAKLLESLD SEQ ID NO: 231 DHD32 Heterodimer b SADDVARASEKVLRVARESAKAADKSLEVFKEVVKRGDKEAFLQVVKINEE VVKINITVIRILIEVSKTAT SEQ ID NO: 232 DHD38 Heterodimer a DEYVKETLKQLREALASLREADKRITELVKEARKKPLSEAARKFAEAIVTH

VKVVVEHVEVVLRHVEVLVEAKKNGVIDKSILDNALRIIENVIRLLSNVIR VVDEVLQDLD SEQ ID NO: 233 DHD38 Heterodimer b DASDVIRRIHELFEEVHRLIEAVHRAIEDVAKAAQKKGLDESAVEILAELS KELAKLSRRLAEISREIQKVVTDPDDKEAVERLKEIIKEIKKQLDELRDRL RKLQDLLYKLK SEQ ID NO: 234 DHD60 Heterodimer a SEDKAHHDIVRVLEELIKIHDELMKISEEILKATSDSTATDETKEELKRRS KEAQKKSDTLVKIVKELEKESRKAQS SEQ ID NO: 235 DHD60 Heterodimer b DDEEKYRQIIREAQEISKTAKRILRDAQEISKRIRHQGVDRSEHQRLVDLL RELIKEHHKLLRRQQEADTRND SEQ ID NO: 236 DHD63 Heterodimer a DRKDKARKASEKLEEVIQRWKTVADKWKKMVDLVSNGKLSQEEVARVTEEL LKIQTELAKLLEEHAKVLQESAS SEQ ID NO: 237 DHD63 Heterodimer b SDEESIKTQSELIKTSEELLKDVKRIDEELQKLRDDPTLDESELKKRVKEW SDRVRKAKEISRKIQEIVKESKKRSS SEQ ID NO: 238 DHD66 Heterodimer a DKDEELRKVIEKYREMVKEYRKVIREYEEVIKSSKTIDKSSLISLSRKMVE LSQRVIDVSDEVAKVLSRKQS SEQ ID NO: 239 DHD66 Heterodimer b TDEERLKKQTKELKEQTKQLEKQKDLLEKISNGEISKDEIQEIIKESKKIA KESQKALDSSRKALEEVS SEQ ID NO: 240 DHD67 Heterodimer a DEKEVSKEIIKVLKDIAKVQQKVIEVSQRLASVLRADDDNVVKRALEEYEK ILEELRELNKEIEKLTDKYRKVTS SEQ ID NO: 241 DHD67 Heterodimer b DSDEQTKELEKLTELHKRHVEKLKKQTKESREVDSNKLWKSKDVKDKLSES EKELQKLSDQDKKAKDALESSRRKND SEQ ID NO: 242 DHD69 Heterodimer a DAEEQLKLLTKLLRHQQRLLQLIKESLKLIEKIDQSSQENQDEIRKWREVT KKLRELIKTSEKLVRELEKSYKKSS SEQ ID NO: 243 DHD69 Heterodimer b SLRDVVRRYQELVRRYDELIKTLTEILKKYQKKGAEDKDASTELVKAVRTS LKLSKELLKLNSELLKEDS SEQ ID NO: 244 DHD71 Heterodimer a SKEELKRKLDELKKRSDTLKELSKKLKEISERNPDDKSVHRTIIRIHREFV KNHKEIVRVIEEIVSDKS SEQ ID NO: 245 DHD71 Heterodimer b SKQDEHDRLLKIHDKLVKQHDELLKLLTKLSRAGDSVTKKKLEEILRKLQE VSKQLEESLKDADKVSKDIN SEQ ID NO: 246 DHD72 Heterodimer a TVQSLLEQHVKIVKRSIEILERHTQILQDIARSQGVSKELEDVERQVKEYR KEVKKLEEDLRQLSRNSK SEQ ID NO: 247 DHD72 Heterodimer b SDSDRIEKLIRESTELLKEQQKLAKRSRELAETVESLPLTEEYLKQQREHQ KKIEKLLKDSEKHLEELKRLVKSEK SEQ ID NO: 248 DHD73 Heterodimer a DSEKRIEDILRTDLELAKRDAELVKEHIKLVKRIDLSEELKKQVEDVEKES KKLEDSSEKLVQKVRKRSS SEQ ID NO: 249 DHD73 Heterodimer b DEEERAKDLRKYLEEQTQYYRTVTEHLRNLEKVVEELERRGKPSSELQQIL ERSQRIYKETTEIYDTSKKLIEELDKHHR SEQ ID NO: 250 DHD148 Heterodimer a PLEDILKRHLDKVRELVRLSEEVNKLAKEVLDILKDKRVDEKELDKVLKEL EKVVEEYERAVKESRDLLRELRETTR SEQ ID NO: 251 DHD148 Heterodimer b DKERLLEIHERIQKLLDRNLEIIERLLRLLREARDIKDDDKLDKVIKRLKE LSEESKDILDKIKELLKESEKELT SEQ ID NO: 252 DHD149 Heterodimer a PEDEVIRVIEELLRIAAEVDEVHRRNVEVQEEASRVTDRERLERLNRESEE LIKRSRELIEEQRKLIERLERLAT SEQ ID NO: 253 DHD149 Heterodimer b DLEELIKEYAEVVRRHHKAVRDLERLVRELANAKHASEEELKRIATEILRI VKELIRVQERLIKLSEDSNEESR SEQ ID NO: 254 DHD150 Heterodimer a PTDEVIEVLKELLRIHRENLRVNEEIVEVNERASRVTDREELERLLRRSNE LIKRSRELNEESKKLIEKLERLAT SEQ ID NO: 255 DHD150 Heterodimer b DNEEIIKEARRVVEEYKKAVDRLEELVRRAENAKHASEKELKDIVREILRI SKELNKVSERLIELWERSQERAR SEQ ID NO: 256 DHD151 Heterodimer a PKEDIDRVSRELVRVHKELLEVLRKSTEIVEAVARNEKDERTIEEVLEEQE RAVRKLEEVSKKHKEAVKRLK SEQ ID NO: 257 DHD151 Heterodimer b ELERLSEEIQKLSDRLIELIRRHSKVLEEIVRLLKHKDNDEREVRRLLKLL RDLTRRYEEVLRKVEEIVKRQEDESR SEQ ID NO: 258 DHD152 Heterodimer a PEEDILRLLRKLVEVDKELLEVVRESTEVVRLVARNEKDVETVERVLRKQE EVVRKYERVSRELEEAVRRLK SEQ ID NO: 259 DHD152 Heterodimer b ELKDLVEEIVKLSKENLKLWEDHSRVLEEIVRLLKHKDNDEREVRRLLKLL EDLTRRAEETSRRIEEIVKEAEDRAR SEQ ID NO: 260 DHD153 Heterodimer a DEERELREVLRKHHRVVREWTKVVEELKRVVELLKRGETSEEDLLRVLKKL LEMDKRILEVNREVLRVLEKRLT SEQ ID NO: 261 DHD153 Heterodimer b SLEEIIEELVELVRRSVEIAKESDEVARRIVESEDKKKELIDTLRDLHREW QEVTKRAEELVREAEKEVR SEQ ID NO: 262 DHD154 Heterodimer a TAEELLEVHKKSDRVTKEHLRVSEEILKVVEVLTRGEVSSEVLKRVLRKLE ELTDKLRRVTEEQRRVVEKLN SEQ ID NO: 263 DHD154 Heterodimer b DLEDLLRRLRRLVDEQRRLVEELERVSRRLEKAVRDNEDERELARLSREHS DIQDKHDKLAREILEVLKRLLERTE SEQ ID NO: 264 DHD155 Heterodimer a PEDDVVRIIKEDLESNREVLREQKEIHRILELVTRGEVSEEAIDRVLKRQE DLLKKQKESTDKARKVVEERR SEQ ID NO: 265 DHD155 Heterodimer b DEVRLITEWLKLSEESTRLLKELVELTRLLRNNVPNVEEILREHERISREL ERLSRRLKDLADKLERTRR SEQ ID NO: 266 DHD156 Heterodimer a DEDEVVKVHEEHVKSHEEIHRSHEEVVRAAEEDKRDSRELRTLMEEHRKLL EENEKSIEEVKKIHERVKR SEQ ID NO: 267 DHD156 Heterodimer b KKEELIDISKEVLDLDDEINKISKEILELIKKLLRLKEEGREDKDKAREVK RRIRELHRRIQELNKRLRELHKRVQETKR SEQ ID NO: 268 DHD157 Heterodimer a PEEDIARRVEDLLRKSEELIKESEKILKESKRLLDRNDSDKRVLETNLRLI DKHTKLLERNLELLEELLKLAEDVAK SEQ ID NO: 269 DHD157 Heterodimer b RFKDLSREYIEVVKRLLELSREALEVLREIKDTDKTDKKRIKELIDRLRKL IEEYKRIIDRLRKLSKDLEEEHR SEQ ID NO: 270 DHD158 Heterodimer a DEEELVKILKELQRLSEESLEINKRLVEILRLLRRGEVPKEEVEKKLREIK KEQEKLDREHEKIKKRIEEITK SEQ ID NO: 271 DHD158 Heterodimer b SLKEKILEIIERNMKLVELSNRSVEIVARILKGEKDDEETLERLLREWDKI TRDYEEIIKESRKLVKELEEEAK SEQ ID NO: 272 DHD159 Heterodimer a SKTEILRKALEIHKEQIDIVRKLIELSEEVLKLVEESKEKNLEKLKRIDEE TDRLLERLDELHKRLTELAERLK SEQ ID NO: 273 DHD159 Heterodimer b SDDEARKQLEEMKRRLREVEKKSKRVEERVRELERLVRENREDEDRVLKTL EDLLRENEKLVRTIERHVREQRELSKEVK SEQ ID NO: 274 DHD160 Heterodimer a SEEELEKKADELRKLSEEWRKLQEEDKRLSEMVEKGELDLQEVDEHSLRVL ERATEVHRTVDKVIEEILRTTN SEQ ID NO: 275 DHD160 Heterodimer b SEKERHRESQETQEEIRRTHEEIIRKLEEILRRAKAGELPEETLDRLRRIM ERLKELSERLDDLVRKLRDDHRREQK SEQ ID NO: 276 DHD161 Heterodimer a SEKEILEELKRILKRVKDISDRLEELDKRTEEIARREPTKELVDELVKIHR DWLRLHEEILKLVDDALKKVEDATK SEQ ID NO: 277 DHD161 Heterodimer b DLRELLELQREASRLHRELVKLLTELVKKLELIAKGEDIREEDLKRIKERL EEIKKRSKRIKEESDEIDKKTK SEQ ID NO: 278 DHD162 Heterodimer a SERELQRELNKIVRRILEIHREVSELHQRAVKLIRENDNSEELEEISRRIE ELSKELEKLVREHDEIVKTIE SEQ ID NO: 279 DHD162 Heterodimer b SEREKLDRNDEELKEINKRVEEIKERSDRITEAIEKNERSEEEIRRLSREQ NEALQRLLELHKKLVKLHRELLEDTR SEQ ID NO: 280 DHD163 Heterodimer a DKEDVIRVHDEQHKLIEEQLELTRRIAELVREIAKNTASEEEIKEMLKEIK RLDDRSREIQDRLQKLLEEIRRKTK SEQ ID NO: 281 DHD163 Heterodimer b TEEEIVELNKDIQRKSKEHIDLQNELVKKIERAIRENNITEELLEELERLL RESEKIVEEIRRITDKIRKDAK SEQ ID NO: 282 DHD164 Heterodimer a SEKEILERLLRLSKEQNEISEEIHRLTERLVELKRRKDDDERLKRILDRQK RLVERAREISKEYEDLLRKLE SEQ ID NO: 283 DHD164 Heterodimer b SMEELLRKNARLSRKQLKIIDEHLELSTKLTRGEAGDETLEEIERRSREML EEQRRVDEESKRIREKLK SEQ ID NO: 284 DHD165 Heterodimer a SEEEIRDIVEKLLRTHEEVLKEIKKLLDDSERVRRRELDKKDLDRIQKEQR DIQEENKEKAKRFDELVKELKKAAK SEQ ID NO: 285 DHD165 Heterodimer b SEEEHRRTMEKVEKEVRDIKRRSEEVKKKVKANTLSEEDLVRLLERLVEDH KRLQDLSQEIIERDEKATK SEQ ID NO: 286 DHD166 Heterodimer a DEDELAKEIEDVQRRNKESQEEHDKSVKKLEAAERGEIDEDSLLRVLEEDI KVLEKDIEVLERSIEVIEKAE SEQ ID NO: 287 DHD166 Heterodimer b SEKELIRRLLEQQRQHLRLSERLIELSRRLVEVVRKGKDNRDLLRELKKLS EEHKKHSKDDHEKVREIREREK SEQ ID NO: 288 DHS 17 Heterodimer a DRKDLLKRNIKLLDRHLKILDTILKLLEKLSELLKKSSSEEVVKEYKKILD EIRKLLEESKEIHKESKEILERES SEQ ID NO: 289 DHD17 Heterodimer b DEEKLIERSKRLQEESEQLLEKFEQILRELTELLEKPDSEELARKIKKLED ELRKIIKRNQELIREEEEILRKRD SEQ ID NO: 290

[0122] In one aspect, the monomer A polypeptide comprises a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of an odd-numbered SEQ ID NO selected from the group consisting of selected from the group SEQ ID NOS: 1-290; wherein GlySer at amino acids 1 and 2 of SEQ ID NO: 1, 55, 81, 83, 101, 105, 115, 117, 119, 121, 123, 125, 127, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, or 193 are optional, e.g., GlySer at amino acids 1 and 2 of SEQ ID NO: 1, 55, 81, 83, 101, 105, 115, 117, 119, 121, 123, 125, 127, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, or 193 are not present, and wherein the odd-numbered SEQ ID NO ("chain a") is the binding partner of the SEQ ID NO. ("chain b") in Tables 1A.

[0123] In another aspect, the monomer B polypeptide comprises a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of an even-numbered SEQ ID NO selected from the group consisting of selected from the group SEQ ID NOS: 1-290, wherein GlySer at amino acids 1 and 2 of SEQ ID NO: 6, 8, 14, 16, 26, 30, 32, 34, 36, 38, 40, 42, 46, 48, 54, 56, 58, 60, 62, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 176, 178, 180, 182, 184, 186, 188, 190, 192, or 194 are optional, e.g., GlySer at amino acids 1 and 2 of SEQ ID NO: 6, 8, 14, 16, 26, 30, 32, 34, 36, 38, 40, 42, 46, 48, 54, 56, 58, 60, 62, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 176, 178, 180, 182, 184, 186, 188, 190, 192, or 194 are not present, wherein the even-numbered SEQ ID NO ("chain b") is the binding partner of the SEQ ID NO. ("chain a") in Table 1A.

[0124] In another embodiment of any of the above embodiments,

[0125] (i) monomer A comprises a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of an odd-numbered SEQ ID NO selected from the group consisting of selected from the group SEQ ID NOS: 1-290, 331, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494; and

[0126] (ii) monomer B comprises a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of an even-numbered SEQ ID NO selected from the group consisting of selected from the group SEQ ID NOS: 1-290, 331, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494, wherein the even-numbered SEQ ID NO is the binding partner of the odd-numbered SEQ ID NO. in step (i).

[0127] The amino acid sequences of SEQ ID NOS: 1-290, 331, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494 are provided in Table 1B. The "binding partners" have similar design names as shown in Table 1B. For example, SEQ ID NO:1 (DHD9 A) and SEQ ID NO:2 (DHD9 B) are binding partners, and For example, SEQ ID NO:331 (DHD9 A) and SEQ ID NO:2 (DHD9 B) are binding partners, so that if monomer A comprises the polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:331, then monomer B comprises the polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of SEQ ID NO:2. Similarly, SEQ ID NOS:3-4 are binding partners, SEQ ID NO:5-6 and 5-332 are binding partners, etc. Those of skill in the art will clearly understand what is meant by binding partner based on the teachings herein.

TABLE-US-00002 TABLE 1B Design Oligomerization name State Chain Design sequence DHD9 Heterodimer a GSPKEEARELIRKQKELIKEQKKLIKEAKQKSDSRDAERIWKRSREINRES KKINKRIKELIKS SEQ ID NO: 1 PKEEARELIRKQKELIKEQKKLIKEAKQKSDSRDAERIWKRSREINRESKK INKRIKELIKS SEQ ID NO: 331 DHD9 Heterodimer b PKKEAEELAEESEELHDRSEKLHERAEQSSNSEEARKILEDIERISERIEE ISDRIERLLRS SEQ ID NO: 2 DHD13_ Heterodimer a GTKEDILERQRKIIERAQEIHRRQQEILEELERIIRKPGSSEEAMKRMLKL XAAA LEESLRLLKELLELSEESAQLLYEQR SEQ ID NO: 3 DHD13_ Heterodimer b GTEKRLLEEAERAHREQKEIIKKAQELERRLEEIVRQSGSSEEAKKEAKKI XAAA LEEIRELSKRSLELLREILYLSQEQKGSLVPR SEQ ID NO: 4 DHD13_ Heterodimer a TKEDILERQRKIIERAQEIIRRQQEILEELERIIRKPGSSEEAMKRMLKLL XAXA EESLRLLKELLELLEESAQLLYEQR SEQ ID NO: 5 DHD13_ Heterodimer b GSTEKRLLEEAERAHREAKEIIKKAQELERRLEEIVRQSGSSEEAKKEAKK XAXA ILEEIRELSKRLLELLREILYLSQEQK SEQ ID NO: 6 TEKRLLEEAERAHREAKEIIKKAQELERRLEEIVRQSGSSEEAKKEAKKIL EEIRELSKRLLELLREILYLSQEQK SEQ ID NO: 332 DHD13_ Heterodimer a TKEDILERARKIIERAQEIHRRQQEILEELERIIRKPGSSEEAMKRMLKLL XAAX EESLRLLKELLELSEELAQLLYEQR SEQ ID NO: 7 DHD13_ Heterodimer b GSTEKRLLEEAERAIREQKEIIKKAQELERRLEEIVRQSGSSEEAKKEAKK XAAX ILEEIRELSKRSLELLREILYLLQEQK SEQ ID NO: 8 TEKRLLEEAERAIREQKEIIKKAQELERRLEEIVRQSGSSEEAKKEAKKIL EEIRELSKRSLELLREILYLLQEQK SEQ ID NO: 334 DHD13_ Heterodimer a TKEDILERQRKIIERAQEIHRRQQEILEELEYIIR SEQ ID NO: 9 2:341 DHD13_ Heterodimer b MSEEAMKRMLKLLEESLRLLKELLELSEESAQLLYEQRKANNGSETEKRLL 2:341 EEAERAHREQKEIIKKAQELERRLEEIVRQSGSSEEAKKEAKKILEEIREL SKRSLELLREILYLSQEQK SEQ ID NO: 10 DHD13_ Heterodimer a MTKEDILERQRKIIERAQEIHRRQQEILKEQEKIIRKPGSSEEAMKRSLKL AAAA IEESLRLLKELLELSEESAQLLYEQR SEQ ID NO: 11 DHD13_ Heterodimer b GTEKRLLEEAERAHREQKEIIKKAQELHKELTKIHQQSGSSEEAKKRALKI AAAA SQEIRELSKRSLELLREILYLSQEQK SEQ ID NO: 12 DHD13_ Heterodimer a TKEDILERQRKIIERAQEIHRRQQEILKRSEEIIRKPGSSEEALETLRELQ BAAA EESLRLLKELLELSEESAQLLYEQR SEQ ID NO: 13 DHD13_ Heterodimer b GSTEKRLLEEAERAHREQKEIIKKAQELERRTEEIIRQSGSSEEAKDELRR BAAA IQEEIRELSKRSLELLREILYLSQEQK SEQ ID NO: 14 TEKRLLEEAERAHREQKEIIKKAQELERRTEEIIRQSGSSEEAKDELRRIQ EEIRELSKRSLELLREILYLSQEQK SEQ ID NO: 336 DHD13_ Heterodimer a TTKRYLEEAERAHREQKEIIKKAQELERRLEEIVRQ SEQ ID NO: 15 4:123 DHD13_ Heterodimer b GSSEEAKKEAKKILEEIRELSKRSLELLREILYLSQQVNDVDEKALERQRK 4:123 IIERAQEIHRRQQEILEELERIIRKPGSSEEAMKRMLKLLEESLRLLKELL ELSEESAQLLYEAR SEQ ID NO: 16 SEEAKKEAKKILEEIRELSKRSLELLREILYLSQQVNDVDEKALERQRKII ERAQEIHRRQQEILEELERIIRKPGSSEEAMKRMLKLLEESLRLLKELLEL SEESAQLLYEAR SEQ ID NO: 338 DHD13_ Heterodimer a EAMKRMLKLLEESLRLLKELLELSEESAQLLYEAR SEQ ID NO: 17 1:234 DHD13_ Heterodimer b TTKRYLEEAERAHREQKEIIKKAQELERRLEEIVRQSGSSEEAKKEAKKIL 1:234 EEIRELSKRSLELLREILYLSQQVNDVDEKALERQRKIIERAQEIHRRQQE ILEELERIIRKPGS SEQ ID NO: 18 DHD15 Heterodimer a TREELLRENIELAKEHIEIMREILELLQKMEELLEKARGADEDVAKTIKEL LRRLKEIIERNQRIAKEHEYIARERS SEQ ID NO: 19 DHD15 Heterodimer b GTERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLKKARGADEKVLDELRK IIERIRELLDRSRKIHERSEEIAYKEE SEQ ID NO: 20 DHD20 Heterodimer a GDRQELIRRNIELLKEHIKILEEISQLIEELSELLDKSSSEEVVKRYKKIL ERYKQLLRKSQEIHKESSEIAKKES SEQ ID NO: 21 DHD20 Heterodimer b GDEQKLIERSQRMQKESLELLKEIIKILDTIEKLLDKPDSEELLDTIKKLE DTLKKIHDRNKKLLKEHEEILRQRSGSLVPR SEQ ID NO: 22 DHD21 Heterodimer a DKEEEYKRLLDEIKEILKESKEVLKDSKRVLEDIKRKVPDDDLVKLLEKHV RLLEEFIVKLLEQLIREAEKSSK SEQ ID NO: 23 DHD21 Heterodimer b QGSSAEELLKKIKESEKKIRDSLRKIKEIIKKSRKEGVDDKQLDLIRKVVE SHRDLLRLIIRDLLRLLREETS SEQ ID NO: 24 DHD25 Heterodimer a DIDESIKEVEKLLEEVEQSLQKLDDSLKKLLEKVNQDPDVDDSVRKIVKRE VEILKRHEEVLKRLIEVVKEHTKTVK SEQ ID NO: 25 DHD25 Heterodimer b GSDREEVHKEIVKLIREIIKIHKKILKIHEKIKNGEIDPSEILKLSEEIKK LTDTIIKIIEDLEQLTRDLRR SEQ ID NO: 26 DREEVHKEIVKLIREIIKIHKKILKIHEKIKNGEIDPSEILKLSEEIKKLT DTIIKIIEDLEQLTRDLRR SEQ ID NO: 340 DHD27 Heterodimer a DRKEIVKREQKVVELLKESSKLLRESSKLLQRLLDKTGDENLQKAVDDQDK AIKRQETAIRKSQEASKKLD SEQ ID NO: 27 DHD27 Heterodimer b DNSEEIKKVAKTSREVAEYSERVAKENDKVVKTLEEGKIDESELLRLLEES IKIFDTALKLHEEAYKLIIQDLVRKVS SEQ ID NO: 28 DHD30 Heterodimer a DESEAASVAIESVQILVESVKLLEESVRILLDAVKKNGVEDLLRVAQRWEK LVDEWLKVVKRWLDNVRDIQR SEQ ID NO: 29 DHD30 Heterodimer b GSDKAEEVEKSVRKIEESIKKIRKSIKKAEDAVQLLKEGKIDAKDFLRIVR EDLEVVKEDVEIVKEDVENVREFSS SEQ ID NO: 30 DKAEEVEKSVRKIEESIKKIRKSIKKAEDAVQLLKEGKIDAKDFLRIVRED LEVVKEDVEIVKEDVENVREFSS SEQ ID NO: 342 DHD33 Heterodimer a SDKEVSDKLLKASKKLLKVSEELLEVVRRLLKALKDDELIKKIADLLRKII DKDKKFIRTSEEIVKESR SEQ ID NO: 31 DHD33 Heterodimer b GSDLKEVLKTVEEAVKEIIKSSEELLQISRKILEISRVGVDEHEYISAIRE YLKALEKHIQILKKFIEILKELIRAVS SEQ ID NO: 32 DLKEVLKTVEEAVKEIIKSSEELLQISRKILEISRVGVDEHEYISAIREYL KALEKHIQILKKFIEILKELIRAVS SEQ ID NO: 344 DHD34_ Heterodimer a SKEEIDKIVKKHKKKIEEEKKKVDELKKLVEEHDKRVSQDKDDKVKKLSEE XAAXA VKKIIKRLEEVSKRLEEVSKKLLKVISDKR SEQ ID NO: 33 DHD34_ Heterodimer b GSNDEELKKILETLDRILKKLDKILTRLIEVLKKSEDPNLDDKDYTELVKQ XAAXA FIELIKKYEEVVKEYEEVVRQLIRLFS SEQ ID NO: 34 NDEELKKILETLDRILKKLDKILTRLIEVLKKSEDPNLDDKDYTELVKQFI ELIKKYEEVVKEYEEVVRQLIRLFS SEQ ID NO: 346 DHD34_ Heterodimer a SKEEIDKIVKKHKKKIEELKKLVDELKKLVEEHDKRVSQDKDDKVKKLSEE XAXXA VKKIIKRVEEVAKRLEEVSKKLLKVISDKR SEQ ID NO: 35 DHD34_ Heterodimer b GSNDEELKKILETLDRILKKLEKILTRLIEVLKKSEDPNLDDKDYTELVKQ XAXXA FIELIKKFEEVIKEYEEVVRQLIRLFS SEQ ID NO: 36 NDEELKKILETLDRILKKLEKILTRLIEVLKKSEDPNLDDKDYTELVKQFI ELIKKFEEVIKEYEEVVRQLIRLFS SEQ ID NO: 348 DHD34_ Heterodimer a SKEEIDKIVKKHKKKIEEEKKKVDEHKKLVEEHDKRVSQDKDDKVKKLSEE XAAAA LKKISKRLEEVSKRLEEVSKKLLKVISDKR SEQ ID NO: 37 DHD34_ Heterodimer b GSNDEELKKILETLDRILKKLDKILTRLDEVLKKSEDPNLDDKDYTELVKQ XAAAA YIELVKKYEEVVKEYEEVVRQLIRLFS SEQ ID NO: 38 NDEELKKILETLDRILKKLDKILTRLDEVLKKSEDPNLDDKDYTELVKQYI ELVKKYEEVVKEYEEVVRQLIRLFS SEQ ID NO: 418 DHD36 Heterodimer a DESRKLKEILDRLRKHVKRLKEHLDELRDLVRQVPEDKLLEHVVKLSDKIL QISERAVREFTKSVDKDS SEQ ID NO: 39 DHD36 Heterodimer b GSDKKDELERILDEIRRLIERLDEILSRLNKLLELLKHGVPNAKEVVKDYI RLLKEYLELVKEFLKLVKREADLVS SEQ ID NO: 40 DKKDELERILDEIRRLIERLDEILSRLNKLLELLKHGVPNAKEVVKDYIRL LKEYLELVKEFLKLVKREADLVS SEQ ID NO: 350 DHD37_ Heterodimer a DSDEHLKKLKTFLENLRRELDRLDKHIKQLRDILSENPEDERVKDVIDLSE ABXB RSVRIVKTVIKIFEDSVRKKE SEQ ID NO: 41 DHD37_ Heterodimer b GSDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVE ABXB LLKREEKAVKELLEIAKTHAKKVE SEQ ID NO: 42 DDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELL KREEKAVKELLEIAKTHAKKVE SEQ ID NO: 352 DHD37_ Heterodimer a MDEEDELKKLKTELEKLERELKLLEDEAKKLEDILKERPEDSAVKESIDEL BBBB RRSIELVRESIEIFRQSVEEEE SEQ ID NO: 43 DHD37_ Heterodimer b GDVKELTKILDTLTKILETATKVIKDATKLLEEERKSDKPDPRLIETHKKL BBBB VEEHETLVRQIIKELAEEHLKRTR SEQ ID NO: 44 DHD37_ Heterodimer a DSDEHLKKLKTFLENLRRELDRLDKLLKELRDILSENPEDERVKDVIDELE XBXB RVIRIVKTVIKIFEDSVRKKE SEQ ID NO: 45 DHD37_ Heterodimer b GSDDKELDKLLDTLEKILQTATKIIDDLNKVLEKLRRSERKDPKVIETVVE XBXB LLKREEKAVKELLEIAKTHAKKVE SEQ ID NO: 46 DDKELDKLLDTLEKILQTATKIIDDLNKVLEKLRRSERKDPKVIETVVELL KREEKAVKELLEIAKTHAKKVE SEQ ID NO: 354 DHD37_ Heterodimer a DSDEHLKKLKTFLENLRRLEDLLDKHIKQLRDILSENPEDERVKDVIDLSE AXXB RVVRTVKTVIKIFEDSVRKKE SEQ ID NO: 47 DHD37_ Heterodimer b GSDDKELDKLLDTLEKILQTATKVVDDANKLLEKLRRSERKDPKVVETYVE AXXB LLKRLEKLIKELLEIAKTEAKKVE SEQ ID NO: 48 DDKELDKLLDTLEKILQTATKVVDDANKLLEKLRRSERKDPKVVETYVELL KRLEKLIKELLEIAKTEAKKVE SEQ ID NO: 356 DHD37_ Heterodimer a DSDEHLKKLKTFLENLRRELDRLDKIIIKQLRDILSEN SEQ ID NO: 49 3:124 DHD37_ Heterodimer b EDERVKDVIDLSERSVRIVKTVIKIFEDSVRKLEKTKPDSKTAKELDKLLD 3:124 TLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKREEKAVKEL LEIAKTEAKKVE SEQ ID NO: 50 DHD37_ Heterodimer a DSDEHLYKLKTFLENLRRELDRLDKHIKQLRDILSENPEDERVKDAIDLSE 1:234 RSVRIVKTVIKIFEDSVRKKEKRPIDKRDDKELDKLLDTLEKILQTATKII DDANKLLEYLRR SEQ ID NO: 51 DHD37_ Heterodimer b GDPKVVETYVELLKREEKAVKELLEIAKTEAKKVE SEQ ID NO: 52 1:234 DHD37_ Heterodimer a DSDEHLDRLDKHLKKLKTFLENLRRHIKQLRDILSENPEDERVKDVIDLSK AXBB TVIKIFEDSVRKKERSVRIVE SEQ ID NO: 53 DHD37_ Heterodimer b GSDDKEATKIIDDLDKLLDTLEKILQTANKLLEKLRRSERKDPKVVETYVK AXBB AVKELLEIAKTHAELLKREEKKVE SEQ ID NO: 54 DDKEATKIIDDLDKLLDTLEKILQTANKLLEKLRRSERKDPKVVETYVKAV KELLEIAKTHAELLKREEKKVE SEQ ID NO: 358 DHD37_ Heterodimer a DSDEHIKQLRDHLDRLDKELKKLKTFLENLRRILSENPEDERVKTVIKIFE XBBA DSVRKKERSVRIVKDVIDLSE SEQ ID NO: 55 DHD37_ Heterodimer b GSDDKEANKLLEKATKIIDDLDKLLDTLEKILQTLRRSERKDPKAVKELLE XBBA IAKTHAELLKREEKVVETYVKKVE SEQ ID NO: 56 DDKEANKLLEKATKIIDDLDKLLDTLEKILQTLRRSERKDPKAVKELLEIA KTHAELLKREEKVVETYVKKVE SEQ ID NO: 360 DHD39 Heterodimer a DHSRKLEEILDRLRKHVKRLLEHLRELLSLVKENPEDKDLVEVLELSLAIL RRSLEAVEAFLKSVTKKDPDDEDLRRKADEIRKEVEEIKKSLAEVEKEIYK LK SEQ ID NO: 57 DHD39 Heterodimer b GSSADDVLEDILKIIRELIEILDQILSLLNQLLKLLREGVPNAKKVVEKYK EILELYLQLVSLFLKIVKTHADAVSGKIDKKAEEEIKKEEEKIKEKLRQAK DILKKLQEEIDKTR SEQ ID NO: 58 SADDVLEDILKIIRELIEILDQILSLLNQLLKLLREGVPNAKKVVEKYKEI LELYLQLVSLFLKIVKTEADAVSGKIDKKAEEEIKKEEEKIKEKLRQAKDI LKKLQEEIDKTR SEQ ID NO: 362 DHD40 Heterodimer a DRDAHLYKLLTFLEQLVRELDRLVKHITQLRDIVKKDPEDERAVDVIRQSV RSLEIVITVLKIFVDSVSDAARSKEAEKIVRKIRKEIDEIRQKLREIDKEV KKTTS SEQ ID NO: 59 DHD40 Heterodimer b GSNDKVLDKILDILDRILRLATRVIDLANKLLQVKKKSTEKDPRIVETYKE LLKIHETAVRLLLELADLERRLKSKDEEANKRVETELDRIRKKVKDIEDKV RKLEDKVRKTAS SEQ ID NO: 60 NDKVLDKILDILDRILRLATRVIDLANKLLQVKKKSTEKDPRIVETYKELL KIHETAVRLLLELADLERRLKSKDEEANKRVETELDRIRKKVKDIEDKVRK LEDKVRKTAS SEQ ID NO: 364 DHD43 Heterodimer a NDLSKEVLKKLEKSVEELLRRVQKSVKEAQKRGLLSDELVDRELKILNQLV KRELELLQEVIKRSDKK SEQ ID NO: 61 DHD43 Heterodimer b GSDEAVKRVVEKSLKILDEVIKKSLDILRELIELQIREAKDDESVIRASKS ALKDAIEALKKSLDEIKKALKRSADEG SEQ ID NO: 62 DEAVKRVVEKSLKILDEVIKKSLDILRELIELQIREAKDDESVIRASKSAL KDAIEALKKSLDEIKKALKRSADEG SEQ ID NO: 366 DHD65 Heterodimer a SSEEVVKVHEKVVKLHKEILELLKKIIKIHETAARDPDDKDSIKKLSDEIK KIVKRIEDISDQAKRESSDAQRKQS SEQ ID NO: 63 DHD65 Heterodimer b DKEEESKELLKKLKEILKRSEELLEESKELLKLAKNGEIDESELADADRKL NKKEEKLVQDIQDLLREHERQDR SEQ ID NO: 64 DHD70 Heterodimer a DEKKKIDKIVKETEDLLQKSEKLLQQSKEAVKRIRSQVKENEIVDRLLRIS

EELLKISRRLVEISRRIASTLS SEQ ID NO: 65 DHD70 Heterodimer b GSSKEEVIRLLKENVRLIKENLELLTRNLKLITDLVRGSNGSEEKIKTLKE LLKEYRELLKRYRKLVEDYKRLVDKED SEQ ID NO: 66 SKEEVIRLLKENVRLIKENLELLTRNLKLITDLVRGSNGSEEKIKTLKELL KEYRELLKRYRKLVEDYKRLVDKED SEQ ID NO: 368 DHD88 Heterodimer a EIQELIKSSRRIIEESKELIKESEEVLRRIKEILDRIRNGVDNQEDLLREI LKLLTKNLKIIQRNLKLLQDNAEILKRLVS SEQ ID NO: 67 DHD88 Heterodimer b GSYIEDVIKKILDVSRELIKLSRTIIKISEEINKQLQQGRDTKDLVKKYDE IIKKYTRIVQHYTELIKELQKLLS SEQ ID NO: 68 YIEDVIKKILDVSRELIKLSRTIIKISEEINKQLQQGRDTKDLVKKYDEII KKYTRIVQHYTELIKELQKLLS SEQ ID NO: 370 DHD89 Heterodimer a SPTEEAIQLSQRVIELSKRVIELSKEILKLLKRVLDLLPDLDKNEEKRLDD YDKELKEYDKELKKYEKRLKDLAS SEQ ID NO: 69 DHD89 Heterodimer b GSEEEEILKIQKELLRIQSEILDKQKKILDTLRSNGAVTEEVRSILEKVER LSEEAKELSKEAKELTKEVSKLIS SEQ ID NO: 70 EEEEILKIQKELLRIQSEILDKQKKILDTLRSNGAVTEEVRSILEKVERLS EEAKELSKEAKELTKEVSKLIS SEQ ID NO: 372 DHD90 Heterodimer a SPLKELNNQLLRLLRELVKVSKKIVDLSKTIIEVLKETDLDPRLLDSLEKS QQELDKSQKELDKVVKELTKVNKKLQ SEQ ID NO: 71 DHD90 Heterodimer b GSPLEDLVRKYDELVKTYEKLVEEFKKAVDKYDKAVKKAPVSKEATDSLDL IRKVLELLDRNLKLIKENAKLIKELLK SEQ ID NO: 72 PLEDLVRKYDELVKTYEKLVEEFKKAVDKYDKAVKKAPVSKEATDSLDLIR KVLELLDRNLKLIKENAKLIKELLK SEQ ID NO: 374 DHD91 Heterodimer a SPTRENEKVIKENEKVISDNERVLEEVVKVVETATDRKEIQDAVDEVRKSV DKLRDSVRKLEESVRTLD SEQ ID NO: 73 DHD91 Heterodimer b GSPIKDISKRLLEISKRLVEISDRIVELLQRIADSKDPNKDLQKEVKDVLE EYKRLVREYREVVKEYEKVVS SEQ ID NO: 74 PIKDISKRLLEISKRLVEISDRIVELLQRIADSKDPNKDLQKEVKDVLEEY KRLVREYREVVKEYEKVVS SEQ ID NO: 376 DHD92 Heterodimer a DEDEHVKQLIKNADLLRKHAELLKELVKLFQEIASQIPDDRVAKKVTDVVD RIDKILKQTEKLVRRTKQILDYSR SEQ ID NO: 75 DHD92 Heterodimer b GSNLEELVKLLKEVLEMHERLLRIHEDLVEAHKSNASDKESERKLKKSDKD IKESLKKIKSIIDQVRYIQS SEQ ID NO: 76 NLEELVKLLKEVLEMHERLLRIHEDLVEAHKSNASDKESERKLKKSDKDIK ESLKKIKSIIDQVRYIQS SEQ ID NO: 378 DHD93 Heterodimer a PVEDIIEESLRLLEESLKLLNRILKLLEDSLRKLPRSEEWRQRLDEFRKKL EDWKEELERWIEDVRYKKT SEQ ID NO: 77 DHD93 Heterodimer b GSDEDYESREIIDEIRKLLDRSKKIVERSQRLVERVKSTPLSEDQEDLIRR HEETINRIIRELVKELEKVLEDHERHIR SEQ ID NO: 78 DEDYESREIIDEIRKLLDRSKKIVERSQRLVERVKSTPLSEDQEDLIRRHE ETINRIIRELVKELEKVLEDHERHIR SEQ ID NO: 380 DHD94 Heterodimer a PEEDSRRVLERFVRVSREVLKVLEEFLRVSEELLREADRDRDRRLEEYERQ VDELREEIRRYKEEVDKFDKEVKYYKK SEQ ID NO: 79 DHD94 Heterodimer b GSPEKDENRKLLDKVRKLVEKSRRLVEELRKLVDQSTKNGLIDEKALRKQQ EVLRKVEEVLEKQERVLRELEEISYRVI SEQ ID NO: 80 PEKDENRKLLDKVRKLVEKSRRLVEELRKLVDQSTKNGLIDEKALRKQQEV LRKVEEVLEKQERVLRELEEISYRVI SEQ ID NO: 382 DHD94_ Heterodimer a GSPERDENRKLLDKVRKLVEKSRRLVEELRKLVDQSTKN SEQ ID 3:214 NO: 81 PERDENRKLLDKVRKLVEKSRRLVEELRKLVDQSTKN SEQ ID NO: 337 DHD94_ Heterodimer b GSDEKALRKQQEVLRKVEEVLEKQERVLRELEEISYRVITRGEDHKAEEDS 3:214 RRVLERFVRVSREVLKVLEEFLRVSEELLREADRDRDRRLEEYERQVDELR EEIRRYKEEVDKFDKEVKYYKK SEQ ID NO: 82 DEKALRKQQEVLRKVEEVLEKQERVLRELEEISYRVITRGEDHKAEEDSRR VLERFVRVSREVLKVLEEFLRVSEELLREADRDRDRRLEEYERQVDELREE IRRYKEEVDKFDKEVKYYKK SEQ ID NO: 384 DHD94_ Heterodimer a GSDRRLEEYERQVDELREEIRRYKEEVDKFDKEVKYYKK SEQ ID 2:143 NO: 83 DRRLEEYERQVDELREEIRRYKEEVDKFDKEVKYYKK SEQ ID NO: 339 DHD94_ Heterodimer b GSPERDENRKLLDKVRKLVEKSRRLVEELRKLVDQSTKNGLIDEKALRKQQ 2143 EVLRKVEEVLEKQERVLRELEEISYRVITRGEDHKAEEDSRRVLERFVRVS REVLKVLEEFLRVSEELLREADR SEQ ID NO: 84 PERDENRKLLDKVRKLVEKSRRLVEELRKLVDQSTKNGLIDEKALRKQQEV LRKVEEVLEKQERVLRELEEISYRVITRGEDHKAEEDSRRVLERFVRVSRE VLKVLEEFLRVSEELLREADR SEQ ID NO: 386 DHD95 Heterodimer a DLSEESKKFVEKVKKLEKESRELEKQVKKIEEDSRSVENDVQKEFLELLKR LLDIQKKVVEVLREVVKVQQYVDS SEQ ID NO: 85 DHD95 Heterodimer b GSDSEYESRQVLRELDTVLKDSETVLEALRQVIRDSQDVVSKSDEESRRVI DDLEKVIQDSKKVLDDIKRLIDKSKSIKS SEQ ID NO: 86 DSEYESRQVLRELDTVLKDSETVLEALRQVIRDSQDVVSKSDEESRRVIDD LEKVIQDSKKVLDDIKRLIDKSKSIKS SEQ ID NO: 388 DHD96 Heterodimer a NEDELLKLLTENLKLLDENLKLLRENLSLLRQANNITDKNRIREIVKQSKE IVKQSREILKQSKEIVERIKYIVS SEQ ID NO: 87 DHD96 Heterodimer b GSSLYELTQRYEKLVQQYEELVKDYRRLVKKLEKLKRDNKPDKRLLKEIVD VIKKSVEIIDRSLKLLEESIKILEETD SEQ ID NO: 88 SLYELTQRYEKLVQQYEELVKDYRRLVKKLEKLKRDNKPDKRLLKEIVDVI KKSVEIIDRSLKLLEESIKILEETD SEQ ID NO: 390 DHD97 Heterodimer a SQERSLEILKRILDVLKESLEILKESLSILRQLASRIKNPNRKIEEILKES DKIIKESDKVLKEIEEVIRYSS SEQ ID NO: 89 DHD97 Heterodimer b GSDIEYESKEILELIKELLKLSRELLKESRRALELVRKSRDDSIVEEVIQV IIKKVLDIFIKEVLKIVRKVVEVERRVKS SEQ ID NO: 90 DIEYESKEILELIKELLKLSRELLKESRRALELVRKSRDDSIVEEVIQVHK KVLDIFIKEVLKIVRKVVEVERRVKS SEQ ID NO: 392 DHD98 Heterodimer a SKKDESTKLERLAEKIDEITKRIEELVKDVKRKSSEGVDKDQQQKIDEVFQ KLLDLQREILEILDRILKVQQYILD SEQ ID NO: 91 DHD98 Heterodimer b GSDLEYLNRRLLQLIKTLIDLNRELLKLIDKLKKLNSREGDEEKIKEESKQ IQEQFKEIVERSKEIIKQIKEIIKRSQ SEQ ID NO: 92 DLEYLNRRLLQLIKTLIDLNRELLKLIDKLKKLNSREGDEEKIKEESKQIQ EQFKEIVERSKEIIKQIKEIIKRSQ SEQ ID NO: 394 DHD99 Heterodimer a DFERSSRRLEKVVEDLRRSSDRLREVIDELRKSADEKDEDEDLRRARKEHR DLIEELKRALEKQEEIIKELQELVYRQL SEQ ID NO: 93 DHD99 Heterodimer b GSEESEEVRKVVERIKKISRELEEVVKELDRVSKEFDREGETDEIVREHER IVEKLEEIVKKETKIVEELAEIVYKQQ SEQ ID NO: 94 EESEEVRKVVERIKKISRELEEVVKELDRVSKEFDREGETDEIVREHERIV EKLEEIVKKETKIVEELAEIVYKQQ SEQ ID NO: 396 DHD100 Heterodimer a SDDDSVRVLDEIVKILDESVKLLKESLKLLDDFLRTKPDDHLKEVVKESKK VVEQSKKVLDRIKKIIYESK SEQ ID NO: 95 DHD100 Heterodimer b GSDLLYLSKELLKLVRELLKLSRELVELSRRLVNSTEKSPELVKKYDKLVK KYQDLLKKLADVADEYLRQRS SEQ ID NO: 96 DLLYLSKELLKLVRELLKLSRELVELSRRLVNSTEKSPELVKKYDKLVKKY QDLLKKLADVADEYLRQRS SEQ ID NO: 398 DHD101 Heterodimer a DEKDYERRLIEHLEDLVRRHEELIKRQKKVVEELERRGLDERLRRVVDRFR RSSERWEEVIERFRQVVDKLRKSVE SEQ ID NO: 97 DHD101 Heterodimer b GSDAYDLDRIVKEHRRLVEEQRELVEELEKLVRRQEDERVDKKESHEILER LERIIRRSTRILTELEKLTDEFERRTR SEQ ID NO: 98 DAYDLDRIVKEHRRLVEEQRELVEELEKLVRRQEDERVDKKESHEILERLE RIIRRSTRILTELEKLTDEFERRTR SEQ ID NO: 400 DHD102 Heterodimer a DERYRAREHIRRVEEHTKRLRHILKRLREHEEKLRRELKPGDEITESVDRF KKIVDQFEESIKKFETVSEELRKSDS SEQ ID NO: 99 DHD102 Heterodimer b GSDRQRILDRLDKILEKLDDILKKLKDILETLSKDDVSDRRHKDLVEKFRE LVDTHEKLVERYRELVYQNR SEQ ID NO: 100 DRQRILDRLDKILEKLDDILKKLKDILETLSKDDVSDRRHKDLVEKFRELV DTHEKLVERYRELVYQNR SEQ ID NO: 402 DHD102_ Heterodimer a GSDEITESVDRFKKIVDQFEESIKKFETVSEELRKSIS SEQ ID 1:243 NO: 101 DEITESVDRFKKIVDQFEESIKKFETVSEELRKSIS SEQ ID NO: 341 DHD102_ Heterodimer b GSDPQRAADRLDKILEKLDDILKKLKDILETLSKDDVKDRRAKDLVEKFRE 1:243 LVDTHEKLVERYRELVYTATAGSDLARELIRRVEEHTKRLRHILKRLREHE EKLRR SEQ ID NO: 102 DPQRAADRLDKILEKLDDILKKLKDILETLSKDDVKDRRAKDLVEKFRELV DTHEKLVERYRELVYTATAGSDLARELIRRVEEHTKRLRHILKRLREHEEK LRR SEQ ID NO: 404 DHD103 Heterodimer a NADDQLATSIKKLEDSIDQLIKIVRKFEESVKKLQKHGVDQHHVEILRKIV EIFRQHIEKLKKELEKLRYTSS SEQ ID NO: 103 DHD103 Heterodimer b GSDKEYLVTEHEKLVREHEKIVSEIEKLVKKHEAGVDESELEEILKKVEKL LRKLDEILEQLTQLLRKTE SEQ ID NO: 104 DKEYLVTEHEKLVREHEKIVSEIEKLVKKHEAGVDESELEEILKKVEKLLR KLDEILEQLTQLLRKTE SEQ ID NO: 406 DHD103_ Heterodimer a GSDQHVVEILRKIVEIFRQHIEKLKKELEKLRYTSS SEQ ID NO: 105 1:423 DQHVVEILRKIVEIFRQHIEKLKKELEKLRYTSS SEQ ID NO: 343 DHD103_ Heterodimer b GSDAEYLVTEHEKLVREHEKIVSEIEKLVKKEEKGVDESELEEILKKVEKL 1:423 LRKLDEILEQLTQLLRKAEKHIDKHSKAADQLATSIKKLEDSIDQLIKIVR KFEESVKKLQKH SEQ ID NO: 106 DAEYLVTEHEKLVREHEKIVSEIEKLVKKEEKGVDESELEEILKKVEKLLR KLDEILEQLTQLLRKAEKHIDKHSKAADQLATSIKKLEDSIDQLIKIVRKF EESVKKLQKH SEQ ID NO: 408 DHD104 Heterodimer a DEDDDIRRVLDESRRVLEHSRRVLKRSEEVLEKASRKKEKDTEEIEKELKR LREEAKKLEKERRELDDFLYKEI SEQ ID NO: 107 DHD104 Heterodimer b GSRDKYLLERLNDILKKLDEIVDKLSDILKRLKDVREDDRLQELVERYKEI VKEYKRIVEEYEKLVREFEEQQR SEQ ID NO: 108 RDKYLLERLNDILKKLDEIVDKLSDILKRLKDVREDDRLQELVERYKEIVK EYKRIVEEYEKLVREFEEQQR SEQ ID NO: 410 DHD105 Heterodimer a DRDYEDKEFKKIIKELEDVQEELKKLQEKIKRFSSELEEPNELLKEQLKVN EEQLEVNKKILKILRDQLKQNE SEQ ID NO: 109 DHD105 Heterodimer b GSDAEYKVRESVKRSKESVKHSEDVVDKLNKSVKLSESGESDAEKASRELV KLVREVVELSREVIKLSEKVLRVIS SEQ ID NO: 110 DAEYKVRESVKRSKESVKHSEDVVDKLNKSVKLSESGESDAEKASRELVKL VREVVELSREVIKLSEKVLRVIS SEQ ID NO: 412 DHD106 Heterodimer a DLQYKQEKLIREFDRVVREWDKLVRKFSKVLEKQKHESKDKELEEASRRVD ELIKRLREQLKRSKEILRRLKELSRKSS SEQ ID NO: 111 DHD106 Heterodimer b GSDWEELLRRLEKVLQEYEEIVKELIDLIERLIKVSEDKSKDASEYKKLVT ELEKLISKLEEISKKLEELVKEYEYKTE SEQ ID NO: 112 DWEELLRRLEKVLQEYEEIVKELIDLIERLIKVSEDKSKDASEYKKLVTEL EKLISKLEEISKKLEELVKEYEYKTE SEQ ID NO: 414 DHD107 Heterodimer a DAKDELEKSLQEIEESLKELKKLLEELDKSLRELTSQGRNKKLEEHIKKVQ KFIELVKKYIKAVQDYLKEVRYDNS SEQ ID NO: 113 DHD107 Heterodimer b GSDKERAARATEEMVKLTKKLLKAVEDLVRDVRRLLKEGLISEKHARIAET ILEVFKKHAKIIKKEVDIVKYDES SEQ ID NO: 114 DKERAARATEEMVKLTKKLLKAVEDLVRDVRRLLKEGLISEKHARIAETIL EVFKKHAKIIKKEVDIVKYDES SEQ ID NO: 416 DHD108 Heterodimer a GSPLKERLLEIQRDLDRVLEEVVERLLRIQERLDSVVERKPPDVHEEYKYI VDEIREIVERVVREYEEIVKRIDEEVR SEQ ID NO: 115 PLKERLLEIQRDLDRVLEEVVERLLRIQERLDSVVERKPPDVHEEYKYIVD EIREIVERVVREYEEIVKRIDEEVR SEQ ID NO: 459 DHD108 Heterodimer b GSEEDERIRYDLDRIRKDVRRKLEEIRQRVRELEKKLRDAGERRDEKELLR ELIETSKDILRLVEELLKKIIDKSEDLLRKTE SEQ ID NO: 116 EEDERIRYDLDRIRKDVRRKLEEIRQRVRELEKKLRDAGERRDEKELLREL IETSKDILRLVEELLKKIIDKSEDLLRKTE SEQ ID NO: 420 DHD109 Heterodimer a GSDEEDYINENVEKDVRDIEDDVRRINERIRELLEKIRTEEVLQRVLEEHE ELVERVLRKLVEILRKHEEENR SEQ ID NO: 117 DEEDYINENVEKDVRDIEDDVRRINERIRELLEKIRTEEVLQRVLEEHHEL VERVLRKLVEILRKHEEENR SEQ ID NO: 345 DHD109 Heterodimer b GSDEEEYYKEKLHKLLREIEELLKHYRELVRRLEELVKRGELDKDTAAHIL ERLSELLERIIRRVAHTLRRLSEERR SEQ ID NO: 118 DEEEYYKEKLEKLLREIEELLKHYRELVRRLEELVKRGELDKDTAAHILER LSELLERIIRRVAHTLRRLSEERR SEQ ID NO: 422 DHD110 Heterodimer a GSDEDEISYDSKRRVEEIVRQAREKSEKSRKDIEDVAEVLRKGDVSEKEVV DELVKVLEEQVKVLREAVERLREVLKKQVDDVR SEQ ID NO: 119 DEDEISYDSKRRVEEIVRQAREKSEKSRKDIEDVAEVLRKGDVSEKEVVDE LVKVLEEQVKVLREAVERLREVLKKQVDDVR SEQ ID NO: 347 DHD110 Heterodimer b GSDIVELVDELLKRSLKLLEELAELVRRLLEKSTELLKRRTEEHKEEVVEE SEYMVRELEERLRRVVDESEKLVRDADKIIIR SEQ ID NO: 120 DIVELVDELLKRSLKLLEELAELVRRLLEKSTELLKRRTEEHKEEVVEESE YMVRELEERLRRVVDESEKLVRDADKIIIR SEQ ID NO: 424 DHD111 Heterodimer a GSKEKDIVKTLVDLLRENLETLERLIEEVVRLLKENVDVRDEGRDDKDSER ILRDIKRRIDEAAKESREIIERIEKEVEYRSR SEQ ID NO: 121 KEKDIVKTLVDLLRENLETLERLIEEVVRLLKENVDVRDEGRDDKDSERIL RDIKRRIDEAAKESREIIERIEKEVEYRSR SEQ ID NO: 349 DHD111 Heterodimer b GSPEVDVLRRIVREILKASEELLRLLRKLIDEALKLSERKRDSQEYREVVD RVKKELERLLDEYRKLVEELKEKLRYDTR SEQ ID NO: 122 PEVDVLRRIVREILKASEELLRLLRKLIDEALKLSERKRDSQEYREVVDRV KKELERLLDEYRKLVEELKEKLRYDTR SEQ ID NO: 426

DHD112 Heterodimer a GSDKRYHSEKLKRRLDEAVEKVREVVERVERESDRVLEEVRRRRESKEVVD KVIEDNDKALEDVLRVVDEVAKVVRDVVRENTR SEQ ID NO: 123 DKRYESEKLKRRLDEAVEKVREVVERVERESDRVLEEVRRRRESKEVVDKV IEDNDKALEDVLRVVDEVAKVVRDVVRENTR SEQ ID NO: 351 DHD112 Heterodimer b GSPREYHSKDILRKVDEILERIRRHADRVKKKSERLKRENVDVNEHSKDVK RVIRELLELVKELLRLAKKESDDQQE SEQ ID NO: 124 PREYESKDILRKVDEILERIRREADRVKKKSERLKRENVDVNEHSKDVKRV IRELLELVKELLRLAKKESDDQQE SEQ ID NO: 428 DHD113 Heterodimer a GSDEDEILYESERLLQKLKKELDDLKEKSRELLEELKKEDPDDRLIERIIR LEDEVLKDLDEVLKNILEVEREVLERLR SEQ ID NO: 125 DEDEILYESERLLQKLKKELDDLKEKSRELLEELKKEDPDDRLIERIIRLH DEVLKDLDEVLKNILEVEREVLERLR SEQ ID NO: 353 DHD113 Heterodimer b DKLDRLLKIHEEALRRAEELIKRLLDIERRALDLARRGELDDYLLKESERE LREIIRRAREELKESRDRLEEISR SEQ ID NO: 126 DHD114 Heterodimer a GSPKEELIRRVLEEVKRLNEKLLEIIRRAAELVKRANDELPETEKLREIDR ELEKKLKEIEDELRRIDKELDDALYEIED SEQ ID NO: 127 PKEELIRRVLEEVKRLNEKLLEIIRRAAELVKRANDELPETEKLREIDREL EKKLKEIEDELRRIDKELDDALYEIED SEQ ID NO: 355 DHD114 Heterodimer b GSPKLDKLRELLERNLEKLREILEEVLKILRTNLERVREDIRDEDVLQEYE RLIRKAEEDLRRVLKEYDDLLKKLVYELR SEQ ID NO: 128 PKLDKLRELLERNLEKLREILEEVLKILRTNLERVREDIRDEDVLQEYERL IRKAEEDLRRVLKEYDDLLKKLVYELR SEQ ID NO: 430 DHD115 Heterodimer a GSKEDESVKRAEEIVRTLLKLLEDSLREAERSLRDIKNGEDEHNLRRISEK LEELSKRITETIERLLRELQYTSR SEQ ID NO: 129 KEDESVKRAEEIVRTLLKLLEDSLREAERSLRDIKNGEDEHNLRRISEKLE ELSKRITETIERLLRELQYTSR SEQ ID NO: 357 DHD115 Heterodimer b GSPNQELLDRVRKILEDLLRLNEELVRLNKELLKRALEMRRKNRDSEEVLE RLAEEYRKRLEEYRRELEKLLEELEETIYRYKR SEQ ID NO: 130 PNQELLDRVRKILEDLLRLNEELVRLNKELLKRALEMRRKNRDSEEVLERL AEEYRKRLEEYRRELEKLLEELEETIYRYKR SEQ ID NO: 432 DHD116 Heterodimer a GSDESEEAQHEVEKVLDDIRRLSEHLQKRLEEVLEEVYELRREGSDRTEVV ELLKEVIREIVRVNREALERLLRVVEEAVKRNE SEQ ID NO: 131 DESEEAQHEVEKVLDDIRRLSEHLQKRLEEVLEEVYELRREGSDRTEVVEL LKEVIREIVRVNREALERLLRVVEEAVKRNE SEQ ID NO: 359 DHD116 Heterodimer b GSDEEELVETVKRIQKEILDRLTELAKLLVEIQREIKKLKDEGEDDKELKR LSDELEEKVRQVVEEIKRLSDELEETVEYVSR SEQ ID NO: 132 DEEELVETVKRIQKEILDRLTELAKLLVEIQREIKKLKDEGEDDKELKRLS DELEEKVRQVVEEIKRLSDELEETVEYVSR SEQ ID NO: 434 DHD117 Heterodimer a GSDEEEEVVRRAEELVKEHEELIERVIRTHEELVYKLEDQGADKKLVDVLK RVVEESERVAREIVKVSRELIRLLEEASR SEQ ID NO: 133 DEEEEVVRRAEELVKEHEELIERVIRTHEELVYKLEDQGADKKLVDVLKRV VEESERVAREIVKVSRELIRLLEEASR SEQ ID NO: 361 DHD117 Heterodimer b GSSKEEILKELEDLQRRLIEELKKLQERVVELLEELIKRLRDRGRDDKELK RLVKEVRRLSEEVLRSIKEVSDRVRYQLR SEQ ID NO: 134 SKEEILKELEDLQRRLIEELKKLQERVVELLEELIKRLRDRGRDDKELKRL VKEVRRLSEEVLRSIKEVSDRVRYQLR SEQ ID NO: 436 DHD118 Heterodimer a GSDKEEESEYLLRDLVRLLEKVKEKIEEVNREVEKLLKKVKDGRLDRREVL REILRLNRELAEIIKEVVDRIREVVERSER SEQ ID NO: 135 DKEEESEYLLRDLVRLLEKVKEKIEEVNREVEKLLKKVKDGRLDRREVLRE ILRLNRELAEIIKEVVDRIREVVERSER SEQ ID NO: 363 DHD118 Heterodimer b GSDLHEVVYETKELLKRIEEVVEELRKKSEDIIRKAERGEISEDELKRLQE EIAREAKKLLDEIKRVLERELEQTL SEQ ID NO: 136 DLHEVVYETKELLKRIEEVVEELRKKSEDIIRKAERGEISEDELKRLQEEI AREAKKLLDEIKRVLERELEQTL SEQ ID NO: 438 DHD119 Heterodimer a GSPVEEIIKEVVKRVIEVQEKVLRIISHAVKRVVEVQKKYDPGSEESNRVV EEVKKTIEDAIRESDEVVDEVVKRIQYTVR SEQ ID NO: 137 PVEEIIKEVVKRVIEVQEKVLRIISHAVKRVVEVQKKYDPGSEESNRVVEE VKKTIEDAIRESDEVVDEVVKRIQYTVR SEQ ID NO: 365 DHD119 Heterodimer b GSPEQEIADRILTEIRESQKELERLARKILKLLDESQEKAKRGRLSEEESD ELLERIKKELDELLERSKELLKKIEYELR SEQ ID NO: 138 PEQEIADRILTEIRESQKELERLARKILKLLDESQEKAKRGRLSEEESDEL LERIKKELDELLERSKELLKKIEYELR SEQ ID NO: 440 DHD120 Heterodimer a GSDEDKEANRVLDEVLKTVRDLLETANEVLKEVLYRLKRTDDQEKVVRTLT EVLKEHLKLVEEIVRILDKVLKEHLETEK SEQ ID NO: 139 DEDKEANRVLDEVLKTVRDLLETANEVLKEVLYRLKRTDDQEKVVRTLTEV LKEHLKLVEEIVRILDKVLKEHLETEK SEQ ID NO: 367 DHD120 Heterodimer b GSPEDDVLRRLEEVSEKILRVAEDVARQLREVSEKITQGKVDRKEWEEDIK RLKRELEELLREWKEEIERLTYELR SEQ ID NO: 140 PEDDVLRRLEEVSEKILRVAEDVARQLREVSEKITQGKVDRKEWEEDIKRL KRELEELLREWKEEIERLTYELR SEQ ID NO: 442 DHD121 Heterodimer a GSRREEVVKRIRELLKRNKELIDRIRELLEENEYLDKDARDKDVLRRSVEL LEELVRILEESVELAKEIIKLLREVVE SEQ ID NO: 141 RREEVVKRIRELLKRNKELIDRIRELLEENEYLDKDARDKDVLRRSVELLE ELVRILEESVELAKEIIKLLREVVE SEQ ID NO: 369 DHD121 Heterodimer b GSDEKEDNRRLQHKIERILEKNEDLQRKLEEILELLERGEADEEKIDRLRK AVEDYRRVVEEIKEDVKRHKYTVR SEQ ID NO: 142 DEKEDNRRLQHKIERILEKNEDLQRKLEEILELLERGEADEEKIDRLRKAV EDYRRVVEEIKEDVKRHKYTVR SEQ ID NO: 444 DHD122 Heterodimer a GSDEKEEAKKASEESVRTVERILEELLKASEESVELLRRGEDAKDVVERSK EALKRVKELLDEVVKRSDEILKYIEN SEQ ID NO: 143 DEKEEAKKASEESVRTVERILEELLKASEESVELLRRGEDAKDVVERSKEA LKRVKELLDEVVKRSDEILKYIEN SEQ ID NO: 371 DHD122 Heterodimer b GSDEKKLINEVVETQKRLIKEAAKRLSEVVREQTELIRELREKNVDDKDVE KLLKESLDLAEEIVRRIKELLDESKKLVEYVSN SEQ ID NO: 144 DEKKLINEVVETQKRLIKEAAKRLSEVVREQTELIRELREKNVDDKDVEKL LKESLDLAEEIVRRIKELLDESKKLVEYVSN SEQ ID NO: 446 DHD123 Heterodimer a GSPDMDEVKRVLDELIEIQEEILREIKRVLEKLIKIQEDNGSEYESREVVR EIVEIARKLVERSRRVVKKITETLQ SEQ ID NO: 145 PDMDEVKRVLDELIEIQEEILREIKRVLEKLIKIQEDNGSEYESREVVREI VEIARKLVERSRRVVKKITETLQ SEQ ID NO: 373 DHD123 Heterodimer b GSDERYATREIVERIERIAREILKRTEEIVREVREVLSRDVDQEEVVRRLA DLLRESVELVQHLVRRVEELLQESVERKK SEQ ID NO: 146 DERYATREIVERIERIAREILKRTEEIVREVREVLSRDVDQEEVVRRLADL LRESVELVQHLVRRVEELLQESVERKK SEQ ID NO: 448 DHD124 Heterodimer a GSPEREALREVLEDLKRVTDRLRELVERVLEELKKVTDEVDSERILRESRR VLKELKDIIEEILRESEKVLEKLKYTED SEQ ID NO: 147 PEREALREVLEDLKRVTDRLRELVERVLEELKKVTDEVDSERILRESRRVL KELKDIIEEILRESEKVLEKLKYTED SEQ ID NO: 375 DHD124 Heterodimer b GSPAREILEEVVKKELEVVEDAARILEEIIREHEKAVREDRDKKELEEISR DLLRKAREALKKVKDISDDLSREIEYVAS SEQ ID NO: 148 PAREILEEVVKKELEVVEDAARILEEIIREHEKAVREDRDKKELEEISRDL LRKAREALKKVKDISDDLSREIEYVAS SEQ ID NO: 450 DHD125 Heterodimer a GSPVEEAIKKVIDDLRDVQRKIRELVEELIRLLEEVQRDNDKRESEYVVER VEEILRRITETSREVVRKAVEDLS SEQ ID NO: 149 PVEEAIKKVIDDLRDVQRKIRELVEELIRLLEEVQRDNDKRESEYVVERVE EILRRITETSREVVRKAVEDLS SEQ ID NO: 377 DHD125 Heterodimer b GSDSDEKAEYLLKEMERVVRESDEVVKKILRDLEEVLERLRRGEISEDDVT EILKELAERHIRAIEELVRRLRELLEREKR SEQ ID NO: 150 DSDEKAEYLLKEMERVVRESDEVVKKILRDLEEVLERLRRGEISEDDVTEI LKELAERHIRAIEELVRRLRELLEREKR SEQ ID NO: 452 DHD126 Heterodimer a GSPVEEVLKELSEVNERVRDIAREIIERLSEVNEEVKETDDEDELKKISKK VVDEVEDLLRKILEVSEEVVRRVEYHDR SEQ ID NO: 151 PVEEVLKELSEVNERVRDIAREIIERLSEVNEEVKETDDEDELKKISKKVV DEVEDLLRKILEVSEEVVRRVEYHDR SEQ ID NO: 379 DHD126 Heterodimer b GSPKEDILREVLRRHKEIVREIVRLVREAVETHLELVKRNSDDRDAQDVIR KLEEDLERLVREAQEVIEEIFYRLH SEQ ID NO: 152 PKEDILREVLRRHKEIVREIVRLVREAVETHLELVKRNSDDRDAQDVIRKL EEDLERLVRHAQEVIEEIFYRLH SEQ ID NO: 454 DHD127 Heterodimer a GSPRSYLLKELADLSQHLVRLLERLVRESERVVEVLERGEVDEEELKRLED LERELEKAVREVRETHREIRERSR SEQ ID NO: 153 PRSYLLKELADLSQHLVRLLERLVRESERVVEVLERGEVDEEELKRLEDLE RELEKAVREVRETHREIRERSR SEQ ID NO: 381 DHD127 Heterodimer b GSDREYIIKDILDSQEHLLRLIEELLETQKELLEILKRRPDSVERVRELVR RSKEIADEIRRQSDRNVRLLEEVSK SEQ ID NO: 154 DREYIIKDILDSQEHLLRLIEELLETQKELLEILKRRPDSVERVRELVRRS KEIADEIRRQSDRNVRLLEEVSK SEQ ID NO: 456 DHD128 Heterodimer a GSDEKDEIREVIESVERLIEDIKRLLKTLRELAHDDSDKKTVKEVLDRVKE MIERERRELEEHRKELERAEYEVR SEQ ID NO: 155 DEKDEIREVIESVERLIEDIKRLLKTLRELAHDDSDKKTVKEVLDRVKEMI ERERRELEEHRKELERAEYEVR SEQ ID NO: 383 DHD128 Heterodimer b GSESEDRIKELLKRHIELVERHEELLHEIKKLIDLEEKDDKDREEAVKRID DAIKESEEMLEESKEILEEIEYLNR SEQ ID NO: 156 ESEDRIKELLKRHIELVERHEELLHEIKKLIDLEEKDDKDREEAVKRIDDA IKESEEMLEESKEILEEIEYLNR SEQ ID NO: 458 DHD129 Heterodimer a GSSLEDSVRLNDEVVKVVERVVRLNQEVVRLIKEATDVEDEETVKYVLERV REVLDESREVLKRVIIELLEESERRLE SEQ ID NO: 157 SLEDSVRLNDEVVKVVERVVRLNQEVVRLIKEATDVEDEETVKYVLERVRE VLDESREVLKRVIIELLEESERRLE SEQ ID NO: 385 DHD129 Heterodimer b GSHEKDIVYKVEDLVRKSDRIAERAREIVKRSRDIMREIRKDKDNKKLSDD LLKVTRDLQRVVDELEELSRELLRVAEESRK SEQ ID NO: 158 HEKDIVYKVEDLVRKSDRIAERAREIVKRSRDIMREIRKDKDNKKLSDDLL KVTRDLQRVVDELEELSRELLRVAEESRK SEQ ID NO: 460 DHD130 Heterodimer a GSPELDEVKKLIDELKKSVERLEESIREVKESIKKLRKGDIDAEENIKLLK ENIKIVRENIKIIKEIIDVVQYVLR SEQ ID NO: 159 PELDEVKKLIDELKKSVERLEESIREVKESIKKLRKGDIDAEENIKLLKEN IKIVRENIKIIKEIIDVVQYVLR SEQ ID NO: 387 DHD130 Heterodimer b GSDEEEIEELLRELEKLLKKSEEALEESKKLIDESEELLRRDRLDKEKHVR ASEEHVKLSEEHLRISREIVKILEKAVYSTR SEQ ID NO: 160 DEEEIEELLRELEKLLKKSEEALEESKKLIDESEELLRRDRLDKEKEVRAS EEFIVKLSEEHLRISREIVKILEKAVYSTR SEQ ID NO: 462 DHD131 Heterodimer a GSDESDRIRKIVEESDEIVKESRKLAERARELIKESEDKRVSEERNERLLE ELLRILDENAELLKRNLELLKEVLYRTR SEQ ID NO: 161 DESDRIRKIVEESDEIVKESRKLAERARELIKESEDKRVSEERNERLLEEL LRILDENAELLKRNLELLKEVLYRTR SEQ ID NO: 389 DHD131 Heterodimer b GSDEDDELERLLREYERVLREYEKLLEELRRLYEEYKRGEVSEEESDRILR EIKEILDKSERLWDLSEEVWRTLLYQAE SEQ ID NO: 162 DEDDELERLLREYERVLREYEKLLEELRRLYEEYKRGEVSEEESDRILREI KEILDKSERLWDLSEEVWRTLLYQAE SEQ ID NO: 464 DHD132 Heterodimer a GSDKKDASRRAIRVLHEFVRVSEEVLEVLRKSVESLKRLDVDEKIKRTHDR IEEELRRWKRELEELIERLREWEYHQD SEQ ID NO: 163 DKKDASRRAIRVLHEFVRVSEEVLEVLRKSVESLKRLDVDEKIKRTHDRIE EELRRWKRELEELIERLREWEYHQD SEQ ID NO: 391 DHD132 Heterodimer b GSDDEEEDKRLLEEVKRSLDTDERILEKLRESLERQLEDVDKDEDSRRVLR ELDEITKRSREVVKRLRKLAYESK SEQ ID NO: 164 DDEEEDKRLLEEVKRSLDTDERILEKLRESLERQLEDVDKDEDSRRVLREL DEITKRSREVVKRLRKLAYESK SEQ ID NO: 466 DHD133 Heterodimer a GSDKEYKLDRILRRLDELIKQLSRILEEIERLVDELEREPLDDKEVQDVIE RIVELIDEHLELLKEYIKLLEEYIKTTK SEQ ID NO: 165 DKEYKLDRILRRLDELIKQLSRILEEIERLVDELEREPLDDKEVQDVIERI VELIDEHLELLKEYIKLLEEYIKTTK SEQ ID NO: 393 DHD133 Heterodimer b GSPSKEYQEKSAERQKELLHEYEKLVRELRELVEKLQRRELDKEEVLRRLV EILERLKDLIIKKIEDAHRKNEEAHKENK SEQ ID NO: 166 PSKEYQEKSAERQKELLHEYEKLVRELRELVEKLQRRELDKEEVLRRLVEI LERLKDLIIKKIEDAHRKNEEAHKENK SEQ ID NO: 468 DHD134 Heterodimer a GSRDRKISEELIKALEDHIRMLEELIRAIEEHIKLAERGVDEKELRESLEE LKKIVDELEKSLEELRKLAERYKYETR SEQ ID NO: 167 RDRKISEELIKALEDHIRMLEELIRAIEEHIKLAERGVDEKELRESLEELK KIVDELEKSLEELRKLAERYKYETR SEQ ID NO: 395 DHD134 Heterodimer b GSPKEESVEELKRVIDKHEEILRELKRVLEEHERVSEDEDENELRRSLERL KHILDRLHESLKELHELLKKNEYTER SEQ ID NO: 168 PKEESVEELKRVIDKHEEILRELKRVLEEHERVSEDEDENELRRSLERLKH ILDRLHESLKELHELLKKNEYTER SEQ ID NO: 470 DHD135 Heterodimer a GSDHEYWVKIVERILRVMEKHAEIVKKELEIVERVVREGPSEDLRRKLKES LREIEESLRELKELLDELDELSEKTR SEQ ID NO: 169 DHEYWVKIVERILRVMEKHAEIVKKELEIVERVVREGPSEDLRRKLKESLR EIEESLRELKELLDELDELSEKTR SEQ ID NO: 397 DHD135 Heterodimer b GSDEEYVTRSQRRLKRLLEEYIKVVEEHARLVERNERDDKELKRSIDELDK LTKELLELVKRYKELVDKTET SEQ ID NO: 170 DEEYVTRSQRRLKRLLEEYIKVVEEHARLVERNERDDKELKRSIDELDKLT KELLELVKRYKELVDKTET SEQ ID NO: 472 DHD136 Heterodimer a GSDKEEIVKLQDEVIKTLERELDILRKEIDLLEKLKDELSEELKERVDRSI KKLEESIKRLERIIEELQELAEYSL SEQ ID NO: 171 DKEEIVKLQDEVIKTLERELDILRKEIDLLEKLKDELSEELKERVDRSIKK LEESIKRLERIIEELQELAEYSL SEQ ID NO: 399 DHD136 Heterodimer b GSREEELKESAEELERSVRELKKEADKYKEEVDRLEYRGKVDKDWVRVVEK LIKLVEEHLELIREHLELLKEERR SEQ ID NO: 172 REEELKESAEELERSVRELKKEADKYKEEVDRLEYRGKVDKDWVRVVEKLI KLVEEHLELIREHLELLKEERR SEQ ID NO: 474 DHD137 Heterodimer a GSDMEYELKKSAEELRKSLEELKRILDELEKSLRELRREGDDEEYVQTVEE LRKELEEHAKKLEEHLKELERVAT SEQ ID NO: 173

DMEYELKKSAEELRKSLEELKRILDELEKSLRELRREGDDEEYVQTVEELR KELEEHAKKLEEHLKELERVAT SEQ ID NO: 401 DHD137 Heterodimer b PEYELKKSVDDLKRDVDRLVEEVEEVFELSKERLREDRKELELVEEMVRLI EKELELIKEHLKLADDEVR SEQ ID NO: 174 DHD138 Heterodimer a GSREKDESKELNDEYKKLLEEYERLLRRSEELVKRAKGPRDEKELKRILEE NEDILRRTKEILERTKEISEEQKYRRR SEQ ID NO: 175 REKDESKELNDEYKKLLEEYERLLRRSEELVKRAKGPRDEKELKRILEENE DILRRTKEILERTKEISEEQKYRRR SEQ ID NO: 403 DHD138 Heterodimer b GSDKDERQERLNEESDKSNEESERSNRESEELNRRARGPNDEKELQEILDR FILELLERNQRLLDENKEILRESQYLND SEQ ID NO: 176 DKDERQERLNEESDKSNEESERSNRESEELNRRARGPNDEKELQEILDREL ELLERNQRLLDENKEILRESQYLND SEQ ID NO: 476 DHD139 Heterodimer a GSENKYILKEILKLLRENLKLLEDILRLLDENLEELEKHGAKDLDDYRRKI EEIRKKVEDYREKIEEIEKKVERDR SEQ ID NO: 177 ENKYILKEILKLLRENLKLLEDILRLLDENLEELEKHGAKDLDDYRRKIEE IRKKVEDYREKIEEIEKKVERDR SEQ ID NO: 405 DHD139 Heterodimer b GSESEYTQEEILELLKESIKLLREILRLLEESEELWRRENTKSERSEEIKE RAKEAIKRSEEILERVKRLSDHSR SEQ ID NO: 178 ESEYTQEEILELLKESIKLLREILRLLEESEELWRRENTKSERSEEIKERA KEAIKRSEEILERVKRLSDHSR SEQ ID NO: 478 DHD140 Heterodimer a GSDEEEANYVSDKAVKIAEDVQELLKELLELSEVVRRGEVDEDEYDRVLRK LQEVMKEYEEVLKEYEEVSRKHE SEQ ID NO: 179 DEEEANYVSDKAVKIAEDVQELLKELLELSEVVRRGEVDEDEYDRVLRKLQ EVMKEYEEVLKEYEEVSRKHE SEQ ID NO: 407 DHD140 Heterodimer b GSPEKYLIKTQEELLRRHAEILEDLIRKVERQVDLRRKVDERDEDLKRELE RSLRELERLVRESSRLVEEIRELSKEIKR SEQ ID NO: 180 PEKYLIKTQEELLRREAEILEDLIRKVERQVDLRRKVDERDEDLKRELERS LRELERLVRESSRLVEEIRELSKEIKR SEQ ID NO: 480 DHD141 Heterodimer a GSDEEYELERISRESKELLERYKRLLREYQELLKELREVKDLDRAVKIIHE LMRVSKELVEISHRLLELHERLVRRRK SEQ ID NO: 181 DEEYELERISRESKELLERYKRLLREYQELLKELREVKDLDRAVKIIHELM RVSKELVEISHRLLELHERLVRRRK SEQ ID NO: 409 DHD141 Heterodimer b GSEKEYIEKLSRKIEEDIRRSEERAKDSERLVRRLEELAKRKRLDLDDVLR VAEENLEILEDNLRILEEILKEQDKSNR SEQ ID NO: 182 EKEYIEKLSRKIEEDIRRSEERAKDSERLVRRLEELAKRKRLDLDDVLRVA EENLEILEDNLRILEEILKEQDKSNR SEQ ID NO: 482 DHD142 Heterodimer a GSPHEEVVELHERVMEISERAVELIQRIIDIIRRIREDDKDIEKLVKTIRD LVREYEELERELEEIDEEIYKKSE SEQ ID NO: 183 PHEEVVELHERVMEISERAVELIQRIIDIIRRIREDDKDIEKLVKTIRDLV REYEELERELEEIDEEIYKKSE SEQ ID NO: 411 DHD142 Heterodimer b GSDHEDVVRLHEDLVRKQEDARRVLEEIVRLAEEIVEVIKKDEKDKDRVTR LVEEIEKLVEEYKKKVDEMRKISDEIKYRSR SEQ ID NO: 184 DEEDVVRLHEDLVRKQEDARRVLEEIVRLAEEIVEVIKKDEKDKDRVTRLV EEIEKLVEEYKKKVDEMRKISDEIKYRSR SEQ ID NO: 484 DHD143 Heterodimer a GSRAREVVKRAKRIIEEWQKILEEWRRILEEWRRLLEDERVDDRDNERIIR ENERVIRENEKIIRDVIRLLEELLYERR SEQ ID NO: 185 RAREVVKRAKRIIEEWQKILEEWRRILEEWRRLLEDERVDDRDNERIIREN ERVIRENEKIIRDVIRLLEELLYERR SEQ ID NO: 413 DHD143 Heterodimer b GSREDEELEEEIDRIRQMVEEYEELVKEYEELTEKYKQGKVDKEESKKIIE KSERLLDLSQDAVRKVKEIIRRILYTNR SEQ ID NO: 186 REDEELEEEIDRIRQMVEEYEELVKEYEELTEKYKQGKVDKEESKKIIEKS ERLLDLSQDAVRKVKEIIRRILYTNR SEQ ID NO: 486 DHD144 Heterodimer a GSPKEEIVKLEDESAELERRSVEVADEILKMHERSKDVDDERESRELSKEI ERLIREVEEVSKRIKRLSEEVEYLVR SEQ ID NO: 187 PKEEIVKLEDESAELERRSVEVADEILKMHERSKDVDDERESRELSKEIER LIREVEEVSKRIKRLSEEVEYLVR SEQ ID NO: 415 DHD144 Heterodimer b GSPLEEILKIQRRINKIQDDINKILHEILRMQEKLNRSSDKDEVEESLRRI RELIKRIKDLSKEIEDLSREVKYRTT SEQ ID NO: 188 PLEEILKIQRRINKIQDDINKILHEILRMQEKLNRSSDKDEVEESLRRIRE LIKRIKDLSKEIEDLSREVKYRTT SEQ ID NO: 488 DHD145 Heterodimer a GSPEDEHVYVVREIYEVLREHAEVLEENREVIERLLEAKKRGDKSEELVKE LKKSIDKLKEISRKLEEIVKELEKVSEKLK SEQ ID NO: 189 PEDEHVYVVREIYEVLREHAEVLEENREVIERLLEAKKRGDKSEELVKELK KSIDKLKEISRKLEEIVKELEKVSEKLK SEQ ID NO: 417 DHD145 Heterodimer b GSDEDETSYRILELLREIVRASRELIRLSEELLEVARRDDKDETVLETLIR EYKELLDRYRRLIEELTRLVEEYEERSR SEQ ID NO: 190 DEDETSYRILELLREIVRASRELIRLSEELLEVARRDDKDETVLETLIREY KELLDRYRRLIEELTRLVEEYEERSR SEQ ID NO: 490 DHD146 Heterodimer a GSTQEEINRIQHEVLRIQEEIDEILRDIVEKLKAISRGELDHEVVKDVEDK VREALEKSEELLDKSRKVEYKSE SEQ ID NO: 191 TQEEINRIQHEVLRIQEEIDEILRDIVEKLKAISRGELDHEVVKDVEDKVR EALEKSEELLDKSRKVEYKSE SEQ ID NO: 419 DHD146 Heterodimer b GSDEEELNRELLEKSKRLVDINRDIIRTAQELIEMLKDSKDGRVDEDTKRE LRDKLRKLEEKLERVREELRKYEELLRYVQR SEQ ID NO: 192 DEEELNRELLEKSKRLVDINRDIIRTAQELIEMLKDSKDGRVDEDTKRELR DKLRKLEEKLERVREELRKYEELLRYVQR SEQ ID NO: 492 DHD147 Heterodimer a GSDEKDRVYEILKEVQRLVKEYRDISKEIEDLVKHYEHITDDEAQEVSKEL IDKSLRASEIVRELIRLIKELLDELE SEQ ID NO: 193 DEKDRVYEILKEVQRLVKEYRDISKEIEDLVKHYEHITDDEAQEVSKELID KSLRASEIVRELIRLIKELLDELE SEQ ID NO: 421 DHD147 Heterodimer b GSDEEDVLYELRELLEELKRVSDDYERLVREIKETSERKDRDTKENKDMLD ELVKAHREQEKLLERLVRLLEELFERKR SEQ ID NO: 194 DEEDVLYELRELLEELKRVSDDYERLVREIKETSERKDRDTKENKDMLDEL VKAHREQEKLLERLVRLLEELFERKR SEQ ID NO: 494 DHD1 Heterodimer a PREQAIRISEEIIRISKKIIEILERTRSSTAREAMKWAKDSIRLAEESKYL LDK SEQ ID NO: 195 DHD1 Heterodimer b IEDDVKKIQDSTKKAQKETIEALERSTSSTARKQMEEQKEQIRLQKEAMYL LKK SEQ ID NO: 196 DHD2 Heterodimer a SREEIAKLQEEVIKLQRRVIELQKEVIELQRRAKELTSSYTKEILEIQRRI EEIQREIEEIQKRIEEIQEEIQRRT SEQ ID NO: 197 DHD2 Heterodimer b SDEEIKRLSEEVIQLSRRVIKMSREAIKLSREVQKLTPSYQKRIKEIADRS IELARESIEIAKRSEKIAEESQRRT SEQ ID NO: 198 DHD3 Heterodimer a PAKDEALKMANESLELAKKSARLIQESSSKEILERIEKIQRRIAELQDRIA YLIKK SEQ ID NO: 199 DHD3 Heterodimer b PAKDEALRMIDESRELIKKSNELIQRSSSKEILERILEIQRKIAELQKRIQ YLLKS SEQ ID NO: 200 DHD4 Heterodimer a TDEARYRSERIVKEAKRLLDEARRRSEKIVREAKQRSNSEDAKRIMEENLR ESEEAARRLREIIRRNLEESRETG SEQ ID NO: 201 DHD4 Heterodimer b TREALEYQRKMAEEIEDLLREALRRQEEMVREAKQRSLSEEFKRIMERILE EQERVMRLAKEALERILEEQKRTG SEQ ID NO: 202 DHD5 Heterodimer a SERTKREAKRSQEEILREAKEAMRRAKESQDHRQNRDGSNSEDLERLSQEQ KRELEEVERRLKELAREQKYKLEDS SEQ ID NO: 203 DHD5 Heterodimer b SEDLKRILKEITERELKLMQDLMEILKKITEDENNLDSNNSEDLKRSIEKA RRILDEALRKLEESARRAKYIQEDN SEQ ID NO: 204 DHD6 Heterodimer a TEDEIRESLKWLDEVLQELREIARESNEVLERNRQKSRSDKLREDIERYKK RMEEARKKLDDQLNKYKKRMDENRS SEQ ID NO: 205 DHD6 Heterodimer b TEEELKESKKFAEDLARSARRALKESKRVLEEISQASRSKKLEEIVRRYKE QVKRWQDEWDERAREYRKRMKENRS SEQ ID NO: 206 DHD7 Heterodimer a TKTEEIERLAREIKKLSEKVERLAQEIEELSRRVKEENSTDRELKEANREI ERAIREIEKANKRMEEALRRMKYNG SEQ ID NO: 207 DHD7 Heterodimer b TKTEEHERLAREISKLADEHRKLAKIIEELARRIKEENLTDDELREAIRKI EDALRKNKEALKIMKEAAERNRYNT SEQ ID NO: 208 DHD8 Heterodimer a TKKEESRELARESEELARESEKLARKSLELARRAESSGSEEEKRRIIDENR KIIERNREIIERNKEIIEYNKELIS SEQ ID NO: 209 DHD8 Heterodimer b TKDEESLELNRESEELNRKSEELNRKSKELNDRAESSNSEEEEKEILREEK EILREHLEILRRHKEILRRIIKYLTS SEQ ID NO: 210 DHD16 Heterodimer a TREELLRENIELAKEHIEIMREILELLQKMEELLERQSSEDILEELRKIIE RIRELLDRSRKIHERSEEIAYKEE SEQ ID NO: 211 DHD16 Heterodimer b SEDIAREIKELLRRLKEIIERNQRIAKEHEYIARERKKLDPSNEKERKLLE RSRRLQEESKRLLDEMAEIMRRIKKLLD SEQ ID NO: 212 DHD18 Heterodimer a DRQKLIEENIKLLDKHIKILEEILRLLKKDIDLLKKSSSEEVLEELKKIHR RIDKLLDESKKIHKRSSEIVKKRS SEQ ID NO: 213 DHD18 Heterodimer b DEQKLIETSQRLQEKSERLLEKFEQILREASDLYRKPDSEELLRRVEKLLR ELEKLIRENQDLARKEEKILRDQS SEQ ID NO: 214 DHD19 Heterodimer a DRQELIRENIELLKKHIKIVKEIQKLIETFIELLKKSSSEEILRRLKKILK RIEKLYRESQEIHKRSEEIAKKRQ SEQ ID NO: 215 DHD19 Heterodimer b DEERLIDKSRELQKESEELLKELLKIFKRIEELLEKPDSEELIREIKKLLE TLSEIHKRNEKLARTHEEILRQQS SEQ ID NO: 216 DHD22 Heterodimer a STRDVQREIAKAFKKMADVQKKLAEEIKREVKNVEKKNKDNDEYRKIATEL LKKATESQKKLKELLDRIRKSDS SEQ ID NO: 217 DHD22 Heterodimer b DKDDRSTSLLKRVEKLIDESDRIIDKFTTLIELSRNGKIDDDQYKKELKEI LELLKKYDKIIVKEVEELLKRLNS SEQ ID NO: 218 DHD23 Heterodimer a SKRKALEVSERVVRISEKVVRVLDESSDLLKKSYDDSDKFAELIDRHEEKI KKWKKLIKEWLEIIQRIIKS SEQ ID NO: 219 DHD23 Heterodimer b SAEEFVKLSEEAVKRSKEILDIVRKQVKLVKAGVDKHEITDSLRKSEKLIE EHKELIKTERDLLRREN SEQ ID NO: 220 DHD24 Heterodimer a SSTEILKRFKRALRESEKIVKHSRRVLKIIREVLKQKPTQAVHDLVRIIET QVKALEEQLKVLKRIVEALERQS SEQ ID NO: 221 DHD24 Heterodimer b DKQKEIKDILEKTRRIAEESRKIAEKFDEIIKRSTEGKIDESLTKELEELV KEVIKLSEDDARTSDDLVRKES SEQ ID NO: 222 DHD26 Heterodimer a DEDESIKLTRKSIEETRKSLKIIKEVVELIREVLKHIKDLDKEIFERIDKI LDKYKKQVDTYDEILKEYEKKQR SEQ ID NO: 223 DHD26 Heterodimer b SELDEQKELIKKQEKLIEEQQRLLSKIRRMFKERVKDQELLREIQKVLKRS QEIVETSKKILDRSDKTTE SEQ ID NO: 224 DHD28 Heterodimer a DQKEINTRIVEKLERIFKKSKEIVRQSERVISTIEKKTEDERELDLLRREV KIVREELKLLEELLKIIKEVQKESE SEQ ID NO: 225 DHD28 Heterodimer b DTEELVKRLNELLKELSKLVKEFIKILETYRKDQTKDTSKISERVDRILKT YEDLLQKYKEILEKIEKQLS SEQ ID NO: 226 DHD29 Heterodimer a DYARLIDQAVEVTREVVEVNVTVARVNDKFAKELGDEELRRVSEELKEVSK DLQEVAKKSKDAARQVK SEQ ID NO: 227 DHD29 Heterodimer b DVSKVAEEYLQISKTLVDISRTLLEISERLVRLVRTVADDRSEVKKAIEDS IEVLKTSEEVVRQIKRASDKLVKAIS SEQ ID NO: 228 DHD31 Heterodimer a DAKEIQRRVVEIQTEVVKLQKKAVDIIRKIIEAFNNSNIDQSLLEAAKEIV KEIDKLEKLTESLLEESKKLLKRSS SEQ ID NO: 229 DHD31 Heterodimer b SAEEVVKLAKIFLELLRESIKLLKRSVDLLRKSSDPSLDKSEAEKVSREIE KVSDTSLKLSKKALDVVKRALKVAS SEQ ID NO: 230 DHD32 Heterodimer a DEKDAARKARKVSEEAKEASKKIEKALEESKRILNTLKQKKDEQEVKVIKE EEDVLRQIEKIQKQVLEIQKEVAKLLESLD SEQ ID NO: 231 DHD32 Heterodimer b SADDVARASEKVLRVARESAKAADKSLEVFKEVVKRGDKEAFLQVVKINEE VVKINITVIRILIEVSKTAT SEQ ID NO: 232 DHD38 Heterodimer a DEYVKETLKQLREALASLREADKRITELVKEARKKPLSEAARKFAEAIVTE VKVVVEEVEVVLREVEVLVEAKKNGVIDKSILDNALRIIENVIRLLSNVIR VVDEVLQDLD SEQ ID NO: 233 DHD38 Heterodimer b DASDVIRRIEELFEEVERLIEAVERAIEDVAKAAQKKGLDESAVEILAELS KELAKLSRRLAEISREIQKVVTDPDDKEAVERLKEIIKEIKKQLDELRDRL RKLQDLLYKLK SEQ ID NO: 234 DHD60 Heterodimer a SEDKAEEDIVRVLEELIKIEDELMKISEEILKATSDSTATDETKEELKRRS KEAQKKSDTLVKIVKELEKESRKAQS SEQ ID NO: 235 DHD60 Heterodimer b DDEEKYRQIIREAQEISKTAKRILRDAQEISKRIREQGVDRSEEQRLVDLL RELIKEEEKLLRRQQEADTRND SEQ ID NO: 236 DHD63 Heterodimer a DRKDKARKASEKLEEVIQRWKTVADKWKKMVDLVSNGKLSQEEVARVTEEL LKIQTELAKLLEEEAKVLQESAS SEQ ID NO: 237 DHD63 Heterodimer b SDEESIKTQSELIKTSEELLKDVKRIDEELQKLRDDPTLDESELKKRVKEW SDRVRKAKEISRKIQEIVKESKKRSS SEQ ID NO: 238 DHD66 Heterodimer a DKDEELRKVIEKYREMVKEYRKVIREYEEVIKSSKTIDKSSLISLSRKMVE LSQRVIDVSDEVAKVLSRKQS SEQ ID NO: 239 DHD66 Heterodimer b TDEERLKKQTKELKEQTKQLEKQKDLLEKISNGEISKDEIQEIIKESKKIA KESQKALDSSRKALEEVS SEQ ID NO: 240 DHD67 Heterodimer a DEKEVSKEIIKVLKDIAKVQQKVIEVSQRLASVLRADDDNVVKRALEEYEK ILEELRELNKEIEKLTDKYRKVTS SEQ ID NO: 241 DHD67 Heterodimer b DSDEQTKELEKLTELEKREVEKLKKQTKESREVDSNKLWKSKDVKDKLSES EKELQKLSDQDKKAKDALESSRRKND SEQ ID NO: 242

DHD69 Heterodimer a DAEEQLKLLTKLLREQQRLLQLIKESLKLIEKIDQSSQENQDEIRKWREVT KKLRELIKTSEKLVRELEKSYKKSS SEQ ID NO: 243 DHD69 Heterodimer b SLRDVVRRYQELVRRYDELIKTLTEILKKYQKKGAEDKDASTELVKAVRTS LKLSKELLKLNSELLKEDS SEQ ID NO: 244 DHD71 Heterodimer a SKEELKRKLDELKKRSDTLKELSKKLKEISERNPDDKSVERTIIRIEREFV KNEKEIVRVIEEIVSDKS SEQ ID NO: 245 DHD71 Heterodimer b SKQDEEDRLLKIEDKLVKQEDELLKLLTKLSRAGDSVTKKKLEEILRKLQE VSKQLEESLKDADKVSKDIN SEQ ID NO: 246 DHD72 Heterodimer a TVQSLLEQEVKIVKRSIEILERETQILQDIARSQGVSKELEDVERQVKEYR KEVKKLEEDLRQLSRNSK SEQ ID NO: 247 DHD72 Heterodimer b SDSDRIEKLIRESTELLKEQQKLAKRSRELAETVESLPLTEEYLKQQREEQ KKIEKLLKDSEKELEELKRLVKSEK SEQ ID NO: 248 DHD73 Heterodimer a DSEKRIEDILRTDLELAKRDAELVKEEIKLVKRIDLSEELKKQVEDVEKES KKLEDSSEKLVQKVRKRSS SEQ ID NO: 249 DHD73 Heterodimer b DEEERAKDLRKYLEEQTQYYRTVTEELRNLEKVVEELERRGKPSSELQQIL ERSQRIYKETTEIYDTSKKLIEELDKEER SEQ ID NO: 250 DHD148 Heterodimer a PLEDILKRELDKVRELVRLSEEVNKLAKEVLDILKDKRVDEKELDKVLKEL EKVVEEYERAVKESRDLLRELRETTR SEQ ID NO: 251 DHD148 Heterodimer b DKERLLEIHERIQKLLDRNLEIIERLLRLLREARDIKDDDKLDKVIKRLKE LSEESKDILDKIKELLKESEKELT SEQ ID NO: 252 DHD149 Heterodimer a PEDEVIRVIEELLRIAAEVDEVERRNVEVQEEASRVTDRERLERLNRESEE LIKRSRELIEEQRKLIERLERLAT SEQ ID NO: 253 DHD149 Heterodimer b DLEELIKEYAEVVRRHHKAVRDLERLVRELANAKHASEEELKRIATEILRI VKELIRVQERLIKLSEDSNEESR SEQ ID NO: 254 DHD150 Heterodimer a PTDEVIEVLKELLRIHRENLRVNEEIVEVNERASRVTDREELERLLRRSNE LIKRSRELNEESKKLIEKLERLAT SEQ ID NO: 255 DHD150 Heterodimer b DNEEIIKEARRVVEEYKKAVDRLEELVRRAENAKHASEKELKDIVREILRI SKELNKVSERLIELWERSQERAR SEQ ID NO: 256 DHD151 Heterodimer a PKEDIDRVSRELVRVHKELLEVLRKSTEIVEAVARNEKDERTIEEVLEEQE RAVRKLEEVSKKHKEAVKRLK SEQ ID NO: 257 DHD151 Heterodimer b ELERLSEEIQKLSDRLIELIRRESKVLEEIVRLLKHKDNDEREVRRLLKLL RDLTRRYEEVLRKVEEIVKRQEDESR SEQ ID NO: 258 DHD152 Heterodimer a PEEDILRLLRKLVEVDKELLEVVRESTEVVRLVARNEKDVETVERVLRKQE EVVRKYERVSRELEEAVRRLK SEQ ID NO: 259 DHD152 Heterodimer b ELKDLVEEIVKLSKENLKLWEDHSRVLEEIVRLLKHKDNDEREVRRLLKLL EDLTRRAEETSRRIEEIVKEAEDRAR SEQ ID NO: 260 DHD153 Heterodimer a DEERELREVLRKHERVVREWTKVVEELKRVVELLKRGETSEEDLLRVLKKL LEMDKRILEVNREVLRVLEKRLT SEQ ID NO: 261 DHD153 Heterodimer b SLEEIIEELVELVRRSVEIAKESDEVARRIVESEDKKKELIDTLRDLEREW QEVTKRAEELVREAEKEVR SEQ ID NO: 262 DHD154 Heterodimer a TAEELLEVHKKSDRVTKEHLRVSEEILKVVEVLTRGEVSSEVLKRVLRKLE ELTDKLRRVTEEQRRVVEKLN SEQ ID NO: 263 DHD154 Heterodimer b DLEDLLRRLRRLVDEQRRLVEELERVSRRLEKAVRDNEDERELARLSREES DIQDKEDKLAREILEVLKRLLERTE SEQ ID NO: 264 DHD155 Heterodimer a PEDDVVRIIKEDLESNREVLREQKEIHRILELVTRGEVSEEAIDRVLKRQE DLLKKQKESTDKARKVVEERR SEQ ID NO: 265 DHD155 Heterodimer b DEVRLITEWLKLSEESTRLLKELVELTRLLRNNVPNVEEILREHERISREL ERLSRRLKDLADKLERTRR SEQ ID NO: 266 DHD156 Heterodimer a DEDEVVKVHEEHVKSHEEIHRSHEEVVRAAEEDKRDSRELRTLMEEHRKLL EENEKSIEEVKKIHERVKR SEQ ID NO: 267 DHD156 Heterodimer b KKEELIDISKEVLDLDDEINKISKEILELIKKLLRLKEEGREDKDKAREVK RRIRELERRIQELNKRLRELHKRVQETKR SEQ ID NO: 268 DHD157 Heterodimer a PEEDIARRVEDLLRKSEELIKESEKILKESKRLLDRNDSDKRVLETNLRLI DKETKLLERNLELLEELLKLAEDVAK SEQ ID NO: 269 DHD157 Heterodimer b RFKDLSREYIEVVKRLLELSREALEVLREIKDTDKTDKKRIKELIDRLRKL IEEYKRIIDRLRKLSKDLEEEHR SEQ ID NO: 270 DHD158 Heterodimer a DEEELVKILKELQRLSEESLEINKRLVEILRLLRRGEVPKEEVEKKLREIK KEQEKLDREHEKIKKRIEEITK SEQ ID NO: 271 DHD158 Heterodimer b SLKEKILEIIERNMKLVELSNRSVEIVARILKGEKDDEETLERLLREWDKI TRDYEEIIKESRKLVKELEEEAK SEQ ID NO: 272 DHD159 Heterodimer a SKTEILRKALEIHKEQIDIVRKLIELSEEVLKLVEESKEKNLEKLKRIDEE TDRLLERLDELEKRLTELAERLK SEQ ID NO: 273 DHD159 Heterodimer b SDDEARKQLEEMKRRLREVEKKSKRVEERVRELERLVRENREDEDRVLKTL EDLLRENEKLVRTIEREVREQRELSKEVK SEQ ID NO: 274 DHD160 Heterodimer a SEEELEKKADELRKLSEEWRKLQEEDKRLSEMVEKGELDLQEVDEHSLRVL ERATEVERTVDKVIEEILRTTN SEQ ID NO: 275 DHD160 Heterodimer b SEKERHRESQETQEEIRRTHEEIIRKLEEILRRAKAGELPEETLDRLRRIM ERLKELSERLDDLVRKLRDDERREQK SEQ ID NO: 276 DHD161 Heterodimer a SEKEILEELKRILKRVKDISDRLEELDKRTEEIARREPTKELVDELVKIHR DWLRLHEEILKLVDDALKKVEDATK SEQ ID NO: 277 DHD161 Heterodimer b DLRELLELQREASRLHRELVKLLTELVKKLELIAKGEDIREEDLKRIKERL EEIKKRSKRIKEESDEIDKKTK SEQ ID NO: 278 DHD162 Heterodimer a SERELQRELNKIVRRILEIHREVSELHQRAVKLIRENDNSEELEEISRRIE ELSKELEKLVREHDEIVKTIE SEQ ID NO: 279 DHD162 Heterodimer b SEREKLDRNDEELKEINKRVEEIKERSDRITEAIEKNERSEEEIRRLSREQ NEALQRLLELIIKKLVKLERELLEDTR SEQ ID NO: 280 DHD163 Heterodimer a DKEDVIRVEDEQEKLIEEQLELTRRIAELVREIAKNTASEEEIKEMLKEIK RLDDRSREIQDRLQKLLEEIRRKTK SEQ ID NO: 281 DHD163 Heterodimer b TEEEIVELNKDIQRKSKEEIDLQNELVKKIERAIRENNITEELLEELERLL RESEKIVEEIRRITDKIRKDAK SEQ ID NO: 282 DHD164 Heterodimer a SEKEILERLLRLSKEQNEISEEIERLTERLVELKRRKDDDERLKRILDRQK RLVERAREISKEYEDLLRKLE SEQ ID NO: 283 DHD164 Heterodimer b SMEELLRKNARLSRKQLKIIDEELELSTKLTRGEAGDETLEEIERRSREML EEQRRVDEESKRIREKLK SEQ ID NO: 284 DHD165 Heterodimer a SEEEIRDIVEKLLRTEEEVLKEIKKLLDDSERVRRRELDKKDLDRIQKEQR DIQEENKEKAKRFDELVKELKKAAK SEQ ID NO: 285 DHD165 Heterodimer b SEEEERRTMEKVEKEVRDIKRRSEEVKKKVKANTLSEEDLVRLLERLVEDE KRLQDLSQEIIERDEKATK SEQ ID NO: 286 DHD166 Heterodimer a DEDELAKEIEDVQRRNKESQEEEDKSVKKLEAAERGEIDEDSLLRVLEEDI KVLEKDIEVLERSIEVIEKAE SEQ ID NO: 287 DHD166 Heterodimer b SEKELIRRLLEQQRQELRLSERLIELSRRLVEVVRKGKDNRDLLRELKKLS EEEKKESKDDEEKVREIREREK SEQ ID NO: 288 DHS 17 Heterodimer a DRKDLLKRNIKLLDRELKILDTILKLLEKLSELLKKSSSEEVVKEYKKILD EIRKLLEESKEIEKESKEILERES SEQ ID NO: 289 DHD17 Heterodimer b DEEKLIERSKRLQEESEQLLEKFEQILRELTELLEKPDSEELARKIKKLED ELRKIIKRNQELIREEEEILRKRD SEQ ID NO: 290

[0128] In some aspects, non-limiting examples of the monomer A polypeptide and monomer B polypeptide pairs are shown in FIG. 16.

[0129] In some aspects, the amino acid sequence of SEQ ID NOs: 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494 useful for the monomer A polypeptide or the monomer B polypeptide is not linked to GlySer at the N terminus of the sequence or does not comprise GlySer at the N terminus. In some aspects, the monomer A polypeptide and/or the monomer B polypeptide comprises at least one amino acid, at least two amino acids, at least three amino acids, at least four amino acids, at least five amino acids, at least six amino acids, at least seven amino acids, at least eight amino acids, at least nine amino acids, or at least ten amino acids at the N terminus or the C terminus of the amino acid sequence. In some aspects, the additional amino acids are not GlySer at the N terminus.

[0130] In some aspects, the protein of the present disclosure comprises a heterodimer comprising a monomer A polypeptide and a monomer B polypeptide, wherein the monomer A polypeptide comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence as set forth in SEQ ID NO: 331, 5, 7, 13, 15, 25, 29, 31, 33, 35, 37, 39, 41, 45, 47, 53, 55, 57, 59, 61, 65, 67, 69, 71, 73, 75, 77, 79, 337, 339, 85, 87, 89, 91, 93, 95, 97, 99, 341, 103, 343, 107, 109, 111, 113, 459, 345, 347, 349, 351, 353, 355, 357, 359, 361, 363, 365, 367, 369, 371, 373, 375, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 407, 409, 411, 413, 415, 417, 419, or 421 and the monomer B polypeptide comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence as set forth in SEQ ID NO: 2, 332, 334, 336, 338, 340, 342, 344, 346, 348, 418, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, 384, 386, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 414, 416, 420, 422, 424, 426, 428, 126, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472, 474, 174, 476, 478, 480, 482, 484, 486, 488, 490, 492, or 494, respectively.

[0131] In some aspects, the protein of the present disclosure comprises a heterodimer comprising a monomer A polypeptide and a monomer B polypeptide, wherein the monomer A polypeptide comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of SEQ ID NO: 331, 5, 7, 13, 15, 25, 29, 31, 33, 35, 37, 39, 41, 45, 47, 53, 55, 57, 59, 61, 65, 67, 69, 71, 73, 75, 77, 79, 337, 339, 85, 87, 89, 91, 93, 95, 97, 99, 341, 103, 343, 107, 109, 111, 113, 459, 345, 347, 349, 351, 353, 355, 357, 359, 361, 363, 365, 367, 369, 371, 373, 375, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 407, 409, 411, 413, 415, 417, 419, or 421, wherein the amino acid sequence of the monomer A polypeptide does not comprise GlySer at the N terminus, and the monomer B polypeptide comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of SEQ ID NO: 2, 332, 334, 336, 338, 340, 342, 344, 346, 348, 418, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, 384, 386, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 414, 416, 420, 422, 424, 426, 428, 126, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472, 474, 174, 476, 478, 480, 482, 484, 486, 488, 490, 492, or 494, respectively, wherein the amino acid sequence of the monomer B polypeptide does not comprise GlySer at the N terminus.

[0132] In some aspects, the protein of the present disclosure comprises a heterodimer comprising a monomer A polypeptide and a monomer B polypeptide, wherein the monomer A polypeptide consists of an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence as set forth in SEQ ID NO: 331, 5, 7, 13, 15, 25, 29, 31, 33, 35, 37, 39, 41, 45, 47, 53, 55, 57, 59, 61, 65, 67, 69, 71, 73, 75, 77, 79, 337, 339, 85, 87, 89, 91, 93, 95, 97, 99, 341, 103, 343, 107, 109, 111, 113, 459, 345, 347, 349, 351, 353, 355, 357, 359, 361, 363, 365, 367, 369, 371, 373, 375, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 407, 409, 411, 413, 415, 417, 419, or 421 and the monomer B polypeptide consists of an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence as set forth in SEQ ID NO: 2, 332, 334, 336, 338, 340, 342, 344, 346, 348, 418, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, 384, 386, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 414, 416, 420, 422, 424, 426, 428, 126, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472, 474, 174, 476, 478, 480, 482, 484, 486, 488, 490, 492, or 494, respectively.

[0133] In one embodiment of any of the above embodiments, amino acid changes from the reference amino acid sequence are conservative amino acid substitutions. As used herein, "conservative amino acid substitution" means an amino acid substitution that does not alter or substantially alter polypeptide function or other characteristics. A given amino acid can be replaced by a residue having similar physiochemical characteristics, e.g., substituting one aliphatic residue for another (such as Ile, Val, Leu, or Ala for one another), or substitution of one polar residue for another (such as between Lys and Arg; Glu and Asp; or Gln and Asn). Other such conservative substitutions, e.g., substitutions of entire regions having similar hydrophobicity characteristics, are well known. Polypeptides comprising conservative amino acid substitutions can be tested in any one of the assays described herein to confirm that a desired activity, e.g. antigen-binding activity and specificity of a native or reference polypeptide is retained.

[0134] Amino acids can be grouped according to similarities in the properties of their side chains (in A. L. Lehninger, in Biochemistry, second ed., pp. 73-75, Worth Publishers, New York (1975)): (1) non-polar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M); (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) acidic: Asp (D), Glu (E); (4) basic: Lys (K), Arg (R), His (H). Alternatively, naturally occurring residues can be divided into groups based on common side-chain properties: (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe. Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Particular conservative substitutions include, for example; Ala into Gly or into Ser; Arg into Lys; Asn into Gln or into H is; Asp into Glu; Cys into Ser; Gln into Asn; Glu into Asp; Gly into Ala or into Pro; His into Asn or into Gln; Ile into Leu or into Val; Leu into Ile or into Val; Lys into Arg, into Gln or into Glu; Met into Leu, into Tyr or into Ile; Phe into Met, into Leu or into Tyr; Ser into Thr; Thr into Ser; Trp into Tyr; Tyr into Trp; and/or Phe into Val, into Ile or into Leu.

[0135] In another embodiment of any of the above embodiments, amino acid residues at 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of defined interface positions are invariant compared to the reference amino acid sequence. Table 2 below provides the residue numbers within each A and B monomer that are present at the interface in the heterodimer. The position of interface residues are the same for A-B binding partners. Table 2 is organized by heterodimer design name (see the left-hand column in Tables 1A and 1B). Note that for purpose of defining the position of interface residues for each polypeptide in Table 1A and 1B, the "GS" residues at the amino terminus, if present, are not included.

TABLE-US-00003 TABLE 2 Interface residues by position number across both chains `a` and `b` DHD_1 [5, 6, 8, 9, 12, 13, 16, 19, 20, 22, 23, 31, 34, 35, 38, 41, 42, 45, 48, 52, 55, 59, 63, 66, 70, 73, 74, 77, 80, 81, 85, 88, 89, 92, 95, 96, 99, 102, 103, 106] DHD_2 [5, 6, 9, 12, 13, 16, 19, 20, 23, 26, 27, 30, 33, 36, 37, 38, 41, 44, 45, 48, 51, 55, 58, 62, 65, 69, 72, 73, 76, 81, 85, 88, 89, 92, 95, 96, 99, 102, 103, 106, 109, 110, 112, 114, 117, 120, 123, 124, 127, 128, 131, 134, 135, 137, 138, 141, 144, 145, 148, 149, 152] DHD_3 [6, 7, 10, 11, 13, 14, 17, 20, 21, 24, 25, 28, 33, 36, 40, 43, 44, 47, 50, 51, 54, 62, 63, 66, 69, 73, 76, 77, 80, 81, 84, 89, 92, 93, 96, 99, 100, 103, 106, 107, 110, 112] DHD_4 [1, 8, 11, 12, 15, 19, 22, 26, 29, 30, 33, 38, 39, 42, 45, 46, 49, 50, 53, 56, 57, 60, 63, 64, 67, 68, 71, 75, 76, 80, 83, 87, 90, 94, 98, 101, 105, 108, 113, 114, 117, 121, 124, 125, 128, 132, 135, 139, 142, 143, 146, 150] DHD_5 [4, 8, 12, 15, 16, 19, 22, 23, 26, 30, 34, 38, 39, 44, 48, 51, 55, 58, 62, 66, 69, 73, 76, 80, 84, 87, 88, 92, 95, 96, 98, 99, 102, 105, 106, 110, 114, 115, 117, 120, 124, 127, 131, 135, 138, 142, 145, 149, 152] DHD_6 [1, 5, 8, 9, 11, 12, 15, 16, 19, 22, 23, 26, 27, 30, 33, 35, 37, 42, 46, 49, 53, 56, 60, 64, 67, 71, 74, 77, 81, 84, 87, 88, 91, 92, 95, 99, 102, 105, 106, 109, 110, 111, 112, 113, 118, 122, 125, 129, 132, 133, 136, 140, 143, 147, 150] DHD_7 [3, 6, 10, 13, 17, 20, 24, 27, 31, 34, 44, 47, 48, 51, 55, 58, 61, 62, 65, 69, 72, 75, 76, 79, 82, 86, 89, 90, 93, 96, 100, 103, 107, 110, 115, 120, 124, 127, 130, 131, 134, 138, 141, 145, 148, 151, 152] DHD_8 [6, 10, 13, 17, 20, 24, 27, 28, 31, 34, 47, 50, 54, 57, 61, 64, 68, 71, 75, 76, 82, 83, 86, 89, 93, 96, 100, 103, 107, 110, 123, 126, 130, 133, 134, 137, 140, 144, 147, 150, 151, 152] DHD_9 [12, 16, 19, 23, 26, 30, 33, 38, 39, 42, 46, 49, 52, 53, 56, 59, 60, 63, 67, 69, 88, 92, 95, 99, 102, 106, 109, 115, 122, 125, 129, 132, 136, 139, 143, 145] DHD_16 [6, 9, 10, 13, 16, 17, 20, 23, 24, 27, 28, 30, 34, 43, 46, 50, 53, 57, 60, 64, 67, 71, 72, 5, 8, 12, 15, 19, 22, 23, 26, 29, 33, 41, 50, 57, 60, 64, 67, 68, 71, 74, 78] DHD_18 [3, 6, 9, 10, 13, 16, 17, 20, 23, 24, 27, 31, 34, 38, 43, 46, 50, 53, 57, 60, 64, 67, 68, 71, 75, 78, 81, 85, 88, 91, 95, 98, 102, 105, 106, 109, 118, 121, 125, 128, 132, 135, 136, 139, 142, 146, 149, 150] DHD_19 [3, 6, 9, 10, 13, 16, 17, 20, 23, 24, 27, 30, 31, 34, 38, 43, 46, 50, 53, 57, 60, 61, 64, 67, 71, 75, 81, 88, 91, 95, 98, 99, 102, 105, 109, 118, 121, 125, 128, 129, 132, 135, 139, 142, 146, 149, 150] DHD_22 [1, 2, 5, 6, 9, 10, 12, 13, 16, 19, 20, 23, 27, 30, 31, 33, 34, 38, 41, 44, 47, 48, 51, 55, 58, 62, 65, 69, 72, 80, 81, 84, 87, 91, 94, 97, 98, 101, 102, 105, 108, 118, 122, 125, 126, 129, 132, 136, 139, 143, 146, 147, 148] DHD_23 [1, 5, 6, 8, 9, 12, 15, 16, 19, 22, 23, 26, 29, 30, 33, 34, 40, 43, 47, 51, 54, 57, 58, 61, 64, 65, 68, 72, 75, 76, 79, 82, 83, 86, 89, 90, 93, 96, 97, 100, 104, 109, 110, 113, 116, 120, 123, 126, 127, 130, 134, 138] DHD_24 [1, 5, 9, 12, 16, 19, 22, 26, 29, 30, 33, 40, 41, 42, 45, 48, 49, 51, 52, 55, 56, 59, 62, 63, 66, 69, 70, 73, 77, 80, 83, 84, 87, 91, 94, 98, 101, 105, 108, 109, 113, 118, 121, 125, 128, 129, 132, 136, 139, 142, 143, 147] DHD_26 [5, 8, 9, 12, 16, 19, 22, 23, 26, 29, 30, 33, 37, 40, 44, 45, 48, 51, 52, 55, 58, 59, 62, 65, 66, 69, 73, 77, 80, 84, 87, 91, 94, 95, 98, 101, 105, 109, 112, 114, 115, 118, 119, 122, 125, 126, 129, 132, 136, 139, 143] DHD_28 [2, 5, 6, 9, 13, 16, 20, 23, 26, 27, 30, 31, 33, 34, 46, 47, 50, 53, 54, 57, 60, 61, 64, 67, 68, 71, 75, 78, 82, 85, 86, 89, 92, 93, 96, 99, 100, 103, 106, 110, 114, 115, 118, 121, 125, 128, 132, 135, 139, 142, 146, 147] DHD_29 [2, 5, 6, 8, 9, 10, 12, 13, 16, 19, 20, 22, 23, 26, 27, 30, 33, 34, 39, 42, 45, 46, 49, 53, 56, 60, 63, 66, 67, 70, 71, 74, 77, 78, 81, 84, 85, 88, 91, 92, 95, 98, 99, 102, 106, 112, 115, 116, 119, 120, 122, 123, 126, 129, 130, 133, 137, 140, 141, 144, 145] DHD_31 [2, 5, 6, 9, 10, 12, 13, 16, 17, 19, 20, 23, 24, 26, 27, 30, 31, 33, 34, 37, 38, 39, 43, 46, 50, 54, 57, 60, 61, 64, 65, 68, 71, 75, 78, 81, 82, 85, 88, 89, 92, 95, 96, 99, 102, 103, 106, 109, 110, 119, 123, 126, 130, 133, 134, 137, 140, 141, 144, 147, 148, 151, 152] DHD_32 [5, 6, 9, 12, 16, 19, 23, 26, 27, 30, 33, 34, 37, 44, 48, 49, 52, 55, 56, 58, 59, 62, 63, 65, 66, 69, 70, 73, 76, 77, 79, 80, 82, 83, 86, 87, 90, 93, 94, 97, 100, 101, 104, 107, 108, 111, 114, 115, 118, 123, 124, 127, 130, 133, 134, 137, 138, 140, 141, 144, 145, 147, 148, 151, 152] DHD_38 [42, 43, 46, 49, 50, 52, 53, 56, 57, 60, 63, 64, 67, 70, 71, 74, 77, 79, 80, 84, 87, 88, 91, 94, 95, 98, 101, 102, 105, 109, 116, 117, 120, 123, 124, 127, 131, 134, 137, 138, 141, 144, 145, 149, 153, 158, 161, 162, 165, 168, 169, 172, 175, 176, 179, 182, 183, 185, 186, 187, 189] DHD_39 [2, 6, 9, 13, 16, 20, 23, 27, 29, 30, 34, 40, 43, 46, 47, 50, 51, 54, 57, 58, 60, 61, 64, 110, 114, 117, 121, 124, 128, 131, 132, 135, 138, 145, 149, 152, 156, 159, 160, 163, 164, 166, 167, 170, 173, 174, 176, 177, 178] DHD_40 [5, 9, 11, 12, 15, 16, 19, 23, 26, 29, 30, 33, 43, 46, 49, 50, 53, 56, 57, 59, 60, 63, 64, 67, 71, 108, 112, 116, 119, 123, 127, 130, 133, 134, 137, 138, 148, 151, 154, 158, 161, 165, 168, 169, 172, 175] DHD_43 [3, 4, 7, 11, 14, 18, 22, 25, 29, 34, 35, 39, 43, 46, 47, 50, 51, 54, 57, 58, 61, 62, 65, 71, 72, 75, 76, 79, 82, 83, 86, 87, 90, 93, 94, 97, 98, 100, 101, 104, 111, 114, 115, 117, 118, 122, 125, 126, 129, 133, 136, 137, 140, 144] DHD_60 [6, 7, 9, 10, 13, 16, 17, 20, 23, 24, 27, 30, 31, 34, 35, 51, 54, 55, 58, 61, 62, 65, 68, 72, 75, 76, 77, 83, 87, 90, 91, 93, 94, 97, 100, 101, 104, 105, 108, 111, 115, 116, 121, 122, 124, 125, 128, 131, 132, 135, 136, 138, 139, 142, 143, 149] DHD_63 [6, 10, 13, 17, 20, 24, 27, 30, 31, 34, 41, 44, 45, 48, 51, 52, 55, 56, 58, 59, 62, 65, 66, 68, 69, 70, 72, 73, 74, 80, 83, 84, 87, 90, 93, 94, 97, 104, 105, 118, 122, 125, 126, 129, 132, 136, 139, 140, 143, 146, 150] DHD_65 [2, 5, 6, 8, 9, 12, 13, 16, 19, 20, 23, 26, 27, 29, 30, 33, 34, 37, 43, 47, 50, 54, 57, 61, 64, 68, 71, 72, 75, 82, 85, 86, 89, 92, 93, 96, 99, 100, 103, 106, 107, 110, 118, 120, 121, 123, 127, 128, 131, 134, 135, 138, 139, 141, 142, 145, 148] DHD_66 [6, 10, 13, 16, 17, 20, 24, 27, 31, 34, 42, 43, 46, 49, 50, 53, 54, 56, 57, 60, 63, 64, 67, 68, 71, 78, 81, 82, 85, 88, 89, 92, 95, 99, 102, 103, 107, 112, 113, 115, 116, 119, 123, 126, 127, 130, 133, 137, 140, 141] DHD_67 [6, 9, 10, 13, 16, 17, 20, 21, 23, 24, 27, 28, 30, 31, 34, 36, 42, 46, 49, 52, 53, 56, 60, 63, 67, 70, 74, 77, 80, 81, 84, 87, 88, 91, 94, 95, 98, 101, 102, 105, 110, 114, 123, 130, 131, 133, 134, 140, 144, 147, 151] DHD_69 [2, 5, 6, 9, 10, 12, 13, 16, 17, 19, 20, 23, 26, 27, 30, 33, 35, 44, 47, 51, 54, 58, 61, 65, 68, 72, 75, 76, 78, 82, 85, 86, 89, 92, 96, 99, 100, 102, 103, 106, 107, 111, 117, 118, 120, 121, 124, 127, 128, 131, 134, 135, 138, 139, 141, 142, 146] DHD_70 [6, 9, 10, 13, 16, 17, 20, 23, 24, 26, 27, 30, 31, 34, 37, 38, 41, 43, 44, 47, 50, 51, 54, 57, 58, 61, 64, 65, 68, 71, 72, 73, 74, 78, 81, 82, 85, 88, 89, 92, 95, 96, 99, 102, 103, 106, 107, 109, 110, 111, 119, 120, 123, 124, 127, 130, 131, 134, 137, 138, 141, 144, 145, 148] DHD_71 [9, 16, 19, 23, 30, 34, 40, 43, 44, 46, 47, 50, 51, 54, 57, 58, 61, 64, 65, 69, 72, 75, 78, 79, 82, 85, 86, 89, 92, 93, 96, 97, 99, 100, 103, 106, 111, 115, 118, 119, 121, 122, 125, 128, 129, 132, 136, 139, 140] DHD_72 [1, 2, 5, 6, 8, 9, 12, 16, 19, 23, 26, 27, 30, 33, 34, 40, 43, 46, 47, 50, 54, 57, 63, 64, 67, 68, 75, 78, 79, 82, 85, 86, 89, 92, 93, 96, 99, 102, 103, 106, 108, 112, 115, 116, 119, 120, 123, 126, 130, 133, 137, 140, 143] DHD_73 [2, 6, 9, 10, 12, 16, 17, 23, 24, 27, 30, 31, 34, 36, 37, 40, 43, 44, 47, 51, 54, 57, 58, 61, 65, 69, 79, 82, 86, 89, 92, 93, 96, 99, 100, 103, 104, 107, 117, 120, 124, 127, 131, 134, 137, 138, 141, 142, 145, 148, 149] DHD_88 [2, 3, 6, 9, 13, 16, 20, 23, 27, 30, 34, 37, 48, 51, 52, 55, 56, 58, 59, 62, 63, 65, 66, 69, 70, 72, 73, 76, 79, 80, 81, 83, 87, 90, 91, 94, 97, 98, 101, 104, 105, 108, 111, 112, 115, 116, 121, 125, 128, 132, 135, 136, 139, 140, 142, 143, 146, 149, 150, 153, 154] DHD_89 [1, 2, 5, 8, 9, 12, 15, 16, 19, 22, 23, 26, 29, 30, 33, 34, 36, 37, 38, 48, 51, 55, 58, 62, 65, 69, 72, 79, 82, 83, 86, 87, 89, 90, 93, 94, 97, 100, 101, 103, 104, 107, 108, 109, 110, 111, 114, 117, 118, 121, 124, 128, 131, 135, 138, 139, 142, 145, 146] DHD_90 [1, 2, 5, 6, 8, 9, 12, 13, 16, 19, 20, 23, 26, 27, 29, 30, 33, 34, 37, 39, 43, 46, 47, 50, 54, 57, 61, 64, 68, 71, 75, 77, 78, 81, 82, 85, 88, 89, 91, 92, 95, 96, 99, 102, 103, 106, 109, 110, 113, 116, 119, 122, 125, 126, 129, 132, 133, 136, 139, 140, 143, 146, 147, 150, 151] DHD_91 [2, 5, 9, 12, 16, 17, 19, 23, 26, 27, 30, 33, 39, 40, 43, 46, 50, 53, 57, 60, 64, 67, 70, 74, 77, 78, 81, 84, 85, 88, 91, 92, 95, 96, 98, 99, 101, 109, 112, 116, 119, 123, 126, 130, 133, 137, 138] DHD_92 [5, 6, 8, 9, 12, 13, 15, 16, 19, 20, 22, 23, 26, 27, 29, 30, 33, 36, 37, 38, 42, 46, 49, 50, 53, 56, 57, 59, 60, 63, 67, 70, 71, 74, 77, 80, 81, 84, 87, 88, 91, 94, 95, 98, 101, 102, 105, 109, 110, 114, 118, 121, 125, 128, 129, 132, 135, 136, 139, 142, 143] DHD_93 [2, 5, 6, 9, 10, 12, 13, 16, 19, 20, 23, 26, 27, 30, 34, 35, 37, 40, 44, 47, 51, 54, 58, 61, 65, 76, 79, 83, 86, 87, 90, 93, 94, 97, 100, 104, 107, 109, 113, 116, 117, 120, 123, 124, 127, 130, 131, 134, 137, 138, 141, 144, 145] DHD_94 [1, 5, 8, 9, 12, 15, 16, 19, 22, 23, 26, 29, 30, 33, 37, 45, 48, 51, 52, 55, 59, 62, 66, 69, 73, 75, 76, 84, 87, 88, 91, 94, 98, 101, 102, 105, 108, 109, 111, 112, 115, 117, 118, 122, 126, 129, 130, 133, 136, 140, 143, 147, 150, 151, 154] DHD_95 [2, 6, 9, 13, 16, 20, 23, 26, 27, 30, 34, 37, 39, 41, 42, 45, 48, 49, 52, 55,

56, 59, 62, 63, 66, 69, 70, 72, 73, 75, 81, 85, 88, 91, 92, 95, 96, 98, 99, 102, 105, 106, 109, 110, 113, 114, 120, 123, 124, 127, 130, 131, 134, 137, 138, 141, 145, 148, 151] DHD_96 [1, 5, 6, 9, 10, 12, 13, 16, 19, 20, 23, 26, 27, 30, 33, 34, 42, 45, 46, 49, 52, 53, 56, 59, 60, 63, 66, 67, 70, 74, 75, 77, 81, 84, 88, 91, 95, 98, 102, 105, 114, 118, 119, 122, 123, 126, 129, 130, 132, 133, 136, 137, 139, 140, 143, 144, 146, 147, 150] DHD_97 [1, 2, 5, 6, 8, 9, 12, 15, 16, 19, 20, 22, 23, 26, 27, 29, 30, 32, 33, 37, 39, 41, 44, 47, 51, 54, 58, 61, 65, 68, 71, 72, 79, 82, 83, 86, 89, 90, 93, 96, 97, 100, 103, 104, 107, 110, 115, 116, 119, 120, 121, 123, 126, 127, 130, 133, 134, 136, 137, 140, 141, 144, 147] DHD_98 [6, 7, 9, 13, 16, 20, 23, 27, 30, 34, 35, 38, 43, 44, 50, 51, 53, 54, 57, 60, 61, 64, 67, 68, 71, 72, 74, 75, 78, 82, 85, 86, 89, 92, 93, 96, 99, 100, 103, 106, 110, 119, 123, 127, 130, 133, 134, 137, 141, 144, 148, 151, 152] DHD_99 [2, 5, 6, 9, 12, 16, 19, 20, 23, 26, 30, 33, 34, 46, 50, 53, 57, 60, 64, 67, 70, 71, 74, 78, 82, 85, 89, 92, 96, 99, 103, 106, 110, 113, 123, 126, 130, 133, 137, 140, 141, 144, 147, 148, 151, 154, 155] DHD_100 [1, 5, 8, 9, 12, 15, 16, 19, 22, 23, 26, 29, 30, 33, 38, 41, 42, 45, 49, 52, 55, 56, 59, 63, 66, 70, 73, 74, 77, 80, 81, 84, 87, 88, 91, 94, 95, 98, 101, 102, 104, 105, 106, 108, 109, 112, 115, 119, 122, 123, 126, 129, 130, 133, 136, 137] DHD_101 [5, 6, 9, 12, 13, 16, 20, 23, 27, 30, 34, 39, 43, 46, 47, 50, 53, 54, 57, 60, 64, 67, 68, 71, 74, 75, 78, 79, 81, 84, 85, 88, 92, 95, 99, 102, 106, 109, 119, 120, 123, 126, 130, 133, 134, 137, 138, 140, 144, 147, 151] DHD_102 [6, 9, 13, 16, 20, 22, 23, 27, 30, 34, 38, 44, 47, 51, 54, 55, 57, 58, 61, 65, 68, 69, 72, 75, 80, 83, 86, 90, 93, 97, 100, 104, 107, 108, 112, 113, 117, 121, 124, 128, 131, 132, 135, 138, 142, 145] DHD_103 [1, 2, 5, 6, 8, 9, 13, 16, 17, 19, 20, 23, 27, 30, 34, 39, 43, 46, 47, 50, 53, 54, 57, 61, 64, 68, 70, 71, 79, 80, 82, 86, 89, 93, 94, 96, 100, 103, 106, 112, 116, 119, 123, 126, 130, 133, 134, 137, 140] DHD_104 [6, 9, 10, 13, 16, 17, 19, 20, 23, 24, 27, 30, 31, 34, 45, 48, 52, 55, 59, 62, 66, 69, 80, 83, 84, 87, 90, 94, 97, 98, 101, 104, 113, 114, 117, 120, 124, 127, 131, 134, 138, 141, 144, 145] DHD_105 [9, 12, 16, 19, 23, 26, 30, 33, 37, 41, 43, 44, 47, 50, 51, 54, 57, 58, 61, 64, 65, 68, 71, 72, 79, 82, 83, 86, 89, 90, 93, 97, 100, 101, 103, 104, 107, 118, 121, 122, 125, 128, 129, 132, 135, 136, 139, 142, 143, 146, 147] DHD_106 [2, 3, 6, 9, 10, 12, 13, 16, 17, 20, 23, 24, 27, 30, 34, 43, 46, 50, 53, 57, 60, 64, 67, 71, 74, 78, 81, 85, 88, 92, 93, 95, 99, 102, 103, 106, 109, 110, 113, 120, 121, 123, 127, 128, 130, 134, 135, 137, 141, 144, 148, 151, 155] DHD_107 [2, 6, 9, 10, 13, 16, 20, 23, 24, 27, 30, 31, 34, 40, 43, 46, 50, 53, 56, 57, 60, 63, 64, 67, 71, 73, 75, 81, 84, 85, 88, 91, 92, 95, 98, 99, 102, 106, 109, 114, 115, 116, 119, 122, 123, 125, 126, 129, 130, 133, 136, 137, 140, 143, 144, 146] DHD_108 [2, 6, 7, 10, 17, 20, 21, 24, 25, 28, 35, 42, 43, 46, 50, 53, 57, 60, 61, 64, 68, 71, 75, 82, 86, 89, 93, 97, 100, 104, 111, 115, 116, 123, 124, 127, 128, 130, 131, 134, 135, 138, 141, 142, 145, 146, 149, 152, 153, 156] DHD_109 [6, 7, 10, 14, 17, 21, 25, 28, 32, 35, 41, 42, 44, 45, 48, 49, 52, 55, 56, 59, 60, 62, 63, 66, 70, 77, 81, 84, 85, 88, 92, 95, 99, 102, 106, 109, 111, 116, 117, 120, 123, 124, 127, 130, 131, 134, 135, 138, 141, 142] DHD_110 [5, 6, 9, 13, 17, 20, 24, 27, 31, 35, 38, 48, 49, 52, 53, 56, 59, 60, 63, 66, 67, 70, 74, 77, 78, 81, 84, 85, 88, 91, 92, 95, 96, 99, 102, 103, 106, 109, 110, 113, 114, 117, 128, 129, 132, 136, 139, 143, 147, 150, 154, 157, 161] DHD_111 [5, 6, 9, 10, 13, 16, 17, 20, 23, 24, 27, 28, 31, 34, 35, 47, 51, 54, 58, 62, 65, 69, 72, 76, 80, 84, 87, 90, 91, 94, 95, 98, 101, 102, 105, 109, 112, 113, 116, 122, 125, 129, 132, 136, 140, 143, 147, 154, 158] DHD_112 [6, 13, 16, 17, 20, 24, 27, 31, 35, 38, 48, 51, 52, 55, 58, 59, 62, 63, 66, 69, 70, 73, 76, 77, 80, 81, 88, 91, 92, 95, 99, 102, 106, 109, 113, 120, 121, 123, 124, 126, 127, 130, 133, 134, 137, 138, 141, 144, 145, 148, 151, 152, 155, 156] DHD_113 [6, 9, 13, 14, 16, 20, 23, 27, 30, 31, 34, 39, 43, 44, 47, 48, 51, 54, 55, 58, 61, 62, 65, 66, 68, 69, 72, 73, 76, 80, 83, 84, 87, 90, 91, 94, 97, 98, 101, 102, 105, 108, 109, 112, 117, 122, 125, 129, 133, 136, 140, 143, 147, 151] DHD_114 [5, 6, 9, 10, 13, 16, 17, 20, 23, 24, 27, 30, 31, 34, 35, 38, 39, 41, 44, 47, 51, 55, 58, 62, 65, 69, 72, 76, 81, 84, 87, 88, 91, 95, 98, 99, 102, 105, 106, 108, 109, 113, 117, 122, 126, 129, 130, 133, 137, 140, 144, 147, 151, 155] DHD_115 [5, 6, 9, 12, 13, 16, 17, 20, 23, 24, 27, 30, 31, 34, 37, 43, 47, 50, 54, 57, 58, 61, 65, 68, 69, 72, 74, 75, 76, 78, 79, 82, 85, 86, 89, 90, 93, 96, 97, 100, 103, 104, 107, 108, 121, 125, 128, 132, 135, 139, 143, 146, 150, 153] DHD_116 [3, 6, 7, 10, 14, 17, 21, 24, 25, 28, 32, 35, 36, 48, 49, 52, 56, 59, 60, 63, 66, 67, 70, 71, 74, 77, 78, 81, 87, 88, 91, 95, 98, 99, 102, 103, 105, 106, 109, 110, 113, 116, 129, 133, 136, 140, 144, 147, 151, 154, 158, 161, 162] DHD_117 [6, 10, 13, 17, 20, 21, 24, 27, 28, 31, 35, 38, 40, 44, 47, 48, 51, 55, 58, 59, 62, 65, 66, 69, 72, 73, 76, 77, 79, 83, 84, 87, 90, 91, 94, 98, 101, 102, 105, 108, 109, 112, 116, 125, 126, 129, 133, 136, 140, 141, 143, 144, 147, 151, 154, 155] DHD_118 [6, 10, 13, 14, 17, 20, 24, 28, 31, 35, 38, 49, 52, 53, 56, 59, 60, 63, 66, 67, 70, 74, 77, 81, 82, 85, 88, 92, 95, 99, 102, 106, 109, 110, 113, 116, 118, 119, 123, 127, 130, 131, 134, 137, 138, 141, 145, 148, 149, 152, 153] DHD_119 [2, 6, 10, 13, 14, 17, 20, 21, 24, 25, 28, 31, 32, 35, 40, 41, 45, 46, 49, 52, 56, 60, 63, 67, 71, 74, 75, 78, 82, 84, 85, 88, 89, 92, 95, 96, 99, 103, 106, 107, 110, 113, 114, 117, 120, 122, 127, 131, 134, 138, 141, 142, 145, 148, 149, 152, 156] DHD_120 [7, 10, 13, 14, 17, 21, 25, 28, 31, 32, 35, 41, 44, 45, 48, 49, 51, 52, 55, 56, 59, 62, 63, 66, 69, 70, 73, 74, 79, 83, 84, 87, 91, 94, 95, 98, 101, 102, 105, 109, 112, 113, 122, 126, 129, 133, 136, 137, 140, 144, 147, 148, 151] DHD_121 [5, 6, 9, 13, 16, 20, 23, 27, 30, 37, 43, 46, 47, 50, 53, 54, 57, 60, 61, 64, 67, 68, 71, 74, 75, 82, 85, 86, 89, 92, 93, 96, 99, 100, 103, 106, 107, 110, 113, 115, 120, 123, 127, 130, 134, 137, 141, 144, 148] DHD_122 [6, 10, 13, 14, 17, 21, 24, 25, 28, 31, 32, 35, 41, 44, 45, 48, 51, 52, 55, 59, 62, 63, 66, 69, 70, 73, 74, 75, 81, 82, 85, 88, 92, 95, 96, 99, 100, 102, 103, 106, 107, 110, 113, 123, 127, 131, 134, 138, 141, 145, 152, 156, 157] DHD_123 [1, 3, 6, 10, 13, 14, 17, 20, 21, 24, 28, 31, 32, 35, 38, 39, 40, 42, 44, 48, 51, 52, 55, 59, 62, 66, 69, 70, 73, 74, 80, 83, 84, 87, 91, 94, 95, 98, 102, 105, 109, 110, 115, 118, 119, 122, 123, 126, 129, 130, 133, 134, 136, 137, 140, 144, 145, 147, 148] DHD_124 [6, 9, 10, 13, 16, 17, 20, 24, 27, 28, 31, 34, 35, 38, 43, 44, 47, 50, 51, 54, 58, 61, 62, 65, 68, 69, 72, 79, 83, 86, 87, 90, 91, 94, 97, 98, 101, 104, 105, 108, 112, 121, 125, 128, 129, 132, 136, 139, 143, 146, 147, 150, 154, 155] DHD_125 [2, 6, 9, 10, 13, 16, 17, 20, 24, 27, 28, 31, 35, 38, 43, 46, 47, 50, 54, 57, 58, 61, 65, 68, 69, 72, 73, 75, 79, 82, 83, 86, 90, 93, 97, 100, 101, 104, 107, 108, 111, 121, 122, 125, 129, 132, 133, 136, 139, 140, 143, 147, 150] DHD_126 [1, 2, 5, 6, 9, 10, 12, 13, 16, 20, 23, 24, 27, 28, 30, 31, 34, 43, 47, 50, 51, 54, 58, 61, 62, 65, 68, 69, 72, 83, 86, 87, 90, 94, 97, 98, 101, 105, 108, 109, 112, 115, 121, 122, 125, 128, 132, 136, 139, 140, 143, 146, 147, 150, 151] DHD_127 [3, 6, 9, 10, 13, 14, 16, 17, 20, 23, 24, 27, 31, 34, 39, 44, 47, 51, 54, 58, 61, 65, 68, 72, 79, 83, 86, 90, 93, 96, 97, 100, 103, 104, 107, 111, 114, 117, 121, 124, 128, 131, 135, 139, 142, 145, 146] DHD_128 [6, 9, 10, 13, 16, 17, 20, 23, 24, 27, 30, 31, 32, 40, 44, 47, 51, 54, 58, 61, 65, 68, 72, 79, 83, 86, 87, 90, 93, 97, 100, 104, 118, 121, 125, 128, 132, 135, 139, 142, 146] DHD_129 [2, 5, 6, 9, 12, 13, 16, 19, 20, 23, 24, 26, 27, 30, 34, 42, 46, 49, 53, 56, 60, 63, 64, 67, 70, 74, 80, 81, 84, 88, 91, 94, 95, 98, 101, 102, 105, 109, 112, 122, 125, 126, 129, 132, 133, 135, 136, 139, 143, 146, 147, 150, 153] DHD_130 [3, 6, 10, 13, 17, 20, 24, 27, 31, 34, 37, 41, 44, 45, 48, 51, 52, 55, 58, 59, 62, 65, 66, 69, 70, 72, 73, 79, 83, 86, 90, 93, 97, 100, 104, 107, 111, 116, 121, 122, 125, 128, 129, 132, 135, 136, 139, 142, 143, 146, 149, 150, 153] DHD_131 [3, 6, 9, 10, 13, 16, 17, 20, 24, 27, 31, 34, 44, 48, 51, 52, 54, 55, 58, 59, 61, 62, 65, 66, 69, 72, 73, 76, 83, 87, 90, 91, 94, 97, 101, 104, 108, 111, 121, 124, 125, 128, 131, 132, 135, 138, 139, 142, 145, 146, 149, 150, 152, 153] DHD_132 [5, 6, 9, 12, 13, 16, 19, 20, 23, 26, 27, 30, 33, 34, 37, 39, 43, 46, 47, 50, 54, 57, 64, 68, 71, 74, 75, 85, 86, 89, 92, 93, 95, 99, 100, 103, 105, 106, 107, 110, 114, 120, 123, 127, 130, 134, 137, 141, 144, 148] DHD_133 [6, 10, 13, 17, 20, 21, 24, 27, 31, 34, 39, 44, 45, 48, 51, 52, 55, 58, 59, 62, 65, 66, 69, 72, 73, 76, 83, 87, 90, 94, 97, 101, 104, 108, 111, 112, 121, 122, 125, 126, 129, 132, 136, 139, 143, 146, 149, 150, 153] DHD_134 [6, 9, 10, 13, 16, 17, 20, 23, 24, 27, 30, 31, 34, 38, 43, 47, 50, 54, 57, 61, 64, 68, 71, 75, 82, 85, 89, 92, 96, 99, 103, 106, 110, 111, 118, 122, 125, 129, 132, 133, 136, 139, 140, 143, 146] DHD_135 [2, 5, 6, 9, 12, 13, 16, 19, 20, 23, 26, 27, 30, 33, 34, 37, 38, 46, 50, 53, 57, 60, 64, 67, 71, 80, 81, 84, 87, 91, 94, 95, 98, 101, 102, 105, 108, 115, 119, 122, 126, 129, 130, 133, 136, 140, 143] DHD_136 [5, 6, 8, 9, 12, 15, 16, 19, 22, 23, 26, 29, 30, 33, 36, 37, 41, 45, 48, 52, 55, 59, 62, 66, 69, 70, 72, 73, 79, 82, 83, 86, 89, 90, 93, 97, 100, 104, 107, 117, 120, 121, 124, 127, 128, 131, 134, 135, 138, 141, 142] DHD_137 [2, 6, 9, 13, 16, 17, 20, 23, 24, 27, 30, 31, 34, 43, 46, 47, 50, 54, 57,

61, 64, 68, 71, 72, 74, 78, 81, 85, 89, 92, 96, 99, 102, 103, 107, 113, 116, 117, 120, 123, 124, 127, 130, 131, 134, 137, 138, 141] DHD_138 [6, 10, 13, 17, 20, 24, 27, 31, 34, 43, 47, 50, 54, 57, 61, 64, 68, 71, 82, 86, 89, 93, 96, 100, 103, 107, 110, 119, 120, 123, 126, 127, 130, 133, 134, 137, 140, 143, 144, 147, 148, 150, 151] DHD_139 [2, 5, 6, 9, 12, 13, 16, 19, 20, 23, 26, 27, 30, 34, 37, 38, 39, 45, 49, 52, 56, 59, 63, 66, 76, 79, 80, 83, 86, 87, 90, 93, 94, 97, 100, 101, 104, 107, 108, 113, 115, 118, 121, 125, 128, 132, 135, 139, 142, 143, 145, 146] DHD_140 [5, 6, 9, 12, 13, 16, 19, 20, 23, 26, 27, 30, 33, 36, 38, 43, 47, 50, 51, 54, 57, 61, 64, 68, 71, 78, 81, 85, 88, 89, 92, 95, 96, 99, 102, 103, 120, 124, 127, 131, 134, 135, 138, 141, 145, 148] DHD_141 [6, 10, 13, 17, 20, 24, 27, 28, 31, 34, 37, 40, 43, 44, 47, 48, 51, 54, 57, 58, 61, 62, 64, 65, 68, 71, 72, 81, 85, 88, 92, 95, 99, 102, 106, 109, 113, 118, 120, 123, 124, 127, 130, 131, 134, 137, 138, 141, 144, 145, 148, 151, 152] DHD_142 [1, 2, 5, 6, 9, 12, 13, 15, 16, 19, 20, 23, 24, 26, 27, 30, 33, 40, 44, 47, 51, 54, 58, 61, 68, 69, 72, 75, 78, 79, 82, 85, 86, 89, 92, 95, 96, 99, 100, 103, 106, 107, 110, 120, 121, 124, 127, 131, 134, 138, 141, 145, 148, 152] DHD_143 [2, 6, 9, 13, 16, 17, 20, 23, 27, 30, 34, 39, 44, 48, 51, 55, 58, 62, 65, 66, 69, 72, 73, 83, 87, 90, 94, 97, 101, 104, 108, 111, 121, 124, 125, 128, 131, 132, 135, 136, 138, 139, 142, 145, 146, 149, 150, 152, 153] DHD_144 [1, 5, 6, 9, 12, 13, 16, 19, 20, 23, 26, 27, 30, 33, 42, 46, 49, 53, 56, 60, 63, 67, 70, 73, 74, 76, 77, 80, 81, 83, 84, 87, 88, 90, 91, 94, 95, 98, 99, 101, 102, 105, 108, 109, 117, 120, 121, 124, 128, 131, 135, 138, 142, 145, 149, 150] DHD_145 [5, 6, 9, 12, 13, 16, 19, 20, 23, 26, 30, 33, 34, 47, 50, 54, 57, 61, 64, 68, 71, 75, 78, 85, 86, 88, 89, 92, 95, 96, 99, 102, 103, 106, 109, 110, 113, 123, 127, 130, 134, 137, 141, 144, 145, 148, 151, 155] DHD_146 [2, 5, 6, 9, 10, 12, 13, 16, 19, 23, 26, 27, 30, 33, 34, 40, 43, 46, 50, 53, 54, 57, 60, 61, 64, 67, 71, 78, 81, 82, 85, 88, 89, 92, 95, 96, 99, 100, 102, 103, 106, 126, 129, 133, 136, 140, 143, 147, 150, 151] DHD_147 [6, 7, 10, 13, 14, 17, 20, 24, 27, 31, 34, 37, 38, 42, 43, 46, 49, 50, 53, 54, 56, 57, 60, 63, 64, 67, 70, 71, 74, 81, 84, 88, 91, 95, 98, 102, 105, 109, 116, 119, 123, 126, 127, 130, 133, 137, 140, 141, 144, 147, 148] DHD_149 [1, 5, 6, 9, 12, 13, 16, 17, 19, 23, 26, 27, 30, 33, 34, 42, 46, 49, 53, 56, 60, 63, 67, 70, 74, 75, 77, 81, 84, 85, 88, 91, 92, 95, 98, 102, 105, 106, 116, 120, 123, 124, 127, 130, 131, 134, 137, 138, 141, 144, 145, 148] DHD_150 [1, 2, 5, 6, 9, 12, 13, 16, 19, 20, 23, 26, 27, 30, 33, 34, 42, 46, 49, 50, 53, 56, 60, 63, 67, 70, 74, 75, 77, 81, 88, 91, 95, 98, 102, 105, 108, 116, 120, 123, 124, 127, 130, 131, 134, 137, 138, 141, 144, 145, 148] DHD_151 [5, 9, 12, 13, 16, 19, 20, 23, 26, 27, 30, 33, 34, 36, 43, 46, 47, 50, 54, 57, 61, 64, 68, 71, 74, 78, 81, 82, 85, 88, 89, 92, 95, 96, 99, 102, 103, 106, 111, 116, 120, 123, 127, 130, 134, 137, 141, 144, 148] DHD_152 [5, 6, 9, 12, 13, 19, 20, 23, 26, 27, 30, 33, 34, 36, 40, 43, 46, 47, 50, 54, 57, 61, 64, 68, 71, 74, 78, 81, 82, 85, 88, 89, 92, 95, 96, 99, 102, 103, 106, 111, 116, 120, 123, 127, 134, 137, 141, 144, 148] DHD_153 [6, 10, 13, 14, 17, 20, 21, 24, 27, 31, 34, 44, 45, 48, 51, 52, 58, 59, 62, 65, 66, 69, 73, 74, 76, 80, 83, 84, 87, 90, 91, 94, 97, 101, 104, 105, 107, 115, 118, 122, 125, 126, 129, 132, 136, 139, 143] DHD_154 [2, 5, 6, 9, 12, 16, 19, 20, 23, 26, 27, 30, 33, 34, 40, 43, 47, 50, 54, 57, 61, 64, 68, 71, 72, 74, 78, 81, 85, 88, 92, 95, 99, 102, 106, 109, 115, 116, 119, 122, 123, 126, 129, 133, 136, 137, 140, 143, 144, 147] DHD_155 [5, 6, 9, 13, 16, 19, 20, 23, 27, 30, 34, 43, 47, 50, 53, 54, 57, 61, 64, 68, 75, 78, 79, 81, 82, 85, 88, 89, 92, 95, 96, 99, 102, 109, 113, 116, 120, 123, 127, 130, 134, 137] DHD_156 [5, 6, 9, 12, 13, 16, 19, 20, 23, 26, 27, 30, 37, 40, 44, 47, 51, 54, 58, 61, 65, 68, 75, 76, 79, 82, 83, 89, 90, 93, 96, 97, 100, 104, 124, 128, 131, 132, 135, 138, 142, 145, 146] DHD_157 [5, 6, 9, 13, 16, 20, 23, 27, 30, 33, 34, 37, 39, 43, 44, 47, 48, 51, 54, 55, 58, 61, 62, 65, 68, 69, 72, 75, 76, 79, 83, 86, 87, 90, 93, 94, 97, 100, 101, 104, 107, 118, 122, 125, 129, 132, 136, 139, 143, 146, 150] DHD13_2341 [4, 5, 8, 11, 12, 15, 18, 19, 22, 25, 29, 32, 33, 36, 39, 41, 71, 91, 95, 98, 102, 105, 106, 109, 112, 113, 116, 117, 119, 121, 125, 126, 129, 132, 133, 136, 137, 139, 140, 143, 144, 146, 147, 150, 153, 154] DHD13_AAAA [6, 9, 13, 16, 17, 20, 23, 24, 27, 30, 34, 39, 44, 47, 48, 51, 54, 55, 58, 61, 62, 65, 68, 69, 72, 75, 82, 85, 89, 92, 96, 99, 100, 103, 106, 107, 109, 110, 111, 115, 123, 124, 127, 128, 130, 134, 137, 138, 141, 144, 145, 148, 149, 151] DHD13_B AAA [6, 9, 12, 13, 16, 17, 20, 23, 24, 27, 30, 34, 37, 38, 39, 44, 47, 51, 54, 55, 58, 61, 62, 65, 68, 69, 72, 75, 82, 85, 89, 92, 95, 96, 99, 100, 103, 106, 110, 115, 123, 127, 130, 134, 137, 138, 141, 144, 145, 148, 149, 151] DHD13_XAAA [6, 9, 13, 16, 17, 20, 23, 24, 27, 30, 34, 37, 38, 39, 44, 47, 48, 51, 54, 55, 58, 61, 62, 65, 68, 69, 72, 75, 82, 85, 89, 92, 96, 99, 100, 103, 106, 109, 110, 115, 123, 127, 130, 134, 137, 138, 141, 144, 145, 148, 149, 151] DHD13_XAAX [6, 9, 12, 13, 16, 17, 20, 23, 24, 27, 30, 34, 37, 38, 39, 44, 47, 48, 51, 54, 55, 58, 61, 62, 65, 68, 69, 72, 75, 82, 85, 89, 92, 96, 99, 100, 103, 106, 109, 110, 115, 123, 127, 130, 134, 137, 138, 141, 144, 145, 148, 149, 151] DHD13_XAXA [6, 9, 13, 16, 17, 20, 23, 24, 27, 30, 34, 37, 38, 39, 44, 47, 48, 51, 54, 55, 58, 61, 62, 65, 68, 69, 72, 75, 82, 85, 89, 92, 96, 99, 100, 103, 106, 109, 110, 115, 123, 127, 130, 134, 137, 138, 141, 144, 145, 148, 149, 151] DHD15 [5, 6, 9, 12, 13, 16, 19, 20, 23, 26, 27, 30, 33, 34, 37, 39, 40, 44, 47, 48, 51, 52, 55, 58, 59, 62, 65, 69, 72, 78, 82, 83, 86, 89, 90, 93, 96, 97, 100, 103, 104, 107, 110, 111, 114, 116, 117, 121, 125, 128, 129, 132, 135, 136, 139, 142, 143, 146, 149] DHD17 [6, 9, 10, 13, 16, 17, 20, 23, 24, 27, 30, 31, 34, 38, 42, 43, 46, 50, 53, 57, 60, 64, 67, 71, 75, 81, 84, 88, 91, 95, 98, 102, 105, 106, 109, 118, 121, 125, 128, 132, 135, 136, 139, 142, 146] DHD20 [3, 6, 9, 10, 13, 16, 17, 20, 23, 24, 27, 30, 31, 34, 38, 42, 43, 46, 50, 53, 57, 60, 61, 64, 67, 68, 71, 75, 78, 81, 85, 88, 91, 92, 95, 98, 99, 102, 105, 109, 118, 121, 125, 128, 132, 135, 139, 142, 146, 150] DHD21 [6, 9, 10, 13, 16, 20, 23, 24, 27, 30, 31, 34, 38, 43, 44, 46, 47, 50, 51, 53, 54, 57, 58, 60, 61, 63, 64, 65, 68, 71, 72, 75, 78, 79, 82, 85, 89, 92, 93, 96, 99, 100, 103, 107, 108, 112, 113, 116, 119, 120, 123, 126, 127, 130, 133, 134, 137, 141, 142] DHD25 [2, 5, 6, 9, 12, 13, 16, 19, 23, 26, 27, 30, 44, 47, 48, 51, 54, 55, 58, 61, 62, 65, 68, 69, 72, 75, 76, 83, 86, 87, 90, 93, 94, 97, 100, 101, 104, 107, 114, 115, 117, 118, 121, 124, 128, 131, 132, 135, 138, 142, 145] DHD27 [5, 6, 9, 12, 15, 16, 19, 22, 23, 26, 29, 30, 33, 37, 41, 42, 45, 49, 52, 56, 59, 63, 66, 70, 73, 74, 77, 81, 84, 88, 91, 95, 98, 102, 105, 108, 115, 116, 119, 122, 123, 126, 129, 130, 133, 136, 137, 140, 141, 143, 144, 147, 148] DHD30 [5, 6, 8, 9, 12, 15, 16, 19, 22, 23, 26, 29, 30, 33, 34, 37, 39, 42, 45, 49, 52, 56, 59, 63, 66, 70, 75, 78, 82, 85, 89, 92, 96, 99, 103, 106, 113, 116, 117, 120, 124, 127, 131, 134, 138, 141, 144, 145] DHD33 [1, 5, 6, 9, 12, 13, 16, 19, 20, 23, 26, 27, 30, 33, 34, 39, 40, 43, 46, 47, 50, 57, 60, 61, 64, 68, 71, 75, 78, 82, 85, 86, 89, 92, 93, 96, 99, 100, 103, 112, 113, 116, 119, 120, 123, 126, 127, 130, 133, 134, 137, 140, 141, 144] DHD34_XAAAA [1, 5, 8, 9, 12, 16, 19, 23, 26, 29, 30, 33, 37, 45, 48, 49, 52, 55, 56, 59, 62, 63, 66, 69, 70, 73, 76, 77, 86, 90, 93, 97, 100, 104, 105, 107, 111, 114, 124, 125, 128, 131, 132, 135, 138, 142, 145, 149, 152, 153, 156, 157] DHD34_XAAXA [1, 5, 8, 9, 12, 16, 19, 23, 26, 29, 30, 33, 37, 45, 48, 49, 52, 55, 56, 59, 62, 63, 66, 69, 70, 73, 76, 77, 86, 90, 93, 97, 100, 104, 105, 107, 108, 111, 114, 124, 125, 128, 131, 132, 135, 138, 142, 145, 149, 152, 153, 156, 157] DHD34_XAXXA [1, 5, 8, 9, 12, 16, 19, 22, 23, 26, 29, 30, 33, 37, 45, 48, 49, 52, 55, 56, 59, 62, 63, 66, 69, 70, 73, 76, 77, 86, 90, 93, 97, 100, 104, 105, 107, 108, 111, 114, 117, 124, 125, 128, 131, 132, 135, 138, 142, 145, 149, 152, 153, 156, 157] DHD36 [2, 6, 9, 13, 16, 20, 23, 27, 30, 33, 34, 39, 40, 42, 43, 46, 47, 50, 51, 53, 54, 57, 58, 61, 64, 75, 79, 82, 86, 89, 93, 96, 97, 100, 103, 110, 114, 117, 118, 121, 124, 125, 128, 131, 132, 135, 138, 139, 142, 143] DHD37_ABXB [2, 5, 9, 11, 12, 15, 16, 19, 23, 26, 29, 30, 33, 37, 43, 46, 49, 50, 53, 56, 57, 59, 60, 63, 64, 67, 77, 81, 84, 88, 91, 92, 95, 98, 99, 102, 105, 113, 116, 119, 120, 123, 126, 130, 133, 134, 137, 140, 141, 144] DHD37_AXBB [2, 5, 9, 12, 16, 18, 19, 22, 23, 26, 29, 30, 33, 37, 43, 46, 49, 50, 52, 53, 56, 57, 60, 67, 70, 71, 77, 78, 81, 84, 88, 91, 95, 96, 99, 102, 105, 113, 116, 119, 120, 123, 126, 127, 130, 133, 134, 137, 140, 144] DHD37_AXXB [2, 5, 9, 11, 12, 15, 16, 19, 22, 23, 26, 29, 30, 33, 37, 43, 46, 49, 50, 53, 56, 57, 59, 60, 63, 64, 67, 77, 81, 84, 88, 89, 92, 95, 98, 99, 102, 105, 113, 116, 119, 120, 123, 126, 130, 133, 134, 137, 140, 141, 144] DFID37_BBBB [5, 9, 12, 16, 19, 22, 23, 26, 30, 33, 42, 43, 46, 50, 53, 56, 57, 60, 63, 64, 66, 67, 74, 77, 78, 81, 84, 85, 88, 92, 95, 98, 99, 102, 105, 108, 111, 113, 116, 119, 123, 126, 130, 133, 137, 140, 141, 144] DHD37_XBBA [2, 5, 8, 9, 12, 16, 19, 23, 25, 26, 29, 30, 33, 37, 43, 45, 46, 49, 50, 53, 60, 63, 64, 67, 70, 71, 77, 78, 81, 84, 85, 88, 91, 95, 98, 102, 103, 105, 113, 116, 119, 120, 123, 126, 127, 130, 133, 137, 140, 141, 144] DHD37_XBXB [2, 5, 9, 11, 12, 15, 16, 19, 23, 26, 30, 33, 37, 43, 46, 50, 53, 56, 57, 59, 60, 63, 64, 67, 77, 81, 84, 88, 92, 95, 98, 99, 102, 105, 113, 116, 119, 120, 123, 126, 130, 133, 134, 137, 140, 141, 144] XAAX [3, 6, 9, 13, 16, 20, 23, 27, 30, 34, 43, 47, 50, 54, 57, 61, 64, 68, 71,

72, 3, 6, 9, 13, 16, 20, 23, 27, 30, 34, 43, 47, 50, 54, 57, 61, 64, 68, 71, 72] XAXA [3, 6, 9, 13, 16, 20, 23, 27, 30, 34, 43, 47, 50, 54, 57, 61, 64, 68, 71, 72, 3, 6, 9, 13, 16, 20, 23, 27, 30, 34, 43, 47, 50, 54, 57, 61, 64, 68, 71, 72]

[0136] In one embodiment, the monomer A polypeptide and the monomer B polypeptide have their interaction specificity determined by at least one designed hydrogen bond network at the interface between the monomer A and the monomer B. In some aspects, (i) monomer A comprises 1 helix, and monomer B comprises 1 helix; (ii) monomer A comprises 1 helix and monomer B comprises 2 helices; (iii) monomer A comprises 1 helix and monomer B comprises 3 helices, (iv) monomer A comprises 1 helix and monomer B comprises 4 helices; or (v) monomer A comprises 1 helix and monomer B comprises 5 helices, wherein the monomer A and the monomer B comprise a hydrogen bond network, e.g., hydrogen bonds that are capable of being formed by the interface residues according to Table 2. In some aspects, (i) monomer A comprises 2 helices, and monomer B comprises 1 helix; (ii) monomer A comprises 2 helices and monomer B comprises 2 helices; (iii) monomer A comprises 2 helices and monomer B comprises 3 helices, (iv) monomer A comprises 2 helices and monomer B comprises 4 helices; or (v) monomer A comprises 2 helices and monomer B comprises 5 helices, wherein the monomer A and the monomer B comprise a hydrogen bond network, e.g., hydrogen bonds that are capable of being formed by the interface residues according to Table 2. In some aspects, (i) monomer A comprises 3 helices, and monomer B comprises 1 helix; (ii) monomer A comprises 3 helices and monomer B comprises 2 helices; (iii) monomer A comprises 3 helices and monomer B comprises 3 helices, (iv) monomer A comprises 3 helices and monomer B comprises 4 helices; or (v) monomer A comprises 3 helices and monomer B comprises 5 helices, wherein the monomer A and the monomer B comprise a hydrogen bond network, e.g., hydrogen bonds that are capable of being formed by the interface residues according to Table 2. In some aspects, (i) monomer A comprises 4 helices, and monomer B comprises 1 helix; (ii) monomer A comprises 4 helices and monomer B comprises 2 helices; (iii) monomer A comprises 4 helices and monomer B comprises 3 helices, (iv) monomer A comprises 4 helices and monomer B comprises 4 helices; or (v) monomer A comprises 4 helices and monomer B comprises 5 helices, wherein the monomer A and the monomer B comprise a hydrogen bond network, e.g., hydrogen bonds that are capable of being formed by the interface residues according to Table 2. In some aspects, (i) monomer A comprises 5 helices, and monomer B comprises 1 helix; (ii) monomer A comprises 5 helices and monomer B comprises 2 helices; (iii) monomer A comprises 5 helices and monomer B comprises 3 helices, (iv) monomer A comprises 5 helices and monomer B comprises 4 helices; or (v) monomer A comprises 5 helices and monomer B comprises 5 helices, wherein the monomer A and the monomer B comprise a hydrogen bond network, e.g., hydrogen bonds that are capable of being formed by the interface residues according to Table 2.

[0137] In a second aspect, the disclosure provides non-naturally occurring polypeptides comprising a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-290, or the group consisting of SEQ ID NOS: 1-290, 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494. The amino acid sequences of SEQ ID NOS: 1-290 are provided in Table 1A, and the amino acid sequences of SEQ ID NOS: 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494 are provided in Table 1B, and can be used, for example, to generate the heterodimers of the disclosure.

[0138] In some aspects, the disclosure provides non-naturally occurring polypeptides comprising a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-290, wherein GlySer at amino acid positions 1 and 2 of SEQ ID NO: 1, 55, 81, 83, 101, 105, 115, 117, 119, 121, 123, 125, 127, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, or 193 are optional, e.g., not present. The amino acid sequences of SEQ ID NOS: 1-290 are provided in Table 1A, and can be used, for example, to generate the heterodimers of the disclosure.

[0139] In some aspects, the disclosure provides non-naturally occurring polypeptides comprising a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-290, wherein GlySer at amino acid positions 1 and 2 of SEQ ID NO: 6, 8, 14, 16, 26, 30, 32, 34, 36, 38, 40, 42, 46, 48, 54, 56, 58, 60, 62, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 176, 178, 180, 182, 184, 186, 188, 190, 192, or 194 are optional, e.g., not present.

[0140] In some aspects, the disclosure provides non-naturally occurring polypeptides comprising a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence selected from the group consisting of SEQ ID NOS: 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494. The amino acid sequences of SEQ ID NOS: 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494 are provided in Table 1B, and can be used, for example, to generate the heterodimers of the disclosure.

[0141] In some aspects, the disclosure provides non-naturally occurring polypeptides comprising a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence selected from the group consisting of SEQ ID NOS: 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494, wherein the SEQ ID NOs: 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494 is not linked to GlySer at the immediate N terminus or the polypeptide does not comprise GlySer at the N terminus.

[0142] In some aspects, the disclosure provides non-naturally occurring polypeptides comprising a polypeptide consisting of an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence selected from the group consisting of SEQ ID NOS: 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494. In some aspects, the disclosure provides non-naturally occurring polypeptides comprising a polypeptide consisting of the sequence of SEQ ID NOs: 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494.

[0143] In one embodiment, the amino acid changes from the reference amino acid sequence are conservative amino acid substitutions. In another embodiment, amino acid residues at 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of defined interface positions are invariant compared to the reference amino acid sequence. The defined interface residues are as provided in Table 2.

[0144] In a second aspect, the disclosure provides proteins comprising 2, 3, 4, or more non-naturally occurring polypeptides having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-290, wherein the 2, 3, 4, or more naturally occurring polypeptides are covalently linked. In some aspects, the disclosure provides proteins comprising 2, 3, 4, or more non-naturally occurring polypeptides having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-290 and 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494, wherein the 2, 3, 4, or more naturally occurring polypeptides are covalently linked. In some aspects, the sequences of monomer A and monomer B listed herein can be modified (substituted) such that the resulting amino acid sequence maintains a hydrogen bond network of the original amino acid sequence as described in Tables 1A and 1B.

[0145] In this aspect, the proteins can be used to generate scaffolds that can be used for any suitable purpose including but not limited to those disclosed herein. In one embodiment, each of the 2, 3, 4, or more non-naturally occurring polypeptides are different. In another embodiment, the 2, 3, 4, or more non-naturally occurring polypeptides may include 2, 3, 4, or more identical polypeptides. In all embodiments, the 2, 3, 4, or more non-naturally occurring polypeptides may, for example, be covalently linked as part of a fusion protein. The 2, 3, 4, or more non-naturally occurring polypeptides may each be separated by an amino acid linker. Any suitable amino acid linker may be used.

[0146] In some aspects, the linker is a flexible linker. In some aspects, the linker is a GS linker. In other aspects, the GS linker comprises (GGS)n, (GSEGS)n (SEQ ID NO:423) or (GGGS)n (SEQ ID NO:425), wherein n is an integer between 1 and 100. In some aspects, the linker comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence as set forth in GSEGSGSEGSGS (SEQ ID NO:427) or GSEGSGSEGSGGS (SEQ ID NO:461). In some aspects, the linker comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence as set forth in GSEGSGSEGS (SEQ ID NO:429). In some aspects, the linker comprises an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence as set forth in (GSEGS)n, wherein n is 1 to 10, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (SEQ ID NO:423).

[0147] In one embodiment, each of the 2, 3, 4, or more non-naturally occurring polypeptides have at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of an odd-numbered SEQ ID NO: selected from the group consisting of SEQ ID NOS: 1-290. In one embodiment, each of the 2, 3, 4, or more non-naturally occurring polypeptides have at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of an odd-numbered SEQ ID NO: selected from the group consisting of SEQ ID NOS:1-290, wherein GlySer at amino acid positions 1 and 2 of SEQ ID NO: 1, 55, 81, 83, 101, 105, 115, 117, 119, 121, 123, 125, 127, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, or 193 are optional, e.g., not present. In another embodiment, each of the 2, 3, 4, or more non-naturally occurring polypeptides have at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of an even-numbered SEQ ID NO: selected from the group consisting of SEQ ID NOS: 1-290. In another embodiment, each of the 2, 3, 4, or more non-naturally occurring polypeptides have at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of an even-numbered SEQ ID NO: selected from the group consisting of SEQ ID NOS:1-290, wherein GlySer at amino acid positions 1 and 2 of SEQ ID NO: 6, 8, 14, 16, 26, 30, 32, 34, 36, 38, 40, 42, 46, 48, 54, 56, 58, 60, 62, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 176, 178, 180, 182, 184, 186, 188, 190, 192, or 194 are optional, e.g., not present. In a further embodiment, the 2, 3, 4, or more non-naturally occurring polypeptides include: (a) polypeptides having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of an odd-numbered SEQ ID NO: selected from the group consisting of SEQ ID NOS: 1-290, or selected from the group consisting of SEQ ID NOS: 1-290, 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494; and

[0148] (b) polypeptides having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of an even-numbered SEQ ID NO: selected from the group consisting of SEQ ID NOS:1-290, or selected from the group consisting of SEQ ID NOS: 1-290, 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494.

[0149] In some aspects, the 2, 3, 4, or more non-naturally occurring polypeptides include:

[0150] (a) a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of chain a in Table 1A and/or 1B; and

[0151] (b) a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of chain b in Table 1A and/or 1B.

[0152] In some aspects, the protein of the present disclosure comprises a heterotrimer. In some aspects, the heterotrimer comprises a monomer having an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence described in Tables 1A and 1B, wherein the amino acid sequence forms a hydrogen bond network, e.g., hydrogen bond network formed by the interface residues according to Table 2. In some aspects, the heterotrimer of the present disclosure comprises at least two monomers, wherein each of the monomers comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence described in Tables 1A and 1B, wherein the amino acid sequence forms a hydrogen bond network, e.g., hydrogen bond network formed by the interface residues according to Table 2.

[0153] In some aspects, the heterotrimer of the present disclosure comprises at least three monomers, wherein each of the monomers comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence described in Tables 1A and 1B, wherein the amino acid sequence forms a hydrogen bond network, e.g., hydrogen bond network formed by the interface residues according to Table 2.

[0154] In some aspects, the heterotrimer of the present disclosure comprises at least one heterodimer, wherein the heterodimer comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence described in Tables 3 and 4, wherein the amino acid sequence forms a hydrogen bond network, e.g., hydrogen bond network formed by the interface residues according to Table 2.

[0155] In some aspects, the heterotrimer of the present disclosure comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence described in Tables 3 and 4, wherein the amino acid sequence forms a hydrogen bond network.

[0156] In some aspects, the protein of the present disclosure comprises a heterotetramer. In some aspects, the heterotetramer comprises a monomer having an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence described in Tables 1A and 1B, wherein the amino acid sequence forms a hydrogen bond network, e.g., hydrogen bond network formed by the interface residues according to Table 2. In some aspects, the heterotetramer of the present disclosure comprises at least two monomers, wherein each of the monomers comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence described in Tables 1A and 1B, wherein the amino acid sequence forms a hydrogen bond network, e.g., hydrogen bond network formed by the interface residues according to Table 2.

[0157] In some aspects, the heterotetramer of the present disclosure comprises at least three monomers, wherein each of the monomers comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence described in Tables 1A and 1B, wherein the amino acid sequence forms a hydrogen bond network, e.g., hydrogen bond network formed by the interface residues according to Table 2.

[0158] In some aspects, the heterotetramer of the present disclosure comprises at least four monomers, wherein each of the monomers comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence described in Tables 1A and 1B, wherein the amino acid sequence forms a hydrogen bond network, e.g., hydrogen bond network formed by the interface residues according to Table 2.

[0159] In some aspects, the heterotetramer of the present disclosure comprises at least one heterodimer, wherein the heterodimer comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence described in Tables 1A and 1B, wherein the amino acid sequence forms a hydrogen bond network, e.g., hydrogen bond network formed by the interface residues according to Table 2.

[0160] In some aspects, the heterotetramer of the present disclosure comprises at least two heterodimers, wherein each of the two heterodimers comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence described in Tables 1A and 1B, wherein the amino acid sequence forms a hydrogen bond network, e.g., hydrogen bond network formed by the interface residues according to Table 2.

[0161] In some aspects, the heterotetramer of the present disclosure comprises at least one heterotrimer, wherein the heterotrimer comprises an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence described in Tables 3 and 4, wherein the amino acid sequence forms a hydrogen bond network.

[0162] In another embodiment, the protein comprises the amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence selected from the group consisting of SEQ ID NOS:291, 294, 296, 299, and 302-305. The amino acid sequence of SEQ ID NOS:291, 294, 296, 299, and 302-305 is provided in Table 3. These are merely exemplary such proteins of this aspect of the disclosure, and those of skill in the art will understand that any suitable combination of the monomers of the disclosure can be used in generating the proteins of this aspect.

TABLE-US-00004 TABLE 3 Design Oligomerization name State Chain Design Sequence DHDSC_ Heterotetramer 9a-13a- PKEEARELIRKQKELIKEQKKLIKEAKQKSDSRDAERIWKRSREINRESKK 9-13-37 (linker 37a INKRIKELIKSGSEGSGSEGSGSTKEDILERQRKIIERAQEIHRRQQEILE italicized and ELERIIRKPGSSEEAMKRMLKLLEESLRLLKELLELSEESAQLLYEQRGSE underlined) GSGSEGSGSDSDEHLKKLKTFLENLRRELDRLDKHIKQLRDILSENPEDER VKDVIDLSERSVRIVKTVIKIFEDSVRKKE SEQ ID NO: 291 DHD9- Heterotrimer 9a-13a PKEEARELIRKQKELIKEQKKLIKEAKQKSDSRDAERIWKRSREINRESKK 13 INKRIKELIKSGSEGSGSEGSGSTKEDILERQRKIIERAQEIHRRQQEILE ELERIIRKPGSSEEAMKRMLKLLEESLRLLKELLELSEESAQLLYEQR SEQ ID NO: 294 DHD15- Heterotrimer 15b-37a TERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLDDPDSEDIAREIKELLR 37 RLKEIIERNQRIAKEHEYIARERSGPGSGSEGSDSDEHLKKLKTFLENLRR HLDRLDKHIKQLRDILSENPEDERVKDVIDLSERSVRIVKTVIKIFEDSVR KKE SEQ ID NO: 296 DHD13- Heterotrimer 13b-37b TEKRLLEEAERAHREQKEIIKKAQELERRLEEIVRQSGSSEEAKKEAKKIL 37 EEIRELSKRSLELLREILYLSQEQKGSEGSGSEGSGSDDKELDKLLDTLEK ILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKREEKAVKELLEIA KTHAKKVE SEQ ID NO: 299 OPHD_ Heterotrimer 15b-9a TERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLDDPDSEDIAREIKELLR 15-9 RLKEIIERNQRIAKEHEYIARERSGSEGSGSEGSGSPKEEARELIRKQKEL IKEQKKLIKEAKQKSDSRDAERIWKRSREINRESKKINKRIKELIKS SEQ ID NO: 302 OPHD_ Heterotrimer 37a-9a PKKEAEELAEESEELHDRSEKLHERAEQSSNSEEARKILEDIERISERIEE 37-9 ISDRIERLLRSGSEGSGSEGSGSDDKELDKLLDTLEKILQTATKIIDDANK LLEKLRRSERKDPKVVETYVELLKREEKAVKELLEIAKTHAKKVE SEQ ID NO: 303 OPHD_ Heterotrimer 13a-9a TKEDILERQRKIIERAQEIHRRQQEILEELERIIRKPGSSEEAMKRMLKLL 13-9 EESLRLLKELLELSEESAQLLYEQRGSEGSGSEGSGSPKEEARELIRKQKE LIKEQKKLIKEAKQKSDSRDAERIWKRSREINRESKKINKRIKELIKS SEQ ID NO: 304 OPHD_ Heterotrimer 9b-37a PKKEAEELAEESEELHDRSEKLHERAEQSSNSEEARKILEDIERISERIEE 9-37 ISDRIERLLRSGSEGSGSEGSDSDEHLKKLKTFLENLRRELDRLDKHIKQL RDILSENPEDERVKDVIDLSERSVRIVKTVIKIFEDSVRKKE SEQ ID NO: 305

[0163] In a third aspect, the disclosure provides protein scaffolds, comprising

[0164] a) a first designed component comprised of any number of monomer A polypeptides and/or monomer B polypeptides, each from different heterodimers, connected into a single component by amino acid linkers.

[0165] b) a second designed component, comprising corresponding monomers for each monomer A and/or monomer B in the first designed component one;

[0166] wherein the first and second designed components interact to form the protein scaffold, and wherein each monomer A only interacts in the scaffold with its monomer B binding partner. In one embodiment, the first designed component may comprise the protein of any embodiment or combination of embodiments disclosed herein, and/or the second designed component may comprise a plurality of individual polypeptides of embodiment or combination of embodiments disclosed herein. In non-limiting embodiments, the first designed component and the second designed component may comprise a set of three (Heterotrimer) or four (Heterotetramer) binding partners as shown in Table 4. As will be understood by those of skill in the art based on the teachings herein, heterotrimers of the disclosure (including but not limited to the exemplary heterotrimers shown in Table 4) include a first component fusion protein of two polypeptides of the disclosure, and the second component comprises two separate polypeptides that are binding partners of the two polypeptides in the fusion protein. For example, the DHD9-13 scaffold comprises a first designed component comprising the DHD9 .ANG. monomer covalently linked to the DHD13 .ANG. monomer, and the second designed component comprises individual DHD9 B and DHD13 B monomers. Different scaffolds are separated in the Table by a blank row. As will be understood by those of skill I the art, these are merely exemplary; the monomers in the first designed component may be linked in any order, and any monomers may be included in the designed components. As will be further understood by those of skill based on the teachings herein, heterotetramers (including but not limited to the exemplary heterotetramer shown in Table 4) include a first component fusion protein of three polypeptides of the disclosure, and the second component comprises three separate polypeptides that are binding partners of the three polypeptides in the fusion protein.

TABLE-US-00005 TABLE 4 DHD9-13 Heterotrimer 9a-13a PKEEARELIRKQKELIKEQKKLIKEAKQKSDSRDAERIWKRSREINRESKK INKRIKELIKSGSEGSGSEGSGSTKEDILERQRKIIERAQEIHRRQQEILE ELERIIRKPGSSEEAMKRMLKLLEESLRLLKELLELSEESAQLLYEQR SEQ ID NO: 294 DHD9-13 Heterotrimer 9b PKKEAEELAEESEELHDRSEKLHERAEQSSNSEEARKILEDIERISERIEE ISDRIERLLRS SEQ ID NO: 2 DHD9-13 Heterotrimer 13b GSHHHHHHGSGSENLYFQGSTEKRLLEEAERAHREQKEIIKKAQELHRRLE EIVRQSGSSEEAKKEAKKILEEIRELSKRSLELLREILYLSQEQK SEQ ID NO: 295 DHD9-13 Heterotrimer 13b HHHHHHGSGSENLYFQGSTEKRLLEEAERAHREQKEIIKKAQELHRRLEEI VRQSGSSEEAKKEAKKILEEIRELSKRSLELLREILYLSQEQK SEQ ID NO: 431 DHD15- Heterotrimer 15b-37a TERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLDDPDSEDIAREIKELLR 37 RLKEIIERNQRIAKEHEYIARERSGPGSGSEGSDSDEHLKKLKTFLENLRR HLDRLDKHIKQLRDILSENPEDERVKDVIDLSERSVRIVKTVIKIFEDSVR KKE SEQ ID NO: 296 DHD15- Heterotrimer 15a TREELLRENIELAKEHIEIMREILELLQKMEELLERQSSEDILEELRKIIE 37 RIRELLDRSRKIHERSEEIAYKEE SEQ ID NO: 297 DHD15- Heterotrimer 37b GSHHHHHHGSGSENLYFQGSDDKELDKLLDTLEKILQTATKIIDDANKLLE 37 KLRRSERKDPKVVETYVELLKREEKAVKELLEIAKTHAKKVE SEQ ID NO: 298 DHD15- Heterotrimer 37b HHHHHHGSGSENLYFQGSDDKELDKLLDTLEKILQTATKIIDDANKLLEKL 37 RRSERKDPKVVETYVELLKREEKAVKELLEIAKTHAKKVE SEQ ID NO: 433 DHD13- Heterotrimer 13b-37b TEKRLLEEAERAHREQKEIIKKAQELHRRLEEIVRQSGSSEEAKKEAKKIL 37 EEIRELSKRSLELLREILYLSQEQKGSEGSGSEGSGSDDKELDKLLDTLEK ILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKREEKAVKELLEIA KTHAKKVE SEQ ID NO: 299 DHD13- Heterotrimer 13a TKEDILERQRKIIERAQEIHRRQQEILEELERIIRKPGSSEEAMKRMLKLL 37 EESLRLLKELLELSEESAQLLYEQR SEQ ID NO: 300 DHD13- Heterotrimer 37a GSSHHHHHHSSGENLYFQGSDSDEHLKKLKTFLENLRRHLDRLDKHIKQLR 37 DILSENPEDERVKDVIDLSERSVRIVKTVIKIFEDSVRKKE SEQ ID NO: 301 DHD13- Heterotrimer 37a SHHHHHHSSGENLYFQGSDSDEHLKKLKTFLENLRRHLDRLDKHIKQLRDI 37 LSENPEDERVKDVIDLSERSVRIVKTVIKIFEDSVRKKE SEQ ID NO: 435 OPHD_15- Heterotrimer 15b-9a TERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLDDPDSEDIAREIKELLR 9 RLKEIIERNQRIAKEHEYIARERSGSEGSGSEGSGSPKEEARELIRKQKEL IKEQKKLIKEAKQKSDSRDAERIWKRSREINRESKKINKRIKELIKS SEQ ID NO: 302 OPHD_15- Heterotrimer 15a TREELLRENIELAKEHIEIMREILELLQKMEELLEKARGADEDVAKTIKEL 9 LRRLKEIIERNQRIAKEHEYIARERS SEQ ID NO: 19 OPHD_15- Heterotrimer 9b PKKEAEELAEESEELHDRSEKLHERAEQSSNSEEARKILEDIERISERIEE 9 ISDRIERLLRS SEQ ID NO: 2 OPHD_37- Heterotrimer 37a-9a PKKEAEELAEESEELHDRSEKLHERAEQSSNSEEARKILEDIERISERIEE 9 ISDRIERLLRSGSEGSGSEGSGSDDKELDKLLDTLEKILQTATKIIDDANK LLEKLRRSERKDPKVVETYVELLKRHEKAVKELLEIAKTHAKKVE SEQ ID NO: 303 OPHD_37- Heterotrimer 37b GSDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVE 9 LLKRHEKAVKELLEIAKTHAKKVE SEQ ID NO: 42 OPHD_37- Heterotrimer 37b DDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELL 9 KRHEKAVKELLEIAKTHAKKVE SEQ ID NO: 352 OPHD_37- Heterotrimer 9b PKKEAEELAEESEELHDRSEKLHERAEQSSNSEEARKILEDIERISERIEE 9 ISDRIERLLRS SEQ ID NO: 2 OPHD_13- Heterotrimer 13a-9a TKEDILERQRKIIERAQEIHRRQQEILEELERIIRKPGSSEEAMKRMLKLL 9 EESLRLLKELLELSEESAQLLYEQRGSEGSGSEGSGSPKEEARELIRKQKE LIKEQKKLIKEAKQKSDSRDAERIWKRSREINRESKKINKRIKELIKS SEQ ID NO: 304 OPHD_13- Heterotrimer 13b GTEKRLLEEAERAHREQKEIIKKAQELHRRLEEIVRQSGSSEEAKKEAKKI 9 LEEIRELSKRSLELLREILYLSQEQKGSLVPR SEQ ID NO: 4 OPHD_13- Heterotrimer 9b PKKEAEELAEESEELHDRSEKLHERAEQSSNSEEARKILEDIERISERIEE 9 ISDRIERLLRS SEQ ID NO: 2 OPHD_9- Heterotrimer 9b-37a PKKEAEELAEESEELHDRSEKLHERAEQSSNSEEARKILEDIERISERIEE 37 ISDRIERLLRSGSEGSGSEGSDSDEHLKKLKTFLENLRRHLDRLDKHIKQL RDILSENPEDERVKDVIDLSERSVRIVKTVIKIFEDSVRKKE SEQ ID NO: 305 OPHD_9- Heterotrimer 9a GSPKEEARELIRKQKELIKEQKKLIKEAKQKSDSRDAERIWKRSREINRES 37 KKINKRIKELIKS SEQ ID NO: 1 OPHD_9- Heterotrimer 9a PKEEARELIRKQKELIKEQKKLIKEAKQKSDSRDAERIWKRSREINRESKK 37 INKRIKELIKS SEQ ID NO: 331 OPHD_9- Heterotrimer 37b GSDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVE 37 LLKRHEKAVKELLEIAKTHAKKVE SEQ ID NO: 42 OPHD_9- Heterotrimer 37b DDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELL 37 KRHEKAVKELLEIAKTHAKKVE SEQ ID NO: 352 DHDSC_9- Heterotetramer 9a-13a- PKEEARELIRKQKELIKEQKKLIKEAKQKSDSRDAERIWKRSREINRESKK 13-37 37a INKRIKELIKSGSEGSGSEGSGSTKEDILERQRKIIERAQEIHRRQQEILE ELERIIRKPGSSEEAMKRMLKLLEESLRLLKELLELSEESAQLLYEQRGSE GSGSEGSGSDSDEHLKKLKTFLENLRRHLDRLDKHIKQLRDILSENPEDER VKDVIDLSERSVRIVKTVIKIFEDSVRKKE SEQ ID NO: 291 DHDSC_9- Heterotetramer 9b PKKEAEELAEESEELHDRSEKLHERAEQSSNSEEARKILEDIERISERIEE 13-37 ISDRIERLLRS SEQ ID NO: 2 DHDSC_9- Heterotetramer 13b TEKRLLEEAERAHREQKEIIKKAQELERRLEEIVRQSGSSEEAKKEAKKIL 13-37 EEIRELSKRSLELLREILYLSQEQK SEQ ID NO: 292 DHDSC_9- Heterotetramer 37b GSSHHHHHHSSGENLYFQGSDDKELDKLLDTLEKILQTATKIIDDANKLLE 13-37 KLRRSERKDPKVVETYVELLKRHEKAVKELLEIAKTHAKKVE SEQ ID NO: 293 DHDSC_9- Heterotetramer 37b SHHHHHHSSGENLYFQGSDDKELDKLLDTLEKILQTATKIIDDANKLLEKL 13-37 RRSERKDPKVVETYVELLKRHEKAVKELLEIAKTHAKKVE SEQ ID NO: 437

[0167] In these embodiments, the scaffold may be stable up to 95.degree. C. and has a guanidine denaturation midpoint of 4 M, as described in the examples that follow.

[0168] In some aspects, the heterotrimer or heterotetramer of the present disclosure does not comprise a His tag.

[0169] In another aspect, the disclosure provides protein scaffolds, comprising

[0170] (a) a fusion protein comprising of 2, 3, 4, or more polypeptides, wherein each polypeptide present in the fusion protein is a non-naturally occurring polypeptide comprises 1-5 alpha helices, wherein adjacent alpha helices may optionally be connected by an amino acid linker;

[0171] wherein each polypeptide in the fusion protein is capable of non-covalently interacting with a binding partner, and wherein the fusion protein does not comprise a binding partner for any polypeptide present in the fusion protein; and

[0172] (b) a binding partner for at least one of the polypeptides present in the fusion protein;

[0173] wherein the fusion protein and the binding partner non-covalently interact to form the protein scaffold, wherein an interaction specificity between the binding partner and the at least polypeptide in the fusion protein are determined by at least one hydrogen bond network at the interface between the binding partner and the at least one polypeptide.

[0174] Binding partners are polypeptides capable of forming heterodimers with a polypeptide present in the fusion protein, and are exemplified above with respect to SEQ ID NO: 1-290. The binding partner for at least one polypeptide in the fusion protein may comprise a binding partner for 2, 3, 4, or all polypeptides in the fusion protein. As will be understood, when more than one binding partner is present, they are present as individual binding partner polypeptides, and not linked together.

[0175] The fusion protein may comprise 2, 3, 4, or more polypeptides. In certain embodiments, the fusion protein comprises at least 3 or 4 polypeptides in total. Exemplary embodiments of such fusion proteins are provided herein, for example in describing heterotrimer and heterotetramer embodiments in Table 4. The polypeptides in the fusion protein may all be the same, may all be different, or may include both identical and distinct polypeptides. In one specific embodiment, each polypeptide in the fusion protein is a different polypeptide.

[0176] In one embodiment,

[0177] (i) the fusion protein comprises 2, 3, 4, or more polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence of SEQ ID NOS: 1-290, or SEQ ID NOS: 1-290, 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494; and

[0178] (ii) the binding partner comprises a binding partner as defined herein for each polypeptide in (i), wherein each binding partner has at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity along the length of the amino acid sequence selected from the group SEQ ID NOS: 1-290, or selected from the group consisting of SEQ ID NOS: 1-290, 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494. As described herein, the odd-numbered SEQ ID NOS: between SEQ ID NO: 1-290, 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494 are noted as "A" monomers and the even-numbered SEQ ID NOS between SEQ ID NO: 1-290, 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494 are the "B" monomers, with adjacent A and B monomers in Tables 1A and 1B capable of forming heterodimers as described in detail herein. Thus, for example, if the fusion protein included the polypeptide of SEQ ID NO:1, then binding partner may include SEQ ID NO:2, while if the fusion protein included the polypeptide of SEQ ID NO:2, then binding partner may include SEQ ID NO:1. The numerous combinations of fusion protein polypeptides and binding partners will be clear to those of skill in the art based on the teachings herein.

[0179] In one embodiment, amino acid changes in the fusion protein and the binding partner from the reference amino acid sequence are conservative amino acid substitutions. In another embodiment amino acid residues at 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of defined interface positions in the polypeptides in the fusion protein and the binding partner are invariant compared to the reference amino acid sequence. In a further embodiment, the at least one hydrogen bond network is asymmetric. In a further embodiment, the binding interface comprises at least 25% hydrophobic residues. In another embodiment, the scaffold is stable up to 95.degree. C. and has a guanidine denaturation midpoint of 4 M.

[0180] In another embodiment, the disclosure provides methods of forming the designed heterodimer disclosed herein, comprising:

[0181] a) providing two of the monomers as unlinked monomers;

[0182] b) providing the other two monomers as linked monomers

[0183] whereby the unlinked monomers associate with their respective monomer of the same heterodimer, and not with any of the other monomers. Further details of this aspect are provided in the examples that follow.

[0184] In another embodiment, the disclosure provides a designed heterodimer protein comprising:

[0185] a) asymmetric buried hydrogen bond networks incorporated into regularly repeating backbone structures; and

[0186] b) helix hairpin helix monomers wherein the supercoil phases of the helices are fixed at 0, 90, 180, or 270 degrees and the supercoil twist (.omega.0) and helical twist (.omega.1 are held constant for either a two layer left handed super coil (.omega.0=-2.85 and .omega.1=102.85), or a 5 layer untwisted bundle (.omega.0=0 and .omega.1=100) 27. Further details of this aspect are provided in the examples that follow.

[0187] In another embodiment, the disclosure provides uses of the polypeptide, protein, heterodimer protein, protein scaffold, nucleic acid, expression vector, and/or cell of any embodiment or combination of embodiments for any suitable purposed, including but not limited to those disclosed herein such as designing protein logic gates

[0188] In a fourth aspect, the disclosure provides fusion proteins comprising a polypeptide of the formula X-B-Z, wherein:

[0189] (a) the X domain is a non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices, wherein the X domain is capable of non-covalently binding to a first target; (b) the Z domain is a non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices, wherein the Z domain is capable of non-covalently binding to either (i) a second target that differs from the first target, or (ii) a different non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices; and

[0190] (c) the B domain is an amino acid linker;

[0191] wherein a combined number of alpha helices from the X domain and the Z domain is 4, 5, or 6; and

[0192] wherein the X domain and the Z domain interact at a binding interface, wherein the binding interface comprises a hydrogen bond network in which at least one side chain in each alpha helix hydrogen of the X domain bonds with a side chain in an alpha helix in the Z domain, and wherein the binding interface comprises a plurality of hydrophobic residues. Each helix in the X domain H-bonds with at least one helix in the Z domain and each helix in the Z domain H-bonds with at least one helix in the X domain.

[0193] In a fifth aspect, the disclosure provides kits or compositions, comprising at least two fusion proteins comprising the formula X-B-Z, wherein

[0194] the B domain in each fusion protein is independently a polypeptide linker;

[0195] the X domain in each fusion protein comprises a first non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices;

[0196] the Z domain in each fusion protein comprises a second non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices, wherein a combined number of alpha helices from the X domain and the Z domain in each individual fusion protein is 4, 5, or 6; wherein the X domain and the Z domain interact at a binding interface, wherein the binding interface comprises a hydrogen bond network in which at least one side chain in each X domain alpha helix bonds with a side chain in an alpha helix in the Z domain; wherein

[0197] the X domain in a first fusion protein is capable of non-covalently binding to a first target;

[0198] the Z domain in a second fusion protein is capable of non-covalently binding to a second target; and

[0199] the X domains and Z domains in each individual fusion protein that are not capable of non-covalently binding to the first target or the second target are capable of non-covalently binding to an X or a Z domain of a different fusion protein in the plurality of fusion proteins.

[0200] The fusion proteins and kits can be used, for example, in the methods disclosed herein such as for logic gate construction, and for any other suitable use as will be appreciated by those of skill in the art based on the teachings herein. Specifically, fusion proteins can be used for designing 2-input AND and OR logic gates built from de novo designed proteins that regulate the association of arbitrary protein units ranging from split enzymes to transcriptional machinery in vitro, and in living cells. Binding interaction cooperativity makes the gates largely insensitive to stoichiometric imbalances in the inputs, and the modularity of the approach enables ready extension to 3-input OR, AND, and disjunctive normal form gates. The modularity and cooperativity of the control elements, coupled with the ability to de novo design an essentially unlimited number of protein components, enables design of sophisticated post-translational control logic over a wide range of biological functions.

[0201] In one embodiment, the Z domain is a non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices, wherein the Z domain is capable of non-covalently binding to a second target that differs from the first target, This embodiment is useful, for example, for generating single component dimerizers for use in AND/NOR gates. In another embodiment, the Z domain is a non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices, wherein the Z domain is capable of non-covalently binding to a different non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices. This embodiment is useful, for example, for generating 2 or 3-component dimerizers for use in AND/NOR gates.

[0202] The first targets and second targets may be any target suitable for an intended use. In non-limiting embodiments, the first target and/or the second target may comprise polypeptides or nucleic acids.

[0203] In one embodiment of the kit or composition,

[0204] (i) the first fusion protein has the formula X1-B1-Z1, wherein the X1 domain is capable of non-covalently binding to the first target; and

[0205] (ii) the second fusion protein has the formula X2-B2-Z2, wherein the Z2 domain is capable of non-covalently binding to the second target; and wherein the Z1 and X2 domains are capable of non-covalently binding to each other.

[0206] In another embodiment of the kit or composition,

[0207] (i) the first fusion protein has the formula X1-B1-Z1, wherein the X1 domain is capable of non-covalently binding to the first target; and

[0208] (ii) the second fusion protein has the formula X2-B2-Z2,

[0209] (iii) the at least two fusion proteins comprise a third fusion protein of formula X3-B3-Z3, wherein the Z3 domain is capable of non-covalently binding to the second target; wherein [0210] (A) the Z1 and X2 domains are capable of non-covalently binding to each other; and [0211] (B) the Z2 and X3 domains are capable of non-covalently binding to each other.

[0212] In one embodiment of the fusion protein or the kits or compositions, the binding interface comprises at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60% or greater hydrophobic residues. The B domain linker may be any suitable amino acid sequence, including but not limited to those described herein. In one embodiment, the B domain for each fusion protein is independently between 6-12, 6-11, 6-10, 7-12, 7-11, 7-10, 8-12, 8-11, 8-10, 9-12, 9-11, 9-10, 10-12, 10-11, 11-12, 6, 7, 8, 9, 10, 11, or 12 amino acids in length.

[0213] In another embodiment, the combined number of alpha helices from the X and Z domains in an individual fusion protein is 4. In a further embodiment, the X domain of each fusion protein has 2 alpha helices and the Z domain of each fusion protein has 2 alpha helices. In one embodiment, either the X domain or the Z domain of each fusion protein has 1 alpha helix and the other has 3 alpha helices.

[0214] In one embodiment, each X domain and each Z domain comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to SEQ ID NOS: 1-290, or selected from the group consisting of SEQ ID NOS: 1-290, 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494, with the proviso that the X domain and the Z domain do not form a heterodimer (a-b) pair. In one embodiment, each X domain and each Z domain comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to SEQ ID NOS: 1-290 and 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494, with the proviso that the X domain and the Z domain do not form a heterodimer (a-b) pair. In one non-limiting embodiment, at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of amino acid residues at defined interface positions as defined in Table 2 are invariant in the polypeptides relative to the reference polypeptide.

[0215] A different nomenclature is used in the examples that follow. Table 5 provides correspondence between the names used in the examples and in Tables 1A and 1B. The first column is the numbering used in the examples, while the second column lists the corresponding name in Tables 1A and 1B. For example, polypeptide 1 in the examples is DHD37_ABXB (a), 1' is DHD37 ABXB (b). Polypeptide 2 is DHD15 (a), 2' is DHD15 (b), and so on.

TABLE-US-00006 TABLE 5 1: DHD 37_ABXB 2: DHD 15 3: DHD 131 4: DHD 101 5: DHD 9 6: DHD 150 7: DHD 154 8: DHD 17 9: DHD 13_XAAA 10: DHD 39 11: DHD 155

[0216] In one embodiment, each fusion protein independently comprises a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to a polypeptide having the amino acid sequence of a sequence selected from the group consisting of SEQ ID NO: 302, 303, 306-326, 439, 441, 443, 445, 447, 449, 451, 453, 455, and 457:

TABLE-US-00007 2'-1'_2-residue_linker (SEQ ID NO: 306) GSTERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLDDPDSEDIAREIKELLRRLKEIIERNQRIAKEHEYIAR- E RSAADDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKELLEIAKTHAK- K VE 2'-1'_2-residue_linker (SEQ ID NO: 439) TERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLDDPDSEDIAREIKELLRRLKEIIERNQRIAKEHEYIARER- S AADDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKELLEIAKTHAKKV- E 2'-1'_6-residue_linker (SEQ ID NO: 307) GSTERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLDDPDSEDIAREIKELLRRLKEIIERNQRIAKEHEYIAR- E RSGGSGSPDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKELLEIAK- T HAKKVE 2'-1'_6-residue_linker (SEQ ID NO: 441) TERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLDDPDSEDIAREIKELLRRLKEIIERNQRIAKEHEYIARER- S GGSGSPDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKELLEIAKTH- A KKVE 2'-1'_12-residue_linker (SEQ ID NO: 308) GSTERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLDDPDSEDIAREIKELLRRLKEIIERNQRIAKEHEYIAR- E RSGGSGSPGGSGSPDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKE- L LEIAKTHAKKVE 2'-1'_12-residue_linker (SEQ ID NO: 443) TERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLDDPDSEDIAREIKELLRRLKEIIERNQRIAKEHEYIARER- S GGSGSPGGSGSPDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKELL- E IAKTHAKKVE 2'-1'_24-residue_linker (SEQ ID NO: 309) GSTERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLDDPDSEDIAREIKELLRRLKEIIERNQRIAKEHEYIAR- E RSGGSGSPGGSGSPGGSGSPGGSGSPDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYV- E LLKRHEKAVKELLEIAKTHAKKVE 2'-1'_24-residue_linker (SEQ ID NO: 445) TERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLDDPDSEDIAREIKELLRRLKEIIERNQRIAKEHEYIARER- S GGSGSPGGSGSPGGSGSPGGSGSPDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVEL- L KRHEKAVKELLEIAKTHAKKVE 11-7' (SEQ ID NO: 310) PEDDVVRIIKEDLESNREVLREQKEIHRILELVTRGEVSEEAIDRVLKRQEDLLKKQKESTDKARKVVEERRGS- E GSGSEGSDLEDLLRRLRRLVDEQRRLVEELERVSRRLEKAVRDNEDERELARLSREHSDIQDKHDKLAREILEV- L KRLLERTE 1'-4' (SEQ ID NO: 311) GSDAYDLDRIVKEHRRLVEEQRELVEELEKLVRRQEDHRVDKKESHEILERLERIIRRSTRILTELEKLTDEFE- R RTRGSEGSGSEGSGSDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVK- E LLEIAKTHAKKVE 1'-4' (SEQ ID NO: 447) DAYDLDRIVKEHRRLVEEQRELVEELEKLVRRQEDHRVDKKESHEILERLERIIRRSTRILTELEKLTDEFERR- T RGSEGSGSEGSGSDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKEL- L EIAKTHAKKVE 4-3' (SEQ ID NO: 312) GSDEDDELERLLREYHRVLREYEKLLEELRRLYEEYKRGEVSEEESDRILREIKEILDKSERLWDLSEEVWRTL- L YQAEGSEGSGSEGSDEKDYHRRLIEHLEDLVRRHEELIKRQKKVVEELERRGLDERLRRVVDRFRRSSERWEEV- I ERFRQVVDKLRKSVE 4-3' (SEQ ID NO: 449) DEDDELERLLREYHRVLREYEKLLEELRRLYEEYKRGEVSEEESDRILREIKEILDKSERLWDLSEEVWRTLLY- Q AEGSEGSGSEGSDEKDYHRRLIEHLEDLVRRHEELIKRQKKVVEELERRGLDERLRRVVDRFRRSSERWEEVIE- R FRQVVDKLRKSVE 3-2'* (SEQ ID NO: 313) GSTERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLKKARGADEKVLDELRKIIERIRELLDRSRKIHERSEEI- A YKEEGSEGSGSEGSGSDESDRIRKIVEESDEIVKESRKLAERARELIKESEDKRVSEERNERLLEELLRILDEN- A ELLKRNLELLKEVLYRTR 3-2'* (SEQ ID NO: 451) TERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLKKARGADEKVLDELRKIIERIRELLDRSRKIHERSEEIAY- K EEGSEGSGSEGSGSDESDRIRKIVEESDEIVKESRKLAERARELIKESEDKRVSEERNERLLEELLRILDENAE- L LKRNLELLKEVLYRTR 1'-3' (SEQ ID NO: 314) GSDEDDELERLLREYHRVLREYEKLLEELRRLYEEYKRGEVSEEESDRILREIKEILDKSERLWDLSEEVWRTL- L YQAEGSEGSGSEGSGSDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAV- K ELLEIAKTHAKKVE 1'-3' (SEQ ID NO: 453) DEDDELERLLREYHRVLREYEKLLEELRRLYEEYKRGEVSEEESDRILREIKEILDKSERLWDLSEEVWRTLLY- Q AEGSEGSGSEGSGSDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKE- L LEIAKTHAKKVE 1'-5 (SEQ ID NO: 303) PKKEAEELAEESEELHDRSEKLHERAEQSSNSEEARKILEDIERISERIEEISDRIERLLRSGSEGSGSEGSGS- D DKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKELLEIAKTHAKKVE 5'-2' (SEQ ID NO: 302) TERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLDDPDSEDIAREIKELLRRLKEIIERNQRIAKEHEYIARER- S GSEGSGSEGSGSPKEEARELIRKQKELIKEQKKLIKEAKQKSDSRDAERIWKRSREINRESKKINKRIKELIKS 1-6 (SEQ ID NO: 315) DSDEHLKKLKTFLENLRRHLDRLDKHIKQLRDILSENPEDERVKDVIDLSERSVRIVKTVIKIFEDSVRKKEGS- E GSGSEGSGSEGSGSEGSGSEGSGSEGSPTDEVIEVLKELLRIHRENLRVNEEIVEVNERASRVTDREELERLLR- R SNELIKRSRELNEESKKLIEKLERLAT 1'-7 (SEQ ID NO: 316) DDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKELLEIAKTHAKKVEG- S EGSGSEGSTAEELLEVHKKSDRVTKEHLRVSEEILKVVEVLTRGEVSSEVLKRVLRKLEELTDKLRRVTEEQRR- V VEKLN 6'-7 (SEQ ID NO: 317) DNEEIIKEARRVVEEYKKAVDRLEELVRRAENAKHASEKELKDIVREILRISKELNKVSERLIELWERSQERAR- G SEGSGSEGSTAEELLEVHKKSDRVTKEHLRVSEEILKVVEVLTRGEVSSEVLKRVLRKLEELTDKLRRVTEEQR- R VVEKLN 1'-6-7 (SEQ ID NO: 318) DDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKELLEIAKTHAKKVEG- S EGSGSEGSGSEGSGSEGSGSEGSGSEGSPTDEVIEVLKELLRIHRENLRVNEEIVEVNERASRVTDREELERLL- R RSNELIKRSRELNEESKKLIEKLERLATGSEGSGSEGSGSEGSGSEGSGSEGSGSEGSTAEELLEVHKKSDRVT- K EHLRVSEEILKVVEVLTRGEVSSEVLKRVLRKLEELTDKLRRVTEEQRRVVEKLN 11-1 (SEQ ID NO: 319) DSDEHLKKLKTFLENLRRHLDRLDKHIKQLRDILSENPEDERVKDVIDLSERSVRIVKTVIKIFEDSVRKKEGS- E GSGSEGSPEDDVVRIIKEDLESNREVLREQKEIHRILELVTRGEVSEEAIDRVLKRQEDLLKKQKESTDKARKV- V EERR 11-6' (SEQ ID NO: 320) DNEEIIKEARRVVEEYKKAVDRLEELVRRAENAKHASEKELKDIVREILRISKELNKVSERLIELWERSQERAR- G SEGSGSEGSPEDDVVRIIKEDLESNREVLREQKEIHRILELVTRGEVSEEAIDRVLKRQEDLLKKQKESTDKAR- K VVEERR 11-7' (SEQ ID NO: 321) DLEDLLRRLRRLVDEQRRLVEELERVSRRLEKAVRDNEDERELARLSREHSDIQDKHDKLAREILEVLKRLLER- T

EGSEGSGSEGSGSEGSGSEGSGSEGSGSEGSPEDDVVRIIKEDLESNREVLREQKEIHRILELVTRGEVSEEAI- D RVLKRQEDLLKKQKESTDKARKVVEERR 1'-6 (SEQ ID NO: 322) GSDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKELLEIAKTHAKKV- E GSEGSGSEGSPTDEVIEVLKELLRIHRENLRVNEEIVEVNERASRVTDREELERLLRRSNELIKRSRELNEESK- K LIEKLERLAT 1'-6 (SEQ ID NO: 455) DDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKELLEIAKTHAKKVEG- S EGSGSEGSPTDEVIEVLKELLRIHRENLRVNEEIVEVNERASRVTDREELERLLRRSNELIKRSRELNEESKKL- I EKLERLAT 7-1 (SEQ ID NO: 323) DSDEHLKKLKTFLENLRRHLDRLDKHIKQLRDILSENPEDERVKDVIDLSERSVRIVKTVIKIFEDSVRKKEGS- E GSGSEGSTAEELLEVHKKSDRVTKEHLRVSEEILKVVEVLTRGEVSSEVLKRVLRKLEELTDKLRRVTEEQRRV- V EKLN 4'-2'* (SEQ ID NO: 324) GTERKLLERSRRLQEESKRLLDEMAEIMRRIKKLLKKARGADEKVLDELRKIIERIRELLDRSRKIHERSEEIA- Y KEEGSEGSGSEGSGSDAYDLDRIVKEHRRLVEEQRELVEELEKLVRRQEDHRVDKKESHEILERLERIIRRSTR- I LTELEKLTDEFERRTR 2*-1' (SEQ ID NO: 325) TREELLRENIELAKEHIEIMREILELLQKMEELLEKARGADEDVAKTIKELLRRLKEIIERNQRIAKEHEYIAR- E RSGSEGSGSEGSGSDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKE- L LEIAKTHAKKVE 1'-9 (SEQ ID NO: 326) GSDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKELLEIAKTHAKKV- E GSEGSGSEGSGTKEDILERQRKIIERAQEIHRRQQEILEELERIIRKPGSSEEAMKRMLKLLEESLRLLKELLE- L SEESAQLLYEQR 1'-9 (SEQ ID NO: 457) DDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVELLKRHEKAVKELLEIAKTHAKKVEG- S EGSGSEGSGTKEDILERQRKIIERAQEIHRRQQEILEELERIIRKPGSSEEAMKRMLKLLEESLRLLKELLELS- E ESAQLLYEQR

[0217] In some aspects, each fusion protein independently comprises a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to, a polypeptide having the amino acid sequence of SEQ ID NO: 302, 303, 306-326, 439, 441, 443, 445, 447, 449, 451, 453, 455, and 457, wherein GlySer at amino acid residues 1 and 2 of any of 302, 303, 306-326, 439, 441, 443, 445, 447, 449, 451, 453, 455, and 457 are optional, e.g., not present.

[0218] In another embodiment, the kits or compositions further comprising the first target and the second target. In one embodiment, the first target and the second target each independently comprise a polypeptide of the formula X10-B10-Z10, wherein

[0219] (a) the X10 domain is a non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices;

[0220] (b) the Z10 domain is a non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices; and

[0221] (c) the B10 domain is an amino acid linker;

[0222] wherein the X domain and the Z domain interact at a target binding interface, wherein the target binding interface comprises a hydrogen bond network in which at least one side chain in each alpha helix hydrogen of the X domain bonds with a side chain in a different alpha helix in the Z domain, and wherein the target binding interface comprises a plurality of hydrophobic residues. In one embodiment, the target binding interface comprises at least 25% hydrophobic residues. In another embodiment, the B10 domain for the first target and the second target is independently between 6-12, 6-11, 6-10, 7-12, 7-11, 7-10, 8-12, 8-11, 8-10, 9-12, 9-11, 9-10, 10-12, 10-11, 11-12, 6, 7, 8, 9, 10, 11, or 12 amino acids in length. In another embodiment, the combined number of alpha helices from the X and Z domains in the first target and the second target protein is 4. In a further embodiment,

[0223] (a) the X10 domain of each of the first target and the second target has 2 alpha helices and the Z10 domain of each of the first target and the second target has 2 alpha helices; or

[0224] (b) either the X10 domain or the Z10 domain of each of the first target and the second target has 1 alpha helix and the other has 3 alpha helices. In one embodiment, each X10 domain and each Z10 domain comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to a polypeptide having the amino acid sequence selected from SEQ ID NOS: 1-290, 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494, with the proviso that the X10 domain forms a heterodimer (a-b) pair with the X domain of the fusion protein, and the Z10 domain forms a heterodimer (a-b) pair with the Z domain of the fusion protein. In one embodiment, at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of amino acid residues at defined interface positions of the first target and/or the second target are invariant compared to the reference polypeptide amino acid sequence (interface residues shown in Table 2).

[0225] In another embodiment, the first target and/or the second target further comprise one or more effector polypeptide domains linked to one or more of the X10 and/or Z10 domains, for example, wherein the one or more effector polypeptide domains may comprise a polypeptide including, but not limited to, nucleic acid binding proteins, transcription factors, receptor binding proteins, split enzymes, effectors of membrane receptors, etc.

[0226] In a sixth aspect, the disclosure provides methods, comprising:

[0227] (i) contacting the fusion protein of embodiment or combination of embodiments of the fifth or sixth aspects disclosed herein with a biological sample under conditions to promote non-covalent binding of the fusion protein with first target and second target present in the sample, and

[0228] (ii) detecting non-covalent binding of the one or more fusion proteins to the first target and/or the second target in the biological sample.

[0229] The detecting may comprise any suitable means for detecting binding, including but not limited to mass spectrometry, yeast-2-hybrid detection, functional assays, or any other suitable assay as will be clear to those of skill in the art based on the current disclosure. In one embodiment, the method comprises detecting cooperative non-covalent binding of the one or more fusion proteins to the first target and the second target in the biological sample. This embodiment comprises use of the fusion proteins in AND gate logic, as described in more detail in the examples that follow. As used herein, "cooperative" binding means binding the fusion protein cannot bind to the first target without also binding to the second target, and the fusion protein cannot bind to the second target without binding to the first target.

[0230] In another embodiment, the method comprises detecting non-covalent binding of the one or more fusion proteins to the first target or the second target in the biological sample. This embodiment comprises use of the fusion proteins in OR gate logic, as described in more detail in the examples that follow.

[0231] In another embodiment, the disclosure provides methods comprising:

[0232] (a) contacting a biological sample with at least two fusion proteins, wherein each of the at least two fusion proteins comprises the formula X-B-Z, wherein

[0233] each B is independently a polypeptide linker;

[0234] each X domain comprises a first non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices;

[0235] each Z domain comprises a second non-naturally occurring polypeptide comprising 1, 2, or 3 alpha helices, wherein a combined number of alpha helices from the X domain and the Z domain in each individual fusion protein is 4, 5, or 6; wherein the X domain and the Z domain interact at a binding interface, wherein the binding interface comprises a hydrogen bond network in which at least one side chain in each X domain alpha helix bonds with a side chain in an alpha helix in the Z domain; wherein

[0236] the X domain in a first fusion protein is capable of non-covalently binding to a first target;

[0237] the Z domain in a second fusion protein is capable of non-covalently binding to a second target; and

[0238] the X domains and Z domains in each individual fusion protein that are not capable of non-covalently binding to the first target or the second target are capable of non-covalently binding to an X or a Z domain of a different fusion protein in the plurality of fusion proteins;

[0239] (b) detecting non-covalent binding of the two or more fusion proteins to the first target and/or the second target in the biological sample. This embodiment comprises use of the fusion proteins in 2 component AND or OR gate logic, as described in more detail in the examples that follow.

[0240] In one embodiment of the AND or OR gate logic, the detecting comprises detecting cooperative non-covalent binding of the two or more fusion proteins to the first target and the second target in the biological sample. In another embodiment,

[0241] (i) the first fusion protein has the formula X1-B1-Z1, wherein the X1 domain is capable of non-covalently binding to the first target; and

[0242] (ii) the second fusion protein has the formula X2-B2-Z2, wherein the Z2 domain is capable of non-covalently binding to the first target; and wherein the Z1 and X2 domains are capable of non-covalently binding to each other.

[0243] In a further embodiment,

[0244] (i) the first fusion protein has the formula X1-B1-Z1, wherein the X1 domain is capable of non-covalently binding to the first target; and

[0245] (ii) the second fusion protein has the formula X2-B2-Z2,

[0246] (iii) the at least two fusion proteins comprise a third fusion protein of formula X3-B3-Z3, wherein the Z3 domain is capable of non-covalently binding to the second target; wherein [0247] (A) the Z1 and X2 domains are capable of non-covalently binding to each other; and [0248] (B) the Z2 and X3 domains are capable of non-covalently binding to each other.

[0249] In another embodiment, the X domains, Y domains, B domains, and or fusion proteins are as recited in any embodiment or combination of embodiments disclosed herein, such as in the fourth and fifth aspects. In one embodiment, at least one of the fusion proteins comprises one or more effector polypeptide domains linked to one or more of the X and/or Z domains, and wherein the detecting step comprises detecting an output signal caused by binding the first target and/or the second target. In another embodiment, the detecting step comprises detecting an output signal from the one or more effector polypeptide caused by cooperative non-covalently binding of the first target and the second target. Such detection may be by any suitable means dependent in part on the output signal to be detected, including but not limited to those disclosed herein. The output signal to be detected may be any suitable output signal including but not limited to fluorescence activity, functional activity, etc.

[0250] Any suitable effector polypeptide domain may be employed as suitable for an intended use. In one embodiment, the one or more effector polypeptide domains may comprise a polypeptide including, but not limited to, nucleic acid binding proteins, transcription factors, receptor binding proteins, nucleic acid binding proteins, transcription factors, receptor binding proteins, split enzymes, effectors of membrane receptors, etc.

[0251] In a seventh aspect, the disclosure provides compositions comprising

[0252] (a) a first polypeptide comprising 2 alpha helices, wherein the first polypeptide is capable of non-covalently binding a first target; and

[0253] (b) a second polypeptide comprising 2 alpha helices, wherein the first polypeptide is capable of non-covalently binding to the second polypeptide, and wherein the second polypeptide is capable of non-covalently binding a second target that differs from the first target; wherein: [0254] (i) a binding affinity of the first polypeptide for the first target is approximately equal to a binding affinity of the second polypeptide for the second target; and [0255] (ii) the binding affinity of the first polypeptide for the first target and the binding affinity of the second polypeptide for the second target are greater than the binding affinity of the first target and the second target for each other.

[0256] Compositions of this seventh aspect can be used, for example, as NOR gates as described in detail in the examples that follow.

[0257] In one embodiment, the composition further comprises the first target and the second target. The first targets and second targets may be any target suitable for an intended use. In non-limiting embodiments, the first target and/or the second target may comprise polypeptides or nucleic acids. In another embodiment, the first target and/or the second target further comprise one or more effector polypeptide domains. Any effector polypeptide domains may be used as suitable for an intended use. In one embodiment, the one or more effector polypeptide domains may comprise a polypeptide including, but not limited to, nucleic acid binding proteins, transcription factors, receptor binding proteins, split enzymes, effectors of membrane receptors, etc. In another embodiment, the first polypeptide and/or the second polypeptide comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NOS:1-290 and 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494, as listed in Tables 1A and 1B. In one embodiment, at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of amino acid residues at defined interface positions of the first polypeptide and/or the second polypeptide are invariant compared to the reference polypeptide amino acid sequence (interface residues shown in Table 2).

[0258] In one non-limiting and exemplary embodiment,

[0259] (a) the first polypeptide comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to one having the amino acid sequence of SEQ ID NO:3

TABLE-US-00008 9 (SEQ ID NO: 3) GTKEDILERQRKIIERAQEIHRRQQEILEELERIIRKPGSSEEAMKRMLK LLEESLRLLKELLELSEESAQLLYEQR;

and

[0260] (b) the second polypeptide comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to one having the amino acid sequence of SEQ ID NO:58.

TABLE-US-00009 10' (SEQ ID NO: 58) GSSADDVLEDILKIIRELIEILDQILSLLNQLLKLLRHGVPNAKKVVEKY KEILELYLQLVSLFLKIVKTHADAVSGKIDKKAEEEIKKEEEKIKEKLRQ AKDILKKLQEEIDKTR

[0261] In one non-limiting and exemplary embodiment,

[0262] (a) the first polypeptide comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to one having the amino acid sequence of SEQ ID NO:3

TABLE-US-00010 9 (SEQ ID NO: 3) GTKEDILERQRKIIERAQEIHRRQQEILEELERIIRKPGSSEEAMKRMLK LLEESLRLLKELLELSEESAQLLYEQR;

and

[0263] (b) the second polypeptide comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to one having the amino acid sequence of SEQ ID NO:362.

TABLE-US-00011 10' (SEQ ID NO: 362) SADDVLEDILKIIRELIEILDQILSLLNQLLKLLRHGVPNAKKVVEKYKE ILELYLQLVSLFLKIVKTHADAVSGKIDKKAEEEIKKEEEKIKEKLRQAK DILKKLQEEIDKTR

[0264] In another embodiment, the first target and/or the second target each comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 1-290, with the proviso that the first target forms a heterodimer (a-b) pair with the first polypeptide, and the second target forms a heterodimer (a-b) pair with the second polypeptide. In another embodiment, the first target and/or the second target each comprises a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 1-290 and 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494, with the proviso that the first target forms a heterodimer (a-b) pair with the first polypeptide, and the second target forms a heterodimer (a-b) pair with the second polypeptide. Heterodimer A-B pairs among the polypeptides of SEQ ID NOS:1-290 and 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494 are described at length above (See also FIG. 16). In one embodiment, at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of amino acid residues at defined interface positions of the first target and/or the second target are invariant compared to the reference polypeptide amino acid sequence (interface residues shown in Table 2).

[0265] The compositions of this seventh aspect can be used for any suitable purpose, including in designing NOR logic gates. In one embodiment, the disclosure provides methods comprising

[0266] (a) contacting a biological sample with the composition of any embodiment or combination of embodiments of the seventh aspect of the disclosure; and

[0267] (b) detecting binding, of the first polypeptide to the first target and binding of the second polypeptide to the second target in the sample, such as detecting an output signal caused by actions of effector polypeptides upon binding. Additional details of the use of the compositions of the seventh aspect of the disclosure in NOR logic gates re described in detail in the examples that follow.

[0268] In an eighth aspect, the disclosure provides compositions comprising:

[0269] (a) a first polypeptide comprising 2 alpha helices, wherein the first polypeptide is capable of non-covalently binding a first target; and

[0270] (b) a second polypeptide comprising 2 alpha helices, wherein the first polypeptide is capable of non-covalently binding to the second polypeptide, and wherein the second polypeptide is capable of non-covalently binding a second target that differs from the first target; wherein: [0271] (i) a binding affinity of the first polypeptide for the second polypeptide is greater than a binding affinity of the second polypeptide for the second target; [0272] (ii) a binding affinity of the first polypeptide for the first target is approximately equal to a binding affinity of the second polypeptide for the second target; and [0273] (iii) the binding affinity of the first polypeptide for the first target and the binding affinity of the second polypeptide for the second target are greater than the binding affinity of the first target and the second target for each other.

[0274] Compositions of this eighth aspect can be used, for example, as XNOR gates as described in detail in the examples that follow. In one embodiment, the composition further comprises the first target and the second target. The first targets and second targets may be any target suitable for an intended use. In non-limiting embodiments, the first target and/or the second target may comprise polypeptides or nucleic acids. In another embodiment, the first target and/or the second target further comprise one or more effector polypeptide domains. Any effector polypeptide domains may be used as suitable for an intended use. In one embodiment, the one or more effector polypeptide domains may comprise a polypeptide including, but not limited to, nucleic acid binding proteins, transcription factors, receptor binding proteins, split enzymes, effectors of membrane receptors, etc. In another embodiment, the first polypeptide and/or the second polypeptide comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-290 and 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494, as listed in Tables 1A and 1B. In one embodiment, at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of amino acid residues at defined interface positions of the first polypeptide and/or the second polypeptide are compared to the reference polypeptide amino acid sequence (interface residues shown in Table 2).

[0275] In one non-limiting and exemplary embodiment,

[0276] (a) the first polypeptide comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to one having the amino acid sequence of SEQ ID NO:3

TABLE-US-00012 9 (SEQ ID NO: 3) GTKEDILERQRKIIERAQEIHRRQQEILEELERIIRKPGSSEEAMKRMLK LLEESLRLLKELLELSEESAQLLYEQR;

and

[0277] (b) the second polypeptide comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 8%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to one having the amino acid sequence of SEQ ID NO:42.

TABLE-US-00013 1' (b) (SEQ ID NO: 42) GSDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYV ELLKRHEKAVKELLEIAKTHAKKVE

[0278] In one non-limiting and exemplary embodiment,

[0279] (a) the first polypeptide comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to one having the amino acid sequence of SEQ ID NO:3

TABLE-US-00014 9 (SEQ ID NO: 3) GTKEDILERQRKIIERAQEIHRRQQEILEELERIIRKPGSSEEAMKRMLK LLEESLRLLKELLELSEESAQLLYEQR;

and

[0280] (b) the second polypeptide comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to one having the amino acid sequence of SEQ ID NO:352.

TABLE-US-00015 1' (b) (SEQ ID NO: 352) DDKELDELLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVEL LERHEKAVKELLEIAKTHAKKVE

[0281] In another embodiment, the first target and/or the second target each comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-290 and 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494, with the proviso that the first target forms a heterodimer (a-b) pair with the first polypeptide, and the second target forms a heterodimer (a-b) pair with the second polypeptide. Heterodimer A-B pairs among the polypeptides of SEQ ID NOS: 1-290 and 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494 are described at length above (See also FIG. 16). In one embodiment, at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of amino acid residues at defined interface positions of the first target and/or the second target are invariant compared to the reference polypeptide amino acid sequence (interface residues shown in Table 2).

[0282] The compositions of this eighth aspect can be used for any suitable purpose, including in designing XNOR logic gates. In one embodiment, the disclosure provides methods comprising

[0283] (a) contacting a biological sample with the composition of any one of claims 50-56; and

[0284] (b) detecting binding interactions between the first polypeptide and the first target. the second polypeptide and the second target, the first polypeptide and the second polypeptide, and the first target and the second target in the sample, such as detecting an output signal caused by actions of effector polypeptides upon binding. Additional details of the use of the compositions of the eighth aspect of the disclosure in XNOR logic gates re described in detail in the examples that follow.

[0285] In a ninth aspect, the disclosure provides compositions comprising:

[0286] (a) a first polypeptide comprising 4 alpha helices, wherein the first polypeptide is capable of non-covalently binding a first target; and

[0287] (b) a second polypeptide comprising 4 alpha helices, wherein the second polypeptide is capable of non-covalently binding a second target that differs from the first target; wherein: [0288] (i) a binding affinity of the first target for the second target is greater than a binding affinity of the first polypeptide for the first target; [0289] (ii) a binding affinity of the first polypeptide for the first target is approximately equal to a binding affinity of the second polypeptide for the second target; and [0290] (iii) the sum of the binding affinity of (A) the first polypeptide for the first target and (B) the binding affinity of the second polypeptide for the second target, is greater than the binding affinity of the first target and the second target.

[0291] Compositions of this ninth aspect can be used, for example, as NAND gates as described in detail in the examples that follow. In one embodiment, the composition further comprises the first target and the second target. The first targets and second targets may be any target suitable for an intended use. In non-limiting embodiments, the first target and/or the second target may comprise polypeptides or nucleic acids. In another embodiment, the first target and/or the second target further comprise one or more effector polypeptide domains. Any effector polypeptide domains may be used as suitable for an intended use. In one embodiment, the one or more effector polypeptide domains may comprise a polypeptide including, but not limited to, nucleic acid binding proteins, transcription factors, receptor binding proteins, split enzymes, effectors of membrane receptors, etc. In another embodiment, the first polypeptide and/or the second polypeptide comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NOS: 1-290 and 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494, as listed in Tables 1A and 1B. In one embodiment, at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of amino acid residues at defined interface positions of the first polypeptide and/or the second polypeptide are invariant compared to the reference polypeptide amino acid sequence (interface residues shown in Table 2).

[0292] In one non-limiting and exemplary embodiment,

[0293] (a) the first polypeptide comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to one having the amino acid sequence of SEQ ID NO:42

TABLE-US-00016 1' (b) (SEQ ID NO: 42) GSDDKELDKLLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYV ELLKRHEKAVKELLEIAKTHAKKVE

[0294] (b) the second polypeptide comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to one having the amino acid sequence of SEQ ID NO: 57.

TABLE-US-00017 10 (SEQ ID NO: 57) DHSRKLEEILDRLRKHVKRLLEHLRELLSLVKENPEDKDLVEVLELSLAI LRRSLEAVEAFLKSVTKKDPDDEDLRRKADEIRKEVEEIKKSLAEVEKEI YKLK

[0295] In one non-limiting and exemplary embodiment,

[0296] (a) the first polypeptide comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to one having the amino acid sequence of SEQ ID NO:352

TABLE-US-00018 1' (b) (SEQ ID NO: 352) DDKELDELLDTLEKILQTATKIIDDANKLLEKLRRSERKDPKVVETYVEL LERHEKAVKELLEIAKTHAKKVE

[0297] (b) the second polypeptide comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to one having the amino acid sequence of SEQ ID NO: 57.

TABLE-US-00019 10 (SEQ ID NO: 57) DHSRKLEEILDRLRKHVKRLLEHLRELLSLVKENPEDKDLVEVLELSLAI LRRSLEAVEAFLKSVTKKDPDDEDLRRKADEIRKEVEEIKKSLAEVEKEI YKLK

[0298] In another embodiment, the first target and/or the second target each comprise a polypeptide that is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of a polypeptide selected from the group including, but not limited to a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-290 and 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494, with the proviso that the first target forms a heterodimer (a-b) pair with the first polypeptide, and the second target forms a heterodimer (a-b) pair with the second polypeptide. Heterodimer A-B pairs among the polypeptides of SEQ ID NOS: 1-290 and 331, 332, 334, 336-422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458-460, 462, 464, 466, 468, 470, 472, 474, 476, 478, 480, 482, 484, 486, 488, 490, 493, and 494 are described at length above (See also FIG. 16). In one embodiment, at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of amino acid residues at defined interface positions of the first target and/or the second target are compared to the reference polypeptide amino acid sequence (interface residues shown in Table 2).

[0299] The compositions of this ninth aspect can be used for any suitable purpose, including in designing NAND logic gates. In one embodiment, the disclosure provides methods comprising

[0300] (a) contacting a biological sample with the composition of any one of claims 60-66; and

[0301] (b) detecting binding interactions between the first polypeptide and the first target. the second polypeptide and the second target, and the first target and the second target in the sample, such as detecting an output signal caused by actions of effector polypeptides upon binding.

[0302] As used throughout the present application, the term "polypeptide" is used in its broadest sense to refer to a sequence of subunit amino acids. The polypeptides of the invention may comprise L-amino acids, D-amino acids (which are resistant to L-amino acid-specific proteases in vivo), or a combination of D- and L-amino acids. The polypeptides described herein may be chemically synthesized or recombinantly expressed. The polypeptides may be linked to other compounds to promote an increased half-life in vivo, such as by PEGylation, HESylation, PASylation, glycosylation, or may be produced as an Fc-fusion or in deimmunized variants. Such linkage can be covalent or non-covalent as is understood by those of skill in the art.

[0303] As will be understood by those of skill in the art, the polypeptides of the invention may include additional residues at the N-terminus, C-terminus, or both that are not present in the polypeptides of the invention; these additional residues are not included in determining the percent identity of the polypeptides of the invention relative to the reference polypeptide.

[0304] As noted above, the polypeptides of the invention may include additional residues at the N-terminus, C-terminus, or both. Such residues may be any residues suitable for an intended use, including but not limited to detection tags (i.e.: fluorescent proteins, antibody epitope tags, etc.), linkers, therapeutic agents, ligands suitable for purposes of purification (His tags, etc.), ligands to drive localization, and peptide domains that add functionality to the polypeptides.

[0305] In a tenth aspect, the disclosure provides nucleic acids encoding the polypeptide, protein, fusion protein, scaffold, or design component of any embodiment or combination of embodiments disclosed herein. The nucleic acid sequence may comprise single stranded or double stranded RNA or DNA in genomic or cDNA form, or DNA-RNA hybrids, each of which may include chemically or biochemically modified, non-natural, or derivatized nucleotide bases. Such nucleic acid sequences may comprise additional sequences useful for promoting expression and/or purification of the encoded polypeptide, including but not limited to polyA sequences, modified Kozak sequences, and sequences encoding epitope tags, export signals, and secretory signals, nuclear localization signals, and plasma membrane localization signals. It will be apparent to those of skill in the art, based on the teachings herein, what nucleic acid sequences will encode the polypeptides of the disclosure.

[0306] In an eleventh aspect, the disclosure provides expression vector comprising one or more nucleic acids of the disclosure operatively linked to a control sequence. "Expression vector" includes vectors that operatively link a nucleic acid coding region or gene to any control sequences capable of effecting expression of the gene product. "Control sequences" operably linked to the nucleic acid sequences of the disclosure are nucleic acid sequences capable of effecting the expression of the nucleic acid molecules. The control sequences need not be contiguous with the nucleic acid sequences, so long as they function to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the nucleic acid sequences and the promoter sequence can still be considered "operably linked" to the coding sequence. Other such control sequences include, but are not limited to, polyadenylation signals, termination signals, and ribosome binding sites. Such expression vectors can be of any type, including but not limited plasmid and viral-based expression vectors. The control sequence used to drive expression of the disclosed nucleic acid sequences in a mammalian system may be constitutive (driven by any of a variety of promoters, including but not limited to, CMV, SV40, RSV, actin, EF) or inducible (driven by any of a number of inducible promoters including, but not limited to, tetracycline, ecdysone, steroid-responsive). The expression vector must be replicable in the host organisms either as an episome or by integration into host chromosomal DNA. In various embodiments, the expression vector may comprise a plasmid, viral-based vector, or any other suitable expression vector.

[0307] In a twelfth aspect, the disclosure provides cells comprising one or more nucleic acid, expression vector, polypeptide, protein, heterodimer protein, and/or protein scaffold of any embodiment or combination of embodiments disclosed herein. Nucleic acids or expression vectors may be episomal or chromosomally integrated. Any suitable cell type may be used, such prokaryotic or eukaryotic cells. The cells can be transiently or stably engineered to incorporate the expression vector of the disclosure, using techniques including but not limited to bacterial transformations, calcium phosphate co-precipitation, electroporation, or liposome mediated-, DEAE dextran mediated-, polycationic mediated-, or viral mediated transfection

[0308] In addition, the disclosure provides methods of producing a polypeptide, fusion protein, protein, heterodimer, etc. (collectively referred to as polypeptide) disclosed herein. In one embodiment, the method comprises the steps of (a) culturing a host according to this aspect of the disclosure under conditions conducive to the expression of the polypeptide, and (b) optionally, recovering the expressed polypeptide. The expressed polypeptide can be recovered from the cell free extract or recovered from the culture medium. In another embodiment, the method comprises chemically synthesizing the polypeptides.

Example 1 Design of Orthogonal Protein Heterodimers

[0309] Abstract: Here we demonstrate that heterodimeric interaction specificity can be achieved using extensive and modular buried hydrogen bond networks. We used the Crick generating equations to produce millions of four helix backbones with varying degrees of supercoiling around a central axis, identified those accommodating extensive hydrogen bond networks, and designed connected pairs of helices with short loops and optimize the remainder of the sequence. 65 of 97 such designs expressed in E. coli formed constitutive heterodimers, and crystal structures of four designs were in close agreement with the computational models and confirmed the designed hydrogen bond networks. In cells, a set of six heterodimers were found to be fully orthogonal, and in vitro, following mixing of 32 chains from sixteen heterodimer designs, denaturation in 5M GdnHCl and reannealing, the vast majority of the interactions were between the designed cognate pairs. The ability to design orthogonal protein heterodimers enables sophisticated protein based control logic for synthetic biology, and illustrates that nature has not fully explored the possibilities for programmable biomolecular interaction modalities. Hydrogen bond networks, including modular hydrogen bond networks are described in published patent application number WO2017173356, incorporated by reference herein.

[0310] Orthogonal sets of protein-protein and protein-peptide interactions play important roles in biological systems. Creation of new specificities by sequence redesign has been difficult, often resulting in promiscuous binding We hypothesized that large sets of designed heterodimers could be generated by incorporating asymmetric buried hydrogen bond networks into regularly repeating backbone structures. We generated helical bundle heterodimers in which each monomer is a helix-turn-helix starting from four-helix backbones. For each of the four helices, we exhaustively sampled the helical phase (.DELTA..PHI..sub.1), supercoil radius (R) and offset along the Z-axis (Z offset) (FIG. 1A), restricting the supercoil phases of the helices to 0, 90, 180 and 270 degrees, and the supercoil twist (.omega..sub.0) and helical twist (.omega..sub.1) to the ideal values for either a two layer left handed super coil (.omega..sub.0=-2.85 and .omega..sub.1=102.85), or a 5 layer untwisted bundle (.omega..sub.0=0 and .omega..sub.1=100) (FIG. 5A-B). This yielded 27 million untwisted and 60 million left-handed supercoiled backbones for both parallel and antiparallel orientations of opposing helices (FIG. 1B).

[0311] To identify the modular hydrogen bond network equivalents to DNA base pairs, we used ROSETTA.TM. HBNET.sup.21 to design buried hydrogen bond networks in the central repeat units of each backbone, and obtained 2251 hydrogen bond networks involving at least 4 side chain residues with all heavy-atom donors and acceptors participating in hydrogen bonds, and connecting all 4 helices (FIG. 1c; FIG. 6, Table 6). We then identified all of the geometrically compatible placements of these hydrogen bond networks in each backbone (FIG. 1d), selected backbones accommodating at least two networks, and connected pairs of helices with short loops (FIG. 1e). Low energy sequences were identified using ROSETTADESIGN.TM. 2.sup.2 calculations in which the hydrogen bond networks were held fixed. Designs with fully satisfied hydrogen bond networks and tight hydrophobic packing were selected for experimental characterization, excluding those with networks with C2 symmetry to disfavor homodimerization of monomers. Designed heterodimers (DHDs) are referred to by numbers with monomers labeled a or b; for example, DHD15_a refers to monomer "a" of design DHD15.

TABLE-US-00020 TABLE 6 The frequency of observing each hydrogen bond networks during the systematic search. HBNet Percentage composition Frequency (%) (S/T)2Q1Y1 13954 3.87071362 (S/T)3Q1 9959 2.76253669 (S/T)2D1H1 8452 2.34450849 (S/T)1Q2Y1 7603 2.10900356 (S/T)1D1Q1Y1 7359 2.04132016 (S/T)3D1 6332 1.75643963 (S/T)3D1Q1 5525 1.53258512 (S/T)1D1Q3 5071 1.40664962 (S/T)1D1Q2 5062 1.4041531 (S/T)2N1Y1 5046 1.39971484 (S/T)1N1Q1Y1 4921 1.36504097 (S/T)2H2 4683 1.29902192 (S/T)2H1Q1 4572 1.26823152 (S/T)3H1 3955 1.09708129 (S/T)2D1Q2 3946 1.09458477 (S/T)1D1N1Q2 3862 1.07128393 (S/T)3N1 3783 1.04937005 (S/T)2D1Y1 3762 1.04354484 (S/T)2D1Q1 3669 1.01774747 (S/T)1D1H1Q1 3653 1.01330922 (S/T)1D1Q1W1 3409 0.94562582 (S/T)1D1Q2Y1 3342 0.92704063 (S/T)2Q3 3111 0.86296331 (S/T)2D1N1Q1 2999 0.83189552 (S/T)2Q2Y1 2850 0.79056427 (S/T)1D1W1Y1 2849 0.79028688 (S/T)2N1Q2 2741 0.76032865 (S/T)2D1Q1Y1 2723 0.75533562 (S/T)1D1N1Q1Y1 2684 0.74451737 (S/T)2Q1W1 2641 0.73258956 (S/T)2H1N1Q1 2591 0.71872001 (S/T)2Q2 2582 0.71622349 (S/T)2N1Q1 2554 0.70845654 (S/T)2D1W1 2467 0.68432353 (S/T)2H1N1 2377 0.65935834 (S/T)4Q1 2305 0.63938619 (S/T)1N1Q2Y1 2296 0.63688967 (S/T)1D2Q2 2285 0.63383837 (S/T)2D1H1Q1 2276 0.63134185 (S/T)2D1Q1W1 2267 0.62884533 (S/T)1H1Q1Y1 2222 0.61636274 (S/T)1D1N1Q1 2207 0.61220187 (S/T)2H1Y1 2150 0.59639059 (S/T)1D1N1Y1 2109 0.58501756 (S/T)1Q1Y2 1962 0.54424109 (S/T)1H1Q2 1957 0.54285413 (S/T)1Q1W1Y1 1954 0.54202196 (S/T)2N1Q1Y1 1935 0.53675153 (S/T)3H1Q1 1901 0.52732024 (S/T)1D1H1W1 1879 0.52121764

[0312] 94 of the 97 selected designs were well-expressed in E. coli with both monomers co-purifying by Ni-affinity chromatography (only one monomer contains a hexahistidine tag). For 85/94, the dominant species observed in size exclusion chromatography (SEC) had the expected size (FIG. 1f). Three designs characterized by CD spectroscopy were found to be all alpha helical and stable at 95.degree. C. (FIG. 1g, FIG. 6). Sequences and other information on the designs are provided in Tables 1A-B (above).

[0313] We explored the extent to which the heterodimer set could be expanded by permuting the hydrogen bond networks in the different helical repeat units, and by permuting the backbone connectivity. Assigning each unique network a letter, DHD37_XBBA indicates a variant where the second, third and fourth repeat units have hydrogen bond networks B, B, and A, and the first heptad has exclusively hydrophobic residues in the core, while DHD103_1:423 indicates a heterodimer where one monomer consists of the first helix of DHD103 and the other monomer consists of helices 2 through 4 (FIG. 7). 13 of 14 hydrogen bond network permuted variants and 9 of 10 "3+1" backbone-permuted heterodimers (generated from five starting "2+2" heterodimers) ran as single peaks on SEC.

[0314] SAXS spectra collected for 44 designs were consistent with the design models (FIG. 1h, FIG. 2f-h). The X-ray crystal structures of DHD131, DHD37_1:234, DHD127 and DHD15 had backbone Ca atom RMSDs to the design models ranging from 0.95 to 1.7 .ANG.. The extensive five-residue buried hydrogen bond network of DHD131 (involving two serines, an asparagine, a tyrosine, and a tryptophan) is nearly identical in the crystal structure, with an additional water molecule bridging the interactions (FIG. 2a). The two designed hydrogen bond networks in DHD37_1:234, which contain buried histidine and tyrosine aromatic side chains sterically disfavoring homodimers, are in close agreement with the crystal structure (FIG. 2b). In DHD127, the histidines in the two hydrogen bond networks adopt a rotamer different from the design model (FIG. 2c), making a hydrogen bond with a water molecule. A crystal structure of DHD15 at pH 7.0 is similar to the design model (FIG. 2d), while a structure at pH 6.5 is of a domain-swapped, hetero-tetramer conformation.

[0315] We built three induced dimerization systems by fusing one monomer each from two different heterodimers via a flexible linker, and testing whether the remaining two monomers from each pair could be brought together by the fusion (FIG. 3a). In each case, the three components co-purified by Ni-NTA chromatography (one monomer has a hexahistidine tag); In yeast two-hybrid assays (Y2H) with monomers from two different heterodimers fused to the DNA binding domain (DBD) and transcriptional activation domain (AD), expression of the heterodimerizer fusion as a separate polypeptide chain increased signal significantly over background (FIG. 3b).

[0316] We covalently linked the monomer chain "a" subunits of 3 DHDs via flexible linkers (FIG. 3C), and co-expressed this "scaffold" and the 3 separate chain "b" monomers, one with a hexahistidine tag, in E. coli. The scaffold plus monomer assembly is stable at 95.degree. C. and has a guanidine denaturation midpoint of 4 M (FIG. 9).

[0317] By generating interfaces with many polar groups which are energetically costly to bury without geometrically matched hydrogen bonding interactions, our design protocol implicitly disfavors non-cognate interactions (explicit negative design to disfavor non-cognate interactions is computationally intractable given the very large number of possible off-target binding modes). For 24 designs, strong interactions were observed by Y2H with the two partners fused to DBD and AD, but not when either partner was fused to both domains; the designed heterodimers, but not the homodimers, form in cells (FIG. 4A). The 24 monomers in 12 of these designs were crossed in an all-by-all Y2H experiment; interactions were observed for all cognate pairs, and 27 of the 552 possible non-cognate interactions (FIG. 9). Orthogonality was higher for an 8 DHD subset: of 240 possible non-cognate interactions, only 4 were observed (FIG. 4B; the interacting polar residues are depicted schematically in FIG. 10). Co-expression of unfused monomers eliminated off-target interactions (FIG. 4C); the cognate interactions are evidently stronger than the non-cognate interactions.

[0318] Our results demonstrate that the domain of unbounded sets of orthogonal heterodimeric biomolecules constructed from a single repeating backbone is not limited to nucleic acids. Interaction specificity arises from extensive buried hydrogen bond networks such as the fully connected TYR-SER-TRP-ASN-SER (SEQ ID NO:333) crystallographically confirmed network in FIG. 2a, and heterogeneity in the size of the residues at the designed interface (FIG. 9d-i), analogous to the contribution of steric effects to Watson-Crick base pairing specificity. Our large set of orthogonal interactions, together with the retention of specificity in the fused monomer systems (the induced dimerizer and scaffold of FIG. 3), and the interaction strength hierarchy illustrated by the cognate interaction competition experiment (FIG. 4c), can be used, by way of non-limiting example, to prepare protein based cellular control circuits with faster response times and better integration with signaling inputs and outputs than current nucleic acid based circuitry.

Methods for Example 1

Computational Design

1. Systematic Sampling of Parametric Helical Backbones

[0319] We used a generalization of the Crick coiled-coil parameters s to independently sample all four helices of the heterodimers supercoiled around the same axis. The supercoil twist (.omega..sub.0) and helical twist (.omega..sub.1) were coupled and ideal values were used .sup.20 with .omega..sub.0 and .omega..sub.1 held constant among the helices. A left-handed supercoil results from .omega..sub.0=-2.85 and .omega..sub.1=102.85, and a straight bundle with no supercoiling from .omega..sub.0=0 and .omega..sub.0=100. The supercoil phases (.DELTA..PHI..sub.0) for the helices were fixed at 0.degree., 90.degree., 180.degree. and 270.degree., respectively. The offset along the Z-axis (Z offset) for the first helix was fixed to 0 as a reference point, with the rest of the helices independently sampling from -1.51 .ANG. to 1.51 .ANG., with a step size of 1.51 .ANG.. All helices sampled helical phases (.DELTA..PHI..sub.1) independently, from 0.degree. to 90.degree., with a step size of 10.degree.. Two of the helices with a .DELTA..PHI..sub.0 separation of 180.degree. sampled the radius from Z-axis (R) from 5 .ANG. to 8 .ANG., while the other two sampled from 7 .ANG. to 10 .ANG., all with a step size of 1 .ANG.. Each helix is set to have 35 residues to accommodate 5 heptad repeats. After removing redundant sample points from the overlapping regions of radii sampling, the supercoiled helical bundles contained more than 60 million unique backbones, and the straight helical bundles contained more than 27 million unique backbones.

2. HBNet Search

[0320] For each parametrically generated backbone, HBNet.TM. .sup.21 was used to search the middle heptad for hydrogen bond networks that connect all four helices, contain at least four side chains contributing hydrogen bonds, have all heavy atom donors and acceptors satisfied, and span the intermolecular interface. Symmetry was not enforced during the HBNet.TM. search. For buried interface positions, only non-charged polar amino acids were considered; for residues that were at the boundary between protein core and surface, all polar amino acids were considered. A subsequent Rosetta.TM. design calculation was performed to optimize hydrophobic packing, with atom pair restraints from HBNet.TM. being put on the newly identified hydrogen bond networks. Finally, a minimization step and side chain repacking step was performed without atom pair restraints on hydrogen bonding residues to evaluate how well the networks remained intact in the absence of the constraints. Designs with at most 5 alanines in the middle heptad and no buried unsatisfied polar heavy atoms were selected for downstream design.

3. Generating Combinations of HBNets.TM. with Heptad Stacking

[0321] The purpose of this step is to identify five-heptad backbones (full backbones) that can accommodate at least 2 HBNets.TM.. Instead of generating one-heptad backbones and full backbones separately, searching for HBNets.TM. in the one-heptad backbones and aligning them to all full backbones, we reasoned the heptad stacking method remains the same if one simply searches for HBNets.TM. in the middle heptad on all full backbones, extracts the middle heptads, and aligns them to all full backbones. We therefore extracted the middle heptads containing HBNets.TM., generated all variants of chain ordering, and did pairwise alignment of middle heptads to full backbones using TMalign .sup.30. All alignments with root mean square deviation (RMSD) less than 0.3 were identified and full backbones that can accommodate at least 2 middle heptads were selected for final design.

4. Connecting Parametric Helical Backbones

[0322] Helical backbones are connected with short 2-5 residue loops such that the RMSD of each loop is less than 0.4 RMSD to a nine residues stretch in a native protein. Distance and directionality between helices limit what loops can connect, as such, our closure extends and shrinks helices by up to 3 residues. We then superimpose all short loops from the PDB onto the first and last two helical residues. The loops with the lowest stub-RMSD are minimized using the Rosetta.TM. score function onto the helical endpoints to ensure a near perfect closure. Loop quality is assessed by measuring the distance in RMSD to the closest nine stretch in the PDB. The loop with the lowest RMSD is returned as the solution. We repeat this procedure to connect all helices and report the solution with the lowest RMSD.

5. Design Calculations

[0323] Backbones were regularized using Cartesian space minimization in Rosetta.TM. to alleviate any torsional strain introduced by heptad stacking. Two consecutive Rosetta.TM. packing rounds were performed with increasing weight on the repulsive energy to optimize hydrophobic packing, while constraining the hydrogen bond network residues. A FastDesign step was subsequently used within a generic Monte Carlo mover to optimize secondary structure shape complementarity, while allowing at most 8% alanine, 3 methionine and 3 phenylalanine in the protein core. The last step of minimization and side chain repacking to identify the movement of HBNets without atom pair constraints is the same as what was described in Step 2.

6. Selection Criteria and Metrics Used to Evaluate Designs

[0324] Designs were selected based on the following criteria: change in polar surface area upon binding (dSASA_polar) greater than 800 .ANG.; secondary structure shape complementarity (ss_sc) score greater than 0.65; holes score around HBNets less than -1.4; no buried unsatisfied heavy atoms; at least one buried bulky polar side chains per monomer. Selected designs were then visually inspected for good packing of hydrophobic side chains, especially the interdigitation of isoleucine, leucine and valine. Surface tyrosines were added at non-interfering positions to aid protein concentration measurement by recording OD280. Surface charge residues for a few of the designs were redesigned to shift the theoretical isoelectric point away from buffer pH.

RMSD Calculations

[0325] Crystal structures and the corresponding design models were superimposed with TMalign using all heavy atoms. From this alignment, RMSD was calculated across all alpha-carbon atoms, and also across heavy atoms of the hydrogen bond network residues.

Logistic Regression

[0326] Designs were first scored with various filters in Rosetta.TM. with the filter values reported. Experimental results and Rosetta.TM. filter values were used as input to a logistic regression method.sup.31 to find correlations between computational metrics and experimental observations.

Visualization and Figures

[0327] All structural images for figures were generated using PyMOL .sup.32.

Buffer and Media Recipe

[0328] TBM-5052: 1.2% [wt/vol] tryptone, 2.4% [wt/vol] yeast extract, 0.5% [wt/vol]glycerol, 0.05% [wt/vol] D-glucose, 0.2% [wt/vol] D-lactose, 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 10 .mu.M FeCl3, 4 .mu.M CaCl.sub.2), 2 .mu.M MnCl2, 2 .mu.M ZnSO4, 400 nM CoCl2, 400 nM NiCl2, 400 nM CuCl2, 400 nM Na2MoO4, 400 nM Na2SeO3, 400 nM H3BO3

[0329] Lysis buffer: 20 mM Tris, 300 mM NaCl, 20 mM Imidazole, pH 8.0 at room temperature

[0330] Wash buffer: 20 mM Tris, 300 mM NaCl, 30 mM Imidazole, pH 8.0 at room temperature

[0331] Elution buffer: 20 mM Tris, 300 mM NaCl, 250 mM Imidazole, pH 8.0 at room temperature

[0332] Buffer W: 100 mM Tris-HCl pH 8.0, 150 mM NaCl and 1 mM EDTA

[0333] Buffer E: Buffer W containing 2.5 mM D-desthiobiotin

[0334] TBS buffer: 20 mM Tris pH 8.0, 100 mM NaCl

Construction of Synthetic Genes

[0335] For the expression of heterodimers, both monomers were encoded in the same plasmid, separated by a ribosome binding sequence (GAAGGAGATATCATC; SEQ ID NO:327). Synthetic genes were ordered from Genscript Inc. (Piscataway, N.J., USA) and delivered in pET21-NESG E. coli expression vector, inserted between the NdeI and XhoI sites. For the pET21-NESG constructs, a hexahistidine tag and a tobacco etch virus (TEV) protease cleavage site (GSSHFHHHHSSGENLYFQGS; SEQ ID NO:328) were added in frame at the N-terminus of the second monomer. A stop codon was introduced at the 3' end of the second monomer to stop expression of the C-terminal hexahistidine tag in the vector. For purification with Strep-tactin resin, a streptavidin tag (SAWSHPQFEKGGGSGGGSGGSAWSHPQFEKSGENLYFQGS; SEQ ID NO:329) coding sequence was cloned in frame 5' of the first monomer sequence.

[0336] For the co-expression of 3 and 4 proteins from the same plasmid (induced dimerization and synthetic scaffold designs), synthetic genes were cloned in the pRSFDuet-1 expression vector. The first (in the case of 3 proteins) or first two (in the case of 4 proteins) genes were cloned between NcoI and HindIII sites, with a ribosome binding site separating the 2 proteins in the latter case. The last two genes were cloned between NdeI and XhoI sites, separated by a ribosome binding site. A hexahistidine tag and a TEV protease cleavage site coding sequence were cloned in frame 5' of the last gene.

[0337] Genes for yeast-two-hybrid (Y2H) studies were cloned into plasmids bearing the GAL4 transcription activation domain (poAD) and the GAL4 DNA-binding domain (poDBD).

Protein Expression

[0338] Plasmids were transformed into chemically competent E. coli expression strains BL21(DE3)Star (Invitrogen) or Lemo21.TM. (DE3) (New England Biolabs) for protein expression. Single colonies were picked from agar plates following transformation and growth overnight, and 5 ml starter cultures were grown at 37.degree. C. in Luria-Bertani (LB) medium containing 100 .mu.g/mL carbenicillin (for pET21-NESG vectors) or kanamycin (for pRSFDuet-1 vectors) with shaking at 225 rpm for 18 hours at 37.degree. C. Starter cultures were diluted into 500 ml TBM-5052 containing 100 .mu.g/mL carbenicillin or kanamycin, and incubated with shaking at 225 rpm for 24 hours at 37.degree. C.

[0339] For expression of .sup.13C.sup.15N-- or .sup.15N-labeled protein, the plasmids were transformed into the Lemo21.TM. (DE3) E. coli expression strain and plated on M9/glucose plates containing 50 g/mL carbenicillin. For the starter culture, a single colony was used for inoculation of 50 mL LB medium with 50 .mu.g/mL carbenicillin in a 250 mL baffled flask, and incubated with shaking at 225 rpm for 18 hours at 37.degree. C. 10 mL of the starter culture was then transferred to a 2 L baffled flask containing 500 mL of Terrific Broth.TM. (Difco), with 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, and 100 .mu.g/mL carbenicillin. The culture was grown at 37.degree. C. to an OD600 of approximately 1.0, then centrifuged at 5000 rcf for 15 minutes to pellet the cells. The Terrific Broth.TM. medium was removed, and the cells were washed briefly with 30 mL of phosphate buffered saline (PBS). The cells were then transferred to a fresh 2 L baffled flask containing 500 mL of labeled media (25 mM Na2HPO4, 25 mM KH2PO4, 50 mM 15NH4C1, 5 mM Na2SO4, 0.2% (w/v).sup.13C glucose), and 100 .mu.g/mL carbenicillin. The cells were allowed to grow at 37.degree. C. for 2 hours, before IPTG (Carbosynth) was added to 1 mM and the temperature was reduced to 18.degree. C. The labeled glucose and NH4C1 were obtained from Cambridge Isotopes.

Affinity Purification

[0340] Cells were harvested by centrifugation for 15 minutes at 5000 rcf at 4.degree. C. and resuspended in 20 ml lysis buffer. Lysozyme, DNAse, and EDTA-free cocktail protease inhibitor (Roche) were added to the resuspended cell pellet before sonication at 70% power for 5 minutes. For Immobilized metal affinity chromatography (IMAC), lysates were clarified by centrifugation at 4.degree. C. and 18,000 rpm for at least 30 minutes and applied to Ni-NTA (Qiagen) columns pre-equilibrated with lysis buffer. The column was washed two times with 5 column volumes (CV) of wash buffer, followed by 5 CV of elution buffer. For Strep tag purification, elution fractions from IMAC were applied to Strep-Tactin.RTM. Superflow resin (IBA) pre-equilibrated in Buffer W. The column was washed with 5 CV Buffer W, before applying 3 CV Buffer E to elute proteins off the column. Mass and purity of eluted proteins were confirmed using electrospray ionization mass spectrometry (ESI-MS) on a Thermo Scientific TSQ Quantum Access mass spectrometer.

Size-Exclusion Chromatography (SEC)

[0341] N-terminal hexahistidine tags and streptavidin tags were cleaved with TEV protease overnight at room temperature, at a ratio of 1 mg TEV for 100 mg of protein. Prior to addition of TEV, buffer was exchanged into lysis buffer. After TEV cleavage, sample was passed over an additional Ni-NTA column and washed with 1.5 CV of lysis buffer, flow through were collected and further purified by SEC using a Superdex.TM. 7510/300 increase column (GE Healthcare) in TBS buffer.

Circular Dichroism (CD) Measurements

[0342] CD wavelength scans (260 to 195 nm) and temperature melts (25 to 95.degree. C.) were performed using an AVIV model 420 CD spectrometer. Temperature melts were carried out at a heating rate of 4.degree. C./min and monitored by the change in ellipticity at 222 nm; protein samples were diluted to 0.25 mg/mL in PBS pH 7.4 in a 0.1 cm cuvette. Guanidinium chloride (GdmCl) titrations were performed on the same spectrometer with automated titration apparatus in PBS pH 7.4 at 25.degree. C., with a protein concentration of 0.025 mg/mL in a 1 cm cuvette with stir bar. Each titration consisted of at least 40 evenly distributed GdmCl concentration points with one minute mixing time for each step. Titrant solution consisted of the same concentration of protein in PBS+GdmCl.

Crystallization of Protein Samples

[0343] Purified protein samples were concentrated to approximately 20 mg/ml in 25 mM Tris pH 8.0 and 150 mM NaCl. Samples were screened with a 5-position deck Mosquito.TM. crystal (ttplabtech) with an active humidity chamber, utilizing the following crystallization screens: JCSG+.TM. (Qiagen), Crystal Screen.TM. (Hampton Research), PEG/Ion.TM. (Hampton Research), PEGRx HT.TM. (Hampton Research), Index.TM. (Hampton Research) and Morpheus.TM. (Molecular Dimensions). The optimal conditions for crystallization of the different designs were found as follows: OPHD_37_N3C1, 0.15 M potassium bromide and 30% w/v polyethylene glycol monomethyl ether 2000; OPHD_127, 0.12 M ethylene glycols, 0.1 M buffer system 3 pH 8.5, and 50% v/v precipitate mix 1 from the Morpheus screen; OPHD_15, 0.2 M Ammonium sulfate, 0.1 M BIS-TRIS pH 6.5, 18% v/v Polyethylene glycol 400; OPHD_15, 0.1 M Imidazole pH 7.0, and 25% v/v Polyethylene glycol monomethyl ether 550; OPHD_131, 0.2 M Ammonium acetate, 0.1 M HEPES pH 7.5, 25% w/v Polyethylene glycol 3,350. Crystals were obtained after 1 to 14 days by the hanging drop vapor diffusion method with the drops consisting of a 1:1, 2:1 and 1:2 mixture of protein solution and reservoir solution.

X-Ray Data Collection and Structure Determination

[0344] The crystals of the designed proteins were looped and placed in the corresponding reservoir solution, containing 20% (v/v) glycerol if the reservoir solution did not contain cryoprotectant, and flash-frozen in liquid nitrogen. The X-ray data sets were collected at the Advanced Light Source at Lawrence Berkeley National Laboratory with beamlines 8.2.1 and 8.2.2. Data sets were indexed and scaled using either XDS .sup.33 or HKL2000 .sup.34. Initial models were generated by the molecular-replacement method with the program PHASER .sup.35 within the Phenix.TM. software suite .sup.36, using the design models as the initial search models. Efforts were made to reduce model bias through refinement with simulated annealing using Phenix.refine.TM. 7, or, if the resolution was sufficient, by using Phenix.autobuild.TM. .sup.38 with rebuild-in-place set to false, simulated annealing and prime-and-switch phasing. Iterative rounds of manual building in COOT .sup.39 and refinement in Phenix.TM. were used to produce the final models. Due to the high degree of self-similarity inherit in coiled-coil-like proteins, datasets for the reported structures suffered from a high degree of pseudo translational non-crystallographic symmetry, as report by Phenix.Xtriage.TM., which complicated structure refinement and may explain the higher than expected R values reported. RMSDs of bond lengths, angles and dihedrals from ideal geometries were calculated with Phenix.TM. .sup.36. The overall quality of all final models was assessed using the program MOLPROBITY.TM. .sup.40

Small Angle X-Ray Scattering (SAXS)

[0345] Samples were purified by SEC in 25 mM Tris pH 8.0, 150 mM NaCl and 2% glycerol; fractions preceding the void volume of the column were used as blanks for buffer subtraction. Scattering measurements were performed at the SIBYLS.TM. 12.3.1 beamline at the Advanced Light Source. The X-ray wavelength (.lamda.) was 1.27 .ANG., and the sample-to-detector distance was 1.5 m, corresponding to a scattering vector q (q=4.pi. sin .theta./.lamda., where 2.theta. is the scattering angle) range of 0.01 to 0.3 .ANG..sup.-1. A series of exposures, in equal sub-second time slices, were taken of each well: 0.3 second exposures for 10 seconds resulting in 32 frames per sample. For each sample, data was collected for two different concentrations to test for concentration-dependent effects; "low" concentration samples ranged from 2-3 mg/mL and "high" concentration samples ranged from 5-7 mg/mL. Data was processed using the SAXS FrameSlice.TM. online serve and analyzed using the Sc.ANG.tter.TM. software package .sup.41,42 FoXS.TM. .sup.43,44 was used to compare design models to experimental scattering profiles and calculate quality of fit (x) values.

Yeast Two-Hybrid Assay

[0346] For each pair of binders tested, chemically competent cells of yeast strain PJ69-4a (MATa trp1-901 leu2-3,112 ura3-52 his3-200 gal4(deleted) gal80(deleted) LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7-lacZ) were transformed with the appropriate pair of plasmids containing DNA binding domain or activation domains, using the LiAc/SS carrier DNA/PEG method .sup.45. In the case of induced dimerization, the heterodimerizer was cloned downstream of one of the "monomer proteins", separated by a p2a and nuclear locolization sequence (GSGATNFSLLKQAGDVEENPGPGDKAELIPEPPKKKRKVELGTA; SEQ ID NO:330). The p2a sequence ensures translational cleavage to make the heterodimerizer a separate protein from the "monomer protein". The selection of transformed yeast cells was performed in synthetic dropout (SDO) media lacking tryptophan and leucine for 48 hours with shaking at 1000 rpm at 30.degree. C. The resulting culture was diluted 1:100 and grown for 16 hours in fresh SDO media lacking tryptophan and leucine, before transferring to a 96 well plate and diluted 1:100 into SDO media containing 100 mM 3-Amino-1,2,4-triazole (3-AT), lacking tryptophan, leucine and histidine (5 mM 3-AT in the case of induced dimerization). The culture was incubated with shaking at 1000 rpm at 30.degree. C. Since bringing the DNA binding domain and the transcription activation domain into proximity is necessary for the growth of yeast cells in media lacking histidine, binding of two proteins was indicated by the growth of yeast cells .sup.46,47. The optical density of yeast cells was recorded after 48 hours. For Y2H assay on agar plates, the 1:100 diluted overnight culture was transferred onto Nunc.TM. OmniTray.TM. (Thermo Fisher) using a 96 Solid Pin Multi-Blot Replicator (V&P Scientific), with the agar lacking tryptophan, leucine and histidine, and containing 100 mM 3-AT. The plates were imaged daily until Day 5 to monitor the sizes of colonies. Images were analyzed by the ColonyArea .sup.48 package on ImageJ.

REFERENCES FOR EXAMPLE 1

[0347] 1. Jones, S. & Thornton, J. M. Principles of protein-protein interactions. Proc. Natl. Acad. Sci. U.S.A. 93, 13-20 (1996). [0348] 2. Harbury, P. B., Zhang, T., Kim, P. S. & Alber, T. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262, 1401-1407 (1993). [0349] 3. Diss, M. L. & Kennan, A. J. Orthogonal recognition in dimeric coiled coils via buried polar-group modulation. J Am. Chem. Soc. 130, 1321-1327 (2008). [0350] 4. Thomas, F., Boyle, A. L., Burton, A. J. & Woolfson, D. N. A set of de novo designed parallel heterodimeric coiled coils with quantified dissociation constants in the micromolar to sub-nanomolar regime. J. Am. Chem. Soc. 135, 5161-5166 (2013). [0351] 5. Crick, F. H. C. The Fourier transform of a coiled-coil. Acta Cryst (1953). Q6, 685-689 [doi:10.11071S0365110X53001952] 6, 1-5 (1953). [0352] 6. Zarrinpar, A., Park, S.-H. & Lim, W. A. Optimization of specificity in a cellular protein interaction network by negative selection. Nature 426, 676-680 (2003). [0353] 7. Aakre, C. D. et al. Evolving new protein-protein interaction specificity through promiscuous intermediates. Cell 163, 594-606 (2015). [0354] 8. Joachimiak, L. A., Kortemme, T., Stoddard, B. L. & Baker, D. Computational design of a new hydrogen bond network and at least a 300-fold specificity switch at a protein-protein interface. J. Mol. Biol. 361, 195-208 (2006). [0355] 9. Skerker, J. M. et al. Rewiring the specificity of two-component signal transduction systems. Cell 133, 1043-1054 (2008). [0356] 10. Crooks, R. O., Baxter, D., Panek, A. S., Lubben, A. T. & Mason, J. M. Deriving Heterospecific Self-Assembling Protein-Protein Interactions Using a Computational Interactome Screen. J Mol. Biol. 428, 385-398 (2016). [0357] 11. Gradi ar, H. & Jerala, R. De novo design of orthogonal peptide pairs forming parallel coiled-coil heterodimers. J Pept. Sci. 17, 100-106 (2011). [0358] 12. Thompson, K. E., Bashor, C. J., Lim, W. A. & Keating, A. E. SYNZIP protein interaction toolbox: in vitro and in vivo specifications of heterospecific coiled-coil interaction domains. ACS Synth. Biol. 1, 118-129 (2012). [0359] 13. Reinke, A. W., Grant, R. A. & Keating, A. E. A synthetic coiled-coil interactome provides heterospecific modules for molecular engineering. J. Am. Chem. Soc. 132, 6025-6031 (2010). [0360] 14. Acharya, A., Rishi, V. & Vinson, C. Stability of 100 homo and heterotypic coiled-coil a-a' pairs for ten amino acids (A, L, I, V, N, K, S, T, E, and R). Biochemistry 45, 11324-11332 (2006). [0361] 15. Grigoryan, G. & Keating, A. E. Structure-based prediction of bZIP partnering specificity. J Mol. Biol. 355, 1125-1142 (2006). [0362] 16. Gonzalez, L., Jr, Woolfson, D. N. & Alber, T. Buried polar residues and structural specificity in the GCN4 leucine zipper. Nat. Struct. Biol. 3, 1011-1018 (1996). [0363] 17. Lumb, K. J. & Kim, P. S. A buried polar interaction imparts structural uniqueness in a designed heterodimeric coiled coil. Biochemistry 34, 8642-8648 (1995). [0364] 18. Tatko, C. D., Nanda, V., Lear, J. D. & DeGrado, W. F. Polar Networks Control Oligomeric Assembly in Membranes. J. Am. Chem. Soc. 128, 4170-4171 (2006). [0365] 19. Grigoryan, G. & DeGrado, W. F. Probing Designability via a Generalized Model of Helical Bundle Geometry. J. Mol. Biol. 405, 1079-1100 (2011). [0366] 20. Huang, P.-S. et al. High thermodynamic stability of parametrically designed helical bundles. Science 346, 481-485 (2014). [0367] 21. Boyken, S. E. et al. De novo design of protein homo-oligomers with modular hydrogen-bond network-mediated specificity. Science 352, 680-687 (2016). [0368] 22. Leaver-Fay, A. et al. ROSETTA.TM.3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 487, 545-574 (2011). [0369] 23. Ruotolo, B. T. & Robinson, C. V. Aspects of native proteins are retained in vacuum. Curr. Opin. Chem. Biol. 10, 402-408 (2006). [0370] 24. Sahasrabuddhe, A. et al. Confirmation of intersubunit connectivity and topology of designed protein complexes by native MS. Proc. Natl. Acad. Sci. U.S.A. 115, 1268-1273 (2018). [0371] 25. Zhou, M., Huang, C. & Wysocki, V. H. Surface-induced dissociation of ion mobility-separated noncovalent complexes in a quadrupole/time-of-flight mass spectrometer. Anal. Chem. 84, 6016-6023 (2012). [0372] 26. Zhou, M. & Wysocki, V. H. Surface induced dissociation: dissecting noncovalent protein complexes in the gas phase. Acc. Chem. Res. 47, 1010-1018 (2014). [0373] 27. Anderson, G. P., Shriver-Lake, L. C., Liu, J. L. & Goldman, E. R. Orthogonal Synthetic Zippers as Protein Scaffolds. ACS Omega 3, 4810-4815 (2018). [0374] 28. Rothemund, P. W. K. Folding DNA to create nanoscale shapes and patterns. Nature 440, 297-302(2006). [0375] 29. Qian, L. & Winfree, E. Scaling up digital circuit computation with DNA strand displacement cascades. Science 332, 1196-1201 (2011). [0376] 30. Zhang, Y. & Skolnick, J. TM-align: a protein structure alignment algorithm based on the TM-score. Nucleic Acids Res. 33, 2302-2309 (2005). [0377] 31. Rocklin, G. J. et al. Global analysis of protein folding using massively parallel design, synthesis, and testing. Science 357, 168-175 (2017). [0378] 32. Schrodinger, LLC. The PyMOL Molecular Graphics System, Version 1.8. (2015). [0379] 33. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010). [0380] 34. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997). [0381] 35. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007). [0382] 36. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010). [0383] 37. Afonine, P. V. et al. Joint X-ray and neutron refinement with phenix.refine. Acta Crystallogr. D Biol. Crystallogr. 66, 1153-1163 (2010). [0384] 38. Terwilliger, T. C. et al. Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. Acta Crystallogr. D Biol. Crystallogr. 64, 61-69 (2008). [0385] 39. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004). [0386] 40. Davis, I. W. et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35, W375-83 (2007). [0387] 41. Dyer, K. N. et al. High-throughput SAXS for the characterization of biomolecules in solution: a practical approach. Methods Mol. Biol. 1091, 245-258 (2014). [0388] 42. Rambo, R. P. & Tamer, J. A. Characterizing flexible and intrinsically unstructured biological macromolecules by SAS using the Porod-Debye law. Biopolymers 95, 559-571 (2011). [0389] 43. Schneidman-Duhovny, D., Hammel, M. & Sali, A. FoXS: a web server for rapid computation and fitting of SAXS profiles. Nucleic Acids Res. 38, W540-4 (2010). [0390] 44. Schneidman-Duhovny, D., Hammel, M., Tamer, J. A. & Sali, A. Accurate SAXS profile computation and its assessment by contrast variation experiments. Biophys. J. 105, 962-974 (2013). [0391] 45. Schiestl, R. H. & Gietz, R. D. High efficiency transformation of intact yeast cells using single stranded nucleic acids as a carrier. Curr. Genet. 16, 339-346 (1989). [0392] 46. Chien, C. T., Bartel, P. L., Sternglanz, R. & Fields, S. The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest. Proc. Natl. Acad. Sci. U.S.A. 88, 9578-9582 (1991). [0393] 47. Bartel, P. L., Roecklein, J. A., SenGupta, D. & Fields, S. A protein linkage map of Escherichia coli bacteriophage T7. Nat. Genet. 12, 72-77 (1996). [0394] 48. Guzmin, C., Bagga, M., Kaur, A., Westermarck, J. & Abankwa, D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS One 9, e92444 (2014). [0395] 49. Dyachenko, A. et al. Tandem Native Mass-Spectrometry on Antibody-Drug Conjugates and Submillion Da Antibody-Antigen Protein Assemblies on an Orbitrap EMR Equipped with a High-Mass Quadrupole Mass Selector. Anal. Chem. 87, 6095-6102 (2015). [0396] 50. Waitt, G. M., Xu, R., Wisely, G. B. & Williams, J. D. Automated in-line gel filtration for native state mass spectrometry. J. Am. Soc. Mass Spectrom. 19, 239-245 (2008). [0397] 51. Marty, M. T. et al. Bayesian deconvolution of mass and ion mobility spectra: from binary interactions to polydisperse ensembles. Anal. Chem. 87, 4370-4376 (2015). [0398] 52. Bern, M. et al. Parsimonious Charge Deconvolution for Native Mass Spectrometry. J.

[0399] Proteome Res. 17, 1216-1226 (2018). [0400] 53. Jones, D. T. Protein secondary structure prediction based on position-specific scoring matrices. J. Mol. Biol. 292, 195-202 (1999).

Example 2. Orthogonal Protein Heterodimers for Designing Modular Protein Logic Gates

[0401] Abstract: The de novo design of modular protein logic for regulating protein function at the post-transcriptional level is a challenge for computational protein design and could have wide ranging applications in synthetic biology. Here we describe the design of 2-input AND, OR, NAND, NOR, XNOR, and NOT gates built from de novo designed proteins that regulate the association of arbitrary protein units ranging from split enzymes to transcriptional machinery in vitro, and in living cells. Binding interaction cooperativity makes the gates largely insensitive to stoichiometric imbalances in the inputs, and the modularity of the approach enables ready extension to 3-input OR, AND, and disjunctive normal form gates. The modularity and cooperativity of the control elements, coupled with the ability to de novo design an essentially unlimited number of protein components, should enable design of sophisticated post-translational control logic over a wide range of biological functions.

INTRODUCTION

[0402] The ability to de novo design protein-based logic gates with modular control of arbitrary protein-protein interactions could open the door to the tunable design of novel bio-orthogonal functionalities.

[0403] In principle, it should be possible to design a wide range of logic gates de novo using a set of orthogonal heterodimeric molecules. For example, given hypothetical heterodimer pairs A:A', B:B', and C:C', an AND gate modulating the association of A with C' can be constructed by genetically fusing A' and B, and B' and C. association occurs only in the presence of both A'-B, and B'-C (here and below ":" denotes noncovalent interaction, and "-", genetic fusion via flexible linkers). Several building block properties are desirable for constructing such associative logic gates. First, there should be many mutually orthogonal heterodimeric pairs, so that gate complexity is not limited by the number of individual elements. Second, the building blocks should be modular and similar in structure so that differences in building block shape and other properties do not have to be considered when constructing the gates. Third, single building blocks should be able to bind to multiple partners with different, tunable affinities, allowing inputs to perform negation operations by disrupting pre-existing lower affinity interactions. Fourth, the interactions should be cooperative so gate activation is not sensitive to stoichiometric imbalances in the inputs. In the above AND gate, for example, if the interactions are not cooperative, a large excess of A'-B will pull the equilibrium towards partially assembled complexes (A'-B with either A or B'-C but not both), which will disrupt gate activation.

[0404] Here, we explored the possibility of designing logic gates satisfying all four of the above criteria using de novo designed protein heterodimers with hydrogen bond network-mediated specificity (34). Sets of 6 (in vivo) and 15 (in vitro) mutually orthogonal designed heterodimers (DHDs, hereafter referred to by numbers, e.g. 1 and 1' form one cognate pair. with hydrogen bond network (see FIG. 11A inset for example) mediated specificity are available for logic gate construction, satisfying condition 1 (orthogonality). The heterodimeric interfaces all share the same four helix bundle topology (FIG. 11A), satisfying condition 2 (modularity). The shared interaction interface allows a limited amount of cross talk between pairs, leading to a hierarchy of binding affinities, satisfying condition 3 (multiple binding specificities). Inspired by cooperatively activatable systems in nature (35, 36), we sought to achieve condition 4 (cooperativity) by constructing the monomer fusions (A `-B and B`-C in the above example) in such a way that the interaction surfaces (with A and C') are buried within the fusions. The free energy required to expose these buried interfaces would oppose gate activation, and we reasoned that the system could be tuned so that only the binding energy provided by both interactions would be sufficient to overcome this barrier, thus ensuring cooperative gate activation (FIG. 11B). If condition 2 (modularity) holds, then a single scheme for ensuring cooperativity could in principle work for a wide range of gate configurations.

Design of Cooperativity

[0405] To explore the design of cooperative building blocks, we focused on the simple system A+A'-B+B' (we refer to this as induced dimerization below, A and B' as the monomers, and A'-B as the dimerizer). If binding is not cooperative, the amount of the trimeric complex decreases when A'-B is in stoichiometric excess relative to A and B': the formation of intermediate dimeric species of the linker protein binding to either of the monomers competes with formation of trimeric complexes. On the contrary, if binding is cooperative such that no binding to either monomer occurs in the absence of the other, the amount of trimeric complex formed becomes insensitive to an excess of the dimerizer. A simple thermodynamic model of the effect of binding cooperativity on the stoichiometric response of such induced dimerization systems (FIG. 11B, supplemental materials modeling section) shows that as the binding cooperativity decreases, there is a corresponding decrease in the final concentration of full trimeric complexes at high dimerizer concentrations (FIG. 11C).

[0406] We hypothesized that a folded four helix bundle like state of the A'-B dimerizer could oppose binding to either A or B', as the relatively hydrophobic interacting surfaces would likely be sequestered within the folded structure (FIG. 14A). We tested different flexible linker lengths connecting A' with B using heterodimers 1:1' and 2:2' as a model system. All designs were found to be folded and stable in circular dichroism (CD) guanidine hydrochloride (GdnHCl) denaturation experiments, with unfolding free energies greater than 13 kcal/mol (FIG. 11D, Table 10). Although 1'-2' dimerizer constructs with short linkers of 0 and 2 residues, or with a very long 24 residue linker could be purified as monomers (FIG. 14B), they were prone to aggregation. In contrast, designs with 6 and 12 residue linkers remained largely monomeric (data not shown). Small angle x-ray scattering (SAXS) experiments (37) indicate their hydrodynamic radii are close to those of folded four-helix bundle DHDs (FIG. 11E). Linkers in this length range likely allow the two monomers (1' and 2') to fold back on each other such that the largely hydrophobic interaction surfaces are buried against each other; such a structure would have to partially unfold for 1'-2' to interact with either 1 or 2 with free energy cost .DELTA.G.sub.open (FIG. 11B), the magnitude of which determines the extent of cooperativity for the gate. We selected a linker length of 6- or 12-residues for all of the following experiments.

[0407] We studied the cooperativity of the induced dimerizer system in vitro using native mass spectrometry (FIG. 11F). 1, 2 and 1'-2' were separately expressed in E. coli and purified. We first measured the extent to which 1 activates the binding of 2 to 1'-2'. At 10 .mu.M each of 2 and 1'-2', the fraction of 2 in complex with 1'-2' increased from 3% to 100% upon addition of 20 .mu.M 1 (data not shown); a fold increase comparable with naturally occurring allosteric systems (35). To assess how this activation of binding influences the sensitivity of binding to stoichiometric imbalance, 10 .mu.M 1 and 2 were titrated with increasing concentrations of 1'-2' (FIG. 11F), and the species formed determined by nMS. The heterotrimeric 1:1'-2':2 complex was observed over a wide range of 1'-2' concentrations (data not shown). Even in the presence of a 6 fold excess of 1'-2', there was no decrease in the amount of 1:1'-2':2 formed, and neither 1:1'-2' or 1'-2':2 were observed (data not shown). We define cooperativity as the ratio of the affinities in the presence and absence of the other monomer, which in our model directly relates to the free energy of opening of the dimerizer (c=e.sup..DELTA.G.sup.open.sup./RT, see supplementary materials). Matching the thermodynamic model to native MS data (data not shown) produces an estimated c value of 991,000, which corresponds to .DELTA.G.sub.open of 7 kcal/mol. This is about half the measured unfolding free energy of 1'-2', suggesting that binding may not require complete unfolding of the four helix bundle state of the dimerizer.

[0408] With linker units displaying cooperative binding, we reasoned that the lack of dependence on stoichiometric excesses of one of the components should extend to more complex gates. Using nMS, we investigated the cooperativity of a 2-input AND gate constructed from the two inputs 1'-3' and 3-2', and monomers 1 and 2 brought together by the two inputs (FIG. 11G). As the concentration of the 2 inputs was increased, the amount of heterotetrameric complex plateaued at a stoichiometry of 2:1, and then remained constant up to a molar ratio of 6:1. Very little partial complexes (heterotrimers and heterodimers) were observed, further indicating high cooperativity (data not shown). We constructed a 3-input AND gate from 1'-4', 4-3', and 3-2', which together should control the association of 1 and 2 (FIG. 11H). Similar to the 2-input AND gate, the amount of full, pentameric complexes only decreased slightly at greater than stoichiometric concentrations of inputs with no detectable competing tetrameric complexes (data not shown).

Modular Logic Gate Construction

[0409] We explored the modular combination of DHDs to generate a range of 2-input Cooperatively Inducible Protein HeterodimeR (CIPHR) logic gates. Monomers from individual DHDs were linked to effector proteins of interest via genetic fusion, whose colocalization or dissociation is dependent upon the inputs. Taking advantage of previously measured all-by-all specificity matrices (34), two modes of interactions were explored: cognate binding between designed protein pairs, or competitive binding involving multispecific interactions. The choice of effector proteins is independent from the input proteins, allowing diverse functional outputs (FIG. 12A).

[0410] We used a variant of the yeast-two-hybrid (Y2H) assay to characterize the behavior of the designed logic gates, using a setup similar to previously described yeast-four-hybrid systems (38, 39). To construct an AND gate, we fused 2 to the Gal4 activation domain (AD), and 1 to the Gal4 DNA binding domain (DBD). The colocalization of AD and DBD, and resulting induction of transcription of the His3 gene, is dependent upon the expression of both input proteins (1'-5, 5'-2'). Growth in media lacking histidine required expression of both inputs (FIG. 12B). An OR gate was similarly constructed by linking the 1-6 fusion to the AD and 7' to the DBD. Expression of either of the inputs 1'-7 or 6'-7 results in growth by driving association of AD with DBD (FIG. 12C).

[0411] We explored the construction of additional boolean logic gates by exploiting binding affinity hierarchies identified in all by all Y2H experiments (34). 8 not only interacts with 8' but also forms homodimers (FIG. 15A); hence 8' must outcompete 8 homodimers to form the heterodimer. We constructed a NOT gate by fusing 8 to both AD or DBD; yeast cells stopped growing in the presence of co-expressed 8' input protein (FIG. 12D). Based on the affinity hierarchy 9:9'.apprxeq.10:10'>9:10' (FIG. 15B), we constructed a NOR gate in which 9 was fused to the AD, 10' to the DBD, with 9' and 10 the two inputs. Either or both of the inputs outcompete the 9:10' interaction and hinder yeast growth (FIG. 12E). Based on the affinity hierarchy 9':1'>9:9'.apprxeq.1:1'>9:1 (FIG. 15B), an XNOR gate was constructed by fusing 9 to 10 AD, 1 to DBD, and using 9' and 1' as the two inputs: the presence of either outcompetes the 9:1 binding and blocks growth, but when both are expressed they instead interact with each other and growth is observed (FIG. 12F). Similarly, a NAND gate was designed based on the interaction hierarchy 1':10'>1:1'.apprxeq.10:10'>1:10 (FIG. 15B). Neither 1 nor 10 alone can outcompete the 1':10' binding and hence growth occurs, but when both are expressed, the free energy of formation of both 1:1' and 10:10' outweighs that of 1':10' and growth is blocked (FIG. 12G).

3 Input CIPHR Logic Gates

[0412] We constructed a 3-input AND gate (FIG. 10M) in which monomers 1 and 2 are brought into proximity by the three inputs 1'-4', 4-3', and 3-2'. We experimentally tested all eight possible input combinations (FIG. 13A), quantifying all complexes using nMS with both 1 and 2 present. Consistent with proper function of a 3-input AND gate, 1 and 2 only showed significant co-assembly when all three inputs are present (data not shown).

[0413] To test the modularity of CIPHR logic gates, we designed two different 3-input CIPHR logic gates using the same 4 pairs of DHDs and tested them via Y2H. To make a 3-input OR gate, 1'-6-7 was fused to AD, and 11' to DBD. Either one of the 3 inputs (11-1, 11-6', 11-7') is able to bring AD to DBD via their linked proteins (FIG. 13B). Y2H results confirmed the correct behavior of this logic gate in cells: any of the input proteins induces cell growth (FIG. 13C). We constructed a CIPHR disjunctive normal form (DNF, [A AND B] OR C) gate by fusing 1'-6 to AD, 11' to DBD with inputs 11-7', 7-1, or 11-6' (FIG. 13D). In Y2H experiments, the DNF gate functioned as designed, with low yeast growth levels when no input or only one of the 11-7' and 7-1 input proteins are present, and high yeast growth levels otherwise (FIG. 13E).

REFERENCES FOR EXAMPLE 2

[0414] 1. R. Nussinov, How do dynamic cellular signals travel long distances? Mol. Biosyst. 8, 22-26 (2012). [0415] 2. A. W. Reinke, J. Baek, O. Ashenberg, A. E. Keating, Networks of bZIP protein-protein interactions diversified over a billion years of evolution. Science. 340, 730-734 (2013). [0416] 3. Y. E. Antebi, J. M. Linton, H. Klumpe, B. Bintu, M. Gong, C. Su, R. McCardell, M. B. Elowitz, Combinatorial Signal Perception in the BMP Pathway. Cell. 170, 1184-1196.e24 (2017). [0417] 4. B. Z. Harris, W. A. Lim, Mechanism and role of PDZ domains in signaling complex assembly. J. Cell Sci. 114, 3219-3231 (2001). [0418] 5. G. Seelig, D. Soloveichik, D. Y. Zhang, E. Winfree, Enzyme-free nucleic acid logic circuits. Science. 314, 1585-1588 (2006). [0419] 6. L. Qian, E. Winfree, Scaling up digital circuit computation with DNA strand displacement cascades. Science. 332, 1196-1201 (2011). [0420] 7. M. B. Elowitz, S. Leibler, A synthetic oscillatory network of transcriptional regulators. Nature. 403, 335-338 (2000). [0421] 8. T. S. Gardner, C. R. Cantor, J. J. Collins, Construction of a genetic toggle switch in Escherichia coli. Nature. 403, 339-342 (2000). [0422] 9. A. Tamsir, J. J. Tabor, C. A. Voigt, Robust multicellular computing using genetically encoded NOR gates and chemical "wires." Nature. 469, 212-215 (2011). [0423] 10. P. Siuti, J. Yazbek, T. K. Lu, Synthetic circuits integrating logic and memory in living cells. Nat. Biotechnol. 31, 448-452 (2013). [0424] 11. J. Bonnet, P. Yin, M. E. Ortiz, P. Subsoontorn, D. Endy, Amplifying genetic logic gates. Science. 340, 599-603 (2013). [0425] 12. B. H. Weinberg, N. T. H. Pham, L. D. Caraballo, T. Lozanoski, A. Engel, S. Bhatia, W. W. Wong, Large-scale design of robust genetic circuits with multiple inputs and outputs for mammalian cells. Nat. Biotechnol. 35, 453-462 (2017). [0426] 13. S. Auslander, D. Auslander, M. Miller, M. Wieland, M. Fussenegger, Programmable single-cell mammalian biocomputers. Nature. 487, 123-127 (2012). [0427] 14. A. S. Khalil, T. K. Lu, C. J. Bashor, C. L. Ramirez, N. C. Pyenson, J. K. Joung, J. J. Collins, A synthetic biology framework for programming eukaryotic transcription functions. Cell. 150, 647-658 (2012). [0428] 15. N. Roquet, A. P. Soleimany, A. C. Ferris, S. Aaronson, T. K. Lu, Synthetic recombinase-based state machines in living cells. Science. 353, aad8559 (2016). [0429] 16. L. B. Andrews, A. A. K. Nielsen, C. A. Voigt, Cellular checkpoint control using programmable sequential logic. Science. 361, eaap8987 (2018). [0430] 17. B. Angelici, E. Mailand, B. Haefliger, Y. Benenson, Synthetic Biology Platform for Sensing and Integrating Endogenous Transcriptional Inputs in Mammalian Cells. Cell Rep. 16, 2525-2537 (2016). [0431] 18. J. J. Lohmueller, T. Z. Armel, P. A. Silver, A tunable zinc finger-based framework for Boolean logic computation in mammalian cells. Nucleic Acids Res. 40, 5180-5187 (2012). [0432] 19. A. A. Green, P. A. Silver, J. J. Collins, P. Yin, Toehold switches: de-novo-designed regulators of gene expression. Cell. 159, 925-939 (2014). [0433] 20. A. A. Green, J. Kim, D. Ma, P. A. Silver, J. J. Collins, P. Yin, Complex cellular logic computation using ribocomputing devices. Nature. 548, 117-121 (2017). [0434] 21. K. Rinaudo, L. Bleris, R. Maddamsetti, S. Subramanian, R. Weiss, Y. Benenson, A universal RNAi-based logic evaluator that operates in mammalian cells. Nat. Biotechnol. 25, 795-801 (2007). [0435] 22. L. Wroblewska, T. Kitada, K. Endo, V. Siciliano, B. Stillo, H. Saito, R. Weiss, Mammalian synthetic circuits with RNA binding proteins for RNA-only delivery. Nat. Biotechnol. 33, 839-841 (2015). [0436] 23. S.-H. Park, A. Zarrinpar, W. A. Lim, Rewiring MAP kinase pathways using alternative scaffold assembly mechanisms. Science. 299, 1061-1064 (2003). [0437] 24. P. L. Howard, M. C. Chia, S. Del Rizzo, F.-F. Liu, T. Pawson, Redirecting tyrosine kinase signaling to an apoptotic caspase pathway through chimeric adaptor proteins. Proc. Natl. Acad. Sci. U.S.A. 100, 11267-11272 (2003). [0438] 25. B. J. Yeh, R. J. Rutigliano, A. Deb, D. Bar-Sagi, W. A. Lim, Rewiring cellular morphology pathways with synthetic guanine nucleotide exchange factors. Nature. 447, 596-600 (2007). [0439] 26. L. Morsut, K. T. Roybal, X. Xiong, R. M. Gordley, S. M. Coyle, M. Thomson, W. A. Lim, Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell. 164, 780-791 (2016). [0440] 27. K. T. Roybal, L. J. Rupp, L. Morsut, W. J. Walker, K. A. McNally, J. S. Park, W. A. Lim, Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. Cell. 164, 770-779 (2016). [0441] 28. J. E. Dueber, B. J. Yeh, K. Chak, W. A. Lim, Reprogramming Control of an Allosteric Signaling Switch Through Modular Recombination. Science. 301, 1904-1908 (2003). [0442] 29. R. M. Gordley, R. E. Williams, C. J. Bashor, J. E. Toettcher, S. Yan, W. A. Lim, Engineering dynamical control of cell fate switching using synthetic phospho-regulons. Proc. Natl. Acad. Sci. U.S.A. 113, 13528-13533 (2016). [0443] 30. J. E. Dueber, E. A. Mirsky, W. A. Lim, Engineering synthetic signaling proteins with ultrasensitive input/output control. Nat. Biotechnol. 25, 660-662 (2007). [0444] 31. X. J. Gao, L. S. Chong, M. S. Kim, M. B. Elowitz, Programmable protein circuits in living cells. Science. 361, 1252-1258 (2018). [0445] 32. T. Fink, J. Lonzarid, A. Praznik, T. Plaper, E. Merljak, K. Leben, N. Jerala, T. Lebar, . Strmsek, F. Lapenta, M. Ben ina, R. Jerala, Design of fast proteolysis-based signaling and logic circuits in mammalian cells. Nat. Chem. Biol. 15, 115-122 (2019). [0446] 33. A. J. Smith, F. Thomas, D. Shoemark, D. N. Woolfson, N. J. Savery, Guiding Biomolecular Interactions in Cells Using de Novo Protein-Protein Interfaces. ACS Synth. Biol. 8, 1284-1293 (2019). [0447] 34. Z. Chen, S. E. Boyken, M. Jia, F. Busch, D. Flores-Solis, M. J. Bick, P. Lu, Z. L. VanAernum, A. Sahasrabuddhe, R. A. Langan, S. Bermeo, T. J. Brunette, V. K. Mulligan, L. P. Carter, F. DiMaio, N. G. Sgourakis, V. H. Wysocki, D. Baker, Programmable design of orthogonal protein heterodimers. Nature. 565, 106-111 (2019). [0448] 35. K. E. Prehoda, J. A. Scott, R. D. Mullins, W. A. Lim, Integration of multiple signals through cooperative regulation of the N-WASP-Arp2/3 complex. Science. 290, 801-806 (2000). [0449] 36. B. Yu, I. R. S. Martins, P. Li, G. K. Amarasinghe, J. Umetani, M. E. Fernandez-Zapico, D. D. Billadeau, M. Machius, D. R. Tomchick, M. K. Rosen, Structural and energetic mechanisms of cooperative autoinhibition and activation of Vav1. Cell. 140, 246-256 (2010). [0450] 37. K. N. Dyer, M. Hammel, R. P. Rambo, S. E. Tsutakawa, I. Rodic, S. Classen, J. A. Tainer, G. L. Hura, High-throughput SAXS for the characterization of biomolecules in solution: a practical approach. Methods Mol. Biol. 1091, 245-258 (2014). [0451] 38. A. Pause, B. Peterson, G. Schaffar, R. Stearman, R. D. Klausner, Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc. Natl. Acad. Sci. U.S.A. 96, 9533-9538 (1999). [0452] 39. B. Sandrock, J. M. Egly, A yeast four-hybrid system identifies Cdk-activating kinase as a regulator of the XPD helicase, a subunit of transcription factor IIH. J. Biol. Chem. 276, 35328-35333 (2001). [0453] 40. A. S. Dixon, M. K. Schwinn, M. P. Hall, K. Zimmerman, P. Otto, T. H. Lubben, B. L. Butler, B. F. Binkowski, T. Machleidt, T. A. Kirkland, M. G. Wood, C. T. Eggers, L. P. Encell, K. V. Wood, NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells. ACS Chem. Biol. 11, 400-408 (2016). [0454] 41. Y.-C. Kwon, M. C. Jewett, High-throughput preparation methods of crude extract for robust cell-free protein synthesis. Sci. Rep. 5, 8663 (2015). [0455] 42. J. R. Porter, C. I. Stains, B. W. Jester, I. Ghosh, A general and rapid cell-free approach for the interrogation of protein-protein, protein-DNA, and protein-RNA interactions and their antagonists utilizing split-protein reporters. J. Am. Chem. Soc. 130, 6488-6497 (2008). [0456] 43. S. L. Maude, T. W. Laetsch, J. Buechner, S. Rives, M. Boyer, H. Bittencourt, P. Bader, M. R. Verneris, H. E. Stefanski, G. D. Myers, M. Qayed, B. De Moerloose, H. Hiramatsu, K. Schlis, K. L. Davis, P. L. Martin, E. R. Nemecek, G. A. Yanik, C. Peters, A. Baruchel, N. Boissel, F. Mechinaud, A. Balduzzi, J. Krueger, C. H. June, B. L. Levine, P. Wood, T. Taran, M. Leung, K. T. Mueller, Y. Zhang, K. Sen, D. Lebwohl, M. A. Pulsipher, S. A. Grupp, Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N. Engl. J. Med. 378, 439-448 (2018). [0457] 44. S. S. Neelapu, F. L. Locke, N. L. Bartlett, L. J. Lekakis, D. B. Miklos, C. A. Jacobson, I. Braunschweig, O. O. Oluwole, T. Siddiqi, Y. Lin, J. M. Timmerman, P. J. Stiff, J. W. Friedberg, I. W. Flinn, A. Goy, B. T. Hill, M. R. Smith, A. Deol, U. Farooq, P. McSweeney, J. Munoz, I. Avivi, J. E. Castro, J. R. Westin, J. C. Chavez, A. Ghobadi, K. V. Komanduri, R. Levy, E. D. Jacobsen, T. E. Witzig, P. Reagan, A. Bot, J. Rossi, L. Navale, Y. Jiang, J. Aycock, M. Elias, D. Chang, J. Wiezorek, W. Y. Go, Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N. Engl. J Med. 377, 2531-2544 (2017). [0458] 45. J. A. Fraietta, S. F. Lacey, E. J. Orlando, I. Pruteanu-Malinici, M. Gohil, S. Lundh, A. C. Boesteanu, Y. Wang, R. S. O'Connor, W.-T. Hwang, E. Pequignot, D. E. Ambrose, C. Zhang, N. Wilcox, F. Bedoya, C. Dorfmeier, F. Chen, L. Tian, H. Parakandi, M. Gupta, R. M. Young, F. B. Johnson, I. Kulikovskaya, L. Liu, J. Xu, S. H. Kassim, M. M. Davis, B. L. Levine, N. V. Frey, D. L. Siegel, A. C. Huang, E. J. Wherry, H. Bitter, J. L. Brogdon, D. L. Porter, C. H. June, J. J. Melenhorst, Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563-571 (2018). [0459] 46. C. H. June, R. S. O'Connor, O. U. Kawalekar, S. Ghassemi, M. C. Milone, CAR T cell immunotherapy for human cancer. Science. 359, 1361-1365 (2018). [0460] 47. A. H. Long, W. M. Haso, J. F. Shern, K. M. Wanhainen, M. Murgai, M. Ingaramo, J. P. Smith, A. J. Walker, M. E. Kohler, V. R. Venkateshwara, R. N. Kaplan, G. H. Patterson, T. J. Fry, R. J. Orentas, C. L. Mackall, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581-590 (2015). [0461] 48. E. J. Wherry, M. Kurachi, Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486-499 (2015). [0462] 49. E. John Wherry, S. J. Ha, S. M. Kaech, W. Nicholas Haining, S. Sarkar, V. Kalia, S. Subramaniam, J. Blattman, D. L. Barber, R. Ahmed, Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection. Immunity. 27 (2007), doi:10.1016/j.immuni.2007.11.006. [0463] 50. K. E. Pauken, M. A. Sammons, P. M. Odorizzi, S. Manne, J. Godec, O. Khan, A. M. Drake, Z. Chen, D. R. Sen, M. Kurachi, R. A. Barnitz, C. Bartman, B. Bengsch, A. C. Huang, J. M. Schenkel, G. Vahedi, W. N. Haining, S. L. Berger, E. J. Wherry, Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. 354, 1160-1165 (2016). [0464] 51. K. E. Prehoda, W. A. Lim, How signaling proteins integrate multiple inputs: a comparison of N-WASP and Cdk2. Curr. Opin. Cell Biol. 14, 149-154 (2002).

[0465] Referring to Table 7, for an induced dimerization system involving proteins A, A'-B, and B', a stoichiometric excess (N) of the A'-B protein results in partially assembled dimeric complexes if the binding is non-cooperative, but fully assembled trimeric complexes if the binding is cooperative.

[0466] We model the cooperatively induced dimerization system at thermodynamic equilibrium. Shown below (Table 8), assuming a `closed` state for A'-B, where the binding interfaces are buried within the four-helix bundle, the binding of A'-B to either A or B' helix hairpins needs to overcome an energy barrier of transitioning from the `closed` to `open` state (.DELTA.G.sub.open). Therefore the free energy of binding between A'-B to A or B' can be expressed as .DELTA.G.sub.A:A'-.DELTA.G.sub.open and .DELTA.G.sub.B:B'-.DELTA.G.sub.open, respectively, where .DELTA.G.sub.A:A' and .DELTA.G.sub.B:B' represent the free energy of binding between the cognate pairs in the absence of the fusion. Once the A:A'-B or A-B`:B complexes form, subsequent binding can be simply represented by the binding between cognate heterodimers: .DELTA.G.sub.A:A' or .DELTA.G.sub.B:B'. We also observed the presence of (A).sub.2 and (B').sub.2 homodimers, therefore added free energy terms describing such processes into the model (.DELTA.G.sub.A:A or .DELTA.G.sub.B':B').

[0467] .DELTA.G relates to equilibrium constants by .DELTA.G=-RTlnK, and we further consider the system in terms of K. We make the simplifying assumption that the affinity of A'-B to either A or B' is identical (K.sub.1=[A:A'-B]/([A][A'-B])=[A'-B:B']/([B][A'-B]). Finally, we define the cooperativity of the system, c, as the ratio between the equilibrium constants in the presence or absence of the other partner (c=K.sub.B:B'/K.sub.1=K.sub.A:A'/K.sub.1). For an entirely non-cooperative process (c=1), K.sub.B:B'=K.sub.1 and K.sub.A:A'=K.sub.1 i.e., the first binding event does not affect the affinity ofthe subsequent binding event.

[0468] Since K.sub.1=exp(-(.DELTA.G.sub.A:A'-.DELTA.G.sub.open)/RT), rewriting the equation for c in terms of free energies leads to c=exp(.DELTA.G.sub.open)/RT. Therefore, the extent of cooperativity is solely determined by the magnitude of the free energy required to partially unfold/expose the buried binding interfaces of the dimerizer A'-B.

[0469] We note that explicitly incorporating the equilibrium constants for homodimerization (K.sub.A:A and K.sub.B':B') only affect the absolute position of each equilibrium, but does not affect the magnitude of the cooperativity (see Table 9). Indeed, taking A as an example, the binding to the closed state becomes K.sub.1*K.sub.A:A, and the binding to the open state becomes K.sub.A:A*K.sub.A:A. Because K.sub.A:A is present in both the numerator and the denominator, they cancel out, and c remains purely defined by the relative magnitudes of K.sub.1 and K.sub.A:A'.

[0470] We solved the following system of equations in Mathematica to simulate the amount of A:A'-B:B' at equilibrium as a function of the initial concentration of A'-B:

K A : A = [ A 2 ] [ A ] .function. [ A ] .times. .times. K B ' : B ' = [ B 2 ' ] [ B ] .function. [ B ] .times. .times. K 1 = [ A .times. : .times. A ' - B ] [ A ] .function. [ A ' - B ] .times. .times. K 1 = [ B ' .times. : .times. A ' - B ] [ B ] .function. [ A ' - B ] .times. .times. K A : A ' = [ A .times. : .times. A ' - B .times. : .times. B ' ] [ A ] .function. [ A ' - B .times. : .times. B ' ] .times. .times. K B : B ' = [ A .times. : .times. A ' - B .times. : .times. B .times. ' ] [ B ] .function. [ A .times. : .times. A - B ] .times. .times. [ A ] tot = 2 * [ A 2 ] + [ A ] + [ A .times. : .times. A ' - B ] + [ A .times. : .times. A ' - B .times. : .times. B ' ] .times. [ B ' ] tot = 2 * [ B 2 ' ] + [ B ' ] + [ A ' - B .times. : .times. B ' ] + [ A .times. : .times. A ' - B .times. : .times. B ' ] .times. [ A ' - B ] tot = [ A ' - B .times. : .times. B ' ] + [ A .times. : .times. A ' - B ' ] + [ A .times. : .times. A ' - B .times. : .times. B ' ] ##EQU00001##

[0471] We knew from previous native MS titration experiments that the equilibrium dissociation constants of cognate designed heterodimers (DHDs) is in the .about.10 nM range (1), therefore K.sub.A:A'=K.sub.B:B'=0.1 nM. Varying values of K.sub.1 (and hence the cooperativity factor, c=K.sub.A:A'/K.sub.1) showed different responses of the amount of A:A'-B:B' at equilibrium as a function of the initial concentration of A'-B, as shown in FIG. 12C.

[0472] We experimentally estimated K.sub.1 using native MS experiments. Mixing 10 .mu.M of 1 and 1'-2' resulted in no detectable amount of the 1:1'-2' complex, suggesting very weak binding. The sensitivity of native MS places a lower-bound on the concentration of species that can be detected (0.0375 M,). Using this value, a lower-bound for the affinity of 1:1'-2' can be estimated (1/K.sub.1.gtoreq.2.65 mM). This is close to the value of 9.91 mM obtained by calculating the affinity based on the c value of 991,000 reported in FIG. 13H.

[0473] This thermodynamic modeling demonstrates that binding cooperativity can be achieved for an induced dimerization system through occlusion of the binding interfaces. We achieved this by fusing hairpins via a flexible linker, rationalizing that the spontaneous folding of these constructs would bury the interaction interfaces on the inside of a four helical bundle like topology. Formation of these structures is corroborated by: i) SAXS profiles that are consistent with DHDs structures, ii) m-values from chemical denaturation experiments consistent with .DELTA.SASA for the unfolding of DHD topologies, and iii) .DELTA.G.sub.open<.DELTA.G.sub.folding, suggesting that exposing the binding interfaces requires partial unfolding of these fused constructs, but does not exceed the folding free energy of these proteins (a physically unrealistic scenario).

Materials and Methods

Buffer and Media Recipe

[0474] TBM-5052: 1.2% [wt/vol] tryptone, 2.4% [wt/vol] yeast extract, 0.5% [wt/vol]glycerol, 0.05% [wt/vol] D-glucose, 0.2% [wt/vol] D-lactose, 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 10 .mu.M FeCl3, 4 .mu.M CaCl.sub.2), 2 .mu.M MnCl2, 2 .mu.M ZnSO4, 400 nM CoCl2, 400 nM NiCl2, 400 nM CuCl2, 400 nM Na2MoO4, 400 nM Na2SeO3, 400 nM H3BO3.

[0475] Lysis buffer: 20 mM Tris, 300 mM NaCl, 20 mM Imidazole, pH 8.0 at room temperature.

[0476] Wash buffer: 20 mM Tris, 300 mM NaCl, 30 mM Imidazole, pH 8.0 at room temperature.

[0477] Elution buffer: 20 mM Tris, 300 mM NaCl, 250 mM Imidazole, pH 8.0 at room temperature.

[0478] TBS buffer: 20 mM Tris pH 8.0, 100 mM NaCl.

[0479] YPAD buffer: Peptone 20 g/L, yeast extract 10 g/L, Adenine hemisulfate 10 .mu.g/L, dextrose (20 g/L).

[0480] C-Trp-Ura-Leu-His+Adenine: hemisulfate+Glucose.

[0481] Yeast nitrogen base w/o amino acids (6.7 g/L), synthetic DO media (-Leu/-His/-Trp/-Ura) (1.4 g/L), dextrose (20 g/L), adenine hemisulfate (10 .mu.g/L).

Construction of Synthetic Genes

[0482] For the expression of proteins in E. coli, synthetic genes were ordered from Genscript Inc. (Piscataway, N.J., USA) and delivered in pET21-NESG E. coli expression vector, inserted between the NdeI and XhoI sites. For each expression construct, a hexahistidine tag followed by a tobacco etch virus (TEV) protease cleavage site (GSSHHHHHHSSGENLYFQGS) (SEQ ID NO:328) were added in frame at the N-terminus of the protein. A stop codon was introduced at the 3' end of the protein coding sequence to prevent expression of the C-terminal hexahistidine tag in the vector.

[0483] Genes for yeast-two-hybrid (Y2H) studies were cloned into plasmids bearing the GAL4 DNA-binding domain (poDBD) and the GAL4 transcription activation domain (poAD) (2). Input proteins were cloned into plasmids V510 (uracil auxotrophic selection marker) and MX1 (bleomycin selection marker). Genes were expressed under the control of ADH1 promoters.

Protein Expression

[0484] Plasmids were transformed into chemically competent E. coli expression strain Lemo21.TM. (DE3) (New England Biolabs) for protein expression. Following transformation and overnight growth, single colonies were picked from agar plates into 5 ml Luria-Bertani (LB) medium containing 100 .mu.g/mL carbenicillin (for pET21-NESG vectors) with shaking at 225 rpm for 18 hours at 37.degree. C. Proteins were expressed using the autoinduction method (7): starter cultures were further diluted into 500 ml TBM-5052 containing 100 .mu.g/mL carbenicillin, and incubated with shaking at 225 rpm for 24 hours at 37.degree. C.

Affinity Purification

[0485] E. coli cells were harvested by centrifugation at 5000 rcf for 15 minutes at 4.degree. C. and the pellet resuspended in 18 ml lysis buffer. EDTA-free cocktail protease inhibitor (Roche), lysozyme, and DNAse were added to the resuspended cell pellet, followed by cell lysis via sonication at 70% power for 5 minutes. Lysates were clarified by centrifugation at 4.degree. C. and 18,000 rpm for 45 minutes and applied to columns containing Ni-NTA (Qiagen) resin pre-equilibrated with lysis buffer. The column was washed two times with 5 column volumes (CV) of wash buffer, followed by 5 CV of elution buffer for protein elution.

Size-Exclusion Chromatography (SEC)

[0486] Eluted proteins were buffer exchanged into lysis buffer. N-terminal hexahistidine tags were removed with TEV protease cleavage overnight at room temperature, at a ratio of 1 mg TEV for 100 mg of protein. After TEV cleavage, sample was passed over a fresh Ni-NTA column and washed with 1.5 CV of lysis buffer, collecting flow through. The resulting proteins were purified by SEC using a Superdex.TM. 75 10/300 increase column (GE Healthcare) in TBS buffer.

Circular Dichroism (CD) Measurements

[0487] Circular dichroism (CD) wavelength scans (260-195 nm) and temperature melts (25-95.degree. C.) were performed using an AVIV.TM. model 420 CD spectrometer, with protein samples diluted to 0.25 mg/ml in PBS pH 7.4 in a 0.1-cm cuvette. Temperature melts were carried out at a heating rate of 4.degree. C./min and monitored by the change in ellipticity at 222 nm.

[0488] GdmCl titrations were performed on a JASCO.TM. model J-1500 with automated titration apparatus in PBS pH 7.4 at 25.degree. C., with protein concentrations between 0.08 mg/ml to 0.025 mg/ml in a 1-cm cuvette with stir bar. Each titration consisted of at least 34 evenly distributed GdmCl concentration points up to 7.4 M with 30 seconds mixing time for each step. Titrant solution consisted of the same concentration of protein in PBS and GdmCl.

CD Data Analysis and Model Fitting

[0489] Folding free energies were obtained by fitting equilibrium denaturation data. Fused hairpin constructs had biphasic unfolding transitions, indicating the existence of an intermediate on their respective energy landscapes. Since native MS showed that Linker 0, Linker 2, Linker 6, and Linker 12 were almost exclusively monomeric in buffer (data not shown), it was concluded that these intermediates were partially folded monomeric species. Thus, the chemical denaturation data of these proteins was fitted to a unimolecular 3-state model:

N.revreaction.I.revreaction.D

where N represents the fully folded state, I a partially folded intermediate, and D the denatured state. The fraction of each species can be written as a function of K.sub.1=[I]/[N] and K.sub.2=[D]/[I], the equilibrium constants for the first and second transitions respectively:

f N = ( 1 + K 1 + K 2 ) - 1 ##EQU00002## f I = ( 1 + K 2 + 1 K 1 ) - 1 ##EQU00002.2## f D = ( 1 + 1 K 2 + 1 K 1 K 2 ) - 1 ##EQU00002.3##

[0490] In the context of equilibrium chemical denaturation experiments, the free energy of unfolding is a linear function of denaturant concentration:

.DELTA.G.sub.[den]=.DELTA.G.sub.buffer-m[den]

where .DELTA.G.sub.[den] represents the free energy of the system at a given concentration of denaturant, .DELTA.G.sub.buffer is the corresponding free energy change in the absence of denaturant, and m is a constant of proportionality that relates to the change in solvent-accessible surface area upon unfolding (.DELTA.SASA). Thus, the effect of denaturant on the equilibrium constant relating to each transition can be written as a function of its free energy difference in buffer, and a specific m-value:

K 1 = exp .times. .times. ( m 1 [ den ] - .DELTA. .times. .times. G 1 R T ) ##EQU00003## K 2 = exp .times. .times. ( m 2 [ den ] - .DELTA. .times. .times. G 2 R T ) ##EQU00003.2##

[0491] By combining these expressions with the definitions for f.sub.N, f.sub.I, f.sub.D, the fractional distribution of each species can be expressed as a function of denaturant concentration, and the free energy change corresponding to each transition (in buffer). Finally, for an ensemble spectroscopic technique such as CD, the observed signal (the dependent variable) as a function of denaturant concentration (the independent variable) can be expressed as a linear combination of the spectroscopic signals corresponding to each species, weighed by their fractional contribution to the ensemble:

MRE.sub.222 nm=f.sub.NMRE.sub.N+f.sub.IMRE.sub.I+f.sub.DMRE.sub.D

[0492] Where MRE.sub.N, MRE.sub.I, MRE.sub.D represent the spectroscopic signatures (baselines) for the native, intermediate, and denatured states respectively. This equation was used to fit chemical denaturation data for the different linker proteins, and the fitted parameters are reported in Table 10. For Linker 24 in buffer, native MS revealed a significant proportion of dimer (data not shown). Therefore, this model is not entirely appropriate for describing the unfolding, and the fitted values for this construct should be interpreted with care. Nevertheless, denaturation performed at different concentrations of protein revealed that the position of the second transition was concentration-independent, and thus unimolecular. For this event, the model holds.

[0493] The total m-values for these linked hairpins were found to be around 3 kcal mol.sup.-1 M.sup.-1. It has been shown that m-values correlate with .DELTA.SASA of unfolding (8). For the folded state, SASA was estimated from the structures of DHDs (1) using PyMOL.TM. to be 8800 .ANG..sup.2. For the unfolded state, SASA was estimated using ProtSA.TM. (9, 10), and is about 20,000 .ANG..sup.2. Thus, .DELTA.SASA for the unimolecular unfolding of a fused hairpin should be around 11,000 .ANG..sup.2, which would have a predicted m-value of 3.3. This number is in close agreement with the fitted parameters reported here, in line with the notion that the folded state for these linker proteins has a four helix bundle topology.

Small Angle X-Ray Scattering (SAXS)

[0494] Protein samples were purified by SEC in 25 mM Tris pH 8.0, 150 mM NaCl and 2% glycerol; elution fractions preceding the void volume of the column were used as blanks for buffer subtraction. Scattering measurements were performed at the SIBYLS.TM. 12.3.1 beamline at the Advanced Light Source. The sample-to-detector distance was 1.5 m, and the X-ray wavelength (.lamda.) was 1.27 .ANG., corresponding to a scattering vector q (q=4.pi. sin .theta./5, where 2.theta. is the scattering angle) range of 0.01 to 0.3 .ANG..sup.-1. A series of exposures were taken of each well, in equal sub-second time slices: 0.3-s exposures for 10 s resulting in 32 frames per sample. For each sample, data were collected for two different concentrations to test for concentration-dependent effects; `low` concentration samples ranged at 2.5 mg/ml and `high` concentration samples at 5 mg/ml. Data were processed using the SAXS FrameSlice.TM. online serve and analyzed using the Sc.ANG.tter.TM. software package (11, 12). The FoXS.TM. online server (13, 14) was used to compare experimental scattering profiles to design models and calculate quality of fit (x) values.

Yeast Two-Hybrid Assay for Logic Gates

[0495] Chemically competent cells of yeast strain PJ69-4a (MATa trp1-901 leu2-3,112 ura3-52 his3-200 gal4(deleted) gal80(deleted) LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7-lacZ) were transformed with the appropriate pair of plasmids containing DNA binding domains (DBD) or activation domains (AD), using the LiAc/SS carrier DNA/PEG method (15). For two input CIPHR logic gates, genes encoding the input proteins (together with selection markers) were genetically integrated into either or both of the Ura3 locus (uracil auxotrophic selection marker) or the YCR043 locus (bleomycin selection marker). In the case of three input CIPHR logic gates, genes encoding two input proteins were genetically integrated as described, with the additional input cloned downstream of either the AD or DBD plasmid, separated by a p2a and nuclear localization sequence (GSGATNFSLLKQAGDVEENPGPGDKAELIPEPPKKKRKVELGTA; SEQ ID NO:330). The p2a sequence ensures translational cleavage to make the additional input protein a separate protein. The selection of transformed yeast cells was performed in synthetic dropout (SDO) medium lacking tryptophan and leucine for 48 h with shaking at 1,000 r.p.m. at 30.degree. C. The resulting culture was diluted 1:100 and grown for 16 h in fresh SDO medium lacking tryptophan and leucine, before being diluted 1:100 in fresh SDO medium lacking tryptophan, leucine and histidine. The culture was incubated with shaking at 1,000 r.p.m. at 30'.degree. C. As it is necessary to bring the DBD and the transcription activation domain into proximity for the growth of yeast cells in medium lacking histidine, successful activation of logic gates was indicated by the growth of yeast cells (16, 17). The optical density of yeast cells was recorded at 24 h, 48 h, and 72 h.

TABLE-US-00021 TABLE 10 Fitted parameters for equilibrium chemical denaturation. Errors represent fitting errors. Linker 0 Linker 2 Linker 6 Linker 12 Linker 24 .DELTA.G.sub.1.sup.(N.revreaction.I) 3.6 (.+-.0.4) 3.5 (.+-.0.2) 3.5 (.+-.0.2) 2.7 (.+-.0.1) 3.7 (.+-.0.3) (kcal mol.sup.-1) .DELTA.G.sub.2.sup.(I.revreaction.D) 9.8 (.+-.0.6) 10.7 (.+-.0.4) 12.2 (.+-.0.4) 10.6 (.+-.0.5) 10.4 (.+-.0.8) (kcal mol.sup.-1) .DELTA.G.sub.tot.sup.(N.revreaction.D) 13.5 (.+-.0.7) 14.1 (.+-.0.4) 15.7 (.+-.0.5) 13.3 (.+-.0.5) 14.1 (.+-.0.8) (kcal mol.sup.-1) m.sub.1 1.1 (.+-.0.2) 1.0 (.+-.0.1) 0.9 (.+-.0.1) 0.75 (.+-.0.05) 1.1 (.+-.0.1) (kcal mol.sup.-1 M.sup.-1) m.sub.2 1.8 (.+-.0.1) 1.97 (.+-.0.07) 2.22 (.+-.0.08) 1.96 (.+-.0.08) 2.0 (.+-.0.1) (kcal mol.sup.-1 M.sup.-1) m.sub.tot 2.9 (.+-.0.2) 3.0 (.+-.0.1) 3.1 (.+-.0.1) 2.71 (.+-.0.09) 3.1 (.+-.0.2) (kcal mol.sup.-1 M.sup.-1) MRE.sub.N -23,574 (.+-.114) -27,561 (.+-.84) -24,712 (.+-.63) -33,849 (.+-.131) -26,438 (.+-.123) (deg cm.sup.2 dmol.sup.-1) MRE.sub.1 -16,330 (.+-.749) -18,139 (.+-.540) -14,779 (.+-.710) -17,362 (.+-.1,158) -15,567 (.+-.914) (deg cm.sup.2 dmol.sup.-1) MRE.sub.D -525 (.+-.107) -785 (.+-.82) -937 (.+-.68) -1,104 (.+-.99) -1,125 (.+-.133) (deg cm.sup.2 dmol.sup.-1)

REFERENCES

[0496] 1. Z. Chen, S. E. Boyken, M. Jia, F. Busch, D. Flores-Solis, M. J. Bick, P. Lu, Z. L. VanAemnum, A. Sahasrabuddhe, R. A. Langan, S. Bermeo, T. J. Brunette, V. K. Mulligan, L. P. Carter, F. DiMaio, N. G. Sgourakis, V. H. Wysocki, D. Baker, Programmable design of orthogonal protein heterodimers. Nature. 565, 106-111 (2019). [0497] 2. S. E. Boyken, Z. Chen, B. Groves, R. A. Langan, G. Oberdorfer, A. Ford, J. M. Gilmore, C. Xu, F. DiMaio, J. H. Pereira, B. Sankaran, G. Seelig, P. H. Zwart, D. Baker, De novo design of protein homo-oligomers with modular hydrogen-bond network-mediated specificity. Science. 352, 680-687 (2016). [0498] 3. A. S. Dixon, M. K. Schwinn, M. P. Hall, K. Zimmerman, P. Otto, T. H. Lubben, B. L. Butler, B. F. Binkowski, T. Machleidt, T. A. Kirkland, M. G. Wood, C. T. Eggers, L. P. Encell, K. V. Wood, NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells. ACS Chem. Biol. 11, 400-408 (2016). [0499] 4. M. E. Lee, W. C. DeLoache, B. Cervantes, J. E. Dueber, A Highly Characterized Yeast Toolkit for Modular, Multipart Assembly. ACS Synth. Biol. 4, 975-986 (2015). [0500] 5. A. S. Khalil, T. K. Lu, C. J. Bashor, C. L. Ramirez, N. C. Pyenson, J. K. Joung, J. J. Collins, A synthetic biology framework for programming eukaryotic transcription functions. Cell. 150, 647-658 (2012). [0501] 6. A. Aranda-Diaz, K. Mace, I. Zuleta, P. Harrigan, H. El-Samad, Robust Synthetic Circuits for Two-Dimensional Control of Gene Expression in Yeast. ACS Synth. Biol. 6, 545-554 (2017). [0502] 7. F. W. Studier, Protein production by auto-induction in high density shaking cultures. Protein Expr. Purif 41, 207-234 (2005). [0503] 8. J. K. Myers, C. N. Pace, J. M. Scholtz, Denaturant m values and heat capacity changes: relation to changes in accessible surface areas of protein unfolding. Protein Sci. 4, 2138-2148 (1995). [0504] 9. P. Bernado, M. Blackledge, J. Sancho, Sequence-specific solvent accessibilities of protein residues in unfolded protein ensembles. Biophys. J 91, 4536-4543 (2006). [0505] 10. J. Estrada, P. Bernado, M. Blackledge, J. Sancho, ProtSA: a web application for calculating sequence specific protein solvent accessibilities in the unfolded ensemble. BMC Bioinformatics. 10, 104 (2009). [0506] 11. K. N. Dyer, M. Hammel, R. P. Rambo, S. E. Tsutakawa, I. Rodic, S. Classen, J. A. Tamer, G. L. Hura, High-throughput SAXS for the characterization of biomolecules in solution: a practical approach. Methods Mol. Biol. 1091, 245-258 (2014). [0507] 12. R. P. Rambo, J. A. Tamer, Characterizing flexible and intrinsically unstructured biological macromolecules by SAS using the Porod-Debye law. Biopolymers. 95, 559-571 (2011). [0508] 13. D. Schneidman-Duhovny, M. Hammel, A. Sali, FoXS: a web server for rapid computation and fitting of SAXS profiles. Nucleic Acids Res. 38, W540-4 (2010). [0509] 14. D. Schneidman-Duhovny, M. Hammel, J. A. Tamer, A. Sali, Accurate SAXS profile computation and its assessment by contrast variation experiments. Biophys. J. 105, 962-974 (2013). [0510] 15. R. H. Schiestl, R. D. Gietz, High efficiency transformation of intact yeast cells using single stranded nucleic acids as a carrier. Curr. Genet. 16, 339-346 (1989). [0511] 16. C. T. Chien, P. L. Bartel, R. Sternglanz, S. Fields, The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest. Proc. Natl. Acad. Sci. U.S.A. 88, 9578-9582 (1991). [0512] 17. P. L. Bartel, J. A. Roecklein, D. SenGupta, S. Fields, A protein linkage map of Escherichia coli bacteriophage T7. Nat. Genet. 12, 72-77 (1996). [0513] 18. Z. L. VanAernum, J. D. Gilbert, M. E. Belov, A. A. Makarov, S. R. Homing, V. H. Wysocki, Surface-Induced Dissociation of Noncovalent Protein Complexes in an Extended Mass Range Orbitrap Mass Spectrometer. Anal. Chem. 91, 3611-3618 (2019). [0514] 19. M. T. Marty, A. J. Baldwin, E. G. Marklund, G. K. A. Hochberg, J. L. P. Benesch, C. V. Robinson, Bayesian deconvolution of mass and ion mobility spectra: from binary interactions to polydisperse ensembles. Anal. Chem. 87, 4370-4376 (2015). [0515] 20. Y.-C. Kwon, M. C. Jewett, High-throughput preparation methods of crude extract for robust cell-free protein synthesis. Sci. Rep. 5, 8663 (2015). [0516] 21. M. C. Jewett, J. R. Swartz, Mimicking the Escherichia coli cytoplasmic environment activates long-lived and efficient cell-free protein synthesis. Biotechnol. Bioeng. 86, 19-26 (2004). [0517] 22. A. D. Silverman, N. Kelley-Loughnane, J. B. Lucks, M. C. Jewett, Deconstructing Cell-Free Extract Preparation for in Vitro Activation of Transcriptional Genetic Circuitry. ACS Synth. Biol. 8, 403-414 (2019). [0518] 23. J. R. Swartz, M. C. Jewett, K. A. Woodrow, in Recombinant Gene Expression: Reviews and Protocols, P. Balbis, A. Lorence, Eds. (Humana Press, Totowa, N.J., 2004), pp. 169-182. [0519] 24. V. Munoz, L. Serrano, Elucidating the folding problem of helical peptides using empirical parameters. III. Temperature and pH dependence. J Mol. Biol. 245, 297-308 (1995). [0520] 23. V. Munoz, L. Serrano, Elucidating the folding problem of helical peptides using empirical parameters. III. Temperature and pH dependence. J Mol. Biol. 245, 297-308 (1995).

Sequence CWU 1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 494 <210> SEQ ID NO 1 <211> LENGTH: 64 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 1 Gly Ser Pro Lys Glu Glu Ala Arg Glu Leu Ile Arg Lys Gln Lys Glu 1 5 10 15 Leu Ile Lys Glu Gln Lys Lys Leu Ile Lys Glu Ala Lys Gln Lys Ser 20 25 30 Asp Ser Arg Asp Ala Glu Arg Ile Trp Lys Arg Ser Arg Glu Ile Asn 35 40 45 Arg Glu Ser Lys Lys Ile Asn Lys Arg Ile Lys Glu Leu Ile Lys Ser 50 55 60 <210> SEQ ID NO 2 <211> LENGTH: 62 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 2 Pro Lys Lys Glu Ala Glu Glu Leu Ala Glu Glu Ser Glu Glu Leu His 1 5 10 15 Asp Arg Ser Glu Lys Leu His Glu Arg Ala Glu Gln Ser Ser Asn Ser 20 25 30 Glu Glu Ala Arg Lys Ile Leu Glu Asp Ile Glu Arg Ile Ser Glu Arg 35 40 45 Ile Glu Glu Ile Ser Asp Arg Ile Glu Arg Leu Leu Arg Ser 50 55 60 <210> SEQ ID NO 3 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 3 Gly Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg Lys Ile Ile Glu Arg 1 5 10 15 Ala Gln Glu Ile His Arg Arg Gln Gln Glu Ile Leu Glu Glu Leu Glu 20 25 30 Arg Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu Ala Met Lys Arg Met 35 40 45 Leu Lys Leu Leu Glu Glu Ser Leu Arg Leu Leu Lys Glu Leu Leu Glu 50 55 60 Leu Ser Glu Glu Ser Ala Gln Leu Leu Tyr Glu Gln Arg 65 70 75 <210> SEQ ID NO 4 <211> LENGTH: 83 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 4 Gly Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg Glu 1 5 10 15 Gln Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu Glu 20 25 30 Glu Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu Ala 35 40 45 Lys Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu 50 55 60 Leu Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys Gly Ser Leu 65 70 75 80 Val Pro Arg <210> SEQ ID NO 5 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 5 Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg Lys Ile Ile Glu Arg Ala 1 5 10 15 Gln Glu Ile Ile Arg Arg Gln Gln Glu Ile Leu Glu Glu Leu Glu Arg 20 25 30 Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu Ala Met Lys Arg Met Leu 35 40 45 Lys Leu Leu Glu Glu Ser Leu Arg Leu Leu Lys Glu Leu Leu Glu Leu 50 55 60 Leu Glu Glu Ser Ala Gln Leu Leu Tyr Glu Gln Arg 65 70 75 <210> SEQ ID NO 6 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 6 Gly Ser Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg 1 5 10 15 Glu Ala Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu 20 25 30 Glu Glu Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu 35 40 45 Ala Lys Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg Leu Leu 50 55 60 Glu Leu Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 65 70 75 <210> SEQ ID NO 7 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 7 Thr Lys Glu Asp Ile Leu Glu Arg Ala Arg Lys Ile Ile Glu Arg Ala 1 5 10 15 Gln Glu Ile His Arg Arg Gln Gln Glu Ile Leu Glu Glu Leu Glu Arg 20 25 30 Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu Ala Met Lys Arg Met Leu 35 40 45 Lys Leu Leu Glu Glu Ser Leu Arg Leu Leu Lys Glu Leu Leu Glu Leu 50 55 60 Ser Glu Glu Leu Ala Gln Leu Leu Tyr Glu Gln Arg 65 70 75 <210> SEQ ID NO 8 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 8 Gly Ser Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala Ile Arg 1 5 10 15 Glu Gln Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu 20 25 30 Glu Glu Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu 35 40 45 Ala Lys Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu 50 55 60 Glu Leu Leu Arg Glu Ile Leu Tyr Leu Leu Gln Glu Gln Lys 65 70 75 <210> SEQ ID NO 9 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 9 Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg Lys Ile Ile Glu Arg Ala 1 5 10 15 Gln Glu Ile His Arg Arg Gln Gln Glu Ile Leu Glu Glu Leu Glu Tyr 20 25 30 Ile Ile Arg 35 <210> SEQ ID NO 10 <211> LENGTH: 121 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 10 Met Ser Glu Glu Ala Met Lys Arg Met Leu Lys Leu Leu Glu Glu Ser 1 5 10 15 Leu Arg Leu Leu Lys Glu Leu Leu Glu Leu Ser Glu Glu Ser Ala Gln 20 25 30 Leu Leu Tyr Glu Gln Arg Lys Ala Asn Asn Gly Ser Glu Thr Glu Lys 35 40 45 Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg Glu Gln Lys Glu Ile 50 55 60 Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu Glu Glu Ile Val Arg 65 70 75 80 Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu Ala Lys Lys Ile Leu 85 90 95 Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu Leu Leu Arg Glu 100 105 110 Ile Leu Tyr Leu Ser Gln Glu Gln Lys 115 120 <210> SEQ ID NO 11 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 11 Met Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg Lys Ile Ile Glu Arg 1 5 10 15 Ala Gln Glu Ile His Arg Arg Gln Gln Glu Ile Leu Lys Glu Gln Glu 20 25 30 Lys Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu Ala Met Lys Arg Ser 35 40 45 Leu Lys Leu Ile Glu Glu Ser Leu Arg Leu Leu Lys Glu Leu Leu Glu 50 55 60 Leu Ser Glu Glu Ser Ala Gln Leu Leu Tyr Glu Gln Arg 65 70 75 <210> SEQ ID NO 12 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 12 Gly Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg Glu 1 5 10 15 Gln Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Lys Glu Leu Thr 20 25 30 Lys Ile His Gln Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Arg Ala 35 40 45 Leu Lys Ile Ser Gln Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu 50 55 60 Leu Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 65 70 75 <210> SEQ ID NO 13 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 13 Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg Lys Ile Ile Glu Arg Ala 1 5 10 15 Gln Glu Ile His Arg Arg Gln Gln Glu Ile Leu Lys Arg Ser Glu Glu 20 25 30 Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu Ala Leu Glu Thr Leu Arg 35 40 45 Glu Leu Gln Glu Glu Ser Leu Arg Leu Leu Lys Glu Leu Leu Glu Leu 50 55 60 Ser Glu Glu Ser Ala Gln Leu Leu Tyr Glu Gln Arg 65 70 75 <210> SEQ ID NO 14 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 14 Gly Ser Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg 1 5 10 15 Glu Gln Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Thr 20 25 30 Glu Glu Ile Ile Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Asp Glu 35 40 45 Leu Arg Arg Ile Gln Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu 50 55 60 Glu Leu Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 65 70 75 <210> SEQ ID NO 15 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 15 Thr Thr Lys Arg Tyr Leu Glu Glu Ala Glu Arg Ala His Arg Glu Gln 1 5 10 15 Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu Glu Glu 20 25 30 Ile Val Arg Gln 35 <210> SEQ ID NO 16 <211> LENGTH: 116 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 16 Gly Ser Ser Glu Glu Ala Lys Lys Glu Ala Lys Lys Ile Leu Glu Glu 1 5 10 15 Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu Leu Leu Arg Glu Ile Leu 20 25 30 Tyr Leu Ser Gln Gln Val Asn Asp Val Asp Glu Lys Ala Leu Glu Arg 35 40 45 Gln Arg Lys Ile Ile Glu Arg Ala Gln Glu Ile His Arg Arg Gln Gln 50 55 60 Glu Ile Leu Glu Glu Leu Glu Arg Ile Ile Arg Lys Pro Gly Ser Ser 65 70 75 80 Glu Glu Ala Met Lys Arg Met Leu Lys Leu Leu Glu Glu Ser Leu Arg 85 90 95 Leu Leu Lys Glu Leu Leu Glu Leu Ser Glu Glu Ser Ala Gln Leu Leu 100 105 110 Tyr Glu Ala Arg 115 <210> SEQ ID NO 17 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 17 Glu Ala Met Lys Arg Met Leu Lys Leu Leu Glu Glu Ser Leu Arg Leu 1 5 10 15 Leu Lys Glu Leu Leu Glu Leu Ser Glu Glu Ser Ala Gln Leu Leu Tyr 20 25 30 Glu Ala Arg 35 <210> SEQ ID NO 18 <211> LENGTH: 116 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 18 Thr Thr Lys Arg Tyr Leu Glu Glu Ala Glu Arg Ala His Arg Glu Gln 1 5 10 15 Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu Glu Glu 20 25 30 Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu Ala Lys 35 40 45 Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu Leu 50 55 60 Leu Arg Glu Ile Leu Tyr Leu Ser Gln Gln Val Asn Asp Val Asp Glu 65 70 75 80 Lys Ala Leu Glu Arg Gln Arg Lys Ile Ile Glu Arg Ala Gln Glu Ile 85 90 95 His Arg Arg Gln Gln Glu Ile Leu Glu Glu Leu Glu Arg Ile Ile Arg 100 105 110 Lys Pro Gly Ser 115 <210> SEQ ID NO 19 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 19 Thr Arg Glu Glu Leu Leu Arg Glu Asn Ile Glu Leu Ala Lys Glu His 1 5 10 15 Ile Glu Ile Met Arg Glu Ile Leu Glu Leu Leu Gln Lys Met Glu Glu 20 25 30 Leu Leu Glu Lys Ala Arg Gly Ala Asp Glu Asp Val Ala Lys Thr Ile 35 40 45 Lys Glu Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg 50 55 60 Ile Ala Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser 65 70 75 <210> SEQ ID NO 20 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 20 Gly Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu 1 5 10 15 Ser Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys 20 25 30 Lys Leu Leu Lys Lys Ala Arg Gly Ala Asp Glu Lys Val Leu Asp Glu 35 40 45 Leu Arg Lys Ile Ile Glu Arg Ile Arg Glu Leu Leu Asp Arg Ser Arg 50 55 60 Lys Ile His Glu Arg Ser Glu Glu Ile Ala Tyr Lys Glu Glu 65 70 75 <210> SEQ ID NO 21 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 21 Gly Asp Arg Gln Glu Leu Ile Arg Arg Asn Ile Glu Leu Leu Lys Glu 1 5 10 15 His Ile Lys Ile Leu Glu Glu Ile Ser Gln Leu Ile Glu Glu Leu Ser 20 25 30 Glu Leu Leu Asp Lys Ser Ser Ser Glu Glu Val Val Lys Arg Tyr Lys 35 40 45 Lys Ile Leu Glu Arg Tyr Lys Gln Leu Leu Arg Lys Ser Gln Glu Ile 50 55 60 His Lys Glu Ser Ser Glu Ile Ala Lys Lys Glu Ser 65 70 75 <210> SEQ ID NO 22 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 22 Gly Asp Glu Gln Lys Leu Ile Glu Arg Ser Gln Arg Met Gln Lys Glu 1 5 10 15 Ser Leu Glu Leu Leu Lys Glu Ile Ile Lys Ile Leu Asp Thr Ile Glu 20 25 30 Lys Leu Leu Asp Lys Pro Asp Ser Glu Glu Leu Leu Asp Thr Ile Lys 35 40 45 Lys Leu His Asp Thr Leu Lys Lys Ile His Asp Arg Asn Lys Lys Leu 50 55 60 Leu Lys Glu His Glu Glu Ile Leu Arg Gln Arg Ser Gly Ser Leu Val 65 70 75 80 Pro Arg <210> SEQ ID NO 23 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 23 Asp Lys Glu Glu Glu Tyr Lys Arg Leu Leu Asp Glu Ile Lys Glu Ile 1 5 10 15 Leu Lys Glu Ser Lys Glu Val Leu Lys Asp Ser Lys Arg Val Leu Glu 20 25 30 Asp Ile Lys Arg Lys Val Pro Asp Asp Asp Leu Val Lys Leu Leu Glu 35 40 45 Lys His Val Arg Leu Leu Glu Glu His Val Lys Leu Leu Glu Gln Leu 50 55 60 Ile Arg Glu Ala Glu Lys Ser Ser Lys 65 70 <210> SEQ ID NO 24 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 24 Gln Gly Ser Ser Ala Glu Glu Leu Leu Lys Lys Ile Lys Glu Ser Glu 1 5 10 15 Lys Lys Ile Arg Asp Ser Leu Arg Lys Ile Lys Glu Ile Ile Lys Lys 20 25 30 Ser Arg Lys Glu Gly Val Asp Asp Lys Gln Leu Asp Leu Ile Arg Lys 35 40 45 Val Val Glu Ser His Arg Asp Leu Leu Arg Leu His Arg Asp Leu Leu 50 55 60 Arg Leu Leu Arg Glu Glu Thr Ser 65 70 <210> SEQ ID NO 25 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 25 Asp Ile Asp Glu Ser Ile Lys Glu Val Glu Lys Leu Leu Glu Glu Val 1 5 10 15 Glu Gln Ser Leu Gln Lys Leu Asp Asp Ser Leu Lys Lys Leu Leu Glu 20 25 30 Lys Val Asn Gln Asp Pro Asp Val Asp Asp Ser Val Arg Lys Ile Val 35 40 45 Lys Arg His Val Glu Ile Leu Lys Arg His Glu Glu Val Leu Lys Arg 50 55 60 Leu Ile Glu Val Val Lys Glu His Thr Lys Thr Val Lys 65 70 75 <210> SEQ ID NO 26 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 26 Gly Ser Asp Arg Glu Glu Val His Lys Glu Ile Val Lys Leu Ile Arg 1 5 10 15 Glu Ile Ile Lys Ile His Lys Lys Ile Leu Lys Ile His Glu Lys Ile 20 25 30 Lys Asn Gly Glu Ile Asp Pro Ser Glu Ile Leu Lys Leu Ser Glu Glu 35 40 45 Ile Lys Lys Leu Thr Asp Thr Ile Ile Lys Ile Ile Glu Asp Leu Glu 50 55 60 Gln Leu Thr Arg Asp Leu Arg Arg 65 70 <210> SEQ ID NO 27 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 27 Asp Arg Lys Glu Ile Val Lys Arg His Gln Lys Val Val Glu Leu Leu 1 5 10 15 Lys Glu Ser Ser Lys Leu Leu Arg Glu Ser Ser Lys Leu Leu Gln Arg 20 25 30 Leu Leu Asp Lys Thr Gly Asp Glu Asn Leu Gln Lys Ala Val Asp Asp 35 40 45 Gln Asp Lys Ala Ile Lys Arg Gln Glu Thr Ala Ile Arg Lys Ser Gln 50 55 60 Glu Ala Ser Lys Lys Leu Asp 65 70 <210> SEQ ID NO 28 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 28 Asp Asn Ser Glu Glu Ile Lys Lys Val Ala Lys Thr Ser Arg Glu Val 1 5 10 15 Ala Glu Tyr Ser Glu Arg Val Ala Lys Glu Asn Asp Lys Val Val Lys 20 25 30 Thr Leu Glu Glu Gly Lys Ile Asp Glu Ser Glu Leu Leu Arg Leu Leu 35 40 45 Glu Glu Ser Ile Lys Ile Phe Asp Thr Ala Leu Lys Leu His Glu Glu 50 55 60 Ala Tyr Lys Leu His Gln Asp Leu Val Arg Lys Val Ser 65 70 75 <210> SEQ ID NO 29 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 29 Asp Glu Ser Glu Ala Ala Ser Val Ala Ile Glu Ser Val Gln Ile Leu 1 5 10 15 Val Glu Ser Val Lys Leu Leu Glu Glu Ser Val Arg Ile Leu Leu Asp 20 25 30 Ala Val Lys Lys Asn Gly Val Glu Asp Leu Leu Arg Val Ala Gln Arg 35 40 45 Trp Glu Lys Leu Val Asp Glu Trp Leu Lys Val Val Lys Arg Trp Leu 50 55 60 Asp Asn Val Arg Asp Ile Gln Arg 65 70 <210> SEQ ID NO 30 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 30 Gly Ser Asp Lys Ala Glu Glu Val Glu Lys Ser Val Arg Lys Ile Glu 1 5 10 15 Glu Ser Ile Lys Lys Ile Arg Lys Ser Ile Lys Lys Ala Glu Asp Ala 20 25 30 Val Gln Leu Leu Lys Glu Gly Lys Ile Asp Ala Lys Asp Phe Leu Arg 35 40 45 Ile Val Arg Glu Asp Leu Glu Val Val Lys Glu Asp Val Glu Ile Val 50 55 60 Lys Glu Asp Val Glu Asn Val Arg Glu Phe Ser Ser 65 70 75 <210> SEQ ID NO 31 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 31 Ser Asp Lys Glu Val Ser Asp Lys Leu Leu Lys Ala Ser Lys Lys Leu 1 5 10 15 Leu Lys Val Ser Glu Glu Leu Leu Glu Val Val Arg Arg Leu Leu Lys 20 25 30 Ala Leu Lys Asp Asp Glu Leu Ile Lys Lys Ile Ala Asp Leu Leu Arg 35 40 45 Lys Ile Ile Asp Lys Asp Lys Lys Phe Ile Arg Thr Ser Glu Glu Ile 50 55 60 Val Lys Glu Ser Arg 65 <210> SEQ ID NO 32 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 32 Gly Ser Asp Leu Lys Glu Val Leu Lys Thr Val Glu Glu Ala Val Lys 1 5 10 15 Glu Ile Ile Lys Ser Ser Glu Glu Leu Leu Gln Ile Ser Arg Lys Ile 20 25 30 Leu Glu Ile Ser Arg Val Gly Val Asp Glu His Glu Tyr Ile Ser Ala 35 40 45 Ile Arg Glu Tyr Leu Lys Ala Leu Glu Lys His Ile Gln Ile Leu Lys 50 55 60 Lys Phe Ile Glu Ile Leu Lys Glu Leu Ile Arg Ala Val Ser 65 70 75 <210> SEQ ID NO 33 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 33 Ser Lys Glu Glu Ile Asp Lys Ile Val Lys Lys His Lys Lys Lys Ile 1 5 10 15 Glu Glu His Lys Lys Lys Val Asp Glu Leu Lys Lys Leu Val Glu Glu 20 25 30 His Asp Lys Arg Val Ser Gln Asp Lys Asp Asp Lys Val Lys Lys Leu 35 40 45 Ser Glu Glu Val Lys Lys Ile Ile Lys Arg Leu Glu Glu Val Ser Lys 50 55 60 Arg Leu Glu Glu Val Ser Lys Lys Leu Leu Lys Val Ile Ser Asp Lys 65 70 75 80 Arg <210> SEQ ID NO 34 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 34 Gly Ser Asn Asp Glu Glu Leu Lys Lys Ile Leu Glu Thr Leu Asp Arg 1 5 10 15 Ile Leu Lys Lys Leu Asp Lys Ile Leu Thr Arg Leu Ile Glu Val Leu 20 25 30 Lys Lys Ser Glu Asp Pro Asn Leu Asp Asp Lys Asp Tyr Thr Glu Leu 35 40 45 Val Lys Gln Phe Ile Glu Leu Ile Lys Lys Tyr Glu Glu Val Val Lys 50 55 60 Glu Tyr Glu Glu Val Val Arg Gln Leu Ile Arg Leu Phe Ser 65 70 75 <210> SEQ ID NO 35 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 35 Ser Lys Glu Glu Ile Asp Lys Ile Val Lys Lys His Lys Lys Lys Ile 1 5 10 15 Glu Glu Leu Lys Lys Leu Val Asp Glu Leu Lys Lys Leu Val Glu Glu 20 25 30 His Asp Lys Arg Val Ser Gln Asp Lys Asp Asp Lys Val Lys Lys Leu 35 40 45 Ser Glu Glu Val Lys Lys Ile Ile Lys Arg Val Glu Glu Val Ala Lys 50 55 60 Arg Leu Glu Glu Val Ser Lys Lys Leu Leu Lys Val Ile Ser Asp Lys 65 70 75 80 Arg <210> SEQ ID NO 36 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 36 Gly Ser Asn Asp Glu Glu Leu Lys Lys Ile Leu Glu Thr Leu Asp Arg 1 5 10 15 Ile Leu Lys Lys Leu Glu Lys Ile Leu Thr Arg Leu Ile Glu Val Leu 20 25 30 Lys Lys Ser Glu Asp Pro Asn Leu Asp Asp Lys Asp Tyr Thr Glu Leu 35 40 45 Val Lys Gln Phe Ile Glu Leu Ile Lys Lys Phe Glu Glu Val Ile Lys 50 55 60 Glu Tyr Glu Glu Val Val Arg Gln Leu Ile Arg Leu Phe Ser 65 70 75 <210> SEQ ID NO 37 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 37 Ser Lys Glu Glu Ile Asp Lys Ile Val Lys Lys His Lys Lys Lys Ile 1 5 10 15 Glu Glu His Lys Lys Lys Val Asp Glu His Lys Lys Leu Val Glu Glu 20 25 30 His Asp Lys Arg Val Ser Gln Asp Lys Asp Asp Lys Val Lys Lys Leu 35 40 45 Ser Glu Glu Leu Lys Lys Ile Ser Lys Arg Leu Glu Glu Val Ser Lys 50 55 60 Arg Leu Glu Glu Val Ser Lys Lys Leu Leu Lys Val Ile Ser Asp Lys 65 70 75 80 Arg <210> SEQ ID NO 38 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 38 Gly Ser Asn Asp Glu Glu Leu Lys Lys Ile Leu Glu Thr Leu Asp Arg 1 5 10 15 Ile Leu Lys Lys Leu Asp Lys Ile Leu Thr Arg Leu Asp Glu Val Leu 20 25 30 Lys Lys Ser Glu Asp Pro Asn Leu Asp Asp Lys Asp Tyr Thr Glu Leu 35 40 45 Val Lys Gln Tyr Ile Glu Leu Val Lys Lys Tyr Glu Glu Val Val Lys 50 55 60 Glu Tyr Glu Glu Val Val Arg Gln Leu Ile Arg Leu Phe Ser 65 70 75 <210> SEQ ID NO 39 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 39 Asp His Ser Arg Lys Leu Lys Glu Ile Leu Asp Arg Leu Arg Lys His 1 5 10 15 Val Lys Arg Leu Lys Glu His Leu Asp Glu Leu Arg Asp Leu Val Arg 20 25 30 Gln Val Pro Glu Asp Lys Leu Leu Glu His Val Val Lys Leu Ser Asp 35 40 45 Lys Ile Leu Gln Ile Ser Glu Arg Ala Val Arg Glu Phe Thr Lys Ser 50 55 60 Val Asp Lys Asp Ser 65 <210> SEQ ID NO 40 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 40 Gly Ser Asp Lys Lys Asp Glu Leu Glu Arg Ile Leu Asp Glu Ile Arg 1 5 10 15 Arg Leu Ile Glu Arg Leu Asp Glu Ile Leu Ser Arg Leu Asn Lys Leu 20 25 30 Leu Glu Leu Leu Lys His Gly Val Pro Asn Ala Lys Glu Val Val Lys 35 40 45 Asp Tyr Ile Arg Leu Leu Lys Glu Tyr Leu Glu Leu Val Lys Glu Phe 50 55 60 Leu Lys Leu Val Lys Arg His Ala Asp Leu Val Ser 65 70 75 <210> SEQ ID NO 41 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 41 Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu Asn Leu 1 5 10 15 Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys Gln Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val Ile Asp 35 40 45 Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val Ile Lys Ile Phe 50 55 60 Glu Asp Ser Val Arg Lys Lys Glu 65 70 <210> SEQ ID NO 42 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 42 Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys 1 5 10 15 Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu 20 25 30 Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr 35 40 45 Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu 50 55 60 Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 65 70 75 <210> SEQ ID NO 43 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 43 Met Asp Glu Glu Asp His Leu Lys Lys Leu Lys Thr His Leu Glu Lys 1 5 10 15 Leu Glu Arg His Leu Lys Leu Leu Glu Asp His Ala Lys Lys Leu Glu 20 25 30 Asp Ile Leu Lys Glu Arg Pro Glu Asp Ser Ala Val Lys Glu Ser Ile 35 40 45 Asp Glu Leu Arg Arg Ser Ile Glu Leu Val Arg Glu Ser Ile Glu Ile 50 55 60 Phe Arg Gln Ser Val Glu Glu Glu Glu 65 70 <210> SEQ ID NO 44 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 44 Gly Asp Val Lys Glu Leu Thr Lys Ile Leu Asp Thr Leu Thr Lys Ile 1 5 10 15 Leu Glu Thr Ala Thr Lys Val Ile Lys Asp Ala Thr Lys Leu Leu Glu 20 25 30 Glu His Arg Lys Ser Asp Lys Pro Asp Pro Arg Leu Ile Glu Thr His 35 40 45 Lys Lys Leu Val Glu Glu His Glu Thr Leu Val Arg Gln His Lys Glu 50 55 60 Leu Ala Glu Glu His Leu Lys Arg Thr Arg 65 70 <210> SEQ ID NO 45 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 45 Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu Asn Leu 1 5 10 15 Arg Arg His Leu Asp Arg Leu Asp Lys Leu Leu Lys Glu Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val Ile Asp 35 40 45 Glu Leu Glu Arg Val Ile Arg Ile Val Lys Thr Val Ile Lys Ile Phe 50 55 60 Glu Asp Ser Val Arg Lys Lys Glu 65 70 <210> SEQ ID NO 46 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 46 Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys 1 5 10 15 Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Leu Asn Lys Val Leu 20 25 30 Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Ile Glu Thr 35 40 45 Val Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu 50 55 60 Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 65 70 75 <210> SEQ ID NO 47 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 47 Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu Asn Leu 1 5 10 15 Arg Arg Leu Glu Asp Leu Leu Asp Lys His Ile Lys Gln Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val Ile Asp 35 40 45 Leu Ser Glu Arg Val Val Arg Thr Val Lys Thr Val Ile Lys Ile Phe 50 55 60 Glu Asp Ser Val Arg Lys Lys Glu 65 70 <210> SEQ ID NO 48 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 48 Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys 1 5 10 15 Ile Leu Gln Thr Ala Thr Lys Val Val Asp Asp Ala Asn Lys Leu Leu 20 25 30 Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr 35 40 45 Tyr Val Glu Leu Leu Lys Arg Leu Glu Lys Leu Ile Lys Glu Leu Leu 50 55 60 Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 65 70 75 <210> SEQ ID NO 49 <211> LENGTH: 37 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 49 Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu Asn Leu 1 5 10 15 Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys Gln Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn 35 <210> SEQ ID NO 50 <211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 50 Glu Asp Glu Arg Val Lys Asp Val Ile Asp Leu Ser Glu Arg Ser Val 1 5 10 15 Arg Ile Val Lys Thr Val Ile Lys Ile Phe Glu Asp Ser Val Arg Lys 20 25 30 Leu Glu Lys Thr Lys Pro Asp Ser Lys Thr Ala Lys Glu Leu Asp Lys 35 40 45 Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile 50 55 60 Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys 65 70 75 80 Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu 85 90 95 Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys 100 105 110 Val Glu <210> SEQ ID NO 51 <211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 51 Asp Ser Asp Glu His Leu Tyr Lys Leu Lys Thr Phe Leu Glu Asn Leu 1 5 10 15 Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys Gln Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Ala Ile Asp 35 40 45 Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val Ile Lys Ile Phe 50 55 60 Glu Asp Ser Val Arg Lys Lys Glu Lys Arg Pro Ile Asp Lys Arg Asp 65 70 75 80 Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln 85 90 95 Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Tyr Leu 100 105 110 Arg Arg <210> SEQ ID NO 52 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 52 Gly Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His 1 5 10 15 Glu Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys 20 25 30 Lys Val Glu 35 <210> SEQ ID NO 53 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 53 Asp Ser Asp Glu His Leu Asp Arg Leu Asp Lys His Leu Lys Lys Leu 1 5 10 15 Lys Thr Phe Leu Glu Asn Leu Arg Arg His Ile Lys Gln Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val Ile Asp 35 40 45 Leu Ser Lys Thr Val Ile Lys Ile Phe Glu Asp Ser Val Arg Lys Lys 50 55 60 Glu Arg Ser Val Arg Ile Val Glu 65 70 <210> SEQ ID NO 54 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 54 Gly Ser Asp Asp Lys Glu Ala Thr Lys Ile Ile Asp Asp Leu Asp Lys 1 5 10 15 Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Asn Lys Leu Leu 20 25 30 Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr 35 40 45 Tyr Val Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala 50 55 60 Glu Leu Leu Lys Arg His Glu Lys Lys Val Glu 65 70 75 <210> SEQ ID NO 55 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 55 Asp Ser Asp Glu His Ile Lys Gln Leu Arg Asp His Leu Asp Arg Leu 1 5 10 15 Asp Lys His Leu Lys Lys Leu Lys Thr Phe Leu Glu Asn Leu Arg Arg 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Thr Val Ile Lys 35 40 45 Ile Phe Glu Asp Ser Val Arg Lys Lys Glu Arg Ser Val Arg Ile Val 50 55 60 Lys Asp Val Ile Asp Leu Ser Glu 65 70 <210> SEQ ID NO 56 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 56 Gly Ser Asp Asp Lys Glu Ala Asn Lys Leu Leu Glu Lys Ala Thr Lys 1 5 10 15 Ile Ile Asp Asp Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu 20 25 30 Gln Thr Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Ala Val Lys Glu 35 40 45 Leu Leu Glu Ile Ala Lys Thr His Ala Glu Leu Leu Lys Arg His Glu 50 55 60 Lys Val Val Glu Thr Tyr Val Lys Lys Val Glu 65 70 75 <210> SEQ ID NO 57 <211> LENGTH: 104 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 57 Asp His Ser Arg Lys Leu Glu Glu Ile Leu Asp Arg Leu Arg Lys His 1 5 10 15 Val Lys Arg Leu Leu Glu His Leu Arg Glu Leu Leu Ser Leu Val Lys 20 25 30 Glu Asn Pro Glu Asp Lys Asp Leu Val Glu Val Leu Glu Leu Ser Leu 35 40 45 Ala Ile Leu Arg Arg Ser Leu Glu Ala Val Glu Ala Phe Leu Lys Ser 50 55 60 Val Thr Lys Lys Asp Pro Asp Asp Glu Asp Leu Arg Arg Lys Ala Asp 65 70 75 80 Glu Ile Arg Lys Glu Val Glu Glu Ile Lys Lys Ser Leu Ala Glu Val 85 90 95 Glu Lys Glu Ile Tyr Lys Leu Lys 100 <210> SEQ ID NO 58 <211> LENGTH: 116 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 58 Gly Ser Ser Ala Asp Asp Val Leu Glu Asp Ile Leu Lys Ile Ile Arg 1 5 10 15 Glu Leu Ile Glu Ile Leu Asp Gln Ile Leu Ser Leu Leu Asn Gln Leu 20 25 30 Leu Lys Leu Leu Arg His Gly Val Pro Asn Ala Lys Lys Val Val Glu 35 40 45 Lys Tyr Lys Glu Ile Leu Glu Leu Tyr Leu Gln Leu Val Ser Leu Phe 50 55 60 Leu Lys Ile Val Lys Thr His Ala Asp Ala Val Ser Gly Lys Ile Asp 65 70 75 80 Lys Lys Ala Glu Glu Glu Ile Lys Lys Glu Glu Glu Lys Ile Lys Glu 85 90 95 Lys Leu Arg Gln Ala Lys Asp Ile Leu Lys Lys Leu Gln Glu Glu Ile 100 105 110 Asp Lys Thr Arg 115 <210> SEQ ID NO 59 <211> LENGTH: 107 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 59 Asp Arg Asp Ala His Leu Tyr Lys Leu Leu Thr Phe Leu Glu Gln Leu 1 5 10 15 Val Arg His Leu Asp Arg Leu Val Lys His Ile Thr Gln Leu Arg Asp 20 25 30 Ile Val Lys Lys Asp Pro Glu Asp Glu Arg Ala Val Asp Val Ile Arg 35 40 45 Gln Ser Val Arg Ser Leu Glu Ile Val Ile Thr Val Leu Lys Ile Phe 50 55 60 Val Asp Ser Val Ser Asp Ala Ala Arg Ser Lys Glu Ala Glu Lys Ile 65 70 75 80 Val Arg Lys Ile Arg Lys Glu Ile Asp Glu Ile Arg Gln Lys Leu Arg 85 90 95 Glu Ile Asp Lys Glu Val Lys Lys Thr Thr Ser 100 105 <210> SEQ ID NO 60 <211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 60 Gly Ser Asn Asp Lys Val Leu Asp Lys Ile Leu Asp Ile Leu Asp Arg 1 5 10 15 Ile Leu Arg Leu Ala Thr Arg Val Ile Asp Leu Ala Asn Lys Leu Leu 20 25 30 Gln Val Lys Lys Lys Ser Thr His Lys Asp Pro Arg Ile Val Glu Thr 35 40 45 Tyr Lys Glu Leu Leu Lys Ile His Glu Thr Ala Val Arg Leu Leu Leu 50 55 60 Glu Leu Ala Asp Leu His Arg Arg Leu Lys Ser Lys Asp Glu Glu Ala 65 70 75 80 Asn Lys Arg Val Glu Thr Glu Leu Asp Arg Ile Arg Lys Lys Val Lys 85 90 95 Asp Ile Glu Asp Lys Val Arg Lys Leu Glu Asp Lys Val Arg Lys Thr 100 105 110 Ala Ser <210> SEQ ID NO 61 <211> LENGTH: 68 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 61 Asn Asp Leu Ser Lys Glu Val Leu Lys Lys Leu Glu Lys Ser Val Glu 1 5 10 15 Glu Leu Leu Arg Arg Val Gln Lys Ser Val Lys Glu Ala Gln Lys Arg 20 25 30 Gly Leu Leu Ser Asp Glu Leu Val Asp Arg His Leu Lys Ile Leu Asn 35 40 45 Gln Leu Val Lys Arg His Leu Glu Leu Leu Gln Glu Val Ile Lys Arg 50 55 60 Ser Asp Lys Lys 65 <210> SEQ ID NO 62 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 62 Gly Ser Asp Glu Ala Val Lys Arg Val Val Glu Lys Ser Leu Lys Ile 1 5 10 15 Leu Asp Glu Val Ile Lys Lys Ser Leu Asp Ile Leu Arg Glu Leu Ile 20 25 30 Glu Leu Gln Ile Arg His Ala Lys Asp Asp Glu Ser Val Ile Arg Ala 35 40 45 Ser Lys Ser Ala Leu Lys Asp Ala Ile Glu Ala Leu Lys Lys Ser Leu 50 55 60 Asp Glu Ile Lys Lys Ala Leu Lys Arg Ser Ala Asp Glu Gly 65 70 75 <210> SEQ ID NO 63 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 63 Ser Ser Glu Glu Val Val Lys Val His Glu Lys Val Val Lys Leu His 1 5 10 15 Lys Glu Ile Leu Glu Leu Leu Lys Lys Ile Ile Lys Ile His Glu Thr 20 25 30 Ala Ala Arg Asp Pro Asp Asp Lys Asp Ser Ile Lys Lys Leu Ser Asp 35 40 45 Glu Ile Lys Lys Ile Val Lys Arg Ile Glu Asp Ile Ser Asp Gln Ala 50 55 60 Lys Arg Glu Ser Ser Asp Ala Gln Arg Lys Gln Ser 65 70 75 <210> SEQ ID NO 64 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 64 Asp Lys Glu Glu Glu Ser Lys Glu Leu Leu Lys Lys Leu Lys Glu Ile 1 5 10 15 Leu Lys Arg Ser Glu Glu Leu Leu Glu Glu Ser Lys Glu Leu Leu Lys 20 25 30 Leu Ala Lys Asn Gly Glu Ile Asp Glu Ser Glu Leu Ala Asp Ala Asp 35 40 45 Arg Lys Leu Asn Lys Lys His Glu Lys Leu Val Gln Asp Ile Gln Asp 50 55 60 Leu Leu Arg Glu His Glu Arg Gln Asp Arg 65 70 <210> SEQ ID NO 65 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 65 Asp Glu Lys Lys Lys Ile Asp Lys Ile Val Lys Glu Thr Glu Asp Leu 1 5 10 15 Leu Gln Lys Ser Glu Lys Leu Leu Gln Gln Ser Lys Glu Ala Val Lys 20 25 30 Arg Ile Arg Ser Gln Val Lys Glu Asn Glu Ile Val Asp Arg Leu Leu 35 40 45 Arg Ile Ser Glu Glu Leu Leu Lys Ile Ser Arg Arg Leu Val Glu Ile 50 55 60 Ser Arg Arg Ile Ala Ser Thr Leu Ser 65 70 <210> SEQ ID NO 66 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 66 Gly Ser Ser Lys Glu Glu Val Ile Arg Leu Leu Lys Glu Asn Val Arg 1 5 10 15 Leu Ile Lys Glu Asn Leu Glu Leu Leu Thr Arg Asn Leu Lys Leu Ile 20 25 30 Thr Asp Leu Val Arg Gly Ser Asn Gly Ser Glu Glu Lys Ile Lys Thr 35 40 45 Leu Lys Glu Leu Leu Lys Glu Tyr Arg Glu Leu Leu Lys Arg Tyr Arg 50 55 60 Lys Leu Val Glu Asp Tyr Lys Arg Leu Val Asp Lys His Asp 65 70 75 <210> SEQ ID NO 67 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 67 Glu Ile Gln Glu Leu Ile Lys Ser Ser Arg Arg Ile Ile Glu Glu Ser 1 5 10 15 Lys Glu Leu Ile Lys Glu Ser Glu Glu Val Leu Arg Arg Ile Lys Glu 20 25 30 Ile Leu Asp Arg Ile Arg Asn Gly Val Asp Asn Gln Glu Asp Leu Leu 35 40 45 Arg Glu Ile Leu Lys Leu Leu Thr Lys Asn Leu Lys Ile Ile Gln Arg 50 55 60 Asn Leu Lys Leu Leu Gln Asp Asn Ala Glu Ile Leu Lys Arg Leu Val 65 70 75 80 Ser <210> SEQ ID NO 68 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 68 Gly Ser Tyr Ile Glu Asp Val Ile Lys Lys Ile Leu Asp Val Ser Arg 1 5 10 15 Glu Leu Ile Lys Leu Ser Arg Thr Ile Ile Lys Ile Ser Glu Glu Ile 20 25 30 Asn Lys Gln Leu Gln Gln Gly Arg Asp Thr Lys Asp Leu Val Lys Lys 35 40 45 Tyr Asp Glu Ile Ile Lys Lys Tyr Thr Arg Ile Val Gln His Tyr Thr 50 55 60 Glu Leu Ile Lys Glu Leu Gln Lys Leu Leu Ser 65 70 75 <210> SEQ ID NO 69 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 69 Ser Pro Thr Glu Glu Ala Ile Gln Leu Ser Gln Arg Val Ile Glu Leu 1 5 10 15 Ser Lys Arg Val Ile Glu Leu Ser Lys Glu Ile Leu Lys Leu Leu Lys 20 25 30 Arg Val Leu Asp Leu Leu Pro Asp Leu Asp Lys Asn Glu Glu Lys Arg 35 40 45 Leu Asp Asp Tyr Asp Lys Glu Leu Lys Glu Tyr Asp Lys Glu Leu Lys 50 55 60 Lys Tyr Glu Lys Arg Leu Lys Asp Leu Ala Ser 65 70 75 <210> SEQ ID NO 70 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 70 Gly Ser Glu Glu Glu Glu Ile Leu Lys Ile Gln Lys Glu Leu Leu Arg 1 5 10 15 Ile Gln Ser Glu Ile Leu Asp Lys Gln Lys Lys Ile Leu Asp Thr Leu 20 25 30 Arg Ser Asn Gly Ala Val Thr Glu Glu Val Arg Ser Ile Leu Glu Lys 35 40 45 Val Glu Arg Leu Ser Glu Glu Ala Lys Glu Leu Ser Lys Glu Ala Lys 50 55 60 Glu Leu Thr Lys Glu Val Ser Lys Leu Ile Ser 65 70 75 <210> SEQ ID NO 71 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 71 Ser Pro Leu Lys Glu Leu Asn Asn Gln Leu Leu Arg Leu Leu Arg Glu 1 5 10 15 Leu Val Lys Val Ser Lys Lys Ile Val Asp Leu Ser Lys Thr Ile Ile 20 25 30 Glu Val Leu Lys His Thr Asp Leu Asp Pro Arg Leu Leu Asp Ser Leu 35 40 45 Glu Lys Ser Gln Gln Glu Leu Asp Lys Ser Gln Lys Glu Leu Asp Lys 50 55 60 Val Val Lys Glu Leu Thr Lys Val Asn Lys Lys Leu Gln 65 70 75 <210> SEQ ID NO 72 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 72 Gly Ser Pro Leu Glu Asp Leu Val Arg Lys Tyr Asp Glu Leu Val Lys 1 5 10 15 Thr Tyr Glu Lys Leu Val Glu Glu Phe Lys Lys Ala Val Asp Lys Tyr 20 25 30 Asp Lys Ala Val Lys Lys Ala Pro Val Ser Lys Glu Ala Thr Asp Ser 35 40 45 Leu Asp Leu Ile Arg Lys Val Leu Glu Leu Leu Asp Arg Asn Leu Lys 50 55 60 Leu Ile Lys Glu Asn Ala Lys Leu Ile Lys Glu Leu Leu Lys 65 70 75 <210> SEQ ID NO 73 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 73 Ser Pro Thr Arg Glu Asn Glu Lys Val Ile Lys Glu Asn Glu Lys Val 1 5 10 15 Ile Ser Asp Asn Glu Arg Val Leu Glu Glu Val Val Lys Val Val Glu 20 25 30 Thr Ala Thr Asp Arg Lys Glu Ile Gln Asp Ala Val Asp Glu Val Arg 35 40 45 Lys Ser Val Asp Lys Leu Arg Asp Ser Val Arg Lys Leu Glu Glu Ser 50 55 60 Val Arg Thr Leu Asp 65 <210> SEQ ID NO 74 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 74 Gly Ser Pro Ile Lys Asp Ile Ser Lys Arg Leu Leu Glu Ile Ser Lys 1 5 10 15 Arg Leu Val Glu Ile Ser Asp Arg Ile Val Glu Leu Leu Gln Arg Ile 20 25 30 Ala Asp Ser Lys Asp Pro Asn Lys Asp Leu Gln Lys Glu Val Lys Asp 35 40 45 Val Leu Glu Glu Tyr Lys Arg Leu Val Arg Glu Tyr Arg Glu Val Val 50 55 60 Lys Glu Tyr Glu Lys Val Val Ser 65 70 <210> SEQ ID NO 75 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 75 Asp Glu Asp Glu His Val Lys Gln Leu Ile Lys Asn Ala Asp Leu Leu 1 5 10 15 Arg Lys His Ala Glu Leu Leu Lys Glu Leu Val Lys Leu Phe Gln Glu 20 25 30 Ile Ala Ser Gln Ile Pro Asp Asp Arg Val Ala Lys Lys Val Thr Asp 35 40 45 Val Val Asp Arg Ile Asp Lys Ile Leu Lys Gln Thr Glu Lys Leu Val 50 55 60 Arg Arg Thr Lys Gln Ile Leu Asp Tyr Ser Arg 65 70 75 <210> SEQ ID NO 76 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 76 Gly Ser Asn Leu Glu Glu Leu Val Lys Leu Leu Lys Glu Val Leu Glu 1 5 10 15 Met His Glu Arg Leu Leu Arg Ile His Glu Asp Leu Val Glu Ala His 20 25 30 Lys Ser Asn Ala Ser Asp Lys Glu Ser Glu Arg Lys Leu Lys Lys Ser 35 40 45 Asp Lys Asp Ile Lys Glu Ser Leu Lys Lys Ile Lys Ser Ile Ile Asp 50 55 60 Gln Val Arg Tyr Ile Gln Ser 65 70 <210> SEQ ID NO 77 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 77 Pro Val Glu Asp Ile Ile Glu Glu Ser Leu Arg Leu Leu Glu Glu Ser 1 5 10 15 Leu Lys Leu Leu Asn Arg Ile Leu Lys Leu Leu Glu Asp Ser Leu Arg 20 25 30 Lys Leu Pro Arg Ser Glu Glu Trp Arg Gln Arg Leu Asp Glu Phe Arg 35 40 45 Lys Lys Leu Glu Asp Trp Lys Glu Glu Leu Glu Arg Trp Ile Glu Asp 50 55 60 Val Arg Tyr Lys Lys Thr 65 70 <210> SEQ ID NO 78 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 78 Gly Ser Asp Glu Asp Tyr Glu Ser Arg Glu Ile Ile Asp Glu Ile Arg 1 5 10 15 Lys Leu Leu Asp Arg Ser Lys Lys Ile Val His Arg Ser Gln Arg Leu 20 25 30 Val Glu Arg Val Lys Ser Thr Pro Leu Ser Glu Asp Gln Glu Asp Leu 35 40 45 Ile Arg Arg His Glu Glu Thr Ile Asn Arg His Arg Glu Leu Val Lys 50 55 60 Glu Leu Glu Lys Val Leu Glu Asp His Glu Arg His Ile Arg 65 70 75 <210> SEQ ID NO 79 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 79 Pro Glu Glu Asp Ser Arg Arg Val Leu Glu Arg Phe Val Arg Val Ser 1 5 10 15 Arg Glu Val Leu Lys Val Leu Glu Glu Phe Leu Arg Val Ser Glu Glu 20 25 30 Leu Leu Arg Glu Ala Asp Arg Asp Arg Asp Arg Arg Leu Glu Glu Tyr 35 40 45 Glu Arg Gln Val Asp Glu Leu Arg Glu Glu Ile Arg Arg Tyr Lys Glu 50 55 60 Glu Val Asp Lys Phe Asp Lys Glu Val Lys Tyr Tyr Lys Lys 65 70 75 <210> SEQ ID NO 80 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 80 Gly Ser Pro Glu Lys Asp Glu Asn Arg Lys Leu Leu Asp Lys Val Arg 1 5 10 15 Lys Leu Val Glu Lys Ser Arg Arg Leu Val Glu Glu Leu Arg Lys Leu 20 25 30 Val Asp Gln Ser Thr Lys Asn Gly Leu Ile Asp Glu Lys Ala Leu Arg 35 40 45 Lys Gln Gln Glu Val Leu Arg Lys Val Glu Glu Val Leu Glu Lys Gln 50 55 60 Glu Arg Val Leu Arg Glu Leu Glu Glu Ile Ser Tyr Arg Val Ile 65 70 75 <210> SEQ ID NO 81 <211> LENGTH: 39 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 81 Gly Ser Pro Glu Arg Asp Glu Asn Arg Lys Leu Leu Asp Lys Val Arg 1 5 10 15 Lys Leu Val Glu Lys Ser Arg Arg Leu Val Glu Glu Leu Arg Lys Leu 20 25 30 Val Asp Gln Ser Thr Lys Asn 35 <210> SEQ ID NO 82 <211> LENGTH: 124 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 82 Gly Ser Asp Glu Lys Ala Leu Arg Lys Gln Gln Glu Val Leu Arg Lys 1 5 10 15 Val Glu Glu Val Leu Glu Lys Gln Glu Arg Val Leu Arg Glu Leu Glu 20 25 30 Glu Ile Ser Tyr Arg Val Ile Thr Arg Gly Glu Asp His Lys Ala Glu 35 40 45 Glu Asp Ser Arg Arg Val Leu Glu Arg Phe Val Arg Val Ser Arg Glu 50 55 60 Val Leu Lys Val Leu Glu Glu Phe Leu Arg Val Ser Glu Glu Leu Leu 65 70 75 80 Arg Glu Ala Asp Arg Asp Arg Asp Arg Arg Leu Glu Glu Tyr Glu Arg 85 90 95 Gln Val Asp Glu Leu Arg Glu Glu Ile Arg Arg Tyr Lys Glu Glu Val 100 105 110 Asp Lys Phe Asp Lys Glu Val Lys Tyr Tyr Lys Lys 115 120 <210> SEQ ID NO 83 <211> LENGTH: 39 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 83 Gly Ser Asp Arg Arg Leu Glu Glu Tyr Glu Arg Gln Val Asp Glu Leu 1 5 10 15 Arg Glu Glu Ile Arg Arg Tyr Lys Glu Glu Val Asp Lys Phe Asp Lys 20 25 30 Glu Val Lys Tyr Tyr Lys Lys 35 <210> SEQ ID NO 84 <211> LENGTH: 125 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 84 Gly Ser Pro Glu Arg Asp Glu Asn Arg Lys Leu Leu Asp Lys Val Arg 1 5 10 15 Lys Leu Val Glu Lys Ser Arg Arg Leu Val Glu Glu Leu Arg Lys Leu 20 25 30 Val Asp Gln Ser Thr Lys Asn Gly Leu Ile Asp Glu Lys Ala Leu Arg 35 40 45 Lys Gln Gln Glu Val Leu Arg Lys Val Glu Glu Val Leu Glu Lys Gln 50 55 60 Glu Arg Val Leu Arg Glu Leu Glu Glu Ile Ser Tyr Arg Val Ile Thr 65 70 75 80 Arg Gly Glu Asp His Lys Ala Glu Glu Asp Ser Arg Arg Val Leu Glu 85 90 95 Arg Phe Val Arg Val Ser Arg Glu Val Leu Lys Val Leu Glu Glu Phe 100 105 110 Leu Arg Val Ser Glu Glu Leu Leu Arg Glu Ala Asp Arg 115 120 125 <210> SEQ ID NO 85 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 85 Asp Leu Ser Glu Glu Ser Lys Lys Phe Val Glu Lys Val Lys Lys Leu 1 5 10 15 Glu Lys Glu Ser Arg Glu Leu Glu Lys Gln Val Lys Lys Ile Glu Glu 20 25 30 Asp Ser Arg Ser Val Glu Asn Asp Val Gln Lys Glu Phe Leu Glu Leu 35 40 45 Leu Lys Arg Leu Leu Asp Ile Gln Lys Lys Val Val Glu Val Leu Arg 50 55 60 Glu Val Val Lys Val Gln Gln Tyr Val Asp Ser 65 70 75 <210> SEQ ID NO 86 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 86 Gly Ser Asp Ser Glu Tyr Glu Ser Arg Gln Val Leu Arg Glu Leu Asp 1 5 10 15 Thr Val Leu Lys Asp Ser His Thr Val Leu Glu Ala Leu Arg Gln Val 20 25 30 Ile Arg Asp Ser Gln Asp Val Val Ser Lys Ser Asp Glu Glu Ser Arg 35 40 45 Arg Val Ile Asp Asp Leu Glu Lys Val Ile Gln Asp Ser Lys Lys Val 50 55 60 Leu Asp Asp Ile Lys Arg Leu Ile Asp Lys Ser Lys Ser Ile Lys Ser 65 70 75 80 <210> SEQ ID NO 87 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 87 Asn Glu Asp Glu Leu Leu Lys Leu Leu Thr Glu Asn Leu Lys Leu Leu 1 5 10 15 Asp Glu Asn Leu Lys Leu Leu Arg Glu Asn Leu Ser Leu Leu Arg Gln 20 25 30 Ala Asn Asn Ile Thr Asp Lys Asn Arg Ile Arg Glu Ile Val Lys Gln 35 40 45 Ser Lys Glu Ile Val Lys Gln Ser Arg Glu Ile Leu Lys Gln Ser Lys 50 55 60 Glu Ile Val Glu Arg Ile Lys Tyr Ile Val Ser 65 70 75 <210> SEQ ID NO 88 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 88 Gly Ser Ser Leu Tyr Glu Leu Thr Gln Arg Tyr Glu Lys Leu Val Gln 1 5 10 15 Gln Tyr Glu Glu Leu Val Lys Asp Tyr Arg Arg Leu Val Lys Lys Leu 20 25 30 Glu Lys Leu Lys Arg Asp Asn Lys Pro Asp Lys Arg Leu Leu Lys Glu 35 40 45 Ile Val Asp Val Ile Lys Lys Ser Val Glu Ile Ile Asp Arg Ser Leu 50 55 60 Lys Leu Leu Glu Glu Ser Ile Lys Ile Leu Glu Glu Thr Asp 65 70 75 <210> SEQ ID NO 89 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 89 Ser Gln Glu Arg Ser Leu Glu Ile Leu Lys Arg Ile Leu Asp Val Leu 1 5 10 15 Lys Glu Ser Leu Glu Ile Leu Lys Glu Ser Leu Ser Ile Leu Arg Gln 20 25 30 Leu Ala Ser Arg Ile Lys Asn Pro Asn Arg Lys Ile Glu Glu Ile Leu 35 40 45 Lys Glu Ser Asp Lys Ile Ile Lys Glu Ser Asp Lys Val Leu Lys Glu 50 55 60 Ile Glu Glu Val Ile Arg Tyr Ser Ser 65 70 <210> SEQ ID NO 90 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 90 Gly Ser Asp Ile Glu Tyr Glu Ser Lys Glu Ile Leu Glu Leu Ile Lys 1 5 10 15 Glu Leu Leu Lys Leu Ser Arg Glu Leu Leu Lys Glu Ser Arg Arg Ala 20 25 30 Leu Glu Leu Val Arg Lys Ser Arg Asp Asp Ser Ile Val Glu Glu Val 35 40 45 Ile Gln Val His Lys Lys Val Leu Asp Ile His Lys Glu Val Leu Lys 50 55 60 Ile Val Arg Lys Val Val Glu Val His Arg Arg Val Lys Ser 65 70 75 <210> SEQ ID NO 91 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 91 Ser Lys Lys Asp Glu Ser Thr Lys Leu Glu Arg Leu Ala Glu Lys Ile 1 5 10 15 Asp Glu Ile Thr Lys Arg Ile Glu Glu Leu Val Lys Asp Val Lys Arg 20 25 30 Lys Ser Ser Glu Gly Val Asp Lys Asp Gln Gln Gln Lys Ile Asp Glu 35 40 45 Val Phe Gln Lys Leu Leu Asp Leu Gln Arg Glu Ile Leu Glu Ile Leu 50 55 60 Asp Arg Ile Leu Lys Val Gln Gln Tyr Ile Leu Asp 65 70 75 <210> SEQ ID NO 92 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 92 Gly Ser Asp Leu Glu Tyr Leu Asn Arg Arg Leu Leu Gln Leu Ile Lys 1 5 10 15 Thr Leu Ile Asp Leu Asn Arg His Leu Leu Lys Leu Ile Asp Lys Leu 20 25 30 Lys Lys Leu Asn Ser Arg Glu Gly Asp Glu Glu Lys Ile Lys Glu Glu 35 40 45 Ser Lys Gln Ile Gln Glu Gln Phe Lys Glu Ile Val Glu Arg Ser Lys 50 55 60 Glu Ile Ile Lys Gln Ile Lys Glu Ile Ile Lys Arg Ser Gln 65 70 75 <210> SEQ ID NO 93 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 93 Asp Phe Glu Arg Ser Ser Arg Arg Leu Glu Lys Val Val Glu Asp Leu 1 5 10 15 Arg Arg Ser Ser Asp Arg Leu Arg Glu Val Ile Asp Glu Leu Arg Lys 20 25 30 Ser Ala Asp Glu Lys Asp Glu Asp Glu Asp Leu Arg Arg Ala Arg Lys 35 40 45 Glu His Arg Asp Leu Ile Glu Glu Leu Lys Arg Ala Leu Glu Lys Gln 50 55 60 Glu Glu Ile Ile Lys His Leu Gln Glu Leu Val Tyr Arg Gln Leu 65 70 75 <210> SEQ ID NO 94 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 94 Gly Ser Glu Glu Ser Glu Glu Val Arg Lys Val Val Glu Arg Ile Lys 1 5 10 15 Lys Ile Ser Arg Glu Leu Glu Glu Val Val Lys Glu Leu Asp Arg Val 20 25 30 Ser Lys Glu Phe Asp Arg His Gly Glu Thr Asp Glu Ile Val Arg Glu 35 40 45 His Glu Arg Ile Val Glu Lys Leu Glu Glu Ile Val Lys Lys His Thr 50 55 60 Lys Ile Val Glu Glu Leu Ala Glu Ile Val Tyr Lys Gln Gln 65 70 75 <210> SEQ ID NO 95 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 95 Ser Asp Asp Asp Ser Val Arg Val Leu Asp Glu Ile Val Lys Ile Leu 1 5 10 15 Asp Glu Ser Val Lys Leu Leu Lys Glu Ser Leu Lys Leu Leu Asp Asp 20 25 30 Phe Leu Arg Thr Lys Pro Asp Asp His Leu Lys Glu Val Val Lys Glu 35 40 45 Ser Lys Lys Val Val Glu Gln Ser Lys Lys Val Leu Asp Arg Ile Lys 50 55 60 Lys Ile Ile Tyr Glu Ser Lys 65 70 <210> SEQ ID NO 96 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 96 Gly Ser Asp Leu Leu Tyr Leu Ser Lys Glu Leu Leu Lys Leu Val Arg 1 5 10 15 Glu Leu Leu Lys Leu Ser Arg Glu Leu Val Glu Leu Ser Arg Arg Leu 20 25 30 Val Asn Ser Thr His Lys Ser Pro Glu Leu Val Lys Lys Tyr Asp Lys 35 40 45 Leu Val Lys Lys Tyr Gln Asp Leu Leu Lys Lys Leu Ala Asp Val Ala 50 55 60 Asp Glu Tyr Leu Arg Gln Arg Ser 65 70 <210> SEQ ID NO 97 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 97 Asp Glu Lys Asp Tyr His Arg Arg Leu Ile Glu His Leu Glu Asp Leu 1 5 10 15 Val Arg Arg His Glu Glu Leu Ile Lys Arg Gln Lys Lys Val Val Glu 20 25 30 Glu Leu Glu Arg Arg Gly Leu Asp Glu Arg Leu Arg Arg Val Val Asp 35 40 45 Arg Phe Arg Arg Ser Ser Glu Arg Trp Glu Glu Val Ile Glu Arg Phe 50 55 60 Arg Gln Val Val Asp Lys Leu Arg Lys Ser Val Glu 65 70 75 <210> SEQ ID NO 98 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 98 Gly Ser Asp Ala Tyr Asp Leu Asp Arg Ile Val Lys Glu His Arg Arg 1 5 10 15 Leu Val Glu Glu Gln Arg Glu Leu Val Glu Glu Leu Glu Lys Leu Val 20 25 30 Arg Arg Gln Glu Asp His Arg Val Asp Lys Lys Glu Ser His Glu Ile 35 40 45 Leu Glu Arg Leu Glu Arg Ile Ile Arg Arg Ser Thr Arg Ile Leu Thr 50 55 60 Glu Leu Glu Lys Leu Thr Asp Glu Phe Glu Arg Arg Thr Arg 65 70 75 <210> SEQ ID NO 99 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 99 Asp Glu Arg Tyr Arg Ala Arg Glu His Ile Arg Arg Val Glu Glu His 1 5 10 15 Thr Lys Arg Leu Arg His Ile Leu Lys Arg Leu Arg Glu His Glu Glu 20 25 30 Lys Leu Arg Arg Glu Leu Lys Pro Gly Asp Glu Ile Thr Glu Ser Val 35 40 45 Asp Arg Phe Lys Lys Ile Val Asp Gln Phe Glu Glu Ser Ile Lys Lys 50 55 60 Phe Glu Thr Val Ser Glu Glu Leu Arg Lys Ser Asp Ser 65 70 75 <210> SEQ ID NO 100 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 100 Gly Ser Asp Arg Gln Arg Ile Leu Asp Arg Leu Asp Lys Ile Leu Glu 1 5 10 15 Lys Leu Asp Asp Ile Leu Lys Lys Leu Lys Asp Ile Leu Glu Thr Leu 20 25 30 Ser Lys Asp Asp Val Ser Asp Arg Arg His Lys Asp Leu Val Glu Lys 35 40 45 Phe Arg Glu Leu Val Asp Thr His His Lys Leu Val Glu Arg Tyr Arg 50 55 60 Glu Leu Val Tyr Gln Asn Arg 65 70 <210> SEQ ID NO 101 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 101 Gly Ser Asp Glu Ile Thr Glu Ser Val Asp Arg Phe Lys Lys Ile Val 1 5 10 15 Asp Gln Phe Glu Glu Ser Ile Lys Lys Phe Glu Thr Val Ser Glu Glu 20 25 30 Leu Arg Lys Ser Ile Ser 35 <210> SEQ ID NO 102 <211> LENGTH: 107 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 102 Gly Ser Asp Pro Gln Arg Ala Ala Asp Arg Leu Asp Lys Ile Leu Glu 1 5 10 15 Lys Leu Asp Asp Ile Leu Lys Lys Leu Lys Asp Ile Leu Glu Thr Leu 20 25 30 Ser Lys Asp Asp Val Lys Asp Arg Arg Ala Lys Asp Leu Val Glu Lys 35 40 45 Phe Arg Glu Leu Val Asp Thr His His Lys Leu Val Glu Arg Tyr Arg 50 55 60 Glu Leu Val Tyr Thr Ala Thr Ala Gly Ser Asp Leu Ala Arg Glu Leu 65 70 75 80 Ile Arg Arg Val Glu Glu His Thr Lys Arg Leu Arg His Ile Leu Lys 85 90 95 Arg Leu Arg Glu His Glu Glu Lys Leu Arg Arg 100 105 <210> SEQ ID NO 103 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 103 Asn Ala Asp Asp Gln Leu Ala Thr Ser Ile Lys Lys Leu Glu Asp Ser 1 5 10 15 Ile Asp Gln Leu Ile Lys Ile Val Arg Lys Phe Glu Glu Ser Val Lys 20 25 30 Lys Leu Gln Lys His Gly Val Asp Gln His His Val Glu Ile Leu Arg 35 40 45 Lys Ile Val Glu Ile Phe Arg Gln His Ile Glu Lys Leu Lys Lys His 50 55 60 Leu Glu Lys Leu Arg Tyr Thr Ser Ser 65 70 <210> SEQ ID NO 104 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 104 Gly Ser Asp Lys Glu Tyr Leu Val Thr Glu His Glu Lys Leu Val Arg 1 5 10 15 Glu His Glu Lys Ile Val Ser Glu Ile Glu Lys Leu Val Lys Lys His 20 25 30 Glu Ala Gly Val Asp Glu Ser Glu Leu Glu Glu Ile Leu Lys Lys Val 35 40 45 Glu Lys Leu Leu Arg Lys Leu Asp Glu Ile Leu Glu Gln Leu Thr Gln 50 55 60 Leu Leu Arg Lys Thr Glu 65 70 <210> SEQ ID NO 105 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 105 Gly Ser Asp Gln His Val Val Glu Ile Leu Arg Lys Ile Val Glu Ile 1 5 10 15 Phe Arg Gln His Ile Glu Lys Leu Lys Lys His Leu Glu Lys Leu Arg 20 25 30 Tyr Thr Ser Ser 35 <210> SEQ ID NO 106 <211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 106 Gly Ser Asp Ala Glu Tyr Leu Val Thr Glu His Glu Lys Leu Val Arg 1 5 10 15 Glu His Glu Lys Ile Val Ser Glu Ile Glu Lys Leu Val Lys Lys His 20 25 30 Glu Lys Gly Val Asp Glu Ser Glu Leu Glu Glu Ile Leu Lys Lys Val 35 40 45 Glu Lys Leu Leu Arg Lys Leu Asp Glu Ile Leu Glu Gln Leu Thr Gln 50 55 60 Leu Leu Arg Lys Ala Glu Lys His Ile Asp Lys His Ser Lys Ala Ala 65 70 75 80 Asp Gln Leu Ala Thr Ser Ile Lys Lys Leu Glu Asp Ser Ile Asp Gln 85 90 95 Leu Ile Lys Ile Val Arg Lys Phe Glu Glu Ser Val Lys Lys Leu Gln 100 105 110 Lys His <210> SEQ ID NO 107 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 107 Asp Glu Asp Asp Asp Ile Arg Arg Val Leu Asp Glu Ser Arg Arg Val 1 5 10 15 Leu Glu His Ser Arg Arg Val Leu Lys Arg Ser Glu Glu Val Leu Glu 20 25 30 Lys Ala Ser Arg Lys Lys Glu Lys Asp Thr Glu Glu Ile Glu Lys His 35 40 45 Leu Lys Arg Leu Arg Glu His Ala Lys Lys Leu Glu Lys His Arg Arg 50 55 60 Glu Leu Asp Asp Phe Leu Tyr Lys Glu Ile 65 70 <210> SEQ ID NO 108 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 108 Gly Ser Arg Asp Lys Tyr Leu Leu Glu Arg Leu Asn Asp Ile Leu Lys 1 5 10 15 Lys Leu Asp Glu Ile Val Asp Lys Leu Ser Asp Ile Leu Lys Arg Leu 20 25 30 Lys Asp Val Arg His Asp Asp Arg Leu Gln Glu Leu Val Glu Arg Tyr 35 40 45 Lys Glu Ile Val Lys Glu Tyr Lys Arg Ile Val Glu Glu Tyr Glu Lys 50 55 60 Leu Val Arg Glu Phe Glu Glu Gln Gln Arg 65 70 <210> SEQ ID NO 109 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 109 Asp Arg Asp Tyr Glu Asp Lys Glu Phe Lys Lys Ile Ile Lys Glu Leu 1 5 10 15 Glu Asp Val Gln Glu Glu Leu Lys Lys Leu Gln Glu Lys Ile Lys Arg 20 25 30 Phe Ser Ser Glu Leu Glu Glu Pro Asn Glu Leu Leu Lys Glu Gln Leu 35 40 45 Lys Val Asn Glu Glu Gln Leu Glu Val Asn Lys Lys Ile Leu Lys Ile 50 55 60 Leu Arg Asp Gln Leu Lys Gln Asn Glu 65 70 <210> SEQ ID NO 110 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 110 Gly Ser Asp Ala Glu Tyr Lys Val Arg Glu Ser Val Lys Arg Ser Lys 1 5 10 15 Glu Ser Val Lys His Ser Glu Asp Val Val Asp Lys Leu Asn Lys Ser 20 25 30 Val Lys Leu Ser Glu Ser Gly His Ser Asp Ala Glu Lys Ala Ser Arg 35 40 45 Glu Leu Val Lys Leu Val Arg Glu Val Val Glu Leu Ser Arg Glu Val 50 55 60 Ile Lys Leu Ser Glu Lys Val Leu Arg Val Ile Ser 65 70 75 <210> SEQ ID NO 111 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 111 Asp Leu Gln Tyr Lys Gln Glu Lys Leu Ile Arg His Phe Asp Arg Val 1 5 10 15 Val Arg Glu Trp Asp Lys Leu Val Arg Lys Phe Ser Lys Val Leu Glu 20 25 30 Lys Gln Lys His Glu Ser Lys Asp Lys Glu Leu Glu Glu Ala Ser Arg 35 40 45 Arg Val Asp Glu Leu Ile Lys Arg Leu Arg Glu Gln Leu Lys Arg Ser 50 55 60 Lys Glu Ile Leu Arg Arg Leu Lys Glu Leu Ser Arg Lys Ser Ser 65 70 75 <210> SEQ ID NO 112 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 112 Gly Ser Asp Trp Glu Glu Leu Leu Arg Arg Leu Glu Lys Val Leu Gln 1 5 10 15 Glu Tyr Glu Glu Ile Val Lys Glu Leu Ile Asp Leu Ile Glu Arg Leu 20 25 30 Ile Lys Val Ser Glu Asp Lys Ser Lys Asp Ala Ser Glu Tyr Lys Lys 35 40 45 Leu Val Thr Glu Leu Glu Lys Leu Ile Ser Lys Leu Glu Glu Ile Ser 50 55 60 Lys Lys Leu Glu Glu Leu Val Lys Glu Tyr Glu Tyr Lys Thr Glu 65 70 75 <210> SEQ ID NO 113 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 113 Asp Ala Lys Asp Glu Leu Glu Lys Ser Leu Gln Glu Ile Glu Glu Ser 1 5 10 15 Leu Lys Glu Leu Lys Lys Leu Leu Glu Glu Leu Asp Lys Ser Leu Arg 20 25 30 Glu Leu Thr Ser Gln Gly Arg Asn Lys Lys Leu Glu Glu His Ile Lys 35 40 45 Lys Val Gln Lys Phe Ile Glu Leu Val Lys Lys Tyr Ile Lys Ala Val 50 55 60 Gln Asp Tyr Leu Lys Glu Val Arg Tyr Asp Asn Ser 65 70 75 <210> SEQ ID NO 114 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 114 Gly Ser Asp Lys Glu Arg Ala Ala Arg Ala Thr Glu Glu Met Val Lys 1 5 10 15 Leu Thr Lys Lys Leu Leu Lys Ala Val Glu Asp Leu Val Arg Asp Val 20 25 30 Arg Arg Leu Leu Lys Glu Gly Leu Ile Ser Glu Lys His Ala Arg Ile 35 40 45 Ala Glu Thr Ile Leu Glu Val Phe Lys Lys His Ala Lys Ile Ile Lys 50 55 60 Lys His Val Asp Ile Val Lys Tyr Asp Glu Ser 65 70 75 <210> SEQ ID NO 115 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 115 Gly Ser Pro Leu Lys Glu Arg Leu Leu Glu Ile Gln Arg Asp Leu Asp 1 5 10 15 Arg Val Leu Glu Glu Val Val Glu Arg Leu Leu Arg Ile Gln Glu Arg 20 25 30 Leu Asp Ser Val Val Glu Arg Lys Pro Pro Asp Val His Glu Glu Tyr 35 40 45 Lys Tyr Ile Val Asp Glu Ile Arg Glu Ile Val Glu Arg Val Val Arg 50 55 60 Glu Tyr Glu Glu Ile Val Lys Arg Ile Asp Glu Glu Val Arg 65 70 75 <210> SEQ ID NO 116 <211> LENGTH: 83 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 116 Gly Ser Glu Glu Asp Glu Arg Ile Arg Tyr Asp Leu Asp Arg Ile Arg 1 5 10 15 Lys Asp Val Arg Arg Lys Leu Glu Glu Ile Arg Gln Arg Val Arg Glu 20 25 30 Leu Glu Lys Lys Leu Arg Asp Ala Gly His Arg Arg Asp Glu Lys Glu 35 40 45 Leu Leu Arg Glu Leu Ile Glu Thr Ser Lys Asp Ile Leu Arg Leu Val 50 55 60 Glu Glu Leu Leu Lys Lys Ile Ile Asp Lys Ser Glu Asp Leu Leu Arg 65 70 75 80 Lys Thr Glu <210> SEQ ID NO 117 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 117 Gly Ser Asp Glu Glu Asp Tyr Ile Asn Glu Asn Val Glu Lys Asp Val 1 5 10 15 Arg Asp Ile Glu Asp Asp Val Arg Arg Ile Asn Glu Arg Ile Arg Glu 20 25 30 Leu Leu Glu Lys Ile Arg Thr Glu Glu Val Leu Gln Arg Val Leu Glu 35 40 45 Glu His His Glu Leu Val Glu Arg Val Leu Arg Lys Leu Val Glu Ile 50 55 60 Leu Arg Lys His Glu Glu Glu Asn Arg 65 70 <210> SEQ ID NO 118 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 118 Gly Ser Asp Glu Glu Glu Tyr Tyr Lys Glu Lys Leu His Lys Leu Leu 1 5 10 15 Arg Glu Ile Glu Glu Leu Leu Lys His Tyr Arg Glu Leu Val Arg Arg 20 25 30 Leu Glu Glu Leu Val Lys Arg Gly Glu Leu Asp Lys Asp Thr Ala Ala 35 40 45 His Ile Leu Glu Arg Leu Ser Glu Leu Leu Glu Arg Ile Ile Arg Arg 50 55 60 Val Ala His Thr Leu Arg Arg Leu Ser Glu Glu Arg Arg 65 70 75 <210> SEQ ID NO 119 <211> LENGTH: 84 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 119 Gly Ser Asp Glu Asp Glu Ile Ser Tyr Asp Ser Lys Arg Arg Val Glu 1 5 10 15 Glu Ile Val Arg Gln Ala Arg Glu Lys Ser Glu Lys Ser Arg Lys Asp 20 25 30 Ile Glu Asp Val Ala Glu Val Leu Arg Lys Gly Asp Val Ser Glu Lys 35 40 45 Glu Val Val Asp Glu Leu Val Lys Val Leu Glu Glu Gln Val Lys Val 50 55 60 Leu Arg Glu Ala Val Glu Arg Leu Arg Glu Val Leu Lys Lys Gln Val 65 70 75 80 Asp Asp Val Arg <210> SEQ ID NO 120 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 120 Gly Ser Asp Ile Val Glu Leu Val Asp His Leu Leu Lys Arg Ser Leu 1 5 10 15 Lys Leu Leu Glu Glu Leu Ala Glu Leu Val Arg Arg Leu Leu Glu Lys 20 25 30 Ser Thr Glu Leu Leu Lys Arg Arg Thr Glu Glu His Lys Glu Glu Val 35 40 45 Val Glu Glu Ser Glu Tyr Met Val Arg Glu Leu Glu Glu Arg Leu Arg 50 55 60 Arg Val Val Asp Glu Ser Glu Lys Leu Val Arg Asp Ala Asp Lys His 65 70 75 80 Ile Arg <210> SEQ ID NO 121 <211> LENGTH: 83 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 121 Gly Ser Lys Glu Lys Asp Ile Val Lys Thr Leu Val Asp Leu Leu Arg 1 5 10 15 Glu Asn Leu Glu Thr Leu Glu Arg Leu Ile Glu Glu Val Val Arg Leu 20 25 30 Leu Lys Glu Asn Val Asp Val Arg Asp Glu Gly Arg Asp Asp Lys Asp 35 40 45 Ser Glu Arg Ile Leu Arg Asp Ile Lys Arg Arg Ile Asp Glu Ala Ala 50 55 60 Lys Glu Ser Arg Glu Ile Ile Glu Arg Ile Glu Lys Glu Val Glu Tyr 65 70 75 80 Arg Ser Arg <210> SEQ ID NO 122 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 122 Gly Ser Pro Glu Val Asp Val Leu Arg Arg Ile Val Arg Glu Ile Leu 1 5 10 15 Lys Ala Ser Glu Glu Leu Leu Arg Leu Leu Arg Lys Leu Ile Asp Glu 20 25 30 Ala Leu Lys Leu Ser Glu Arg Lys Arg Asp Ser Gln Glu Tyr Arg Glu 35 40 45 Val Val Asp Arg Val Lys Lys Glu Leu Glu Arg Leu Leu Asp Glu Tyr 50 55 60 Arg Lys Leu Val Glu Glu Leu Lys Glu Lys Leu Arg Tyr Asp Thr Arg 65 70 75 80 <210> SEQ ID NO 123 <211> LENGTH: 84 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 123 Gly Ser Asp Lys Arg Tyr Glu Ser Glu Lys Leu Lys Arg Arg Leu Asp 1 5 10 15 Glu Ala Val Glu Lys Val Arg Glu Val Val Glu Arg Val Glu Arg Glu 20 25 30 Ser Asp Arg Val Leu Glu Glu Val Arg Arg Arg Arg Glu Ser Lys Glu 35 40 45 Val Val Asp Lys Val Ile Glu Asp Asn Asp Lys Ala Leu Glu Asp Val 50 55 60 Leu Arg Val Val Asp Glu Val Ala Lys Val Val Arg Asp Val Val Arg 65 70 75 80 Glu Asn Thr Arg <210> SEQ ID NO 124 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 124 Gly Ser Pro Arg Glu Tyr His Ser Lys Asp Ile Leu Arg Lys Val Asp 1 5 10 15 Glu Ile Leu Glu Arg Ile Arg Arg His Ala Asp Arg Val Lys Lys Lys 20 25 30 Ser Glu Arg Leu Lys Arg Glu Asn Val Asp Val Asn Glu His Ser Lys 35 40 45 Asp Val Lys Arg Val Ile Arg Glu Leu Leu Glu Leu Val Lys Glu Leu 50 55 60 Leu Arg Leu Ala Lys Lys His Ser Asp Asp Gln Gln Glu 65 70 75 <210> SEQ ID NO 125 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 125 Gly Ser Asp Glu Asp Glu Ile Leu Tyr His Ser Glu Arg Leu Leu Gln 1 5 10 15 Lys Leu Lys Lys Glu Leu Asp Asp Leu Lys Glu Lys Ser Arg Glu Leu 20 25 30 Leu Glu Glu Leu Lys Lys Glu Asp Pro Asp Asp Arg Leu Ile Glu Arg 35 40 45 Ile Ile Arg Leu His Asp Glu Val Leu Lys Asp Leu Asp Glu Val Leu 50 55 60 Lys Asn Ile Leu Glu Val His Arg Glu Val Leu Glu Arg Leu Arg 65 70 75 <210> SEQ ID NO 126 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 126 Asp Lys Leu Asp Arg Leu Leu Lys Ile His Glu Glu Ala Leu Arg Arg 1 5 10 15 Ala Glu Glu Leu Ile Lys Arg Leu Leu Asp Ile His Arg Arg Ala Leu 20 25 30 Asp Leu Ala Arg Arg Gly Glu Leu Asp Asp Tyr Leu Leu Lys Glu Ser 35 40 45 Glu Arg Glu Leu Arg Glu Ile Ile Arg Arg Ala Arg Glu Glu Leu Lys 50 55 60 Glu Ser Arg Asp Arg Leu Glu Glu Ile Ser Arg 65 70 75 <210> SEQ ID NO 127 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 127 Gly Ser Pro Lys Glu Glu Leu Ile Arg Arg Val Leu Glu Glu Val Lys 1 5 10 15 Arg Leu Asn Glu Lys Leu Leu Glu Ile Ile Arg Arg Ala Ala Glu Leu 20 25 30 Val Lys Arg Ala Asn Asp Glu Leu Pro Glu Thr Glu Lys Leu Arg Glu 35 40 45 Ile Asp Arg Glu Leu Glu Lys Lys Leu Lys Glu Ile Glu Asp Glu Leu 50 55 60 Arg Arg Ile Asp Lys Glu Leu Asp Asp Ala Leu Tyr Glu Ile Glu Asp 65 70 75 80 <210> SEQ ID NO 128 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 128 Gly Ser Pro Lys Leu Asp Lys Leu Arg Glu Leu Leu Glu Arg Asn Leu 1 5 10 15 Glu Lys Leu Arg Glu Ile Leu Glu Glu Val Leu Lys Ile Leu Arg Thr 20 25 30 Asn Leu Glu Arg Val Arg Glu Asp Ile Arg Asp Glu Asp Val Leu Gln 35 40 45 Glu Tyr Glu Arg Leu Ile Arg Lys Ala Glu Glu Asp Leu Arg Arg Val 50 55 60 Leu Lys Glu Tyr Asp Asp Leu Leu Lys Lys Leu Val Tyr Glu Leu Arg 65 70 75 80 <210> SEQ ID NO 129 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 129 Gly Ser Lys Glu Asp Glu Ser Val Lys Arg Ala Glu Glu Ile Val Arg 1 5 10 15 Thr Leu Leu Lys Leu Leu Glu Asp Ser Leu Arg Glu Ala Glu Arg Ser 20 25 30 Leu Arg Asp Ile Lys Asn Gly Glu Asp Glu His Asn Leu Arg Arg Ile 35 40 45 Ser Glu Lys Leu Glu Glu Leu Ser Lys Arg Ile Thr Glu Thr Ile Glu 50 55 60 Arg Leu Leu Arg Glu Leu Gln Tyr Thr Ser Arg 65 70 75 <210> SEQ ID NO 130 <211> LENGTH: 84 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 130 Gly Ser Pro Asn Gln Glu Leu Leu Asp Arg Val Arg Lys Ile Leu Glu 1 5 10 15 Asp Leu Leu Arg Leu Asn Glu Glu Leu Val Arg Leu Asn Lys Glu Leu 20 25 30 Leu Lys Arg Ala Leu Glu Met Arg Arg Lys Asn Arg Asp Ser Glu Glu 35 40 45 Val Leu Glu Arg Leu Ala Glu Glu Tyr Arg Lys Arg Leu Glu Glu Tyr 50 55 60 Arg Arg Glu Leu Glu Lys Leu Leu Glu Glu Leu Glu Glu Thr Ile Tyr 65 70 75 80 Arg Tyr Lys Arg <210> SEQ ID NO 131 <211> LENGTH: 84 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 131 Gly Ser Asp Glu Ser Glu Glu Ala Gln His Glu Val Glu Lys Val Leu 1 5 10 15 Asp Asp Ile Arg Arg Leu Ser Glu His Leu Gln Lys Arg Leu Glu Glu 20 25 30 Val Leu Glu Glu Val Tyr Glu Leu Arg Arg Glu Gly Ser Asp Arg Thr 35 40 45 Glu Val Val Glu Leu Leu Lys Glu Val Ile Arg Glu Ile Val Arg Val 50 55 60 Asn Arg Glu Ala Leu Glu Arg Leu Leu Arg Val Val Glu Glu Ala Val 65 70 75 80 Lys Arg Asn Glu <210> SEQ ID NO 132 <211> LENGTH: 83 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 132 Gly Ser Asp Glu Glu Glu Leu Val Glu Thr Val Lys Arg Ile Gln Lys 1 5 10 15 Glu Ile Leu Asp Arg Leu Thr Glu Leu Ala Lys Leu Leu Val Glu Ile 20 25 30 Gln Arg Glu Ile Lys Lys Leu Lys Asp Glu Gly Glu Asp Asp Lys Glu 35 40 45 Leu Lys Arg Leu Ser Asp Glu Leu Glu Glu Lys Val Arg Gln Val Val 50 55 60 Glu Glu Ile Lys Arg Leu Ser Asp Glu Leu Glu Glu Thr Val Glu Tyr 65 70 75 80 Val Ser Arg <210> SEQ ID NO 133 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 133 Gly Ser Asp Glu Glu Glu Glu Val Val Arg Arg Ala Glu Glu Leu Val 1 5 10 15 Lys Glu His Glu Glu Leu Ile Glu Arg Val Ile Arg Thr His Glu Glu 20 25 30 Leu Val Tyr Lys Leu Glu Asp Gln Gly Ala Asp Lys Lys Leu Val Asp 35 40 45 Val Leu Lys Arg Val Val Glu Glu Ser Glu Arg Val Ala Arg Glu Ile 50 55 60 Val Lys Val Ser Arg Glu Leu Ile Arg Leu Leu Glu Glu Ala Ser Arg 65 70 75 80 <210> SEQ ID NO 134 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 134 Gly Ser Ser Lys Glu Glu Ile Leu Lys Glu Leu Glu Asp Leu Gln Arg 1 5 10 15 Arg Leu Ile Glu Glu Leu Lys Lys Leu Gln Glu Arg Val Val Glu Leu 20 25 30 Leu Glu Glu Leu Ile Lys Arg Leu Arg Asp Arg Gly Arg Asp Asp Lys 35 40 45 His Leu Lys Arg Leu Val Lys Glu Val Arg Arg Leu Ser Glu Glu Val 50 55 60 Leu Arg Ser Ile Lys Glu Val Ser Asp Arg Val Arg Tyr Gln Leu Arg 65 70 75 80 <210> SEQ ID NO 135 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 135 Gly Ser Asp Lys Glu Glu Glu Ser Glu Tyr Leu Leu Arg Asp Leu Val 1 5 10 15 Arg Leu Leu Glu Lys Val Lys Glu Lys Ile Glu Glu Val Asn Arg Glu 20 25 30 Val Glu Lys Leu Leu Lys Lys Val Lys Asp Gly Arg Leu Asp Arg Arg 35 40 45 Glu Val Leu Arg Glu Ile Leu Arg Leu Asn Arg Glu Leu Ala Glu Ile 50 55 60 Ile Lys Glu Val Val Asp Arg Ile Arg His Val Val Glu Arg Ser Glu 65 70 75 80 Arg <210> SEQ ID NO 136 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 136 Gly Ser Asp Leu His Glu Val Val Tyr Glu Thr Lys Glu Leu Leu Lys 1 5 10 15 Arg Ile Glu Glu Val Val Glu Glu Leu Arg Lys Lys Ser Glu Asp Ile 20 25 30 Ile Arg Lys Ala Glu Arg Gly Glu Ile Ser Glu Asp Glu Leu Lys Arg 35 40 45 Leu Gln Glu Glu Ile Ala Arg Glu Ala Lys Lys Leu Leu Asp Glu Ile 50 55 60 Lys Arg Val Leu Glu Arg His Leu Glu Gln Thr Leu 65 70 75 <210> SEQ ID NO 137 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 137 Gly Ser Pro Val Glu Glu Ile Ile Lys Glu Val Val Lys Arg Val Ile 1 5 10 15 Glu Val Gln Glu Lys Val Leu Arg Ile Ile Ser His Ala Val Lys Arg 20 25 30 Val Val Glu Val Gln Lys Lys Tyr Asp Pro Gly Ser Glu Glu Ser Asn 35 40 45 Arg Val Val Glu Glu Val Lys Lys Thr Ile Glu Asp Ala Ile Arg Glu 50 55 60 Ser Asp Glu Val Val Asp Glu Val Val Lys Arg Ile Gln Tyr Thr Val 65 70 75 80 Arg <210> SEQ ID NO 138 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 138 Gly Ser Pro Glu Gln Glu Ile Ala Asp Arg Ile Leu Thr Glu Ile Arg 1 5 10 15 Glu Ser Gln Lys Glu Leu Glu Arg Leu Ala Arg Lys Ile Leu Lys Leu 20 25 30 Leu Asp Glu Ser Gln Glu Lys Ala Lys Arg Gly Arg Leu Ser Glu Glu 35 40 45 Glu Ser Asp Glu Leu Leu Glu Arg Ile Lys Lys Glu Leu Asp Glu Leu 50 55 60 Leu Glu Arg Ser Lys Glu Leu Leu Lys Lys Ile Glu Tyr Glu Leu Arg 65 70 75 80 <210> SEQ ID NO 139 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 139 Gly Ser Asp Glu Asp Lys Glu Ala Asn Arg Val Leu Asp Glu Val Leu 1 5 10 15 Lys Thr Val Arg Asp Leu Leu Glu Thr Ala Asn Glu Val Leu Lys Glu 20 25 30 Val Leu Tyr Arg Leu Lys Arg Thr Asp Asp Gln Glu Lys Val Val Arg 35 40 45 Thr Leu Thr Glu Val Leu Lys Glu His Leu Lys Leu Val Glu Glu Ile 50 55 60 Val Arg Ile Leu Asp Lys Val Leu Lys Glu His Leu Glu Thr Glu Lys 65 70 75 80 <210> SEQ ID NO 140 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 140 Gly Ser Pro Glu Asp Asp Val Leu Arg Arg Leu Glu Glu Val Ser Glu 1 5 10 15 Lys Ile Leu Arg Val Ala Glu Asp Val Ala Arg Gln Leu Arg Glu Val 20 25 30 Ser Glu Lys Ile Thr Gln Gly Lys Val Asp Arg Lys Glu Trp Glu Glu 35 40 45 Asp Ile Lys Arg Leu Lys Arg Glu Leu Glu Glu Leu Leu Arg Glu Trp 50 55 60 Lys Glu Glu Ile Glu Arg Leu Thr Tyr Glu Leu Arg 65 70 75 <210> SEQ ID NO 141 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 141 Gly Ser Arg Arg Glu Glu Val Val Lys Arg Ile Arg Glu Leu Leu Lys 1 5 10 15 Arg Asn Lys Glu Leu Ile Asp Arg Ile Arg Glu Leu Leu Glu Glu Asn 20 25 30 Glu Tyr Leu Asp Lys Asp Ala Arg Asp Lys Asp Val Leu Arg Arg Ser 35 40 45 Val Glu Leu Leu Glu Glu Leu Val Arg Ile Leu Glu Glu Ser Val Glu 50 55 60 Leu Ala Lys Glu Ile Ile Lys Leu Leu Arg Glu Val Val Glu 65 70 75 <210> SEQ ID NO 142 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 142 Gly Ser Asp Glu Lys Glu Asp Asn Arg Arg Leu Gln His Lys Ile Glu 1 5 10 15 Arg Ile Leu Glu Lys Asn Glu Asp Leu Gln Arg Lys Leu Glu Glu Ile 20 25 30 Leu Glu Leu Leu Glu Arg Gly Glu Ala Asp Glu Glu Lys Ile Asp Arg 35 40 45 Leu Arg Lys Ala Val Glu Asp Tyr Arg Arg Val Val Glu Glu Ile Lys 50 55 60 Glu Asp Val Lys Arg His Lys Tyr Thr Val Arg 65 70 75 <210> SEQ ID NO 143 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 143 Gly Ser Asp Glu Lys Glu Glu Ala Lys Lys Ala Ser Glu Glu Ser Val 1 5 10 15 Arg Thr Val Glu Arg Ile Leu Glu Glu Leu Leu Lys Ala Ser Glu Glu 20 25 30 Ser Val Glu Leu Leu Arg Arg Gly Glu Asp Ala Lys Asp Val Val Glu 35 40 45 Arg Ser Lys Glu Ala Leu Lys Arg Val Lys Glu Leu Leu Asp Glu Val 50 55 60 Val Lys Arg Ser Asp Glu Ile Leu Lys Tyr Ile His Asn 65 70 75 <210> SEQ ID NO 144 <211> LENGTH: 84 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 144 Gly Ser Asp Glu Lys Lys Leu Ile Asn Glu Val Val Glu Thr Gln Lys 1 5 10 15 Arg Leu Ile Lys Glu Ala Ala Lys Arg Leu Ser Glu Val Val Arg His 20 25 30 Gln Thr Glu Leu Ile Arg Glu Leu Arg Glu Lys Asn Val Asp Asp Lys 35 40 45 Asp Val Glu Lys Leu Leu Lys Glu Ser Leu Asp Leu Ala Glu Glu Ile 50 55 60 Val Arg Arg Ile Lys Glu Leu Leu Asp Glu Ser Lys Lys Leu Val Glu 65 70 75 80 Tyr Val Ser Asn <210> SEQ ID NO 145 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 145 Gly Ser Pro Asp Met Asp Glu Val Lys Arg Val Leu Asp Glu Leu Ile 1 5 10 15 Glu Ile Gln Glu Glu Ile Leu Arg Glu Ile Lys Arg Val Leu Glu Lys 20 25 30 Leu Ile Lys Ile Gln Glu Asp Asn Gly Ser Glu Tyr Glu Ser Arg Glu 35 40 45 Val Val Arg Glu Ile Val Glu Ile Ala Arg Lys Leu Val Glu Arg Ser 50 55 60 Arg Arg Val Val Lys Lys Ile Thr Glu Thr Leu Gln 65 70 75 <210> SEQ ID NO 146 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 146 Gly Ser Asp Glu Arg Tyr Ala Thr Arg Glu Ile Val Glu Arg Ile Glu 1 5 10 15 Arg Ile Ala Arg Glu Ile Leu Lys Arg Thr Glu Glu Ile Val Arg Glu 20 25 30 Val Arg Glu Val Leu Ser Arg Asp Val Asp Gln Glu Glu Val Val Arg 35 40 45 Arg Leu Ala Asp Leu Leu Arg Glu Ser Val Glu Leu Val Gln His Leu 50 55 60 Val Arg Arg Val Glu Glu Leu Leu Gln Glu Ser Val Glu Arg Lys Lys 65 70 75 80 <210> SEQ ID NO 147 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 147 Gly Ser Pro Glu Arg Glu Ala Leu Arg Glu Val Leu Glu Asp Leu Lys 1 5 10 15 Arg Val Thr Asp Arg Leu Arg Glu Leu Val Glu Arg Val Leu Glu Glu 20 25 30 Leu Lys Lys Val Thr Asp His Val Asp Ser Glu Arg Ile Leu Arg Glu 35 40 45 Ser Arg Arg Val Leu Lys Glu Leu Lys Asp Ile Ile Glu Glu Ile Leu 50 55 60 Arg Glu Ser Glu Lys Val Leu Glu Lys Leu Lys Tyr Thr Glu Asp 65 70 75 <210> SEQ ID NO 148 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 148 Gly Ser Pro Ala Arg Glu Ile Leu Glu Glu Val Val Lys Lys His Leu 1 5 10 15 Glu Val Val Glu Asp Ala Ala Arg Ile Leu Glu Glu Ile Ile Arg Glu 20 25 30 His Glu Lys Ala Val Arg Glu Asp Arg Asp Lys Lys Glu Leu Glu Glu 35 40 45 Ile Ser Arg Asp Leu Leu Arg Lys Ala Arg Glu Ala Leu Lys Lys Val 50 55 60 Lys Asp Ile Ser Asp Asp Leu Ser Arg Glu Ile Glu Tyr Val Ala Ser 65 70 75 80 <210> SEQ ID NO 149 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 149 Gly Ser Pro Val Glu Glu Ala Ile Lys Lys Val Ile Asp Asp Leu Arg 1 5 10 15 Asp Val Gln Arg Lys Ile Arg Glu Leu Val Glu Glu Leu Ile Arg Leu 20 25 30 Leu Glu Glu Val Gln Arg Asp Asn Asp Lys Arg Glu Ser Glu Tyr Val 35 40 45 Val Glu Arg Val Glu Glu Ile Leu Arg Arg Ile Thr Glu Thr Ser Arg 50 55 60 Glu Val Val Arg Lys Ala Val Glu Asp Leu Ser 65 70 75 <210> SEQ ID NO 150 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 150 Gly Ser Asp Ser Asp Glu Lys Ala Glu Tyr Leu Leu Lys Glu Met Glu 1 5 10 15 Arg Val Val Arg Glu Ser Asp Glu Val Val Lys Lys Ile Leu Arg Asp 20 25 30 Leu Glu Glu Val Leu Glu Arg Leu Arg Arg Gly Glu Ile Ser Glu Asp 35 40 45 Asp Val Thr Glu Ile Leu Lys Glu Leu Ala Glu Arg His Ile Arg Ala 50 55 60 Ile Glu Glu Leu Val Arg Arg Leu Arg Glu Leu Leu Glu Arg His Lys 65 70 75 80 Arg <210> SEQ ID NO 151 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 151 Gly Ser Pro Val Glu Glu Val Leu Lys Glu Leu Ser Glu Val Asn Glu 1 5 10 15 Arg Val Arg Asp Ile Ala Arg Glu Ile Ile Glu Arg Leu Ser Glu Val 20 25 30 Asn Glu Glu Val Lys Glu Thr Asp Asp Glu Asp Glu Leu Lys Lys Ile 35 40 45 Ser Lys Lys Val Val Asp Glu Val Glu Asp Leu Leu Arg Lys Ile Leu 50 55 60 Glu Val Ser Glu Glu Val Val Arg Arg Val Glu Tyr His Asp Arg 65 70 75 <210> SEQ ID NO 152 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 152 Gly Ser Pro Lys Glu Asp Ile Leu Arg Glu Val Leu Arg Arg His Lys 1 5 10 15 Glu Ile Val Arg Glu Ile Val Arg Leu Val Arg Glu Ala Val Glu Thr 20 25 30 His Leu Glu Leu Val Lys Arg Asn Ser Asp Asp Arg Asp Ala Gln Asp 35 40 45 Val Ile Arg Lys Leu Glu Glu Asp Leu Glu Arg Leu Val Arg His Ala 50 55 60 Gln Glu Val Ile Glu Glu Ile Phe Tyr Arg Leu His 65 70 75 <210> SEQ ID NO 153 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 153 Gly Ser Pro Arg Ser Tyr Leu Leu Lys Glu Leu Ala Asp Leu Ser Gln 1 5 10 15 His Leu Val Arg Leu Leu Glu Arg Leu Val Arg Glu Ser Glu Arg Val 20 25 30 Val Glu Val Leu Glu Arg Gly Glu Val Asp Glu Glu Glu Leu Lys Arg 35 40 45 Leu Glu Asp Leu His Arg Glu Leu Glu Lys Ala Val Arg Glu Val Arg 50 55 60 Glu Thr His Arg Glu Ile Arg Glu Arg Ser Arg 65 70 75 <210> SEQ ID NO 154 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 154 Gly Ser Asp Arg Glu Tyr Ile Ile Lys Asp Ile Leu Asp Ser Gln Glu 1 5 10 15 His Leu Leu Arg Leu Ile Glu Glu Leu Leu Glu Thr Gln Lys Glu Leu 20 25 30 Leu Glu Ile Leu Lys Arg Arg Pro Asp Ser Val Glu Arg Val Arg Glu 35 40 45 Leu Val Arg Arg Ser Lys Glu Ile Ala Asp Glu Ile Arg Arg Gln Ser 50 55 60 Asp Arg Asn Val Arg Leu Leu Glu Glu Val Ser Lys 65 70 75 <210> SEQ ID NO 155 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 155 Gly Ser Asp Glu Lys Asp Glu Ile Arg His Val Ile Glu Ser Val Glu 1 5 10 15 Arg Leu Ile Glu Asp Ile Lys Arg Leu Leu Lys Thr Leu Arg Glu Leu 20 25 30 Ala His Asp Asp Ser Asp Lys Lys Thr Val Lys Glu Val Leu Asp Arg 35 40 45 Val Lys Glu Met Ile Glu Arg His Arg Arg Glu Leu Glu Glu His Arg 50 55 60 Lys Glu Leu Glu Arg Ala Glu Tyr Glu Val Arg 65 70 75 <210> SEQ ID NO 156 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 156 Gly Ser Glu Ser Glu Asp Arg Ile Lys Glu Leu Leu Lys Arg His Ile 1 5 10 15 Glu Leu Val Glu Arg His Glu Glu Leu Leu His Glu Ile Lys Lys Leu 20 25 30 Ile Asp Leu Glu Glu Lys Asp Asp Lys Asp Arg Glu Glu Ala Val Lys 35 40 45 Arg Ile Asp Asp Ala Ile Lys Glu Ser Glu Glu Met Leu Glu Glu Ser 50 55 60 Lys Glu Ile Leu Glu Glu Ile Glu Tyr Leu Asn Arg 65 70 75 <210> SEQ ID NO 157 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 157 Gly Ser Ser Leu Glu Asp Ser Val Arg Leu Asn Asp Glu Val Val Lys 1 5 10 15 Val Val Glu Arg Val Val Arg Leu Asn Gln Glu Val Val Arg Leu Ile 20 25 30 Lys His Ala Thr Asp Val Glu Asp Glu Glu Thr Val Lys Tyr Val Leu 35 40 45 Glu Arg Val Arg Glu Val Leu Asp Glu Ser Arg Glu Val Leu Lys Arg 50 55 60 Val His Glu Leu Leu Glu Glu Ser Glu Arg Arg Leu Glu 65 70 75 <210> SEQ ID NO 158 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 158 Gly Ser His Glu Lys Asp Ile Val Tyr Lys Val Glu Asp Leu Val Arg 1 5 10 15 Lys Ser Asp Arg Ile Ala Glu Arg Ala Arg Glu Ile Val Lys Arg Ser 20 25 30 Arg Asp Ile Met Arg Glu Ile Arg Lys Asp Lys Asp Asn Lys Lys Leu 35 40 45 Ser Asp Asp Leu Leu Lys Val Thr Arg Asp Leu Gln Arg Val Val Asp 50 55 60 Glu Leu Glu Glu Leu Ser Arg Glu Leu Leu Arg Val Ala Glu Glu Ser 65 70 75 80 Arg Lys <210> SEQ ID NO 159 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 159 Gly Ser Pro Glu Leu Asp Glu Val Lys Lys Leu Ile Asp Glu Leu Lys 1 5 10 15 Lys Ser Val Glu Arg Leu Glu Glu Ser Ile Arg Glu Val Lys Glu Ser 20 25 30 Ile Lys Lys Leu Arg Lys Gly Asp Ile Asp Ala Glu Glu Asn Ile Lys 35 40 45 Leu Leu Lys Glu Asn Ile Lys Ile Val Arg Glu Asn Ile Lys Ile Ile 50 55 60 Lys Glu Ile Ile Asp Val Val Gln Tyr Val Leu Arg 65 70 75 <210> SEQ ID NO 160 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 160 Gly Ser Asp Glu Glu Glu Ile Glu Glu Leu Leu Arg Glu Leu Glu Lys 1 5 10 15 Leu Leu Lys Lys Ser Glu Glu Ala Leu Glu Glu Ser Lys Lys Leu Ile 20 25 30 Asp Glu Ser Glu Glu Leu Leu Arg Arg Asp Arg Leu Asp Lys Glu Lys 35 40 45 His Val Arg Ala Ser Glu Glu His Val Lys Leu Ser Glu Glu His Leu 50 55 60 Arg Ile Ser Arg Glu Ile Val Lys Ile Leu Glu Lys Ala Val Tyr Ser 65 70 75 80 Thr Arg <210> SEQ ID NO 161 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 161 Gly Ser Asp Glu Ser Asp Arg Ile Arg Lys Ile Val Glu Glu Ser Asp 1 5 10 15 Glu Ile Val Lys Glu Ser Arg Lys Leu Ala Glu Arg Ala Arg Glu Leu 20 25 30 Ile Lys Glu Ser Glu Asp Lys Arg Val Ser Glu Glu Arg Asn Glu Arg 35 40 45 Leu Leu Glu Glu Leu Leu Arg Ile Leu Asp Glu Asn Ala Glu Leu Leu 50 55 60 Lys Arg Asn Leu Glu Leu Leu Lys Glu Val Leu Tyr Arg Thr Arg 65 70 75 <210> SEQ ID NO 162 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 162 Gly Ser Asp Glu Asp Asp Glu Leu Glu Arg Leu Leu Arg Glu Tyr His 1 5 10 15 Arg Val Leu Arg Glu Tyr Glu Lys Leu Leu Glu Glu Leu Arg Arg Leu 20 25 30 Tyr Glu Glu Tyr Lys Arg Gly Glu Val Ser Glu Glu Glu Ser Asp Arg 35 40 45 Ile Leu Arg Glu Ile Lys Glu Ile Leu Asp Lys Ser Glu Arg Leu Trp 50 55 60 Asp Leu Ser Glu Glu Val Trp Arg Thr Leu Leu Tyr Gln Ala Glu 65 70 75 <210> SEQ ID NO 163 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 163 Gly Ser Asp Lys Lys Asp Ala Ser Arg Arg Ala Ile Arg Val Leu His 1 5 10 15 Glu Phe Val Arg Val Ser Glu Glu Val Leu Glu Val Leu Arg Lys Ser 20 25 30 Val Glu Ser Leu Lys Arg Leu Asp Val Asp Glu Lys Ile Lys Arg Thr 35 40 45 His Asp Arg Ile Glu Glu Glu Leu Arg Arg Trp Lys Arg Glu Leu Glu 50 55 60 Glu Leu Ile Glu Arg Leu Arg Glu Trp Glu Tyr His Gln Asp 65 70 75 <210> SEQ ID NO 164 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 164 Gly Ser Asp Asp Glu Glu Glu Asp Lys Arg Leu Leu Glu Glu Val Lys 1 5 10 15 Arg Ser Leu Asp Thr Asp Glu Arg Ile Leu Glu Lys Leu Arg His Ser 20 25 30 Leu Glu Arg Gln Leu Glu Asp Val Asp Lys Asp Glu Asp Ser Arg Arg 35 40 45 Val Leu Arg Glu Leu Asp Glu Ile Thr Lys Arg Ser Arg Glu Val Val 50 55 60 Lys Arg Leu Arg Lys Leu Ala Tyr Glu Ser Lys 65 70 75 <210> SEQ ID NO 165 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 165 Gly Ser Asp Lys Glu Tyr Lys Leu Asp Arg Ile Leu Arg Arg Leu Asp 1 5 10 15 Glu Leu Ile Lys Gln Leu Ser Arg Ile Leu Glu Glu Ile Glu Arg Leu 20 25 30 Val Asp Glu Leu Glu Arg Glu Pro Leu Asp Asp Lys Glu Val Gln Asp 35 40 45 Val Ile Glu Arg Ile Val Glu Leu Ile Asp Glu His Leu Glu Leu Leu 50 55 60 Lys Glu Tyr Ile Lys Leu Leu Glu Glu Tyr Ile Lys Thr Thr Lys 65 70 75 <210> SEQ ID NO 166 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 166 Gly Ser Pro Ser Lys Glu Tyr Gln Glu Lys Ser Ala Glu Arg Gln Lys 1 5 10 15 Glu Leu Leu His Glu Tyr Glu Lys Leu Val Arg His Leu Arg Glu Leu 20 25 30 Val Glu Lys Leu Gln Arg Arg Glu Leu Asp Lys Glu Glu Val Leu Arg 35 40 45 Arg Leu Val Glu Ile Leu Glu Arg Leu Lys Asp Leu His Lys Lys Ile 50 55 60 Glu Asp Ala His Arg Lys Asn Glu Glu Ala His Lys Glu Asn Lys 65 70 75 <210> SEQ ID NO 167 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 167 Gly Ser Arg Asp Arg Lys Ile Ser Glu Glu Leu Ile Lys Ala Leu Glu 1 5 10 15 Asp His Ile Arg Met Leu Glu Glu Leu Ile Arg Ala Ile Glu Glu His 20 25 30 Ile Lys Leu Ala Glu Arg Gly Val Asp Glu Lys Glu Leu Arg Glu Ser 35 40 45 Leu Glu Glu Leu Lys Lys Ile Val Asp Glu Leu Glu Lys Ser Leu Glu 50 55 60 Glu Leu Arg Lys Leu Ala Glu Arg Tyr Lys Tyr Glu Thr Arg 65 70 75 <210> SEQ ID NO 168 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 168 Gly Ser Pro Lys Glu Glu Ser Val Glu Glu Leu Lys Arg Val Ile Asp 1 5 10 15 Lys His Glu Glu Ile Leu Arg Glu Leu Lys Arg Val Leu Glu Glu His 20 25 30 Glu Arg Val Ser His Asp Glu Asp Glu Asn Glu Leu Arg Arg Ser Leu 35 40 45 Glu Arg Leu Lys His Ile Leu Asp Arg Leu His Glu Ser Leu Lys Glu 50 55 60 Leu His Glu Leu Leu Lys Lys Asn Glu Tyr Thr Glu Arg 65 70 75 <210> SEQ ID NO 169 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 169 Gly Ser Asp His Glu Tyr Trp Val Lys Ile Val Glu Arg Ile Leu Arg 1 5 10 15 Val Met Glu Lys His Ala Glu Ile Val Lys Lys His Leu Glu Ile Val 20 25 30 Glu Arg Val Val Arg Glu Gly Pro Ser Glu Asp Leu Arg Arg Lys Leu 35 40 45 Lys Glu Ser Leu Arg Glu Ile Glu Glu Ser Leu Arg Glu Leu Lys Glu 50 55 60 Leu Leu Asp Glu Leu Asp Glu Leu Ser Glu Lys Thr Arg 65 70 75 <210> SEQ ID NO 170 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 170 Gly Ser Asp Glu Glu Tyr Val Thr Arg Ser Gln Arg Arg Leu Lys Arg 1 5 10 15 Leu Leu Glu Glu Tyr Ile Lys Val Val Glu Glu His Ala Arg Leu Val 20 25 30 Glu Arg Asn Glu Arg Asp Asp Lys Glu Leu Lys Arg Ser Ile Asp Glu 35 40 45 Leu Asp Lys Leu Thr Lys Glu Leu Leu Glu Leu Val Lys Arg Tyr Lys 50 55 60 Glu Leu Val Asp Lys Thr Glu Thr 65 70 <210> SEQ ID NO 171 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 171 Gly Ser Asp Lys Glu Glu Ile Val Lys Leu Gln Asp Glu Val Ile Lys 1 5 10 15 Thr Leu Glu Arg His Leu Asp Ile Leu Arg Lys His Ile Asp Leu Leu 20 25 30 Glu Lys Leu Lys Asp His Leu Ser Glu Glu Leu Lys Glu Arg Val Asp 35 40 45 Arg Ser Ile Lys Lys Leu Glu Glu Ser Ile Lys Arg Leu Glu Arg Ile 50 55 60 Ile Glu Glu Leu Gln Glu Leu Ala Glu Tyr Ser Leu 65 70 75 <210> SEQ ID NO 172 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 172 Gly Ser Arg Glu Glu Glu Leu Lys Glu Ser Ala Glu Glu Leu Glu Arg 1 5 10 15 Ser Val Arg Glu Leu Lys Lys Glu Ala Asp Lys Tyr Lys Glu Glu Val 20 25 30 Asp Arg Leu His Tyr Arg Gly Lys Val Asp Lys Asp Trp Val Arg Val 35 40 45 Val Glu Lys Leu Ile Lys Leu Val Glu Glu His Leu Glu Leu Ile Arg 50 55 60 Glu His Leu Glu Leu Leu Lys Glu Glu Arg Arg 65 70 75 <210> SEQ ID NO 173 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 173 Gly Ser Asp Met Glu Tyr Glu Leu Lys Lys Ser Ala Glu Glu Leu Arg 1 5 10 15 Lys Ser Leu Glu Glu Leu Lys Arg Ile Leu Asp Glu Leu His Lys Ser 20 25 30 Leu Arg Glu Leu Arg Arg His Gly Asp Asp Glu Glu Tyr Val Gln Thr 35 40 45 Val Glu Glu Leu Arg Lys Glu Leu Glu Glu His Ala Lys Lys Leu Glu 50 55 60 Glu His Leu Lys Glu Leu Glu Arg Val Ala Thr 65 70 75 <210> SEQ ID NO 174 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 174 Pro Glu Tyr Glu Leu Lys Lys Ser Val Asp Asp Leu Lys Arg Asp Val 1 5 10 15 Asp Arg Leu Val Glu Glu Val Glu Glu Val Phe Glu Leu Ser Lys Glu 20 25 30 Arg Leu Arg Glu Asp Arg Lys His Leu Glu Leu Val Glu Glu Met Val 35 40 45 Arg Leu Ile Glu Lys His Leu Glu Leu Ile Lys Glu His Leu Lys Leu 50 55 60 Ala Asp Asp His Val Arg 65 70 <210> SEQ ID NO 175 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 175 Gly Ser Arg Glu Lys Asp Glu Ser Lys Glu Leu Asn Asp Glu Tyr Lys 1 5 10 15 Lys Leu Leu Glu Glu Tyr Glu Arg Leu Leu Arg Arg Ser Glu Glu Leu 20 25 30 Val Lys Arg Ala Lys Gly Pro Arg Asp Glu Lys Glu Leu Lys Arg Ile 35 40 45 Leu Glu Glu Asn Glu Asp Ile Leu Arg Arg Thr Lys Glu Ile Leu Glu 50 55 60 Arg Thr Lys Glu Ile Ser Glu Glu Gln Lys Tyr Arg Arg Arg 65 70 75 <210> SEQ ID NO 176 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 176 Gly Ser Asp Lys Asp Glu Arg Gln Glu Arg Leu Asn Glu Glu Ser Asp 1 5 10 15 Lys Ser Asn Glu Glu Ser Glu Arg Ser Asn Arg Glu Ser Glu Glu Leu 20 25 30 Asn Arg Arg Ala Arg Gly Pro Asn Asp Glu Lys Glu Leu Gln Glu Ile 35 40 45 Leu Asp Arg His Leu Glu Leu Leu Glu Arg Asn Gln Arg Leu Leu Asp 50 55 60 Glu Asn Lys Glu Ile Leu Arg Glu Ser Gln Tyr Leu Asn Asp 65 70 75 <210> SEQ ID NO 177 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 177 Gly Ser Glu Asn Lys Tyr Ile Leu Lys Glu Ile Leu Lys Leu Leu Arg 1 5 10 15 Glu Asn Leu Lys Leu Leu His Asp Ile Leu Arg Leu Leu Asp Glu Asn 20 25 30 Leu Glu Glu Leu Glu Lys His Gly Ala Lys Asp Leu Asp Asp Tyr Arg 35 40 45 Arg Lys Ile Glu Glu Ile Arg Lys Lys Val Glu Asp Tyr Arg Glu Lys 50 55 60 Ile Glu Glu Ile Glu Lys Lys Val Glu Arg Asp Arg 65 70 75 <210> SEQ ID NO 178 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 178 Gly Ser Glu Ser Glu Tyr Thr Gln Glu Glu Ile Leu Glu Leu Leu Lys 1 5 10 15 Glu Ser Ile Lys Leu Leu Arg Glu Ile Leu Arg Leu Leu Glu Glu Ser 20 25 30 Glu Glu Leu Trp Arg Arg Glu Asn Thr Lys Ser Glu Arg Ser Glu Glu 35 40 45 Ile Lys Glu Arg Ala Lys Glu Ala Ile Lys Arg Ser Glu Glu Ile Leu 50 55 60 Glu Arg Val Lys Arg Leu Ser Asp His Ser Arg 65 70 75 <210> SEQ ID NO 179 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 179 Gly Ser Asp Glu Glu Glu Ala Asn Tyr Val Ser Asp Lys Ala Val Lys 1 5 10 15 Ile Ala Glu Asp Val Gln Glu Leu Leu Lys Glu Leu Leu Glu Leu Ser 20 25 30 Glu Val Val Arg Arg Gly Glu Val Asp Glu Asp Glu Tyr Asp Arg Val 35 40 45 Leu Arg Lys Leu Gln Glu Val Met Lys Glu Tyr Glu Glu Val Leu Lys 50 55 60 Glu Tyr Glu Glu Val Ser Arg Lys His Glu 65 70 <210> SEQ ID NO 180 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 180 Gly Ser Pro Glu Lys Tyr Leu Ile Lys Thr Gln Glu Glu Leu Leu Arg 1 5 10 15 Arg His Ala Glu Ile Leu Glu Asp Leu Ile Arg Lys Val Glu Arg Gln 20 25 30 Val Asp Leu Arg Arg Lys Val Asp Glu Arg Asp Glu Asp Leu Lys Arg 35 40 45 Glu Leu Glu Arg Ser Leu Arg Glu Leu Glu Arg Leu Val Arg Glu Ser 50 55 60 Ser Arg Leu Val Glu Glu Ile Arg Glu Leu Ser Lys Glu Ile Lys Arg 65 70 75 80 <210> SEQ ID NO 181 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 181 Gly Ser Asp Glu Glu Tyr Glu Leu Glu Arg Ile Ser Arg Glu Ser Lys 1 5 10 15 Glu Leu Leu Glu Arg Tyr Lys Arg Leu Leu Arg Glu Tyr Gln Glu Leu 20 25 30 Leu Lys Glu Leu Arg His Val Lys Asp Leu Asp Arg Ala Val Lys Ile 35 40 45 Ile His Glu Leu Met Arg Val Ser Lys Glu Leu Val Glu Ile Ser His 50 55 60 Arg Leu Leu Glu Leu His Glu Arg Leu Val Arg Arg Arg Lys 65 70 75 <210> SEQ ID NO 182 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 182 Gly Ser Glu Lys Glu Tyr Ile Glu Lys Leu Ser Arg Lys Ile Glu Glu 1 5 10 15 Asp Ile Arg Arg Ser Glu Glu Arg Ala Lys Asp Ser Glu Arg Leu Val 20 25 30 Arg Arg Leu Glu Glu Leu Ala Lys Arg Lys Arg Leu Asp Leu Asp Asp 35 40 45 Val Leu Arg Val Ala Glu Glu Asn Leu Glu Ile Leu Glu Asp Asn Leu 50 55 60 Arg Ile Leu Glu Glu Ile Leu Lys Glu Gln Asp Lys Ser Asn Arg 65 70 75 <210> SEQ ID NO 183 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 183 Gly Ser Pro His Glu Glu Val Val Glu Leu His Glu Arg Val Met Glu 1 5 10 15 Ile Ser Glu Arg Ala Val Glu Leu Ile Gln Arg Ile Ile Asp Ile Ile 20 25 30 Arg Arg Ile Arg Glu Asp Asp Lys Asp Ile Glu Lys Leu Val Lys Thr 35 40 45 Ile Arg Asp Leu Val Arg Glu Tyr Glu Glu Leu His Arg Glu Leu Glu 50 55 60 Glu Ile Asp Glu Glu Ile Tyr Lys Lys Ser Glu 65 70 75 <210> SEQ ID NO 184 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 184 Gly Ser Asp His Glu Asp Val Val Arg Leu His Glu Asp Leu Val Arg 1 5 10 15 Lys Gln Glu Asp Ala Arg Arg Val Leu Glu Glu Ile Val Arg Leu Ala 20 25 30 Glu Glu Ile Val Glu Val Ile Lys Lys Asp Glu Lys Asp Lys Asp Arg 35 40 45 Val Thr Arg Leu Val Glu Glu Ile Glu Lys Leu Val Glu Glu Tyr Lys 50 55 60 Lys Lys Val Asp Glu Met Arg Lys Ile Ser Asp Glu Ile Lys Tyr Arg 65 70 75 80 Ser Arg <210> SEQ ID NO 185 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 185 Gly Ser Arg Ala Arg Glu Val Val Lys Arg Ala Lys Arg Ile Ile Glu 1 5 10 15 Glu Trp Gln Lys Ile Leu Glu Glu Trp Arg Arg Ile Leu Glu Glu Trp 20 25 30 Arg Arg Leu Leu Glu Asp Glu Arg Val Asp Asp Arg Asp Asn Glu Arg 35 40 45 Ile Ile Arg Glu Asn Glu Arg Val Ile Arg Glu Asn Glu Lys Ile Ile 50 55 60 Arg Asp Val Ile Arg Leu Leu Glu Glu Leu Leu Tyr Glu Arg Arg 65 70 75 <210> SEQ ID NO 186 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 186 Gly Ser Arg Glu Asp Glu Glu Leu Glu Glu Glu Ile Asp Arg Ile Arg 1 5 10 15 Gln Met Val Glu Glu Tyr Glu Glu Leu Val Lys Glu Tyr Glu Glu Leu 20 25 30 Thr Glu Lys Tyr Lys Gln Gly Lys Val Asp Lys Glu Glu Ser Lys Lys 35 40 45 Ile Ile Glu Lys Ser Glu Arg Leu Leu Asp Leu Ser Gln Asp Ala Val 50 55 60 Arg Lys Val Lys Glu Ile Ile Arg Arg Ile Leu Tyr Thr Asn Arg 65 70 75 <210> SEQ ID NO 187 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 187 Gly Ser Pro Lys Glu Glu Ile Val Lys Leu His Asp Glu Ser Ala Glu 1 5 10 15 Leu His Arg Arg Ser Val Glu Val Ala Asp Glu Ile Leu Lys Met His 20 25 30 Glu Arg Ser Lys Asp Val Asp Asp Glu Arg Glu Ser Arg Glu Leu Ser 35 40 45 Lys Glu Ile Glu Arg Leu Ile Arg Glu Val Glu Glu Val Ser Lys Arg 50 55 60 Ile Lys Arg Leu Ser Glu Glu Val Glu Tyr Leu Val Arg 65 70 75 <210> SEQ ID NO 188 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 188 Gly Ser Pro Leu Glu Glu Ile Leu Lys Ile Gln Arg Arg Ile Asn Lys 1 5 10 15 Ile Gln Asp Asp Ile Asn Lys Ile Leu His Glu Ile Leu Arg Met Gln 20 25 30 Glu Lys Leu Asn Arg Ser Ser Asp Lys Asp Glu Val Glu Glu Ser Leu 35 40 45 Arg Arg Ile Arg Glu Leu Ile Lys Arg Ile Lys Asp Leu Ser Lys Glu 50 55 60 Ile Glu Asp Leu Ser Arg Glu Val Lys Tyr Arg Thr Thr 65 70 75 <210> SEQ ID NO 189 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 189 Gly Ser Pro Glu Asp Glu His Val Tyr Val Val Arg Glu Ile Tyr Glu 1 5 10 15 Val Leu Arg Glu His Ala Glu Val Leu Glu Glu Asn Arg Glu Val Ile 20 25 30 Glu Arg Leu Leu Glu Ala Lys Lys Arg Gly Asp Lys Ser Glu Glu Leu 35 40 45 Val Lys Glu Leu Lys Lys Ser Ile Asp Lys Leu Lys Glu Ile Ser Arg 50 55 60 Lys Leu Glu Glu Ile Val Lys Glu Leu Glu Lys Val Ser Glu Lys Leu 65 70 75 80 Lys <210> SEQ ID NO 190 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 190 Gly Ser Asp Glu Asp Glu Thr Ser Tyr Arg Ile Leu Glu Leu Leu Arg 1 5 10 15 Glu Ile Val Arg Ala Ser Arg Glu Leu Ile Arg Leu Ser Glu Glu Leu 20 25 30 Leu Glu Val Ala Arg Arg Asp Asp Lys Asp Glu Thr Val Leu Glu Thr 35 40 45 Leu Ile Arg Glu Tyr Lys Glu Leu Leu Asp Arg Tyr Arg Arg Leu Ile 50 55 60 Glu Glu Leu Thr Arg Leu Val Glu Glu Tyr Glu Glu Arg Ser Arg 65 70 75 <210> SEQ ID NO 191 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 191 Gly Ser Thr Gln Glu Glu Ile Asn Arg Ile Gln His Glu Val Leu Arg 1 5 10 15 Ile Gln Glu Glu Ile Asp Glu Ile Leu Arg Asp Ile Val Glu Lys Leu 20 25 30 Lys Ala Ile Ser Arg Gly Glu Leu Asp His Glu Val Val Lys Asp Val 35 40 45 Glu Asp Lys Val Arg Glu Ala Leu Glu Lys Ser Glu Glu Leu Leu Asp 50 55 60 Lys Ser Arg Lys Val Glu Tyr Lys Ser Glu 65 70 <210> SEQ ID NO 192 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 192 Gly Ser Asp Glu Glu Glu Leu Asn Arg Glu Leu Leu Glu Lys Ser Lys 1 5 10 15 Arg Leu Val Asp Ile Asn Arg Asp Ile Ile Arg Thr Ala Gln Glu Leu 20 25 30 Ile Glu Met Leu Lys Asp Ser Lys Asp Gly Arg Val Asp Glu Asp Thr 35 40 45 Lys Arg Glu Leu Arg Asp Lys Leu Arg Lys Leu Glu Glu Lys Leu Glu 50 55 60 Arg Val Arg Glu Glu Leu Arg Lys Tyr Glu Glu Leu Leu Arg Tyr Val 65 70 75 80 Gln Arg <210> SEQ ID NO 193 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 193 Gly Ser Asp Glu Lys Asp Arg Val Tyr Glu Ile Leu Lys Glu Val Gln 1 5 10 15 Arg Leu Val Lys Glu Tyr Arg Asp Ile Ser Lys Glu Ile Glu Asp Leu 20 25 30 Val Lys His Tyr Glu His Ile Thr Asp Asp Glu Ala Gln Glu Val Ser 35 40 45 Lys Glu Leu Ile Asp Lys Ser Leu Arg Ala Ser Glu Ile Val Arg Glu 50 55 60 Leu Ile Arg Leu Ile Lys Glu Leu Leu Asp Glu Leu Glu 65 70 75 <210> SEQ ID NO 194 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 194 Gly Ser Asp Glu Glu Asp Val Leu Tyr His Leu Arg Glu Leu Leu Glu 1 5 10 15 Glu Leu Lys Arg Val Ser Asp Asp Tyr Glu Arg Leu Val Arg Glu Ile 20 25 30 Lys Glu Thr Ser Glu Arg Lys Asp Arg Asp Thr Lys Glu Asn Lys Asp 35 40 45 Met Leu Asp Glu Leu Val Lys Ala His Arg Glu Gln Glu Lys Leu Leu 50 55 60 Glu Arg Leu Val Arg Leu Leu Glu Glu Leu Phe Glu Arg Lys Arg 65 70 75 <210> SEQ ID NO 195 <211> LENGTH: 54 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 195 Pro Arg Glu Gln Ala Ile Arg Ile Ser Glu Glu Ile Ile Arg Ile Ser 1 5 10 15 Lys Lys Ile Ile Glu Ile Leu Glu Arg Thr Arg Ser Ser Thr Ala Arg 20 25 30 Glu Ala Met Lys Trp Ala Lys Asp Ser Ile Arg Leu Ala Glu Glu Ser 35 40 45 Lys Tyr Leu Leu Asp Lys 50 <210> SEQ ID NO 196 <211> LENGTH: 54 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 196 Ile Glu Asp Asp Val Lys Lys Ile Gln Asp Ser Thr Lys Lys Ala Gln 1 5 10 15 Lys Glu Thr Ile Glu Ala Leu Glu Arg Ser Thr Ser Ser Thr Ala Arg 20 25 30 Lys Gln Met Glu Glu Gln Lys Glu Gln Ile Arg Leu Gln Lys Glu Ala 35 40 45 Met Tyr Leu Leu Lys Lys 50 <210> SEQ ID NO 197 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 197 Ser Arg Glu Glu Ile Ala Lys Leu Gln Glu Glu Val Ile Lys Leu Gln 1 5 10 15 Arg Arg Val Ile Glu Leu Gln Lys Glu Val Ile Glu Leu Gln Arg Arg 20 25 30 Ala Lys Glu Leu Thr Ser Ser Tyr Thr Lys Glu Ile Leu Glu Ile Gln 35 40 45 Arg Arg Ile Glu Glu Ile Gln Arg Glu Ile Glu Glu Ile Gln Lys Arg 50 55 60 Ile Glu Glu Ile Gln Glu Glu Ile Gln Arg Arg Thr 65 70 75 <210> SEQ ID NO 198 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 198 Ser Asp Glu Glu Ile Lys Arg Leu Ser Glu Glu Val Ile Gln Leu Ser 1 5 10 15 Arg Arg Val Ile Lys Met Ser Arg Glu Ala Ile Lys Leu Ser Arg Glu 20 25 30 Val Gln Lys Leu Thr Pro Ser Tyr Gln Lys Arg Ile Lys Glu Ile Ala 35 40 45 Asp Arg Ser Ile Glu Leu Ala Arg Glu Ser Ile Glu Ile Ala Lys Arg 50 55 60 Ser Glu Lys Ile Ala Glu Glu Ser Gln Arg Arg Thr 65 70 75 <210> SEQ ID NO 199 <211> LENGTH: 56 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 199 Pro Ala Lys Asp Glu Ala Leu Lys Met Ala Asn Glu Ser Leu Glu Leu 1 5 10 15 Ala Lys Lys Ser Ala Arg Leu Ile Gln Glu Ser Ser Ser Lys Glu Ile 20 25 30 Leu Glu Arg Ile Glu Lys Ile Gln Arg Arg Ile Ala Glu Leu Gln Asp 35 40 45 Arg Ile Ala Tyr Leu Ile Lys Lys 50 55 <210> SEQ ID NO 200 <211> LENGTH: 56 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 200 Pro Ala Lys Asp Glu Ala Leu Arg Met Ile Asp Glu Ser Arg Glu Leu 1 5 10 15 Ile Lys Lys Ser Asn Glu Leu Ile Gln Arg Ser Ser Ser Lys Glu Ile 20 25 30 Leu Glu Arg Ile Leu Glu Ile Gln Arg Lys Ile Ala Glu Leu Gln Lys 35 40 45 Arg Ile Gln Tyr Leu Leu Lys Ser 50 55 <210> SEQ ID NO 201 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 201 Thr Asp Glu Ala Arg Tyr Arg Ser Glu Arg Ile Val Lys Glu Ala Lys 1 5 10 15 Arg Leu Leu Asp Glu Ala Arg Arg Arg Ser Glu Lys Ile Val Arg Glu 20 25 30 Ala Lys Gln Arg Ser Asn Ser Glu Asp Ala Lys Arg Ile Met Glu Glu 35 40 45 Asn Leu Arg Glu Ser Glu Glu Ala Ala Arg Arg Leu Arg Glu Ile Ile 50 55 60 Arg Arg Asn Leu Glu Glu Ser Arg Glu Thr Gly 65 70 75 <210> SEQ ID NO 202 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 202 Thr Arg Glu Ala Leu Glu Tyr Gln Arg Lys Met Ala Glu Glu Ile Glu 1 5 10 15 Asp Leu Leu Arg Glu Ala Leu Arg Arg Gln Glu Glu Met Val Arg Glu 20 25 30 Ala Lys Gln Arg Ser Leu Ser Glu Glu Phe Lys Arg Ile Met Glu Arg 35 40 45 Ile Leu Glu Glu Gln Glu Arg Val Met Arg Leu Ala Lys Glu Ala Leu 50 55 60 Glu Arg Ile Leu Glu Glu Gln Lys Arg Thr Gly 65 70 75 <210> SEQ ID NO 203 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 203 Ser Glu Arg Thr Lys Arg Glu Ala Lys Arg Ser Gln Glu Glu Ile Leu 1 5 10 15 Arg Glu Ala Lys Glu Ala Met Arg Arg Ala Lys Glu Ser Gln Asp His 20 25 30 Arg Gln Asn Arg Asp Gly Ser Asn Ser Glu Asp Leu Glu Arg Leu Ser 35 40 45 Gln Glu Gln Lys Arg Glu Leu Glu Glu Val Glu Arg Arg Leu Lys Glu 50 55 60 Leu Ala Arg Glu Gln Lys Tyr Lys Leu Glu Asp Ser 65 70 75 <210> SEQ ID NO 204 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 204 Ser Glu Asp Leu Lys Arg Ile Leu Lys Glu Ile Thr Glu Arg Glu Leu 1 5 10 15 Lys Leu Met Gln Asp Leu Met Glu Ile Leu Lys Lys Ile Thr Glu Asp 20 25 30 Glu Asn Asn Leu Asp Ser Asn Asn Ser Glu Asp Leu Lys Arg Ser Ile 35 40 45 Glu Lys Ala Arg Arg Ile Leu Asp Glu Ala Leu Arg Lys Leu Glu Glu 50 55 60 Ser Ala Arg Arg Ala Lys Tyr Ile Gln Glu Asp Asn 65 70 75 <210> SEQ ID NO 205 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 205 Thr Glu Asp Glu Ile Arg Glu Ser Leu Lys Trp Leu Asp Glu Val Leu 1 5 10 15 Gln Glu Leu Arg Glu Ile Ala Arg Glu Ser Asn Glu Val Leu Glu Arg 20 25 30 Asn Arg Gln Lys Ser Arg Ser Asp Lys Leu Arg Glu Asp Ile Glu Arg 35 40 45 Tyr Lys Lys Arg Met Glu Glu Ala Arg Lys Lys Leu Asp Asp Gln Leu 50 55 60 Asn Lys Tyr Lys Lys Arg Met Asp Glu Asn Arg Ser 65 70 75 <210> SEQ ID NO 206 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 206 Thr Glu Glu Glu Leu Lys Glu Ser Lys Lys Phe Ala Glu Asp Leu Ala 1 5 10 15 Arg Ser Ala Arg Arg Ala Leu Lys Glu Ser Lys Arg Val Leu Glu Glu 20 25 30 Ile Ser Gln Ala Ser Arg Ser Lys Lys Leu Glu Glu Ile Val Arg Arg 35 40 45 Tyr Lys Glu Gln Val Lys Arg Trp Gln Asp Glu Trp Asp Glu Arg Ala 50 55 60 Arg Glu Tyr Arg Lys Arg Met Lys Glu Asn Arg Ser 65 70 75 <210> SEQ ID NO 207 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 207 Thr Lys Thr Glu Glu Ile Glu Arg Leu Ala Arg Glu Ile Lys Lys Leu 1 5 10 15 Ser Glu Lys Val Glu Arg Leu Ala Gln Glu Ile Glu Glu Leu Ser Arg 20 25 30 Arg Val Lys Glu Glu Asn Ser Thr Asp Arg Glu Leu Lys Glu Ala Asn 35 40 45 Arg Glu Ile Glu Arg Ala Ile Arg Glu Ile Glu Lys Ala Asn Lys Arg 50 55 60 Met Glu Glu Ala Leu Arg Arg Met Lys Tyr Asn Gly 65 70 75 <210> SEQ ID NO 208 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 208 Thr Lys Thr Glu Glu His Glu Arg Leu Ala Arg Glu Ile Ser Lys Leu 1 5 10 15 Ala Asp Glu His Arg Lys Leu Ala Lys Ile Ile Glu Glu Leu Ala Arg 20 25 30 Arg Ile Lys Glu Glu Asn Leu Thr Asp Asp Glu Leu Arg Glu Ala Ile 35 40 45 Arg Lys Ile Glu Asp Ala Leu Arg Lys Asn Lys Glu Ala Leu Lys Ile 50 55 60 Met Lys Glu Ala Ala Glu Arg Asn Arg Tyr Asn Thr 65 70 75 <210> SEQ ID NO 209 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 209 Thr Lys Lys Glu Glu Ser Arg Glu Leu Ala Arg Glu Ser Glu Glu Leu 1 5 10 15 Ala Arg Glu Ser Glu Lys Leu Ala Arg Lys Ser Leu Glu Leu Ala Arg 20 25 30 Arg Ala Glu Ser Ser Gly Ser Glu Glu Glu Lys Arg Arg Ile Ile Asp 35 40 45 Glu Asn Arg Lys Ile Ile Glu Arg Asn Arg Glu Ile Ile Glu Arg Asn 50 55 60 Lys Glu Ile Ile Glu Tyr Asn Lys Glu Leu Ile Ser 65 70 75 <210> SEQ ID NO 210 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 210 Thr Lys Asp Glu Glu Ser Leu Glu Leu Asn Arg Glu Ser Glu Glu Leu 1 5 10 15 Asn Arg Lys Ser Glu Glu Leu Asn Arg Lys Ser Lys Glu Leu Asn Asp 20 25 30 Arg Ala Glu Ser Ser Asn Ser Glu Glu Glu Glu Lys Glu Ile Leu Arg 35 40 45 Glu His Lys Glu Ile Leu Arg Glu His Leu Glu Ile Leu Arg Arg His 50 55 60 Lys Glu Ile Leu Arg Arg His Lys Tyr Leu Thr Ser 65 70 75 <210> SEQ ID NO 211 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 211 Thr Arg Glu Glu Leu Leu Arg Glu Asn Ile Glu Leu Ala Lys Glu His 1 5 10 15 Ile Glu Ile Met Arg Glu Ile Leu Glu Leu Leu Gln Lys Met Glu Glu 20 25 30 Leu Leu Glu Arg Gln Ser Ser Glu Asp Ile Leu Glu Glu Leu Arg Lys 35 40 45 Ile Ile Glu Arg Ile Arg Glu Leu Leu Asp Arg Ser Arg Lys Ile His 50 55 60 Glu Arg Ser Glu Glu Ile Ala Tyr Lys Glu Glu 65 70 75 <210> SEQ ID NO 212 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 212 Ser Glu Asp Ile Ala Arg Glu Ile Lys Glu Leu Leu Arg Arg Leu Lys 1 5 10 15 Glu Ile Ile Glu Arg Asn Gln Arg Ile Ala Lys Glu His Glu Tyr Ile 20 25 30 Ala Arg Glu Arg Lys Lys Leu Asp Pro Ser Asn Glu Lys Glu Arg Lys 35 40 45 Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu Ser Lys Arg Leu Leu 50 55 60 Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys Lys Leu Leu Asp 65 70 75 <210> SEQ ID NO 213 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 213 Asp Arg Gln Lys Leu Ile Glu Glu Asn Ile Lys Leu Leu Asp Lys His 1 5 10 15 Ile Lys Ile Leu Glu Glu Ile Leu Arg Leu Leu Lys Lys Asp Ile Asp 20 25 30 Leu Leu Lys Lys Ser Ser Ser Glu Glu Val Leu Glu Glu Leu Lys Lys 35 40 45 Ile His Arg Arg Ile Asp Lys Leu Leu Asp Glu Ser Lys Lys Ile His 50 55 60 Lys Arg Ser Ser Glu Ile Val Lys Lys Arg Ser 65 70 75 <210> SEQ ID NO 214 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 214 Asp Glu Gln Lys Leu Ile Glu Thr Ser Gln Arg Leu Gln Glu Lys Ser 1 5 10 15 Glu Arg Leu Leu Glu Lys Phe Glu Gln Ile Leu Arg Glu Ala Ser Asp 20 25 30 Leu Tyr Arg Lys Pro Asp Ser Glu Glu Leu Leu Arg Arg Val Glu Lys 35 40 45 Leu Leu Arg Glu Leu Glu Lys Leu Ile Arg Glu Asn Gln Asp Leu Ala 50 55 60 Arg Lys His Glu Lys Ile Leu Arg Asp Gln Ser 65 70 75 <210> SEQ ID NO 215 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 215 Asp Arg Gln Glu Leu Ile Arg Glu Asn Ile Glu Leu Leu Lys Lys His 1 5 10 15 Ile Lys Ile Val Lys Glu Ile Gln Lys Leu Ile Glu Thr Phe Ile Glu 20 25 30 Leu Leu Lys Lys Ser Ser Ser Glu Glu Ile Leu Arg Arg Leu Lys Lys 35 40 45 Ile Leu Lys Arg Ile Glu Lys Leu Tyr Arg Glu Ser Gln Glu Ile His 50 55 60 Lys Arg Ser Glu Glu Ile Ala Lys Lys Arg Gln 65 70 75 <210> SEQ ID NO 216 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 216 Asp Glu Glu Arg Leu Ile Asp Lys Ser Arg Glu Leu Gln Lys Glu Ser 1 5 10 15 Glu Glu Leu Leu Lys Glu Leu Leu Lys Ile Phe Lys Arg Ile Glu Glu 20 25 30 Leu Leu Glu Lys Pro Asp Ser Glu Glu Leu Ile Arg Glu Ile Lys Lys 35 40 45 Leu Leu Glu Thr Leu Ser Glu Ile His Lys Arg Asn Glu Lys Leu Ala 50 55 60 Arg Thr His Glu Glu Ile Leu Arg Gln Gln Ser 65 70 75 <210> SEQ ID NO 217 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 217 Ser Thr Arg Asp Val Gln Arg Glu Ile Ala Lys Ala Phe Lys Lys Met 1 5 10 15 Ala Asp Val Gln Lys Lys Leu Ala Glu Glu Ile Lys Arg His Val Lys 20 25 30 Asn Val Glu Lys Lys Asn Lys Asp Asn Asp Glu Tyr Arg Lys Ile Ala 35 40 45 Thr Glu Leu Leu Lys Lys Ala Thr Glu Ser Gln Lys Lys Leu Lys Glu 50 55 60 Leu Leu Asp Arg Ile Arg Lys Ser Asp Ser 65 70 <210> SEQ ID NO 218 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 218 Asp Lys Asp Asp Arg Ser Thr Ser Leu Leu Lys Arg Val Glu Lys Leu 1 5 10 15 Ile Asp Glu Ser Asp Arg Ile Ile Asp Lys Phe Thr Thr Leu Ile Glu 20 25 30 Leu Ser Arg Asn Gly Lys Ile Asp Asp Asp Gln Tyr Lys Lys Glu Leu 35 40 45 Lys Glu Ile Leu Glu Leu Leu Lys Lys Tyr Asp Lys His Val Lys Glu 50 55 60 Val Glu Glu Leu Leu Lys Arg Leu Asn Ser 65 70 <210> SEQ ID NO 219 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 219 Ser Lys Arg Lys Ala Leu Glu Val Ser Glu Arg Val Val Arg Ile Ser 1 5 10 15 Glu Lys Val Val Arg Val Leu Asp Glu Ser Ser Asp Leu Leu Lys Lys 20 25 30 Ser Tyr Asp Asp Ser Asp Lys Phe Ala Glu Leu Ile Asp Arg His Glu 35 40 45 Glu Lys Ile Lys Lys Trp Lys Lys Leu Ile Lys Glu Trp Leu Glu Ile 50 55 60 Ile Gln Arg His Lys Ser 65 70 <210> SEQ ID NO 220 <211> LENGTH: 68 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 220 Ser Ala Glu Glu Phe Val Lys Leu Ser Glu Glu Ala Val Lys Arg Ser 1 5 10 15 Lys Glu Ile Leu Asp Ile Val Arg Lys Gln Val Lys Leu Val Lys Ala 20 25 30 Gly Val Asp Lys His Glu Ile Thr Asp Ser Leu Arg Lys Ser Glu Lys 35 40 45 Leu Ile Glu Glu His Lys Glu Leu Ile Lys Thr His Arg Asp Leu Leu 50 55 60 Arg Arg Glu Asn 65 <210> SEQ ID NO 221 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 221 Ser Ser Thr Glu Ile Leu Lys Arg Phe Lys Arg Ala Leu Arg Glu Ser 1 5 10 15 Glu Lys Ile Val Lys His Ser Arg Arg Val Leu Lys Ile Ile Arg Glu 20 25 30 Val Leu Lys Gln Lys Pro Thr Gln Ala Val His Asp Leu Val Arg Ile 35 40 45 Ile Glu Thr Gln Val Lys Ala Leu Glu Glu Gln Leu Lys Val Leu Lys 50 55 60 Arg Ile Val Glu Ala Leu Glu Arg Gln Ser 65 70 <210> SEQ ID NO 222 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 222 Asp Lys Gln Lys Glu Ile Lys Asp Ile Leu Glu Lys Thr Arg Arg Ile 1 5 10 15 Ala Glu Glu Ser Arg Lys Ile Ala Glu Lys Phe Asp Glu Ile Ile Lys 20 25 30 Arg Ser Thr Glu Gly Lys Ile Asp Glu Ser Leu Thr Lys Glu Leu Glu 35 40 45 Glu Leu Val Lys Glu Val Ile Lys Leu Ser Glu Asp Asp Ala Arg Thr 50 55 60 Ser Asp Asp Leu Val Arg Lys Glu Ser 65 70 <210> SEQ ID NO 223 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 223 Asp Glu Asp Glu Ser Ile Lys Leu Thr Arg Lys Ser Ile Glu Glu Thr 1 5 10 15 Arg Lys Ser Leu Lys Ile Ile Lys Glu Val Val Glu Leu Ile Arg Glu 20 25 30 Val Leu Lys His Ile Lys Asp Leu Asp Lys Glu Ile Phe Glu Arg Ile 35 40 45 Asp Lys Ile Leu Asp Lys Tyr Lys Lys Gln Val Asp Thr Tyr Asp Glu 50 55 60 Ile Leu Lys Glu Tyr Glu Lys Lys Gln Arg 65 70 <210> SEQ ID NO 224 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 224 Ser Glu Leu Asp Glu Gln Lys Glu Leu Ile Lys Lys Gln Glu Lys Leu 1 5 10 15 Ile Glu Glu Gln Gln Arg Leu Leu Ser Lys Ile Arg Arg Met Phe Lys 20 25 30 Glu Arg Val Lys Asp Gln Glu Leu Leu Arg Glu Ile Gln Lys Val Leu 35 40 45 Lys Arg Ser Gln Glu Ile Val Glu Thr Ser Lys Lys Ile Leu Asp Arg 50 55 60 Ser Asp Lys Thr Thr Glu 65 70 <210> SEQ ID NO 225 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 225 Asp Gln Lys Glu Ile Asn Thr Arg Ile Val Glu Lys Leu Glu Arg Ile 1 5 10 15 Phe Lys Lys Ser Lys Glu Ile Val Arg Gln Ser Glu Arg Val Ile Ser 20 25 30 Thr Ile Glu Lys Lys Thr Glu Asp Glu Arg Glu Leu Asp Leu Leu Arg 35 40 45 Arg His Val Lys Ile Val Arg Glu His Leu Lys Leu Leu Glu Glu Leu 50 55 60 Leu Lys Ile Ile Lys Glu Val Gln Lys Glu Ser Glu 65 70 75 <210> SEQ ID NO 226 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 226 Asp Thr Glu Glu Leu Val Lys Arg Leu Asn Glu Leu Leu Lys Glu Leu 1 5 10 15 Ser Lys Leu Val Lys Glu Phe Ile Lys Ile Leu Glu Thr Tyr Arg Lys 20 25 30 Asp Gln Thr Lys Asp Thr Ser Lys Ile Ser Glu Arg Val Asp Arg Ile 35 40 45 Leu Lys Thr Tyr Glu Asp Leu Leu Gln Lys Tyr Lys Glu Ile Leu Glu 50 55 60 Lys Ile Glu Lys Gln Leu Ser 65 70 <210> SEQ ID NO 227 <211> LENGTH: 68 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 227 Asp Tyr Ala Arg Leu Ile Asp Gln Ala Val Glu Val Thr Arg Lys Val 1 5 10 15 Val Glu Val Asn Val Thr Val Ala Arg Val Asn Asp Lys Phe Ala Lys 20 25 30 His Leu Gly Asp Glu Glu Leu Arg Arg Val Ser Glu His Leu Lys Glu 35 40 45 Val Ser Lys Asp Leu Gln Glu Val Ala Lys Lys Ser Lys Asp Ala Ala 50 55 60 Arg Gln Val Lys 65 <210> SEQ ID NO 228 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 228 Asp Val Ser Lys Val Ala Glu Glu Tyr Leu Gln Ile Ser Lys Thr Leu 1 5 10 15 Val Asp Ile Ser Arg Thr Leu Leu Glu Ile Ser Glu Arg Leu Val Arg 20 25 30 Leu Val Arg Thr Val Ala Asp Asp Arg Ser Glu Val Lys Lys Ala Ile 35 40 45 Glu Asp Ser Ile Glu Val Leu Lys Thr Ser Glu Glu Val Val Arg Gln 50 55 60 Ile Lys Arg Ala Ser Asp Lys Leu Val Lys Ala Ile Ser 65 70 75 <210> SEQ ID NO 229 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 229 Asp Ala Lys Glu Ile Gln Arg Arg Val Val Glu Ile Gln Thr Glu Val 1 5 10 15 Val Lys Leu Gln Lys Lys Ala Val Asp Ile Ile Arg Lys Ile Ile Glu 20 25 30 Ala Phe Asn Asn Ser Asn Ile Asp Gln Ser Leu Leu Glu Ala Ala Lys 35 40 45 Glu Ile Val Lys Glu Ile Asp Lys Leu Glu Lys Leu Thr Glu Ser Leu 50 55 60 Leu Glu Glu Ser Lys Lys Leu Leu Lys Arg Ser Ser 65 70 75 <210> SEQ ID NO 230 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 230 Ser Ala Glu Glu Val Val Lys Leu Ala Lys Ile Phe Leu Glu Leu Leu 1 5 10 15 Arg Glu Ser Ile Lys Leu Leu Lys Arg Ser Val Asp Leu Leu Arg Lys 20 25 30 Ser Ser Asp Pro Ser Leu Asp Lys Ser Glu Ala Glu Lys Val Ser Arg 35 40 45 Glu Ile Glu Lys Val Ser Asp Thr Ser Leu Lys Leu Ser Lys Lys Ala 50 55 60 Leu Asp Val Val Lys Arg Ala Leu Lys Val Ala Ser 65 70 75 <210> SEQ ID NO 231 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 231 Asp Glu Lys Asp Ala Ala Arg Lys Ala Arg Lys Val Ser Glu Glu Ala 1 5 10 15 Lys Glu Ala Ser Lys Lys Ile Glu Lys Ala Leu Glu Glu Ser Lys Arg 20 25 30 Ile Leu Asn Thr Leu Lys Gln Lys Lys Asp Glu Gln Glu Val Lys Val 35 40 45 Ile Lys Glu His Glu Asp Val Leu Arg Gln Ile Glu Lys Ile Gln Lys 50 55 60 Gln Val Leu Glu Ile Gln Lys Glu Val Ala Lys Leu Leu Glu Ser Leu 65 70 75 80 Asp <210> SEQ ID NO 232 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 232 Ser Ala Asp Asp Val Ala Arg Ala Ser Glu Lys Val Leu Arg Val Ala 1 5 10 15 Arg Glu Ser Ala Lys Ala Ala Asp Lys Ser Leu Glu Val Phe Lys Glu 20 25 30 Val Val Lys Arg Gly Asp Lys Glu Ala Phe Leu Gln Val Val Lys Ile 35 40 45 Asn Glu Glu Val Val Lys Ile Asn Ile Thr Val Ile Arg Ile Leu Ile 50 55 60 Glu Val Ser Lys Thr Ala Thr 65 70 <210> SEQ ID NO 233 <211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 233 Asp Glu Tyr Val Lys Glu Thr Leu Lys Gln Leu Arg Glu Ala Leu Ala 1 5 10 15 Ser Leu Arg Glu Ala Asp Lys Arg Ile Thr Glu Leu Val Lys Glu Ala 20 25 30 Arg Lys Lys Pro Leu Ser Glu Ala Ala Arg Lys Phe Ala Glu Ala Ile 35 40 45 Val Thr His Val Lys Val Val Val Glu His Val Glu Val Val Leu Arg 50 55 60 His Val Glu Val Leu Val Glu Ala Lys Lys Asn Gly Val Ile Asp Lys 65 70 75 80 Ser Ile Leu Asp Asn Ala Leu Arg Ile Ile Glu Asn Val Ile Arg Leu 85 90 95 Leu Ser Asn Val Ile Arg Val Val Asp Glu Val Leu Gln Asp Leu Asp 100 105 110 <210> SEQ ID NO 234 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 234 Asp Ala Ser Asp Val Ile Arg Arg Ile His Glu Leu Phe Glu Glu Val 1 5 10 15 His Arg Leu Ile Glu Ala Val His Arg Ala Ile Glu Asp Val Ala Lys 20 25 30 Ala Ala Gln Lys Lys Gly Leu Asp Glu Ser Ala Val Glu Ile Leu Ala 35 40 45 Glu Leu Ser Lys Glu Leu Ala Lys Leu Ser Arg Arg Leu Ala Glu Ile 50 55 60 Ser Arg Glu Ile Gln Lys Val Val Thr Asp Pro Asp Asp Lys Glu Ala 65 70 75 80 Val Glu Arg Leu Lys Glu Ile Ile Lys Glu Ile Lys Lys Gln Leu Asp 85 90 95 Glu Leu Arg Asp Arg Leu Arg Lys Leu Gln Asp Leu Leu Tyr Lys Leu 100 105 110 Lys <210> SEQ ID NO 235 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 235 Ser Glu Asp Lys Ala His His Asp Ile Val Arg Val Leu Glu Glu Leu 1 5 10 15 Ile Lys Ile His Asp Glu Leu Met Lys Ile Ser Glu Glu Ile Leu Lys 20 25 30 Ala Thr Ser Asp Ser Thr Ala Thr Asp Glu Thr Lys Glu Glu Leu Lys 35 40 45 Arg Arg Ser Lys Glu Ala Gln Lys Lys Ser Asp Thr Leu Val Lys Ile 50 55 60 Val Lys Glu Leu Glu Lys Glu Ser Arg Lys Ala Gln Ser 65 70 75 <210> SEQ ID NO 236 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 236 Asp Asp Glu Glu Lys Tyr Arg Gln Ile Ile Arg Glu Ala Gln Glu Ile 1 5 10 15 Ser Lys Thr Ala Lys Arg Ile Leu Arg Asp Ala Gln Glu Ile Ser Lys 20 25 30 Arg Ile Arg His Gln Gly Val Asp Arg Ser Glu His Gln Arg Leu Val 35 40 45 Asp Leu Leu Arg Glu Leu Ile Lys Glu His His Lys Leu Leu Arg Arg 50 55 60 Gln Gln Glu Ala Asp Thr Arg Asn Asp 65 70 <210> SEQ ID NO 237 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 237 Asp Arg Lys Asp Lys Ala Arg Lys Ala Ser Glu Lys Leu Glu Glu Val 1 5 10 15 Ile Gln Arg Trp Lys Thr Val Ala Asp Lys Trp Lys Lys Met Val Asp 20 25 30 Leu Val Ser Asn Gly Lys Leu Ser Gln Glu Glu Val Ala Arg Val Thr 35 40 45 Glu Glu Leu Leu Lys Ile Gln Thr Glu Leu Ala Lys Leu Leu Glu Glu 50 55 60 His Ala Lys Val Leu Gln Glu Ser Ala Ser 65 70 <210> SEQ ID NO 238 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 238 Ser Asp Glu Glu Ser Ile Lys Thr Gln Ser Glu Leu Ile Lys Thr Ser 1 5 10 15 Glu Glu Leu Leu Lys Asp Val Lys Arg Ile Asp Glu Glu Leu Gln Lys 20 25 30 Leu Arg Asp Asp Pro Thr Leu Asp Glu Ser Glu Leu Lys Lys Arg Val 35 40 45 Lys Glu Trp Ser Asp Arg Val Arg Lys Ala Lys Glu Ile Ser Arg Lys 50 55 60 Ile Gln Glu Ile Val Lys Glu Ser Lys Lys Arg Ser Ser 65 70 75 <210> SEQ ID NO 239 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 239 Asp Lys Asp Glu Glu Leu Arg Lys Val Ile Glu Lys Tyr Arg Glu Met 1 5 10 15 Val Lys Glu Tyr Arg Lys Val Ile Arg Glu Tyr Glu Glu Val Ile Lys 20 25 30 Ser Ser Lys Thr Ile Asp Lys Ser Ser Leu Ile Ser Leu Ser Arg Lys 35 40 45 Met Val Glu Leu Ser Gln Arg Val Ile Asp Val Ser Asp Glu Val Ala 50 55 60 Lys Val Leu Ser Arg Lys Gln Ser 65 70 <210> SEQ ID NO 240 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 240 Thr Asp Glu Glu Arg Leu Lys Lys Gln Thr Lys Glu Leu Lys Glu Gln 1 5 10 15 Thr Lys Gln Leu Glu Lys Gln Lys Asp Leu Leu Glu Lys Ile Ser Asn 20 25 30 Gly Glu Ile Ser Lys Asp Glu Ile Gln Glu Ile Ile Lys Glu Ser Lys 35 40 45 Lys Ile Ala Lys Glu Ser Gln Lys Ala Leu Asp Ser Ser Arg Lys Ala 50 55 60 Leu Glu Glu Val Ser 65 <210> SEQ ID NO 241 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 241 Asp Glu Lys Glu Val Ser Lys Glu Ile Ile Lys Val Leu Lys Asp Ile 1 5 10 15 Ala Lys Val Gln Gln Lys Val Ile Glu Val Ser Gln Arg Leu Ala Ser 20 25 30 Val Leu Arg Ala Asp Asp Asp Asn Val Val Lys Arg Ala Leu Glu Glu 35 40 45 Tyr Glu Lys Ile Leu Glu Glu Leu Arg Glu Leu Asn Lys Glu Ile Glu 50 55 60 Lys Leu Thr Asp Lys Tyr Arg Lys Val Thr Ser 65 70 75 <210> SEQ ID NO 242 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 242 Asp Ser Asp Glu Gln Thr Lys Glu Leu Glu Lys Leu Thr Glu Leu His 1 5 10 15 Lys Arg His Val Glu Lys Leu Lys Lys Gln Thr Lys Glu Ser Arg Glu 20 25 30 Val Asp Ser Asn Lys Leu Trp Lys Ser Lys Asp Val Lys Asp Lys Leu 35 40 45 Ser Glu Ser Glu Lys Glu Leu Gln Lys Leu Ser Asp Gln Asp Lys Lys 50 55 60 Ala Lys Asp Ala Leu Glu Ser Ser Arg Arg Lys Asn Asp 65 70 75 <210> SEQ ID NO 243 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 243 Asp Ala Glu Glu Gln Leu Lys Leu Leu Thr Lys Leu Leu Arg His Gln 1 5 10 15 Gln Arg Leu Leu Gln Leu Ile Lys Glu Ser Leu Lys Leu Ile Glu Lys 20 25 30 Ile Asp Gln Ser Ser Gln Glu Asn Gln Asp Glu Ile Arg Lys Trp Arg 35 40 45 Glu Val Thr Lys Lys Leu Arg Glu Leu Ile Lys Thr Ser Glu Lys Leu 50 55 60 Val Arg Glu Leu Glu Lys Ser Tyr Lys Lys Ser Ser 65 70 75 <210> SEQ ID NO 244 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 244 Ser Leu Arg Asp Val Val Arg Arg Tyr Gln Glu Leu Val Arg Arg Tyr 1 5 10 15 Asp Glu Leu Ile Lys Thr Leu Thr Glu Ile Leu Lys Lys Tyr Gln Lys 20 25 30 Lys Gly Ala Glu Asp Lys Asp Ala Ser Thr Glu Leu Val Lys Ala Val 35 40 45 Arg Thr Ser Leu Lys Leu Ser Lys Glu Leu Leu Lys Leu Asn Ser Glu 50 55 60 Leu Leu Lys Glu Asp Ser 65 70 <210> SEQ ID NO 245 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 245 Ser Lys Glu Glu Leu Lys Arg Lys Leu Asp Glu Leu Lys Lys Arg Ser 1 5 10 15 Asp Thr Leu Lys Glu Leu Ser Lys Lys Leu Lys Glu Ile Ser Glu Arg 20 25 30 Asn Pro Asp Asp Lys Ser Val His Arg Thr Ile Ile Arg Ile His Arg 35 40 45 Glu Phe Val Lys Asn His Lys Glu Ile Val Arg Val Ile Glu Glu Ile 50 55 60 Val Ser Asp Lys Ser 65 <210> SEQ ID NO 246 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 246 Ser Lys Gln Asp Glu His Asp Arg Leu Leu Lys Ile His Asp Lys Leu 1 5 10 15 Val Lys Gln His Asp Glu Leu Leu Lys Leu Leu Thr Lys Leu Ser Arg 20 25 30 Ala Gly Asp Ser Val Thr Lys Lys Lys Leu Glu Glu Ile Leu Arg Lys 35 40 45 Leu Gln Glu Val Ser Lys Gln Leu Glu Glu Ser Leu Lys Asp Ala Asp 50 55 60 Lys Val Ser Lys Asp Ile Asn 65 70 <210> SEQ ID NO 247 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 247 Thr Val Gln Ser Leu Leu Glu Gln His Val Lys Ile Val Lys Arg Ser 1 5 10 15 Ile Glu Ile Leu Glu Arg His Thr Gln Ile Leu Gln Asp Ile Ala Arg 20 25 30 Ser Gln Gly Val Ser Lys Glu Leu Glu Asp Val Glu Arg Gln Val Lys 35 40 45 Glu Tyr Arg Lys Glu Val Lys Lys Leu Glu Glu Asp Leu Arg Gln Leu 50 55 60 Ser Arg Asn Ser Lys 65 <210> SEQ ID NO 248 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 248 Ser Asp Ser Asp Arg Ile Glu Lys Leu Ile Arg Glu Ser Thr Glu Leu 1 5 10 15 Leu Lys Glu Gln Gln Lys Leu Ala Lys Arg Ser Arg Glu Leu Ala Glu 20 25 30 Thr Val Glu Ser Leu Pro Leu Thr Glu Glu Tyr Leu Lys Gln Gln Arg 35 40 45 Glu His Gln Lys Lys Ile Glu Lys Leu Leu Lys Asp Ser Glu Lys His 50 55 60 Leu Glu Glu Leu Lys Arg Leu Val Lys Ser Glu Lys 65 70 75 <210> SEQ ID NO 249 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 249 Asp Ser Glu Lys Arg Ile Glu Asp Ile Leu Arg Thr Asp Leu Glu Leu 1 5 10 15 Ala Lys Arg Asp Ala Glu Leu Val Lys Glu His Ile Lys Leu Val Lys 20 25 30 Arg Ile Asp Leu Ser Glu Glu Leu Lys Lys Gln Val Glu Asp Val Glu 35 40 45 Lys Glu Ser Lys Lys Leu Glu Asp Ser Ser Glu Lys Leu Val Gln Lys 50 55 60 Val Arg Lys Arg Ser Ser 65 70 <210> SEQ ID NO 250 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 250 Asp Glu Glu Glu Arg Ala Lys Asp Leu Arg Lys Tyr Leu Glu Glu Gln 1 5 10 15 Thr Gln Tyr Tyr Arg Thr Val Thr Glu His Leu Arg Asn Leu Glu Lys 20 25 30 Val Val Glu Glu Leu Glu Arg Arg Gly Lys Pro Ser Ser Glu Leu Gln 35 40 45 Gln Ile Leu Glu Arg Ser Gln Arg Ile Tyr Lys Glu Thr Thr Glu Ile 50 55 60 Tyr Asp Thr Ser Lys Lys Leu Ile Glu Glu Leu Asp Lys His His Arg 65 70 75 80 <210> SEQ ID NO 251 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 251 Pro Leu Glu Asp Ile Leu Lys Arg His Leu Asp Lys Val Arg Glu Leu 1 5 10 15 Val Arg Leu Ser Glu Glu Val Asn Lys Leu Ala Lys Glu Val Leu Asp 20 25 30 Ile Leu Lys Asp Lys Arg Val Asp Glu Lys Glu Leu Asp Lys Val Leu 35 40 45 Lys Glu Leu Glu Lys Val Val Glu Glu Tyr Glu Arg Ala Val Lys Glu 50 55 60 Ser Arg Asp Leu Leu Arg Glu Leu Arg Glu Thr Thr Arg 65 70 75 <210> SEQ ID NO 252 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 252 Asp Lys Glu Arg Leu Leu Glu Ile His Glu Arg Ile Gln Lys Leu Leu 1 5 10 15 Asp Arg Asn Leu Glu Ile Ile Glu Arg Leu Leu Arg Leu Leu Arg Glu 20 25 30 Ala Arg Asp Ile Lys Asp Asp Asp Lys Leu Asp Lys Val Ile Lys Arg 35 40 45 Leu Lys Glu Leu Ser Glu Glu Ser Lys Asp Ile Leu Asp Lys Ile Lys 50 55 60 Glu Leu Leu Lys Glu Ser Glu Lys Glu Leu Thr 65 70 75 <210> SEQ ID NO 253 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 253 Pro Glu Asp Glu Val Ile Arg Val Ile Glu Glu Leu Leu Arg Ile Ala 1 5 10 15 Ala Glu Val Asp Glu Val His Arg Arg Asn Val Glu Val Gln Glu Glu 20 25 30 Ala Ser Arg Val Thr Asp Arg Glu Arg Leu Glu Arg Leu Asn Arg Glu 35 40 45 Ser Glu Glu Leu Ile Lys Arg Ser Arg Glu Leu Ile Glu Glu Gln Arg 50 55 60 Lys Leu Ile Glu Arg Leu Glu Arg Leu Ala Thr 65 70 75 <210> SEQ ID NO 254 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 254 Asp Leu Glu Glu Leu Ile Lys Glu Tyr Ala Glu Val Val Arg Arg His 1 5 10 15 His Lys Ala Val Arg Asp Leu Glu Arg Leu Val Arg Glu Leu Ala Asn 20 25 30 Ala Lys His Ala Ser Glu Glu Glu Leu Lys Arg Ile Ala Thr Glu Ile 35 40 45 Leu Arg Ile Val Lys Glu Leu Ile Arg Val Gln Glu Arg Leu Ile Lys 50 55 60 Leu Ser Glu Asp Ser Asn Glu Glu Ser Arg 65 70 <210> SEQ ID NO 255 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 255 Pro Thr Asp Glu Val Ile Glu Val Leu Lys Glu Leu Leu Arg Ile His 1 5 10 15 Arg Glu Asn Leu Arg Val Asn Glu Glu Ile Val Glu Val Asn Glu Arg 20 25 30 Ala Ser Arg Val Thr Asp Arg Glu Glu Leu Glu Arg Leu Leu Arg Arg 35 40 45 Ser Asn Glu Leu Ile Lys Arg Ser Arg Glu Leu Asn Glu Glu Ser Lys 50 55 60 Lys Leu Ile Glu Lys Leu Glu Arg Leu Ala Thr 65 70 75 <210> SEQ ID NO 256 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 256 Asp Asn Glu Glu Ile Ile Lys Glu Ala Arg Arg Val Val Glu Glu Tyr 1 5 10 15 Lys Lys Ala Val Asp Arg Leu Glu Glu Leu Val Arg Arg Ala Glu Asn 20 25 30 Ala Lys His Ala Ser Glu Lys Glu Leu Lys Asp Ile Val Arg Glu Ile 35 40 45 Leu Arg Ile Ser Lys Glu Leu Asn Lys Val Ser Glu Arg Leu Ile Glu 50 55 60 Leu Trp Glu Arg Ser Gln Glu Arg Ala Arg 65 70 <210> SEQ ID NO 257 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 257 Pro Lys Glu Asp Ile Asp Arg Val Ser Arg Glu Leu Val Arg Val His 1 5 10 15 Lys Glu Leu Leu Glu Val Leu Arg Lys Ser Thr Glu Ile Val Glu Ala 20 25 30 Val Ala Arg Asn Glu Lys Asp Glu Arg Thr Ile Glu Glu Val Leu Glu 35 40 45 Glu Gln Glu Arg Ala Val Arg Lys Leu Glu Glu Val Ser Lys Lys His 50 55 60 Lys Glu Ala Val Lys Arg Leu Lys 65 70 <210> SEQ ID NO 258 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 258 Glu Leu Glu Arg Leu Ser Glu Glu Ile Gln Lys Leu Ser Asp Arg Leu 1 5 10 15 Ile Glu Leu Ile Arg Arg His Ser Lys Val Leu Glu Glu Ile Val Arg 20 25 30 Leu Leu Lys His Lys Asp Asn Asp Glu Arg Glu Val Arg Arg Leu Leu 35 40 45 Lys Leu Leu Arg Asp Leu Thr Arg Arg Tyr Glu Glu Val Leu Arg Lys 50 55 60 Val Glu Glu Ile Val Lys Arg Gln Glu Asp Glu Ser Arg 65 70 75 <210> SEQ ID NO 259 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 259 Pro Glu Glu Asp Ile Leu Arg Leu Leu Arg Lys Leu Val Glu Val Asp 1 5 10 15 Lys Glu Leu Leu Glu Val Val Arg Glu Ser Thr Glu Val Val Arg Leu 20 25 30 Val Ala Arg Asn Glu Lys Asp Val Glu Thr Val Glu Arg Val Leu Arg 35 40 45 Lys Gln Glu Glu Val Val Arg Lys Tyr Glu Arg Val Ser Arg Glu Leu 50 55 60 Glu Glu Ala Val Arg Arg Leu Lys 65 70 <210> SEQ ID NO 260 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 260 Glu Leu Lys Asp Leu Val Glu Glu Ile Val Lys Leu Ser Lys Glu Asn 1 5 10 15 Leu Lys Leu Trp Glu Asp His Ser Arg Val Leu Glu Glu Ile Val Arg 20 25 30 Leu Leu Lys His Lys Asp Asn Asp Glu Arg Glu Val Arg Arg Leu Leu 35 40 45 Lys Leu Leu Glu Asp Leu Thr Arg Arg Ala Glu Glu Thr Ser Arg Arg 50 55 60 Ile Glu Glu Ile Val Lys Glu Ala Glu Asp Arg Ala Arg 65 70 75 <210> SEQ ID NO 261 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 261 Asp Glu Glu Arg Glu Leu Arg Glu Val Leu Arg Lys His His Arg Val 1 5 10 15 Val Arg Glu Trp Thr Lys Val Val Glu Glu Leu Lys Arg Val Val Glu 20 25 30 Leu Leu Lys Arg Gly Glu Thr Ser Glu Glu Asp Leu Leu Arg Val Leu 35 40 45 Lys Lys Leu Leu Glu Met Asp Lys Arg Ile Leu Glu Val Asn Arg Glu 50 55 60 Val Leu Arg Val Leu Glu Lys Arg Leu Thr 65 70 <210> SEQ ID NO 262 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 262 Ser Leu Glu Glu Ile Ile Glu Glu Leu Val Glu Leu Val Arg Arg Ser 1 5 10 15 Val Glu Ile Ala Lys Glu Ser Asp Glu Val Ala Arg Arg Ile Val Glu 20 25 30 Ser Glu Asp Lys Lys Lys Glu Leu Ile Asp Thr Leu Arg Asp Leu His 35 40 45 Arg Glu Trp Gln Glu Val Thr Lys Arg Ala Glu Glu Leu Val Arg Glu 50 55 60 Ala Glu Lys Glu Val Arg 65 70 <210> SEQ ID NO 263 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 263 Thr Ala Glu Glu Leu Leu Glu Val His Lys Lys Ser Asp Arg Val Thr 1 5 10 15 Lys Glu His Leu Arg Val Ser Glu Glu Ile Leu Lys Val Val Glu Val 20 25 30 Leu Thr Arg Gly Glu Val Ser Ser Glu Val Leu Lys Arg Val Leu Arg 35 40 45 Lys Leu Glu Glu Leu Thr Asp Lys Leu Arg Arg Val Thr Glu Glu Gln 50 55 60 Arg Arg Val Val Glu Lys Leu Asn 65 70 <210> SEQ ID NO 264 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 264 Asp Leu Glu Asp Leu Leu Arg Arg Leu Arg Arg Leu Val Asp Glu Gln 1 5 10 15 Arg Arg Leu Val Glu Glu Leu Glu Arg Val Ser Arg Arg Leu Glu Lys 20 25 30 Ala Val Arg Asp Asn Glu Asp Glu Arg Glu Leu Ala Arg Leu Ser Arg 35 40 45 Glu His Ser Asp Ile Gln Asp Lys His Asp Lys Leu Ala Arg Glu Ile 50 55 60 Leu Glu Val Leu Lys Arg Leu Leu Glu Arg Thr Glu 65 70 75 <210> SEQ ID NO 265 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 265 Pro Glu Asp Asp Val Val Arg Ile Ile Lys Glu Asp Leu Glu Ser Asn 1 5 10 15 Arg Glu Val Leu Arg Glu Gln Lys Glu Ile His Arg Ile Leu Glu Leu 20 25 30 Val Thr Arg Gly Glu Val Ser Glu Glu Ala Ile Asp Arg Val Leu Lys 35 40 45 Arg Gln Glu Asp Leu Leu Lys Lys Gln Lys Glu Ser Thr Asp Lys Ala 50 55 60 Arg Lys Val Val Glu Glu Arg Arg 65 70 <210> SEQ ID NO 266 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 266 Asp Glu Val Arg Leu Ile Thr Glu Trp Leu Lys Leu Ser Glu Glu Ser 1 5 10 15 Thr Arg Leu Leu Lys Glu Leu Val Glu Leu Thr Arg Leu Leu Arg Asn 20 25 30 Asn Val Pro Asn Val Glu Glu Ile Leu Arg Glu His Glu Arg Ile Ser 35 40 45 Arg Glu Leu Glu Arg Leu Ser Arg Arg Leu Lys Asp Leu Ala Asp Lys 50 55 60 Leu Glu Arg Thr Arg Arg 65 70 <210> SEQ ID NO 267 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 267 Asp Glu Asp Glu Val Val Lys Val His Glu Glu His Val Lys Ser His 1 5 10 15 Glu Glu Ile His Arg Ser His Glu Glu Val Val Arg Ala Ala Glu Glu 20 25 30 Asp Lys Arg Asp Ser Arg Glu Leu Arg Thr Leu Met Glu Glu His Arg 35 40 45 Lys Leu Leu Glu Glu Asn Glu Lys Ser Ile Glu Glu Val Lys Lys Ile 50 55 60 His Glu Arg Val Lys Arg 65 70 <210> SEQ ID NO 268 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 268 Lys Lys Glu Glu Leu Ile Asp Ile Ser Lys Glu Val Leu Asp Leu Asp 1 5 10 15 Asp Glu Ile Asn Lys Ile Ser Lys Glu Ile Leu Glu Leu Ile Lys Lys 20 25 30 Leu Leu Arg Leu Lys Glu Glu Gly Arg Glu Asp Lys Asp Lys Ala Arg 35 40 45 Glu Val Lys Arg Arg Ile Arg Glu Leu His Arg Arg Ile Gln Glu Leu 50 55 60 Asn Lys Arg Leu Arg Glu Leu His Lys Arg Val Gln Glu Thr Lys Arg 65 70 75 80 <210> SEQ ID NO 269 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 269 Pro Glu Glu Asp Ile Ala Arg Arg Val Glu Asp Leu Leu Arg Lys Ser 1 5 10 15 Glu Glu Leu Ile Lys Glu Ser Glu Lys Ile Leu Lys Glu Ser Lys Arg 20 25 30 Leu Leu Asp Arg Asn Asp Ser Asp Lys Arg Val Leu Glu Thr Asn Leu 35 40 45 Arg Leu Ile Asp Lys His Thr Lys Leu Leu Glu Arg Asn Leu Glu Leu 50 55 60 Leu Glu Glu Leu Leu Lys Leu Ala Glu Asp Val Ala Lys 65 70 75 <210> SEQ ID NO 270 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 270 Arg Phe Lys Asp Leu Ser Arg Glu Tyr Ile Glu Val Val Lys Arg Leu 1 5 10 15 Leu Glu Leu Ser Arg Glu Ala Leu Glu Val Leu Arg Glu Ile Lys Asp 20 25 30 Thr Asp Lys Thr Asp Lys Lys Arg Ile Lys Glu Leu Ile Asp Arg Leu 35 40 45 Arg Lys Leu Ile Glu Glu Tyr Lys Arg Ile Ile Asp Arg Leu Arg Lys 50 55 60 Leu Ser Lys Asp Leu Glu Glu Glu His Arg 65 70 <210> SEQ ID NO 271 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 271 Asp Glu Glu Glu Leu Val Lys Ile Leu Lys Glu Leu Gln Arg Leu Ser 1 5 10 15 Glu Glu Ser Leu Glu Ile Asn Lys Arg Leu Val Glu Ile Leu Arg Leu 20 25 30 Leu Arg Arg Gly Glu Val Pro Lys Glu Glu Val Glu Lys Lys Leu Arg 35 40 45 Glu Ile Lys Lys Glu Gln Glu Lys Leu Asp Arg Glu His Glu Lys Ile 50 55 60 Lys Lys Arg Ile Glu Glu Ile Thr Lys 65 70 <210> SEQ ID NO 272 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 272 Ser Leu Lys Glu Lys Ile Leu Glu Ile Ile Glu Arg Asn Met Lys Leu 1 5 10 15 Val Glu Leu Ser Asn Arg Ser Val Glu Ile Val Ala Arg Ile Leu Lys 20 25 30 Gly Glu Lys Asp Asp Glu Glu Thr Leu Glu Arg Leu Leu Arg Glu Trp 35 40 45 Asp Lys Ile Thr Arg Asp Tyr Glu Glu Ile Ile Lys Glu Ser Arg Lys 50 55 60 Leu Val Lys Glu Leu Glu Glu Glu Ala Lys 65 70 <210> SEQ ID NO 273 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 273 Ser Lys Thr Glu Ile Leu Arg Lys Ala Leu Glu Ile His Lys Glu Gln 1 5 10 15 Ile Asp Ile Val Arg Lys Leu Ile Glu Leu Ser Glu Glu Val Leu Lys 20 25 30 Leu Val Glu Glu Ser Lys Glu Lys Asn Leu Glu Lys Leu Lys Arg Ile 35 40 45 Asp Glu Glu Thr Asp Arg Leu Leu Glu Arg Leu Asp Glu Leu His Lys 50 55 60 Arg Leu Thr Glu Leu Ala Glu Arg Leu Lys 65 70 <210> SEQ ID NO 274 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 274 Ser Asp Asp Glu Ala Arg Lys Gln Leu Glu Glu Met Lys Arg Arg Leu 1 5 10 15 Arg Glu Val Glu Lys Lys Ser Lys Arg Val Glu Glu Arg Val Arg Glu 20 25 30 Leu Glu Arg Leu Val Arg Glu Asn Arg Glu Asp Glu Asp Arg Val Leu 35 40 45 Lys Thr Leu Glu Asp Leu Leu Arg Glu Asn Glu Lys Leu Val Arg Thr 50 55 60 Ile Glu Arg His Val Arg Glu Gln Arg Glu Leu Ser Lys Glu Val Lys 65 70 75 80 <210> SEQ ID NO 275 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 275 Ser Glu Glu Glu Leu Glu Lys Lys Ala Asp Glu Leu Arg Lys Leu Ser 1 5 10 15 Glu Glu Trp Arg Lys Leu Gln Glu Glu Asp Lys Arg Leu Ser Glu Met 20 25 30 Val Glu Lys Gly Glu Leu Asp Leu Gln Glu Val Asp Glu His Ser Leu 35 40 45 Arg Val Leu Glu Arg Ala Thr Glu Val His Arg Thr Val Asp Lys Val 50 55 60 Ile Glu Glu Ile Leu Arg Thr Thr Asn 65 70 <210> SEQ ID NO 276 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 276 Ser Glu Lys Glu Arg His Arg Glu Ser Gln Glu Thr Gln Glu Glu Ile 1 5 10 15 Arg Arg Thr His Glu Glu Ile Ile Arg Lys Leu Glu Glu Ile Leu Arg 20 25 30 Arg Ala Lys Ala Gly Glu Leu Pro Glu Glu Thr Leu Asp Arg Leu Arg 35 40 45 Arg Ile Met Glu Arg Leu Lys Glu Leu Ser Glu Arg Leu Asp Asp Leu 50 55 60 Val Arg Lys Leu Arg Asp Asp His Arg Arg Glu Gln Lys 65 70 75 <210> SEQ ID NO 277 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 277 Ser Glu Lys Glu Ile Leu Glu Glu Leu Lys Arg Ile Leu Lys Arg Val 1 5 10 15 Lys Asp Ile Ser Asp Arg Leu Glu Glu Leu Asp Lys Arg Thr Glu Glu 20 25 30 Ile Ala Arg Arg Glu Pro Thr Lys Glu Leu Val Asp Glu Leu Val Lys 35 40 45 Ile His Arg Asp Trp Leu Arg Leu His Glu Glu Ile Leu Lys Leu Val 50 55 60 Asp Asp Ala Leu Lys Lys Val Glu Asp Ala Thr Lys 65 70 75 <210> SEQ ID NO 278 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 278 Asp Leu Arg Glu Leu Leu Glu Leu Gln Arg Glu Ala Ser Arg Leu His 1 5 10 15 Arg Glu Leu Val Lys Leu Leu Thr Glu Leu Val Lys Lys Leu Glu Leu 20 25 30 Ile Ala Lys Gly Glu Asp Ile Arg Glu Glu Asp Leu Lys Arg Ile Lys 35 40 45 Glu Arg Leu Glu Glu Ile Lys Lys Arg Ser Lys Arg Ile Lys Glu Glu 50 55 60 Ser Asp Glu Ile Asp Lys Lys Thr Lys 65 70 <210> SEQ ID NO 279 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 279 Ser Glu Arg Glu Leu Gln Arg Glu Leu Asn Lys Ile Val Arg Arg Ile 1 5 10 15 Leu Glu Ile His Arg Glu Val Ser Glu Leu His Gln Arg Ala Val Lys 20 25 30 Leu Ile Arg Glu Asn Asp Asn Ser Glu Glu Leu Glu Glu Ile Ser Arg 35 40 45 Arg Ile Glu Glu Leu Ser Lys Glu Leu Glu Lys Leu Val Arg Glu His 50 55 60 Asp Glu Ile Val Lys Thr Ile Glu 65 70 <210> SEQ ID NO 280 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 280 Ser Glu Arg Glu Lys Leu Asp Arg Asn Asp Glu Glu Leu Lys Glu Ile 1 5 10 15 Asn Lys Arg Val Glu Glu Ile Lys Glu Arg Ser Asp Arg Ile Thr Glu 20 25 30 Ala Ile Glu Lys Asn Glu Arg Ser Glu Glu Glu Ile Arg Arg Leu Ser 35 40 45 Arg Glu Gln Asn Glu Ala Leu Gln Arg Leu Leu Glu Leu His Lys Lys 50 55 60 Leu Val Lys Leu His Arg Glu Leu Leu Glu Asp Thr Arg 65 70 75 <210> SEQ ID NO 281 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 281 Asp Lys Glu Asp Val Ile Arg Val His Asp Glu Gln His Lys Leu Ile 1 5 10 15 Glu Glu Gln Leu Glu Leu Thr Arg Arg Ile Ala Glu Leu Val Arg Glu 20 25 30 Ile Ala Lys Asn Thr Ala Ser Glu Glu Glu Ile Lys Glu Met Leu Lys 35 40 45 Glu Ile Lys Arg Leu Asp Asp Arg Ser Arg Glu Ile Gln Asp Arg Leu 50 55 60 Gln Lys Leu Leu Glu Glu Ile Arg Arg Lys Thr Lys 65 70 75 <210> SEQ ID NO 282 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 282 Thr Glu Glu Glu Ile Val Glu Leu Asn Lys Asp Ile Gln Arg Lys Ser 1 5 10 15 Lys Glu His Ile Asp Leu Gln Asn Glu Leu Val Lys Lys Ile Glu Arg 20 25 30 Ala Ile Arg Glu Asn Asn Ile Thr Glu Glu Leu Leu Glu Glu Leu Glu 35 40 45 Arg Leu Leu Arg Glu Ser Glu Lys Ile Val Glu Glu Ile Arg Arg Ile 50 55 60 Thr Asp Lys Ile Arg Lys Asp Ala Lys 65 70 <210> SEQ ID NO 283 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 283 Ser Glu Lys Glu Ile Leu Glu Arg Leu Leu Arg Leu Ser Lys Glu Gln 1 5 10 15 Asn Glu Ile Ser Glu Glu Ile His Arg Leu Thr Glu Arg Leu Val Glu 20 25 30 Leu Lys Arg Arg Lys Asp Asp Asp Glu Arg Leu Lys Arg Ile Leu Asp 35 40 45 Arg Gln Lys Arg Leu Val Glu Arg Ala Arg Glu Ile Ser Lys Glu Tyr 50 55 60 Glu Asp Leu Leu Arg Lys Leu Glu 65 70 <210> SEQ ID NO 284 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 284 Ser Met Glu Glu Leu Leu Arg Lys Asn Ala Arg Leu Ser Arg Lys Gln 1 5 10 15 Leu Lys Ile Ile Asp Glu His Leu Glu Leu Ser Thr Lys Leu Thr Arg 20 25 30 Gly Glu Ala Gly Asp Glu Thr Leu Glu Glu Ile Glu Arg Arg Ser Arg 35 40 45 Glu Met Leu Glu Glu Gln Arg Arg Val Asp Glu Glu Ser Lys Arg Ile 50 55 60 Arg Glu Lys Leu Lys 65 <210> SEQ ID NO 285 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 285 Ser Glu Glu Glu Ile Arg Asp Ile Val Glu Lys Leu Leu Arg Thr His 1 5 10 15 Glu Glu Val Leu Lys Glu Ile Lys Lys Leu Leu Asp Asp Ser Glu Arg 20 25 30 Val Arg Arg Arg Glu Leu Asp Lys Lys Asp Leu Asp Arg Ile Gln Lys 35 40 45 Glu Gln Arg Asp Ile Gln Glu Glu Asn Lys Glu Lys Ala Lys Arg Phe 50 55 60 Asp Glu Leu Val Lys Glu Leu Lys Lys Ala Ala Lys 65 70 75 <210> SEQ ID NO 286 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 286 Ser Glu Glu Glu His Arg Arg Thr Met Glu Lys Val Glu Lys Glu Val 1 5 10 15 Arg Asp Ile Lys Arg Arg Ser Glu Glu Val Lys Lys Lys Val Lys Ala 20 25 30 Asn Thr Leu Ser Glu Glu Asp Leu Val Arg Leu Leu Glu Arg Leu Val 35 40 45 Glu Asp His Lys Arg Leu Gln Asp Leu Ser Gln Glu Ile Ile Glu Arg 50 55 60 Asp Glu Lys Ala Thr Lys 65 70 <210> SEQ ID NO 287 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 287 Asp Glu Asp Glu Leu Ala Lys Glu Ile Glu Asp Val Gln Arg Arg Asn 1 5 10 15 Lys Glu Ser Gln Glu Glu His Asp Lys Ser Val Lys Lys Leu Glu Ala 20 25 30 Ala Glu Arg Gly Glu Ile Asp Glu Asp Ser Leu Leu Arg Val Leu Glu 35 40 45 Glu Asp Ile Lys Val Leu Glu Lys Asp Ile Glu Val Leu Glu Arg Ser 50 55 60 Ile Glu Val Ile Glu Lys Ala Glu 65 70 <210> SEQ ID NO 288 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 288 Ser Glu Lys Glu Leu Ile Arg Arg Leu Leu Glu Gln Gln Arg Gln His 1 5 10 15 Leu Arg Leu Ser Glu Arg Leu Ile Glu Leu Ser Arg Arg Leu Val Glu 20 25 30 Val Val Arg Lys Gly Lys Asp Asn Arg Asp Leu Leu Arg Glu Leu Lys 35 40 45 Lys Leu Ser Glu Glu His Lys Lys His Ser Lys Asp Asp His Glu Lys 50 55 60 Val Arg Glu Ile Arg Glu Arg Glu Lys 65 70 <210> SEQ ID NO 289 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 289 Asp Arg Lys Asp Leu Leu Lys Arg Asn Ile Lys Leu Leu Asp Arg His 1 5 10 15 Leu Lys Ile Leu Asp Thr Ile Leu Lys Leu Leu Glu Lys Leu Ser Glu 20 25 30 Leu Leu Lys Lys Ser Ser Ser Glu Glu Val Val Lys Glu Tyr Lys Lys 35 40 45 Ile Leu Asp Glu Ile Arg Lys Leu Leu Glu Glu Ser Lys Glu Ile His 50 55 60 Lys Glu Ser Lys Glu Ile Leu Glu Arg Glu Ser 65 70 75 <210> SEQ ID NO 290 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 290 Asp Glu Glu Lys Leu Ile Glu Arg Ser Lys Arg Leu Gln Glu Glu Ser 1 5 10 15 Glu Gln Leu Leu Glu Lys Phe Glu Gln Ile Leu Arg Glu Leu Thr Glu 20 25 30 Leu Leu Glu Lys Pro Asp Ser Glu Glu Leu Ala Arg Lys Ile Lys Lys 35 40 45 Leu His Asp Glu Leu Arg Lys Ile Ile Lys Arg Asn Gln Glu Leu Ile 50 55 60 Arg Glu His Glu Glu Ile Leu Arg Lys Arg Asp 65 70 75 <210> SEQ ID NO 291 <211> LENGTH: 234 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 291 Pro Lys Glu Glu Ala Arg Glu Leu Ile Arg Lys Gln Lys Glu Leu Ile 1 5 10 15 Lys Glu Gln Lys Lys Leu Ile Lys Glu Ala Lys Gln Lys Ser Asp Ser 20 25 30 Arg Asp Ala Glu Arg Ile Trp Lys Arg Ser Arg Glu Ile Asn Arg Glu 35 40 45 Ser Lys Lys Ile Asn Lys Arg Ile Lys Glu Leu Ile Lys Ser Gly Ser 50 55 60 Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Thr Lys Glu Asp Ile Leu 65 70 75 80 Glu Arg Gln Arg Lys Ile Ile Glu Arg Ala Gln Glu Ile His Arg Arg 85 90 95 Gln Gln Glu Ile Leu Glu Glu Leu Glu Arg Ile Ile Arg Lys Pro Gly 100 105 110 Ser Ser Glu Glu Ala Met Lys Arg Met Leu Lys Leu Leu Glu Glu Ser 115 120 125 Leu Arg Leu Leu Lys Glu Leu Leu Glu Leu Ser Glu Glu Ser Ala Gln 130 135 140 Leu Leu Tyr Glu Gln Arg Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser 145 150 155 160 Gly Ser Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu 165 170 175 Asn Leu Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys Gln Leu 180 185 190 Arg Asp Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val 195 200 205 Ile Asp Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val Ile Lys 210 215 220 Ile Phe Glu Asp Ser Val Arg Lys Lys Glu 225 230 <210> SEQ ID NO 292 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 292 Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg Glu Gln 1 5 10 15 Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu Glu Glu 20 25 30 Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu Ala Lys 35 40 45 Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu Leu 50 55 60 Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 65 70 75 <210> SEQ ID NO 293 <211> LENGTH: 93 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 293 Gly Ser Ser His His His His His His Ser Ser Gly Glu Asn Leu Tyr 1 5 10 15 Phe Gln Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu 20 25 30 Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys 35 40 45 Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val 50 55 60 Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu 65 70 75 80 Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 85 90 <210> SEQ ID NO 294 <211> LENGTH: 150 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 294 Pro Lys Glu Glu Ala Arg Glu Leu Ile Arg Lys Gln Lys Glu Leu Ile 1 5 10 15 Lys Glu Gln Lys Lys Leu Ile Lys Glu Ala Lys Gln Lys Ser Asp Ser 20 25 30 Arg Asp Ala Glu Arg Ile Trp Lys Arg Ser Arg Glu Ile Asn Arg Glu 35 40 45 Ser Lys Lys Ile Asn Lys Arg Ile Lys Glu Leu Ile Lys Ser Gly Ser 50 55 60 Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Thr Lys Glu Asp Ile Leu 65 70 75 80 Glu Arg Gln Arg Lys Ile Ile Glu Arg Ala Gln Glu Ile His Arg Arg 85 90 95 Gln Gln Glu Ile Leu Glu Glu Leu Glu Arg Ile Ile Arg Lys Pro Gly 100 105 110 Ser Ser Glu Glu Ala Met Lys Arg Met Leu Lys Leu Leu Glu Glu Ser 115 120 125 Leu Arg Leu Leu Lys Glu Leu Leu Glu Leu Ser Glu Glu Ser Ala Gln 130 135 140 Leu Leu Tyr Glu Gln Arg 145 150 <210> SEQ ID NO 295 <211> LENGTH: 96 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 295 Gly Ser His His His His His His Gly Ser Gly Ser Glu Asn Leu Tyr 1 5 10 15 Phe Gln Gly Ser Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala 20 25 30 His Arg Glu Gln Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg 35 40 45 Arg Leu Glu Glu Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys 50 55 60 Lys Glu Ala Lys Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg 65 70 75 80 Ser Leu Glu Leu Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 85 90 95 <210> SEQ ID NO 296 <211> LENGTH: 156 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 296 Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu Ser 1 5 10 15 Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys Lys 20 25 30 Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile Lys Glu 35 40 45 Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg Ile Ala 50 55 60 Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Pro Gly Ser Gly 65 70 75 80 Ser Glu Gly Ser Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe 85 90 95 Leu Glu Asn Leu Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys 100 105 110 Gln Leu Arg Asp Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys 115 120 125 Asp Val Ile Asp Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val 130 135 140 Ile Lys Ile Phe Glu Asp Ser Val Arg Lys Lys Glu 145 150 155 <210> SEQ ID NO 297 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 297 Thr Arg Glu Glu Leu Leu Arg Glu Asn Ile Glu Leu Ala Lys Glu His 1 5 10 15 Ile Glu Ile Met Arg Glu Ile Leu Glu Leu Leu Gln Lys Met Glu Glu 20 25 30 Leu Leu Glu Arg Gln Ser Ser Glu Asp Ile Leu Glu Glu Leu Arg Lys 35 40 45 Ile Ile Glu Arg Ile Arg Glu Leu Leu Asp Arg Ser Arg Lys Ile His 50 55 60 Glu Arg Ser Glu Glu Ile Ala Tyr Lys Glu Glu 65 70 75 <210> SEQ ID NO 298 <211> LENGTH: 93 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 298 Gly Ser His His His His His His Gly Ser Gly Ser Glu Asn Leu Tyr 1 5 10 15 Phe Gln Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu 20 25 30 Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys 35 40 45 Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val 50 55 60 Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu 65 70 75 80 Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 85 90 <210> SEQ ID NO 299 <211> LENGTH: 161 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 299 Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg Glu Gln 1 5 10 15 Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu Glu Glu 20 25 30 Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu Ala Lys 35 40 45 Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu Leu 50 55 60 Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys Gly Ser Glu Gly 65 70 75 80 Ser Gly Ser Glu Gly Ser Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu 85 90 95 Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp 100 105 110 Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp 115 120 125 Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu Lys 130 135 140 Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys Val 145 150 155 160 Glu <210> SEQ ID NO 300 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 300 Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg Lys Ile Ile Glu Arg Ala 1 5 10 15 Gln Glu Ile His Arg Arg Gln Gln Glu Ile Leu Glu Glu Leu Glu Arg 20 25 30 Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu Ala Met Lys Arg Met Leu 35 40 45 Lys Leu Leu Glu Glu Ser Leu Arg Leu Leu Lys Glu Leu Leu Glu Leu 50 55 60 Ser Glu Glu Ser Ala Gln Leu Leu Tyr Glu Gln Arg 65 70 75 <210> SEQ ID NO 301 <211> LENGTH: 92 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 301 Gly Ser Ser His His His His His His Ser Ser Gly Glu Asn Leu Tyr 1 5 10 15 Phe Gln Gly Ser Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe 20 25 30 Leu Glu Asn Leu Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys 35 40 45 Gln Leu Arg Asp Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys 50 55 60 Asp Val Ile Asp Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val 65 70 75 80 Ile Lys Ile Phe Glu Asp Ser Val Arg Lys Lys Glu 85 90 <210> SEQ ID NO 302 <211> LENGTH: 149 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 302 Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu Ser 1 5 10 15 Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys Lys 20 25 30 Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile Lys Glu 35 40 45 Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg Ile Ala 50 55 60 Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Ser Glu Gly Ser 65 70 75 80 Gly Ser Glu Gly Ser Gly Ser Pro Lys Glu Glu Ala Arg Glu Leu Ile 85 90 95 Arg Lys Gln Lys Glu Leu Ile Lys Glu Gln Lys Lys Leu Ile Lys Glu 100 105 110 Ala Lys Gln Lys Ser Asp Ser Arg Asp Ala Glu Arg Ile Trp Lys Arg 115 120 125 Ser Arg Glu Ile Asn Arg Glu Ser Lys Lys Ile Asn Lys Arg Ile Lys 130 135 140 Glu Leu Ile Lys Ser 145 <210> SEQ ID NO 303 <211> LENGTH: 147 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 303 Pro Lys Lys Glu Ala Glu Glu Leu Ala Glu Glu Ser Glu Glu Leu His 1 5 10 15 Asp Arg Ser Glu Lys Leu His Glu Arg Ala Glu Gln Ser Ser Asn Ser 20 25 30 Glu Glu Ala Arg Lys Ile Leu Glu Asp Ile Glu Arg Ile Ser Glu Arg 35 40 45 Ile Glu Glu Ile Ser Asp Arg Ile Glu Arg Leu Leu Arg Ser Gly Ser 50 55 60 Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Asp Asp Lys Glu Leu Asp 65 70 75 80 Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile 85 90 95 Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg 100 105 110 Lys Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His 115 120 125 Glu Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys 130 135 140 Lys Val Glu 145 <210> SEQ ID NO 304 <211> LENGTH: 150 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 304 Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg Lys Ile Ile Glu Arg Ala 1 5 10 15 Gln Glu Ile His Arg Arg Gln Gln Glu Ile Leu Glu Glu Leu Glu Arg 20 25 30 Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu Ala Met Lys Arg Met Leu 35 40 45 Lys Leu Leu Glu Glu Ser Leu Arg Leu Leu Lys Glu Leu Leu Glu Leu 50 55 60 Ser Glu Glu Ser Ala Gln Leu Leu Tyr Glu Gln Arg Gly Ser Glu Gly 65 70 75 80 Ser Gly Ser Glu Gly Ser Gly Ser Pro Lys Glu Glu Ala Arg Glu Leu 85 90 95 Ile Arg Lys Gln Lys Glu Leu Ile Lys Glu Gln Lys Lys Leu Ile Lys 100 105 110 Glu Ala Lys Gln Lys Ser Asp Ser Arg Asp Ala Glu Arg Ile Trp Lys 115 120 125 Arg Ser Arg Glu Ile Asn Arg Glu Ser Lys Lys Ile Asn Lys Arg Ile 130 135 140 Lys Glu Leu Ile Lys Ser 145 150 <210> SEQ ID NO 305 <211> LENGTH: 144 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 305 Pro Lys Lys Glu Ala Glu Glu Leu Ala Glu Glu Ser Glu Glu Leu His 1 5 10 15 Asp Arg Ser Glu Lys Leu His Glu Arg Ala Glu Gln Ser Ser Asn Ser 20 25 30 Glu Glu Ala Arg Lys Ile Leu Glu Asp Ile Glu Arg Ile Ser Glu Arg 35 40 45 Ile Glu Glu Ile Ser Asp Arg Ile Glu Arg Leu Leu Arg Ser Gly Ser 50 55 60 Glu Gly Ser Gly Ser Glu Gly Ser Asp Ser Asp Glu His Leu Lys Lys 65 70 75 80 Leu Lys Thr Phe Leu Glu Asn Leu Arg Arg His Leu Asp Arg Leu Asp 85 90 95 Lys His Ile Lys Gln Leu Arg Asp Ile Leu Ser Glu Asn Pro Glu Asp 100 105 110 Glu Arg Val Lys Asp Val Ile Asp Leu Ser Glu Arg Ser Val Arg Ile 115 120 125 Val Lys Thr Val Ile Lys Ile Phe Glu Asp Ser Val Arg Lys Lys Glu 130 135 140 <210> SEQ ID NO 306 <211> LENGTH: 152 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 306 Gly Ser Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu 1 5 10 15 Glu Ser Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile 20 25 30 Lys Lys Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile 35 40 45 Lys Glu Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg 50 55 60 Ile Ala Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Ala Ala Asp 65 70 75 80 Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln 85 90 95 Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu 100 105 110 Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val Glu 115 120 125 Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile Ala 130 135 140 Lys Thr His Ala Lys Lys Val Glu 145 150 <210> SEQ ID NO 307 <211> LENGTH: 156 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 307 Gly Ser Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu 1 5 10 15 Glu Ser Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile 20 25 30 Lys Lys Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile 35 40 45 Lys Glu Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg 50 55 60 Ile Ala Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Gly Ser 65 70 75 80 Gly Ser Pro Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu 85 90 95 Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu 100 105 110 Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu 115 120 125 Thr Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu 130 135 140 Leu Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 145 150 155 <210> SEQ ID NO 308 <211> LENGTH: 162 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 308 Gly Ser Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu 1 5 10 15 Glu Ser Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile 20 25 30 Lys Lys Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile 35 40 45 Lys Glu Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg 50 55 60 Ile Ala Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Gly Ser 65 70 75 80 Gly Ser Pro Gly Gly Ser Gly Ser Pro Asp Asp Lys Glu Leu Asp Lys 85 90 95 Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile 100 105 110 Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys 115 120 125 Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu 130 135 140 Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys 145 150 155 160 Val Glu <210> SEQ ID NO 309 <211> LENGTH: 174 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 309 Gly Ser Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu 1 5 10 15 Glu Ser Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile 20 25 30 Lys Lys Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile 35 40 45 Lys Glu Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg 50 55 60 Ile Ala Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Gly Ser 65 70 75 80 Gly Ser Pro Gly Gly Ser Gly Ser Pro Gly Gly Ser Gly Ser Pro Gly 85 90 95 Gly Ser Gly Ser Pro Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr 100 105 110 Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn 115 120 125 Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val 130 135 140 Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys 145 150 155 160 Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 165 170 <210> SEQ ID NO 310 <211> LENGTH: 158 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 310 Pro Glu Asp Asp Val Val Arg Ile Ile Lys Glu Asp Leu Glu Ser Asn 1 5 10 15 Arg Glu Val Leu Arg Glu Gln Lys Glu Ile His Arg Ile Leu Glu Leu 20 25 30 Val Thr Arg Gly Glu Val Ser Glu Glu Ala Ile Asp Arg Val Leu Lys 35 40 45 Arg Gln Glu Asp Leu Leu Lys Lys Gln Lys Glu Ser Thr Asp Lys Ala 50 55 60 Arg Lys Val Val Glu Glu Arg Arg Gly Ser Glu Gly Ser Gly Ser Glu 65 70 75 80 Gly Ser Asp Leu Glu Asp Leu Leu Arg Arg Leu Arg Arg Leu Val Asp 85 90 95 Glu Gln Arg Arg Leu Val Glu Glu Leu Glu Arg Val Ser Arg Arg Leu 100 105 110 Glu Lys Ala Val Arg Asp Asn Glu Asp Glu Arg Glu Leu Ala Arg Leu 115 120 125 Ser Arg Glu His Ser Asp Ile Gln Asp Lys His Asp Lys Leu Ala Arg 130 135 140 Glu Ile Leu Glu Val Leu Lys Arg Leu Leu Glu Arg Thr Glu 145 150 155 <210> SEQ ID NO 311 <211> LENGTH: 163 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 311 Gly Ser Asp Ala Tyr Asp Leu Asp Arg Ile Val Lys Glu His Arg Arg 1 5 10 15 Leu Val Glu Glu Gln Arg Glu Leu Val Glu Glu Leu Glu Lys Leu Val 20 25 30 Arg Arg Gln Glu Asp His Arg Val Asp Lys Lys Glu Ser His Glu Ile 35 40 45 Leu Glu Arg Leu Glu Arg Ile Ile Arg Arg Ser Thr Arg Ile Leu Thr 50 55 60 Glu Leu Glu Lys Leu Thr Asp Glu Phe Glu Arg Arg Thr Arg Gly Ser 65 70 75 80 Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Asp Asp Lys Glu Leu Asp 85 90 95 Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile 100 105 110 Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg 115 120 125 Lys Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His 130 135 140 Glu Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys 145 150 155 160 Lys Val Glu <210> SEQ ID NO 312 <211> LENGTH: 165 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 312 Gly Ser Asp Glu Asp Asp Glu Leu Glu Arg Leu Leu Arg Glu Tyr His 1 5 10 15 Arg Val Leu Arg Glu Tyr Glu Lys Leu Leu Glu Glu Leu Arg Arg Leu 20 25 30 Tyr Glu Glu Tyr Lys Arg Gly Glu Val Ser Glu Glu Glu Ser Asp Arg 35 40 45 Ile Leu Arg Glu Ile Lys Glu Ile Leu Asp Lys Ser Glu Arg Leu Trp 50 55 60 Asp Leu Ser Glu Glu Val Trp Arg Thr Leu Leu Tyr Gln Ala Glu Gly 65 70 75 80 Ser Glu Gly Ser Gly Ser Glu Gly Ser Asp Glu Lys Asp Tyr His Arg 85 90 95 Arg Leu Ile Glu His Leu Glu Asp Leu Val Arg Arg His Glu Glu Leu 100 105 110 Ile Lys Arg Gln Lys Lys Val Val Glu Glu Leu Glu Arg Arg Gly Leu 115 120 125 Asp Glu Arg Leu Arg Arg Val Val Asp Arg Phe Arg Arg Ser Ser Glu 130 135 140 Arg Trp Glu Glu Val Ile Glu Arg Phe Arg Gln Val Val Asp Lys Leu 145 150 155 160 Arg Lys Ser Val Glu 165 <210> SEQ ID NO 313 <211> LENGTH: 168 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 313 Gly Ser Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu 1 5 10 15 Glu Ser Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile 20 25 30 Lys Lys Leu Leu Lys Lys Ala Arg Gly Ala Asp Glu Lys Val Leu Asp 35 40 45 Glu Leu Arg Lys Ile Ile Glu Arg Ile Arg Glu Leu Leu Asp Arg Ser 50 55 60 Arg Lys Ile His Glu Arg Ser Glu Glu Ile Ala Tyr Lys Glu Glu Gly 65 70 75 80 Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Asp Glu Ser Asp Arg 85 90 95 Ile Arg Lys Ile Val Glu Glu Ser Asp Glu Ile Val Lys Glu Ser Arg 100 105 110 Lys Leu Ala Glu Arg Ala Arg Glu Leu Ile Lys Glu Ser Glu Asp Lys 115 120 125 Arg Val Ser Glu Glu Arg Asn Glu Arg Leu Leu Glu Glu Leu Leu Arg 130 135 140 Ile Leu Asp Glu Asn Ala Glu Leu Leu Lys Arg Asn Leu Glu Leu Leu 145 150 155 160 Lys Glu Val Leu Tyr Arg Thr Arg 165 <210> SEQ ID NO 314 <211> LENGTH: 164 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 314 Gly Ser Asp Glu Asp Asp Glu Leu Glu Arg Leu Leu Arg Glu Tyr His 1 5 10 15 Arg Val Leu Arg Glu Tyr Glu Lys Leu Leu Glu Glu Leu Arg Arg Leu 20 25 30 Tyr Glu Glu Tyr Lys Arg Gly Glu Val Ser Glu Glu Glu Ser Asp Arg 35 40 45 Ile Leu Arg Glu Ile Lys Glu Ile Leu Asp Lys Ser Glu Arg Leu Trp 50 55 60 Asp Leu Ser Glu Glu Val Trp Arg Thr Leu Leu Tyr Gln Ala Glu Gly 65 70 75 80 Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Asp Asp Lys Glu Leu 85 90 95 Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys 100 105 110 Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu 115 120 125 Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg 130 135 140 His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala 145 150 155 160 Lys Lys Val Glu <210> SEQ ID NO 315 <211> LENGTH: 177 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 315 Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu Asn Leu 1 5 10 15 Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys Gln Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val Ile Asp 35 40 45 Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val Ile Lys Ile Phe 50 55 60 Glu Asp Ser Val Arg Lys Lys Glu Gly Ser Glu Gly Ser Gly Ser Glu 65 70 75 80 Gly Ser Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Glu Gly 85 90 95 Ser Gly Ser Glu Gly Ser Pro Thr Asp Glu Val Ile Glu Val Leu Lys 100 105 110 Glu Leu Leu Arg Ile His Arg Glu Asn Leu Arg Val Asn Glu Glu Ile 115 120 125 Val Glu Val Asn Glu Arg Ala Ser Arg Val Thr Asp Arg Glu Glu Leu 130 135 140 Glu Arg Leu Leu Arg Arg Ser Asn Glu Leu Ile Lys Arg Ser Arg Glu 145 150 155 160 Leu Asn Glu Glu Ser Lys Lys Leu Ile Glu Lys Leu Glu Arg Leu Ala 165 170 175 Thr <210> SEQ ID NO 316 <211> LENGTH: 155 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 316 Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu 1 5 10 15 Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val 35 40 45 Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile 50 55 60 Ala Lys Thr His Ala Lys Lys Val Glu Gly Ser Glu Gly Ser Gly Ser 65 70 75 80 Glu Gly Ser Thr Ala Glu Glu Leu Leu Glu Val His Lys Lys Ser Asp 85 90 95 Arg Val Thr Lys Glu His Leu Arg Val Ser Glu Glu Ile Leu Lys Val 100 105 110 Val Glu Val Leu Thr Arg Gly Glu Val Ser Ser Glu Val Leu Lys Arg 115 120 125 Val Leu Arg Lys Leu Glu Glu Leu Thr Asp Lys Leu Arg Arg Val Thr 130 135 140 Glu Glu Gln Arg Arg Val Val Glu Lys Leu Asn 145 150 155 <210> SEQ ID NO 317 <211> LENGTH: 156 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 317 Asp Asn Glu Glu Ile Ile Lys Glu Ala Arg Arg Val Val Glu Glu Tyr 1 5 10 15 Lys Lys Ala Val Asp Arg Leu Glu Glu Leu Val Arg Arg Ala Glu Asn 20 25 30 Ala Lys His Ala Ser Glu Lys Glu Leu Lys Asp Ile Val Arg Glu Ile 35 40 45 Leu Arg Ile Ser Lys Glu Leu Asn Lys Val Ser Glu Arg Leu Ile Glu 50 55 60 Leu Trp Glu Arg Ser Gln Glu Arg Ala Arg Gly Ser Glu Gly Ser Gly 65 70 75 80 Ser Glu Gly Ser Thr Ala Glu Glu Leu Leu Glu Val His Lys Lys Ser 85 90 95 Asp Arg Val Thr Lys Glu His Leu Arg Val Ser Glu Glu Ile Leu Lys 100 105 110 Val Val Glu Val Leu Thr Arg Gly Glu Val Ser Ser Glu Val Leu Lys 115 120 125 Arg Val Leu Arg Lys Leu Glu Glu Leu Thr Asp Lys Leu Arg Arg Val 130 135 140 Thr Glu Glu Gln Arg Arg Val Val Glu Lys Leu Asn 145 150 155 <210> SEQ ID NO 318 <211> LENGTH: 280 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 318 Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu 1 5 10 15 Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val 35 40 45 Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile 50 55 60 Ala Lys Thr His Ala Lys Lys Val Glu Gly Ser Glu Gly Ser Gly Ser 65 70 75 80 Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Glu 85 90 95 Gly Ser Gly Ser Glu Gly Ser Pro Thr Asp Glu Val Ile Glu Val Leu 100 105 110 Lys Glu Leu Leu Arg Ile His Arg Glu Asn Leu Arg Val Asn Glu Glu 115 120 125 Ile Val Glu Val Asn Glu Arg Ala Ser Arg Val Thr Asp Arg Glu Glu 130 135 140 Leu Glu Arg Leu Leu Arg Arg Ser Asn Glu Leu Ile Lys Arg Ser Arg 145 150 155 160 Glu Leu Asn Glu Glu Ser Lys Lys Leu Ile Glu Lys Leu Glu Arg Leu 165 170 175 Ala Thr Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Glu Gly 180 185 190 Ser Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser 195 200 205 Thr Ala Glu Glu Leu Leu Glu Val His Lys Lys Ser Asp Arg Val Thr 210 215 220 Lys Glu His Leu Arg Val Ser Glu Glu Ile Leu Lys Val Val Glu Val 225 230 235 240 Leu Thr Arg Gly Glu Val Ser Ser Glu Val Leu Lys Arg Val Leu Arg 245 250 255 Lys Leu Glu Glu Leu Thr Asp Lys Leu Arg Arg Val Thr Glu Glu Gln 260 265 270 Arg Arg Val Val Glu Lys Leu Asn 275 280 <210> SEQ ID NO 319 <211> LENGTH: 154 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 319 Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu Asn Leu 1 5 10 15 Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys Gln Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val Ile Asp 35 40 45 Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val Ile Lys Ile Phe 50 55 60 Glu Asp Ser Val Arg Lys Lys Glu Gly Ser Glu Gly Ser Gly Ser Glu 65 70 75 80 Gly Ser Pro Glu Asp Asp Val Val Arg Ile Ile Lys Glu Asp Leu Glu 85 90 95 Ser Asn Arg Glu Val Leu Arg Glu Gln Lys Glu Ile His Arg Ile Leu 100 105 110 Glu Leu Val Thr Arg Gly Glu Val Ser Glu Glu Ala Ile Asp Arg Val 115 120 125 Leu Lys Arg Gln Glu Asp Leu Leu Lys Lys Gln Lys Glu Ser Thr Asp 130 135 140 Lys Ala Arg Lys Val Val Glu Glu Arg Arg 145 150 <210> SEQ ID NO 320 <211> LENGTH: 156 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 320 Asp Asn Glu Glu Ile Ile Lys Glu Ala Arg Arg Val Val Glu Glu Tyr 1 5 10 15 Lys Lys Ala Val Asp Arg Leu Glu Glu Leu Val Arg Arg Ala Glu Asn 20 25 30 Ala Lys His Ala Ser Glu Lys Glu Leu Lys Asp Ile Val Arg Glu Ile 35 40 45 Leu Arg Ile Ser Lys Glu Leu Asn Lys Val Ser Glu Arg Leu Ile Glu 50 55 60 Leu Trp Glu Arg Ser Gln Glu Arg Ala Arg Gly Ser Glu Gly Ser Gly 65 70 75 80 Ser Glu Gly Ser Pro Glu Asp Asp Val Val Arg Ile Ile Lys Glu Asp 85 90 95 Leu Glu Ser Asn Arg Glu Val Leu Arg Glu Gln Lys Glu Ile His Arg 100 105 110 Ile Leu Glu Leu Val Thr Arg Gly Glu Val Ser Glu Glu Ala Ile Asp 115 120 125 Arg Val Leu Lys Arg Gln Glu Asp Leu Leu Lys Lys Gln Lys Glu Ser 130 135 140 Thr Asp Lys Ala Arg Lys Val Val Glu Glu Arg Arg 145 150 155 <210> SEQ ID NO 321 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 321 Asp Leu Glu Asp Leu Leu Arg Arg Leu Arg Arg Leu Val Asp Glu Gln 1 5 10 15 Arg Arg Leu Val Glu Glu Leu Glu Arg Val Ser Arg Arg Leu Glu Lys 20 25 30 Ala Val Arg Asp Asn Glu Asp Glu Arg Glu Leu Ala Arg Leu Ser Arg 35 40 45 Glu His Ser Asp Ile Gln Asp Lys His Asp Lys Leu Ala Arg Glu Ile 50 55 60 Leu Glu Val Leu Lys Arg Leu Leu Glu Arg Thr Glu Gly Ser Glu Gly 65 70 75 80 Ser Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser 85 90 95 Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser Pro Glu Asp Asp Val Val 100 105 110 Arg Ile Ile Lys Glu Asp Leu Glu Ser Asn Arg Glu Val Leu Arg Glu 115 120 125 Gln Lys Glu Ile His Arg Ile Leu Glu Leu Val Thr Arg Gly Glu Val 130 135 140 Ser Glu Glu Ala Ile Asp Arg Val Leu Lys Arg Gln Glu Asp Leu Leu 145 150 155 160 Lys Lys Gln Lys Glu Ser Thr Asp Lys Ala Arg Lys Val Val Glu Glu 165 170 175 Arg Arg <210> SEQ ID NO 322 <211> LENGTH: 160 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 322 Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys 1 5 10 15 Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu 20 25 30 Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr 35 40 45 Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu 50 55 60 Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu Gly Ser Glu Gly Ser 65 70 75 80 Gly Ser Glu Gly Ser Pro Thr Asp Glu Val Ile Glu Val Leu Lys Glu 85 90 95 Leu Leu Arg Ile His Arg Glu Asn Leu Arg Val Asn Glu Glu Ile Val 100 105 110 Glu Val Asn Glu Arg Ala Ser Arg Val Thr Asp Arg Glu Glu Leu Glu 115 120 125 Arg Leu Leu Arg Arg Ser Asn Glu Leu Ile Lys Arg Ser Arg Glu Leu 130 135 140 Asn Glu Glu Ser Lys Lys Leu Ile Glu Lys Leu Glu Arg Leu Ala Thr 145 150 155 160 <210> SEQ ID NO 323 <211> LENGTH: 154 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 323 Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu Asn Leu 1 5 10 15 Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys Gln Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val Ile Asp 35 40 45 Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val Ile Lys Ile Phe 50 55 60 Glu Asp Ser Val Arg Lys Lys Glu Gly Ser Glu Gly Ser Gly Ser Glu 65 70 75 80 Gly Ser Thr Ala Glu Glu Leu Leu Glu Val His Lys Lys Ser Asp Arg 85 90 95 Val Thr Lys Glu His Leu Arg Val Ser Glu Glu Ile Leu Lys Val Val 100 105 110 Glu Val Leu Thr Arg Gly Glu Val Ser Ser Glu Val Leu Lys Arg Val 115 120 125 Leu Arg Lys Leu Glu Glu Leu Thr Asp Lys Leu Arg Arg Val Thr Glu 130 135 140 Glu Gln Arg Arg Val Val Glu Lys Leu Asn 145 150 <210> SEQ ID NO 324 <211> LENGTH: 166 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 324 Gly Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu 1 5 10 15 Ser Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys 20 25 30 Lys Leu Leu Lys Lys Ala Arg Gly Ala Asp Glu Lys Val Leu Asp Glu 35 40 45 Leu Arg Lys Ile Ile Glu Arg Ile Arg Glu Leu Leu Asp Arg Ser Arg 50 55 60 Lys Ile His Glu Arg Ser Glu Glu Ile Ala Tyr Lys Glu Glu Gly Ser 65 70 75 80 Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Asp Ala Tyr Asp Leu Asp 85 90 95 Arg Ile Val Lys Glu His Arg Arg Leu Val Glu Glu Gln Arg Glu Leu 100 105 110 Val Glu Glu Leu Glu Lys Leu Val Arg Arg Gln Glu Asp His Arg Val 115 120 125 Asp Lys Lys Glu Ser His Glu Ile Leu Glu Arg Leu Glu Arg Ile Ile 130 135 140 Arg Arg Ser Thr Arg Ile Leu Thr Glu Leu Glu Lys Leu Thr Asp Glu 145 150 155 160 Phe Glu Arg Arg Thr Arg 165 <210> SEQ ID NO 325 <211> LENGTH: 162 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 325 Thr Arg Glu Glu Leu Leu Arg Glu Asn Ile Glu Leu Ala Lys Glu His 1 5 10 15 Ile Glu Ile Met Arg Glu Ile Leu Glu Leu Leu Gln Lys Met Glu Glu 20 25 30 Leu Leu Glu Lys Ala Arg Gly Ala Asp Glu Asp Val Ala Lys Thr Ile 35 40 45 Lys Glu Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg 50 55 60 Ile Ala Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Ser Glu 65 70 75 80 Gly Ser Gly Ser Glu Gly Ser Gly Ser Asp Asp Lys Glu Leu Asp Lys 85 90 95 Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile 100 105 110 Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys 115 120 125 Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu 130 135 140 Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys 145 150 155 160 Val Glu <210> SEQ ID NO 326 <211> LENGTH: 162 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 326 Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys 1 5 10 15 Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu 20 25 30 Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr 35 40 45 Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu 50 55 60 Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu Gly Ser Glu Gly Ser 65 70 75 80 Gly Ser Glu Gly Ser Gly Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg 85 90 95 Lys Ile Ile Glu Arg Ala Gln Glu Ile His Arg Arg Gln Gln Glu Ile 100 105 110 Leu Glu Glu Leu Glu Arg Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu 115 120 125 Ala Met Lys Arg Met Leu Lys Leu Leu Glu Glu Ser Leu Arg Leu Leu 130 135 140 Lys Glu Leu Leu Glu Leu Ser Glu Glu Ser Ala Gln Leu Leu Tyr Glu 145 150 155 160 Gln Arg <210> SEQ ID NO 327 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 327 Gly Ala Ala Gly Gly Ala Gly Ala Thr Ala Thr Cys Ala Thr Cys 1 5 10 15 <210> SEQ ID NO 328 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 328 Gly Ser Ser His His His His His His Ser Ser Gly Glu Asn Leu Tyr 1 5 10 15 Phe Gln Gly Ser 20 <210> SEQ ID NO 329 <211> LENGTH: 40 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 329 Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Ser Gly Gly 1 5 10 15 Gly Ser Gly Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys Ser Gly 20 25 30 Glu Asn Leu Tyr Phe Gln Gly Ser 35 40 <210> SEQ ID NO 330 <211> LENGTH: 44 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 330 Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val 1 5 10 15 Glu Glu Asn Pro Gly Pro Gly Asp Lys Ala Glu Leu Ile Pro Glu Pro 20 25 30 Pro Lys Lys Lys Arg Lys Val Glu Leu Gly Thr Ala 35 40 <210> SEQ ID NO 331 <211> LENGTH: 62 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 331 Pro Lys Glu Glu Ala Arg Glu Leu Ile Arg Lys Gln Lys Glu Leu Ile 1 5 10 15 Lys Glu Gln Lys Lys Leu Ile Lys Glu Ala Lys Gln Lys Ser Asp Ser 20 25 30 Arg Asp Ala Glu Arg Ile Trp Lys Arg Ser Arg Glu Ile Asn Arg Glu 35 40 45 Ser Lys Lys Ile Asn Lys Arg Ile Lys Glu Leu Ile Lys Ser 50 55 60 <210> SEQ ID NO 332 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 332 Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg Glu Ala 1 5 10 15 Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu Glu Glu 20 25 30 Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu Ala Lys 35 40 45 Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg Leu Leu Glu Leu 50 55 60 Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 65 70 75 <210> SEQ ID NO 333 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 333 Tyr Ser Trp Asn Ser 1 5 <210> SEQ ID NO 334 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 334 Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg Glu Gln 1 5 10 15 Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Thr Glu Glu 20 25 30 Ile Ile Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Asp Glu Leu Arg 35 40 45 Arg Ile Gln Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu Leu 50 55 60 Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 65 70 75 <210> SEQ ID NO 335 <400> SEQUENCE: 335 000 <210> SEQ ID NO 336 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 336 Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg Glu Gln 1 5 10 15 Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Thr Glu Glu 20 25 30 Ile Ile Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Asp Glu Leu Arg 35 40 45 Arg Ile Gln Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu Leu 50 55 60 Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 65 70 75 <210> SEQ ID NO 337 <211> LENGTH: 37 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 337 Pro Glu Arg Asp Glu Asn Arg Lys Leu Leu Asp Lys Val Arg Lys Leu 1 5 10 15 Val Glu Lys Ser Arg Arg Leu Val Glu Glu Leu Arg Lys Leu Val Asp 20 25 30 Gln Ser Thr Lys Asn 35 <210> SEQ ID NO 338 <211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 338 Ser Glu Glu Ala Lys Lys Glu Ala Lys Lys Ile Leu Glu Glu Ile Arg 1 5 10 15 Glu Leu Ser Lys Arg Ser Leu Glu Leu Leu Arg Glu Ile Leu Tyr Leu 20 25 30 Ser Gln Gln Val Asn Asp Val Asp Glu Lys Ala Leu Glu Arg Gln Arg 35 40 45 Lys Ile Ile Glu Arg Ala Gln Glu Ile His Arg Arg Gln Gln Glu Ile 50 55 60 Leu Glu Glu Leu Glu Arg Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu 65 70 75 80 Ala Met Lys Arg Met Leu Lys Leu Leu Glu Glu Ser Leu Arg Leu Leu 85 90 95 Lys Glu Leu Leu Glu Leu Ser Glu Glu Ser Ala Gln Leu Leu Tyr Glu 100 105 110 Ala Arg <210> SEQ ID NO 339 <211> LENGTH: 37 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 339 Asp Arg Arg Leu Glu Glu Tyr Glu Arg Gln Val Asp Glu Leu Arg Glu 1 5 10 15 Glu Ile Arg Arg Tyr Lys Glu Glu Val Asp Lys Phe Asp Lys Glu Val 20 25 30 Lys Tyr Tyr Lys Lys 35 <210> SEQ ID NO 340 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 340 Asp Arg Glu Glu Val His Lys Glu Ile Val Lys Leu Ile Arg Glu Ile 1 5 10 15 Ile Lys Ile His Lys Lys Ile Leu Lys Ile His Glu Lys Ile Lys Asn 20 25 30 Gly Glu Ile Asp Pro Ser Glu Ile Leu Lys Leu Ser Glu Glu Ile Lys 35 40 45 Lys Leu Thr Asp Thr Ile Ile Lys Ile Ile Glu Asp Leu Glu Gln Leu 50 55 60 Thr Arg Asp Leu Arg Arg 65 70 <210> SEQ ID NO 341 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 341 Asp Glu Ile Thr Glu Ser Val Asp Arg Phe Lys Lys Ile Val Asp Gln 1 5 10 15 Phe Glu Glu Ser Ile Lys Lys Phe Glu Thr Val Ser Glu Glu Leu Arg 20 25 30 Lys Ser Ile Ser 35 <210> SEQ ID NO 342 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 342 Asp Lys Ala Glu Glu Val Glu Lys Ser Val Arg Lys Ile Glu Glu Ser 1 5 10 15 Ile Lys Lys Ile Arg Lys Ser Ile Lys Lys Ala Glu Asp Ala Val Gln 20 25 30 Leu Leu Lys Glu Gly Lys Ile Asp Ala Lys Asp Phe Leu Arg Ile Val 35 40 45 Arg Glu Asp Leu Glu Val Val Lys Glu Asp Val Glu Ile Val Lys Glu 50 55 60 Asp Val Glu Asn Val Arg Glu Phe Ser Ser 65 70 <210> SEQ ID NO 343 <211> LENGTH: 34 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 343 Asp Gln His Val Val Glu Ile Leu Arg Lys Ile Val Glu Ile Phe Arg 1 5 10 15 Gln His Ile Glu Lys Leu Lys Lys His Leu Glu Lys Leu Arg Tyr Thr 20 25 30 Ser Ser <210> SEQ ID NO 344 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 344 Asp Leu Lys Glu Val Leu Lys Thr Val Glu Glu Ala Val Lys Glu Ile 1 5 10 15 Ile Lys Ser Ser Glu Glu Leu Leu Gln Ile Ser Arg Lys Ile Leu Glu 20 25 30 Ile Ser Arg Val Gly Val Asp Glu His Glu Tyr Ile Ser Ala Ile Arg 35 40 45 Glu Tyr Leu Lys Ala Leu Glu Lys His Ile Gln Ile Leu Lys Lys Phe 50 55 60 Ile Glu Ile Leu Lys Glu Leu Ile Arg Ala Val Ser 65 70 75 <210> SEQ ID NO 345 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 345 Asp Glu Glu Asp Tyr Ile Asn Glu Asn Val Glu Lys Asp Val Arg Asp 1 5 10 15 Ile Glu Asp Asp Val Arg Arg Ile Asn Glu Arg Ile Arg Glu Leu Leu 20 25 30 Glu Lys Ile Arg Thr Glu Glu Val Leu Gln Arg Val Leu Glu Glu His 35 40 45 His Glu Leu Val Glu Arg Val Leu Arg Lys Leu Val Glu Ile Leu Arg 50 55 60 Lys His Glu Glu Glu Asn Arg 65 70 <210> SEQ ID NO 346 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 346 Asn Asp Glu Glu Leu Lys Lys Ile Leu Glu Thr Leu Asp Arg Ile Leu 1 5 10 15 Lys Lys Leu Asp Lys Ile Leu Thr Arg Leu Ile Glu Val Leu Lys Lys 20 25 30 Ser Glu Asp Pro Asn Leu Asp Asp Lys Asp Tyr Thr Glu Leu Val Lys 35 40 45 Gln Phe Ile Glu Leu Ile Lys Lys Tyr Glu Glu Val Val Lys Glu Tyr 50 55 60 Glu Glu Val Val Arg Gln Leu Ile Arg Leu Phe Ser 65 70 75 <210> SEQ ID NO 347 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 347 Asp Glu Asp Glu Ile Ser Tyr Asp Ser Lys Arg Arg Val Glu Glu Ile 1 5 10 15 Val Arg Gln Ala Arg Glu Lys Ser Glu Lys Ser Arg Lys Asp Ile Glu 20 25 30 Asp Val Ala Glu Val Leu Arg Lys Gly Asp Val Ser Glu Lys Glu Val 35 40 45 Val Asp Glu Leu Val Lys Val Leu Glu Glu Gln Val Lys Val Leu Arg 50 55 60 Glu Ala Val Glu Arg Leu Arg Glu Val Leu Lys Lys Gln Val Asp Asp 65 70 75 80 Val Arg <210> SEQ ID NO 348 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 348 Asn Asp Glu Glu Leu Lys Lys Ile Leu Glu Thr Leu Asp Arg Ile Leu 1 5 10 15 Lys Lys Leu Glu Lys Ile Leu Thr Arg Leu Ile Glu Val Leu Lys Lys 20 25 30 Ser Glu Asp Pro Asn Leu Asp Asp Lys Asp Tyr Thr Glu Leu Val Lys 35 40 45 Gln Phe Ile Glu Leu Ile Lys Lys Phe Glu Glu Val Ile Lys Glu Tyr 50 55 60 Glu Glu Val Val Arg Gln Leu Ile Arg Leu Phe Ser 65 70 75 <210> SEQ ID NO 349 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 349 Lys Glu Lys Asp Ile Val Lys Thr Leu Val Asp Leu Leu Arg Glu Asn 1 5 10 15 Leu Glu Thr Leu Glu Arg Leu Ile Glu Glu Val Val Arg Leu Leu Lys 20 25 30 Glu Asn Val Asp Val Arg Asp Glu Gly Arg Asp Asp Lys Asp Ser Glu 35 40 45 Arg Ile Leu Arg Asp Ile Lys Arg Arg Ile Asp Glu Ala Ala Lys Glu 50 55 60 Ser Arg Glu Ile Ile Glu Arg Ile Glu Lys Glu Val Glu Tyr Arg Ser 65 70 75 80 Arg <210> SEQ ID NO 350 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 350 Asp Lys Lys Asp Glu Leu Glu Arg Ile Leu Asp Glu Ile Arg Arg Leu 1 5 10 15 Ile Glu Arg Leu Asp Glu Ile Leu Ser Arg Leu Asn Lys Leu Leu Glu 20 25 30 Leu Leu Lys His Gly Val Pro Asn Ala Lys Glu Val Val Lys Asp Tyr 35 40 45 Ile Arg Leu Leu Lys Glu Tyr Leu Glu Leu Val Lys Glu Phe Leu Lys 50 55 60 Leu Val Lys Arg His Ala Asp Leu Val Ser 65 70 <210> SEQ ID NO 351 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 351 Asp Lys Arg Tyr Glu Ser Glu Lys Leu Lys Arg Arg Leu Asp Glu Ala 1 5 10 15 Val Glu Lys Val Arg Glu Val Val Glu Arg Val Glu Arg Glu Ser Asp 20 25 30 Arg Val Leu Glu Glu Val Arg Arg Arg Arg Glu Ser Lys Glu Val Val 35 40 45 Asp Lys Val Ile Glu Asp Asn Asp Lys Ala Leu Glu Asp Val Leu Arg 50 55 60 Val Val Asp Glu Val Ala Lys Val Val Arg Asp Val Val Arg Glu Asn 65 70 75 80 Thr Arg <210> SEQ ID NO 352 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 352 Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu 1 5 10 15 Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val 35 40 45 Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile 50 55 60 Ala Lys Thr His Ala Lys Lys Val Glu 65 70 <210> SEQ ID NO 353 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 353 Asp Glu Asp Glu Ile Leu Tyr His Ser Glu Arg Leu Leu Gln Lys Leu 1 5 10 15 Lys Lys Glu Leu Asp Asp Leu Lys Glu Lys Ser Arg Glu Leu Leu Glu 20 25 30 Glu Leu Lys Lys Glu Asp Pro Asp Asp Arg Leu Ile Glu Arg Ile Ile 35 40 45 Arg Leu His Asp Glu Val Leu Lys Asp Leu Asp Glu Val Leu Lys Asn 50 55 60 Ile Leu Glu Val His Arg Glu Val Leu Glu Arg Leu Arg 65 70 75 <210> SEQ ID NO 354 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 354 Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu 1 5 10 15 Gln Thr Ala Thr Lys Ile Ile Asp Asp Leu Asn Lys Val Leu Glu Lys 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Ile Glu Thr Val Val 35 40 45 Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile 50 55 60 Ala Lys Thr His Ala Lys Lys Val Glu 65 70 <210> SEQ ID NO 355 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 355 Pro Lys Glu Glu Leu Ile Arg Arg Val Leu Glu Glu Val Lys Arg Leu 1 5 10 15 Asn Glu Lys Leu Leu Glu Ile Ile Arg Arg Ala Ala Glu Leu Val Lys 20 25 30 Arg Ala Asn Asp Glu Leu Pro Glu Thr Glu Lys Leu Arg Glu Ile Asp 35 40 45 Arg Glu Leu Glu Lys Lys Leu Lys Glu Ile Glu Asp Glu Leu Arg Arg 50 55 60 Ile Asp Lys Glu Leu Asp Asp Ala Leu Tyr Glu Ile Glu Asp 65 70 75 <210> SEQ ID NO 356 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 356 Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu 1 5 10 15 Gln Thr Ala Thr Lys Val Val Asp Asp Ala Asn Lys Leu Leu Glu Lys 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val 35 40 45 Glu Leu Leu Lys Arg Leu Glu Lys Leu Ile Lys Glu Leu Leu Glu Ile 50 55 60 Ala Lys Thr His Ala Lys Lys Val Glu 65 70 <210> SEQ ID NO 357 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 357 Lys Glu Asp Glu Ser Val Lys Arg Ala Glu Glu Ile Val Arg Thr Leu 1 5 10 15 Leu Lys Leu Leu Glu Asp Ser Leu Arg Glu Ala Glu Arg Ser Leu Arg 20 25 30 Asp Ile Lys Asn Gly Glu Asp Glu His Asn Leu Arg Arg Ile Ser Glu 35 40 45 Lys Leu Glu Glu Leu Ser Lys Arg Ile Thr Glu Thr Ile Glu Arg Leu 50 55 60 Leu Arg Glu Leu Gln Tyr Thr Ser Arg 65 70 <210> SEQ ID NO 358 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 358 Asp Asp Lys Glu Ala Thr Lys Ile Ile Asp Asp Leu Asp Lys Leu Leu 1 5 10 15 Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Asn Lys Leu Leu Glu Lys 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val 35 40 45 Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Glu Leu 50 55 60 Leu Lys Arg His Glu Lys Lys Val Glu 65 70 <210> SEQ ID NO 359 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 359 Asp Glu Ser Glu Glu Ala Gln His Glu Val Glu Lys Val Leu Asp Asp 1 5 10 15 Ile Arg Arg Leu Ser Glu His Leu Gln Lys Arg Leu Glu Glu Val Leu 20 25 30 Glu Glu Val Tyr Glu Leu Arg Arg Glu Gly Ser Asp Arg Thr Glu Val 35 40 45 Val Glu Leu Leu Lys Glu Val Ile Arg Glu Ile Val Arg Val Asn Arg 50 55 60 Glu Ala Leu Glu Arg Leu Leu Arg Val Val Glu Glu Ala Val Lys Arg 65 70 75 80 Asn Glu <210> SEQ ID NO 360 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 360 Asp Asp Lys Glu Ala Asn Lys Leu Leu Glu Lys Ala Thr Lys Ile Ile 1 5 10 15 Asp Asp Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Ala Val Lys Glu Leu Leu 35 40 45 Glu Ile Ala Lys Thr His Ala Glu Leu Leu Lys Arg His Glu Lys Val 50 55 60 Val Glu Thr Tyr Val Lys Lys Val Glu 65 70 <210> SEQ ID NO 361 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 361 Asp Glu Glu Glu Glu Val Val Arg Arg Ala Glu Glu Leu Val Lys Glu 1 5 10 15 His Glu Glu Leu Ile Glu Arg Val Ile Arg Thr His Glu Glu Leu Val 20 25 30 Tyr Lys Leu Glu Asp Gln Gly Ala Asp Lys Lys Leu Val Asp Val Leu 35 40 45 Lys Arg Val Val Glu Glu Ser Glu Arg Val Ala Arg Glu Ile Val Lys 50 55 60 Val Ser Arg Glu Leu Ile Arg Leu Leu Glu Glu Ala Ser Arg 65 70 75 <210> SEQ ID NO 362 <211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 362 Ser Ala Asp Asp Val Leu Glu Asp Ile Leu Lys Ile Ile Arg Glu Leu 1 5 10 15 Ile Glu Ile Leu Asp Gln Ile Leu Ser Leu Leu Asn Gln Leu Leu Lys 20 25 30 Leu Leu Arg His Gly Val Pro Asn Ala Lys Lys Val Val Glu Lys Tyr 35 40 45 Lys Glu Ile Leu Glu Leu Tyr Leu Gln Leu Val Ser Leu Phe Leu Lys 50 55 60 Ile Val Lys Thr His Ala Asp Ala Val Ser Gly Lys Ile Asp Lys Lys 65 70 75 80 Ala Glu Glu Glu Ile Lys Lys Glu Glu Glu Lys Ile Lys Glu Lys Leu 85 90 95 Arg Gln Ala Lys Asp Ile Leu Lys Lys Leu Gln Glu Glu Ile Asp Lys 100 105 110 Thr Arg <210> SEQ ID NO 363 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 363 Asp Lys Glu Glu Glu Ser Glu Tyr Leu Leu Arg Asp Leu Val Arg Leu 1 5 10 15 Leu Glu Lys Val Lys Glu Lys Ile Glu Glu Val Asn Arg Glu Val Glu 20 25 30 Lys Leu Leu Lys Lys Val Lys Asp Gly Arg Leu Asp Arg Arg Glu Val 35 40 45 Leu Arg Glu Ile Leu Arg Leu Asn Arg Glu Leu Ala Glu Ile Ile Lys 50 55 60 Glu Val Val Asp Arg Ile Arg His Val Val Glu Arg Ser Glu Arg 65 70 75 <210> SEQ ID NO 364 <211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 364 Asn Asp Lys Val Leu Asp Lys Ile Leu Asp Ile Leu Asp Arg Ile Leu 1 5 10 15 Arg Leu Ala Thr Arg Val Ile Asp Leu Ala Asn Lys Leu Leu Gln Val 20 25 30 Lys Lys Lys Ser Thr His Lys Asp Pro Arg Ile Val Glu Thr Tyr Lys 35 40 45 Glu Leu Leu Lys Ile His Glu Thr Ala Val Arg Leu Leu Leu Glu Leu 50 55 60 Ala Asp Leu His Arg Arg Leu Lys Ser Lys Asp Glu Glu Ala Asn Lys 65 70 75 80 Arg Val Glu Thr Glu Leu Asp Arg Ile Arg Lys Lys Val Lys Asp Ile 85 90 95 Glu Asp Lys Val Arg Lys Leu Glu Asp Lys Val Arg Lys Thr Ala Ser 100 105 110 <210> SEQ ID NO 365 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 365 Pro Val Glu Glu Ile Ile Lys Glu Val Val Lys Arg Val Ile Glu Val 1 5 10 15 Gln Glu Lys Val Leu Arg Ile Ile Ser His Ala Val Lys Arg Val Val 20 25 30 Glu Val Gln Lys Lys Tyr Asp Pro Gly Ser Glu Glu Ser Asn Arg Val 35 40 45 Val Glu Glu Val Lys Lys Thr Ile Glu Asp Ala Ile Arg Glu Ser Asp 50 55 60 Glu Val Val Asp Glu Val Val Lys Arg Ile Gln Tyr Thr Val Arg 65 70 75 <210> SEQ ID NO 366 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 366 Asp Glu Ala Val Lys Arg Val Val Glu Lys Ser Leu Lys Ile Leu Asp 1 5 10 15 Glu Val Ile Lys Lys Ser Leu Asp Ile Leu Arg Glu Leu Ile Glu Leu 20 25 30 Gln Ile Arg His Ala Lys Asp Asp Glu Ser Val Ile Arg Ala Ser Lys 35 40 45 Ser Ala Leu Lys Asp Ala Ile Glu Ala Leu Lys Lys Ser Leu Asp Glu 50 55 60 Ile Lys Lys Ala Leu Lys Arg Ser Ala Asp Glu Gly 65 70 75 <210> SEQ ID NO 367 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 367 Asp Glu Asp Lys Glu Ala Asn Arg Val Leu Asp Glu Val Leu Lys Thr 1 5 10 15 Val Arg Asp Leu Leu Glu Thr Ala Asn Glu Val Leu Lys Glu Val Leu 20 25 30 Tyr Arg Leu Lys Arg Thr Asp Asp Gln Glu Lys Val Val Arg Thr Leu 35 40 45 Thr Glu Val Leu Lys Glu His Leu Lys Leu Val Glu Glu Ile Val Arg 50 55 60 Ile Leu Asp Lys Val Leu Lys Glu His Leu Glu Thr Glu Lys 65 70 75 <210> SEQ ID NO 368 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 368 Ser Lys Glu Glu Val Ile Arg Leu Leu Lys Glu Asn Val Arg Leu Ile 1 5 10 15 Lys Glu Asn Leu Glu Leu Leu Thr Arg Asn Leu Lys Leu Ile Thr Asp 20 25 30 Leu Val Arg Gly Ser Asn Gly Ser Glu Glu Lys Ile Lys Thr Leu Lys 35 40 45 Glu Leu Leu Lys Glu Tyr Arg Glu Leu Leu Lys Arg Tyr Arg Lys Leu 50 55 60 Val Glu Asp Tyr Lys Arg Leu Val Asp Lys His Asp 65 70 75 <210> SEQ ID NO 369 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 369 Arg Arg Glu Glu Val Val Lys Arg Ile Arg Glu Leu Leu Lys Arg Asn 1 5 10 15 Lys Glu Leu Ile Asp Arg Ile Arg Glu Leu Leu Glu Glu Asn Glu Tyr 20 25 30 Leu Asp Lys Asp Ala Arg Asp Lys Asp Val Leu Arg Arg Ser Val Glu 35 40 45 Leu Leu Glu Glu Leu Val Arg Ile Leu Glu Glu Ser Val Glu Leu Ala 50 55 60 Lys Glu Ile Ile Lys Leu Leu Arg Glu Val Val Glu 65 70 75 <210> SEQ ID NO 370 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 370 Tyr Ile Glu Asp Val Ile Lys Lys Ile Leu Asp Val Ser Arg Glu Leu 1 5 10 15 Ile Lys Leu Ser Arg Thr Ile Ile Lys Ile Ser Glu Glu Ile Asn Lys 20 25 30 Gln Leu Gln Gln Gly Arg Asp Thr Lys Asp Leu Val Lys Lys Tyr Asp 35 40 45 Glu Ile Ile Lys Lys Tyr Thr Arg Ile Val Gln His Tyr Thr Glu Leu 50 55 60 Ile Lys Glu Leu Gln Lys Leu Leu Ser 65 70 <210> SEQ ID NO 371 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 371 Asp Glu Lys Glu Glu Ala Lys Lys Ala Ser Glu Glu Ser Val Arg Thr 1 5 10 15 Val Glu Arg Ile Leu Glu Glu Leu Leu Lys Ala Ser Glu Glu Ser Val 20 25 30 Glu Leu Leu Arg Arg Gly Glu Asp Ala Lys Asp Val Val Glu Arg Ser 35 40 45 Lys Glu Ala Leu Lys Arg Val Lys Glu Leu Leu Asp Glu Val Val Lys 50 55 60 Arg Ser Asp Glu Ile Leu Lys Tyr Ile His Asn 65 70 75 <210> SEQ ID NO 372 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 372 Glu Glu Glu Glu Ile Leu Lys Ile Gln Lys Glu Leu Leu Arg Ile Gln 1 5 10 15 Ser Glu Ile Leu Asp Lys Gln Lys Lys Ile Leu Asp Thr Leu Arg Ser 20 25 30 Asn Gly Ala Val Thr Glu Glu Val Arg Ser Ile Leu Glu Lys Val Glu 35 40 45 Arg Leu Ser Glu Glu Ala Lys Glu Leu Ser Lys Glu Ala Lys Glu Leu 50 55 60 Thr Lys Glu Val Ser Lys Leu Ile Ser 65 70 <210> SEQ ID NO 373 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 373 Pro Asp Met Asp Glu Val Lys Arg Val Leu Asp Glu Leu Ile Glu Ile 1 5 10 15 Gln Glu Glu Ile Leu Arg Glu Ile Lys Arg Val Leu Glu Lys Leu Ile 20 25 30 Lys Ile Gln Glu Asp Asn Gly Ser Glu Tyr Glu Ser Arg Glu Val Val 35 40 45 Arg Glu Ile Val Glu Ile Ala Arg Lys Leu Val Glu Arg Ser Arg Arg 50 55 60 Val Val Lys Lys Ile Thr Glu Thr Leu Gln 65 70 <210> SEQ ID NO 374 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 374 Pro Leu Glu Asp Leu Val Arg Lys Tyr Asp Glu Leu Val Lys Thr Tyr 1 5 10 15 Glu Lys Leu Val Glu Glu Phe Lys Lys Ala Val Asp Lys Tyr Asp Lys 20 25 30 Ala Val Lys Lys Ala Pro Val Ser Lys Glu Ala Thr Asp Ser Leu Asp 35 40 45 Leu Ile Arg Lys Val Leu Glu Leu Leu Asp Arg Asn Leu Lys Leu Ile 50 55 60 Lys Glu Asn Ala Lys Leu Ile Lys Glu Leu Leu Lys 65 70 75 <210> SEQ ID NO 375 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 375 Pro Glu Arg Glu Ala Leu Arg Glu Val Leu Glu Asp Leu Lys Arg Val 1 5 10 15 Thr Asp Arg Leu Arg Glu Leu Val Glu Arg Val Leu Glu Glu Leu Lys 20 25 30 Lys Val Thr Asp His Val Asp Ser Glu Arg Ile Leu Arg Glu Ser Arg 35 40 45 Arg Val Leu Lys Glu Leu Lys Asp Ile Ile Glu Glu Ile Leu Arg Glu 50 55 60 Ser Glu Lys Val Leu Glu Lys Leu Lys Tyr Thr Glu Asp 65 70 75 <210> SEQ ID NO 376 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 376 Pro Ile Lys Asp Ile Ser Lys Arg Leu Leu Glu Ile Ser Lys Arg Leu 1 5 10 15 Val Glu Ile Ser Asp Arg Ile Val Glu Leu Leu Gln Arg Ile Ala Asp 20 25 30 Ser Lys Asp Pro Asn Lys Asp Leu Gln Lys Glu Val Lys Asp Val Leu 35 40 45 Glu Glu Tyr Lys Arg Leu Val Arg Glu Tyr Arg Glu Val Val Lys Glu 50 55 60 Tyr Glu Lys Val Val Ser 65 70 <210> SEQ ID NO 377 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 377 Pro Val Glu Glu Ala Ile Lys Lys Val Ile Asp Asp Leu Arg Asp Val 1 5 10 15 Gln Arg Lys Ile Arg Glu Leu Val Glu Glu Leu Ile Arg Leu Leu Glu 20 25 30 Glu Val Gln Arg Asp Asn Asp Lys Arg Glu Ser Glu Tyr Val Val Glu 35 40 45 Arg Val Glu Glu Ile Leu Arg Arg Ile Thr Glu Thr Ser Arg Glu Val 50 55 60 Val Arg Lys Ala Val Glu Asp Leu Ser 65 70 <210> SEQ ID NO 378 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 378 Asn Leu Glu Glu Leu Val Lys Leu Leu Lys Glu Val Leu Glu Met His 1 5 10 15 Glu Arg Leu Leu Arg Ile His Glu Asp Leu Val Glu Ala His Lys Ser 20 25 30 Asn Ala Ser Asp Lys Glu Ser Glu Arg Lys Leu Lys Lys Ser Asp Lys 35 40 45 Asp Ile Lys Glu Ser Leu Lys Lys Ile Lys Ser Ile Ile Asp Gln Val 50 55 60 Arg Tyr Ile Gln Ser 65 <210> SEQ ID NO 379 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 379 Pro Val Glu Glu Val Leu Lys Glu Leu Ser Glu Val Asn Glu Arg Val 1 5 10 15 Arg Asp Ile Ala Arg Glu Ile Ile Glu Arg Leu Ser Glu Val Asn Glu 20 25 30 Glu Val Lys Glu Thr Asp Asp Glu Asp Glu Leu Lys Lys Ile Ser Lys 35 40 45 Lys Val Val Asp Glu Val Glu Asp Leu Leu Arg Lys Ile Leu Glu Val 50 55 60 Ser Glu Glu Val Val Arg Arg Val Glu Tyr His Asp Arg 65 70 75 <210> SEQ ID NO 380 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 380 Asp Glu Asp Tyr Glu Ser Arg Glu Ile Ile Asp Glu Ile Arg Lys Leu 1 5 10 15 Leu Asp Arg Ser Lys Lys Ile Val His Arg Ser Gln Arg Leu Val Glu 20 25 30 Arg Val Lys Ser Thr Pro Leu Ser Glu Asp Gln Glu Asp Leu Ile Arg 35 40 45 Arg His Glu Glu Thr Ile Asn Arg His Arg Glu Leu Val Lys Glu Leu 50 55 60 Glu Lys Val Leu Glu Asp His Glu Arg His Ile Arg 65 70 75 <210> SEQ ID NO 381 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 381 Pro Arg Ser Tyr Leu Leu Lys Glu Leu Ala Asp Leu Ser Gln His Leu 1 5 10 15 Val Arg Leu Leu Glu Arg Leu Val Arg Glu Ser Glu Arg Val Val Glu 20 25 30 Val Leu Glu Arg Gly Glu Val Asp Glu Glu Glu Leu Lys Arg Leu Glu 35 40 45 Asp Leu His Arg Glu Leu Glu Lys Ala Val Arg Glu Val Arg Glu Thr 50 55 60 His Arg Glu Ile Arg Glu Arg Ser Arg 65 70 <210> SEQ ID NO 382 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 382 Pro Glu Lys Asp Glu Asn Arg Lys Leu Leu Asp Lys Val Arg Lys Leu 1 5 10 15 Val Glu Lys Ser Arg Arg Leu Val Glu Glu Leu Arg Lys Leu Val Asp 20 25 30 Gln Ser Thr Lys Asn Gly Leu Ile Asp Glu Lys Ala Leu Arg Lys Gln 35 40 45 Gln Glu Val Leu Arg Lys Val Glu Glu Val Leu Glu Lys Gln Glu Arg 50 55 60 Val Leu Arg Glu Leu Glu Glu Ile Ser Tyr Arg Val Ile 65 70 75 <210> SEQ ID NO 383 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 383 Asp Glu Lys Asp Glu Ile Arg His Val Ile Glu Ser Val Glu Arg Leu 1 5 10 15 Ile Glu Asp Ile Lys Arg Leu Leu Lys Thr Leu Arg Glu Leu Ala His 20 25 30 Asp Asp Ser Asp Lys Lys Thr Val Lys Glu Val Leu Asp Arg Val Lys 35 40 45 Glu Met Ile Glu Arg His Arg Arg Glu Leu Glu Glu His Arg Lys Glu 50 55 60 Leu Glu Arg Ala Glu Tyr Glu Val Arg 65 70 <210> SEQ ID NO 384 <211> LENGTH: 122 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 384 Asp Glu Lys Ala Leu Arg Lys Gln Gln Glu Val Leu Arg Lys Val Glu 1 5 10 15 Glu Val Leu Glu Lys Gln Glu Arg Val Leu Arg Glu Leu Glu Glu Ile 20 25 30 Ser Tyr Arg Val Ile Thr Arg Gly Glu Asp His Lys Ala Glu Glu Asp 35 40 45 Ser Arg Arg Val Leu Glu Arg Phe Val Arg Val Ser Arg Glu Val Leu 50 55 60 Lys Val Leu Glu Glu Phe Leu Arg Val Ser Glu Glu Leu Leu Arg Glu 65 70 75 80 Ala Asp Arg Asp Arg Asp Arg Arg Leu Glu Glu Tyr Glu Arg Gln Val 85 90 95 Asp Glu Leu Arg Glu Glu Ile Arg Arg Tyr Lys Glu Glu Val Asp Lys 100 105 110 Phe Asp Lys Glu Val Lys Tyr Tyr Lys Lys 115 120 <210> SEQ ID NO 385 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 385 Ser Leu Glu Asp Ser Val Arg Leu Asn Asp Glu Val Val Lys Val Val 1 5 10 15 Glu Arg Val Val Arg Leu Asn Gln Glu Val Val Arg Leu Ile Lys His 20 25 30 Ala Thr Asp Val Glu Asp Glu Glu Thr Val Lys Tyr Val Leu Glu Arg 35 40 45 Val Arg Glu Val Leu Asp Glu Ser Arg Glu Val Leu Lys Arg Val His 50 55 60 Glu Leu Leu Glu Glu Ser Glu Arg Arg Leu Glu 65 70 75 <210> SEQ ID NO 386 <211> LENGTH: 123 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 386 Pro Glu Arg Asp Glu Asn Arg Lys Leu Leu Asp Lys Val Arg Lys Leu 1 5 10 15 Val Glu Lys Ser Arg Arg Leu Val Glu Glu Leu Arg Lys Leu Val Asp 20 25 30 Gln Ser Thr Lys Asn Gly Leu Ile Asp Glu Lys Ala Leu Arg Lys Gln 35 40 45 Gln Glu Val Leu Arg Lys Val Glu Glu Val Leu Glu Lys Gln Glu Arg 50 55 60 Val Leu Arg Glu Leu Glu Glu Ile Ser Tyr Arg Val Ile Thr Arg Gly 65 70 75 80 Glu Asp His Lys Ala Glu Glu Asp Ser Arg Arg Val Leu Glu Arg Phe 85 90 95 Val Arg Val Ser Arg Glu Val Leu Lys Val Leu Glu Glu Phe Leu Arg 100 105 110 Val Ser Glu Glu Leu Leu Arg Glu Ala Asp Arg 115 120 <210> SEQ ID NO 387 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 387 Pro Glu Leu Asp Glu Val Lys Lys Leu Ile Asp Glu Leu Lys Lys Ser 1 5 10 15 Val Glu Arg Leu Glu Glu Ser Ile Arg Glu Val Lys Glu Ser Ile Lys 20 25 30 Lys Leu Arg Lys Gly Asp Ile Asp Ala Glu Glu Asn Ile Lys Leu Leu 35 40 45 Lys Glu Asn Ile Lys Ile Val Arg Glu Asn Ile Lys Ile Ile Lys Glu 50 55 60 Ile Ile Asp Val Val Gln Tyr Val Leu Arg 65 70 <210> SEQ ID NO 388 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 388 Asp Ser Glu Tyr Glu Ser Arg Gln Val Leu Arg Glu Leu Asp Thr Val 1 5 10 15 Leu Lys Asp Ser His Thr Val Leu Glu Ala Leu Arg Gln Val Ile Arg 20 25 30 Asp Ser Gln Asp Val Val Ser Lys Ser Asp Glu Glu Ser Arg Arg Val 35 40 45 Ile Asp Asp Leu Glu Lys Val Ile Gln Asp Ser Lys Lys Val Leu Asp 50 55 60 Asp Ile Lys Arg Leu Ile Asp Lys Ser Lys Ser Ile Lys Ser 65 70 75 <210> SEQ ID NO 389 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 389 Asp Glu Ser Asp Arg Ile Arg Lys Ile Val Glu Glu Ser Asp Glu Ile 1 5 10 15 Val Lys Glu Ser Arg Lys Leu Ala Glu Arg Ala Arg Glu Leu Ile Lys 20 25 30 Glu Ser Glu Asp Lys Arg Val Ser Glu Glu Arg Asn Glu Arg Leu Leu 35 40 45 Glu Glu Leu Leu Arg Ile Leu Asp Glu Asn Ala Glu Leu Leu Lys Arg 50 55 60 Asn Leu Glu Leu Leu Lys Glu Val Leu Tyr Arg Thr Arg 65 70 75 <210> SEQ ID NO 390 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 390 Ser Leu Tyr Glu Leu Thr Gln Arg Tyr Glu Lys Leu Val Gln Gln Tyr 1 5 10 15 Glu Glu Leu Val Lys Asp Tyr Arg Arg Leu Val Lys Lys Leu Glu Lys 20 25 30 Leu Lys Arg Asp Asn Lys Pro Asp Lys Arg Leu Leu Lys Glu Ile Val 35 40 45 Asp Val Ile Lys Lys Ser Val Glu Ile Ile Asp Arg Ser Leu Lys Leu 50 55 60 Leu Glu Glu Ser Ile Lys Ile Leu Glu Glu Thr Asp 65 70 75 <210> SEQ ID NO 391 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 391 Asp Lys Lys Asp Ala Ser Arg Arg Ala Ile Arg Val Leu His Glu Phe 1 5 10 15 Val Arg Val Ser Glu Glu Val Leu Glu Val Leu Arg Lys Ser Val Glu 20 25 30 Ser Leu Lys Arg Leu Asp Val Asp Glu Lys Ile Lys Arg Thr His Asp 35 40 45 Arg Ile Glu Glu Glu Leu Arg Arg Trp Lys Arg Glu Leu Glu Glu Leu 50 55 60 Ile Glu Arg Leu Arg Glu Trp Glu Tyr His Gln Asp 65 70 75 <210> SEQ ID NO 392 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 392 Asp Ile Glu Tyr Glu Ser Lys Glu Ile Leu Glu Leu Ile Lys Glu Leu 1 5 10 15 Leu Lys Leu Ser Arg Glu Leu Leu Lys Glu Ser Arg Arg Ala Leu Glu 20 25 30 Leu Val Arg Lys Ser Arg Asp Asp Ser Ile Val Glu Glu Val Ile Gln 35 40 45 Val His Lys Lys Val Leu Asp Ile His Lys Glu Val Leu Lys Ile Val 50 55 60 Arg Lys Val Val Glu Val His Arg Arg Val Lys Ser 65 70 75 <210> SEQ ID NO 393 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 393 Asp Lys Glu Tyr Lys Leu Asp Arg Ile Leu Arg Arg Leu Asp Glu Leu 1 5 10 15 Ile Lys Gln Leu Ser Arg Ile Leu Glu Glu Ile Glu Arg Leu Val Asp 20 25 30 Glu Leu Glu Arg Glu Pro Leu Asp Asp Lys Glu Val Gln Asp Val Ile 35 40 45 Glu Arg Ile Val Glu Leu Ile Asp Glu His Leu Glu Leu Leu Lys Glu 50 55 60 Tyr Ile Lys Leu Leu Glu Glu Tyr Ile Lys Thr Thr Lys 65 70 75 <210> SEQ ID NO 394 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 394 Asp Leu Glu Tyr Leu Asn Arg Arg Leu Leu Gln Leu Ile Lys Thr Leu 1 5 10 15 Ile Asp Leu Asn Arg His Leu Leu Lys Leu Ile Asp Lys Leu Lys Lys 20 25 30 Leu Asn Ser Arg Glu Gly Asp Glu Glu Lys Ile Lys Glu Glu Ser Lys 35 40 45 Gln Ile Gln Glu Gln Phe Lys Glu Ile Val Glu Arg Ser Lys Glu Ile 50 55 60 Ile Lys Gln Ile Lys Glu Ile Ile Lys Arg Ser Gln 65 70 75 <210> SEQ ID NO 395 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 395 Arg Asp Arg Lys Ile Ser Glu Glu Leu Ile Lys Ala Leu Glu Asp His 1 5 10 15 Ile Arg Met Leu Glu Glu Leu Ile Arg Ala Ile Glu Glu His Ile Lys 20 25 30 Leu Ala Glu Arg Gly Val Asp Glu Lys Glu Leu Arg Glu Ser Leu Glu 35 40 45 Glu Leu Lys Lys Ile Val Asp Glu Leu Glu Lys Ser Leu Glu Glu Leu 50 55 60 Arg Lys Leu Ala Glu Arg Tyr Lys Tyr Glu Thr Arg 65 70 75 <210> SEQ ID NO 396 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 396 Glu Glu Ser Glu Glu Val Arg Lys Val Val Glu Arg Ile Lys Lys Ile 1 5 10 15 Ser Arg Glu Leu Glu Glu Val Val Lys Glu Leu Asp Arg Val Ser Lys 20 25 30 Glu Phe Asp Arg His Gly Glu Thr Asp Glu Ile Val Arg Glu His Glu 35 40 45 Arg Ile Val Glu Lys Leu Glu Glu Ile Val Lys Lys His Thr Lys Ile 50 55 60 Val Glu Glu Leu Ala Glu Ile Val Tyr Lys Gln Gln 65 70 75 <210> SEQ ID NO 397 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 397 Asp His Glu Tyr Trp Val Lys Ile Val Glu Arg Ile Leu Arg Val Met 1 5 10 15 Glu Lys His Ala Glu Ile Val Lys Lys His Leu Glu Ile Val Glu Arg 20 25 30 Val Val Arg Glu Gly Pro Ser Glu Asp Leu Arg Arg Lys Leu Lys Glu 35 40 45 Ser Leu Arg Glu Ile Glu Glu Ser Leu Arg Glu Leu Lys Glu Leu Leu 50 55 60 Asp Glu Leu Asp Glu Leu Ser Glu Lys Thr Arg 65 70 75 <210> SEQ ID NO 398 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 398 Asp Leu Leu Tyr Leu Ser Lys Glu Leu Leu Lys Leu Val Arg Glu Leu 1 5 10 15 Leu Lys Leu Ser Arg Glu Leu Val Glu Leu Ser Arg Arg Leu Val Asn 20 25 30 Ser Thr His Lys Ser Pro Glu Leu Val Lys Lys Tyr Asp Lys Leu Val 35 40 45 Lys Lys Tyr Gln Asp Leu Leu Lys Lys Leu Ala Asp Val Ala Asp Glu 50 55 60 Tyr Leu Arg Gln Arg Ser 65 70 <210> SEQ ID NO 399 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 399 Asp Lys Glu Glu Ile Val Lys Leu Gln Asp Glu Val Ile Lys Thr Leu 1 5 10 15 Glu Arg His Leu Asp Ile Leu Arg Lys His Ile Asp Leu Leu Glu Lys 20 25 30 Leu Lys Asp His Leu Ser Glu Glu Leu Lys Glu Arg Val Asp Arg Ser 35 40 45 Ile Lys Lys Leu Glu Glu Ser Ile Lys Arg Leu Glu Arg Ile Ile Glu 50 55 60 Glu Leu Gln Glu Leu Ala Glu Tyr Ser Leu 65 70 <210> SEQ ID NO 400 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 400 Asp Ala Tyr Asp Leu Asp Arg Ile Val Lys Glu His Arg Arg Leu Val 1 5 10 15 Glu Glu Gln Arg Glu Leu Val Glu Glu Leu Glu Lys Leu Val Arg Arg 20 25 30 Gln Glu Asp His Arg Val Asp Lys Lys Glu Ser His Glu Ile Leu Glu 35 40 45 Arg Leu Glu Arg Ile Ile Arg Arg Ser Thr Arg Ile Leu Thr Glu Leu 50 55 60 Glu Lys Leu Thr Asp Glu Phe Glu Arg Arg Thr Arg 65 70 75 <210> SEQ ID NO 401 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 401 Asp Met Glu Tyr Glu Leu Lys Lys Ser Ala Glu Glu Leu Arg Lys Ser 1 5 10 15 Leu Glu Glu Leu Lys Arg Ile Leu Asp Glu Leu His Lys Ser Leu Arg 20 25 30 Glu Leu Arg Arg His Gly Asp Asp Glu Glu Tyr Val Gln Thr Val Glu 35 40 45 Glu Leu Arg Lys Glu Leu Glu Glu His Ala Lys Lys Leu Glu Glu His 50 55 60 Leu Lys Glu Leu Glu Arg Val Ala Thr 65 70 <210> SEQ ID NO 402 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 402 Asp Arg Gln Arg Ile Leu Asp Arg Leu Asp Lys Ile Leu Glu Lys Leu 1 5 10 15 Asp Asp Ile Leu Lys Lys Leu Lys Asp Ile Leu Glu Thr Leu Ser Lys 20 25 30 Asp Asp Val Ser Asp Arg Arg His Lys Asp Leu Val Glu Lys Phe Arg 35 40 45 Glu Leu Val Asp Thr His His Lys Leu Val Glu Arg Tyr Arg Glu Leu 50 55 60 Val Tyr Gln Asn Arg 65 <210> SEQ ID NO 403 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 403 Arg Glu Lys Asp Glu Ser Lys Glu Leu Asn Asp Glu Tyr Lys Lys Leu 1 5 10 15 Leu Glu Glu Tyr Glu Arg Leu Leu Arg Arg Ser Glu Glu Leu Val Lys 20 25 30 Arg Ala Lys Gly Pro Arg Asp Glu Lys Glu Leu Lys Arg Ile Leu Glu 35 40 45 Glu Asn Glu Asp Ile Leu Arg Arg Thr Lys Glu Ile Leu Glu Arg Thr 50 55 60 Lys Glu Ile Ser Glu Glu Gln Lys Tyr Arg Arg Arg 65 70 75 <210> SEQ ID NO 404 <211> LENGTH: 105 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 404 Asp Pro Gln Arg Ala Ala Asp Arg Leu Asp Lys Ile Leu Glu Lys Leu 1 5 10 15 Asp Asp Ile Leu Lys Lys Leu Lys Asp Ile Leu Glu Thr Leu Ser Lys 20 25 30 Asp Asp Val Lys Asp Arg Arg Ala Lys Asp Leu Val Glu Lys Phe Arg 35 40 45 Glu Leu Val Asp Thr His His Lys Leu Val Glu Arg Tyr Arg Glu Leu 50 55 60 Val Tyr Thr Ala Thr Ala Gly Ser Asp Leu Ala Arg Glu Leu Ile Arg 65 70 75 80 Arg Val Glu Glu His Thr Lys Arg Leu Arg His Ile Leu Lys Arg Leu 85 90 95 Arg Glu His Glu Glu Lys Leu Arg Arg 100 105 <210> SEQ ID NO 405 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 405 Glu Asn Lys Tyr Ile Leu Lys Glu Ile Leu Lys Leu Leu Arg Glu Asn 1 5 10 15 Leu Lys Leu Leu His Asp Ile Leu Arg Leu Leu Asp Glu Asn Leu Glu 20 25 30 Glu Leu Glu Lys His Gly Ala Lys Asp Leu Asp Asp Tyr Arg Arg Lys 35 40 45 Ile Glu Glu Ile Arg Lys Lys Val Glu Asp Tyr Arg Glu Lys Ile Glu 50 55 60 Glu Ile Glu Lys Lys Val Glu Arg Asp Arg 65 70 <210> SEQ ID NO 406 <211> LENGTH: 68 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 406 Asp Lys Glu Tyr Leu Val Thr Glu His Glu Lys Leu Val Arg Glu His 1 5 10 15 Glu Lys Ile Val Ser Glu Ile Glu Lys Leu Val Lys Lys His Glu Ala 20 25 30 Gly Val Asp Glu Ser Glu Leu Glu Glu Ile Leu Lys Lys Val Glu Lys 35 40 45 Leu Leu Arg Lys Leu Asp Glu Ile Leu Glu Gln Leu Thr Gln Leu Leu 50 55 60 Arg Lys Thr Glu 65 <210> SEQ ID NO 407 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 407 Asp Glu Glu Glu Ala Asn Tyr Val Ser Asp Lys Ala Val Lys Ile Ala 1 5 10 15 Glu Asp Val Gln Glu Leu Leu Lys Glu Leu Leu Glu Leu Ser Glu Val 20 25 30 Val Arg Arg Gly Glu Val Asp Glu Asp Glu Tyr Asp Arg Val Leu Arg 35 40 45 Lys Leu Gln Glu Val Met Lys Glu Tyr Glu Glu Val Leu Lys Glu Tyr 50 55 60 Glu Glu Val Ser Arg Lys His Glu 65 70 <210> SEQ ID NO 408 <211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 408 Asp Ala Glu Tyr Leu Val Thr Glu His Glu Lys Leu Val Arg Glu His 1 5 10 15 Glu Lys Ile Val Ser Glu Ile Glu Lys Leu Val Lys Lys His Glu Lys 20 25 30 Gly Val Asp Glu Ser Glu Leu Glu Glu Ile Leu Lys Lys Val Glu Lys 35 40 45 Leu Leu Arg Lys Leu Asp Glu Ile Leu Glu Gln Leu Thr Gln Leu Leu 50 55 60 Arg Lys Ala Glu Lys His Ile Asp Lys His Ser Lys Ala Ala Asp Gln 65 70 75 80 Leu Ala Thr Ser Ile Lys Lys Leu Glu Asp Ser Ile Asp Gln Leu Ile 85 90 95 Lys Ile Val Arg Lys Phe Glu Glu Ser Val Lys Lys Leu Gln Lys His 100 105 110 <210> SEQ ID NO 409 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 409 Asp Glu Glu Tyr Glu Leu Glu Arg Ile Ser Arg Glu Ser Lys Glu Leu 1 5 10 15 Leu Glu Arg Tyr Lys Arg Leu Leu Arg Glu Tyr Gln Glu Leu Leu Lys 20 25 30 Glu Leu Arg His Val Lys Asp Leu Asp Arg Ala Val Lys Ile Ile His 35 40 45 Glu Leu Met Arg Val Ser Lys Glu Leu Val Glu Ile Ser His Arg Leu 50 55 60 Leu Glu Leu His Glu Arg Leu Val Arg Arg Arg Lys 65 70 75 <210> SEQ ID NO 410 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 410 Arg Asp Lys Tyr Leu Leu Glu Arg Leu Asn Asp Ile Leu Lys Lys Leu 1 5 10 15 Asp Glu Ile Val Asp Lys Leu Ser Asp Ile Leu Lys Arg Leu Lys Asp 20 25 30 Val Arg His Asp Asp Arg Leu Gln Glu Leu Val Glu Arg Tyr Lys Glu 35 40 45 Ile Val Lys Glu Tyr Lys Arg Ile Val Glu Glu Tyr Glu Lys Leu Val 50 55 60 Arg Glu Phe Glu Glu Gln Gln Arg 65 70 <210> SEQ ID NO 411 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 411 Pro His Glu Glu Val Val Glu Leu His Glu Arg Val Met Glu Ile Ser 1 5 10 15 Glu Arg Ala Val Glu Leu Ile Gln Arg Ile Ile Asp Ile Ile Arg Arg 20 25 30 Ile Arg Glu Asp Asp Lys Asp Ile Glu Lys Leu Val Lys Thr Ile Arg 35 40 45 Asp Leu Val Arg Glu Tyr Glu Glu Leu His Arg Glu Leu Glu Glu Ile 50 55 60 Asp Glu Glu Ile Tyr Lys Lys Ser Glu 65 70 <210> SEQ ID NO 412 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 412 Asp Ala Glu Tyr Lys Val Arg Glu Ser Val Lys Arg Ser Lys Glu Ser 1 5 10 15 Val Lys His Ser Glu Asp Val Val Asp Lys Leu Asn Lys Ser Val Lys 20 25 30 Leu Ser Glu Ser Gly His Ser Asp Ala Glu Lys Ala Ser Arg Glu Leu 35 40 45 Val Lys Leu Val Arg Glu Val Val Glu Leu Ser Arg Glu Val Ile Lys 50 55 60 Leu Ser Glu Lys Val Leu Arg Val Ile Ser 65 70 <210> SEQ ID NO 413 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 413 Arg Ala Arg Glu Val Val Lys Arg Ala Lys Arg Ile Ile Glu Glu Trp 1 5 10 15 Gln Lys Ile Leu Glu Glu Trp Arg Arg Ile Leu Glu Glu Trp Arg Arg 20 25 30 Leu Leu Glu Asp Glu Arg Val Asp Asp Arg Asp Asn Glu Arg Ile Ile 35 40 45 Arg Glu Asn Glu Arg Val Ile Arg Glu Asn Glu Lys Ile Ile Arg Asp 50 55 60 Val Ile Arg Leu Leu Glu Glu Leu Leu Tyr Glu Arg Arg 65 70 75 <210> SEQ ID NO 414 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 414 Asp Trp Glu Glu Leu Leu Arg Arg Leu Glu Lys Val Leu Gln Glu Tyr 1 5 10 15 Glu Glu Ile Val Lys Glu Leu Ile Asp Leu Ile Glu Arg Leu Ile Lys 20 25 30 Val Ser Glu Asp Lys Ser Lys Asp Ala Ser Glu Tyr Lys Lys Leu Val 35 40 45 Thr Glu Leu Glu Lys Leu Ile Ser Lys Leu Glu Glu Ile Ser Lys Lys 50 55 60 Leu Glu Glu Leu Val Lys Glu Tyr Glu Tyr Lys Thr Glu 65 70 75 <210> SEQ ID NO 415 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 415 Pro Lys Glu Glu Ile Val Lys Leu His Asp Glu Ser Ala Glu Leu His 1 5 10 15 Arg Arg Ser Val Glu Val Ala Asp Glu Ile Leu Lys Met His Glu Arg 20 25 30 Ser Lys Asp Val Asp Asp Glu Arg Glu Ser Arg Glu Leu Ser Lys Glu 35 40 45 Ile Glu Arg Leu Ile Arg Glu Val Glu Glu Val Ser Lys Arg Ile Lys 50 55 60 Arg Leu Ser Glu Glu Val Glu Tyr Leu Val Arg 65 70 75 <210> SEQ ID NO 416 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 416 Asp Lys Glu Arg Ala Ala Arg Ala Thr Glu Glu Met Val Lys Leu Thr 1 5 10 15 Lys Lys Leu Leu Lys Ala Val Glu Asp Leu Val Arg Asp Val Arg Arg 20 25 30 Leu Leu Lys Glu Gly Leu Ile Ser Glu Lys His Ala Arg Ile Ala Glu 35 40 45 Thr Ile Leu Glu Val Phe Lys Lys His Ala Lys Ile Ile Lys Lys His 50 55 60 Val Asp Ile Val Lys Tyr Asp Glu Ser 65 70 <210> SEQ ID NO 417 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 417 Pro Glu Asp Glu His Val Tyr Val Val Arg Glu Ile Tyr Glu Val Leu 1 5 10 15 Arg Glu His Ala Glu Val Leu Glu Glu Asn Arg Glu Val Ile Glu Arg 20 25 30 Leu Leu Glu Ala Lys Lys Arg Gly Asp Lys Ser Glu Glu Leu Val Lys 35 40 45 Glu Leu Lys Lys Ser Ile Asp Lys Leu Lys Glu Ile Ser Arg Lys Leu 50 55 60 Glu Glu Ile Val Lys Glu Leu Glu Lys Val Ser Glu Lys Leu Lys 65 70 75 <210> SEQ ID NO 418 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 418 Asn Asp Glu Glu Leu Lys Lys Ile Leu Glu Thr Leu Asp Arg Ile Leu 1 5 10 15 Lys Lys Leu Asp Lys Ile Leu Thr Arg Leu Asp Glu Val Leu Lys Lys 20 25 30 Ser Glu Asp Pro Asn Leu Asp Asp Lys Asp Tyr Thr Glu Leu Val Lys 35 40 45 Gln Tyr Ile Glu Leu Val Lys Lys Tyr Glu Glu Val Val Lys Glu Tyr 50 55 60 Glu Glu Val Val Arg Gln Leu Ile Arg Leu Phe Ser 65 70 75 <210> SEQ ID NO 419 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 419 Thr Gln Glu Glu Ile Asn Arg Ile Gln His Glu Val Leu Arg Ile Gln 1 5 10 15 Glu Glu Ile Asp Glu Ile Leu Arg Asp Ile Val Glu Lys Leu Lys Ala 20 25 30 Ile Ser Arg Gly Glu Leu Asp His Glu Val Val Lys Asp Val Glu Asp 35 40 45 Lys Val Arg Glu Ala Leu Glu Lys Ser Glu Glu Leu Leu Asp Lys Ser 50 55 60 Arg Lys Val Glu Tyr Lys Ser Glu 65 70 <210> SEQ ID NO 420 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 420 Glu Glu Asp Glu Arg Ile Arg Tyr Asp Leu Asp Arg Ile Arg Lys Asp 1 5 10 15 Val Arg Arg Lys Leu Glu Glu Ile Arg Gln Arg Val Arg Glu Leu Glu 20 25 30 Lys Lys Leu Arg Asp Ala Gly His Arg Arg Asp Glu Lys Glu Leu Leu 35 40 45 Arg Glu Leu Ile Glu Thr Ser Lys Asp Ile Leu Arg Leu Val Glu Glu 50 55 60 Leu Leu Lys Lys Ile Ile Asp Lys Ser Glu Asp Leu Leu Arg Lys Thr 65 70 75 80 Glu <210> SEQ ID NO 421 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 421 Asp Glu Lys Asp Arg Val Tyr Glu Ile Leu Lys Glu Val Gln Arg Leu 1 5 10 15 Val Lys Glu Tyr Arg Asp Ile Ser Lys Glu Ile Glu Asp Leu Val Lys 20 25 30 His Tyr Glu His Ile Thr Asp Asp Glu Ala Gln Glu Val Ser Lys Glu 35 40 45 Leu Ile Asp Lys Ser Leu Arg Ala Ser Glu Ile Val Arg Glu Leu Ile 50 55 60 Arg Leu Ile Lys Glu Leu Leu Asp Glu Leu Glu 65 70 75 <210> SEQ ID NO 422 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 422 Asp Glu Glu Glu Tyr Tyr Lys Glu Lys Leu His Lys Leu Leu Arg Glu 1 5 10 15 Ile Glu Glu Leu Leu Lys His Tyr Arg Glu Leu Val Arg Arg Leu Glu 20 25 30 Glu Leu Val Lys Arg Gly Glu Leu Asp Lys Asp Thr Ala Ala His Ile 35 40 45 Leu Glu Arg Leu Ser Glu Leu Leu Glu Arg Ile Ile Arg Arg Val Ala 50 55 60 His Thr Leu Arg Arg Leu Ser Glu Glu Arg Arg 65 70 75 <210> SEQ ID NO 423 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 423 Gly Ser Glu Gly Ser 1 5 <210> SEQ ID NO 424 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 424 Asp Ile Val Glu Leu Val Asp His Leu Leu Lys Arg Ser Leu Lys Leu 1 5 10 15 Leu Glu Glu Leu Ala Glu Leu Val Arg Arg Leu Leu Glu Lys Ser Thr 20 25 30 Glu Leu Leu Lys Arg Arg Thr Glu Glu His Lys Glu Glu Val Val Glu 35 40 45 Glu Ser Glu Tyr Met Val Arg Glu Leu Glu Glu Arg Leu Arg Arg Val 50 55 60 Val Asp Glu Ser Glu Lys Leu Val Arg Asp Ala Asp Lys His Ile Arg 65 70 75 80 <210> SEQ ID NO 425 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 425 Gly Gly Gly Ser 1 <210> SEQ ID NO 426 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 426 Pro Glu Val Asp Val Leu Arg Arg Ile Val Arg Glu Ile Leu Lys Ala 1 5 10 15 Ser Glu Glu Leu Leu Arg Leu Leu Arg Lys Leu Ile Asp Glu Ala Leu 20 25 30 Lys Leu Ser Glu Arg Lys Arg Asp Ser Gln Glu Tyr Arg Glu Val Val 35 40 45 Asp Arg Val Lys Lys Glu Leu Glu Arg Leu Leu Asp Glu Tyr Arg Lys 50 55 60 Leu Val Glu Glu Leu Lys Glu Lys Leu Arg Tyr Asp Thr Arg 65 70 75 <210> SEQ ID NO 427 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 427 Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser 1 5 10 <210> SEQ ID NO 428 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 428 Pro Arg Glu Tyr His Ser Lys Asp Ile Leu Arg Lys Val Asp Glu Ile 1 5 10 15 Leu Glu Arg Ile Arg Arg His Ala Asp Arg Val Lys Lys Lys Ser Glu 20 25 30 Arg Leu Lys Arg Glu Asn Val Asp Val Asn Glu His Ser Lys Asp Val 35 40 45 Lys Arg Val Ile Arg Glu Leu Leu Glu Leu Val Lys Glu Leu Leu Arg 50 55 60 Leu Ala Lys Lys His Ser Asp Asp Gln Gln Glu 65 70 75 <210> SEQ ID NO 429 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 429 Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser 1 5 10 <210> SEQ ID NO 430 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 430 Pro Lys Leu Asp Lys Leu Arg Glu Leu Leu Glu Arg Asn Leu Glu Lys 1 5 10 15 Leu Arg Glu Ile Leu Glu Glu Val Leu Lys Ile Leu Arg Thr Asn Leu 20 25 30 Glu Arg Val Arg Glu Asp Ile Arg Asp Glu Asp Val Leu Gln Glu Tyr 35 40 45 Glu Arg Leu Ile Arg Lys Ala Glu Glu Asp Leu Arg Arg Val Leu Lys 50 55 60 Glu Tyr Asp Asp Leu Leu Lys Lys Leu Val Tyr Glu Leu Arg 65 70 75 <210> SEQ ID NO 431 <211> LENGTH: 94 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 431 His His His His His His Gly Ser Gly Ser Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Ser Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg 20 25 30 Glu Gln Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu 35 40 45 Glu Glu Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu 50 55 60 Ala Lys Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu 65 70 75 80 Glu Leu Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 85 90 <210> SEQ ID NO 432 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 432 Pro Asn Gln Glu Leu Leu Asp Arg Val Arg Lys Ile Leu Glu Asp Leu 1 5 10 15 Leu Arg Leu Asn Glu Glu Leu Val Arg Leu Asn Lys Glu Leu Leu Lys 20 25 30 Arg Ala Leu Glu Met Arg Arg Lys Asn Arg Asp Ser Glu Glu Val Leu 35 40 45 Glu Arg Leu Ala Glu Glu Tyr Arg Lys Arg Leu Glu Glu Tyr Arg Arg 50 55 60 Glu Leu Glu Lys Leu Leu Glu Glu Leu Glu Glu Thr Ile Tyr Arg Tyr 65 70 75 80 Lys Arg <210> SEQ ID NO 433 <211> LENGTH: 91 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 433 His His His His His His Gly Ser Gly Ser Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys 20 25 30 Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu 35 40 45 Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr 50 55 60 Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu 65 70 75 80 Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 85 90 <210> SEQ ID NO 434 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 434 Asp Glu Glu Glu Leu Val Glu Thr Val Lys Arg Ile Gln Lys Glu Ile 1 5 10 15 Leu Asp Arg Leu Thr Glu Leu Ala Lys Leu Leu Val Glu Ile Gln Arg 20 25 30 Glu Ile Lys Lys Leu Lys Asp Glu Gly Glu Asp Asp Lys Glu Leu Lys 35 40 45 Arg Leu Ser Asp Glu Leu Glu Glu Lys Val Arg Gln Val Val Glu Glu 50 55 60 Ile Lys Arg Leu Ser Asp Glu Leu Glu Glu Thr Val Glu Tyr Val Ser 65 70 75 80 Arg <210> SEQ ID NO 435 <211> LENGTH: 90 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 435 Ser His His His His His His Ser Ser Gly Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Ser Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu 20 25 30 Asn Leu Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys Gln Leu 35 40 45 Arg Asp Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val 50 55 60 Ile Asp Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val Ile Lys 65 70 75 80 Ile Phe Glu Asp Ser Val Arg Lys Lys Glu 85 90 <210> SEQ ID NO 436 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 436 Ser Lys Glu Glu Ile Leu Lys Glu Leu Glu Asp Leu Gln Arg Arg Leu 1 5 10 15 Ile Glu Glu Leu Lys Lys Leu Gln Glu Arg Val Val Glu Leu Leu Glu 20 25 30 Glu Leu Ile Lys Arg Leu Arg Asp Arg Gly Arg Asp Asp Lys His Leu 35 40 45 Lys Arg Leu Val Lys Glu Val Arg Arg Leu Ser Glu Glu Val Leu Arg 50 55 60 Ser Ile Lys Glu Val Ser Asp Arg Val Arg Tyr Gln Leu Arg 65 70 75 <210> SEQ ID NO 437 <211> LENGTH: 91 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 437 Ser His His His His His His Ser Ser Gly Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys 20 25 30 Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu 35 40 45 Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr 50 55 60 Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu 65 70 75 80 Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 85 90 <210> SEQ ID NO 438 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 438 Asp Leu His Glu Val Val Tyr Glu Thr Lys Glu Leu Leu Lys Arg Ile 1 5 10 15 Glu Glu Val Val Glu Glu Leu Arg Lys Lys Ser Glu Asp Ile Ile Arg 20 25 30 Lys Ala Glu Arg Gly Glu Ile Ser Glu Asp Glu Leu Lys Arg Leu Gln 35 40 45 Glu Glu Ile Ala Arg Glu Ala Lys Lys Leu Leu Asp Glu Ile Lys Arg 50 55 60 Val Leu Glu Arg His Leu Glu Gln Thr Leu 65 70 <210> SEQ ID NO 439 <211> LENGTH: 150 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 439 Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu Ser 1 5 10 15 Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys Lys 20 25 30 Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile Lys Glu 35 40 45 Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg Ile Ala 50 55 60 Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Ala Ala Asp Asp Lys 65 70 75 80 Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala 85 90 95 Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg 100 105 110 Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu 115 120 125 Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr 130 135 140 His Ala Lys Lys Val Glu 145 150 <210> SEQ ID NO 440 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 440 Pro Glu Gln Glu Ile Ala Asp Arg Ile Leu Thr Glu Ile Arg Glu Ser 1 5 10 15 Gln Lys Glu Leu Glu Arg Leu Ala Arg Lys Ile Leu Lys Leu Leu Asp 20 25 30 Glu Ser Gln Glu Lys Ala Lys Arg Gly Arg Leu Ser Glu Glu Glu Ser 35 40 45 Asp Glu Leu Leu Glu Arg Ile Lys Lys Glu Leu Asp Glu Leu Leu Glu 50 55 60 Arg Ser Lys Glu Leu Leu Lys Lys Ile Glu Tyr Glu Leu Arg 65 70 75 <210> SEQ ID NO 441 <211> LENGTH: 154 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 441 Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu Ser 1 5 10 15 Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys Lys 20 25 30 Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile Lys Glu 35 40 45 Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg Ile Ala 50 55 60 Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Gly Ser Gly Ser 65 70 75 80 Pro Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile 85 90 95 Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu 100 105 110 Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr 115 120 125 Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu 130 135 140 Ile Ala Lys Thr His Ala Lys Lys Val Glu 145 150 <210> SEQ ID NO 442 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 442 Pro Glu Asp Asp Val Leu Arg Arg Leu Glu Glu Val Ser Glu Lys Ile 1 5 10 15 Leu Arg Val Ala Glu Asp Val Ala Arg Gln Leu Arg Glu Val Ser Glu 20 25 30 Lys Ile Thr Gln Gly Lys Val Asp Arg Lys Glu Trp Glu Glu Asp Ile 35 40 45 Lys Arg Leu Lys Arg Glu Leu Glu Glu Leu Leu Arg Glu Trp Lys Glu 50 55 60 Glu Ile Glu Arg Leu Thr Tyr Glu Leu Arg 65 70 <210> SEQ ID NO 443 <211> LENGTH: 160 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 443 Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu Ser 1 5 10 15 Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys Lys 20 25 30 Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile Lys Glu 35 40 45 Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg Ile Ala 50 55 60 Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Gly Ser Gly Ser 65 70 75 80 Pro Gly Gly Ser Gly Ser Pro Asp Asp Lys Glu Leu Asp Lys Leu Leu 85 90 95 Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp 100 105 110 Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro 115 120 125 Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala 130 135 140 Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 145 150 155 160 <210> SEQ ID NO 444 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 444 Asp Glu Lys Glu Asp Asn Arg Arg Leu Gln His Lys Ile Glu Arg Ile 1 5 10 15 Leu Glu Lys Asn Glu Asp Leu Gln Arg Lys Leu Glu Glu Ile Leu Glu 20 25 30 Leu Leu Glu Arg Gly Glu Ala Asp Glu Glu Lys Ile Asp Arg Leu Arg 35 40 45 Lys Ala Val Glu Asp Tyr Arg Arg Val Val Glu Glu Ile Lys Glu Asp 50 55 60 Val Lys Arg His Lys Tyr Thr Val Arg 65 70 <210> SEQ ID NO 445 <211> LENGTH: 172 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 445 Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu Ser 1 5 10 15 Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys Lys 20 25 30 Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile Lys Glu 35 40 45 Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg Ile Ala 50 55 60 Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Gly Ser Gly Ser 65 70 75 80 Pro Gly Gly Ser Gly Ser Pro Gly Gly Ser Gly Ser Pro Gly Gly Ser 85 90 95 Gly Ser Pro Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu 100 105 110 Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu 115 120 125 Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu 130 135 140 Thr Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu 145 150 155 160 Leu Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 165 170 <210> SEQ ID NO 446 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 446 Asp Glu Lys Lys Leu Ile Asn Glu Val Val Glu Thr Gln Lys Arg Leu 1 5 10 15 Ile Lys Glu Ala Ala Lys Arg Leu Ser Glu Val Val Arg His Gln Thr 20 25 30 Glu Leu Ile Arg Glu Leu Arg Glu Lys Asn Val Asp Asp Lys Asp Val 35 40 45 Glu Lys Leu Leu Lys Glu Ser Leu Asp Leu Ala Glu Glu Ile Val Arg 50 55 60 Arg Ile Lys Glu Leu Leu Asp Glu Ser Lys Lys Leu Val Glu Tyr Val 65 70 75 80 Ser Asn <210> SEQ ID NO 447 <211> LENGTH: 161 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 447 Asp Ala Tyr Asp Leu Asp Arg Ile Val Lys Glu His Arg Arg Leu Val 1 5 10 15 Glu Glu Gln Arg Glu Leu Val Glu Glu Leu Glu Lys Leu Val Arg Arg 20 25 30 Gln Glu Asp His Arg Val Asp Lys Lys Glu Ser His Glu Ile Leu Glu 35 40 45 Arg Leu Glu Arg Ile Ile Arg Arg Ser Thr Arg Ile Leu Thr Glu Leu 50 55 60 Glu Lys Leu Thr Asp Glu Phe Glu Arg Arg Thr Arg Gly Ser Glu Gly 65 70 75 80 Ser Gly Ser Glu Gly Ser Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu 85 90 95 Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp 100 105 110 Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp 115 120 125 Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu Lys 130 135 140 Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys Val 145 150 155 160 Glu <210> SEQ ID NO 448 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 448 Asp Glu Arg Tyr Ala Thr Arg Glu Ile Val Glu Arg Ile Glu Arg Ile 1 5 10 15 Ala Arg Glu Ile Leu Lys Arg Thr Glu Glu Ile Val Arg Glu Val Arg 20 25 30 Glu Val Leu Ser Arg Asp Val Asp Gln Glu Glu Val Val Arg Arg Leu 35 40 45 Ala Asp Leu Leu Arg Glu Ser Val Glu Leu Val Gln His Leu Val Arg 50 55 60 Arg Val Glu Glu Leu Leu Gln Glu Ser Val Glu Arg Lys Lys 65 70 75 <210> SEQ ID NO 449 <211> LENGTH: 163 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 449 Asp Glu Asp Asp Glu Leu Glu Arg Leu Leu Arg Glu Tyr His Arg Val 1 5 10 15 Leu Arg Glu Tyr Glu Lys Leu Leu Glu Glu Leu Arg Arg Leu Tyr Glu 20 25 30 Glu Tyr Lys Arg Gly Glu Val Ser Glu Glu Glu Ser Asp Arg Ile Leu 35 40 45 Arg Glu Ile Lys Glu Ile Leu Asp Lys Ser Glu Arg Leu Trp Asp Leu 50 55 60 Ser Glu Glu Val Trp Arg Thr Leu Leu Tyr Gln Ala Glu Gly Ser Glu 65 70 75 80 Gly Ser Gly Ser Glu Gly Ser Asp Glu Lys Asp Tyr His Arg Arg Leu 85 90 95 Ile Glu His Leu Glu Asp Leu Val Arg Arg His Glu Glu Leu Ile Lys 100 105 110 Arg Gln Lys Lys Val Val Glu Glu Leu Glu Arg Arg Gly Leu Asp Glu 115 120 125 Arg Leu Arg Arg Val Val Asp Arg Phe Arg Arg Ser Ser Glu Arg Trp 130 135 140 Glu Glu Val Ile Glu Arg Phe Arg Gln Val Val Asp Lys Leu Arg Lys 145 150 155 160 Ser Val Glu <210> SEQ ID NO 450 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 450 Pro Ala Arg Glu Ile Leu Glu Glu Val Val Lys Lys His Leu Glu Val 1 5 10 15 Val Glu Asp Ala Ala Arg Ile Leu Glu Glu Ile Ile Arg Glu His Glu 20 25 30 Lys Ala Val Arg Glu Asp Arg Asp Lys Lys Glu Leu Glu Glu Ile Ser 35 40 45 Arg Asp Leu Leu Arg Lys Ala Arg Glu Ala Leu Lys Lys Val Lys Asp 50 55 60 Ile Ser Asp Asp Leu Ser Arg Glu Ile Glu Tyr Val Ala Ser 65 70 75 <210> SEQ ID NO 451 <211> LENGTH: 166 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 451 Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu Ser 1 5 10 15 Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys Lys 20 25 30 Leu Leu Lys Lys Ala Arg Gly Ala Asp Glu Lys Val Leu Asp Glu Leu 35 40 45 Arg Lys Ile Ile Glu Arg Ile Arg Glu Leu Leu Asp Arg Ser Arg Lys 50 55 60 Ile His Glu Arg Ser Glu Glu Ile Ala Tyr Lys Glu Glu Gly Ser Glu 65 70 75 80 Gly Ser Gly Ser Glu Gly Ser Gly Ser Asp Glu Ser Asp Arg Ile Arg 85 90 95 Lys Ile Val Glu Glu Ser Asp Glu Ile Val Lys Glu Ser Arg Lys Leu 100 105 110 Ala Glu Arg Ala Arg Glu Leu Ile Lys Glu Ser Glu Asp Lys Arg Val 115 120 125 Ser Glu Glu Arg Asn Glu Arg Leu Leu Glu Glu Leu Leu Arg Ile Leu 130 135 140 Asp Glu Asn Ala Glu Leu Leu Lys Arg Asn Leu Glu Leu Leu Lys Glu 145 150 155 160 Val Leu Tyr Arg Thr Arg 165 <210> SEQ ID NO 452 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 452 Asp Ser Asp Glu Lys Ala Glu Tyr Leu Leu Lys Glu Met Glu Arg Val 1 5 10 15 Val Arg Glu Ser Asp Glu Val Val Lys Lys Ile Leu Arg Asp Leu Glu 20 25 30 Glu Val Leu Glu Arg Leu Arg Arg Gly Glu Ile Ser Glu Asp Asp Val 35 40 45 Thr Glu Ile Leu Lys Glu Leu Ala Glu Arg His Ile Arg Ala Ile Glu 50 55 60 Glu Leu Val Arg Arg Leu Arg Glu Leu Leu Glu Arg His Lys Arg 65 70 75 <210> SEQ ID NO 453 <211> LENGTH: 162 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 453 Asp Glu Asp Asp Glu Leu Glu Arg Leu Leu Arg Glu Tyr His Arg Val 1 5 10 15 Leu Arg Glu Tyr Glu Lys Leu Leu Glu Glu Leu Arg Arg Leu Tyr Glu 20 25 30 Glu Tyr Lys Arg Gly Glu Val Ser Glu Glu Glu Ser Asp Arg Ile Leu 35 40 45 Arg Glu Ile Lys Glu Ile Leu Asp Lys Ser Glu Arg Leu Trp Asp Leu 50 55 60 Ser Glu Glu Val Trp Arg Thr Leu Leu Tyr Gln Ala Glu Gly Ser Glu 65 70 75 80 Gly Ser Gly Ser Glu Gly Ser Gly Ser Asp Asp Lys Glu Leu Asp Lys 85 90 95 Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile 100 105 110 Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys 115 120 125 Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu 130 135 140 Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys 145 150 155 160 Val Glu <210> SEQ ID NO 454 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 454 Pro Lys Glu Asp Ile Leu Arg Glu Val Leu Arg Arg His Lys Glu Ile 1 5 10 15 Val Arg Glu Ile Val Arg Leu Val Arg Glu Ala Val Glu Thr His Leu 20 25 30 Glu Leu Val Lys Arg Asn Ser Asp Asp Arg Asp Ala Gln Asp Val Ile 35 40 45 Arg Lys Leu Glu Glu Asp Leu Glu Arg Leu Val Arg His Ala Gln Glu 50 55 60 Val Ile Glu Glu Ile Phe Tyr Arg Leu His 65 70 <210> SEQ ID NO 455 <211> LENGTH: 158 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 455 Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu 1 5 10 15 Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val 35 40 45 Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile 50 55 60 Ala Lys Thr His Ala Lys Lys Val Glu Gly Ser Glu Gly Ser Gly Ser 65 70 75 80 Glu Gly Ser Pro Thr Asp Glu Val Ile Glu Val Leu Lys Glu Leu Leu 85 90 95 Arg Ile His Arg Glu Asn Leu Arg Val Asn Glu Glu Ile Val Glu Val 100 105 110 Asn Glu Arg Ala Ser Arg Val Thr Asp Arg Glu Glu Leu Glu Arg Leu 115 120 125 Leu Arg Arg Ser Asn Glu Leu Ile Lys Arg Ser Arg Glu Leu Asn Glu 130 135 140 Glu Ser Lys Lys Leu Ile Glu Lys Leu Glu Arg Leu Ala Thr 145 150 155 <210> SEQ ID NO 456 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 456 Asp Arg Glu Tyr Ile Ile Lys Asp Ile Leu Asp Ser Gln Glu His Leu 1 5 10 15 Leu Arg Leu Ile Glu Glu Leu Leu Glu Thr Gln Lys Glu Leu Leu Glu 20 25 30 Ile Leu Lys Arg Arg Pro Asp Ser Val Glu Arg Val Arg Glu Leu Val 35 40 45 Arg Arg Ser Lys Glu Ile Ala Asp Glu Ile Arg Arg Gln Ser Asp Arg 50 55 60 Asn Val Arg Leu Leu Glu Glu Val Ser Lys 65 70 <210> SEQ ID NO 457 <211> LENGTH: 160 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 457 Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu 1 5 10 15 Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val 35 40 45 Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile 50 55 60 Ala Lys Thr His Ala Lys Lys Val Glu Gly Ser Glu Gly Ser Gly Ser 65 70 75 80 Glu Gly Ser Gly Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg Lys Ile 85 90 95 Ile Glu Arg Ala Gln Glu Ile His Arg Arg Gln Gln Glu Ile Leu Glu 100 105 110 Glu Leu Glu Arg Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu Ala Met 115 120 125 Lys Arg Met Leu Lys Leu Leu Glu Glu Ser Leu Arg Leu Leu Lys Glu 130 135 140 Leu Leu Glu Leu Ser Glu Glu Ser Ala Gln Leu Leu Tyr Glu Gln Arg 145 150 155 160 <210> SEQ ID NO 458 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 458 Glu Ser Glu Asp Arg Ile Lys Glu Leu Leu Lys Arg His Ile Glu Leu 1 5 10 15 Val Glu Arg His Glu Glu Leu Leu His Glu Ile Lys Lys Leu Ile Asp 20 25 30 Leu Glu Glu Lys Asp Asp Lys Asp Arg Glu Glu Ala Val Lys Arg Ile 35 40 45 Asp Asp Ala Ile Lys Glu Ser Glu Glu Met Leu Glu Glu Ser Lys Glu 50 55 60 Ile Leu Glu Glu Ile Glu Tyr Leu Asn Arg 65 70 <210> SEQ ID NO 459 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 459 Pro Leu Lys Glu Arg Leu Leu Glu Ile Gln Arg Asp Leu Asp Arg Val 1 5 10 15 Leu Glu Glu Val Val Glu Arg Leu Leu Arg Ile Gln Glu Arg Leu Asp 20 25 30 Ser Val Val Glu Arg Lys Pro Pro Asp Val His Glu Glu Tyr Lys Tyr 35 40 45 Ile Val Asp Glu Ile Arg Glu Ile Val Glu Arg Val Val Arg Glu Tyr 50 55 60 Glu Glu Ile Val Lys Arg Ile Asp Glu Glu Val Arg 65 70 75 <210> SEQ ID NO 460 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 460 His Glu Lys Asp Ile Val Tyr Lys Val Glu Asp Leu Val Arg Lys Ser 1 5 10 15 Asp Arg Ile Ala Glu Arg Ala Arg Glu Ile Val Lys Arg Ser Arg Asp 20 25 30 Ile Met Arg Glu Ile Arg Lys Asp Lys Asp Asn Lys Lys Leu Ser Asp 35 40 45 Asp Leu Leu Lys Val Thr Arg Asp Leu Gln Arg Val Val Asp Glu Leu 50 55 60 Glu Glu Leu Ser Arg Glu Leu Leu Arg Val Ala Glu Glu Ser Arg Lys 65 70 75 80 <210> SEQ ID NO 461 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 461 Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Gly Ser 1 5 10 <210> SEQ ID NO 462 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 462 Asp Glu Glu Glu Ile Glu Glu Leu Leu Arg Glu Leu Glu Lys Leu Leu 1 5 10 15 Lys Lys Ser Glu Glu Ala Leu Glu Glu Ser Lys Lys Leu Ile Asp Glu 20 25 30 Ser Glu Glu Leu Leu Arg Arg Asp Arg Leu Asp Lys Glu Lys His Val 35 40 45 Arg Ala Ser Glu Glu His Val Lys Leu Ser Glu Glu His Leu Arg Ile 50 55 60 Ser Arg Glu Ile Val Lys Ile Leu Glu Lys Ala Val Tyr Ser Thr Arg 65 70 75 80 <210> SEQ ID NO 463 <400> SEQUENCE: 463 000 <210> SEQ ID NO 464 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 464 Asp Glu Asp Asp Glu Leu Glu Arg Leu Leu Arg Glu Tyr His Arg Val 1 5 10 15 Leu Arg Glu Tyr Glu Lys Leu Leu Glu Glu Leu Arg Arg Leu Tyr Glu 20 25 30 Glu Tyr Lys Arg Gly Glu Val Ser Glu Glu Glu Ser Asp Arg Ile Leu 35 40 45 Arg Glu Ile Lys Glu Ile Leu Asp Lys Ser Glu Arg Leu Trp Asp Leu 50 55 60 Ser Glu Glu Val Trp Arg Thr Leu Leu Tyr Gln Ala Glu 65 70 75 <210> SEQ ID NO 465 <400> SEQUENCE: 465 000 <210> SEQ ID NO 466 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 466 Asp Asp Glu Glu Glu Asp Lys Arg Leu Leu Glu Glu Val Lys Arg Ser 1 5 10 15 Leu Asp Thr Asp Glu Arg Ile Leu Glu Lys Leu Arg His Ser Leu Glu 20 25 30 Arg Gln Leu Glu Asp Val Asp Lys Asp Glu Asp Ser Arg Arg Val Leu 35 40 45 Arg Glu Leu Asp Glu Ile Thr Lys Arg Ser Arg Glu Val Val Lys Arg 50 55 60 Leu Arg Lys Leu Ala Tyr Glu Ser Lys 65 70 <210> SEQ ID NO 467 <400> SEQUENCE: 467 000 <210> SEQ ID NO 468 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 468 Pro Ser Lys Glu Tyr Gln Glu Lys Ser Ala Glu Arg Gln Lys Glu Leu 1 5 10 15 Leu His Glu Tyr Glu Lys Leu Val Arg His Leu Arg Glu Leu Val Glu 20 25 30 Lys Leu Gln Arg Arg Glu Leu Asp Lys Glu Glu Val Leu Arg Arg Leu 35 40 45 Val Glu Ile Leu Glu Arg Leu Lys Asp Leu His Lys Lys Ile Glu Asp 50 55 60 Ala His Arg Lys Asn Glu Glu Ala His Lys Glu Asn Lys 65 70 75 <210> SEQ ID NO 469 <400> SEQUENCE: 469 000 <210> SEQ ID NO 470 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 470 Pro Lys Glu Glu Ser Val Glu Glu Leu Lys Arg Val Ile Asp Lys His 1 5 10 15 Glu Glu Ile Leu Arg Glu Leu Lys Arg Val Leu Glu Glu His Glu Arg 20 25 30 Val Ser His Asp Glu Asp Glu Asn Glu Leu Arg Arg Ser Leu Glu Arg 35 40 45 Leu Lys His Ile Leu Asp Arg Leu His Glu Ser Leu Lys Glu Leu His 50 55 60 Glu Leu Leu Lys Lys Asn Glu Tyr Thr Glu Arg 65 70 75 <210> SEQ ID NO 471 <400> SEQUENCE: 471 000 <210> SEQ ID NO 472 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 472 Asp Glu Glu Tyr Val Thr Arg Ser Gln Arg Arg Leu Lys Arg Leu Leu 1 5 10 15 Glu Glu Tyr Ile Lys Val Val Glu Glu His Ala Arg Leu Val Glu Arg 20 25 30 Asn Glu Arg Asp Asp Lys Glu Leu Lys Arg Ser Ile Asp Glu Leu Asp 35 40 45 Lys Leu Thr Lys Glu Leu Leu Glu Leu Val Lys Arg Tyr Lys Glu Leu 50 55 60 Val Asp Lys Thr Glu Thr 65 70 <210> SEQ ID NO 473 <400> SEQUENCE: 473 000 <210> SEQ ID NO 474 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 474 Arg Glu Glu Glu Leu Lys Glu Ser Ala Glu Glu Leu Glu Arg Ser Val 1 5 10 15 Arg Glu Leu Lys Lys Glu Ala Asp Lys Tyr Lys Glu Glu Val Asp Arg 20 25 30 Leu His Tyr Arg Gly Lys Val Asp Lys Asp Trp Val Arg Val Val Glu 35 40 45 Lys Leu Ile Lys Leu Val Glu Glu His Leu Glu Leu Ile Arg Glu His 50 55 60 Leu Glu Leu Leu Lys Glu Glu Arg Arg 65 70 <210> SEQ ID NO 475 <400> SEQUENCE: 475 000 <210> SEQ ID NO 476 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 476 Asp Lys Asp Glu Arg Gln Glu Arg Leu Asn Glu Glu Ser Asp Lys Ser 1 5 10 15 Asn Glu Glu Ser Glu Arg Ser Asn Arg Glu Ser Glu Glu Leu Asn Arg 20 25 30 Arg Ala Arg Gly Pro Asn Asp Glu Lys Glu Leu Gln Glu Ile Leu Asp 35 40 45 Arg His Leu Glu Leu Leu Glu Arg Asn Gln Arg Leu Leu Asp Glu Asn 50 55 60 Lys Glu Ile Leu Arg Glu Ser Gln Tyr Leu Asn Asp 65 70 75 <210> SEQ ID NO 477 <400> SEQUENCE: 477 000 <210> SEQ ID NO 478 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 478 Glu Ser Glu Tyr Thr Gln Glu Glu Ile Leu Glu Leu Leu Lys Glu Ser 1 5 10 15 Ile Lys Leu Leu Arg Glu Ile Leu Arg Leu Leu Glu Glu Ser Glu Glu 20 25 30 Leu Trp Arg Arg Glu Asn Thr Lys Ser Glu Arg Ser Glu Glu Ile Lys 35 40 45 Glu Arg Ala Lys Glu Ala Ile Lys Arg Ser Glu Glu Ile Leu Glu Arg 50 55 60 Val Lys Arg Leu Ser Asp His Ser Arg 65 70 <210> SEQ ID NO 479 <400> SEQUENCE: 479 000 <210> SEQ ID NO 480 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 480 Pro Glu Lys Tyr Leu Ile Lys Thr Gln Glu Glu Leu Leu Arg Arg His 1 5 10 15 Ala Glu Ile Leu Glu Asp Leu Ile Arg Lys Val Glu Arg Gln Val Asp 20 25 30 Leu Arg Arg Lys Val Asp Glu Arg Asp Glu Asp Leu Lys Arg Glu Leu 35 40 45 Glu Arg Ser Leu Arg Glu Leu Glu Arg Leu Val Arg Glu Ser Ser Arg 50 55 60 Leu Val Glu Glu Ile Arg Glu Leu Ser Lys Glu Ile Lys Arg 65 70 75 <210> SEQ ID NO 481 <400> SEQUENCE: 481 000 <210> SEQ ID NO 482 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 482 Glu Lys Glu Tyr Ile Glu Lys Leu Ser Arg Lys Ile Glu Glu Asp Ile 1 5 10 15 Arg Arg Ser Glu Glu Arg Ala Lys Asp Ser Glu Arg Leu Val Arg Arg 20 25 30 Leu Glu Glu Leu Ala Lys Arg Lys Arg Leu Asp Leu Asp Asp Val Leu 35 40 45 Arg Val Ala Glu Glu Asn Leu Glu Ile Leu Glu Asp Asn Leu Arg Ile 50 55 60 Leu Glu Glu Ile Leu Lys Glu Gln Asp Lys Ser Asn Arg 65 70 75 <210> SEQ ID NO 483 <400> SEQUENCE: 483 000 <210> SEQ ID NO 484 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 484 Asp His Glu Asp Val Val Arg Leu His Glu Asp Leu Val Arg Lys Gln 1 5 10 15 Glu Asp Ala Arg Arg Val Leu Glu Glu Ile Val Arg Leu Ala Glu Glu 20 25 30 Ile Val Glu Val Ile Lys Lys Asp Glu Lys Asp Lys Asp Arg Val Thr 35 40 45 Arg Leu Val Glu Glu Ile Glu Lys Leu Val Glu Glu Tyr Lys Lys Lys 50 55 60 Val Asp Glu Met Arg Lys Ile Ser Asp Glu Ile Lys Tyr Arg Ser Arg 65 70 75 80 <210> SEQ ID NO 485 <400> SEQUENCE: 485 000 <210> SEQ ID NO 486 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 486 Arg Glu Asp Glu Glu Leu Glu Glu Glu Ile Asp Arg Ile Arg Gln Met 1 5 10 15 Val Glu Glu Tyr Glu Glu Leu Val Lys Glu Tyr Glu Glu Leu Thr Glu 20 25 30 Lys Tyr Lys Gln Gly Lys Val Asp Lys Glu Glu Ser Lys Lys Ile Ile 35 40 45 Glu Lys Ser Glu Arg Leu Leu Asp Leu Ser Gln Asp Ala Val Arg Lys 50 55 60 Val Lys Glu Ile Ile Arg Arg Ile Leu Tyr Thr Asn Arg 65 70 75 <210> SEQ ID NO 487 <400> SEQUENCE: 487 000 <210> SEQ ID NO 488 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 488 Pro Leu Glu Glu Ile Leu Lys Ile Gln Arg Arg Ile Asn Lys Ile Gln 1 5 10 15 Asp Asp Ile Asn Lys Ile Leu His Glu Ile Leu Arg Met Gln Glu Lys 20 25 30 Leu Asn Arg Ser Ser Asp Lys Asp Glu Val Glu Glu Ser Leu Arg Arg 35 40 45 Ile Arg Glu Leu Ile Lys Arg Ile Lys Asp Leu Ser Lys Glu Ile Glu 50 55 60 Asp Leu Ser Arg Glu Val Lys Tyr Arg Thr Thr 65 70 75 <210> SEQ ID NO 489 <400> SEQUENCE: 489 000 <210> SEQ ID NO 490 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 490 Asp Glu Asp Glu Thr Ser Tyr Arg Ile Leu Glu Leu Leu Arg Glu Ile 1 5 10 15 Val Arg Ala Ser Arg Glu Leu Ile Arg Leu Ser Glu Glu Leu Leu Glu 20 25 30 Val Ala Arg Arg Asp Asp Lys Asp Glu Thr Val Leu Glu Thr Leu Ile 35 40 45 Arg Glu Tyr Lys Glu Leu Leu Asp Arg Tyr Arg Arg Leu Ile Glu Glu 50 55 60 Leu Thr Arg Leu Val Glu Glu Tyr Glu Glu Arg Ser Arg 65 70 75 <210> SEQ ID NO 491 <400> SEQUENCE: 491 000 <210> SEQ ID NO 492 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 492 Asp Glu Glu Glu Leu Asn Arg Glu Leu Leu Glu Lys Ser Lys Arg Leu 1 5 10 15 Val Asp Ile Asn Arg Asp Ile Ile Arg Thr Ala Gln Glu Leu Ile Glu 20 25 30 Met Leu Lys Asp Ser Lys Asp Gly Arg Val Asp Glu Asp Thr Lys Arg 35 40 45 Glu Leu Arg Asp Lys Leu Arg Lys Leu Glu Glu Lys Leu Glu Arg Val 50 55 60 Arg Glu Glu Leu Arg Lys Tyr Glu Glu Leu Leu Arg Tyr Val Gln Arg 65 70 75 80 <210> SEQ ID NO 493 <400> SEQUENCE: 493 000 <210> SEQ ID NO 494 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 494 Asp Glu Glu Asp Val Leu Tyr His Leu Arg Glu Leu Leu Glu Glu Leu 1 5 10 15 Lys Arg Val Ser Asp Asp Tyr Glu Arg Leu Val Arg Glu Ile Lys Glu 20 25 30 Thr Ser Glu Arg Lys Asp Arg Asp Thr Lys Glu Asn Lys Asp Met Leu 35 40 45 Asp Glu Leu Val Lys Ala His Arg Glu Gln Glu Lys Leu Leu Glu Arg 50 55 60 Leu Val Arg Leu Leu Glu Glu Leu Phe Glu Arg Lys Arg 65 70 75

1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 494 <210> SEQ ID NO 1 <211> LENGTH: 64 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 1 Gly Ser Pro Lys Glu Glu Ala Arg Glu Leu Ile Arg Lys Gln Lys Glu 1 5 10 15 Leu Ile Lys Glu Gln Lys Lys Leu Ile Lys Glu Ala Lys Gln Lys Ser 20 25 30 Asp Ser Arg Asp Ala Glu Arg Ile Trp Lys Arg Ser Arg Glu Ile Asn 35 40 45 Arg Glu Ser Lys Lys Ile Asn Lys Arg Ile Lys Glu Leu Ile Lys Ser 50 55 60 <210> SEQ ID NO 2 <211> LENGTH: 62 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 2 Pro Lys Lys Glu Ala Glu Glu Leu Ala Glu Glu Ser Glu Glu Leu His 1 5 10 15 Asp Arg Ser Glu Lys Leu His Glu Arg Ala Glu Gln Ser Ser Asn Ser 20 25 30 Glu Glu Ala Arg Lys Ile Leu Glu Asp Ile Glu Arg Ile Ser Glu Arg 35 40 45 Ile Glu Glu Ile Ser Asp Arg Ile Glu Arg Leu Leu Arg Ser 50 55 60 <210> SEQ ID NO 3 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 3 Gly Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg Lys Ile Ile Glu Arg 1 5 10 15 Ala Gln Glu Ile His Arg Arg Gln Gln Glu Ile Leu Glu Glu Leu Glu 20 25 30 Arg Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu Ala Met Lys Arg Met 35 40 45 Leu Lys Leu Leu Glu Glu Ser Leu Arg Leu Leu Lys Glu Leu Leu Glu 50 55 60 Leu Ser Glu Glu Ser Ala Gln Leu Leu Tyr Glu Gln Arg 65 70 75 <210> SEQ ID NO 4 <211> LENGTH: 83 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 4 Gly Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg Glu 1 5 10 15 Gln Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu Glu 20 25 30 Glu Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu Ala 35 40 45 Lys Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu 50 55 60 Leu Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys Gly Ser Leu 65 70 75 80 Val Pro Arg <210> SEQ ID NO 5 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 5 Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg Lys Ile Ile Glu Arg Ala 1 5 10 15 Gln Glu Ile Ile Arg Arg Gln Gln Glu Ile Leu Glu Glu Leu Glu Arg 20 25 30 Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu Ala Met Lys Arg Met Leu 35 40 45 Lys Leu Leu Glu Glu Ser Leu Arg Leu Leu Lys Glu Leu Leu Glu Leu 50 55 60 Leu Glu Glu Ser Ala Gln Leu Leu Tyr Glu Gln Arg 65 70 75 <210> SEQ ID NO 6 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 6 Gly Ser Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg 1 5 10 15 Glu Ala Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu 20 25 30 Glu Glu Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu 35 40 45 Ala Lys Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg Leu Leu 50 55 60 Glu Leu Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 65 70 75 <210> SEQ ID NO 7 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 7 Thr Lys Glu Asp Ile Leu Glu Arg Ala Arg Lys Ile Ile Glu Arg Ala 1 5 10 15 Gln Glu Ile His Arg Arg Gln Gln Glu Ile Leu Glu Glu Leu Glu Arg 20 25 30 Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu Ala Met Lys Arg Met Leu 35 40 45 Lys Leu Leu Glu Glu Ser Leu Arg Leu Leu Lys Glu Leu Leu Glu Leu 50 55 60 Ser Glu Glu Leu Ala Gln Leu Leu Tyr Glu Gln Arg 65 70 75 <210> SEQ ID NO 8 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 8 Gly Ser Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala Ile Arg 1 5 10 15 Glu Gln Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu 20 25 30 Glu Glu Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu 35 40 45 Ala Lys Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu 50 55 60 Glu Leu Leu Arg Glu Ile Leu Tyr Leu Leu Gln Glu Gln Lys 65 70 75 <210> SEQ ID NO 9 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 9 Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg Lys Ile Ile Glu Arg Ala 1 5 10 15 Gln Glu Ile His Arg Arg Gln Gln Glu Ile Leu Glu Glu Leu Glu Tyr 20 25 30 Ile Ile Arg 35 <210> SEQ ID NO 10 <211> LENGTH: 121 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 10 Met Ser Glu Glu Ala Met Lys Arg Met Leu Lys Leu Leu Glu Glu Ser 1 5 10 15 Leu Arg Leu Leu Lys Glu Leu Leu Glu Leu Ser Glu Glu Ser Ala Gln 20 25 30 Leu Leu Tyr Glu Gln Arg Lys Ala Asn Asn Gly Ser Glu Thr Glu Lys 35 40 45 Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg Glu Gln Lys Glu Ile 50 55 60 Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu Glu Glu Ile Val Arg 65 70 75 80 Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu Ala Lys Lys Ile Leu 85 90 95 Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu Leu Leu Arg Glu 100 105 110

Ile Leu Tyr Leu Ser Gln Glu Gln Lys 115 120 <210> SEQ ID NO 11 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 11 Met Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg Lys Ile Ile Glu Arg 1 5 10 15 Ala Gln Glu Ile His Arg Arg Gln Gln Glu Ile Leu Lys Glu Gln Glu 20 25 30 Lys Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu Ala Met Lys Arg Ser 35 40 45 Leu Lys Leu Ile Glu Glu Ser Leu Arg Leu Leu Lys Glu Leu Leu Glu 50 55 60 Leu Ser Glu Glu Ser Ala Gln Leu Leu Tyr Glu Gln Arg 65 70 75 <210> SEQ ID NO 12 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 12 Gly Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg Glu 1 5 10 15 Gln Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Lys Glu Leu Thr 20 25 30 Lys Ile His Gln Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Arg Ala 35 40 45 Leu Lys Ile Ser Gln Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu 50 55 60 Leu Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 65 70 75 <210> SEQ ID NO 13 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 13 Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg Lys Ile Ile Glu Arg Ala 1 5 10 15 Gln Glu Ile His Arg Arg Gln Gln Glu Ile Leu Lys Arg Ser Glu Glu 20 25 30 Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu Ala Leu Glu Thr Leu Arg 35 40 45 Glu Leu Gln Glu Glu Ser Leu Arg Leu Leu Lys Glu Leu Leu Glu Leu 50 55 60 Ser Glu Glu Ser Ala Gln Leu Leu Tyr Glu Gln Arg 65 70 75 <210> SEQ ID NO 14 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 14 Gly Ser Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg 1 5 10 15 Glu Gln Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Thr 20 25 30 Glu Glu Ile Ile Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Asp Glu 35 40 45 Leu Arg Arg Ile Gln Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu 50 55 60 Glu Leu Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 65 70 75 <210> SEQ ID NO 15 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 15 Thr Thr Lys Arg Tyr Leu Glu Glu Ala Glu Arg Ala His Arg Glu Gln 1 5 10 15 Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu Glu Glu 20 25 30 Ile Val Arg Gln 35 <210> SEQ ID NO 16 <211> LENGTH: 116 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 16 Gly Ser Ser Glu Glu Ala Lys Lys Glu Ala Lys Lys Ile Leu Glu Glu 1 5 10 15 Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu Leu Leu Arg Glu Ile Leu 20 25 30 Tyr Leu Ser Gln Gln Val Asn Asp Val Asp Glu Lys Ala Leu Glu Arg 35 40 45 Gln Arg Lys Ile Ile Glu Arg Ala Gln Glu Ile His Arg Arg Gln Gln 50 55 60 Glu Ile Leu Glu Glu Leu Glu Arg Ile Ile Arg Lys Pro Gly Ser Ser 65 70 75 80 Glu Glu Ala Met Lys Arg Met Leu Lys Leu Leu Glu Glu Ser Leu Arg 85 90 95 Leu Leu Lys Glu Leu Leu Glu Leu Ser Glu Glu Ser Ala Gln Leu Leu 100 105 110 Tyr Glu Ala Arg 115 <210> SEQ ID NO 17 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 17 Glu Ala Met Lys Arg Met Leu Lys Leu Leu Glu Glu Ser Leu Arg Leu 1 5 10 15 Leu Lys Glu Leu Leu Glu Leu Ser Glu Glu Ser Ala Gln Leu Leu Tyr 20 25 30 Glu Ala Arg 35 <210> SEQ ID NO 18 <211> LENGTH: 116 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 18 Thr Thr Lys Arg Tyr Leu Glu Glu Ala Glu Arg Ala His Arg Glu Gln 1 5 10 15 Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu Glu Glu 20 25 30 Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu Ala Lys 35 40 45 Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu Leu 50 55 60 Leu Arg Glu Ile Leu Tyr Leu Ser Gln Gln Val Asn Asp Val Asp Glu 65 70 75 80 Lys Ala Leu Glu Arg Gln Arg Lys Ile Ile Glu Arg Ala Gln Glu Ile 85 90 95 His Arg Arg Gln Gln Glu Ile Leu Glu Glu Leu Glu Arg Ile Ile Arg 100 105 110 Lys Pro Gly Ser 115 <210> SEQ ID NO 19 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 19 Thr Arg Glu Glu Leu Leu Arg Glu Asn Ile Glu Leu Ala Lys Glu His 1 5 10 15 Ile Glu Ile Met Arg Glu Ile Leu Glu Leu Leu Gln Lys Met Glu Glu 20 25 30 Leu Leu Glu Lys Ala Arg Gly Ala Asp Glu Asp Val Ala Lys Thr Ile 35 40 45 Lys Glu Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg 50 55 60 Ile Ala Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser 65 70 75 <210> SEQ ID NO 20 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 20 Gly Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu 1 5 10 15 Ser Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys 20 25 30

Lys Leu Leu Lys Lys Ala Arg Gly Ala Asp Glu Lys Val Leu Asp Glu 35 40 45 Leu Arg Lys Ile Ile Glu Arg Ile Arg Glu Leu Leu Asp Arg Ser Arg 50 55 60 Lys Ile His Glu Arg Ser Glu Glu Ile Ala Tyr Lys Glu Glu 65 70 75 <210> SEQ ID NO 21 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 21 Gly Asp Arg Gln Glu Leu Ile Arg Arg Asn Ile Glu Leu Leu Lys Glu 1 5 10 15 His Ile Lys Ile Leu Glu Glu Ile Ser Gln Leu Ile Glu Glu Leu Ser 20 25 30 Glu Leu Leu Asp Lys Ser Ser Ser Glu Glu Val Val Lys Arg Tyr Lys 35 40 45 Lys Ile Leu Glu Arg Tyr Lys Gln Leu Leu Arg Lys Ser Gln Glu Ile 50 55 60 His Lys Glu Ser Ser Glu Ile Ala Lys Lys Glu Ser 65 70 75 <210> SEQ ID NO 22 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 22 Gly Asp Glu Gln Lys Leu Ile Glu Arg Ser Gln Arg Met Gln Lys Glu 1 5 10 15 Ser Leu Glu Leu Leu Lys Glu Ile Ile Lys Ile Leu Asp Thr Ile Glu 20 25 30 Lys Leu Leu Asp Lys Pro Asp Ser Glu Glu Leu Leu Asp Thr Ile Lys 35 40 45 Lys Leu His Asp Thr Leu Lys Lys Ile His Asp Arg Asn Lys Lys Leu 50 55 60 Leu Lys Glu His Glu Glu Ile Leu Arg Gln Arg Ser Gly Ser Leu Val 65 70 75 80 Pro Arg <210> SEQ ID NO 23 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 23 Asp Lys Glu Glu Glu Tyr Lys Arg Leu Leu Asp Glu Ile Lys Glu Ile 1 5 10 15 Leu Lys Glu Ser Lys Glu Val Leu Lys Asp Ser Lys Arg Val Leu Glu 20 25 30 Asp Ile Lys Arg Lys Val Pro Asp Asp Asp Leu Val Lys Leu Leu Glu 35 40 45 Lys His Val Arg Leu Leu Glu Glu His Val Lys Leu Leu Glu Gln Leu 50 55 60 Ile Arg Glu Ala Glu Lys Ser Ser Lys 65 70 <210> SEQ ID NO 24 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 24 Gln Gly Ser Ser Ala Glu Glu Leu Leu Lys Lys Ile Lys Glu Ser Glu 1 5 10 15 Lys Lys Ile Arg Asp Ser Leu Arg Lys Ile Lys Glu Ile Ile Lys Lys 20 25 30 Ser Arg Lys Glu Gly Val Asp Asp Lys Gln Leu Asp Leu Ile Arg Lys 35 40 45 Val Val Glu Ser His Arg Asp Leu Leu Arg Leu His Arg Asp Leu Leu 50 55 60 Arg Leu Leu Arg Glu Glu Thr Ser 65 70 <210> SEQ ID NO 25 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 25 Asp Ile Asp Glu Ser Ile Lys Glu Val Glu Lys Leu Leu Glu Glu Val 1 5 10 15 Glu Gln Ser Leu Gln Lys Leu Asp Asp Ser Leu Lys Lys Leu Leu Glu 20 25 30 Lys Val Asn Gln Asp Pro Asp Val Asp Asp Ser Val Arg Lys Ile Val 35 40 45 Lys Arg His Val Glu Ile Leu Lys Arg His Glu Glu Val Leu Lys Arg 50 55 60 Leu Ile Glu Val Val Lys Glu His Thr Lys Thr Val Lys 65 70 75 <210> SEQ ID NO 26 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 26 Gly Ser Asp Arg Glu Glu Val His Lys Glu Ile Val Lys Leu Ile Arg 1 5 10 15 Glu Ile Ile Lys Ile His Lys Lys Ile Leu Lys Ile His Glu Lys Ile 20 25 30 Lys Asn Gly Glu Ile Asp Pro Ser Glu Ile Leu Lys Leu Ser Glu Glu 35 40 45 Ile Lys Lys Leu Thr Asp Thr Ile Ile Lys Ile Ile Glu Asp Leu Glu 50 55 60 Gln Leu Thr Arg Asp Leu Arg Arg 65 70 <210> SEQ ID NO 27 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 27 Asp Arg Lys Glu Ile Val Lys Arg His Gln Lys Val Val Glu Leu Leu 1 5 10 15 Lys Glu Ser Ser Lys Leu Leu Arg Glu Ser Ser Lys Leu Leu Gln Arg 20 25 30 Leu Leu Asp Lys Thr Gly Asp Glu Asn Leu Gln Lys Ala Val Asp Asp 35 40 45 Gln Asp Lys Ala Ile Lys Arg Gln Glu Thr Ala Ile Arg Lys Ser Gln 50 55 60 Glu Ala Ser Lys Lys Leu Asp 65 70 <210> SEQ ID NO 28 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 28 Asp Asn Ser Glu Glu Ile Lys Lys Val Ala Lys Thr Ser Arg Glu Val 1 5 10 15 Ala Glu Tyr Ser Glu Arg Val Ala Lys Glu Asn Asp Lys Val Val Lys 20 25 30 Thr Leu Glu Glu Gly Lys Ile Asp Glu Ser Glu Leu Leu Arg Leu Leu 35 40 45 Glu Glu Ser Ile Lys Ile Phe Asp Thr Ala Leu Lys Leu His Glu Glu 50 55 60 Ala Tyr Lys Leu His Gln Asp Leu Val Arg Lys Val Ser 65 70 75 <210> SEQ ID NO 29 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 29 Asp Glu Ser Glu Ala Ala Ser Val Ala Ile Glu Ser Val Gln Ile Leu 1 5 10 15 Val Glu Ser Val Lys Leu Leu Glu Glu Ser Val Arg Ile Leu Leu Asp 20 25 30 Ala Val Lys Lys Asn Gly Val Glu Asp Leu Leu Arg Val Ala Gln Arg 35 40 45 Trp Glu Lys Leu Val Asp Glu Trp Leu Lys Val Val Lys Arg Trp Leu 50 55 60 Asp Asn Val Arg Asp Ile Gln Arg 65 70 <210> SEQ ID NO 30 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 30 Gly Ser Asp Lys Ala Glu Glu Val Glu Lys Ser Val Arg Lys Ile Glu 1 5 10 15 Glu Ser Ile Lys Lys Ile Arg Lys Ser Ile Lys Lys Ala Glu Asp Ala 20 25 30

Val Gln Leu Leu Lys Glu Gly Lys Ile Asp Ala Lys Asp Phe Leu Arg 35 40 45 Ile Val Arg Glu Asp Leu Glu Val Val Lys Glu Asp Val Glu Ile Val 50 55 60 Lys Glu Asp Val Glu Asn Val Arg Glu Phe Ser Ser 65 70 75 <210> SEQ ID NO 31 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 31 Ser Asp Lys Glu Val Ser Asp Lys Leu Leu Lys Ala Ser Lys Lys Leu 1 5 10 15 Leu Lys Val Ser Glu Glu Leu Leu Glu Val Val Arg Arg Leu Leu Lys 20 25 30 Ala Leu Lys Asp Asp Glu Leu Ile Lys Lys Ile Ala Asp Leu Leu Arg 35 40 45 Lys Ile Ile Asp Lys Asp Lys Lys Phe Ile Arg Thr Ser Glu Glu Ile 50 55 60 Val Lys Glu Ser Arg 65 <210> SEQ ID NO 32 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 32 Gly Ser Asp Leu Lys Glu Val Leu Lys Thr Val Glu Glu Ala Val Lys 1 5 10 15 Glu Ile Ile Lys Ser Ser Glu Glu Leu Leu Gln Ile Ser Arg Lys Ile 20 25 30 Leu Glu Ile Ser Arg Val Gly Val Asp Glu His Glu Tyr Ile Ser Ala 35 40 45 Ile Arg Glu Tyr Leu Lys Ala Leu Glu Lys His Ile Gln Ile Leu Lys 50 55 60 Lys Phe Ile Glu Ile Leu Lys Glu Leu Ile Arg Ala Val Ser 65 70 75 <210> SEQ ID NO 33 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 33 Ser Lys Glu Glu Ile Asp Lys Ile Val Lys Lys His Lys Lys Lys Ile 1 5 10 15 Glu Glu His Lys Lys Lys Val Asp Glu Leu Lys Lys Leu Val Glu Glu 20 25 30 His Asp Lys Arg Val Ser Gln Asp Lys Asp Asp Lys Val Lys Lys Leu 35 40 45 Ser Glu Glu Val Lys Lys Ile Ile Lys Arg Leu Glu Glu Val Ser Lys 50 55 60 Arg Leu Glu Glu Val Ser Lys Lys Leu Leu Lys Val Ile Ser Asp Lys 65 70 75 80 Arg <210> SEQ ID NO 34 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 34 Gly Ser Asn Asp Glu Glu Leu Lys Lys Ile Leu Glu Thr Leu Asp Arg 1 5 10 15 Ile Leu Lys Lys Leu Asp Lys Ile Leu Thr Arg Leu Ile Glu Val Leu 20 25 30 Lys Lys Ser Glu Asp Pro Asn Leu Asp Asp Lys Asp Tyr Thr Glu Leu 35 40 45 Val Lys Gln Phe Ile Glu Leu Ile Lys Lys Tyr Glu Glu Val Val Lys 50 55 60 Glu Tyr Glu Glu Val Val Arg Gln Leu Ile Arg Leu Phe Ser 65 70 75 <210> SEQ ID NO 35 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 35 Ser Lys Glu Glu Ile Asp Lys Ile Val Lys Lys His Lys Lys Lys Ile 1 5 10 15 Glu Glu Leu Lys Lys Leu Val Asp Glu Leu Lys Lys Leu Val Glu Glu 20 25 30 His Asp Lys Arg Val Ser Gln Asp Lys Asp Asp Lys Val Lys Lys Leu 35 40 45 Ser Glu Glu Val Lys Lys Ile Ile Lys Arg Val Glu Glu Val Ala Lys 50 55 60 Arg Leu Glu Glu Val Ser Lys Lys Leu Leu Lys Val Ile Ser Asp Lys 65 70 75 80 Arg <210> SEQ ID NO 36 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 36 Gly Ser Asn Asp Glu Glu Leu Lys Lys Ile Leu Glu Thr Leu Asp Arg 1 5 10 15 Ile Leu Lys Lys Leu Glu Lys Ile Leu Thr Arg Leu Ile Glu Val Leu 20 25 30 Lys Lys Ser Glu Asp Pro Asn Leu Asp Asp Lys Asp Tyr Thr Glu Leu 35 40 45 Val Lys Gln Phe Ile Glu Leu Ile Lys Lys Phe Glu Glu Val Ile Lys 50 55 60 Glu Tyr Glu Glu Val Val Arg Gln Leu Ile Arg Leu Phe Ser 65 70 75 <210> SEQ ID NO 37 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 37 Ser Lys Glu Glu Ile Asp Lys Ile Val Lys Lys His Lys Lys Lys Ile 1 5 10 15 Glu Glu His Lys Lys Lys Val Asp Glu His Lys Lys Leu Val Glu Glu 20 25 30 His Asp Lys Arg Val Ser Gln Asp Lys Asp Asp Lys Val Lys Lys Leu 35 40 45 Ser Glu Glu Leu Lys Lys Ile Ser Lys Arg Leu Glu Glu Val Ser Lys 50 55 60 Arg Leu Glu Glu Val Ser Lys Lys Leu Leu Lys Val Ile Ser Asp Lys 65 70 75 80 Arg <210> SEQ ID NO 38 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 38 Gly Ser Asn Asp Glu Glu Leu Lys Lys Ile Leu Glu Thr Leu Asp Arg 1 5 10 15 Ile Leu Lys Lys Leu Asp Lys Ile Leu Thr Arg Leu Asp Glu Val Leu 20 25 30 Lys Lys Ser Glu Asp Pro Asn Leu Asp Asp Lys Asp Tyr Thr Glu Leu 35 40 45 Val Lys Gln Tyr Ile Glu Leu Val Lys Lys Tyr Glu Glu Val Val Lys 50 55 60 Glu Tyr Glu Glu Val Val Arg Gln Leu Ile Arg Leu Phe Ser 65 70 75 <210> SEQ ID NO 39 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 39 Asp His Ser Arg Lys Leu Lys Glu Ile Leu Asp Arg Leu Arg Lys His 1 5 10 15 Val Lys Arg Leu Lys Glu His Leu Asp Glu Leu Arg Asp Leu Val Arg 20 25 30 Gln Val Pro Glu Asp Lys Leu Leu Glu His Val Val Lys Leu Ser Asp 35 40 45 Lys Ile Leu Gln Ile Ser Glu Arg Ala Val Arg Glu Phe Thr Lys Ser 50 55 60 Val Asp Lys Asp Ser 65 <210> SEQ ID NO 40 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 40

Gly Ser Asp Lys Lys Asp Glu Leu Glu Arg Ile Leu Asp Glu Ile Arg 1 5 10 15 Arg Leu Ile Glu Arg Leu Asp Glu Ile Leu Ser Arg Leu Asn Lys Leu 20 25 30 Leu Glu Leu Leu Lys His Gly Val Pro Asn Ala Lys Glu Val Val Lys 35 40 45 Asp Tyr Ile Arg Leu Leu Lys Glu Tyr Leu Glu Leu Val Lys Glu Phe 50 55 60 Leu Lys Leu Val Lys Arg His Ala Asp Leu Val Ser 65 70 75 <210> SEQ ID NO 41 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 41 Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu Asn Leu 1 5 10 15 Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys Gln Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val Ile Asp 35 40 45 Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val Ile Lys Ile Phe 50 55 60 Glu Asp Ser Val Arg Lys Lys Glu 65 70 <210> SEQ ID NO 42 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 42 Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys 1 5 10 15 Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu 20 25 30 Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr 35 40 45 Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu 50 55 60 Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 65 70 75 <210> SEQ ID NO 43 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 43 Met Asp Glu Glu Asp His Leu Lys Lys Leu Lys Thr His Leu Glu Lys 1 5 10 15 Leu Glu Arg His Leu Lys Leu Leu Glu Asp His Ala Lys Lys Leu Glu 20 25 30 Asp Ile Leu Lys Glu Arg Pro Glu Asp Ser Ala Val Lys Glu Ser Ile 35 40 45 Asp Glu Leu Arg Arg Ser Ile Glu Leu Val Arg Glu Ser Ile Glu Ile 50 55 60 Phe Arg Gln Ser Val Glu Glu Glu Glu 65 70 <210> SEQ ID NO 44 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 44 Gly Asp Val Lys Glu Leu Thr Lys Ile Leu Asp Thr Leu Thr Lys Ile 1 5 10 15 Leu Glu Thr Ala Thr Lys Val Ile Lys Asp Ala Thr Lys Leu Leu Glu 20 25 30 Glu His Arg Lys Ser Asp Lys Pro Asp Pro Arg Leu Ile Glu Thr His 35 40 45 Lys Lys Leu Val Glu Glu His Glu Thr Leu Val Arg Gln His Lys Glu 50 55 60 Leu Ala Glu Glu His Leu Lys Arg Thr Arg 65 70 <210> SEQ ID NO 45 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 45 Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu Asn Leu 1 5 10 15 Arg Arg His Leu Asp Arg Leu Asp Lys Leu Leu Lys Glu Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val Ile Asp 35 40 45 Glu Leu Glu Arg Val Ile Arg Ile Val Lys Thr Val Ile Lys Ile Phe 50 55 60 Glu Asp Ser Val Arg Lys Lys Glu 65 70 <210> SEQ ID NO 46 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 46 Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys 1 5 10 15 Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Leu Asn Lys Val Leu 20 25 30 Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Ile Glu Thr 35 40 45 Val Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu 50 55 60 Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 65 70 75 <210> SEQ ID NO 47 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 47 Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu Asn Leu 1 5 10 15 Arg Arg Leu Glu Asp Leu Leu Asp Lys His Ile Lys Gln Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val Ile Asp 35 40 45 Leu Ser Glu Arg Val Val Arg Thr Val Lys Thr Val Ile Lys Ile Phe 50 55 60 Glu Asp Ser Val Arg Lys Lys Glu 65 70 <210> SEQ ID NO 48 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 48 Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys 1 5 10 15 Ile Leu Gln Thr Ala Thr Lys Val Val Asp Asp Ala Asn Lys Leu Leu 20 25 30 Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr 35 40 45 Tyr Val Glu Leu Leu Lys Arg Leu Glu Lys Leu Ile Lys Glu Leu Leu 50 55 60 Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 65 70 75 <210> SEQ ID NO 49 <211> LENGTH: 37 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 49 Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu Asn Leu 1 5 10 15 Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys Gln Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn 35 <210> SEQ ID NO 50 <211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 50 Glu Asp Glu Arg Val Lys Asp Val Ile Asp Leu Ser Glu Arg Ser Val 1 5 10 15 Arg Ile Val Lys Thr Val Ile Lys Ile Phe Glu Asp Ser Val Arg Lys 20 25 30 Leu Glu Lys Thr Lys Pro Asp Ser Lys Thr Ala Lys Glu Leu Asp Lys

35 40 45 Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile 50 55 60 Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys 65 70 75 80 Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu 85 90 95 Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys 100 105 110 Val Glu <210> SEQ ID NO 51 <211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 51 Asp Ser Asp Glu His Leu Tyr Lys Leu Lys Thr Phe Leu Glu Asn Leu 1 5 10 15 Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys Gln Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Ala Ile Asp 35 40 45 Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val Ile Lys Ile Phe 50 55 60 Glu Asp Ser Val Arg Lys Lys Glu Lys Arg Pro Ile Asp Lys Arg Asp 65 70 75 80 Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln 85 90 95 Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Tyr Leu 100 105 110 Arg Arg <210> SEQ ID NO 52 <211> LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 52 Gly Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His 1 5 10 15 Glu Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys 20 25 30 Lys Val Glu 35 <210> SEQ ID NO 53 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 53 Asp Ser Asp Glu His Leu Asp Arg Leu Asp Lys His Leu Lys Lys Leu 1 5 10 15 Lys Thr Phe Leu Glu Asn Leu Arg Arg His Ile Lys Gln Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val Ile Asp 35 40 45 Leu Ser Lys Thr Val Ile Lys Ile Phe Glu Asp Ser Val Arg Lys Lys 50 55 60 Glu Arg Ser Val Arg Ile Val Glu 65 70 <210> SEQ ID NO 54 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 54 Gly Ser Asp Asp Lys Glu Ala Thr Lys Ile Ile Asp Asp Leu Asp Lys 1 5 10 15 Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Asn Lys Leu Leu 20 25 30 Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr 35 40 45 Tyr Val Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala 50 55 60 Glu Leu Leu Lys Arg His Glu Lys Lys Val Glu 65 70 75 <210> SEQ ID NO 55 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 55 Asp Ser Asp Glu His Ile Lys Gln Leu Arg Asp His Leu Asp Arg Leu 1 5 10 15 Asp Lys His Leu Lys Lys Leu Lys Thr Phe Leu Glu Asn Leu Arg Arg 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Thr Val Ile Lys 35 40 45 Ile Phe Glu Asp Ser Val Arg Lys Lys Glu Arg Ser Val Arg Ile Val 50 55 60 Lys Asp Val Ile Asp Leu Ser Glu 65 70 <210> SEQ ID NO 56 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 56 Gly Ser Asp Asp Lys Glu Ala Asn Lys Leu Leu Glu Lys Ala Thr Lys 1 5 10 15 Ile Ile Asp Asp Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu 20 25 30 Gln Thr Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Ala Val Lys Glu 35 40 45 Leu Leu Glu Ile Ala Lys Thr His Ala Glu Leu Leu Lys Arg His Glu 50 55 60 Lys Val Val Glu Thr Tyr Val Lys Lys Val Glu 65 70 75 <210> SEQ ID NO 57 <211> LENGTH: 104 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 57 Asp His Ser Arg Lys Leu Glu Glu Ile Leu Asp Arg Leu Arg Lys His 1 5 10 15 Val Lys Arg Leu Leu Glu His Leu Arg Glu Leu Leu Ser Leu Val Lys 20 25 30 Glu Asn Pro Glu Asp Lys Asp Leu Val Glu Val Leu Glu Leu Ser Leu 35 40 45 Ala Ile Leu Arg Arg Ser Leu Glu Ala Val Glu Ala Phe Leu Lys Ser 50 55 60 Val Thr Lys Lys Asp Pro Asp Asp Glu Asp Leu Arg Arg Lys Ala Asp 65 70 75 80 Glu Ile Arg Lys Glu Val Glu Glu Ile Lys Lys Ser Leu Ala Glu Val 85 90 95 Glu Lys Glu Ile Tyr Lys Leu Lys 100 <210> SEQ ID NO 58 <211> LENGTH: 116 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 58 Gly Ser Ser Ala Asp Asp Val Leu Glu Asp Ile Leu Lys Ile Ile Arg 1 5 10 15 Glu Leu Ile Glu Ile Leu Asp Gln Ile Leu Ser Leu Leu Asn Gln Leu 20 25 30 Leu Lys Leu Leu Arg His Gly Val Pro Asn Ala Lys Lys Val Val Glu 35 40 45 Lys Tyr Lys Glu Ile Leu Glu Leu Tyr Leu Gln Leu Val Ser Leu Phe 50 55 60 Leu Lys Ile Val Lys Thr His Ala Asp Ala Val Ser Gly Lys Ile Asp 65 70 75 80 Lys Lys Ala Glu Glu Glu Ile Lys Lys Glu Glu Glu Lys Ile Lys Glu 85 90 95 Lys Leu Arg Gln Ala Lys Asp Ile Leu Lys Lys Leu Gln Glu Glu Ile 100 105 110 Asp Lys Thr Arg 115 <210> SEQ ID NO 59 <211> LENGTH: 107 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 59 Asp Arg Asp Ala His Leu Tyr Lys Leu Leu Thr Phe Leu Glu Gln Leu 1 5 10 15 Val Arg His Leu Asp Arg Leu Val Lys His Ile Thr Gln Leu Arg Asp 20 25 30 Ile Val Lys Lys Asp Pro Glu Asp Glu Arg Ala Val Asp Val Ile Arg 35 40 45

Gln Ser Val Arg Ser Leu Glu Ile Val Ile Thr Val Leu Lys Ile Phe 50 55 60 Val Asp Ser Val Ser Asp Ala Ala Arg Ser Lys Glu Ala Glu Lys Ile 65 70 75 80 Val Arg Lys Ile Arg Lys Glu Ile Asp Glu Ile Arg Gln Lys Leu Arg 85 90 95 Glu Ile Asp Lys Glu Val Lys Lys Thr Thr Ser 100 105 <210> SEQ ID NO 60 <211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 60 Gly Ser Asn Asp Lys Val Leu Asp Lys Ile Leu Asp Ile Leu Asp Arg 1 5 10 15 Ile Leu Arg Leu Ala Thr Arg Val Ile Asp Leu Ala Asn Lys Leu Leu 20 25 30 Gln Val Lys Lys Lys Ser Thr His Lys Asp Pro Arg Ile Val Glu Thr 35 40 45 Tyr Lys Glu Leu Leu Lys Ile His Glu Thr Ala Val Arg Leu Leu Leu 50 55 60 Glu Leu Ala Asp Leu His Arg Arg Leu Lys Ser Lys Asp Glu Glu Ala 65 70 75 80 Asn Lys Arg Val Glu Thr Glu Leu Asp Arg Ile Arg Lys Lys Val Lys 85 90 95 Asp Ile Glu Asp Lys Val Arg Lys Leu Glu Asp Lys Val Arg Lys Thr 100 105 110 Ala Ser <210> SEQ ID NO 61 <211> LENGTH: 68 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 61 Asn Asp Leu Ser Lys Glu Val Leu Lys Lys Leu Glu Lys Ser Val Glu 1 5 10 15 Glu Leu Leu Arg Arg Val Gln Lys Ser Val Lys Glu Ala Gln Lys Arg 20 25 30 Gly Leu Leu Ser Asp Glu Leu Val Asp Arg His Leu Lys Ile Leu Asn 35 40 45 Gln Leu Val Lys Arg His Leu Glu Leu Leu Gln Glu Val Ile Lys Arg 50 55 60 Ser Asp Lys Lys 65 <210> SEQ ID NO 62 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 62 Gly Ser Asp Glu Ala Val Lys Arg Val Val Glu Lys Ser Leu Lys Ile 1 5 10 15 Leu Asp Glu Val Ile Lys Lys Ser Leu Asp Ile Leu Arg Glu Leu Ile 20 25 30 Glu Leu Gln Ile Arg His Ala Lys Asp Asp Glu Ser Val Ile Arg Ala 35 40 45 Ser Lys Ser Ala Leu Lys Asp Ala Ile Glu Ala Leu Lys Lys Ser Leu 50 55 60 Asp Glu Ile Lys Lys Ala Leu Lys Arg Ser Ala Asp Glu Gly 65 70 75 <210> SEQ ID NO 63 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 63 Ser Ser Glu Glu Val Val Lys Val His Glu Lys Val Val Lys Leu His 1 5 10 15 Lys Glu Ile Leu Glu Leu Leu Lys Lys Ile Ile Lys Ile His Glu Thr 20 25 30 Ala Ala Arg Asp Pro Asp Asp Lys Asp Ser Ile Lys Lys Leu Ser Asp 35 40 45 Glu Ile Lys Lys Ile Val Lys Arg Ile Glu Asp Ile Ser Asp Gln Ala 50 55 60 Lys Arg Glu Ser Ser Asp Ala Gln Arg Lys Gln Ser 65 70 75 <210> SEQ ID NO 64 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 64 Asp Lys Glu Glu Glu Ser Lys Glu Leu Leu Lys Lys Leu Lys Glu Ile 1 5 10 15 Leu Lys Arg Ser Glu Glu Leu Leu Glu Glu Ser Lys Glu Leu Leu Lys 20 25 30 Leu Ala Lys Asn Gly Glu Ile Asp Glu Ser Glu Leu Ala Asp Ala Asp 35 40 45 Arg Lys Leu Asn Lys Lys His Glu Lys Leu Val Gln Asp Ile Gln Asp 50 55 60 Leu Leu Arg Glu His Glu Arg Gln Asp Arg 65 70 <210> SEQ ID NO 65 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 65 Asp Glu Lys Lys Lys Ile Asp Lys Ile Val Lys Glu Thr Glu Asp Leu 1 5 10 15 Leu Gln Lys Ser Glu Lys Leu Leu Gln Gln Ser Lys Glu Ala Val Lys 20 25 30 Arg Ile Arg Ser Gln Val Lys Glu Asn Glu Ile Val Asp Arg Leu Leu 35 40 45 Arg Ile Ser Glu Glu Leu Leu Lys Ile Ser Arg Arg Leu Val Glu Ile 50 55 60 Ser Arg Arg Ile Ala Ser Thr Leu Ser 65 70 <210> SEQ ID NO 66 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 66 Gly Ser Ser Lys Glu Glu Val Ile Arg Leu Leu Lys Glu Asn Val Arg 1 5 10 15 Leu Ile Lys Glu Asn Leu Glu Leu Leu Thr Arg Asn Leu Lys Leu Ile 20 25 30 Thr Asp Leu Val Arg Gly Ser Asn Gly Ser Glu Glu Lys Ile Lys Thr 35 40 45 Leu Lys Glu Leu Leu Lys Glu Tyr Arg Glu Leu Leu Lys Arg Tyr Arg 50 55 60 Lys Leu Val Glu Asp Tyr Lys Arg Leu Val Asp Lys His Asp 65 70 75 <210> SEQ ID NO 67 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 67 Glu Ile Gln Glu Leu Ile Lys Ser Ser Arg Arg Ile Ile Glu Glu Ser 1 5 10 15 Lys Glu Leu Ile Lys Glu Ser Glu Glu Val Leu Arg Arg Ile Lys Glu 20 25 30 Ile Leu Asp Arg Ile Arg Asn Gly Val Asp Asn Gln Glu Asp Leu Leu 35 40 45 Arg Glu Ile Leu Lys Leu Leu Thr Lys Asn Leu Lys Ile Ile Gln Arg 50 55 60 Asn Leu Lys Leu Leu Gln Asp Asn Ala Glu Ile Leu Lys Arg Leu Val 65 70 75 80 Ser <210> SEQ ID NO 68 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 68 Gly Ser Tyr Ile Glu Asp Val Ile Lys Lys Ile Leu Asp Val Ser Arg 1 5 10 15 Glu Leu Ile Lys Leu Ser Arg Thr Ile Ile Lys Ile Ser Glu Glu Ile 20 25 30 Asn Lys Gln Leu Gln Gln Gly Arg Asp Thr Lys Asp Leu Val Lys Lys 35 40 45 Tyr Asp Glu Ile Ile Lys Lys Tyr Thr Arg Ile Val Gln His Tyr Thr 50 55 60 Glu Leu Ile Lys Glu Leu Gln Lys Leu Leu Ser 65 70 75 <210> SEQ ID NO 69 <211> LENGTH: 75

<212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 69 Ser Pro Thr Glu Glu Ala Ile Gln Leu Ser Gln Arg Val Ile Glu Leu 1 5 10 15 Ser Lys Arg Val Ile Glu Leu Ser Lys Glu Ile Leu Lys Leu Leu Lys 20 25 30 Arg Val Leu Asp Leu Leu Pro Asp Leu Asp Lys Asn Glu Glu Lys Arg 35 40 45 Leu Asp Asp Tyr Asp Lys Glu Leu Lys Glu Tyr Asp Lys Glu Leu Lys 50 55 60 Lys Tyr Glu Lys Arg Leu Lys Asp Leu Ala Ser 65 70 75 <210> SEQ ID NO 70 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 70 Gly Ser Glu Glu Glu Glu Ile Leu Lys Ile Gln Lys Glu Leu Leu Arg 1 5 10 15 Ile Gln Ser Glu Ile Leu Asp Lys Gln Lys Lys Ile Leu Asp Thr Leu 20 25 30 Arg Ser Asn Gly Ala Val Thr Glu Glu Val Arg Ser Ile Leu Glu Lys 35 40 45 Val Glu Arg Leu Ser Glu Glu Ala Lys Glu Leu Ser Lys Glu Ala Lys 50 55 60 Glu Leu Thr Lys Glu Val Ser Lys Leu Ile Ser 65 70 75 <210> SEQ ID NO 71 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 71 Ser Pro Leu Lys Glu Leu Asn Asn Gln Leu Leu Arg Leu Leu Arg Glu 1 5 10 15 Leu Val Lys Val Ser Lys Lys Ile Val Asp Leu Ser Lys Thr Ile Ile 20 25 30 Glu Val Leu Lys His Thr Asp Leu Asp Pro Arg Leu Leu Asp Ser Leu 35 40 45 Glu Lys Ser Gln Gln Glu Leu Asp Lys Ser Gln Lys Glu Leu Asp Lys 50 55 60 Val Val Lys Glu Leu Thr Lys Val Asn Lys Lys Leu Gln 65 70 75 <210> SEQ ID NO 72 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 72 Gly Ser Pro Leu Glu Asp Leu Val Arg Lys Tyr Asp Glu Leu Val Lys 1 5 10 15 Thr Tyr Glu Lys Leu Val Glu Glu Phe Lys Lys Ala Val Asp Lys Tyr 20 25 30 Asp Lys Ala Val Lys Lys Ala Pro Val Ser Lys Glu Ala Thr Asp Ser 35 40 45 Leu Asp Leu Ile Arg Lys Val Leu Glu Leu Leu Asp Arg Asn Leu Lys 50 55 60 Leu Ile Lys Glu Asn Ala Lys Leu Ile Lys Glu Leu Leu Lys 65 70 75 <210> SEQ ID NO 73 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 73 Ser Pro Thr Arg Glu Asn Glu Lys Val Ile Lys Glu Asn Glu Lys Val 1 5 10 15 Ile Ser Asp Asn Glu Arg Val Leu Glu Glu Val Val Lys Val Val Glu 20 25 30 Thr Ala Thr Asp Arg Lys Glu Ile Gln Asp Ala Val Asp Glu Val Arg 35 40 45 Lys Ser Val Asp Lys Leu Arg Asp Ser Val Arg Lys Leu Glu Glu Ser 50 55 60 Val Arg Thr Leu Asp 65 <210> SEQ ID NO 74 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 74 Gly Ser Pro Ile Lys Asp Ile Ser Lys Arg Leu Leu Glu Ile Ser Lys 1 5 10 15 Arg Leu Val Glu Ile Ser Asp Arg Ile Val Glu Leu Leu Gln Arg Ile 20 25 30 Ala Asp Ser Lys Asp Pro Asn Lys Asp Leu Gln Lys Glu Val Lys Asp 35 40 45 Val Leu Glu Glu Tyr Lys Arg Leu Val Arg Glu Tyr Arg Glu Val Val 50 55 60 Lys Glu Tyr Glu Lys Val Val Ser 65 70 <210> SEQ ID NO 75 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 75 Asp Glu Asp Glu His Val Lys Gln Leu Ile Lys Asn Ala Asp Leu Leu 1 5 10 15 Arg Lys His Ala Glu Leu Leu Lys Glu Leu Val Lys Leu Phe Gln Glu 20 25 30 Ile Ala Ser Gln Ile Pro Asp Asp Arg Val Ala Lys Lys Val Thr Asp 35 40 45 Val Val Asp Arg Ile Asp Lys Ile Leu Lys Gln Thr Glu Lys Leu Val 50 55 60 Arg Arg Thr Lys Gln Ile Leu Asp Tyr Ser Arg 65 70 75 <210> SEQ ID NO 76 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 76 Gly Ser Asn Leu Glu Glu Leu Val Lys Leu Leu Lys Glu Val Leu Glu 1 5 10 15 Met His Glu Arg Leu Leu Arg Ile His Glu Asp Leu Val Glu Ala His 20 25 30 Lys Ser Asn Ala Ser Asp Lys Glu Ser Glu Arg Lys Leu Lys Lys Ser 35 40 45 Asp Lys Asp Ile Lys Glu Ser Leu Lys Lys Ile Lys Ser Ile Ile Asp 50 55 60 Gln Val Arg Tyr Ile Gln Ser 65 70 <210> SEQ ID NO 77 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 77 Pro Val Glu Asp Ile Ile Glu Glu Ser Leu Arg Leu Leu Glu Glu Ser 1 5 10 15 Leu Lys Leu Leu Asn Arg Ile Leu Lys Leu Leu Glu Asp Ser Leu Arg 20 25 30 Lys Leu Pro Arg Ser Glu Glu Trp Arg Gln Arg Leu Asp Glu Phe Arg 35 40 45 Lys Lys Leu Glu Asp Trp Lys Glu Glu Leu Glu Arg Trp Ile Glu Asp 50 55 60 Val Arg Tyr Lys Lys Thr 65 70 <210> SEQ ID NO 78 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 78 Gly Ser Asp Glu Asp Tyr Glu Ser Arg Glu Ile Ile Asp Glu Ile Arg 1 5 10 15 Lys Leu Leu Asp Arg Ser Lys Lys Ile Val His Arg Ser Gln Arg Leu 20 25 30 Val Glu Arg Val Lys Ser Thr Pro Leu Ser Glu Asp Gln Glu Asp Leu 35 40 45 Ile Arg Arg His Glu Glu Thr Ile Asn Arg His Arg Glu Leu Val Lys 50 55 60 Glu Leu Glu Lys Val Leu Glu Asp His Glu Arg His Ile Arg 65 70 75 <210> SEQ ID NO 79 <211> LENGTH: 78 <212> TYPE: PRT

<213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 79 Pro Glu Glu Asp Ser Arg Arg Val Leu Glu Arg Phe Val Arg Val Ser 1 5 10 15 Arg Glu Val Leu Lys Val Leu Glu Glu Phe Leu Arg Val Ser Glu Glu 20 25 30 Leu Leu Arg Glu Ala Asp Arg Asp Arg Asp Arg Arg Leu Glu Glu Tyr 35 40 45 Glu Arg Gln Val Asp Glu Leu Arg Glu Glu Ile Arg Arg Tyr Lys Glu 50 55 60 Glu Val Asp Lys Phe Asp Lys Glu Val Lys Tyr Tyr Lys Lys 65 70 75 <210> SEQ ID NO 80 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 80 Gly Ser Pro Glu Lys Asp Glu Asn Arg Lys Leu Leu Asp Lys Val Arg 1 5 10 15 Lys Leu Val Glu Lys Ser Arg Arg Leu Val Glu Glu Leu Arg Lys Leu 20 25 30 Val Asp Gln Ser Thr Lys Asn Gly Leu Ile Asp Glu Lys Ala Leu Arg 35 40 45 Lys Gln Gln Glu Val Leu Arg Lys Val Glu Glu Val Leu Glu Lys Gln 50 55 60 Glu Arg Val Leu Arg Glu Leu Glu Glu Ile Ser Tyr Arg Val Ile 65 70 75 <210> SEQ ID NO 81 <211> LENGTH: 39 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 81 Gly Ser Pro Glu Arg Asp Glu Asn Arg Lys Leu Leu Asp Lys Val Arg 1 5 10 15 Lys Leu Val Glu Lys Ser Arg Arg Leu Val Glu Glu Leu Arg Lys Leu 20 25 30 Val Asp Gln Ser Thr Lys Asn 35 <210> SEQ ID NO 82 <211> LENGTH: 124 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 82 Gly Ser Asp Glu Lys Ala Leu Arg Lys Gln Gln Glu Val Leu Arg Lys 1 5 10 15 Val Glu Glu Val Leu Glu Lys Gln Glu Arg Val Leu Arg Glu Leu Glu 20 25 30 Glu Ile Ser Tyr Arg Val Ile Thr Arg Gly Glu Asp His Lys Ala Glu 35 40 45 Glu Asp Ser Arg Arg Val Leu Glu Arg Phe Val Arg Val Ser Arg Glu 50 55 60 Val Leu Lys Val Leu Glu Glu Phe Leu Arg Val Ser Glu Glu Leu Leu 65 70 75 80 Arg Glu Ala Asp Arg Asp Arg Asp Arg Arg Leu Glu Glu Tyr Glu Arg 85 90 95 Gln Val Asp Glu Leu Arg Glu Glu Ile Arg Arg Tyr Lys Glu Glu Val 100 105 110 Asp Lys Phe Asp Lys Glu Val Lys Tyr Tyr Lys Lys 115 120 <210> SEQ ID NO 83 <211> LENGTH: 39 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 83 Gly Ser Asp Arg Arg Leu Glu Glu Tyr Glu Arg Gln Val Asp Glu Leu 1 5 10 15 Arg Glu Glu Ile Arg Arg Tyr Lys Glu Glu Val Asp Lys Phe Asp Lys 20 25 30 Glu Val Lys Tyr Tyr Lys Lys 35 <210> SEQ ID NO 84 <211> LENGTH: 125 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 84 Gly Ser Pro Glu Arg Asp Glu Asn Arg Lys Leu Leu Asp Lys Val Arg 1 5 10 15 Lys Leu Val Glu Lys Ser Arg Arg Leu Val Glu Glu Leu Arg Lys Leu 20 25 30 Val Asp Gln Ser Thr Lys Asn Gly Leu Ile Asp Glu Lys Ala Leu Arg 35 40 45 Lys Gln Gln Glu Val Leu Arg Lys Val Glu Glu Val Leu Glu Lys Gln 50 55 60 Glu Arg Val Leu Arg Glu Leu Glu Glu Ile Ser Tyr Arg Val Ile Thr 65 70 75 80 Arg Gly Glu Asp His Lys Ala Glu Glu Asp Ser Arg Arg Val Leu Glu 85 90 95 Arg Phe Val Arg Val Ser Arg Glu Val Leu Lys Val Leu Glu Glu Phe 100 105 110 Leu Arg Val Ser Glu Glu Leu Leu Arg Glu Ala Asp Arg 115 120 125 <210> SEQ ID NO 85 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 85 Asp Leu Ser Glu Glu Ser Lys Lys Phe Val Glu Lys Val Lys Lys Leu 1 5 10 15 Glu Lys Glu Ser Arg Glu Leu Glu Lys Gln Val Lys Lys Ile Glu Glu 20 25 30 Asp Ser Arg Ser Val Glu Asn Asp Val Gln Lys Glu Phe Leu Glu Leu 35 40 45 Leu Lys Arg Leu Leu Asp Ile Gln Lys Lys Val Val Glu Val Leu Arg 50 55 60 Glu Val Val Lys Val Gln Gln Tyr Val Asp Ser 65 70 75 <210> SEQ ID NO 86 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 86 Gly Ser Asp Ser Glu Tyr Glu Ser Arg Gln Val Leu Arg Glu Leu Asp 1 5 10 15 Thr Val Leu Lys Asp Ser His Thr Val Leu Glu Ala Leu Arg Gln Val 20 25 30 Ile Arg Asp Ser Gln Asp Val Val Ser Lys Ser Asp Glu Glu Ser Arg 35 40 45 Arg Val Ile Asp Asp Leu Glu Lys Val Ile Gln Asp Ser Lys Lys Val 50 55 60 Leu Asp Asp Ile Lys Arg Leu Ile Asp Lys Ser Lys Ser Ile Lys Ser 65 70 75 80 <210> SEQ ID NO 87 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 87 Asn Glu Asp Glu Leu Leu Lys Leu Leu Thr Glu Asn Leu Lys Leu Leu 1 5 10 15 Asp Glu Asn Leu Lys Leu Leu Arg Glu Asn Leu Ser Leu Leu Arg Gln 20 25 30 Ala Asn Asn Ile Thr Asp Lys Asn Arg Ile Arg Glu Ile Val Lys Gln 35 40 45 Ser Lys Glu Ile Val Lys Gln Ser Arg Glu Ile Leu Lys Gln Ser Lys 50 55 60 Glu Ile Val Glu Arg Ile Lys Tyr Ile Val Ser 65 70 75 <210> SEQ ID NO 88 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 88 Gly Ser Ser Leu Tyr Glu Leu Thr Gln Arg Tyr Glu Lys Leu Val Gln 1 5 10 15 Gln Tyr Glu Glu Leu Val Lys Asp Tyr Arg Arg Leu Val Lys Lys Leu 20 25 30 Glu Lys Leu Lys Arg Asp Asn Lys Pro Asp Lys Arg Leu Leu Lys Glu 35 40 45 Ile Val Asp Val Ile Lys Lys Ser Val Glu Ile Ile Asp Arg Ser Leu 50 55 60 Lys Leu Leu Glu Glu Ser Ile Lys Ile Leu Glu Glu Thr Asp 65 70 75

<210> SEQ ID NO 89 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 89 Ser Gln Glu Arg Ser Leu Glu Ile Leu Lys Arg Ile Leu Asp Val Leu 1 5 10 15 Lys Glu Ser Leu Glu Ile Leu Lys Glu Ser Leu Ser Ile Leu Arg Gln 20 25 30 Leu Ala Ser Arg Ile Lys Asn Pro Asn Arg Lys Ile Glu Glu Ile Leu 35 40 45 Lys Glu Ser Asp Lys Ile Ile Lys Glu Ser Asp Lys Val Leu Lys Glu 50 55 60 Ile Glu Glu Val Ile Arg Tyr Ser Ser 65 70 <210> SEQ ID NO 90 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 90 Gly Ser Asp Ile Glu Tyr Glu Ser Lys Glu Ile Leu Glu Leu Ile Lys 1 5 10 15 Glu Leu Leu Lys Leu Ser Arg Glu Leu Leu Lys Glu Ser Arg Arg Ala 20 25 30 Leu Glu Leu Val Arg Lys Ser Arg Asp Asp Ser Ile Val Glu Glu Val 35 40 45 Ile Gln Val His Lys Lys Val Leu Asp Ile His Lys Glu Val Leu Lys 50 55 60 Ile Val Arg Lys Val Val Glu Val His Arg Arg Val Lys Ser 65 70 75 <210> SEQ ID NO 91 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 91 Ser Lys Lys Asp Glu Ser Thr Lys Leu Glu Arg Leu Ala Glu Lys Ile 1 5 10 15 Asp Glu Ile Thr Lys Arg Ile Glu Glu Leu Val Lys Asp Val Lys Arg 20 25 30 Lys Ser Ser Glu Gly Val Asp Lys Asp Gln Gln Gln Lys Ile Asp Glu 35 40 45 Val Phe Gln Lys Leu Leu Asp Leu Gln Arg Glu Ile Leu Glu Ile Leu 50 55 60 Asp Arg Ile Leu Lys Val Gln Gln Tyr Ile Leu Asp 65 70 75 <210> SEQ ID NO 92 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 92 Gly Ser Asp Leu Glu Tyr Leu Asn Arg Arg Leu Leu Gln Leu Ile Lys 1 5 10 15 Thr Leu Ile Asp Leu Asn Arg His Leu Leu Lys Leu Ile Asp Lys Leu 20 25 30 Lys Lys Leu Asn Ser Arg Glu Gly Asp Glu Glu Lys Ile Lys Glu Glu 35 40 45 Ser Lys Gln Ile Gln Glu Gln Phe Lys Glu Ile Val Glu Arg Ser Lys 50 55 60 Glu Ile Ile Lys Gln Ile Lys Glu Ile Ile Lys Arg Ser Gln 65 70 75 <210> SEQ ID NO 93 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 93 Asp Phe Glu Arg Ser Ser Arg Arg Leu Glu Lys Val Val Glu Asp Leu 1 5 10 15 Arg Arg Ser Ser Asp Arg Leu Arg Glu Val Ile Asp Glu Leu Arg Lys 20 25 30 Ser Ala Asp Glu Lys Asp Glu Asp Glu Asp Leu Arg Arg Ala Arg Lys 35 40 45 Glu His Arg Asp Leu Ile Glu Glu Leu Lys Arg Ala Leu Glu Lys Gln 50 55 60 Glu Glu Ile Ile Lys His Leu Gln Glu Leu Val Tyr Arg Gln Leu 65 70 75 <210> SEQ ID NO 94 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 94 Gly Ser Glu Glu Ser Glu Glu Val Arg Lys Val Val Glu Arg Ile Lys 1 5 10 15 Lys Ile Ser Arg Glu Leu Glu Glu Val Val Lys Glu Leu Asp Arg Val 20 25 30 Ser Lys Glu Phe Asp Arg His Gly Glu Thr Asp Glu Ile Val Arg Glu 35 40 45 His Glu Arg Ile Val Glu Lys Leu Glu Glu Ile Val Lys Lys His Thr 50 55 60 Lys Ile Val Glu Glu Leu Ala Glu Ile Val Tyr Lys Gln Gln 65 70 75 <210> SEQ ID NO 95 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 95 Ser Asp Asp Asp Ser Val Arg Val Leu Asp Glu Ile Val Lys Ile Leu 1 5 10 15 Asp Glu Ser Val Lys Leu Leu Lys Glu Ser Leu Lys Leu Leu Asp Asp 20 25 30 Phe Leu Arg Thr Lys Pro Asp Asp His Leu Lys Glu Val Val Lys Glu 35 40 45 Ser Lys Lys Val Val Glu Gln Ser Lys Lys Val Leu Asp Arg Ile Lys 50 55 60 Lys Ile Ile Tyr Glu Ser Lys 65 70 <210> SEQ ID NO 96 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 96 Gly Ser Asp Leu Leu Tyr Leu Ser Lys Glu Leu Leu Lys Leu Val Arg 1 5 10 15 Glu Leu Leu Lys Leu Ser Arg Glu Leu Val Glu Leu Ser Arg Arg Leu 20 25 30 Val Asn Ser Thr His Lys Ser Pro Glu Leu Val Lys Lys Tyr Asp Lys 35 40 45 Leu Val Lys Lys Tyr Gln Asp Leu Leu Lys Lys Leu Ala Asp Val Ala 50 55 60 Asp Glu Tyr Leu Arg Gln Arg Ser 65 70 <210> SEQ ID NO 97 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 97 Asp Glu Lys Asp Tyr His Arg Arg Leu Ile Glu His Leu Glu Asp Leu 1 5 10 15 Val Arg Arg His Glu Glu Leu Ile Lys Arg Gln Lys Lys Val Val Glu 20 25 30 Glu Leu Glu Arg Arg Gly Leu Asp Glu Arg Leu Arg Arg Val Val Asp 35 40 45 Arg Phe Arg Arg Ser Ser Glu Arg Trp Glu Glu Val Ile Glu Arg Phe 50 55 60 Arg Gln Val Val Asp Lys Leu Arg Lys Ser Val Glu 65 70 75 <210> SEQ ID NO 98 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 98 Gly Ser Asp Ala Tyr Asp Leu Asp Arg Ile Val Lys Glu His Arg Arg 1 5 10 15 Leu Val Glu Glu Gln Arg Glu Leu Val Glu Glu Leu Glu Lys Leu Val 20 25 30 Arg Arg Gln Glu Asp His Arg Val Asp Lys Lys Glu Ser His Glu Ile 35 40 45 Leu Glu Arg Leu Glu Arg Ile Ile Arg Arg Ser Thr Arg Ile Leu Thr 50 55 60 Glu Leu Glu Lys Leu Thr Asp Glu Phe Glu Arg Arg Thr Arg 65 70 75

<210> SEQ ID NO 99 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 99 Asp Glu Arg Tyr Arg Ala Arg Glu His Ile Arg Arg Val Glu Glu His 1 5 10 15 Thr Lys Arg Leu Arg His Ile Leu Lys Arg Leu Arg Glu His Glu Glu 20 25 30 Lys Leu Arg Arg Glu Leu Lys Pro Gly Asp Glu Ile Thr Glu Ser Val 35 40 45 Asp Arg Phe Lys Lys Ile Val Asp Gln Phe Glu Glu Ser Ile Lys Lys 50 55 60 Phe Glu Thr Val Ser Glu Glu Leu Arg Lys Ser Asp Ser 65 70 75 <210> SEQ ID NO 100 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 100 Gly Ser Asp Arg Gln Arg Ile Leu Asp Arg Leu Asp Lys Ile Leu Glu 1 5 10 15 Lys Leu Asp Asp Ile Leu Lys Lys Leu Lys Asp Ile Leu Glu Thr Leu 20 25 30 Ser Lys Asp Asp Val Ser Asp Arg Arg His Lys Asp Leu Val Glu Lys 35 40 45 Phe Arg Glu Leu Val Asp Thr His His Lys Leu Val Glu Arg Tyr Arg 50 55 60 Glu Leu Val Tyr Gln Asn Arg 65 70 <210> SEQ ID NO 101 <211> LENGTH: 38 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 101 Gly Ser Asp Glu Ile Thr Glu Ser Val Asp Arg Phe Lys Lys Ile Val 1 5 10 15 Asp Gln Phe Glu Glu Ser Ile Lys Lys Phe Glu Thr Val Ser Glu Glu 20 25 30 Leu Arg Lys Ser Ile Ser 35 <210> SEQ ID NO 102 <211> LENGTH: 107 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 102 Gly Ser Asp Pro Gln Arg Ala Ala Asp Arg Leu Asp Lys Ile Leu Glu 1 5 10 15 Lys Leu Asp Asp Ile Leu Lys Lys Leu Lys Asp Ile Leu Glu Thr Leu 20 25 30 Ser Lys Asp Asp Val Lys Asp Arg Arg Ala Lys Asp Leu Val Glu Lys 35 40 45 Phe Arg Glu Leu Val Asp Thr His His Lys Leu Val Glu Arg Tyr Arg 50 55 60 Glu Leu Val Tyr Thr Ala Thr Ala Gly Ser Asp Leu Ala Arg Glu Leu 65 70 75 80 Ile Arg Arg Val Glu Glu His Thr Lys Arg Leu Arg His Ile Leu Lys 85 90 95 Arg Leu Arg Glu His Glu Glu Lys Leu Arg Arg 100 105 <210> SEQ ID NO 103 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 103 Asn Ala Asp Asp Gln Leu Ala Thr Ser Ile Lys Lys Leu Glu Asp Ser 1 5 10 15 Ile Asp Gln Leu Ile Lys Ile Val Arg Lys Phe Glu Glu Ser Val Lys 20 25 30 Lys Leu Gln Lys His Gly Val Asp Gln His His Val Glu Ile Leu Arg 35 40 45 Lys Ile Val Glu Ile Phe Arg Gln His Ile Glu Lys Leu Lys Lys His 50 55 60 Leu Glu Lys Leu Arg Tyr Thr Ser Ser 65 70 <210> SEQ ID NO 104 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 104 Gly Ser Asp Lys Glu Tyr Leu Val Thr Glu His Glu Lys Leu Val Arg 1 5 10 15 Glu His Glu Lys Ile Val Ser Glu Ile Glu Lys Leu Val Lys Lys His 20 25 30 Glu Ala Gly Val Asp Glu Ser Glu Leu Glu Glu Ile Leu Lys Lys Val 35 40 45 Glu Lys Leu Leu Arg Lys Leu Asp Glu Ile Leu Glu Gln Leu Thr Gln 50 55 60 Leu Leu Arg Lys Thr Glu 65 70 <210> SEQ ID NO 105 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 105 Gly Ser Asp Gln His Val Val Glu Ile Leu Arg Lys Ile Val Glu Ile 1 5 10 15 Phe Arg Gln His Ile Glu Lys Leu Lys Lys His Leu Glu Lys Leu Arg 20 25 30 Tyr Thr Ser Ser 35 <210> SEQ ID NO 106 <211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 106 Gly Ser Asp Ala Glu Tyr Leu Val Thr Glu His Glu Lys Leu Val Arg 1 5 10 15 Glu His Glu Lys Ile Val Ser Glu Ile Glu Lys Leu Val Lys Lys His 20 25 30 Glu Lys Gly Val Asp Glu Ser Glu Leu Glu Glu Ile Leu Lys Lys Val 35 40 45 Glu Lys Leu Leu Arg Lys Leu Asp Glu Ile Leu Glu Gln Leu Thr Gln 50 55 60 Leu Leu Arg Lys Ala Glu Lys His Ile Asp Lys His Ser Lys Ala Ala 65 70 75 80 Asp Gln Leu Ala Thr Ser Ile Lys Lys Leu Glu Asp Ser Ile Asp Gln 85 90 95 Leu Ile Lys Ile Val Arg Lys Phe Glu Glu Ser Val Lys Lys Leu Gln 100 105 110 Lys His <210> SEQ ID NO 107 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 107 Asp Glu Asp Asp Asp Ile Arg Arg Val Leu Asp Glu Ser Arg Arg Val 1 5 10 15 Leu Glu His Ser Arg Arg Val Leu Lys Arg Ser Glu Glu Val Leu Glu 20 25 30 Lys Ala Ser Arg Lys Lys Glu Lys Asp Thr Glu Glu Ile Glu Lys His 35 40 45 Leu Lys Arg Leu Arg Glu His Ala Lys Lys Leu Glu Lys His Arg Arg 50 55 60 Glu Leu Asp Asp Phe Leu Tyr Lys Glu Ile 65 70 <210> SEQ ID NO 108 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 108 Gly Ser Arg Asp Lys Tyr Leu Leu Glu Arg Leu Asn Asp Ile Leu Lys 1 5 10 15 Lys Leu Asp Glu Ile Val Asp Lys Leu Ser Asp Ile Leu Lys Arg Leu 20 25 30 Lys Asp Val Arg His Asp Asp Arg Leu Gln Glu Leu Val Glu Arg Tyr 35 40 45 Lys Glu Ile Val Lys Glu Tyr Lys Arg Ile Val Glu Glu Tyr Glu Lys 50 55 60 Leu Val Arg Glu Phe Glu Glu Gln Gln Arg 65 70

<210> SEQ ID NO 109 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 109 Asp Arg Asp Tyr Glu Asp Lys Glu Phe Lys Lys Ile Ile Lys Glu Leu 1 5 10 15 Glu Asp Val Gln Glu Glu Leu Lys Lys Leu Gln Glu Lys Ile Lys Arg 20 25 30 Phe Ser Ser Glu Leu Glu Glu Pro Asn Glu Leu Leu Lys Glu Gln Leu 35 40 45 Lys Val Asn Glu Glu Gln Leu Glu Val Asn Lys Lys Ile Leu Lys Ile 50 55 60 Leu Arg Asp Gln Leu Lys Gln Asn Glu 65 70 <210> SEQ ID NO 110 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 110 Gly Ser Asp Ala Glu Tyr Lys Val Arg Glu Ser Val Lys Arg Ser Lys 1 5 10 15 Glu Ser Val Lys His Ser Glu Asp Val Val Asp Lys Leu Asn Lys Ser 20 25 30 Val Lys Leu Ser Glu Ser Gly His Ser Asp Ala Glu Lys Ala Ser Arg 35 40 45 Glu Leu Val Lys Leu Val Arg Glu Val Val Glu Leu Ser Arg Glu Val 50 55 60 Ile Lys Leu Ser Glu Lys Val Leu Arg Val Ile Ser 65 70 75 <210> SEQ ID NO 111 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 111 Asp Leu Gln Tyr Lys Gln Glu Lys Leu Ile Arg His Phe Asp Arg Val 1 5 10 15 Val Arg Glu Trp Asp Lys Leu Val Arg Lys Phe Ser Lys Val Leu Glu 20 25 30 Lys Gln Lys His Glu Ser Lys Asp Lys Glu Leu Glu Glu Ala Ser Arg 35 40 45 Arg Val Asp Glu Leu Ile Lys Arg Leu Arg Glu Gln Leu Lys Arg Ser 50 55 60 Lys Glu Ile Leu Arg Arg Leu Lys Glu Leu Ser Arg Lys Ser Ser 65 70 75 <210> SEQ ID NO 112 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 112 Gly Ser Asp Trp Glu Glu Leu Leu Arg Arg Leu Glu Lys Val Leu Gln 1 5 10 15 Glu Tyr Glu Glu Ile Val Lys Glu Leu Ile Asp Leu Ile Glu Arg Leu 20 25 30 Ile Lys Val Ser Glu Asp Lys Ser Lys Asp Ala Ser Glu Tyr Lys Lys 35 40 45 Leu Val Thr Glu Leu Glu Lys Leu Ile Ser Lys Leu Glu Glu Ile Ser 50 55 60 Lys Lys Leu Glu Glu Leu Val Lys Glu Tyr Glu Tyr Lys Thr Glu 65 70 75 <210> SEQ ID NO 113 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 113 Asp Ala Lys Asp Glu Leu Glu Lys Ser Leu Gln Glu Ile Glu Glu Ser 1 5 10 15 Leu Lys Glu Leu Lys Lys Leu Leu Glu Glu Leu Asp Lys Ser Leu Arg 20 25 30 Glu Leu Thr Ser Gln Gly Arg Asn Lys Lys Leu Glu Glu His Ile Lys 35 40 45 Lys Val Gln Lys Phe Ile Glu Leu Val Lys Lys Tyr Ile Lys Ala Val 50 55 60 Gln Asp Tyr Leu Lys Glu Val Arg Tyr Asp Asn Ser 65 70 75 <210> SEQ ID NO 114 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 114 Gly Ser Asp Lys Glu Arg Ala Ala Arg Ala Thr Glu Glu Met Val Lys 1 5 10 15 Leu Thr Lys Lys Leu Leu Lys Ala Val Glu Asp Leu Val Arg Asp Val 20 25 30 Arg Arg Leu Leu Lys Glu Gly Leu Ile Ser Glu Lys His Ala Arg Ile 35 40 45 Ala Glu Thr Ile Leu Glu Val Phe Lys Lys His Ala Lys Ile Ile Lys 50 55 60 Lys His Val Asp Ile Val Lys Tyr Asp Glu Ser 65 70 75 <210> SEQ ID NO 115 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 115 Gly Ser Pro Leu Lys Glu Arg Leu Leu Glu Ile Gln Arg Asp Leu Asp 1 5 10 15 Arg Val Leu Glu Glu Val Val Glu Arg Leu Leu Arg Ile Gln Glu Arg 20 25 30 Leu Asp Ser Val Val Glu Arg Lys Pro Pro Asp Val His Glu Glu Tyr 35 40 45 Lys Tyr Ile Val Asp Glu Ile Arg Glu Ile Val Glu Arg Val Val Arg 50 55 60 Glu Tyr Glu Glu Ile Val Lys Arg Ile Asp Glu Glu Val Arg 65 70 75 <210> SEQ ID NO 116 <211> LENGTH: 83 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 116 Gly Ser Glu Glu Asp Glu Arg Ile Arg Tyr Asp Leu Asp Arg Ile Arg 1 5 10 15 Lys Asp Val Arg Arg Lys Leu Glu Glu Ile Arg Gln Arg Val Arg Glu 20 25 30 Leu Glu Lys Lys Leu Arg Asp Ala Gly His Arg Arg Asp Glu Lys Glu 35 40 45 Leu Leu Arg Glu Leu Ile Glu Thr Ser Lys Asp Ile Leu Arg Leu Val 50 55 60 Glu Glu Leu Leu Lys Lys Ile Ile Asp Lys Ser Glu Asp Leu Leu Arg 65 70 75 80 Lys Thr Glu <210> SEQ ID NO 117 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 117 Gly Ser Asp Glu Glu Asp Tyr Ile Asn Glu Asn Val Glu Lys Asp Val 1 5 10 15 Arg Asp Ile Glu Asp Asp Val Arg Arg Ile Asn Glu Arg Ile Arg Glu 20 25 30 Leu Leu Glu Lys Ile Arg Thr Glu Glu Val Leu Gln Arg Val Leu Glu 35 40 45 Glu His His Glu Leu Val Glu Arg Val Leu Arg Lys Leu Val Glu Ile 50 55 60 Leu Arg Lys His Glu Glu Glu Asn Arg 65 70 <210> SEQ ID NO 118 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 118 Gly Ser Asp Glu Glu Glu Tyr Tyr Lys Glu Lys Leu His Lys Leu Leu 1 5 10 15 Arg Glu Ile Glu Glu Leu Leu Lys His Tyr Arg Glu Leu Val Arg Arg 20 25 30 Leu Glu Glu Leu Val Lys Arg Gly Glu Leu Asp Lys Asp Thr Ala Ala 35 40 45 His Ile Leu Glu Arg Leu Ser Glu Leu Leu Glu Arg Ile Ile Arg Arg 50 55 60 Val Ala His Thr Leu Arg Arg Leu Ser Glu Glu Arg Arg

65 70 75 <210> SEQ ID NO 119 <211> LENGTH: 84 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 119 Gly Ser Asp Glu Asp Glu Ile Ser Tyr Asp Ser Lys Arg Arg Val Glu 1 5 10 15 Glu Ile Val Arg Gln Ala Arg Glu Lys Ser Glu Lys Ser Arg Lys Asp 20 25 30 Ile Glu Asp Val Ala Glu Val Leu Arg Lys Gly Asp Val Ser Glu Lys 35 40 45 Glu Val Val Asp Glu Leu Val Lys Val Leu Glu Glu Gln Val Lys Val 50 55 60 Leu Arg Glu Ala Val Glu Arg Leu Arg Glu Val Leu Lys Lys Gln Val 65 70 75 80 Asp Asp Val Arg <210> SEQ ID NO 120 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 120 Gly Ser Asp Ile Val Glu Leu Val Asp His Leu Leu Lys Arg Ser Leu 1 5 10 15 Lys Leu Leu Glu Glu Leu Ala Glu Leu Val Arg Arg Leu Leu Glu Lys 20 25 30 Ser Thr Glu Leu Leu Lys Arg Arg Thr Glu Glu His Lys Glu Glu Val 35 40 45 Val Glu Glu Ser Glu Tyr Met Val Arg Glu Leu Glu Glu Arg Leu Arg 50 55 60 Arg Val Val Asp Glu Ser Glu Lys Leu Val Arg Asp Ala Asp Lys His 65 70 75 80 Ile Arg <210> SEQ ID NO 121 <211> LENGTH: 83 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 121 Gly Ser Lys Glu Lys Asp Ile Val Lys Thr Leu Val Asp Leu Leu Arg 1 5 10 15 Glu Asn Leu Glu Thr Leu Glu Arg Leu Ile Glu Glu Val Val Arg Leu 20 25 30 Leu Lys Glu Asn Val Asp Val Arg Asp Glu Gly Arg Asp Asp Lys Asp 35 40 45 Ser Glu Arg Ile Leu Arg Asp Ile Lys Arg Arg Ile Asp Glu Ala Ala 50 55 60 Lys Glu Ser Arg Glu Ile Ile Glu Arg Ile Glu Lys Glu Val Glu Tyr 65 70 75 80 Arg Ser Arg <210> SEQ ID NO 122 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 122 Gly Ser Pro Glu Val Asp Val Leu Arg Arg Ile Val Arg Glu Ile Leu 1 5 10 15 Lys Ala Ser Glu Glu Leu Leu Arg Leu Leu Arg Lys Leu Ile Asp Glu 20 25 30 Ala Leu Lys Leu Ser Glu Arg Lys Arg Asp Ser Gln Glu Tyr Arg Glu 35 40 45 Val Val Asp Arg Val Lys Lys Glu Leu Glu Arg Leu Leu Asp Glu Tyr 50 55 60 Arg Lys Leu Val Glu Glu Leu Lys Glu Lys Leu Arg Tyr Asp Thr Arg 65 70 75 80 <210> SEQ ID NO 123 <211> LENGTH: 84 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 123 Gly Ser Asp Lys Arg Tyr Glu Ser Glu Lys Leu Lys Arg Arg Leu Asp 1 5 10 15 Glu Ala Val Glu Lys Val Arg Glu Val Val Glu Arg Val Glu Arg Glu 20 25 30 Ser Asp Arg Val Leu Glu Glu Val Arg Arg Arg Arg Glu Ser Lys Glu 35 40 45 Val Val Asp Lys Val Ile Glu Asp Asn Asp Lys Ala Leu Glu Asp Val 50 55 60 Leu Arg Val Val Asp Glu Val Ala Lys Val Val Arg Asp Val Val Arg 65 70 75 80 Glu Asn Thr Arg <210> SEQ ID NO 124 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 124 Gly Ser Pro Arg Glu Tyr His Ser Lys Asp Ile Leu Arg Lys Val Asp 1 5 10 15 Glu Ile Leu Glu Arg Ile Arg Arg His Ala Asp Arg Val Lys Lys Lys 20 25 30 Ser Glu Arg Leu Lys Arg Glu Asn Val Asp Val Asn Glu His Ser Lys 35 40 45 Asp Val Lys Arg Val Ile Arg Glu Leu Leu Glu Leu Val Lys Glu Leu 50 55 60 Leu Arg Leu Ala Lys Lys His Ser Asp Asp Gln Gln Glu 65 70 75 <210> SEQ ID NO 125 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 125 Gly Ser Asp Glu Asp Glu Ile Leu Tyr His Ser Glu Arg Leu Leu Gln 1 5 10 15 Lys Leu Lys Lys Glu Leu Asp Asp Leu Lys Glu Lys Ser Arg Glu Leu 20 25 30 Leu Glu Glu Leu Lys Lys Glu Asp Pro Asp Asp Arg Leu Ile Glu Arg 35 40 45 Ile Ile Arg Leu His Asp Glu Val Leu Lys Asp Leu Asp Glu Val Leu 50 55 60 Lys Asn Ile Leu Glu Val His Arg Glu Val Leu Glu Arg Leu Arg 65 70 75 <210> SEQ ID NO 126 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 126 Asp Lys Leu Asp Arg Leu Leu Lys Ile His Glu Glu Ala Leu Arg Arg 1 5 10 15 Ala Glu Glu Leu Ile Lys Arg Leu Leu Asp Ile His Arg Arg Ala Leu 20 25 30 Asp Leu Ala Arg Arg Gly Glu Leu Asp Asp Tyr Leu Leu Lys Glu Ser 35 40 45 Glu Arg Glu Leu Arg Glu Ile Ile Arg Arg Ala Arg Glu Glu Leu Lys 50 55 60 Glu Ser Arg Asp Arg Leu Glu Glu Ile Ser Arg 65 70 75 <210> SEQ ID NO 127 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 127 Gly Ser Pro Lys Glu Glu Leu Ile Arg Arg Val Leu Glu Glu Val Lys 1 5 10 15 Arg Leu Asn Glu Lys Leu Leu Glu Ile Ile Arg Arg Ala Ala Glu Leu 20 25 30 Val Lys Arg Ala Asn Asp Glu Leu Pro Glu Thr Glu Lys Leu Arg Glu 35 40 45 Ile Asp Arg Glu Leu Glu Lys Lys Leu Lys Glu Ile Glu Asp Glu Leu 50 55 60 Arg Arg Ile Asp Lys Glu Leu Asp Asp Ala Leu Tyr Glu Ile Glu Asp 65 70 75 80 <210> SEQ ID NO 128 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 128 Gly Ser Pro Lys Leu Asp Lys Leu Arg Glu Leu Leu Glu Arg Asn Leu 1 5 10 15 Glu Lys Leu Arg Glu Ile Leu Glu Glu Val Leu Lys Ile Leu Arg Thr 20 25 30

Asn Leu Glu Arg Val Arg Glu Asp Ile Arg Asp Glu Asp Val Leu Gln 35 40 45 Glu Tyr Glu Arg Leu Ile Arg Lys Ala Glu Glu Asp Leu Arg Arg Val 50 55 60 Leu Lys Glu Tyr Asp Asp Leu Leu Lys Lys Leu Val Tyr Glu Leu Arg 65 70 75 80 <210> SEQ ID NO 129 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 129 Gly Ser Lys Glu Asp Glu Ser Val Lys Arg Ala Glu Glu Ile Val Arg 1 5 10 15 Thr Leu Leu Lys Leu Leu Glu Asp Ser Leu Arg Glu Ala Glu Arg Ser 20 25 30 Leu Arg Asp Ile Lys Asn Gly Glu Asp Glu His Asn Leu Arg Arg Ile 35 40 45 Ser Glu Lys Leu Glu Glu Leu Ser Lys Arg Ile Thr Glu Thr Ile Glu 50 55 60 Arg Leu Leu Arg Glu Leu Gln Tyr Thr Ser Arg 65 70 75 <210> SEQ ID NO 130 <211> LENGTH: 84 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 130 Gly Ser Pro Asn Gln Glu Leu Leu Asp Arg Val Arg Lys Ile Leu Glu 1 5 10 15 Asp Leu Leu Arg Leu Asn Glu Glu Leu Val Arg Leu Asn Lys Glu Leu 20 25 30 Leu Lys Arg Ala Leu Glu Met Arg Arg Lys Asn Arg Asp Ser Glu Glu 35 40 45 Val Leu Glu Arg Leu Ala Glu Glu Tyr Arg Lys Arg Leu Glu Glu Tyr 50 55 60 Arg Arg Glu Leu Glu Lys Leu Leu Glu Glu Leu Glu Glu Thr Ile Tyr 65 70 75 80 Arg Tyr Lys Arg <210> SEQ ID NO 131 <211> LENGTH: 84 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 131 Gly Ser Asp Glu Ser Glu Glu Ala Gln His Glu Val Glu Lys Val Leu 1 5 10 15 Asp Asp Ile Arg Arg Leu Ser Glu His Leu Gln Lys Arg Leu Glu Glu 20 25 30 Val Leu Glu Glu Val Tyr Glu Leu Arg Arg Glu Gly Ser Asp Arg Thr 35 40 45 Glu Val Val Glu Leu Leu Lys Glu Val Ile Arg Glu Ile Val Arg Val 50 55 60 Asn Arg Glu Ala Leu Glu Arg Leu Leu Arg Val Val Glu Glu Ala Val 65 70 75 80 Lys Arg Asn Glu <210> SEQ ID NO 132 <211> LENGTH: 83 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 132 Gly Ser Asp Glu Glu Glu Leu Val Glu Thr Val Lys Arg Ile Gln Lys 1 5 10 15 Glu Ile Leu Asp Arg Leu Thr Glu Leu Ala Lys Leu Leu Val Glu Ile 20 25 30 Gln Arg Glu Ile Lys Lys Leu Lys Asp Glu Gly Glu Asp Asp Lys Glu 35 40 45 Leu Lys Arg Leu Ser Asp Glu Leu Glu Glu Lys Val Arg Gln Val Val 50 55 60 Glu Glu Ile Lys Arg Leu Ser Asp Glu Leu Glu Glu Thr Val Glu Tyr 65 70 75 80 Val Ser Arg <210> SEQ ID NO 133 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 133 Gly Ser Asp Glu Glu Glu Glu Val Val Arg Arg Ala Glu Glu Leu Val 1 5 10 15 Lys Glu His Glu Glu Leu Ile Glu Arg Val Ile Arg Thr His Glu Glu 20 25 30 Leu Val Tyr Lys Leu Glu Asp Gln Gly Ala Asp Lys Lys Leu Val Asp 35 40 45 Val Leu Lys Arg Val Val Glu Glu Ser Glu Arg Val Ala Arg Glu Ile 50 55 60 Val Lys Val Ser Arg Glu Leu Ile Arg Leu Leu Glu Glu Ala Ser Arg 65 70 75 80 <210> SEQ ID NO 134 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 134 Gly Ser Ser Lys Glu Glu Ile Leu Lys Glu Leu Glu Asp Leu Gln Arg 1 5 10 15 Arg Leu Ile Glu Glu Leu Lys Lys Leu Gln Glu Arg Val Val Glu Leu 20 25 30 Leu Glu Glu Leu Ile Lys Arg Leu Arg Asp Arg Gly Arg Asp Asp Lys 35 40 45 His Leu Lys Arg Leu Val Lys Glu Val Arg Arg Leu Ser Glu Glu Val 50 55 60 Leu Arg Ser Ile Lys Glu Val Ser Asp Arg Val Arg Tyr Gln Leu Arg 65 70 75 80 <210> SEQ ID NO 135 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 135 Gly Ser Asp Lys Glu Glu Glu Ser Glu Tyr Leu Leu Arg Asp Leu Val 1 5 10 15 Arg Leu Leu Glu Lys Val Lys Glu Lys Ile Glu Glu Val Asn Arg Glu 20 25 30 Val Glu Lys Leu Leu Lys Lys Val Lys Asp Gly Arg Leu Asp Arg Arg 35 40 45 Glu Val Leu Arg Glu Ile Leu Arg Leu Asn Arg Glu Leu Ala Glu Ile 50 55 60 Ile Lys Glu Val Val Asp Arg Ile Arg His Val Val Glu Arg Ser Glu 65 70 75 80 Arg <210> SEQ ID NO 136 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 136 Gly Ser Asp Leu His Glu Val Val Tyr Glu Thr Lys Glu Leu Leu Lys 1 5 10 15 Arg Ile Glu Glu Val Val Glu Glu Leu Arg Lys Lys Ser Glu Asp Ile 20 25 30 Ile Arg Lys Ala Glu Arg Gly Glu Ile Ser Glu Asp Glu Leu Lys Arg 35 40 45 Leu Gln Glu Glu Ile Ala Arg Glu Ala Lys Lys Leu Leu Asp Glu Ile 50 55 60 Lys Arg Val Leu Glu Arg His Leu Glu Gln Thr Leu 65 70 75 <210> SEQ ID NO 137 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 137 Gly Ser Pro Val Glu Glu Ile Ile Lys Glu Val Val Lys Arg Val Ile 1 5 10 15 Glu Val Gln Glu Lys Val Leu Arg Ile Ile Ser His Ala Val Lys Arg 20 25 30 Val Val Glu Val Gln Lys Lys Tyr Asp Pro Gly Ser Glu Glu Ser Asn 35 40 45 Arg Val Val Glu Glu Val Lys Lys Thr Ile Glu Asp Ala Ile Arg Glu 50 55 60 Ser Asp Glu Val Val Asp Glu Val Val Lys Arg Ile Gln Tyr Thr Val 65 70 75 80 Arg <210> SEQ ID NO 138 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 138 Gly Ser Pro Glu Gln Glu Ile Ala Asp Arg Ile Leu Thr Glu Ile Arg 1 5 10 15 Glu Ser Gln Lys Glu Leu Glu Arg Leu Ala Arg Lys Ile Leu Lys Leu 20 25 30 Leu Asp Glu Ser Gln Glu Lys Ala Lys Arg Gly Arg Leu Ser Glu Glu 35 40 45 Glu Ser Asp Glu Leu Leu Glu Arg Ile Lys Lys Glu Leu Asp Glu Leu 50 55 60 Leu Glu Arg Ser Lys Glu Leu Leu Lys Lys Ile Glu Tyr Glu Leu Arg 65 70 75 80 <210> SEQ ID NO 139 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 139 Gly Ser Asp Glu Asp Lys Glu Ala Asn Arg Val Leu Asp Glu Val Leu 1 5 10 15 Lys Thr Val Arg Asp Leu Leu Glu Thr Ala Asn Glu Val Leu Lys Glu 20 25 30 Val Leu Tyr Arg Leu Lys Arg Thr Asp Asp Gln Glu Lys Val Val Arg 35 40 45 Thr Leu Thr Glu Val Leu Lys Glu His Leu Lys Leu Val Glu Glu Ile 50 55 60 Val Arg Ile Leu Asp Lys Val Leu Lys Glu His Leu Glu Thr Glu Lys 65 70 75 80 <210> SEQ ID NO 140 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 140 Gly Ser Pro Glu Asp Asp Val Leu Arg Arg Leu Glu Glu Val Ser Glu 1 5 10 15 Lys Ile Leu Arg Val Ala Glu Asp Val Ala Arg Gln Leu Arg Glu Val 20 25 30 Ser Glu Lys Ile Thr Gln Gly Lys Val Asp Arg Lys Glu Trp Glu Glu 35 40 45 Asp Ile Lys Arg Leu Lys Arg Glu Leu Glu Glu Leu Leu Arg Glu Trp 50 55 60 Lys Glu Glu Ile Glu Arg Leu Thr Tyr Glu Leu Arg 65 70 75 <210> SEQ ID NO 141 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 141 Gly Ser Arg Arg Glu Glu Val Val Lys Arg Ile Arg Glu Leu Leu Lys 1 5 10 15 Arg Asn Lys Glu Leu Ile Asp Arg Ile Arg Glu Leu Leu Glu Glu Asn 20 25 30 Glu Tyr Leu Asp Lys Asp Ala Arg Asp Lys Asp Val Leu Arg Arg Ser 35 40 45 Val Glu Leu Leu Glu Glu Leu Val Arg Ile Leu Glu Glu Ser Val Glu 50 55 60 Leu Ala Lys Glu Ile Ile Lys Leu Leu Arg Glu Val Val Glu 65 70 75 <210> SEQ ID NO 142 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 142 Gly Ser Asp Glu Lys Glu Asp Asn Arg Arg Leu Gln His Lys Ile Glu 1 5 10 15 Arg Ile Leu Glu Lys Asn Glu Asp Leu Gln Arg Lys Leu Glu Glu Ile 20 25 30 Leu Glu Leu Leu Glu Arg Gly Glu Ala Asp Glu Glu Lys Ile Asp Arg 35 40 45 Leu Arg Lys Ala Val Glu Asp Tyr Arg Arg Val Val Glu Glu Ile Lys 50 55 60 Glu Asp Val Lys Arg His Lys Tyr Thr Val Arg 65 70 75 <210> SEQ ID NO 143 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 143 Gly Ser Asp Glu Lys Glu Glu Ala Lys Lys Ala Ser Glu Glu Ser Val 1 5 10 15 Arg Thr Val Glu Arg Ile Leu Glu Glu Leu Leu Lys Ala Ser Glu Glu 20 25 30 Ser Val Glu Leu Leu Arg Arg Gly Glu Asp Ala Lys Asp Val Val Glu 35 40 45 Arg Ser Lys Glu Ala Leu Lys Arg Val Lys Glu Leu Leu Asp Glu Val 50 55 60 Val Lys Arg Ser Asp Glu Ile Leu Lys Tyr Ile His Asn 65 70 75 <210> SEQ ID NO 144 <211> LENGTH: 84 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 144 Gly Ser Asp Glu Lys Lys Leu Ile Asn Glu Val Val Glu Thr Gln Lys 1 5 10 15 Arg Leu Ile Lys Glu Ala Ala Lys Arg Leu Ser Glu Val Val Arg His 20 25 30 Gln Thr Glu Leu Ile Arg Glu Leu Arg Glu Lys Asn Val Asp Asp Lys 35 40 45 Asp Val Glu Lys Leu Leu Lys Glu Ser Leu Asp Leu Ala Glu Glu Ile 50 55 60 Val Arg Arg Ile Lys Glu Leu Leu Asp Glu Ser Lys Lys Leu Val Glu 65 70 75 80 Tyr Val Ser Asn <210> SEQ ID NO 145 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 145 Gly Ser Pro Asp Met Asp Glu Val Lys Arg Val Leu Asp Glu Leu Ile 1 5 10 15 Glu Ile Gln Glu Glu Ile Leu Arg Glu Ile Lys Arg Val Leu Glu Lys 20 25 30 Leu Ile Lys Ile Gln Glu Asp Asn Gly Ser Glu Tyr Glu Ser Arg Glu 35 40 45 Val Val Arg Glu Ile Val Glu Ile Ala Arg Lys Leu Val Glu Arg Ser 50 55 60 Arg Arg Val Val Lys Lys Ile Thr Glu Thr Leu Gln 65 70 75 <210> SEQ ID NO 146 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 146 Gly Ser Asp Glu Arg Tyr Ala Thr Arg Glu Ile Val Glu Arg Ile Glu 1 5 10 15 Arg Ile Ala Arg Glu Ile Leu Lys Arg Thr Glu Glu Ile Val Arg Glu 20 25 30 Val Arg Glu Val Leu Ser Arg Asp Val Asp Gln Glu Glu Val Val Arg 35 40 45 Arg Leu Ala Asp Leu Leu Arg Glu Ser Val Glu Leu Val Gln His Leu 50 55 60 Val Arg Arg Val Glu Glu Leu Leu Gln Glu Ser Val Glu Arg Lys Lys 65 70 75 80 <210> SEQ ID NO 147 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 147 Gly Ser Pro Glu Arg Glu Ala Leu Arg Glu Val Leu Glu Asp Leu Lys 1 5 10 15 Arg Val Thr Asp Arg Leu Arg Glu Leu Val Glu Arg Val Leu Glu Glu 20 25 30 Leu Lys Lys Val Thr Asp His Val Asp Ser Glu Arg Ile Leu Arg Glu 35 40 45 Ser Arg Arg Val Leu Lys Glu Leu Lys Asp Ile Ile Glu Glu Ile Leu 50 55 60 Arg Glu Ser Glu Lys Val Leu Glu Lys Leu Lys Tyr Thr Glu Asp 65 70 75 <210> SEQ ID NO 148 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:

<223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 148 Gly Ser Pro Ala Arg Glu Ile Leu Glu Glu Val Val Lys Lys His Leu 1 5 10 15 Glu Val Val Glu Asp Ala Ala Arg Ile Leu Glu Glu Ile Ile Arg Glu 20 25 30 His Glu Lys Ala Val Arg Glu Asp Arg Asp Lys Lys Glu Leu Glu Glu 35 40 45 Ile Ser Arg Asp Leu Leu Arg Lys Ala Arg Glu Ala Leu Lys Lys Val 50 55 60 Lys Asp Ile Ser Asp Asp Leu Ser Arg Glu Ile Glu Tyr Val Ala Ser 65 70 75 80 <210> SEQ ID NO 149 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 149 Gly Ser Pro Val Glu Glu Ala Ile Lys Lys Val Ile Asp Asp Leu Arg 1 5 10 15 Asp Val Gln Arg Lys Ile Arg Glu Leu Val Glu Glu Leu Ile Arg Leu 20 25 30 Leu Glu Glu Val Gln Arg Asp Asn Asp Lys Arg Glu Ser Glu Tyr Val 35 40 45 Val Glu Arg Val Glu Glu Ile Leu Arg Arg Ile Thr Glu Thr Ser Arg 50 55 60 Glu Val Val Arg Lys Ala Val Glu Asp Leu Ser 65 70 75 <210> SEQ ID NO 150 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 150 Gly Ser Asp Ser Asp Glu Lys Ala Glu Tyr Leu Leu Lys Glu Met Glu 1 5 10 15 Arg Val Val Arg Glu Ser Asp Glu Val Val Lys Lys Ile Leu Arg Asp 20 25 30 Leu Glu Glu Val Leu Glu Arg Leu Arg Arg Gly Glu Ile Ser Glu Asp 35 40 45 Asp Val Thr Glu Ile Leu Lys Glu Leu Ala Glu Arg His Ile Arg Ala 50 55 60 Ile Glu Glu Leu Val Arg Arg Leu Arg Glu Leu Leu Glu Arg His Lys 65 70 75 80 Arg <210> SEQ ID NO 151 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 151 Gly Ser Pro Val Glu Glu Val Leu Lys Glu Leu Ser Glu Val Asn Glu 1 5 10 15 Arg Val Arg Asp Ile Ala Arg Glu Ile Ile Glu Arg Leu Ser Glu Val 20 25 30 Asn Glu Glu Val Lys Glu Thr Asp Asp Glu Asp Glu Leu Lys Lys Ile 35 40 45 Ser Lys Lys Val Val Asp Glu Val Glu Asp Leu Leu Arg Lys Ile Leu 50 55 60 Glu Val Ser Glu Glu Val Val Arg Arg Val Glu Tyr His Asp Arg 65 70 75 <210> SEQ ID NO 152 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 152 Gly Ser Pro Lys Glu Asp Ile Leu Arg Glu Val Leu Arg Arg His Lys 1 5 10 15 Glu Ile Val Arg Glu Ile Val Arg Leu Val Arg Glu Ala Val Glu Thr 20 25 30 His Leu Glu Leu Val Lys Arg Asn Ser Asp Asp Arg Asp Ala Gln Asp 35 40 45 Val Ile Arg Lys Leu Glu Glu Asp Leu Glu Arg Leu Val Arg His Ala 50 55 60 Gln Glu Val Ile Glu Glu Ile Phe Tyr Arg Leu His 65 70 75 <210> SEQ ID NO 153 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 153 Gly Ser Pro Arg Ser Tyr Leu Leu Lys Glu Leu Ala Asp Leu Ser Gln 1 5 10 15 His Leu Val Arg Leu Leu Glu Arg Leu Val Arg Glu Ser Glu Arg Val 20 25 30 Val Glu Val Leu Glu Arg Gly Glu Val Asp Glu Glu Glu Leu Lys Arg 35 40 45 Leu Glu Asp Leu His Arg Glu Leu Glu Lys Ala Val Arg Glu Val Arg 50 55 60 Glu Thr His Arg Glu Ile Arg Glu Arg Ser Arg 65 70 75 <210> SEQ ID NO 154 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 154 Gly Ser Asp Arg Glu Tyr Ile Ile Lys Asp Ile Leu Asp Ser Gln Glu 1 5 10 15 His Leu Leu Arg Leu Ile Glu Glu Leu Leu Glu Thr Gln Lys Glu Leu 20 25 30 Leu Glu Ile Leu Lys Arg Arg Pro Asp Ser Val Glu Arg Val Arg Glu 35 40 45 Leu Val Arg Arg Ser Lys Glu Ile Ala Asp Glu Ile Arg Arg Gln Ser 50 55 60 Asp Arg Asn Val Arg Leu Leu Glu Glu Val Ser Lys 65 70 75 <210> SEQ ID NO 155 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 155 Gly Ser Asp Glu Lys Asp Glu Ile Arg His Val Ile Glu Ser Val Glu 1 5 10 15 Arg Leu Ile Glu Asp Ile Lys Arg Leu Leu Lys Thr Leu Arg Glu Leu 20 25 30 Ala His Asp Asp Ser Asp Lys Lys Thr Val Lys Glu Val Leu Asp Arg 35 40 45 Val Lys Glu Met Ile Glu Arg His Arg Arg Glu Leu Glu Glu His Arg 50 55 60 Lys Glu Leu Glu Arg Ala Glu Tyr Glu Val Arg 65 70 75 <210> SEQ ID NO 156 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 156 Gly Ser Glu Ser Glu Asp Arg Ile Lys Glu Leu Leu Lys Arg His Ile 1 5 10 15 Glu Leu Val Glu Arg His Glu Glu Leu Leu His Glu Ile Lys Lys Leu 20 25 30 Ile Asp Leu Glu Glu Lys Asp Asp Lys Asp Arg Glu Glu Ala Val Lys 35 40 45 Arg Ile Asp Asp Ala Ile Lys Glu Ser Glu Glu Met Leu Glu Glu Ser 50 55 60 Lys Glu Ile Leu Glu Glu Ile Glu Tyr Leu Asn Arg 65 70 75 <210> SEQ ID NO 157 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 157 Gly Ser Ser Leu Glu Asp Ser Val Arg Leu Asn Asp Glu Val Val Lys 1 5 10 15 Val Val Glu Arg Val Val Arg Leu Asn Gln Glu Val Val Arg Leu Ile 20 25 30 Lys His Ala Thr Asp Val Glu Asp Glu Glu Thr Val Lys Tyr Val Leu 35 40 45 Glu Arg Val Arg Glu Val Leu Asp Glu Ser Arg Glu Val Leu Lys Arg 50 55 60 Val His Glu Leu Leu Glu Glu Ser Glu Arg Arg Leu Glu 65 70 75 <210> SEQ ID NO 158 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence

<220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 158 Gly Ser His Glu Lys Asp Ile Val Tyr Lys Val Glu Asp Leu Val Arg 1 5 10 15 Lys Ser Asp Arg Ile Ala Glu Arg Ala Arg Glu Ile Val Lys Arg Ser 20 25 30 Arg Asp Ile Met Arg Glu Ile Arg Lys Asp Lys Asp Asn Lys Lys Leu 35 40 45 Ser Asp Asp Leu Leu Lys Val Thr Arg Asp Leu Gln Arg Val Val Asp 50 55 60 Glu Leu Glu Glu Leu Ser Arg Glu Leu Leu Arg Val Ala Glu Glu Ser 65 70 75 80 Arg Lys <210> SEQ ID NO 159 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 159 Gly Ser Pro Glu Leu Asp Glu Val Lys Lys Leu Ile Asp Glu Leu Lys 1 5 10 15 Lys Ser Val Glu Arg Leu Glu Glu Ser Ile Arg Glu Val Lys Glu Ser 20 25 30 Ile Lys Lys Leu Arg Lys Gly Asp Ile Asp Ala Glu Glu Asn Ile Lys 35 40 45 Leu Leu Lys Glu Asn Ile Lys Ile Val Arg Glu Asn Ile Lys Ile Ile 50 55 60 Lys Glu Ile Ile Asp Val Val Gln Tyr Val Leu Arg 65 70 75 <210> SEQ ID NO 160 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 160 Gly Ser Asp Glu Glu Glu Ile Glu Glu Leu Leu Arg Glu Leu Glu Lys 1 5 10 15 Leu Leu Lys Lys Ser Glu Glu Ala Leu Glu Glu Ser Lys Lys Leu Ile 20 25 30 Asp Glu Ser Glu Glu Leu Leu Arg Arg Asp Arg Leu Asp Lys Glu Lys 35 40 45 His Val Arg Ala Ser Glu Glu His Val Lys Leu Ser Glu Glu His Leu 50 55 60 Arg Ile Ser Arg Glu Ile Val Lys Ile Leu Glu Lys Ala Val Tyr Ser 65 70 75 80 Thr Arg <210> SEQ ID NO 161 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 161 Gly Ser Asp Glu Ser Asp Arg Ile Arg Lys Ile Val Glu Glu Ser Asp 1 5 10 15 Glu Ile Val Lys Glu Ser Arg Lys Leu Ala Glu Arg Ala Arg Glu Leu 20 25 30 Ile Lys Glu Ser Glu Asp Lys Arg Val Ser Glu Glu Arg Asn Glu Arg 35 40 45 Leu Leu Glu Glu Leu Leu Arg Ile Leu Asp Glu Asn Ala Glu Leu Leu 50 55 60 Lys Arg Asn Leu Glu Leu Leu Lys Glu Val Leu Tyr Arg Thr Arg 65 70 75 <210> SEQ ID NO 162 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 162 Gly Ser Asp Glu Asp Asp Glu Leu Glu Arg Leu Leu Arg Glu Tyr His 1 5 10 15 Arg Val Leu Arg Glu Tyr Glu Lys Leu Leu Glu Glu Leu Arg Arg Leu 20 25 30 Tyr Glu Glu Tyr Lys Arg Gly Glu Val Ser Glu Glu Glu Ser Asp Arg 35 40 45 Ile Leu Arg Glu Ile Lys Glu Ile Leu Asp Lys Ser Glu Arg Leu Trp 50 55 60 Asp Leu Ser Glu Glu Val Trp Arg Thr Leu Leu Tyr Gln Ala Glu 65 70 75 <210> SEQ ID NO 163 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 163 Gly Ser Asp Lys Lys Asp Ala Ser Arg Arg Ala Ile Arg Val Leu His 1 5 10 15 Glu Phe Val Arg Val Ser Glu Glu Val Leu Glu Val Leu Arg Lys Ser 20 25 30 Val Glu Ser Leu Lys Arg Leu Asp Val Asp Glu Lys Ile Lys Arg Thr 35 40 45 His Asp Arg Ile Glu Glu Glu Leu Arg Arg Trp Lys Arg Glu Leu Glu 50 55 60 Glu Leu Ile Glu Arg Leu Arg Glu Trp Glu Tyr His Gln Asp 65 70 75 <210> SEQ ID NO 164 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 164 Gly Ser Asp Asp Glu Glu Glu Asp Lys Arg Leu Leu Glu Glu Val Lys 1 5 10 15 Arg Ser Leu Asp Thr Asp Glu Arg Ile Leu Glu Lys Leu Arg His Ser 20 25 30 Leu Glu Arg Gln Leu Glu Asp Val Asp Lys Asp Glu Asp Ser Arg Arg 35 40 45 Val Leu Arg Glu Leu Asp Glu Ile Thr Lys Arg Ser Arg Glu Val Val 50 55 60 Lys Arg Leu Arg Lys Leu Ala Tyr Glu Ser Lys 65 70 75 <210> SEQ ID NO 165 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 165 Gly Ser Asp Lys Glu Tyr Lys Leu Asp Arg Ile Leu Arg Arg Leu Asp 1 5 10 15 Glu Leu Ile Lys Gln Leu Ser Arg Ile Leu Glu Glu Ile Glu Arg Leu 20 25 30 Val Asp Glu Leu Glu Arg Glu Pro Leu Asp Asp Lys Glu Val Gln Asp 35 40 45 Val Ile Glu Arg Ile Val Glu Leu Ile Asp Glu His Leu Glu Leu Leu 50 55 60 Lys Glu Tyr Ile Lys Leu Leu Glu Glu Tyr Ile Lys Thr Thr Lys 65 70 75 <210> SEQ ID NO 166 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 166 Gly Ser Pro Ser Lys Glu Tyr Gln Glu Lys Ser Ala Glu Arg Gln Lys 1 5 10 15 Glu Leu Leu His Glu Tyr Glu Lys Leu Val Arg His Leu Arg Glu Leu 20 25 30 Val Glu Lys Leu Gln Arg Arg Glu Leu Asp Lys Glu Glu Val Leu Arg 35 40 45 Arg Leu Val Glu Ile Leu Glu Arg Leu Lys Asp Leu His Lys Lys Ile 50 55 60 Glu Asp Ala His Arg Lys Asn Glu Glu Ala His Lys Glu Asn Lys 65 70 75 <210> SEQ ID NO 167 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 167 Gly Ser Arg Asp Arg Lys Ile Ser Glu Glu Leu Ile Lys Ala Leu Glu 1 5 10 15 Asp His Ile Arg Met Leu Glu Glu Leu Ile Arg Ala Ile Glu Glu His 20 25 30 Ile Lys Leu Ala Glu Arg Gly Val Asp Glu Lys Glu Leu Arg Glu Ser 35 40 45 Leu Glu Glu Leu Lys Lys Ile Val Asp Glu Leu Glu Lys Ser Leu Glu 50 55 60 Glu Leu Arg Lys Leu Ala Glu Arg Tyr Lys Tyr Glu Thr Arg 65 70 75 <210> SEQ ID NO 168

<211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 168 Gly Ser Pro Lys Glu Glu Ser Val Glu Glu Leu Lys Arg Val Ile Asp 1 5 10 15 Lys His Glu Glu Ile Leu Arg Glu Leu Lys Arg Val Leu Glu Glu His 20 25 30 Glu Arg Val Ser His Asp Glu Asp Glu Asn Glu Leu Arg Arg Ser Leu 35 40 45 Glu Arg Leu Lys His Ile Leu Asp Arg Leu His Glu Ser Leu Lys Glu 50 55 60 Leu His Glu Leu Leu Lys Lys Asn Glu Tyr Thr Glu Arg 65 70 75 <210> SEQ ID NO 169 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 169 Gly Ser Asp His Glu Tyr Trp Val Lys Ile Val Glu Arg Ile Leu Arg 1 5 10 15 Val Met Glu Lys His Ala Glu Ile Val Lys Lys His Leu Glu Ile Val 20 25 30 Glu Arg Val Val Arg Glu Gly Pro Ser Glu Asp Leu Arg Arg Lys Leu 35 40 45 Lys Glu Ser Leu Arg Glu Ile Glu Glu Ser Leu Arg Glu Leu Lys Glu 50 55 60 Leu Leu Asp Glu Leu Asp Glu Leu Ser Glu Lys Thr Arg 65 70 75 <210> SEQ ID NO 170 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 170 Gly Ser Asp Glu Glu Tyr Val Thr Arg Ser Gln Arg Arg Leu Lys Arg 1 5 10 15 Leu Leu Glu Glu Tyr Ile Lys Val Val Glu Glu His Ala Arg Leu Val 20 25 30 Glu Arg Asn Glu Arg Asp Asp Lys Glu Leu Lys Arg Ser Ile Asp Glu 35 40 45 Leu Asp Lys Leu Thr Lys Glu Leu Leu Glu Leu Val Lys Arg Tyr Lys 50 55 60 Glu Leu Val Asp Lys Thr Glu Thr 65 70 <210> SEQ ID NO 171 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 171 Gly Ser Asp Lys Glu Glu Ile Val Lys Leu Gln Asp Glu Val Ile Lys 1 5 10 15 Thr Leu Glu Arg His Leu Asp Ile Leu Arg Lys His Ile Asp Leu Leu 20 25 30 Glu Lys Leu Lys Asp His Leu Ser Glu Glu Leu Lys Glu Arg Val Asp 35 40 45 Arg Ser Ile Lys Lys Leu Glu Glu Ser Ile Lys Arg Leu Glu Arg Ile 50 55 60 Ile Glu Glu Leu Gln Glu Leu Ala Glu Tyr Ser Leu 65 70 75 <210> SEQ ID NO 172 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 172 Gly Ser Arg Glu Glu Glu Leu Lys Glu Ser Ala Glu Glu Leu Glu Arg 1 5 10 15 Ser Val Arg Glu Leu Lys Lys Glu Ala Asp Lys Tyr Lys Glu Glu Val 20 25 30 Asp Arg Leu His Tyr Arg Gly Lys Val Asp Lys Asp Trp Val Arg Val 35 40 45 Val Glu Lys Leu Ile Lys Leu Val Glu Glu His Leu Glu Leu Ile Arg 50 55 60 Glu His Leu Glu Leu Leu Lys Glu Glu Arg Arg 65 70 75 <210> SEQ ID NO 173 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 173 Gly Ser Asp Met Glu Tyr Glu Leu Lys Lys Ser Ala Glu Glu Leu Arg 1 5 10 15 Lys Ser Leu Glu Glu Leu Lys Arg Ile Leu Asp Glu Leu His Lys Ser 20 25 30 Leu Arg Glu Leu Arg Arg His Gly Asp Asp Glu Glu Tyr Val Gln Thr 35 40 45 Val Glu Glu Leu Arg Lys Glu Leu Glu Glu His Ala Lys Lys Leu Glu 50 55 60 Glu His Leu Lys Glu Leu Glu Arg Val Ala Thr 65 70 75 <210> SEQ ID NO 174 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 174 Pro Glu Tyr Glu Leu Lys Lys Ser Val Asp Asp Leu Lys Arg Asp Val 1 5 10 15 Asp Arg Leu Val Glu Glu Val Glu Glu Val Phe Glu Leu Ser Lys Glu 20 25 30 Arg Leu Arg Glu Asp Arg Lys His Leu Glu Leu Val Glu Glu Met Val 35 40 45 Arg Leu Ile Glu Lys His Leu Glu Leu Ile Lys Glu His Leu Lys Leu 50 55 60 Ala Asp Asp His Val Arg 65 70 <210> SEQ ID NO 175 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 175 Gly Ser Arg Glu Lys Asp Glu Ser Lys Glu Leu Asn Asp Glu Tyr Lys 1 5 10 15 Lys Leu Leu Glu Glu Tyr Glu Arg Leu Leu Arg Arg Ser Glu Glu Leu 20 25 30 Val Lys Arg Ala Lys Gly Pro Arg Asp Glu Lys Glu Leu Lys Arg Ile 35 40 45 Leu Glu Glu Asn Glu Asp Ile Leu Arg Arg Thr Lys Glu Ile Leu Glu 50 55 60 Arg Thr Lys Glu Ile Ser Glu Glu Gln Lys Tyr Arg Arg Arg 65 70 75 <210> SEQ ID NO 176 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 176 Gly Ser Asp Lys Asp Glu Arg Gln Glu Arg Leu Asn Glu Glu Ser Asp 1 5 10 15 Lys Ser Asn Glu Glu Ser Glu Arg Ser Asn Arg Glu Ser Glu Glu Leu 20 25 30 Asn Arg Arg Ala Arg Gly Pro Asn Asp Glu Lys Glu Leu Gln Glu Ile 35 40 45 Leu Asp Arg His Leu Glu Leu Leu Glu Arg Asn Gln Arg Leu Leu Asp 50 55 60 Glu Asn Lys Glu Ile Leu Arg Glu Ser Gln Tyr Leu Asn Asp 65 70 75 <210> SEQ ID NO 177 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 177 Gly Ser Glu Asn Lys Tyr Ile Leu Lys Glu Ile Leu Lys Leu Leu Arg 1 5 10 15 Glu Asn Leu Lys Leu Leu His Asp Ile Leu Arg Leu Leu Asp Glu Asn 20 25 30 Leu Glu Glu Leu Glu Lys His Gly Ala Lys Asp Leu Asp Asp Tyr Arg 35 40 45 Arg Lys Ile Glu Glu Ile Arg Lys Lys Val Glu Asp Tyr Arg Glu Lys 50 55 60 Ile Glu Glu Ile Glu Lys Lys Val Glu Arg Asp Arg 65 70 75 <210> SEQ ID NO 178 <211> LENGTH: 75

<212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 178 Gly Ser Glu Ser Glu Tyr Thr Gln Glu Glu Ile Leu Glu Leu Leu Lys 1 5 10 15 Glu Ser Ile Lys Leu Leu Arg Glu Ile Leu Arg Leu Leu Glu Glu Ser 20 25 30 Glu Glu Leu Trp Arg Arg Glu Asn Thr Lys Ser Glu Arg Ser Glu Glu 35 40 45 Ile Lys Glu Arg Ala Lys Glu Ala Ile Lys Arg Ser Glu Glu Ile Leu 50 55 60 Glu Arg Val Lys Arg Leu Ser Asp His Ser Arg 65 70 75 <210> SEQ ID NO 179 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 179 Gly Ser Asp Glu Glu Glu Ala Asn Tyr Val Ser Asp Lys Ala Val Lys 1 5 10 15 Ile Ala Glu Asp Val Gln Glu Leu Leu Lys Glu Leu Leu Glu Leu Ser 20 25 30 Glu Val Val Arg Arg Gly Glu Val Asp Glu Asp Glu Tyr Asp Arg Val 35 40 45 Leu Arg Lys Leu Gln Glu Val Met Lys Glu Tyr Glu Glu Val Leu Lys 50 55 60 Glu Tyr Glu Glu Val Ser Arg Lys His Glu 65 70 <210> SEQ ID NO 180 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 180 Gly Ser Pro Glu Lys Tyr Leu Ile Lys Thr Gln Glu Glu Leu Leu Arg 1 5 10 15 Arg His Ala Glu Ile Leu Glu Asp Leu Ile Arg Lys Val Glu Arg Gln 20 25 30 Val Asp Leu Arg Arg Lys Val Asp Glu Arg Asp Glu Asp Leu Lys Arg 35 40 45 Glu Leu Glu Arg Ser Leu Arg Glu Leu Glu Arg Leu Val Arg Glu Ser 50 55 60 Ser Arg Leu Val Glu Glu Ile Arg Glu Leu Ser Lys Glu Ile Lys Arg 65 70 75 80 <210> SEQ ID NO 181 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 181 Gly Ser Asp Glu Glu Tyr Glu Leu Glu Arg Ile Ser Arg Glu Ser Lys 1 5 10 15 Glu Leu Leu Glu Arg Tyr Lys Arg Leu Leu Arg Glu Tyr Gln Glu Leu 20 25 30 Leu Lys Glu Leu Arg His Val Lys Asp Leu Asp Arg Ala Val Lys Ile 35 40 45 Ile His Glu Leu Met Arg Val Ser Lys Glu Leu Val Glu Ile Ser His 50 55 60 Arg Leu Leu Glu Leu His Glu Arg Leu Val Arg Arg Arg Lys 65 70 75 <210> SEQ ID NO 182 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 182 Gly Ser Glu Lys Glu Tyr Ile Glu Lys Leu Ser Arg Lys Ile Glu Glu 1 5 10 15 Asp Ile Arg Arg Ser Glu Glu Arg Ala Lys Asp Ser Glu Arg Leu Val 20 25 30 Arg Arg Leu Glu Glu Leu Ala Lys Arg Lys Arg Leu Asp Leu Asp Asp 35 40 45 Val Leu Arg Val Ala Glu Glu Asn Leu Glu Ile Leu Glu Asp Asn Leu 50 55 60 Arg Ile Leu Glu Glu Ile Leu Lys Glu Gln Asp Lys Ser Asn Arg 65 70 75 <210> SEQ ID NO 183 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 183 Gly Ser Pro His Glu Glu Val Val Glu Leu His Glu Arg Val Met Glu 1 5 10 15 Ile Ser Glu Arg Ala Val Glu Leu Ile Gln Arg Ile Ile Asp Ile Ile 20 25 30 Arg Arg Ile Arg Glu Asp Asp Lys Asp Ile Glu Lys Leu Val Lys Thr 35 40 45 Ile Arg Asp Leu Val Arg Glu Tyr Glu Glu Leu His Arg Glu Leu Glu 50 55 60 Glu Ile Asp Glu Glu Ile Tyr Lys Lys Ser Glu 65 70 75 <210> SEQ ID NO 184 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 184 Gly Ser Asp His Glu Asp Val Val Arg Leu His Glu Asp Leu Val Arg 1 5 10 15 Lys Gln Glu Asp Ala Arg Arg Val Leu Glu Glu Ile Val Arg Leu Ala 20 25 30 Glu Glu Ile Val Glu Val Ile Lys Lys Asp Glu Lys Asp Lys Asp Arg 35 40 45 Val Thr Arg Leu Val Glu Glu Ile Glu Lys Leu Val Glu Glu Tyr Lys 50 55 60 Lys Lys Val Asp Glu Met Arg Lys Ile Ser Asp Glu Ile Lys Tyr Arg 65 70 75 80 Ser Arg <210> SEQ ID NO 185 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 185 Gly Ser Arg Ala Arg Glu Val Val Lys Arg Ala Lys Arg Ile Ile Glu 1 5 10 15 Glu Trp Gln Lys Ile Leu Glu Glu Trp Arg Arg Ile Leu Glu Glu Trp 20 25 30 Arg Arg Leu Leu Glu Asp Glu Arg Val Asp Asp Arg Asp Asn Glu Arg 35 40 45 Ile Ile Arg Glu Asn Glu Arg Val Ile Arg Glu Asn Glu Lys Ile Ile 50 55 60 Arg Asp Val Ile Arg Leu Leu Glu Glu Leu Leu Tyr Glu Arg Arg 65 70 75 <210> SEQ ID NO 186 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 186 Gly Ser Arg Glu Asp Glu Glu Leu Glu Glu Glu Ile Asp Arg Ile Arg 1 5 10 15 Gln Met Val Glu Glu Tyr Glu Glu Leu Val Lys Glu Tyr Glu Glu Leu 20 25 30 Thr Glu Lys Tyr Lys Gln Gly Lys Val Asp Lys Glu Glu Ser Lys Lys 35 40 45 Ile Ile Glu Lys Ser Glu Arg Leu Leu Asp Leu Ser Gln Asp Ala Val 50 55 60 Arg Lys Val Lys Glu Ile Ile Arg Arg Ile Leu Tyr Thr Asn Arg 65 70 75 <210> SEQ ID NO 187 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 187 Gly Ser Pro Lys Glu Glu Ile Val Lys Leu His Asp Glu Ser Ala Glu 1 5 10 15 Leu His Arg Arg Ser Val Glu Val Ala Asp Glu Ile Leu Lys Met His 20 25 30 Glu Arg Ser Lys Asp Val Asp Asp Glu Arg Glu Ser Arg Glu Leu Ser 35 40 45 Lys Glu Ile Glu Arg Leu Ile Arg Glu Val Glu Glu Val Ser Lys Arg 50 55 60 Ile Lys Arg Leu Ser Glu Glu Val Glu Tyr Leu Val Arg 65 70 75 <210> SEQ ID NO 188

<211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 188 Gly Ser Pro Leu Glu Glu Ile Leu Lys Ile Gln Arg Arg Ile Asn Lys 1 5 10 15 Ile Gln Asp Asp Ile Asn Lys Ile Leu His Glu Ile Leu Arg Met Gln 20 25 30 Glu Lys Leu Asn Arg Ser Ser Asp Lys Asp Glu Val Glu Glu Ser Leu 35 40 45 Arg Arg Ile Arg Glu Leu Ile Lys Arg Ile Lys Asp Leu Ser Lys Glu 50 55 60 Ile Glu Asp Leu Ser Arg Glu Val Lys Tyr Arg Thr Thr 65 70 75 <210> SEQ ID NO 189 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 189 Gly Ser Pro Glu Asp Glu His Val Tyr Val Val Arg Glu Ile Tyr Glu 1 5 10 15 Val Leu Arg Glu His Ala Glu Val Leu Glu Glu Asn Arg Glu Val Ile 20 25 30 Glu Arg Leu Leu Glu Ala Lys Lys Arg Gly Asp Lys Ser Glu Glu Leu 35 40 45 Val Lys Glu Leu Lys Lys Ser Ile Asp Lys Leu Lys Glu Ile Ser Arg 50 55 60 Lys Leu Glu Glu Ile Val Lys Glu Leu Glu Lys Val Ser Glu Lys Leu 65 70 75 80 Lys <210> SEQ ID NO 190 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 190 Gly Ser Asp Glu Asp Glu Thr Ser Tyr Arg Ile Leu Glu Leu Leu Arg 1 5 10 15 Glu Ile Val Arg Ala Ser Arg Glu Leu Ile Arg Leu Ser Glu Glu Leu 20 25 30 Leu Glu Val Ala Arg Arg Asp Asp Lys Asp Glu Thr Val Leu Glu Thr 35 40 45 Leu Ile Arg Glu Tyr Lys Glu Leu Leu Asp Arg Tyr Arg Arg Leu Ile 50 55 60 Glu Glu Leu Thr Arg Leu Val Glu Glu Tyr Glu Glu Arg Ser Arg 65 70 75 <210> SEQ ID NO 191 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 191 Gly Ser Thr Gln Glu Glu Ile Asn Arg Ile Gln His Glu Val Leu Arg 1 5 10 15 Ile Gln Glu Glu Ile Asp Glu Ile Leu Arg Asp Ile Val Glu Lys Leu 20 25 30 Lys Ala Ile Ser Arg Gly Glu Leu Asp His Glu Val Val Lys Asp Val 35 40 45 Glu Asp Lys Val Arg Glu Ala Leu Glu Lys Ser Glu Glu Leu Leu Asp 50 55 60 Lys Ser Arg Lys Val Glu Tyr Lys Ser Glu 65 70 <210> SEQ ID NO 192 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 192 Gly Ser Asp Glu Glu Glu Leu Asn Arg Glu Leu Leu Glu Lys Ser Lys 1 5 10 15 Arg Leu Val Asp Ile Asn Arg Asp Ile Ile Arg Thr Ala Gln Glu Leu 20 25 30 Ile Glu Met Leu Lys Asp Ser Lys Asp Gly Arg Val Asp Glu Asp Thr 35 40 45 Lys Arg Glu Leu Arg Asp Lys Leu Arg Lys Leu Glu Glu Lys Leu Glu 50 55 60 Arg Val Arg Glu Glu Leu Arg Lys Tyr Glu Glu Leu Leu Arg Tyr Val 65 70 75 80 Gln Arg <210> SEQ ID NO 193 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 193 Gly Ser Asp Glu Lys Asp Arg Val Tyr Glu Ile Leu Lys Glu Val Gln 1 5 10 15 Arg Leu Val Lys Glu Tyr Arg Asp Ile Ser Lys Glu Ile Glu Asp Leu 20 25 30 Val Lys His Tyr Glu His Ile Thr Asp Asp Glu Ala Gln Glu Val Ser 35 40 45 Lys Glu Leu Ile Asp Lys Ser Leu Arg Ala Ser Glu Ile Val Arg Glu 50 55 60 Leu Ile Arg Leu Ile Lys Glu Leu Leu Asp Glu Leu Glu 65 70 75 <210> SEQ ID NO 194 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 194 Gly Ser Asp Glu Glu Asp Val Leu Tyr His Leu Arg Glu Leu Leu Glu 1 5 10 15 Glu Leu Lys Arg Val Ser Asp Asp Tyr Glu Arg Leu Val Arg Glu Ile 20 25 30 Lys Glu Thr Ser Glu Arg Lys Asp Arg Asp Thr Lys Glu Asn Lys Asp 35 40 45 Met Leu Asp Glu Leu Val Lys Ala His Arg Glu Gln Glu Lys Leu Leu 50 55 60 Glu Arg Leu Val Arg Leu Leu Glu Glu Leu Phe Glu Arg Lys Arg 65 70 75 <210> SEQ ID NO 195 <211> LENGTH: 54 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 195 Pro Arg Glu Gln Ala Ile Arg Ile Ser Glu Glu Ile Ile Arg Ile Ser 1 5 10 15 Lys Lys Ile Ile Glu Ile Leu Glu Arg Thr Arg Ser Ser Thr Ala Arg 20 25 30 Glu Ala Met Lys Trp Ala Lys Asp Ser Ile Arg Leu Ala Glu Glu Ser 35 40 45 Lys Tyr Leu Leu Asp Lys 50 <210> SEQ ID NO 196 <211> LENGTH: 54 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 196 Ile Glu Asp Asp Val Lys Lys Ile Gln Asp Ser Thr Lys Lys Ala Gln 1 5 10 15 Lys Glu Thr Ile Glu Ala Leu Glu Arg Ser Thr Ser Ser Thr Ala Arg 20 25 30 Lys Gln Met Glu Glu Gln Lys Glu Gln Ile Arg Leu Gln Lys Glu Ala 35 40 45 Met Tyr Leu Leu Lys Lys 50 <210> SEQ ID NO 197 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 197 Ser Arg Glu Glu Ile Ala Lys Leu Gln Glu Glu Val Ile Lys Leu Gln 1 5 10 15 Arg Arg Val Ile Glu Leu Gln Lys Glu Val Ile Glu Leu Gln Arg Arg 20 25 30 Ala Lys Glu Leu Thr Ser Ser Tyr Thr Lys Glu Ile Leu Glu Ile Gln 35 40 45 Arg Arg Ile Glu Glu Ile Gln Arg Glu Ile Glu Glu Ile Gln Lys Arg 50 55 60 Ile Glu Glu Ile Gln Glu Glu Ile Gln Arg Arg Thr 65 70 75 <210> SEQ ID NO 198 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence

<220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 198 Ser Asp Glu Glu Ile Lys Arg Leu Ser Glu Glu Val Ile Gln Leu Ser 1 5 10 15 Arg Arg Val Ile Lys Met Ser Arg Glu Ala Ile Lys Leu Ser Arg Glu 20 25 30 Val Gln Lys Leu Thr Pro Ser Tyr Gln Lys Arg Ile Lys Glu Ile Ala 35 40 45 Asp Arg Ser Ile Glu Leu Ala Arg Glu Ser Ile Glu Ile Ala Lys Arg 50 55 60 Ser Glu Lys Ile Ala Glu Glu Ser Gln Arg Arg Thr 65 70 75 <210> SEQ ID NO 199 <211> LENGTH: 56 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 199 Pro Ala Lys Asp Glu Ala Leu Lys Met Ala Asn Glu Ser Leu Glu Leu 1 5 10 15 Ala Lys Lys Ser Ala Arg Leu Ile Gln Glu Ser Ser Ser Lys Glu Ile 20 25 30 Leu Glu Arg Ile Glu Lys Ile Gln Arg Arg Ile Ala Glu Leu Gln Asp 35 40 45 Arg Ile Ala Tyr Leu Ile Lys Lys 50 55 <210> SEQ ID NO 200 <211> LENGTH: 56 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 200 Pro Ala Lys Asp Glu Ala Leu Arg Met Ile Asp Glu Ser Arg Glu Leu 1 5 10 15 Ile Lys Lys Ser Asn Glu Leu Ile Gln Arg Ser Ser Ser Lys Glu Ile 20 25 30 Leu Glu Arg Ile Leu Glu Ile Gln Arg Lys Ile Ala Glu Leu Gln Lys 35 40 45 Arg Ile Gln Tyr Leu Leu Lys Ser 50 55 <210> SEQ ID NO 201 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 201 Thr Asp Glu Ala Arg Tyr Arg Ser Glu Arg Ile Val Lys Glu Ala Lys 1 5 10 15 Arg Leu Leu Asp Glu Ala Arg Arg Arg Ser Glu Lys Ile Val Arg Glu 20 25 30 Ala Lys Gln Arg Ser Asn Ser Glu Asp Ala Lys Arg Ile Met Glu Glu 35 40 45 Asn Leu Arg Glu Ser Glu Glu Ala Ala Arg Arg Leu Arg Glu Ile Ile 50 55 60 Arg Arg Asn Leu Glu Glu Ser Arg Glu Thr Gly 65 70 75 <210> SEQ ID NO 202 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 202 Thr Arg Glu Ala Leu Glu Tyr Gln Arg Lys Met Ala Glu Glu Ile Glu 1 5 10 15 Asp Leu Leu Arg Glu Ala Leu Arg Arg Gln Glu Glu Met Val Arg Glu 20 25 30 Ala Lys Gln Arg Ser Leu Ser Glu Glu Phe Lys Arg Ile Met Glu Arg 35 40 45 Ile Leu Glu Glu Gln Glu Arg Val Met Arg Leu Ala Lys Glu Ala Leu 50 55 60 Glu Arg Ile Leu Glu Glu Gln Lys Arg Thr Gly 65 70 75 <210> SEQ ID NO 203 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 203 Ser Glu Arg Thr Lys Arg Glu Ala Lys Arg Ser Gln Glu Glu Ile Leu 1 5 10 15 Arg Glu Ala Lys Glu Ala Met Arg Arg Ala Lys Glu Ser Gln Asp His 20 25 30 Arg Gln Asn Arg Asp Gly Ser Asn Ser Glu Asp Leu Glu Arg Leu Ser 35 40 45 Gln Glu Gln Lys Arg Glu Leu Glu Glu Val Glu Arg Arg Leu Lys Glu 50 55 60 Leu Ala Arg Glu Gln Lys Tyr Lys Leu Glu Asp Ser 65 70 75 <210> SEQ ID NO 204 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 204 Ser Glu Asp Leu Lys Arg Ile Leu Lys Glu Ile Thr Glu Arg Glu Leu 1 5 10 15 Lys Leu Met Gln Asp Leu Met Glu Ile Leu Lys Lys Ile Thr Glu Asp 20 25 30 Glu Asn Asn Leu Asp Ser Asn Asn Ser Glu Asp Leu Lys Arg Ser Ile 35 40 45 Glu Lys Ala Arg Arg Ile Leu Asp Glu Ala Leu Arg Lys Leu Glu Glu 50 55 60 Ser Ala Arg Arg Ala Lys Tyr Ile Gln Glu Asp Asn 65 70 75 <210> SEQ ID NO 205 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 205 Thr Glu Asp Glu Ile Arg Glu Ser Leu Lys Trp Leu Asp Glu Val Leu 1 5 10 15 Gln Glu Leu Arg Glu Ile Ala Arg Glu Ser Asn Glu Val Leu Glu Arg 20 25 30 Asn Arg Gln Lys Ser Arg Ser Asp Lys Leu Arg Glu Asp Ile Glu Arg 35 40 45 Tyr Lys Lys Arg Met Glu Glu Ala Arg Lys Lys Leu Asp Asp Gln Leu 50 55 60 Asn Lys Tyr Lys Lys Arg Met Asp Glu Asn Arg Ser 65 70 75 <210> SEQ ID NO 206 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 206 Thr Glu Glu Glu Leu Lys Glu Ser Lys Lys Phe Ala Glu Asp Leu Ala 1 5 10 15 Arg Ser Ala Arg Arg Ala Leu Lys Glu Ser Lys Arg Val Leu Glu Glu 20 25 30 Ile Ser Gln Ala Ser Arg Ser Lys Lys Leu Glu Glu Ile Val Arg Arg 35 40 45 Tyr Lys Glu Gln Val Lys Arg Trp Gln Asp Glu Trp Asp Glu Arg Ala 50 55 60 Arg Glu Tyr Arg Lys Arg Met Lys Glu Asn Arg Ser 65 70 75 <210> SEQ ID NO 207 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 207 Thr Lys Thr Glu Glu Ile Glu Arg Leu Ala Arg Glu Ile Lys Lys Leu 1 5 10 15 Ser Glu Lys Val Glu Arg Leu Ala Gln Glu Ile Glu Glu Leu Ser Arg 20 25 30 Arg Val Lys Glu Glu Asn Ser Thr Asp Arg Glu Leu Lys Glu Ala Asn 35 40 45 Arg Glu Ile Glu Arg Ala Ile Arg Glu Ile Glu Lys Ala Asn Lys Arg 50 55 60 Met Glu Glu Ala Leu Arg Arg Met Lys Tyr Asn Gly 65 70 75 <210> SEQ ID NO 208 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 208 Thr Lys Thr Glu Glu His Glu Arg Leu Ala Arg Glu Ile Ser Lys Leu 1 5 10 15

Ala Asp Glu His Arg Lys Leu Ala Lys Ile Ile Glu Glu Leu Ala Arg 20 25 30 Arg Ile Lys Glu Glu Asn Leu Thr Asp Asp Glu Leu Arg Glu Ala Ile 35 40 45 Arg Lys Ile Glu Asp Ala Leu Arg Lys Asn Lys Glu Ala Leu Lys Ile 50 55 60 Met Lys Glu Ala Ala Glu Arg Asn Arg Tyr Asn Thr 65 70 75 <210> SEQ ID NO 209 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 209 Thr Lys Lys Glu Glu Ser Arg Glu Leu Ala Arg Glu Ser Glu Glu Leu 1 5 10 15 Ala Arg Glu Ser Glu Lys Leu Ala Arg Lys Ser Leu Glu Leu Ala Arg 20 25 30 Arg Ala Glu Ser Ser Gly Ser Glu Glu Glu Lys Arg Arg Ile Ile Asp 35 40 45 Glu Asn Arg Lys Ile Ile Glu Arg Asn Arg Glu Ile Ile Glu Arg Asn 50 55 60 Lys Glu Ile Ile Glu Tyr Asn Lys Glu Leu Ile Ser 65 70 75 <210> SEQ ID NO 210 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 210 Thr Lys Asp Glu Glu Ser Leu Glu Leu Asn Arg Glu Ser Glu Glu Leu 1 5 10 15 Asn Arg Lys Ser Glu Glu Leu Asn Arg Lys Ser Lys Glu Leu Asn Asp 20 25 30 Arg Ala Glu Ser Ser Asn Ser Glu Glu Glu Glu Lys Glu Ile Leu Arg 35 40 45 Glu His Lys Glu Ile Leu Arg Glu His Leu Glu Ile Leu Arg Arg His 50 55 60 Lys Glu Ile Leu Arg Arg His Lys Tyr Leu Thr Ser 65 70 75 <210> SEQ ID NO 211 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 211 Thr Arg Glu Glu Leu Leu Arg Glu Asn Ile Glu Leu Ala Lys Glu His 1 5 10 15 Ile Glu Ile Met Arg Glu Ile Leu Glu Leu Leu Gln Lys Met Glu Glu 20 25 30 Leu Leu Glu Arg Gln Ser Ser Glu Asp Ile Leu Glu Glu Leu Arg Lys 35 40 45 Ile Ile Glu Arg Ile Arg Glu Leu Leu Asp Arg Ser Arg Lys Ile His 50 55 60 Glu Arg Ser Glu Glu Ile Ala Tyr Lys Glu Glu 65 70 75 <210> SEQ ID NO 212 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 212 Ser Glu Asp Ile Ala Arg Glu Ile Lys Glu Leu Leu Arg Arg Leu Lys 1 5 10 15 Glu Ile Ile Glu Arg Asn Gln Arg Ile Ala Lys Glu His Glu Tyr Ile 20 25 30 Ala Arg Glu Arg Lys Lys Leu Asp Pro Ser Asn Glu Lys Glu Arg Lys 35 40 45 Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu Ser Lys Arg Leu Leu 50 55 60 Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys Lys Leu Leu Asp 65 70 75 <210> SEQ ID NO 213 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 213 Asp Arg Gln Lys Leu Ile Glu Glu Asn Ile Lys Leu Leu Asp Lys His 1 5 10 15 Ile Lys Ile Leu Glu Glu Ile Leu Arg Leu Leu Lys Lys Asp Ile Asp 20 25 30 Leu Leu Lys Lys Ser Ser Ser Glu Glu Val Leu Glu Glu Leu Lys Lys 35 40 45 Ile His Arg Arg Ile Asp Lys Leu Leu Asp Glu Ser Lys Lys Ile His 50 55 60 Lys Arg Ser Ser Glu Ile Val Lys Lys Arg Ser 65 70 75 <210> SEQ ID NO 214 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 214 Asp Glu Gln Lys Leu Ile Glu Thr Ser Gln Arg Leu Gln Glu Lys Ser 1 5 10 15 Glu Arg Leu Leu Glu Lys Phe Glu Gln Ile Leu Arg Glu Ala Ser Asp 20 25 30 Leu Tyr Arg Lys Pro Asp Ser Glu Glu Leu Leu Arg Arg Val Glu Lys 35 40 45 Leu Leu Arg Glu Leu Glu Lys Leu Ile Arg Glu Asn Gln Asp Leu Ala 50 55 60 Arg Lys His Glu Lys Ile Leu Arg Asp Gln Ser 65 70 75 <210> SEQ ID NO 215 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 215 Asp Arg Gln Glu Leu Ile Arg Glu Asn Ile Glu Leu Leu Lys Lys His 1 5 10 15 Ile Lys Ile Val Lys Glu Ile Gln Lys Leu Ile Glu Thr Phe Ile Glu 20 25 30 Leu Leu Lys Lys Ser Ser Ser Glu Glu Ile Leu Arg Arg Leu Lys Lys 35 40 45 Ile Leu Lys Arg Ile Glu Lys Leu Tyr Arg Glu Ser Gln Glu Ile His 50 55 60 Lys Arg Ser Glu Glu Ile Ala Lys Lys Arg Gln 65 70 75 <210> SEQ ID NO 216 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 216 Asp Glu Glu Arg Leu Ile Asp Lys Ser Arg Glu Leu Gln Lys Glu Ser 1 5 10 15 Glu Glu Leu Leu Lys Glu Leu Leu Lys Ile Phe Lys Arg Ile Glu Glu 20 25 30 Leu Leu Glu Lys Pro Asp Ser Glu Glu Leu Ile Arg Glu Ile Lys Lys 35 40 45 Leu Leu Glu Thr Leu Ser Glu Ile His Lys Arg Asn Glu Lys Leu Ala 50 55 60 Arg Thr His Glu Glu Ile Leu Arg Gln Gln Ser 65 70 75 <210> SEQ ID NO 217 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 217 Ser Thr Arg Asp Val Gln Arg Glu Ile Ala Lys Ala Phe Lys Lys Met 1 5 10 15 Ala Asp Val Gln Lys Lys Leu Ala Glu Glu Ile Lys Arg His Val Lys 20 25 30 Asn Val Glu Lys Lys Asn Lys Asp Asn Asp Glu Tyr Arg Lys Ile Ala 35 40 45 Thr Glu Leu Leu Lys Lys Ala Thr Glu Ser Gln Lys Lys Leu Lys Glu 50 55 60 Leu Leu Asp Arg Ile Arg Lys Ser Asp Ser 65 70 <210> SEQ ID NO 218 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 218 Asp Lys Asp Asp Arg Ser Thr Ser Leu Leu Lys Arg Val Glu Lys Leu 1 5 10 15

Ile Asp Glu Ser Asp Arg Ile Ile Asp Lys Phe Thr Thr Leu Ile Glu 20 25 30 Leu Ser Arg Asn Gly Lys Ile Asp Asp Asp Gln Tyr Lys Lys Glu Leu 35 40 45 Lys Glu Ile Leu Glu Leu Leu Lys Lys Tyr Asp Lys His Val Lys Glu 50 55 60 Val Glu Glu Leu Leu Lys Arg Leu Asn Ser 65 70 <210> SEQ ID NO 219 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 219 Ser Lys Arg Lys Ala Leu Glu Val Ser Glu Arg Val Val Arg Ile Ser 1 5 10 15 Glu Lys Val Val Arg Val Leu Asp Glu Ser Ser Asp Leu Leu Lys Lys 20 25 30 Ser Tyr Asp Asp Ser Asp Lys Phe Ala Glu Leu Ile Asp Arg His Glu 35 40 45 Glu Lys Ile Lys Lys Trp Lys Lys Leu Ile Lys Glu Trp Leu Glu Ile 50 55 60 Ile Gln Arg His Lys Ser 65 70 <210> SEQ ID NO 220 <211> LENGTH: 68 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 220 Ser Ala Glu Glu Phe Val Lys Leu Ser Glu Glu Ala Val Lys Arg Ser 1 5 10 15 Lys Glu Ile Leu Asp Ile Val Arg Lys Gln Val Lys Leu Val Lys Ala 20 25 30 Gly Val Asp Lys His Glu Ile Thr Asp Ser Leu Arg Lys Ser Glu Lys 35 40 45 Leu Ile Glu Glu His Lys Glu Leu Ile Lys Thr His Arg Asp Leu Leu 50 55 60 Arg Arg Glu Asn 65 <210> SEQ ID NO 221 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 221 Ser Ser Thr Glu Ile Leu Lys Arg Phe Lys Arg Ala Leu Arg Glu Ser 1 5 10 15 Glu Lys Ile Val Lys His Ser Arg Arg Val Leu Lys Ile Ile Arg Glu 20 25 30 Val Leu Lys Gln Lys Pro Thr Gln Ala Val His Asp Leu Val Arg Ile 35 40 45 Ile Glu Thr Gln Val Lys Ala Leu Glu Glu Gln Leu Lys Val Leu Lys 50 55 60 Arg Ile Val Glu Ala Leu Glu Arg Gln Ser 65 70 <210> SEQ ID NO 222 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 222 Asp Lys Gln Lys Glu Ile Lys Asp Ile Leu Glu Lys Thr Arg Arg Ile 1 5 10 15 Ala Glu Glu Ser Arg Lys Ile Ala Glu Lys Phe Asp Glu Ile Ile Lys 20 25 30 Arg Ser Thr Glu Gly Lys Ile Asp Glu Ser Leu Thr Lys Glu Leu Glu 35 40 45 Glu Leu Val Lys Glu Val Ile Lys Leu Ser Glu Asp Asp Ala Arg Thr 50 55 60 Ser Asp Asp Leu Val Arg Lys Glu Ser 65 70 <210> SEQ ID NO 223 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 223 Asp Glu Asp Glu Ser Ile Lys Leu Thr Arg Lys Ser Ile Glu Glu Thr 1 5 10 15 Arg Lys Ser Leu Lys Ile Ile Lys Glu Val Val Glu Leu Ile Arg Glu 20 25 30 Val Leu Lys His Ile Lys Asp Leu Asp Lys Glu Ile Phe Glu Arg Ile 35 40 45 Asp Lys Ile Leu Asp Lys Tyr Lys Lys Gln Val Asp Thr Tyr Asp Glu 50 55 60 Ile Leu Lys Glu Tyr Glu Lys Lys Gln Arg 65 70 <210> SEQ ID NO 224 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 224 Ser Glu Leu Asp Glu Gln Lys Glu Leu Ile Lys Lys Gln Glu Lys Leu 1 5 10 15 Ile Glu Glu Gln Gln Arg Leu Leu Ser Lys Ile Arg Arg Met Phe Lys 20 25 30 Glu Arg Val Lys Asp Gln Glu Leu Leu Arg Glu Ile Gln Lys Val Leu 35 40 45 Lys Arg Ser Gln Glu Ile Val Glu Thr Ser Lys Lys Ile Leu Asp Arg 50 55 60 Ser Asp Lys Thr Thr Glu 65 70 <210> SEQ ID NO 225 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 225 Asp Gln Lys Glu Ile Asn Thr Arg Ile Val Glu Lys Leu Glu Arg Ile 1 5 10 15 Phe Lys Lys Ser Lys Glu Ile Val Arg Gln Ser Glu Arg Val Ile Ser 20 25 30 Thr Ile Glu Lys Lys Thr Glu Asp Glu Arg Glu Leu Asp Leu Leu Arg 35 40 45 Arg His Val Lys Ile Val Arg Glu His Leu Lys Leu Leu Glu Glu Leu 50 55 60 Leu Lys Ile Ile Lys Glu Val Gln Lys Glu Ser Glu 65 70 75 <210> SEQ ID NO 226 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 226 Asp Thr Glu Glu Leu Val Lys Arg Leu Asn Glu Leu Leu Lys Glu Leu 1 5 10 15 Ser Lys Leu Val Lys Glu Phe Ile Lys Ile Leu Glu Thr Tyr Arg Lys 20 25 30 Asp Gln Thr Lys Asp Thr Ser Lys Ile Ser Glu Arg Val Asp Arg Ile 35 40 45 Leu Lys Thr Tyr Glu Asp Leu Leu Gln Lys Tyr Lys Glu Ile Leu Glu 50 55 60 Lys Ile Glu Lys Gln Leu Ser 65 70 <210> SEQ ID NO 227 <211> LENGTH: 68 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 227 Asp Tyr Ala Arg Leu Ile Asp Gln Ala Val Glu Val Thr Arg Lys Val 1 5 10 15 Val Glu Val Asn Val Thr Val Ala Arg Val Asn Asp Lys Phe Ala Lys 20 25 30 His Leu Gly Asp Glu Glu Leu Arg Arg Val Ser Glu His Leu Lys Glu 35 40 45 Val Ser Lys Asp Leu Gln Glu Val Ala Lys Lys Ser Lys Asp Ala Ala 50 55 60 Arg Gln Val Lys 65 <210> SEQ ID NO 228 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 228 Asp Val Ser Lys Val Ala Glu Glu Tyr Leu Gln Ile Ser Lys Thr Leu 1 5 10 15 Val Asp Ile Ser Arg Thr Leu Leu Glu Ile Ser Glu Arg Leu Val Arg

20 25 30 Leu Val Arg Thr Val Ala Asp Asp Arg Ser Glu Val Lys Lys Ala Ile 35 40 45 Glu Asp Ser Ile Glu Val Leu Lys Thr Ser Glu Glu Val Val Arg Gln 50 55 60 Ile Lys Arg Ala Ser Asp Lys Leu Val Lys Ala Ile Ser 65 70 75 <210> SEQ ID NO 229 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 229 Asp Ala Lys Glu Ile Gln Arg Arg Val Val Glu Ile Gln Thr Glu Val 1 5 10 15 Val Lys Leu Gln Lys Lys Ala Val Asp Ile Ile Arg Lys Ile Ile Glu 20 25 30 Ala Phe Asn Asn Ser Asn Ile Asp Gln Ser Leu Leu Glu Ala Ala Lys 35 40 45 Glu Ile Val Lys Glu Ile Asp Lys Leu Glu Lys Leu Thr Glu Ser Leu 50 55 60 Leu Glu Glu Ser Lys Lys Leu Leu Lys Arg Ser Ser 65 70 75 <210> SEQ ID NO 230 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 230 Ser Ala Glu Glu Val Val Lys Leu Ala Lys Ile Phe Leu Glu Leu Leu 1 5 10 15 Arg Glu Ser Ile Lys Leu Leu Lys Arg Ser Val Asp Leu Leu Arg Lys 20 25 30 Ser Ser Asp Pro Ser Leu Asp Lys Ser Glu Ala Glu Lys Val Ser Arg 35 40 45 Glu Ile Glu Lys Val Ser Asp Thr Ser Leu Lys Leu Ser Lys Lys Ala 50 55 60 Leu Asp Val Val Lys Arg Ala Leu Lys Val Ala Ser 65 70 75 <210> SEQ ID NO 231 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 231 Asp Glu Lys Asp Ala Ala Arg Lys Ala Arg Lys Val Ser Glu Glu Ala 1 5 10 15 Lys Glu Ala Ser Lys Lys Ile Glu Lys Ala Leu Glu Glu Ser Lys Arg 20 25 30 Ile Leu Asn Thr Leu Lys Gln Lys Lys Asp Glu Gln Glu Val Lys Val 35 40 45 Ile Lys Glu His Glu Asp Val Leu Arg Gln Ile Glu Lys Ile Gln Lys 50 55 60 Gln Val Leu Glu Ile Gln Lys Glu Val Ala Lys Leu Leu Glu Ser Leu 65 70 75 80 Asp <210> SEQ ID NO 232 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 232 Ser Ala Asp Asp Val Ala Arg Ala Ser Glu Lys Val Leu Arg Val Ala 1 5 10 15 Arg Glu Ser Ala Lys Ala Ala Asp Lys Ser Leu Glu Val Phe Lys Glu 20 25 30 Val Val Lys Arg Gly Asp Lys Glu Ala Phe Leu Gln Val Val Lys Ile 35 40 45 Asn Glu Glu Val Val Lys Ile Asn Ile Thr Val Ile Arg Ile Leu Ile 50 55 60 Glu Val Ser Lys Thr Ala Thr 65 70 <210> SEQ ID NO 233 <211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 233 Asp Glu Tyr Val Lys Glu Thr Leu Lys Gln Leu Arg Glu Ala Leu Ala 1 5 10 15 Ser Leu Arg Glu Ala Asp Lys Arg Ile Thr Glu Leu Val Lys Glu Ala 20 25 30 Arg Lys Lys Pro Leu Ser Glu Ala Ala Arg Lys Phe Ala Glu Ala Ile 35 40 45 Val Thr His Val Lys Val Val Val Glu His Val Glu Val Val Leu Arg 50 55 60 His Val Glu Val Leu Val Glu Ala Lys Lys Asn Gly Val Ile Asp Lys 65 70 75 80 Ser Ile Leu Asp Asn Ala Leu Arg Ile Ile Glu Asn Val Ile Arg Leu 85 90 95 Leu Ser Asn Val Ile Arg Val Val Asp Glu Val Leu Gln Asp Leu Asp 100 105 110 <210> SEQ ID NO 234 <211> LENGTH: 113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 234 Asp Ala Ser Asp Val Ile Arg Arg Ile His Glu Leu Phe Glu Glu Val 1 5 10 15 His Arg Leu Ile Glu Ala Val His Arg Ala Ile Glu Asp Val Ala Lys 20 25 30 Ala Ala Gln Lys Lys Gly Leu Asp Glu Ser Ala Val Glu Ile Leu Ala 35 40 45 Glu Leu Ser Lys Glu Leu Ala Lys Leu Ser Arg Arg Leu Ala Glu Ile 50 55 60 Ser Arg Glu Ile Gln Lys Val Val Thr Asp Pro Asp Asp Lys Glu Ala 65 70 75 80 Val Glu Arg Leu Lys Glu Ile Ile Lys Glu Ile Lys Lys Gln Leu Asp 85 90 95 Glu Leu Arg Asp Arg Leu Arg Lys Leu Gln Asp Leu Leu Tyr Lys Leu 100 105 110 Lys <210> SEQ ID NO 235 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 235 Ser Glu Asp Lys Ala His His Asp Ile Val Arg Val Leu Glu Glu Leu 1 5 10 15 Ile Lys Ile His Asp Glu Leu Met Lys Ile Ser Glu Glu Ile Leu Lys 20 25 30 Ala Thr Ser Asp Ser Thr Ala Thr Asp Glu Thr Lys Glu Glu Leu Lys 35 40 45 Arg Arg Ser Lys Glu Ala Gln Lys Lys Ser Asp Thr Leu Val Lys Ile 50 55 60 Val Lys Glu Leu Glu Lys Glu Ser Arg Lys Ala Gln Ser 65 70 75 <210> SEQ ID NO 236 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 236 Asp Asp Glu Glu Lys Tyr Arg Gln Ile Ile Arg Glu Ala Gln Glu Ile 1 5 10 15 Ser Lys Thr Ala Lys Arg Ile Leu Arg Asp Ala Gln Glu Ile Ser Lys 20 25 30 Arg Ile Arg His Gln Gly Val Asp Arg Ser Glu His Gln Arg Leu Val 35 40 45 Asp Leu Leu Arg Glu Leu Ile Lys Glu His His Lys Leu Leu Arg Arg 50 55 60 Gln Gln Glu Ala Asp Thr Arg Asn Asp 65 70 <210> SEQ ID NO 237 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 237 Asp Arg Lys Asp Lys Ala Arg Lys Ala Ser Glu Lys Leu Glu Glu Val 1 5 10 15 Ile Gln Arg Trp Lys Thr Val Ala Asp Lys Trp Lys Lys Met Val Asp 20 25 30 Leu Val Ser Asn Gly Lys Leu Ser Gln Glu Glu Val Ala Arg Val Thr 35 40 45 Glu Glu Leu Leu Lys Ile Gln Thr Glu Leu Ala Lys Leu Leu Glu Glu 50 55 60 His Ala Lys Val Leu Gln Glu Ser Ala Ser 65 70

<210> SEQ ID NO 238 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 238 Ser Asp Glu Glu Ser Ile Lys Thr Gln Ser Glu Leu Ile Lys Thr Ser 1 5 10 15 Glu Glu Leu Leu Lys Asp Val Lys Arg Ile Asp Glu Glu Leu Gln Lys 20 25 30 Leu Arg Asp Asp Pro Thr Leu Asp Glu Ser Glu Leu Lys Lys Arg Val 35 40 45 Lys Glu Trp Ser Asp Arg Val Arg Lys Ala Lys Glu Ile Ser Arg Lys 50 55 60 Ile Gln Glu Ile Val Lys Glu Ser Lys Lys Arg Ser Ser 65 70 75 <210> SEQ ID NO 239 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 239 Asp Lys Asp Glu Glu Leu Arg Lys Val Ile Glu Lys Tyr Arg Glu Met 1 5 10 15 Val Lys Glu Tyr Arg Lys Val Ile Arg Glu Tyr Glu Glu Val Ile Lys 20 25 30 Ser Ser Lys Thr Ile Asp Lys Ser Ser Leu Ile Ser Leu Ser Arg Lys 35 40 45 Met Val Glu Leu Ser Gln Arg Val Ile Asp Val Ser Asp Glu Val Ala 50 55 60 Lys Val Leu Ser Arg Lys Gln Ser 65 70 <210> SEQ ID NO 240 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 240 Thr Asp Glu Glu Arg Leu Lys Lys Gln Thr Lys Glu Leu Lys Glu Gln 1 5 10 15 Thr Lys Gln Leu Glu Lys Gln Lys Asp Leu Leu Glu Lys Ile Ser Asn 20 25 30 Gly Glu Ile Ser Lys Asp Glu Ile Gln Glu Ile Ile Lys Glu Ser Lys 35 40 45 Lys Ile Ala Lys Glu Ser Gln Lys Ala Leu Asp Ser Ser Arg Lys Ala 50 55 60 Leu Glu Glu Val Ser 65 <210> SEQ ID NO 241 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 241 Asp Glu Lys Glu Val Ser Lys Glu Ile Ile Lys Val Leu Lys Asp Ile 1 5 10 15 Ala Lys Val Gln Gln Lys Val Ile Glu Val Ser Gln Arg Leu Ala Ser 20 25 30 Val Leu Arg Ala Asp Asp Asp Asn Val Val Lys Arg Ala Leu Glu Glu 35 40 45 Tyr Glu Lys Ile Leu Glu Glu Leu Arg Glu Leu Asn Lys Glu Ile Glu 50 55 60 Lys Leu Thr Asp Lys Tyr Arg Lys Val Thr Ser 65 70 75 <210> SEQ ID NO 242 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 242 Asp Ser Asp Glu Gln Thr Lys Glu Leu Glu Lys Leu Thr Glu Leu His 1 5 10 15 Lys Arg His Val Glu Lys Leu Lys Lys Gln Thr Lys Glu Ser Arg Glu 20 25 30 Val Asp Ser Asn Lys Leu Trp Lys Ser Lys Asp Val Lys Asp Lys Leu 35 40 45 Ser Glu Ser Glu Lys Glu Leu Gln Lys Leu Ser Asp Gln Asp Lys Lys 50 55 60 Ala Lys Asp Ala Leu Glu Ser Ser Arg Arg Lys Asn Asp 65 70 75 <210> SEQ ID NO 243 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 243 Asp Ala Glu Glu Gln Leu Lys Leu Leu Thr Lys Leu Leu Arg His Gln 1 5 10 15 Gln Arg Leu Leu Gln Leu Ile Lys Glu Ser Leu Lys Leu Ile Glu Lys 20 25 30 Ile Asp Gln Ser Ser Gln Glu Asn Gln Asp Glu Ile Arg Lys Trp Arg 35 40 45 Glu Val Thr Lys Lys Leu Arg Glu Leu Ile Lys Thr Ser Glu Lys Leu 50 55 60 Val Arg Glu Leu Glu Lys Ser Tyr Lys Lys Ser Ser 65 70 75 <210> SEQ ID NO 244 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 244 Ser Leu Arg Asp Val Val Arg Arg Tyr Gln Glu Leu Val Arg Arg Tyr 1 5 10 15 Asp Glu Leu Ile Lys Thr Leu Thr Glu Ile Leu Lys Lys Tyr Gln Lys 20 25 30 Lys Gly Ala Glu Asp Lys Asp Ala Ser Thr Glu Leu Val Lys Ala Val 35 40 45 Arg Thr Ser Leu Lys Leu Ser Lys Glu Leu Leu Lys Leu Asn Ser Glu 50 55 60 Leu Leu Lys Glu Asp Ser 65 70 <210> SEQ ID NO 245 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 245 Ser Lys Glu Glu Leu Lys Arg Lys Leu Asp Glu Leu Lys Lys Arg Ser 1 5 10 15 Asp Thr Leu Lys Glu Leu Ser Lys Lys Leu Lys Glu Ile Ser Glu Arg 20 25 30 Asn Pro Asp Asp Lys Ser Val His Arg Thr Ile Ile Arg Ile His Arg 35 40 45 Glu Phe Val Lys Asn His Lys Glu Ile Val Arg Val Ile Glu Glu Ile 50 55 60 Val Ser Asp Lys Ser 65 <210> SEQ ID NO 246 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 246 Ser Lys Gln Asp Glu His Asp Arg Leu Leu Lys Ile His Asp Lys Leu 1 5 10 15 Val Lys Gln His Asp Glu Leu Leu Lys Leu Leu Thr Lys Leu Ser Arg 20 25 30 Ala Gly Asp Ser Val Thr Lys Lys Lys Leu Glu Glu Ile Leu Arg Lys 35 40 45 Leu Gln Glu Val Ser Lys Gln Leu Glu Glu Ser Leu Lys Asp Ala Asp 50 55 60 Lys Val Ser Lys Asp Ile Asn 65 70 <210> SEQ ID NO 247 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 247 Thr Val Gln Ser Leu Leu Glu Gln His Val Lys Ile Val Lys Arg Ser 1 5 10 15 Ile Glu Ile Leu Glu Arg His Thr Gln Ile Leu Gln Asp Ile Ala Arg 20 25 30 Ser Gln Gly Val Ser Lys Glu Leu Glu Asp Val Glu Arg Gln Val Lys 35 40 45 Glu Tyr Arg Lys Glu Val Lys Lys Leu Glu Glu Asp Leu Arg Gln Leu 50 55 60 Ser Arg Asn Ser Lys 65

<210> SEQ ID NO 248 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 248 Ser Asp Ser Asp Arg Ile Glu Lys Leu Ile Arg Glu Ser Thr Glu Leu 1 5 10 15 Leu Lys Glu Gln Gln Lys Leu Ala Lys Arg Ser Arg Glu Leu Ala Glu 20 25 30 Thr Val Glu Ser Leu Pro Leu Thr Glu Glu Tyr Leu Lys Gln Gln Arg 35 40 45 Glu His Gln Lys Lys Ile Glu Lys Leu Leu Lys Asp Ser Glu Lys His 50 55 60 Leu Glu Glu Leu Lys Arg Leu Val Lys Ser Glu Lys 65 70 75 <210> SEQ ID NO 249 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 249 Asp Ser Glu Lys Arg Ile Glu Asp Ile Leu Arg Thr Asp Leu Glu Leu 1 5 10 15 Ala Lys Arg Asp Ala Glu Leu Val Lys Glu His Ile Lys Leu Val Lys 20 25 30 Arg Ile Asp Leu Ser Glu Glu Leu Lys Lys Gln Val Glu Asp Val Glu 35 40 45 Lys Glu Ser Lys Lys Leu Glu Asp Ser Ser Glu Lys Leu Val Gln Lys 50 55 60 Val Arg Lys Arg Ser Ser 65 70 <210> SEQ ID NO 250 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 250 Asp Glu Glu Glu Arg Ala Lys Asp Leu Arg Lys Tyr Leu Glu Glu Gln 1 5 10 15 Thr Gln Tyr Tyr Arg Thr Val Thr Glu His Leu Arg Asn Leu Glu Lys 20 25 30 Val Val Glu Glu Leu Glu Arg Arg Gly Lys Pro Ser Ser Glu Leu Gln 35 40 45 Gln Ile Leu Glu Arg Ser Gln Arg Ile Tyr Lys Glu Thr Thr Glu Ile 50 55 60 Tyr Asp Thr Ser Lys Lys Leu Ile Glu Glu Leu Asp Lys His His Arg 65 70 75 80 <210> SEQ ID NO 251 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 251 Pro Leu Glu Asp Ile Leu Lys Arg His Leu Asp Lys Val Arg Glu Leu 1 5 10 15 Val Arg Leu Ser Glu Glu Val Asn Lys Leu Ala Lys Glu Val Leu Asp 20 25 30 Ile Leu Lys Asp Lys Arg Val Asp Glu Lys Glu Leu Asp Lys Val Leu 35 40 45 Lys Glu Leu Glu Lys Val Val Glu Glu Tyr Glu Arg Ala Val Lys Glu 50 55 60 Ser Arg Asp Leu Leu Arg Glu Leu Arg Glu Thr Thr Arg 65 70 75 <210> SEQ ID NO 252 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 252 Asp Lys Glu Arg Leu Leu Glu Ile His Glu Arg Ile Gln Lys Leu Leu 1 5 10 15 Asp Arg Asn Leu Glu Ile Ile Glu Arg Leu Leu Arg Leu Leu Arg Glu 20 25 30 Ala Arg Asp Ile Lys Asp Asp Asp Lys Leu Asp Lys Val Ile Lys Arg 35 40 45 Leu Lys Glu Leu Ser Glu Glu Ser Lys Asp Ile Leu Asp Lys Ile Lys 50 55 60 Glu Leu Leu Lys Glu Ser Glu Lys Glu Leu Thr 65 70 75 <210> SEQ ID NO 253 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 253 Pro Glu Asp Glu Val Ile Arg Val Ile Glu Glu Leu Leu Arg Ile Ala 1 5 10 15 Ala Glu Val Asp Glu Val His Arg Arg Asn Val Glu Val Gln Glu Glu 20 25 30 Ala Ser Arg Val Thr Asp Arg Glu Arg Leu Glu Arg Leu Asn Arg Glu 35 40 45 Ser Glu Glu Leu Ile Lys Arg Ser Arg Glu Leu Ile Glu Glu Gln Arg 50 55 60 Lys Leu Ile Glu Arg Leu Glu Arg Leu Ala Thr 65 70 75 <210> SEQ ID NO 254 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 254 Asp Leu Glu Glu Leu Ile Lys Glu Tyr Ala Glu Val Val Arg Arg His 1 5 10 15 His Lys Ala Val Arg Asp Leu Glu Arg Leu Val Arg Glu Leu Ala Asn 20 25 30 Ala Lys His Ala Ser Glu Glu Glu Leu Lys Arg Ile Ala Thr Glu Ile 35 40 45 Leu Arg Ile Val Lys Glu Leu Ile Arg Val Gln Glu Arg Leu Ile Lys 50 55 60 Leu Ser Glu Asp Ser Asn Glu Glu Ser Arg 65 70 <210> SEQ ID NO 255 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 255 Pro Thr Asp Glu Val Ile Glu Val Leu Lys Glu Leu Leu Arg Ile His 1 5 10 15 Arg Glu Asn Leu Arg Val Asn Glu Glu Ile Val Glu Val Asn Glu Arg 20 25 30 Ala Ser Arg Val Thr Asp Arg Glu Glu Leu Glu Arg Leu Leu Arg Arg 35 40 45 Ser Asn Glu Leu Ile Lys Arg Ser Arg Glu Leu Asn Glu Glu Ser Lys 50 55 60 Lys Leu Ile Glu Lys Leu Glu Arg Leu Ala Thr 65 70 75 <210> SEQ ID NO 256 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 256 Asp Asn Glu Glu Ile Ile Lys Glu Ala Arg Arg Val Val Glu Glu Tyr 1 5 10 15 Lys Lys Ala Val Asp Arg Leu Glu Glu Leu Val Arg Arg Ala Glu Asn 20 25 30 Ala Lys His Ala Ser Glu Lys Glu Leu Lys Asp Ile Val Arg Glu Ile 35 40 45 Leu Arg Ile Ser Lys Glu Leu Asn Lys Val Ser Glu Arg Leu Ile Glu 50 55 60 Leu Trp Glu Arg Ser Gln Glu Arg Ala Arg 65 70 <210> SEQ ID NO 257 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 257 Pro Lys Glu Asp Ile Asp Arg Val Ser Arg Glu Leu Val Arg Val His 1 5 10 15 Lys Glu Leu Leu Glu Val Leu Arg Lys Ser Thr Glu Ile Val Glu Ala 20 25 30 Val Ala Arg Asn Glu Lys Asp Glu Arg Thr Ile Glu Glu Val Leu Glu 35 40 45 Glu Gln Glu Arg Ala Val Arg Lys Leu Glu Glu Val Ser Lys Lys His 50 55 60 Lys Glu Ala Val Lys Arg Leu Lys 65 70

<210> SEQ ID NO 258 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 258 Glu Leu Glu Arg Leu Ser Glu Glu Ile Gln Lys Leu Ser Asp Arg Leu 1 5 10 15 Ile Glu Leu Ile Arg Arg His Ser Lys Val Leu Glu Glu Ile Val Arg 20 25 30 Leu Leu Lys His Lys Asp Asn Asp Glu Arg Glu Val Arg Arg Leu Leu 35 40 45 Lys Leu Leu Arg Asp Leu Thr Arg Arg Tyr Glu Glu Val Leu Arg Lys 50 55 60 Val Glu Glu Ile Val Lys Arg Gln Glu Asp Glu Ser Arg 65 70 75 <210> SEQ ID NO 259 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 259 Pro Glu Glu Asp Ile Leu Arg Leu Leu Arg Lys Leu Val Glu Val Asp 1 5 10 15 Lys Glu Leu Leu Glu Val Val Arg Glu Ser Thr Glu Val Val Arg Leu 20 25 30 Val Ala Arg Asn Glu Lys Asp Val Glu Thr Val Glu Arg Val Leu Arg 35 40 45 Lys Gln Glu Glu Val Val Arg Lys Tyr Glu Arg Val Ser Arg Glu Leu 50 55 60 Glu Glu Ala Val Arg Arg Leu Lys 65 70 <210> SEQ ID NO 260 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 260 Glu Leu Lys Asp Leu Val Glu Glu Ile Val Lys Leu Ser Lys Glu Asn 1 5 10 15 Leu Lys Leu Trp Glu Asp His Ser Arg Val Leu Glu Glu Ile Val Arg 20 25 30 Leu Leu Lys His Lys Asp Asn Asp Glu Arg Glu Val Arg Arg Leu Leu 35 40 45 Lys Leu Leu Glu Asp Leu Thr Arg Arg Ala Glu Glu Thr Ser Arg Arg 50 55 60 Ile Glu Glu Ile Val Lys Glu Ala Glu Asp Arg Ala Arg 65 70 75 <210> SEQ ID NO 261 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 261 Asp Glu Glu Arg Glu Leu Arg Glu Val Leu Arg Lys His His Arg Val 1 5 10 15 Val Arg Glu Trp Thr Lys Val Val Glu Glu Leu Lys Arg Val Val Glu 20 25 30 Leu Leu Lys Arg Gly Glu Thr Ser Glu Glu Asp Leu Leu Arg Val Leu 35 40 45 Lys Lys Leu Leu Glu Met Asp Lys Arg Ile Leu Glu Val Asn Arg Glu 50 55 60 Val Leu Arg Val Leu Glu Lys Arg Leu Thr 65 70 <210> SEQ ID NO 262 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 262 Ser Leu Glu Glu Ile Ile Glu Glu Leu Val Glu Leu Val Arg Arg Ser 1 5 10 15 Val Glu Ile Ala Lys Glu Ser Asp Glu Val Ala Arg Arg Ile Val Glu 20 25 30 Ser Glu Asp Lys Lys Lys Glu Leu Ile Asp Thr Leu Arg Asp Leu His 35 40 45 Arg Glu Trp Gln Glu Val Thr Lys Arg Ala Glu Glu Leu Val Arg Glu 50 55 60 Ala Glu Lys Glu Val Arg 65 70 <210> SEQ ID NO 263 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 263 Thr Ala Glu Glu Leu Leu Glu Val His Lys Lys Ser Asp Arg Val Thr 1 5 10 15 Lys Glu His Leu Arg Val Ser Glu Glu Ile Leu Lys Val Val Glu Val 20 25 30 Leu Thr Arg Gly Glu Val Ser Ser Glu Val Leu Lys Arg Val Leu Arg 35 40 45 Lys Leu Glu Glu Leu Thr Asp Lys Leu Arg Arg Val Thr Glu Glu Gln 50 55 60 Arg Arg Val Val Glu Lys Leu Asn 65 70 <210> SEQ ID NO 264 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 264 Asp Leu Glu Asp Leu Leu Arg Arg Leu Arg Arg Leu Val Asp Glu Gln 1 5 10 15 Arg Arg Leu Val Glu Glu Leu Glu Arg Val Ser Arg Arg Leu Glu Lys 20 25 30 Ala Val Arg Asp Asn Glu Asp Glu Arg Glu Leu Ala Arg Leu Ser Arg 35 40 45 Glu His Ser Asp Ile Gln Asp Lys His Asp Lys Leu Ala Arg Glu Ile 50 55 60 Leu Glu Val Leu Lys Arg Leu Leu Glu Arg Thr Glu 65 70 75 <210> SEQ ID NO 265 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 265 Pro Glu Asp Asp Val Val Arg Ile Ile Lys Glu Asp Leu Glu Ser Asn 1 5 10 15 Arg Glu Val Leu Arg Glu Gln Lys Glu Ile His Arg Ile Leu Glu Leu 20 25 30 Val Thr Arg Gly Glu Val Ser Glu Glu Ala Ile Asp Arg Val Leu Lys 35 40 45 Arg Gln Glu Asp Leu Leu Lys Lys Gln Lys Glu Ser Thr Asp Lys Ala 50 55 60 Arg Lys Val Val Glu Glu Arg Arg 65 70 <210> SEQ ID NO 266 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 266 Asp Glu Val Arg Leu Ile Thr Glu Trp Leu Lys Leu Ser Glu Glu Ser 1 5 10 15 Thr Arg Leu Leu Lys Glu Leu Val Glu Leu Thr Arg Leu Leu Arg Asn 20 25 30 Asn Val Pro Asn Val Glu Glu Ile Leu Arg Glu His Glu Arg Ile Ser 35 40 45 Arg Glu Leu Glu Arg Leu Ser Arg Arg Leu Lys Asp Leu Ala Asp Lys 50 55 60 Leu Glu Arg Thr Arg Arg 65 70 <210> SEQ ID NO 267 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 267 Asp Glu Asp Glu Val Val Lys Val His Glu Glu His Val Lys Ser His 1 5 10 15 Glu Glu Ile His Arg Ser His Glu Glu Val Val Arg Ala Ala Glu Glu 20 25 30 Asp Lys Arg Asp Ser Arg Glu Leu Arg Thr Leu Met Glu Glu His Arg 35 40 45 Lys Leu Leu Glu Glu Asn Glu Lys Ser Ile Glu Glu Val Lys Lys Ile 50 55 60 His Glu Arg Val Lys Arg 65 70 <210> SEQ ID NO 268

<211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 268 Lys Lys Glu Glu Leu Ile Asp Ile Ser Lys Glu Val Leu Asp Leu Asp 1 5 10 15 Asp Glu Ile Asn Lys Ile Ser Lys Glu Ile Leu Glu Leu Ile Lys Lys 20 25 30 Leu Leu Arg Leu Lys Glu Glu Gly Arg Glu Asp Lys Asp Lys Ala Arg 35 40 45 Glu Val Lys Arg Arg Ile Arg Glu Leu His Arg Arg Ile Gln Glu Leu 50 55 60 Asn Lys Arg Leu Arg Glu Leu His Lys Arg Val Gln Glu Thr Lys Arg 65 70 75 80 <210> SEQ ID NO 269 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 269 Pro Glu Glu Asp Ile Ala Arg Arg Val Glu Asp Leu Leu Arg Lys Ser 1 5 10 15 Glu Glu Leu Ile Lys Glu Ser Glu Lys Ile Leu Lys Glu Ser Lys Arg 20 25 30 Leu Leu Asp Arg Asn Asp Ser Asp Lys Arg Val Leu Glu Thr Asn Leu 35 40 45 Arg Leu Ile Asp Lys His Thr Lys Leu Leu Glu Arg Asn Leu Glu Leu 50 55 60 Leu Glu Glu Leu Leu Lys Leu Ala Glu Asp Val Ala Lys 65 70 75 <210> SEQ ID NO 270 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 270 Arg Phe Lys Asp Leu Ser Arg Glu Tyr Ile Glu Val Val Lys Arg Leu 1 5 10 15 Leu Glu Leu Ser Arg Glu Ala Leu Glu Val Leu Arg Glu Ile Lys Asp 20 25 30 Thr Asp Lys Thr Asp Lys Lys Arg Ile Lys Glu Leu Ile Asp Arg Leu 35 40 45 Arg Lys Leu Ile Glu Glu Tyr Lys Arg Ile Ile Asp Arg Leu Arg Lys 50 55 60 Leu Ser Lys Asp Leu Glu Glu Glu His Arg 65 70 <210> SEQ ID NO 271 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 271 Asp Glu Glu Glu Leu Val Lys Ile Leu Lys Glu Leu Gln Arg Leu Ser 1 5 10 15 Glu Glu Ser Leu Glu Ile Asn Lys Arg Leu Val Glu Ile Leu Arg Leu 20 25 30 Leu Arg Arg Gly Glu Val Pro Lys Glu Glu Val Glu Lys Lys Leu Arg 35 40 45 Glu Ile Lys Lys Glu Gln Glu Lys Leu Asp Arg Glu His Glu Lys Ile 50 55 60 Lys Lys Arg Ile Glu Glu Ile Thr Lys 65 70 <210> SEQ ID NO 272 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 272 Ser Leu Lys Glu Lys Ile Leu Glu Ile Ile Glu Arg Asn Met Lys Leu 1 5 10 15 Val Glu Leu Ser Asn Arg Ser Val Glu Ile Val Ala Arg Ile Leu Lys 20 25 30 Gly Glu Lys Asp Asp Glu Glu Thr Leu Glu Arg Leu Leu Arg Glu Trp 35 40 45 Asp Lys Ile Thr Arg Asp Tyr Glu Glu Ile Ile Lys Glu Ser Arg Lys 50 55 60 Leu Val Lys Glu Leu Glu Glu Glu Ala Lys 65 70 <210> SEQ ID NO 273 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 273 Ser Lys Thr Glu Ile Leu Arg Lys Ala Leu Glu Ile His Lys Glu Gln 1 5 10 15 Ile Asp Ile Val Arg Lys Leu Ile Glu Leu Ser Glu Glu Val Leu Lys 20 25 30 Leu Val Glu Glu Ser Lys Glu Lys Asn Leu Glu Lys Leu Lys Arg Ile 35 40 45 Asp Glu Glu Thr Asp Arg Leu Leu Glu Arg Leu Asp Glu Leu His Lys 50 55 60 Arg Leu Thr Glu Leu Ala Glu Arg Leu Lys 65 70 <210> SEQ ID NO 274 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 274 Ser Asp Asp Glu Ala Arg Lys Gln Leu Glu Glu Met Lys Arg Arg Leu 1 5 10 15 Arg Glu Val Glu Lys Lys Ser Lys Arg Val Glu Glu Arg Val Arg Glu 20 25 30 Leu Glu Arg Leu Val Arg Glu Asn Arg Glu Asp Glu Asp Arg Val Leu 35 40 45 Lys Thr Leu Glu Asp Leu Leu Arg Glu Asn Glu Lys Leu Val Arg Thr 50 55 60 Ile Glu Arg His Val Arg Glu Gln Arg Glu Leu Ser Lys Glu Val Lys 65 70 75 80 <210> SEQ ID NO 275 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 275 Ser Glu Glu Glu Leu Glu Lys Lys Ala Asp Glu Leu Arg Lys Leu Ser 1 5 10 15 Glu Glu Trp Arg Lys Leu Gln Glu Glu Asp Lys Arg Leu Ser Glu Met 20 25 30 Val Glu Lys Gly Glu Leu Asp Leu Gln Glu Val Asp Glu His Ser Leu 35 40 45 Arg Val Leu Glu Arg Ala Thr Glu Val His Arg Thr Val Asp Lys Val 50 55 60 Ile Glu Glu Ile Leu Arg Thr Thr Asn 65 70 <210> SEQ ID NO 276 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 276 Ser Glu Lys Glu Arg His Arg Glu Ser Gln Glu Thr Gln Glu Glu Ile 1 5 10 15 Arg Arg Thr His Glu Glu Ile Ile Arg Lys Leu Glu Glu Ile Leu Arg 20 25 30 Arg Ala Lys Ala Gly Glu Leu Pro Glu Glu Thr Leu Asp Arg Leu Arg 35 40 45 Arg Ile Met Glu Arg Leu Lys Glu Leu Ser Glu Arg Leu Asp Asp Leu 50 55 60 Val Arg Lys Leu Arg Asp Asp His Arg Arg Glu Gln Lys 65 70 75 <210> SEQ ID NO 277 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 277 Ser Glu Lys Glu Ile Leu Glu Glu Leu Lys Arg Ile Leu Lys Arg Val 1 5 10 15 Lys Asp Ile Ser Asp Arg Leu Glu Glu Leu Asp Lys Arg Thr Glu Glu 20 25 30 Ile Ala Arg Arg Glu Pro Thr Lys Glu Leu Val Asp Glu Leu Val Lys 35 40 45 Ile His Arg Asp Trp Leu Arg Leu His Glu Glu Ile Leu Lys Leu Val 50 55 60 Asp Asp Ala Leu Lys Lys Val Glu Asp Ala Thr Lys 65 70 75 <210> SEQ ID NO 278 <211> LENGTH: 73

<212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 278 Asp Leu Arg Glu Leu Leu Glu Leu Gln Arg Glu Ala Ser Arg Leu His 1 5 10 15 Arg Glu Leu Val Lys Leu Leu Thr Glu Leu Val Lys Lys Leu Glu Leu 20 25 30 Ile Ala Lys Gly Glu Asp Ile Arg Glu Glu Asp Leu Lys Arg Ile Lys 35 40 45 Glu Arg Leu Glu Glu Ile Lys Lys Arg Ser Lys Arg Ile Lys Glu Glu 50 55 60 Ser Asp Glu Ile Asp Lys Lys Thr Lys 65 70 <210> SEQ ID NO 279 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 279 Ser Glu Arg Glu Leu Gln Arg Glu Leu Asn Lys Ile Val Arg Arg Ile 1 5 10 15 Leu Glu Ile His Arg Glu Val Ser Glu Leu His Gln Arg Ala Val Lys 20 25 30 Leu Ile Arg Glu Asn Asp Asn Ser Glu Glu Leu Glu Glu Ile Ser Arg 35 40 45 Arg Ile Glu Glu Leu Ser Lys Glu Leu Glu Lys Leu Val Arg Glu His 50 55 60 Asp Glu Ile Val Lys Thr Ile Glu 65 70 <210> SEQ ID NO 280 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 280 Ser Glu Arg Glu Lys Leu Asp Arg Asn Asp Glu Glu Leu Lys Glu Ile 1 5 10 15 Asn Lys Arg Val Glu Glu Ile Lys Glu Arg Ser Asp Arg Ile Thr Glu 20 25 30 Ala Ile Glu Lys Asn Glu Arg Ser Glu Glu Glu Ile Arg Arg Leu Ser 35 40 45 Arg Glu Gln Asn Glu Ala Leu Gln Arg Leu Leu Glu Leu His Lys Lys 50 55 60 Leu Val Lys Leu His Arg Glu Leu Leu Glu Asp Thr Arg 65 70 75 <210> SEQ ID NO 281 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 281 Asp Lys Glu Asp Val Ile Arg Val His Asp Glu Gln His Lys Leu Ile 1 5 10 15 Glu Glu Gln Leu Glu Leu Thr Arg Arg Ile Ala Glu Leu Val Arg Glu 20 25 30 Ile Ala Lys Asn Thr Ala Ser Glu Glu Glu Ile Lys Glu Met Leu Lys 35 40 45 Glu Ile Lys Arg Leu Asp Asp Arg Ser Arg Glu Ile Gln Asp Arg Leu 50 55 60 Gln Lys Leu Leu Glu Glu Ile Arg Arg Lys Thr Lys 65 70 75 <210> SEQ ID NO 282 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 282 Thr Glu Glu Glu Ile Val Glu Leu Asn Lys Asp Ile Gln Arg Lys Ser 1 5 10 15 Lys Glu His Ile Asp Leu Gln Asn Glu Leu Val Lys Lys Ile Glu Arg 20 25 30 Ala Ile Arg Glu Asn Asn Ile Thr Glu Glu Leu Leu Glu Glu Leu Glu 35 40 45 Arg Leu Leu Arg Glu Ser Glu Lys Ile Val Glu Glu Ile Arg Arg Ile 50 55 60 Thr Asp Lys Ile Arg Lys Asp Ala Lys 65 70 <210> SEQ ID NO 283 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 283 Ser Glu Lys Glu Ile Leu Glu Arg Leu Leu Arg Leu Ser Lys Glu Gln 1 5 10 15 Asn Glu Ile Ser Glu Glu Ile His Arg Leu Thr Glu Arg Leu Val Glu 20 25 30 Leu Lys Arg Arg Lys Asp Asp Asp Glu Arg Leu Lys Arg Ile Leu Asp 35 40 45 Arg Gln Lys Arg Leu Val Glu Arg Ala Arg Glu Ile Ser Lys Glu Tyr 50 55 60 Glu Asp Leu Leu Arg Lys Leu Glu 65 70 <210> SEQ ID NO 284 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 284 Ser Met Glu Glu Leu Leu Arg Lys Asn Ala Arg Leu Ser Arg Lys Gln 1 5 10 15 Leu Lys Ile Ile Asp Glu His Leu Glu Leu Ser Thr Lys Leu Thr Arg 20 25 30 Gly Glu Ala Gly Asp Glu Thr Leu Glu Glu Ile Glu Arg Arg Ser Arg 35 40 45 Glu Met Leu Glu Glu Gln Arg Arg Val Asp Glu Glu Ser Lys Arg Ile 50 55 60 Arg Glu Lys Leu Lys 65 <210> SEQ ID NO 285 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 285 Ser Glu Glu Glu Ile Arg Asp Ile Val Glu Lys Leu Leu Arg Thr His 1 5 10 15 Glu Glu Val Leu Lys Glu Ile Lys Lys Leu Leu Asp Asp Ser Glu Arg 20 25 30 Val Arg Arg Arg Glu Leu Asp Lys Lys Asp Leu Asp Arg Ile Gln Lys 35 40 45 Glu Gln Arg Asp Ile Gln Glu Glu Asn Lys Glu Lys Ala Lys Arg Phe 50 55 60 Asp Glu Leu Val Lys Glu Leu Lys Lys Ala Ala Lys 65 70 75 <210> SEQ ID NO 286 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 286 Ser Glu Glu Glu His Arg Arg Thr Met Glu Lys Val Glu Lys Glu Val 1 5 10 15 Arg Asp Ile Lys Arg Arg Ser Glu Glu Val Lys Lys Lys Val Lys Ala 20 25 30 Asn Thr Leu Ser Glu Glu Asp Leu Val Arg Leu Leu Glu Arg Leu Val 35 40 45 Glu Asp His Lys Arg Leu Gln Asp Leu Ser Gln Glu Ile Ile Glu Arg 50 55 60 Asp Glu Lys Ala Thr Lys 65 70 <210> SEQ ID NO 287 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 287 Asp Glu Asp Glu Leu Ala Lys Glu Ile Glu Asp Val Gln Arg Arg Asn 1 5 10 15 Lys Glu Ser Gln Glu Glu His Asp Lys Ser Val Lys Lys Leu Glu Ala 20 25 30 Ala Glu Arg Gly Glu Ile Asp Glu Asp Ser Leu Leu Arg Val Leu Glu 35 40 45 Glu Asp Ile Lys Val Leu Glu Lys Asp Ile Glu Val Leu Glu Arg Ser 50 55 60 Ile Glu Val Ile Glu Lys Ala Glu 65 70 <210> SEQ ID NO 288 <211> LENGTH: 73 <212> TYPE: PRT

<213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 288 Ser Glu Lys Glu Leu Ile Arg Arg Leu Leu Glu Gln Gln Arg Gln His 1 5 10 15 Leu Arg Leu Ser Glu Arg Leu Ile Glu Leu Ser Arg Arg Leu Val Glu 20 25 30 Val Val Arg Lys Gly Lys Asp Asn Arg Asp Leu Leu Arg Glu Leu Lys 35 40 45 Lys Leu Ser Glu Glu His Lys Lys His Ser Lys Asp Asp His Glu Lys 50 55 60 Val Arg Glu Ile Arg Glu Arg Glu Lys 65 70 <210> SEQ ID NO 289 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 289 Asp Arg Lys Asp Leu Leu Lys Arg Asn Ile Lys Leu Leu Asp Arg His 1 5 10 15 Leu Lys Ile Leu Asp Thr Ile Leu Lys Leu Leu Glu Lys Leu Ser Glu 20 25 30 Leu Leu Lys Lys Ser Ser Ser Glu Glu Val Val Lys Glu Tyr Lys Lys 35 40 45 Ile Leu Asp Glu Ile Arg Lys Leu Leu Glu Glu Ser Lys Glu Ile His 50 55 60 Lys Glu Ser Lys Glu Ile Leu Glu Arg Glu Ser 65 70 75 <210> SEQ ID NO 290 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 290 Asp Glu Glu Lys Leu Ile Glu Arg Ser Lys Arg Leu Gln Glu Glu Ser 1 5 10 15 Glu Gln Leu Leu Glu Lys Phe Glu Gln Ile Leu Arg Glu Leu Thr Glu 20 25 30 Leu Leu Glu Lys Pro Asp Ser Glu Glu Leu Ala Arg Lys Ile Lys Lys 35 40 45 Leu His Asp Glu Leu Arg Lys Ile Ile Lys Arg Asn Gln Glu Leu Ile 50 55 60 Arg Glu His Glu Glu Ile Leu Arg Lys Arg Asp 65 70 75 <210> SEQ ID NO 291 <211> LENGTH: 234 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 291 Pro Lys Glu Glu Ala Arg Glu Leu Ile Arg Lys Gln Lys Glu Leu Ile 1 5 10 15 Lys Glu Gln Lys Lys Leu Ile Lys Glu Ala Lys Gln Lys Ser Asp Ser 20 25 30 Arg Asp Ala Glu Arg Ile Trp Lys Arg Ser Arg Glu Ile Asn Arg Glu 35 40 45 Ser Lys Lys Ile Asn Lys Arg Ile Lys Glu Leu Ile Lys Ser Gly Ser 50 55 60 Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Thr Lys Glu Asp Ile Leu 65 70 75 80 Glu Arg Gln Arg Lys Ile Ile Glu Arg Ala Gln Glu Ile His Arg Arg 85 90 95 Gln Gln Glu Ile Leu Glu Glu Leu Glu Arg Ile Ile Arg Lys Pro Gly 100 105 110 Ser Ser Glu Glu Ala Met Lys Arg Met Leu Lys Leu Leu Glu Glu Ser 115 120 125 Leu Arg Leu Leu Lys Glu Leu Leu Glu Leu Ser Glu Glu Ser Ala Gln 130 135 140 Leu Leu Tyr Glu Gln Arg Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser 145 150 155 160 Gly Ser Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu 165 170 175 Asn Leu Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys Gln Leu 180 185 190 Arg Asp Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val 195 200 205 Ile Asp Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val Ile Lys 210 215 220 Ile Phe Glu Asp Ser Val Arg Lys Lys Glu 225 230 <210> SEQ ID NO 292 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 292 Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg Glu Gln 1 5 10 15 Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu Glu Glu 20 25 30 Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu Ala Lys 35 40 45 Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu Leu 50 55 60 Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 65 70 75 <210> SEQ ID NO 293 <211> LENGTH: 93 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 293 Gly Ser Ser His His His His His His Ser Ser Gly Glu Asn Leu Tyr 1 5 10 15 Phe Gln Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu 20 25 30 Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys 35 40 45 Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val 50 55 60 Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu 65 70 75 80 Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 85 90 <210> SEQ ID NO 294 <211> LENGTH: 150 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 294 Pro Lys Glu Glu Ala Arg Glu Leu Ile Arg Lys Gln Lys Glu Leu Ile 1 5 10 15 Lys Glu Gln Lys Lys Leu Ile Lys Glu Ala Lys Gln Lys Ser Asp Ser 20 25 30 Arg Asp Ala Glu Arg Ile Trp Lys Arg Ser Arg Glu Ile Asn Arg Glu 35 40 45 Ser Lys Lys Ile Asn Lys Arg Ile Lys Glu Leu Ile Lys Ser Gly Ser 50 55 60 Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Thr Lys Glu Asp Ile Leu 65 70 75 80 Glu Arg Gln Arg Lys Ile Ile Glu Arg Ala Gln Glu Ile His Arg Arg 85 90 95 Gln Gln Glu Ile Leu Glu Glu Leu Glu Arg Ile Ile Arg Lys Pro Gly 100 105 110 Ser Ser Glu Glu Ala Met Lys Arg Met Leu Lys Leu Leu Glu Glu Ser 115 120 125 Leu Arg Leu Leu Lys Glu Leu Leu Glu Leu Ser Glu Glu Ser Ala Gln 130 135 140 Leu Leu Tyr Glu Gln Arg 145 150 <210> SEQ ID NO 295 <211> LENGTH: 96 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 295 Gly Ser His His His His His His Gly Ser Gly Ser Glu Asn Leu Tyr 1 5 10 15 Phe Gln Gly Ser Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala 20 25 30 His Arg Glu Gln Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg 35 40 45 Arg Leu Glu Glu Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys 50 55 60 Lys Glu Ala Lys Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg 65 70 75 80 Ser Leu Glu Leu Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 85 90 95 <210> SEQ ID NO 296 <211> LENGTH: 156 <212> TYPE: PRT

<213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 296 Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu Ser 1 5 10 15 Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys Lys 20 25 30 Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile Lys Glu 35 40 45 Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg Ile Ala 50 55 60 Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Pro Gly Ser Gly 65 70 75 80 Ser Glu Gly Ser Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe 85 90 95 Leu Glu Asn Leu Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys 100 105 110 Gln Leu Arg Asp Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys 115 120 125 Asp Val Ile Asp Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val 130 135 140 Ile Lys Ile Phe Glu Asp Ser Val Arg Lys Lys Glu 145 150 155 <210> SEQ ID NO 297 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 297 Thr Arg Glu Glu Leu Leu Arg Glu Asn Ile Glu Leu Ala Lys Glu His 1 5 10 15 Ile Glu Ile Met Arg Glu Ile Leu Glu Leu Leu Gln Lys Met Glu Glu 20 25 30 Leu Leu Glu Arg Gln Ser Ser Glu Asp Ile Leu Glu Glu Leu Arg Lys 35 40 45 Ile Ile Glu Arg Ile Arg Glu Leu Leu Asp Arg Ser Arg Lys Ile His 50 55 60 Glu Arg Ser Glu Glu Ile Ala Tyr Lys Glu Glu 65 70 75 <210> SEQ ID NO 298 <211> LENGTH: 93 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 298 Gly Ser His His His His His His Gly Ser Gly Ser Glu Asn Leu Tyr 1 5 10 15 Phe Gln Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu 20 25 30 Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys 35 40 45 Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val 50 55 60 Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu 65 70 75 80 Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 85 90 <210> SEQ ID NO 299 <211> LENGTH: 161 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 299 Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg Glu Gln 1 5 10 15 Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu Glu Glu 20 25 30 Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu Ala Lys 35 40 45 Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu Leu 50 55 60 Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys Gly Ser Glu Gly 65 70 75 80 Ser Gly Ser Glu Gly Ser Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu 85 90 95 Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp 100 105 110 Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp 115 120 125 Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu Lys 130 135 140 Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys Val 145 150 155 160 Glu <210> SEQ ID NO 300 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 300 Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg Lys Ile Ile Glu Arg Ala 1 5 10 15 Gln Glu Ile His Arg Arg Gln Gln Glu Ile Leu Glu Glu Leu Glu Arg 20 25 30 Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu Ala Met Lys Arg Met Leu 35 40 45 Lys Leu Leu Glu Glu Ser Leu Arg Leu Leu Lys Glu Leu Leu Glu Leu 50 55 60 Ser Glu Glu Ser Ala Gln Leu Leu Tyr Glu Gln Arg 65 70 75 <210> SEQ ID NO 301 <211> LENGTH: 92 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 301 Gly Ser Ser His His His His His His Ser Ser Gly Glu Asn Leu Tyr 1 5 10 15 Phe Gln Gly Ser Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe 20 25 30 Leu Glu Asn Leu Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys 35 40 45 Gln Leu Arg Asp Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys 50 55 60 Asp Val Ile Asp Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val 65 70 75 80 Ile Lys Ile Phe Glu Asp Ser Val Arg Lys Lys Glu 85 90 <210> SEQ ID NO 302 <211> LENGTH: 149 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 302 Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu Ser 1 5 10 15 Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys Lys 20 25 30 Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile Lys Glu 35 40 45 Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg Ile Ala 50 55 60 Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Ser Glu Gly Ser 65 70 75 80 Gly Ser Glu Gly Ser Gly Ser Pro Lys Glu Glu Ala Arg Glu Leu Ile 85 90 95 Arg Lys Gln Lys Glu Leu Ile Lys Glu Gln Lys Lys Leu Ile Lys Glu 100 105 110 Ala Lys Gln Lys Ser Asp Ser Arg Asp Ala Glu Arg Ile Trp Lys Arg 115 120 125 Ser Arg Glu Ile Asn Arg Glu Ser Lys Lys Ile Asn Lys Arg Ile Lys 130 135 140 Glu Leu Ile Lys Ser 145 <210> SEQ ID NO 303 <211> LENGTH: 147 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 303 Pro Lys Lys Glu Ala Glu Glu Leu Ala Glu Glu Ser Glu Glu Leu His 1 5 10 15 Asp Arg Ser Glu Lys Leu His Glu Arg Ala Glu Gln Ser Ser Asn Ser 20 25 30 Glu Glu Ala Arg Lys Ile Leu Glu Asp Ile Glu Arg Ile Ser Glu Arg 35 40 45 Ile Glu Glu Ile Ser Asp Arg Ile Glu Arg Leu Leu Arg Ser Gly Ser 50 55 60 Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Asp Asp Lys Glu Leu Asp 65 70 75 80 Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile 85 90 95

Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg 100 105 110 Lys Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His 115 120 125 Glu Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys 130 135 140 Lys Val Glu 145 <210> SEQ ID NO 304 <211> LENGTH: 150 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 304 Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg Lys Ile Ile Glu Arg Ala 1 5 10 15 Gln Glu Ile His Arg Arg Gln Gln Glu Ile Leu Glu Glu Leu Glu Arg 20 25 30 Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu Ala Met Lys Arg Met Leu 35 40 45 Lys Leu Leu Glu Glu Ser Leu Arg Leu Leu Lys Glu Leu Leu Glu Leu 50 55 60 Ser Glu Glu Ser Ala Gln Leu Leu Tyr Glu Gln Arg Gly Ser Glu Gly 65 70 75 80 Ser Gly Ser Glu Gly Ser Gly Ser Pro Lys Glu Glu Ala Arg Glu Leu 85 90 95 Ile Arg Lys Gln Lys Glu Leu Ile Lys Glu Gln Lys Lys Leu Ile Lys 100 105 110 Glu Ala Lys Gln Lys Ser Asp Ser Arg Asp Ala Glu Arg Ile Trp Lys 115 120 125 Arg Ser Arg Glu Ile Asn Arg Glu Ser Lys Lys Ile Asn Lys Arg Ile 130 135 140 Lys Glu Leu Ile Lys Ser 145 150 <210> SEQ ID NO 305 <211> LENGTH: 144 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 305 Pro Lys Lys Glu Ala Glu Glu Leu Ala Glu Glu Ser Glu Glu Leu His 1 5 10 15 Asp Arg Ser Glu Lys Leu His Glu Arg Ala Glu Gln Ser Ser Asn Ser 20 25 30 Glu Glu Ala Arg Lys Ile Leu Glu Asp Ile Glu Arg Ile Ser Glu Arg 35 40 45 Ile Glu Glu Ile Ser Asp Arg Ile Glu Arg Leu Leu Arg Ser Gly Ser 50 55 60 Glu Gly Ser Gly Ser Glu Gly Ser Asp Ser Asp Glu His Leu Lys Lys 65 70 75 80 Leu Lys Thr Phe Leu Glu Asn Leu Arg Arg His Leu Asp Arg Leu Asp 85 90 95 Lys His Ile Lys Gln Leu Arg Asp Ile Leu Ser Glu Asn Pro Glu Asp 100 105 110 Glu Arg Val Lys Asp Val Ile Asp Leu Ser Glu Arg Ser Val Arg Ile 115 120 125 Val Lys Thr Val Ile Lys Ile Phe Glu Asp Ser Val Arg Lys Lys Glu 130 135 140 <210> SEQ ID NO 306 <211> LENGTH: 152 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 306 Gly Ser Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu 1 5 10 15 Glu Ser Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile 20 25 30 Lys Lys Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile 35 40 45 Lys Glu Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg 50 55 60 Ile Ala Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Ala Ala Asp 65 70 75 80 Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln 85 90 95 Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu 100 105 110 Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val Glu 115 120 125 Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile Ala 130 135 140 Lys Thr His Ala Lys Lys Val Glu 145 150 <210> SEQ ID NO 307 <211> LENGTH: 156 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 307 Gly Ser Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu 1 5 10 15 Glu Ser Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile 20 25 30 Lys Lys Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile 35 40 45 Lys Glu Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg 50 55 60 Ile Ala Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Gly Ser 65 70 75 80 Gly Ser Pro Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu 85 90 95 Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu 100 105 110 Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu 115 120 125 Thr Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu 130 135 140 Leu Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 145 150 155 <210> SEQ ID NO 308 <211> LENGTH: 162 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 308 Gly Ser Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu 1 5 10 15 Glu Ser Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile 20 25 30 Lys Lys Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile 35 40 45 Lys Glu Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg 50 55 60 Ile Ala Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Gly Ser 65 70 75 80 Gly Ser Pro Gly Gly Ser Gly Ser Pro Asp Asp Lys Glu Leu Asp Lys 85 90 95 Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile 100 105 110 Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys 115 120 125 Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu 130 135 140 Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys 145 150 155 160 Val Glu <210> SEQ ID NO 309 <211> LENGTH: 174 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 309 Gly Ser Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu 1 5 10 15 Glu Ser Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile 20 25 30 Lys Lys Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile 35 40 45 Lys Glu Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg 50 55 60 Ile Ala Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Gly Ser 65 70 75 80 Gly Ser Pro Gly Gly Ser Gly Ser Pro Gly Gly Ser Gly Ser Pro Gly 85 90 95 Gly Ser Gly Ser Pro Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr 100 105 110 Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn 115 120 125 Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val 130 135 140 Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys 145 150 155 160

Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 165 170 <210> SEQ ID NO 310 <211> LENGTH: 158 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 310 Pro Glu Asp Asp Val Val Arg Ile Ile Lys Glu Asp Leu Glu Ser Asn 1 5 10 15 Arg Glu Val Leu Arg Glu Gln Lys Glu Ile His Arg Ile Leu Glu Leu 20 25 30 Val Thr Arg Gly Glu Val Ser Glu Glu Ala Ile Asp Arg Val Leu Lys 35 40 45 Arg Gln Glu Asp Leu Leu Lys Lys Gln Lys Glu Ser Thr Asp Lys Ala 50 55 60 Arg Lys Val Val Glu Glu Arg Arg Gly Ser Glu Gly Ser Gly Ser Glu 65 70 75 80 Gly Ser Asp Leu Glu Asp Leu Leu Arg Arg Leu Arg Arg Leu Val Asp 85 90 95 Glu Gln Arg Arg Leu Val Glu Glu Leu Glu Arg Val Ser Arg Arg Leu 100 105 110 Glu Lys Ala Val Arg Asp Asn Glu Asp Glu Arg Glu Leu Ala Arg Leu 115 120 125 Ser Arg Glu His Ser Asp Ile Gln Asp Lys His Asp Lys Leu Ala Arg 130 135 140 Glu Ile Leu Glu Val Leu Lys Arg Leu Leu Glu Arg Thr Glu 145 150 155 <210> SEQ ID NO 311 <211> LENGTH: 163 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 311 Gly Ser Asp Ala Tyr Asp Leu Asp Arg Ile Val Lys Glu His Arg Arg 1 5 10 15 Leu Val Glu Glu Gln Arg Glu Leu Val Glu Glu Leu Glu Lys Leu Val 20 25 30 Arg Arg Gln Glu Asp His Arg Val Asp Lys Lys Glu Ser His Glu Ile 35 40 45 Leu Glu Arg Leu Glu Arg Ile Ile Arg Arg Ser Thr Arg Ile Leu Thr 50 55 60 Glu Leu Glu Lys Leu Thr Asp Glu Phe Glu Arg Arg Thr Arg Gly Ser 65 70 75 80 Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Asp Asp Lys Glu Leu Asp 85 90 95 Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile 100 105 110 Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg 115 120 125 Lys Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His 130 135 140 Glu Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys 145 150 155 160 Lys Val Glu <210> SEQ ID NO 312 <211> LENGTH: 165 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 312 Gly Ser Asp Glu Asp Asp Glu Leu Glu Arg Leu Leu Arg Glu Tyr His 1 5 10 15 Arg Val Leu Arg Glu Tyr Glu Lys Leu Leu Glu Glu Leu Arg Arg Leu 20 25 30 Tyr Glu Glu Tyr Lys Arg Gly Glu Val Ser Glu Glu Glu Ser Asp Arg 35 40 45 Ile Leu Arg Glu Ile Lys Glu Ile Leu Asp Lys Ser Glu Arg Leu Trp 50 55 60 Asp Leu Ser Glu Glu Val Trp Arg Thr Leu Leu Tyr Gln Ala Glu Gly 65 70 75 80 Ser Glu Gly Ser Gly Ser Glu Gly Ser Asp Glu Lys Asp Tyr His Arg 85 90 95 Arg Leu Ile Glu His Leu Glu Asp Leu Val Arg Arg His Glu Glu Leu 100 105 110 Ile Lys Arg Gln Lys Lys Val Val Glu Glu Leu Glu Arg Arg Gly Leu 115 120 125 Asp Glu Arg Leu Arg Arg Val Val Asp Arg Phe Arg Arg Ser Ser Glu 130 135 140 Arg Trp Glu Glu Val Ile Glu Arg Phe Arg Gln Val Val Asp Lys Leu 145 150 155 160 Arg Lys Ser Val Glu 165 <210> SEQ ID NO 313 <211> LENGTH: 168 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 313 Gly Ser Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu 1 5 10 15 Glu Ser Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile 20 25 30 Lys Lys Leu Leu Lys Lys Ala Arg Gly Ala Asp Glu Lys Val Leu Asp 35 40 45 Glu Leu Arg Lys Ile Ile Glu Arg Ile Arg Glu Leu Leu Asp Arg Ser 50 55 60 Arg Lys Ile His Glu Arg Ser Glu Glu Ile Ala Tyr Lys Glu Glu Gly 65 70 75 80 Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Asp Glu Ser Asp Arg 85 90 95 Ile Arg Lys Ile Val Glu Glu Ser Asp Glu Ile Val Lys Glu Ser Arg 100 105 110 Lys Leu Ala Glu Arg Ala Arg Glu Leu Ile Lys Glu Ser Glu Asp Lys 115 120 125 Arg Val Ser Glu Glu Arg Asn Glu Arg Leu Leu Glu Glu Leu Leu Arg 130 135 140 Ile Leu Asp Glu Asn Ala Glu Leu Leu Lys Arg Asn Leu Glu Leu Leu 145 150 155 160 Lys Glu Val Leu Tyr Arg Thr Arg 165 <210> SEQ ID NO 314 <211> LENGTH: 164 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 314 Gly Ser Asp Glu Asp Asp Glu Leu Glu Arg Leu Leu Arg Glu Tyr His 1 5 10 15 Arg Val Leu Arg Glu Tyr Glu Lys Leu Leu Glu Glu Leu Arg Arg Leu 20 25 30 Tyr Glu Glu Tyr Lys Arg Gly Glu Val Ser Glu Glu Glu Ser Asp Arg 35 40 45 Ile Leu Arg Glu Ile Lys Glu Ile Leu Asp Lys Ser Glu Arg Leu Trp 50 55 60 Asp Leu Ser Glu Glu Val Trp Arg Thr Leu Leu Tyr Gln Ala Glu Gly 65 70 75 80 Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Asp Asp Lys Glu Leu 85 90 95 Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys 100 105 110 Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu 115 120 125 Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg 130 135 140 His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala 145 150 155 160 Lys Lys Val Glu <210> SEQ ID NO 315 <211> LENGTH: 177 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 315 Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu Asn Leu 1 5 10 15 Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys Gln Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val Ile Asp 35 40 45 Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val Ile Lys Ile Phe 50 55 60 Glu Asp Ser Val Arg Lys Lys Glu Gly Ser Glu Gly Ser Gly Ser Glu 65 70 75 80 Gly Ser Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Glu Gly 85 90 95 Ser Gly Ser Glu Gly Ser Pro Thr Asp Glu Val Ile Glu Val Leu Lys 100 105 110 Glu Leu Leu Arg Ile His Arg Glu Asn Leu Arg Val Asn Glu Glu Ile 115 120 125 Val Glu Val Asn Glu Arg Ala Ser Arg Val Thr Asp Arg Glu Glu Leu 130 135 140

Glu Arg Leu Leu Arg Arg Ser Asn Glu Leu Ile Lys Arg Ser Arg Glu 145 150 155 160 Leu Asn Glu Glu Ser Lys Lys Leu Ile Glu Lys Leu Glu Arg Leu Ala 165 170 175 Thr <210> SEQ ID NO 316 <211> LENGTH: 155 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 316 Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu 1 5 10 15 Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val 35 40 45 Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile 50 55 60 Ala Lys Thr His Ala Lys Lys Val Glu Gly Ser Glu Gly Ser Gly Ser 65 70 75 80 Glu Gly Ser Thr Ala Glu Glu Leu Leu Glu Val His Lys Lys Ser Asp 85 90 95 Arg Val Thr Lys Glu His Leu Arg Val Ser Glu Glu Ile Leu Lys Val 100 105 110 Val Glu Val Leu Thr Arg Gly Glu Val Ser Ser Glu Val Leu Lys Arg 115 120 125 Val Leu Arg Lys Leu Glu Glu Leu Thr Asp Lys Leu Arg Arg Val Thr 130 135 140 Glu Glu Gln Arg Arg Val Val Glu Lys Leu Asn 145 150 155 <210> SEQ ID NO 317 <211> LENGTH: 156 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 317 Asp Asn Glu Glu Ile Ile Lys Glu Ala Arg Arg Val Val Glu Glu Tyr 1 5 10 15 Lys Lys Ala Val Asp Arg Leu Glu Glu Leu Val Arg Arg Ala Glu Asn 20 25 30 Ala Lys His Ala Ser Glu Lys Glu Leu Lys Asp Ile Val Arg Glu Ile 35 40 45 Leu Arg Ile Ser Lys Glu Leu Asn Lys Val Ser Glu Arg Leu Ile Glu 50 55 60 Leu Trp Glu Arg Ser Gln Glu Arg Ala Arg Gly Ser Glu Gly Ser Gly 65 70 75 80 Ser Glu Gly Ser Thr Ala Glu Glu Leu Leu Glu Val His Lys Lys Ser 85 90 95 Asp Arg Val Thr Lys Glu His Leu Arg Val Ser Glu Glu Ile Leu Lys 100 105 110 Val Val Glu Val Leu Thr Arg Gly Glu Val Ser Ser Glu Val Leu Lys 115 120 125 Arg Val Leu Arg Lys Leu Glu Glu Leu Thr Asp Lys Leu Arg Arg Val 130 135 140 Thr Glu Glu Gln Arg Arg Val Val Glu Lys Leu Asn 145 150 155 <210> SEQ ID NO 318 <211> LENGTH: 280 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 318 Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu 1 5 10 15 Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val 35 40 45 Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile 50 55 60 Ala Lys Thr His Ala Lys Lys Val Glu Gly Ser Glu Gly Ser Gly Ser 65 70 75 80 Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Glu 85 90 95 Gly Ser Gly Ser Glu Gly Ser Pro Thr Asp Glu Val Ile Glu Val Leu 100 105 110 Lys Glu Leu Leu Arg Ile His Arg Glu Asn Leu Arg Val Asn Glu Glu 115 120 125 Ile Val Glu Val Asn Glu Arg Ala Ser Arg Val Thr Asp Arg Glu Glu 130 135 140 Leu Glu Arg Leu Leu Arg Arg Ser Asn Glu Leu Ile Lys Arg Ser Arg 145 150 155 160 Glu Leu Asn Glu Glu Ser Lys Lys Leu Ile Glu Lys Leu Glu Arg Leu 165 170 175 Ala Thr Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Glu Gly 180 185 190 Ser Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser 195 200 205 Thr Ala Glu Glu Leu Leu Glu Val His Lys Lys Ser Asp Arg Val Thr 210 215 220 Lys Glu His Leu Arg Val Ser Glu Glu Ile Leu Lys Val Val Glu Val 225 230 235 240 Leu Thr Arg Gly Glu Val Ser Ser Glu Val Leu Lys Arg Val Leu Arg 245 250 255 Lys Leu Glu Glu Leu Thr Asp Lys Leu Arg Arg Val Thr Glu Glu Gln 260 265 270 Arg Arg Val Val Glu Lys Leu Asn 275 280 <210> SEQ ID NO 319 <211> LENGTH: 154 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 319 Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu Asn Leu 1 5 10 15 Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys Gln Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val Ile Asp 35 40 45 Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val Ile Lys Ile Phe 50 55 60 Glu Asp Ser Val Arg Lys Lys Glu Gly Ser Glu Gly Ser Gly Ser Glu 65 70 75 80 Gly Ser Pro Glu Asp Asp Val Val Arg Ile Ile Lys Glu Asp Leu Glu 85 90 95 Ser Asn Arg Glu Val Leu Arg Glu Gln Lys Glu Ile His Arg Ile Leu 100 105 110 Glu Leu Val Thr Arg Gly Glu Val Ser Glu Glu Ala Ile Asp Arg Val 115 120 125 Leu Lys Arg Gln Glu Asp Leu Leu Lys Lys Gln Lys Glu Ser Thr Asp 130 135 140 Lys Ala Arg Lys Val Val Glu Glu Arg Arg 145 150 <210> SEQ ID NO 320 <211> LENGTH: 156 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 320 Asp Asn Glu Glu Ile Ile Lys Glu Ala Arg Arg Val Val Glu Glu Tyr 1 5 10 15 Lys Lys Ala Val Asp Arg Leu Glu Glu Leu Val Arg Arg Ala Glu Asn 20 25 30 Ala Lys His Ala Ser Glu Lys Glu Leu Lys Asp Ile Val Arg Glu Ile 35 40 45 Leu Arg Ile Ser Lys Glu Leu Asn Lys Val Ser Glu Arg Leu Ile Glu 50 55 60 Leu Trp Glu Arg Ser Gln Glu Arg Ala Arg Gly Ser Glu Gly Ser Gly 65 70 75 80 Ser Glu Gly Ser Pro Glu Asp Asp Val Val Arg Ile Ile Lys Glu Asp 85 90 95 Leu Glu Ser Asn Arg Glu Val Leu Arg Glu Gln Lys Glu Ile His Arg 100 105 110 Ile Leu Glu Leu Val Thr Arg Gly Glu Val Ser Glu Glu Ala Ile Asp 115 120 125 Arg Val Leu Lys Arg Gln Glu Asp Leu Leu Lys Lys Gln Lys Glu Ser 130 135 140 Thr Asp Lys Ala Arg Lys Val Val Glu Glu Arg Arg 145 150 155 <210> SEQ ID NO 321 <211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 321 Asp Leu Glu Asp Leu Leu Arg Arg Leu Arg Arg Leu Val Asp Glu Gln 1 5 10 15 Arg Arg Leu Val Glu Glu Leu Glu Arg Val Ser Arg Arg Leu Glu Lys 20 25 30 Ala Val Arg Asp Asn Glu Asp Glu Arg Glu Leu Ala Arg Leu Ser Arg 35 40 45

Glu His Ser Asp Ile Gln Asp Lys His Asp Lys Leu Ala Arg Glu Ile 50 55 60 Leu Glu Val Leu Lys Arg Leu Leu Glu Arg Thr Glu Gly Ser Glu Gly 65 70 75 80 Ser Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser 85 90 95 Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser Pro Glu Asp Asp Val Val 100 105 110 Arg Ile Ile Lys Glu Asp Leu Glu Ser Asn Arg Glu Val Leu Arg Glu 115 120 125 Gln Lys Glu Ile His Arg Ile Leu Glu Leu Val Thr Arg Gly Glu Val 130 135 140 Ser Glu Glu Ala Ile Asp Arg Val Leu Lys Arg Gln Glu Asp Leu Leu 145 150 155 160 Lys Lys Gln Lys Glu Ser Thr Asp Lys Ala Arg Lys Val Val Glu Glu 165 170 175 Arg Arg <210> SEQ ID NO 322 <211> LENGTH: 160 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 322 Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys 1 5 10 15 Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu 20 25 30 Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr 35 40 45 Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu 50 55 60 Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu Gly Ser Glu Gly Ser 65 70 75 80 Gly Ser Glu Gly Ser Pro Thr Asp Glu Val Ile Glu Val Leu Lys Glu 85 90 95 Leu Leu Arg Ile His Arg Glu Asn Leu Arg Val Asn Glu Glu Ile Val 100 105 110 Glu Val Asn Glu Arg Ala Ser Arg Val Thr Asp Arg Glu Glu Leu Glu 115 120 125 Arg Leu Leu Arg Arg Ser Asn Glu Leu Ile Lys Arg Ser Arg Glu Leu 130 135 140 Asn Glu Glu Ser Lys Lys Leu Ile Glu Lys Leu Glu Arg Leu Ala Thr 145 150 155 160 <210> SEQ ID NO 323 <211> LENGTH: 154 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 323 Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu Asn Leu 1 5 10 15 Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys Gln Leu Arg Asp 20 25 30 Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val Ile Asp 35 40 45 Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val Ile Lys Ile Phe 50 55 60 Glu Asp Ser Val Arg Lys Lys Glu Gly Ser Glu Gly Ser Gly Ser Glu 65 70 75 80 Gly Ser Thr Ala Glu Glu Leu Leu Glu Val His Lys Lys Ser Asp Arg 85 90 95 Val Thr Lys Glu His Leu Arg Val Ser Glu Glu Ile Leu Lys Val Val 100 105 110 Glu Val Leu Thr Arg Gly Glu Val Ser Ser Glu Val Leu Lys Arg Val 115 120 125 Leu Arg Lys Leu Glu Glu Leu Thr Asp Lys Leu Arg Arg Val Thr Glu 130 135 140 Glu Gln Arg Arg Val Val Glu Lys Leu Asn 145 150 <210> SEQ ID NO 324 <211> LENGTH: 166 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 324 Gly Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu 1 5 10 15 Ser Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys 20 25 30 Lys Leu Leu Lys Lys Ala Arg Gly Ala Asp Glu Lys Val Leu Asp Glu 35 40 45 Leu Arg Lys Ile Ile Glu Arg Ile Arg Glu Leu Leu Asp Arg Ser Arg 50 55 60 Lys Ile His Glu Arg Ser Glu Glu Ile Ala Tyr Lys Glu Glu Gly Ser 65 70 75 80 Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser Asp Ala Tyr Asp Leu Asp 85 90 95 Arg Ile Val Lys Glu His Arg Arg Leu Val Glu Glu Gln Arg Glu Leu 100 105 110 Val Glu Glu Leu Glu Lys Leu Val Arg Arg Gln Glu Asp His Arg Val 115 120 125 Asp Lys Lys Glu Ser His Glu Ile Leu Glu Arg Leu Glu Arg Ile Ile 130 135 140 Arg Arg Ser Thr Arg Ile Leu Thr Glu Leu Glu Lys Leu Thr Asp Glu 145 150 155 160 Phe Glu Arg Arg Thr Arg 165 <210> SEQ ID NO 325 <211> LENGTH: 162 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 325 Thr Arg Glu Glu Leu Leu Arg Glu Asn Ile Glu Leu Ala Lys Glu His 1 5 10 15 Ile Glu Ile Met Arg Glu Ile Leu Glu Leu Leu Gln Lys Met Glu Glu 20 25 30 Leu Leu Glu Lys Ala Arg Gly Ala Asp Glu Asp Val Ala Lys Thr Ile 35 40 45 Lys Glu Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg 50 55 60 Ile Ala Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Ser Glu 65 70 75 80 Gly Ser Gly Ser Glu Gly Ser Gly Ser Asp Asp Lys Glu Leu Asp Lys 85 90 95 Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile 100 105 110 Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys 115 120 125 Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu 130 135 140 Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys 145 150 155 160 Val Glu <210> SEQ ID NO 326 <211> LENGTH: 162 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 326 Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys 1 5 10 15 Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu 20 25 30 Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr 35 40 45 Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu 50 55 60 Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu Gly Ser Glu Gly Ser 65 70 75 80 Gly Ser Glu Gly Ser Gly Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg 85 90 95 Lys Ile Ile Glu Arg Ala Gln Glu Ile His Arg Arg Gln Gln Glu Ile 100 105 110 Leu Glu Glu Leu Glu Arg Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu 115 120 125 Ala Met Lys Arg Met Leu Lys Leu Leu Glu Glu Ser Leu Arg Leu Leu 130 135 140 Lys Glu Leu Leu Glu Leu Ser Glu Glu Ser Ala Gln Leu Leu Tyr Glu 145 150 155 160 Gln Arg <210> SEQ ID NO 327 <211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 327 Gly Ala Ala Gly Gly Ala Gly Ala Thr Ala Thr Cys Ala Thr Cys 1 5 10 15 <210> SEQ ID NO 328 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence

<220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 328 Gly Ser Ser His His His His His His Ser Ser Gly Glu Asn Leu Tyr 1 5 10 15 Phe Gln Gly Ser 20 <210> SEQ ID NO 329 <211> LENGTH: 40 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 329 Ser Ala Trp Ser His Pro Gln Phe Glu Lys Gly Gly Gly Ser Gly Gly 1 5 10 15 Gly Ser Gly Gly Ser Ala Trp Ser His Pro Gln Phe Glu Lys Ser Gly 20 25 30 Glu Asn Leu Tyr Phe Gln Gly Ser 35 40 <210> SEQ ID NO 330 <211> LENGTH: 44 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 330 Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val 1 5 10 15 Glu Glu Asn Pro Gly Pro Gly Asp Lys Ala Glu Leu Ile Pro Glu Pro 20 25 30 Pro Lys Lys Lys Arg Lys Val Glu Leu Gly Thr Ala 35 40 <210> SEQ ID NO 331 <211> LENGTH: 62 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 331 Pro Lys Glu Glu Ala Arg Glu Leu Ile Arg Lys Gln Lys Glu Leu Ile 1 5 10 15 Lys Glu Gln Lys Lys Leu Ile Lys Glu Ala Lys Gln Lys Ser Asp Ser 20 25 30 Arg Asp Ala Glu Arg Ile Trp Lys Arg Ser Arg Glu Ile Asn Arg Glu 35 40 45 Ser Lys Lys Ile Asn Lys Arg Ile Lys Glu Leu Ile Lys Ser 50 55 60 <210> SEQ ID NO 332 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 332 Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg Glu Ala 1 5 10 15 Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu Glu Glu 20 25 30 Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu Ala Lys 35 40 45 Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg Leu Leu Glu Leu 50 55 60 Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 65 70 75 <210> SEQ ID NO 333 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 333 Tyr Ser Trp Asn Ser 1 5 <210> SEQ ID NO 334 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 334 Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg Glu Gln 1 5 10 15 Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Thr Glu Glu 20 25 30 Ile Ile Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Asp Glu Leu Arg 35 40 45 Arg Ile Gln Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu Leu 50 55 60 Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 65 70 75 <210> SEQ ID NO 335 <400> SEQUENCE: 335 000 <210> SEQ ID NO 336 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 336 Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg Glu Gln 1 5 10 15 Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Thr Glu Glu 20 25 30 Ile Ile Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Asp Glu Leu Arg 35 40 45 Arg Ile Gln Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu Glu Leu 50 55 60 Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 65 70 75 <210> SEQ ID NO 337 <211> LENGTH: 37 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 337 Pro Glu Arg Asp Glu Asn Arg Lys Leu Leu Asp Lys Val Arg Lys Leu 1 5 10 15 Val Glu Lys Ser Arg Arg Leu Val Glu Glu Leu Arg Lys Leu Val Asp 20 25 30 Gln Ser Thr Lys Asn 35 <210> SEQ ID NO 338 <211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 338 Ser Glu Glu Ala Lys Lys Glu Ala Lys Lys Ile Leu Glu Glu Ile Arg 1 5 10 15 Glu Leu Ser Lys Arg Ser Leu Glu Leu Leu Arg Glu Ile Leu Tyr Leu 20 25 30 Ser Gln Gln Val Asn Asp Val Asp Glu Lys Ala Leu Glu Arg Gln Arg 35 40 45 Lys Ile Ile Glu Arg Ala Gln Glu Ile His Arg Arg Gln Gln Glu Ile 50 55 60 Leu Glu Glu Leu Glu Arg Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu 65 70 75 80 Ala Met Lys Arg Met Leu Lys Leu Leu Glu Glu Ser Leu Arg Leu Leu 85 90 95 Lys Glu Leu Leu Glu Leu Ser Glu Glu Ser Ala Gln Leu Leu Tyr Glu 100 105 110 Ala Arg <210> SEQ ID NO 339 <211> LENGTH: 37 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 339 Asp Arg Arg Leu Glu Glu Tyr Glu Arg Gln Val Asp Glu Leu Arg Glu 1 5 10 15 Glu Ile Arg Arg Tyr Lys Glu Glu Val Asp Lys Phe Asp Lys Glu Val 20 25 30 Lys Tyr Tyr Lys Lys 35 <210> SEQ ID NO 340 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 340 Asp Arg Glu Glu Val His Lys Glu Ile Val Lys Leu Ile Arg Glu Ile 1 5 10 15 Ile Lys Ile His Lys Lys Ile Leu Lys Ile His Glu Lys Ile Lys Asn

20 25 30 Gly Glu Ile Asp Pro Ser Glu Ile Leu Lys Leu Ser Glu Glu Ile Lys 35 40 45 Lys Leu Thr Asp Thr Ile Ile Lys Ile Ile Glu Asp Leu Glu Gln Leu 50 55 60 Thr Arg Asp Leu Arg Arg 65 70 <210> SEQ ID NO 341 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 341 Asp Glu Ile Thr Glu Ser Val Asp Arg Phe Lys Lys Ile Val Asp Gln 1 5 10 15 Phe Glu Glu Ser Ile Lys Lys Phe Glu Thr Val Ser Glu Glu Leu Arg 20 25 30 Lys Ser Ile Ser 35 <210> SEQ ID NO 342 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 342 Asp Lys Ala Glu Glu Val Glu Lys Ser Val Arg Lys Ile Glu Glu Ser 1 5 10 15 Ile Lys Lys Ile Arg Lys Ser Ile Lys Lys Ala Glu Asp Ala Val Gln 20 25 30 Leu Leu Lys Glu Gly Lys Ile Asp Ala Lys Asp Phe Leu Arg Ile Val 35 40 45 Arg Glu Asp Leu Glu Val Val Lys Glu Asp Val Glu Ile Val Lys Glu 50 55 60 Asp Val Glu Asn Val Arg Glu Phe Ser Ser 65 70 <210> SEQ ID NO 343 <211> LENGTH: 34 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 343 Asp Gln His Val Val Glu Ile Leu Arg Lys Ile Val Glu Ile Phe Arg 1 5 10 15 Gln His Ile Glu Lys Leu Lys Lys His Leu Glu Lys Leu Arg Tyr Thr 20 25 30 Ser Ser <210> SEQ ID NO 344 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 344 Asp Leu Lys Glu Val Leu Lys Thr Val Glu Glu Ala Val Lys Glu Ile 1 5 10 15 Ile Lys Ser Ser Glu Glu Leu Leu Gln Ile Ser Arg Lys Ile Leu Glu 20 25 30 Ile Ser Arg Val Gly Val Asp Glu His Glu Tyr Ile Ser Ala Ile Arg 35 40 45 Glu Tyr Leu Lys Ala Leu Glu Lys His Ile Gln Ile Leu Lys Lys Phe 50 55 60 Ile Glu Ile Leu Lys Glu Leu Ile Arg Ala Val Ser 65 70 75 <210> SEQ ID NO 345 <211> LENGTH: 71 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 345 Asp Glu Glu Asp Tyr Ile Asn Glu Asn Val Glu Lys Asp Val Arg Asp 1 5 10 15 Ile Glu Asp Asp Val Arg Arg Ile Asn Glu Arg Ile Arg Glu Leu Leu 20 25 30 Glu Lys Ile Arg Thr Glu Glu Val Leu Gln Arg Val Leu Glu Glu His 35 40 45 His Glu Leu Val Glu Arg Val Leu Arg Lys Leu Val Glu Ile Leu Arg 50 55 60 Lys His Glu Glu Glu Asn Arg 65 70 <210> SEQ ID NO 346 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 346 Asn Asp Glu Glu Leu Lys Lys Ile Leu Glu Thr Leu Asp Arg Ile Leu 1 5 10 15 Lys Lys Leu Asp Lys Ile Leu Thr Arg Leu Ile Glu Val Leu Lys Lys 20 25 30 Ser Glu Asp Pro Asn Leu Asp Asp Lys Asp Tyr Thr Glu Leu Val Lys 35 40 45 Gln Phe Ile Glu Leu Ile Lys Lys Tyr Glu Glu Val Val Lys Glu Tyr 50 55 60 Glu Glu Val Val Arg Gln Leu Ile Arg Leu Phe Ser 65 70 75 <210> SEQ ID NO 347 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 347 Asp Glu Asp Glu Ile Ser Tyr Asp Ser Lys Arg Arg Val Glu Glu Ile 1 5 10 15 Val Arg Gln Ala Arg Glu Lys Ser Glu Lys Ser Arg Lys Asp Ile Glu 20 25 30 Asp Val Ala Glu Val Leu Arg Lys Gly Asp Val Ser Glu Lys Glu Val 35 40 45 Val Asp Glu Leu Val Lys Val Leu Glu Glu Gln Val Lys Val Leu Arg 50 55 60 Glu Ala Val Glu Arg Leu Arg Glu Val Leu Lys Lys Gln Val Asp Asp 65 70 75 80 Val Arg <210> SEQ ID NO 348 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 348 Asn Asp Glu Glu Leu Lys Lys Ile Leu Glu Thr Leu Asp Arg Ile Leu 1 5 10 15 Lys Lys Leu Glu Lys Ile Leu Thr Arg Leu Ile Glu Val Leu Lys Lys 20 25 30 Ser Glu Asp Pro Asn Leu Asp Asp Lys Asp Tyr Thr Glu Leu Val Lys 35 40 45 Gln Phe Ile Glu Leu Ile Lys Lys Phe Glu Glu Val Ile Lys Glu Tyr 50 55 60 Glu Glu Val Val Arg Gln Leu Ile Arg Leu Phe Ser 65 70 75 <210> SEQ ID NO 349 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 349 Lys Glu Lys Asp Ile Val Lys Thr Leu Val Asp Leu Leu Arg Glu Asn 1 5 10 15 Leu Glu Thr Leu Glu Arg Leu Ile Glu Glu Val Val Arg Leu Leu Lys 20 25 30 Glu Asn Val Asp Val Arg Asp Glu Gly Arg Asp Asp Lys Asp Ser Glu 35 40 45 Arg Ile Leu Arg Asp Ile Lys Arg Arg Ile Asp Glu Ala Ala Lys Glu 50 55 60 Ser Arg Glu Ile Ile Glu Arg Ile Glu Lys Glu Val Glu Tyr Arg Ser 65 70 75 80 Arg <210> SEQ ID NO 350 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 350 Asp Lys Lys Asp Glu Leu Glu Arg Ile Leu Asp Glu Ile Arg Arg Leu 1 5 10 15 Ile Glu Arg Leu Asp Glu Ile Leu Ser Arg Leu Asn Lys Leu Leu Glu 20 25 30 Leu Leu Lys His Gly Val Pro Asn Ala Lys Glu Val Val Lys Asp Tyr 35 40 45 Ile Arg Leu Leu Lys Glu Tyr Leu Glu Leu Val Lys Glu Phe Leu Lys 50 55 60 Leu Val Lys Arg His Ala Asp Leu Val Ser 65 70

<210> SEQ ID NO 351 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 351 Asp Lys Arg Tyr Glu Ser Glu Lys Leu Lys Arg Arg Leu Asp Glu Ala 1 5 10 15 Val Glu Lys Val Arg Glu Val Val Glu Arg Val Glu Arg Glu Ser Asp 20 25 30 Arg Val Leu Glu Glu Val Arg Arg Arg Arg Glu Ser Lys Glu Val Val 35 40 45 Asp Lys Val Ile Glu Asp Asn Asp Lys Ala Leu Glu Asp Val Leu Arg 50 55 60 Val Val Asp Glu Val Ala Lys Val Val Arg Asp Val Val Arg Glu Asn 65 70 75 80 Thr Arg <210> SEQ ID NO 352 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 352 Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu 1 5 10 15 Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val 35 40 45 Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile 50 55 60 Ala Lys Thr His Ala Lys Lys Val Glu 65 70 <210> SEQ ID NO 353 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 353 Asp Glu Asp Glu Ile Leu Tyr His Ser Glu Arg Leu Leu Gln Lys Leu 1 5 10 15 Lys Lys Glu Leu Asp Asp Leu Lys Glu Lys Ser Arg Glu Leu Leu Glu 20 25 30 Glu Leu Lys Lys Glu Asp Pro Asp Asp Arg Leu Ile Glu Arg Ile Ile 35 40 45 Arg Leu His Asp Glu Val Leu Lys Asp Leu Asp Glu Val Leu Lys Asn 50 55 60 Ile Leu Glu Val His Arg Glu Val Leu Glu Arg Leu Arg 65 70 75 <210> SEQ ID NO 354 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 354 Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu 1 5 10 15 Gln Thr Ala Thr Lys Ile Ile Asp Asp Leu Asn Lys Val Leu Glu Lys 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Ile Glu Thr Val Val 35 40 45 Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile 50 55 60 Ala Lys Thr His Ala Lys Lys Val Glu 65 70 <210> SEQ ID NO 355 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 355 Pro Lys Glu Glu Leu Ile Arg Arg Val Leu Glu Glu Val Lys Arg Leu 1 5 10 15 Asn Glu Lys Leu Leu Glu Ile Ile Arg Arg Ala Ala Glu Leu Val Lys 20 25 30 Arg Ala Asn Asp Glu Leu Pro Glu Thr Glu Lys Leu Arg Glu Ile Asp 35 40 45 Arg Glu Leu Glu Lys Lys Leu Lys Glu Ile Glu Asp Glu Leu Arg Arg 50 55 60 Ile Asp Lys Glu Leu Asp Asp Ala Leu Tyr Glu Ile Glu Asp 65 70 75 <210> SEQ ID NO 356 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 356 Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu 1 5 10 15 Gln Thr Ala Thr Lys Val Val Asp Asp Ala Asn Lys Leu Leu Glu Lys 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val 35 40 45 Glu Leu Leu Lys Arg Leu Glu Lys Leu Ile Lys Glu Leu Leu Glu Ile 50 55 60 Ala Lys Thr His Ala Lys Lys Val Glu 65 70 <210> SEQ ID NO 357 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 357 Lys Glu Asp Glu Ser Val Lys Arg Ala Glu Glu Ile Val Arg Thr Leu 1 5 10 15 Leu Lys Leu Leu Glu Asp Ser Leu Arg Glu Ala Glu Arg Ser Leu Arg 20 25 30 Asp Ile Lys Asn Gly Glu Asp Glu His Asn Leu Arg Arg Ile Ser Glu 35 40 45 Lys Leu Glu Glu Leu Ser Lys Arg Ile Thr Glu Thr Ile Glu Arg Leu 50 55 60 Leu Arg Glu Leu Gln Tyr Thr Ser Arg 65 70 <210> SEQ ID NO 358 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 358 Asp Asp Lys Glu Ala Thr Lys Ile Ile Asp Asp Leu Asp Lys Leu Leu 1 5 10 15 Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Asn Lys Leu Leu Glu Lys 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val 35 40 45 Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Glu Leu 50 55 60 Leu Lys Arg His Glu Lys Lys Val Glu 65 70 <210> SEQ ID NO 359 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 359 Asp Glu Ser Glu Glu Ala Gln His Glu Val Glu Lys Val Leu Asp Asp 1 5 10 15 Ile Arg Arg Leu Ser Glu His Leu Gln Lys Arg Leu Glu Glu Val Leu 20 25 30 Glu Glu Val Tyr Glu Leu Arg Arg Glu Gly Ser Asp Arg Thr Glu Val 35 40 45 Val Glu Leu Leu Lys Glu Val Ile Arg Glu Ile Val Arg Val Asn Arg 50 55 60 Glu Ala Leu Glu Arg Leu Leu Arg Val Val Glu Glu Ala Val Lys Arg 65 70 75 80 Asn Glu <210> SEQ ID NO 360 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 360 Asp Asp Lys Glu Ala Asn Lys Leu Leu Glu Lys Ala Thr Lys Ile Ile 1 5 10 15 Asp Asp Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Ala Val Lys Glu Leu Leu 35 40 45 Glu Ile Ala Lys Thr His Ala Glu Leu Leu Lys Arg His Glu Lys Val 50 55 60

Val Glu Thr Tyr Val Lys Lys Val Glu 65 70 <210> SEQ ID NO 361 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 361 Asp Glu Glu Glu Glu Val Val Arg Arg Ala Glu Glu Leu Val Lys Glu 1 5 10 15 His Glu Glu Leu Ile Glu Arg Val Ile Arg Thr His Glu Glu Leu Val 20 25 30 Tyr Lys Leu Glu Asp Gln Gly Ala Asp Lys Lys Leu Val Asp Val Leu 35 40 45 Lys Arg Val Val Glu Glu Ser Glu Arg Val Ala Arg Glu Ile Val Lys 50 55 60 Val Ser Arg Glu Leu Ile Arg Leu Leu Glu Glu Ala Ser Arg 65 70 75 <210> SEQ ID NO 362 <211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 362 Ser Ala Asp Asp Val Leu Glu Asp Ile Leu Lys Ile Ile Arg Glu Leu 1 5 10 15 Ile Glu Ile Leu Asp Gln Ile Leu Ser Leu Leu Asn Gln Leu Leu Lys 20 25 30 Leu Leu Arg His Gly Val Pro Asn Ala Lys Lys Val Val Glu Lys Tyr 35 40 45 Lys Glu Ile Leu Glu Leu Tyr Leu Gln Leu Val Ser Leu Phe Leu Lys 50 55 60 Ile Val Lys Thr His Ala Asp Ala Val Ser Gly Lys Ile Asp Lys Lys 65 70 75 80 Ala Glu Glu Glu Ile Lys Lys Glu Glu Glu Lys Ile Lys Glu Lys Leu 85 90 95 Arg Gln Ala Lys Asp Ile Leu Lys Lys Leu Gln Glu Glu Ile Asp Lys 100 105 110 Thr Arg <210> SEQ ID NO 363 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 363 Asp Lys Glu Glu Glu Ser Glu Tyr Leu Leu Arg Asp Leu Val Arg Leu 1 5 10 15 Leu Glu Lys Val Lys Glu Lys Ile Glu Glu Val Asn Arg Glu Val Glu 20 25 30 Lys Leu Leu Lys Lys Val Lys Asp Gly Arg Leu Asp Arg Arg Glu Val 35 40 45 Leu Arg Glu Ile Leu Arg Leu Asn Arg Glu Leu Ala Glu Ile Ile Lys 50 55 60 Glu Val Val Asp Arg Ile Arg His Val Val Glu Arg Ser Glu Arg 65 70 75 <210> SEQ ID NO 364 <211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 364 Asn Asp Lys Val Leu Asp Lys Ile Leu Asp Ile Leu Asp Arg Ile Leu 1 5 10 15 Arg Leu Ala Thr Arg Val Ile Asp Leu Ala Asn Lys Leu Leu Gln Val 20 25 30 Lys Lys Lys Ser Thr His Lys Asp Pro Arg Ile Val Glu Thr Tyr Lys 35 40 45 Glu Leu Leu Lys Ile His Glu Thr Ala Val Arg Leu Leu Leu Glu Leu 50 55 60 Ala Asp Leu His Arg Arg Leu Lys Ser Lys Asp Glu Glu Ala Asn Lys 65 70 75 80 Arg Val Glu Thr Glu Leu Asp Arg Ile Arg Lys Lys Val Lys Asp Ile 85 90 95 Glu Asp Lys Val Arg Lys Leu Glu Asp Lys Val Arg Lys Thr Ala Ser 100 105 110 <210> SEQ ID NO 365 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 365 Pro Val Glu Glu Ile Ile Lys Glu Val Val Lys Arg Val Ile Glu Val 1 5 10 15 Gln Glu Lys Val Leu Arg Ile Ile Ser His Ala Val Lys Arg Val Val 20 25 30 Glu Val Gln Lys Lys Tyr Asp Pro Gly Ser Glu Glu Ser Asn Arg Val 35 40 45 Val Glu Glu Val Lys Lys Thr Ile Glu Asp Ala Ile Arg Glu Ser Asp 50 55 60 Glu Val Val Asp Glu Val Val Lys Arg Ile Gln Tyr Thr Val Arg 65 70 75 <210> SEQ ID NO 366 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 366 Asp Glu Ala Val Lys Arg Val Val Glu Lys Ser Leu Lys Ile Leu Asp 1 5 10 15 Glu Val Ile Lys Lys Ser Leu Asp Ile Leu Arg Glu Leu Ile Glu Leu 20 25 30 Gln Ile Arg His Ala Lys Asp Asp Glu Ser Val Ile Arg Ala Ser Lys 35 40 45 Ser Ala Leu Lys Asp Ala Ile Glu Ala Leu Lys Lys Ser Leu Asp Glu 50 55 60 Ile Lys Lys Ala Leu Lys Arg Ser Ala Asp Glu Gly 65 70 75 <210> SEQ ID NO 367 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 367 Asp Glu Asp Lys Glu Ala Asn Arg Val Leu Asp Glu Val Leu Lys Thr 1 5 10 15 Val Arg Asp Leu Leu Glu Thr Ala Asn Glu Val Leu Lys Glu Val Leu 20 25 30 Tyr Arg Leu Lys Arg Thr Asp Asp Gln Glu Lys Val Val Arg Thr Leu 35 40 45 Thr Glu Val Leu Lys Glu His Leu Lys Leu Val Glu Glu Ile Val Arg 50 55 60 Ile Leu Asp Lys Val Leu Lys Glu His Leu Glu Thr Glu Lys 65 70 75 <210> SEQ ID NO 368 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 368 Ser Lys Glu Glu Val Ile Arg Leu Leu Lys Glu Asn Val Arg Leu Ile 1 5 10 15 Lys Glu Asn Leu Glu Leu Leu Thr Arg Asn Leu Lys Leu Ile Thr Asp 20 25 30 Leu Val Arg Gly Ser Asn Gly Ser Glu Glu Lys Ile Lys Thr Leu Lys 35 40 45 Glu Leu Leu Lys Glu Tyr Arg Glu Leu Leu Lys Arg Tyr Arg Lys Leu 50 55 60 Val Glu Asp Tyr Lys Arg Leu Val Asp Lys His Asp 65 70 75 <210> SEQ ID NO 369 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 369 Arg Arg Glu Glu Val Val Lys Arg Ile Arg Glu Leu Leu Lys Arg Asn 1 5 10 15 Lys Glu Leu Ile Asp Arg Ile Arg Glu Leu Leu Glu Glu Asn Glu Tyr 20 25 30 Leu Asp Lys Asp Ala Arg Asp Lys Asp Val Leu Arg Arg Ser Val Glu 35 40 45 Leu Leu Glu Glu Leu Val Arg Ile Leu Glu Glu Ser Val Glu Leu Ala 50 55 60 Lys Glu Ile Ile Lys Leu Leu Arg Glu Val Val Glu 65 70 75 <210> SEQ ID NO 370 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 370 Tyr Ile Glu Asp Val Ile Lys Lys Ile Leu Asp Val Ser Arg Glu Leu 1 5 10 15 Ile Lys Leu Ser Arg Thr Ile Ile Lys Ile Ser Glu Glu Ile Asn Lys 20 25 30 Gln Leu Gln Gln Gly Arg Asp Thr Lys Asp Leu Val Lys Lys Tyr Asp 35 40 45 Glu Ile Ile Lys Lys Tyr Thr Arg Ile Val Gln His Tyr Thr Glu Leu 50 55 60 Ile Lys Glu Leu Gln Lys Leu Leu Ser 65 70 <210> SEQ ID NO 371 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 371 Asp Glu Lys Glu Glu Ala Lys Lys Ala Ser Glu Glu Ser Val Arg Thr 1 5 10 15 Val Glu Arg Ile Leu Glu Glu Leu Leu Lys Ala Ser Glu Glu Ser Val 20 25 30 Glu Leu Leu Arg Arg Gly Glu Asp Ala Lys Asp Val Val Glu Arg Ser 35 40 45 Lys Glu Ala Leu Lys Arg Val Lys Glu Leu Leu Asp Glu Val Val Lys 50 55 60 Arg Ser Asp Glu Ile Leu Lys Tyr Ile His Asn 65 70 75 <210> SEQ ID NO 372 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 372 Glu Glu Glu Glu Ile Leu Lys Ile Gln Lys Glu Leu Leu Arg Ile Gln 1 5 10 15 Ser Glu Ile Leu Asp Lys Gln Lys Lys Ile Leu Asp Thr Leu Arg Ser 20 25 30 Asn Gly Ala Val Thr Glu Glu Val Arg Ser Ile Leu Glu Lys Val Glu 35 40 45 Arg Leu Ser Glu Glu Ala Lys Glu Leu Ser Lys Glu Ala Lys Glu Leu 50 55 60 Thr Lys Glu Val Ser Lys Leu Ile Ser 65 70 <210> SEQ ID NO 373 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 373 Pro Asp Met Asp Glu Val Lys Arg Val Leu Asp Glu Leu Ile Glu Ile 1 5 10 15 Gln Glu Glu Ile Leu Arg Glu Ile Lys Arg Val Leu Glu Lys Leu Ile 20 25 30 Lys Ile Gln Glu Asp Asn Gly Ser Glu Tyr Glu Ser Arg Glu Val Val 35 40 45 Arg Glu Ile Val Glu Ile Ala Arg Lys Leu Val Glu Arg Ser Arg Arg 50 55 60 Val Val Lys Lys Ile Thr Glu Thr Leu Gln 65 70 <210> SEQ ID NO 374 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 374 Pro Leu Glu Asp Leu Val Arg Lys Tyr Asp Glu Leu Val Lys Thr Tyr 1 5 10 15 Glu Lys Leu Val Glu Glu Phe Lys Lys Ala Val Asp Lys Tyr Asp Lys 20 25 30 Ala Val Lys Lys Ala Pro Val Ser Lys Glu Ala Thr Asp Ser Leu Asp 35 40 45 Leu Ile Arg Lys Val Leu Glu Leu Leu Asp Arg Asn Leu Lys Leu Ile 50 55 60 Lys Glu Asn Ala Lys Leu Ile Lys Glu Leu Leu Lys 65 70 75 <210> SEQ ID NO 375 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 375 Pro Glu Arg Glu Ala Leu Arg Glu Val Leu Glu Asp Leu Lys Arg Val 1 5 10 15 Thr Asp Arg Leu Arg Glu Leu Val Glu Arg Val Leu Glu Glu Leu Lys 20 25 30 Lys Val Thr Asp His Val Asp Ser Glu Arg Ile Leu Arg Glu Ser Arg 35 40 45 Arg Val Leu Lys Glu Leu Lys Asp Ile Ile Glu Glu Ile Leu Arg Glu 50 55 60 Ser Glu Lys Val Leu Glu Lys Leu Lys Tyr Thr Glu Asp 65 70 75 <210> SEQ ID NO 376 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 376 Pro Ile Lys Asp Ile Ser Lys Arg Leu Leu Glu Ile Ser Lys Arg Leu 1 5 10 15 Val Glu Ile Ser Asp Arg Ile Val Glu Leu Leu Gln Arg Ile Ala Asp 20 25 30 Ser Lys Asp Pro Asn Lys Asp Leu Gln Lys Glu Val Lys Asp Val Leu 35 40 45 Glu Glu Tyr Lys Arg Leu Val Arg Glu Tyr Arg Glu Val Val Lys Glu 50 55 60 Tyr Glu Lys Val Val Ser 65 70 <210> SEQ ID NO 377 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 377 Pro Val Glu Glu Ala Ile Lys Lys Val Ile Asp Asp Leu Arg Asp Val 1 5 10 15 Gln Arg Lys Ile Arg Glu Leu Val Glu Glu Leu Ile Arg Leu Leu Glu 20 25 30 Glu Val Gln Arg Asp Asn Asp Lys Arg Glu Ser Glu Tyr Val Val Glu 35 40 45 Arg Val Glu Glu Ile Leu Arg Arg Ile Thr Glu Thr Ser Arg Glu Val 50 55 60 Val Arg Lys Ala Val Glu Asp Leu Ser 65 70 <210> SEQ ID NO 378 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 378 Asn Leu Glu Glu Leu Val Lys Leu Leu Lys Glu Val Leu Glu Met His 1 5 10 15 Glu Arg Leu Leu Arg Ile His Glu Asp Leu Val Glu Ala His Lys Ser 20 25 30 Asn Ala Ser Asp Lys Glu Ser Glu Arg Lys Leu Lys Lys Ser Asp Lys 35 40 45 Asp Ile Lys Glu Ser Leu Lys Lys Ile Lys Ser Ile Ile Asp Gln Val 50 55 60 Arg Tyr Ile Gln Ser 65 <210> SEQ ID NO 379 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 379 Pro Val Glu Glu Val Leu Lys Glu Leu Ser Glu Val Asn Glu Arg Val 1 5 10 15 Arg Asp Ile Ala Arg Glu Ile Ile Glu Arg Leu Ser Glu Val Asn Glu 20 25 30 Glu Val Lys Glu Thr Asp Asp Glu Asp Glu Leu Lys Lys Ile Ser Lys 35 40 45 Lys Val Val Asp Glu Val Glu Asp Leu Leu Arg Lys Ile Leu Glu Val 50 55 60 Ser Glu Glu Val Val Arg Arg Val Glu Tyr His Asp Arg 65 70 75 <210> SEQ ID NO 380 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 380

Asp Glu Asp Tyr Glu Ser Arg Glu Ile Ile Asp Glu Ile Arg Lys Leu 1 5 10 15 Leu Asp Arg Ser Lys Lys Ile Val His Arg Ser Gln Arg Leu Val Glu 20 25 30 Arg Val Lys Ser Thr Pro Leu Ser Glu Asp Gln Glu Asp Leu Ile Arg 35 40 45 Arg His Glu Glu Thr Ile Asn Arg His Arg Glu Leu Val Lys Glu Leu 50 55 60 Glu Lys Val Leu Glu Asp His Glu Arg His Ile Arg 65 70 75 <210> SEQ ID NO 381 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 381 Pro Arg Ser Tyr Leu Leu Lys Glu Leu Ala Asp Leu Ser Gln His Leu 1 5 10 15 Val Arg Leu Leu Glu Arg Leu Val Arg Glu Ser Glu Arg Val Val Glu 20 25 30 Val Leu Glu Arg Gly Glu Val Asp Glu Glu Glu Leu Lys Arg Leu Glu 35 40 45 Asp Leu His Arg Glu Leu Glu Lys Ala Val Arg Glu Val Arg Glu Thr 50 55 60 His Arg Glu Ile Arg Glu Arg Ser Arg 65 70 <210> SEQ ID NO 382 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 382 Pro Glu Lys Asp Glu Asn Arg Lys Leu Leu Asp Lys Val Arg Lys Leu 1 5 10 15 Val Glu Lys Ser Arg Arg Leu Val Glu Glu Leu Arg Lys Leu Val Asp 20 25 30 Gln Ser Thr Lys Asn Gly Leu Ile Asp Glu Lys Ala Leu Arg Lys Gln 35 40 45 Gln Glu Val Leu Arg Lys Val Glu Glu Val Leu Glu Lys Gln Glu Arg 50 55 60 Val Leu Arg Glu Leu Glu Glu Ile Ser Tyr Arg Val Ile 65 70 75 <210> SEQ ID NO 383 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 383 Asp Glu Lys Asp Glu Ile Arg His Val Ile Glu Ser Val Glu Arg Leu 1 5 10 15 Ile Glu Asp Ile Lys Arg Leu Leu Lys Thr Leu Arg Glu Leu Ala His 20 25 30 Asp Asp Ser Asp Lys Lys Thr Val Lys Glu Val Leu Asp Arg Val Lys 35 40 45 Glu Met Ile Glu Arg His Arg Arg Glu Leu Glu Glu His Arg Lys Glu 50 55 60 Leu Glu Arg Ala Glu Tyr Glu Val Arg 65 70 <210> SEQ ID NO 384 <211> LENGTH: 122 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 384 Asp Glu Lys Ala Leu Arg Lys Gln Gln Glu Val Leu Arg Lys Val Glu 1 5 10 15 Glu Val Leu Glu Lys Gln Glu Arg Val Leu Arg Glu Leu Glu Glu Ile 20 25 30 Ser Tyr Arg Val Ile Thr Arg Gly Glu Asp His Lys Ala Glu Glu Asp 35 40 45 Ser Arg Arg Val Leu Glu Arg Phe Val Arg Val Ser Arg Glu Val Leu 50 55 60 Lys Val Leu Glu Glu Phe Leu Arg Val Ser Glu Glu Leu Leu Arg Glu 65 70 75 80 Ala Asp Arg Asp Arg Asp Arg Arg Leu Glu Glu Tyr Glu Arg Gln Val 85 90 95 Asp Glu Leu Arg Glu Glu Ile Arg Arg Tyr Lys Glu Glu Val Asp Lys 100 105 110 Phe Asp Lys Glu Val Lys Tyr Tyr Lys Lys 115 120 <210> SEQ ID NO 385 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 385 Ser Leu Glu Asp Ser Val Arg Leu Asn Asp Glu Val Val Lys Val Val 1 5 10 15 Glu Arg Val Val Arg Leu Asn Gln Glu Val Val Arg Leu Ile Lys His 20 25 30 Ala Thr Asp Val Glu Asp Glu Glu Thr Val Lys Tyr Val Leu Glu Arg 35 40 45 Val Arg Glu Val Leu Asp Glu Ser Arg Glu Val Leu Lys Arg Val His 50 55 60 Glu Leu Leu Glu Glu Ser Glu Arg Arg Leu Glu 65 70 75 <210> SEQ ID NO 386 <211> LENGTH: 123 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 386 Pro Glu Arg Asp Glu Asn Arg Lys Leu Leu Asp Lys Val Arg Lys Leu 1 5 10 15 Val Glu Lys Ser Arg Arg Leu Val Glu Glu Leu Arg Lys Leu Val Asp 20 25 30 Gln Ser Thr Lys Asn Gly Leu Ile Asp Glu Lys Ala Leu Arg Lys Gln 35 40 45 Gln Glu Val Leu Arg Lys Val Glu Glu Val Leu Glu Lys Gln Glu Arg 50 55 60 Val Leu Arg Glu Leu Glu Glu Ile Ser Tyr Arg Val Ile Thr Arg Gly 65 70 75 80 Glu Asp His Lys Ala Glu Glu Asp Ser Arg Arg Val Leu Glu Arg Phe 85 90 95 Val Arg Val Ser Arg Glu Val Leu Lys Val Leu Glu Glu Phe Leu Arg 100 105 110 Val Ser Glu Glu Leu Leu Arg Glu Ala Asp Arg 115 120 <210> SEQ ID NO 387 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 387 Pro Glu Leu Asp Glu Val Lys Lys Leu Ile Asp Glu Leu Lys Lys Ser 1 5 10 15 Val Glu Arg Leu Glu Glu Ser Ile Arg Glu Val Lys Glu Ser Ile Lys 20 25 30 Lys Leu Arg Lys Gly Asp Ile Asp Ala Glu Glu Asn Ile Lys Leu Leu 35 40 45 Lys Glu Asn Ile Lys Ile Val Arg Glu Asn Ile Lys Ile Ile Lys Glu 50 55 60 Ile Ile Asp Val Val Gln Tyr Val Leu Arg 65 70 <210> SEQ ID NO 388 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 388 Asp Ser Glu Tyr Glu Ser Arg Gln Val Leu Arg Glu Leu Asp Thr Val 1 5 10 15 Leu Lys Asp Ser His Thr Val Leu Glu Ala Leu Arg Gln Val Ile Arg 20 25 30 Asp Ser Gln Asp Val Val Ser Lys Ser Asp Glu Glu Ser Arg Arg Val 35 40 45 Ile Asp Asp Leu Glu Lys Val Ile Gln Asp Ser Lys Lys Val Leu Asp 50 55 60 Asp Ile Lys Arg Leu Ile Asp Lys Ser Lys Ser Ile Lys Ser 65 70 75 <210> SEQ ID NO 389 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 389 Asp Glu Ser Asp Arg Ile Arg Lys Ile Val Glu Glu Ser Asp Glu Ile 1 5 10 15 Val Lys Glu Ser Arg Lys Leu Ala Glu Arg Ala Arg Glu Leu Ile Lys 20 25 30 Glu Ser Glu Asp Lys Arg Val Ser Glu Glu Arg Asn Glu Arg Leu Leu

35 40 45 Glu Glu Leu Leu Arg Ile Leu Asp Glu Asn Ala Glu Leu Leu Lys Arg 50 55 60 Asn Leu Glu Leu Leu Lys Glu Val Leu Tyr Arg Thr Arg 65 70 75 <210> SEQ ID NO 390 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 390 Ser Leu Tyr Glu Leu Thr Gln Arg Tyr Glu Lys Leu Val Gln Gln Tyr 1 5 10 15 Glu Glu Leu Val Lys Asp Tyr Arg Arg Leu Val Lys Lys Leu Glu Lys 20 25 30 Leu Lys Arg Asp Asn Lys Pro Asp Lys Arg Leu Leu Lys Glu Ile Val 35 40 45 Asp Val Ile Lys Lys Ser Val Glu Ile Ile Asp Arg Ser Leu Lys Leu 50 55 60 Leu Glu Glu Ser Ile Lys Ile Leu Glu Glu Thr Asp 65 70 75 <210> SEQ ID NO 391 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 391 Asp Lys Lys Asp Ala Ser Arg Arg Ala Ile Arg Val Leu His Glu Phe 1 5 10 15 Val Arg Val Ser Glu Glu Val Leu Glu Val Leu Arg Lys Ser Val Glu 20 25 30 Ser Leu Lys Arg Leu Asp Val Asp Glu Lys Ile Lys Arg Thr His Asp 35 40 45 Arg Ile Glu Glu Glu Leu Arg Arg Trp Lys Arg Glu Leu Glu Glu Leu 50 55 60 Ile Glu Arg Leu Arg Glu Trp Glu Tyr His Gln Asp 65 70 75 <210> SEQ ID NO 392 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 392 Asp Ile Glu Tyr Glu Ser Lys Glu Ile Leu Glu Leu Ile Lys Glu Leu 1 5 10 15 Leu Lys Leu Ser Arg Glu Leu Leu Lys Glu Ser Arg Arg Ala Leu Glu 20 25 30 Leu Val Arg Lys Ser Arg Asp Asp Ser Ile Val Glu Glu Val Ile Gln 35 40 45 Val His Lys Lys Val Leu Asp Ile His Lys Glu Val Leu Lys Ile Val 50 55 60 Arg Lys Val Val Glu Val His Arg Arg Val Lys Ser 65 70 75 <210> SEQ ID NO 393 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 393 Asp Lys Glu Tyr Lys Leu Asp Arg Ile Leu Arg Arg Leu Asp Glu Leu 1 5 10 15 Ile Lys Gln Leu Ser Arg Ile Leu Glu Glu Ile Glu Arg Leu Val Asp 20 25 30 Glu Leu Glu Arg Glu Pro Leu Asp Asp Lys Glu Val Gln Asp Val Ile 35 40 45 Glu Arg Ile Val Glu Leu Ile Asp Glu His Leu Glu Leu Leu Lys Glu 50 55 60 Tyr Ile Lys Leu Leu Glu Glu Tyr Ile Lys Thr Thr Lys 65 70 75 <210> SEQ ID NO 394 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 394 Asp Leu Glu Tyr Leu Asn Arg Arg Leu Leu Gln Leu Ile Lys Thr Leu 1 5 10 15 Ile Asp Leu Asn Arg His Leu Leu Lys Leu Ile Asp Lys Leu Lys Lys 20 25 30 Leu Asn Ser Arg Glu Gly Asp Glu Glu Lys Ile Lys Glu Glu Ser Lys 35 40 45 Gln Ile Gln Glu Gln Phe Lys Glu Ile Val Glu Arg Ser Lys Glu Ile 50 55 60 Ile Lys Gln Ile Lys Glu Ile Ile Lys Arg Ser Gln 65 70 75 <210> SEQ ID NO 395 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 395 Arg Asp Arg Lys Ile Ser Glu Glu Leu Ile Lys Ala Leu Glu Asp His 1 5 10 15 Ile Arg Met Leu Glu Glu Leu Ile Arg Ala Ile Glu Glu His Ile Lys 20 25 30 Leu Ala Glu Arg Gly Val Asp Glu Lys Glu Leu Arg Glu Ser Leu Glu 35 40 45 Glu Leu Lys Lys Ile Val Asp Glu Leu Glu Lys Ser Leu Glu Glu Leu 50 55 60 Arg Lys Leu Ala Glu Arg Tyr Lys Tyr Glu Thr Arg 65 70 75 <210> SEQ ID NO 396 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 396 Glu Glu Ser Glu Glu Val Arg Lys Val Val Glu Arg Ile Lys Lys Ile 1 5 10 15 Ser Arg Glu Leu Glu Glu Val Val Lys Glu Leu Asp Arg Val Ser Lys 20 25 30 Glu Phe Asp Arg His Gly Glu Thr Asp Glu Ile Val Arg Glu His Glu 35 40 45 Arg Ile Val Glu Lys Leu Glu Glu Ile Val Lys Lys His Thr Lys Ile 50 55 60 Val Glu Glu Leu Ala Glu Ile Val Tyr Lys Gln Gln 65 70 75 <210> SEQ ID NO 397 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 397 Asp His Glu Tyr Trp Val Lys Ile Val Glu Arg Ile Leu Arg Val Met 1 5 10 15 Glu Lys His Ala Glu Ile Val Lys Lys His Leu Glu Ile Val Glu Arg 20 25 30 Val Val Arg Glu Gly Pro Ser Glu Asp Leu Arg Arg Lys Leu Lys Glu 35 40 45 Ser Leu Arg Glu Ile Glu Glu Ser Leu Arg Glu Leu Lys Glu Leu Leu 50 55 60 Asp Glu Leu Asp Glu Leu Ser Glu Lys Thr Arg 65 70 75 <210> SEQ ID NO 398 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 398 Asp Leu Leu Tyr Leu Ser Lys Glu Leu Leu Lys Leu Val Arg Glu Leu 1 5 10 15 Leu Lys Leu Ser Arg Glu Leu Val Glu Leu Ser Arg Arg Leu Val Asn 20 25 30 Ser Thr His Lys Ser Pro Glu Leu Val Lys Lys Tyr Asp Lys Leu Val 35 40 45 Lys Lys Tyr Gln Asp Leu Leu Lys Lys Leu Ala Asp Val Ala Asp Glu 50 55 60 Tyr Leu Arg Gln Arg Ser 65 70 <210> SEQ ID NO 399 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 399 Asp Lys Glu Glu Ile Val Lys Leu Gln Asp Glu Val Ile Lys Thr Leu 1 5 10 15 Glu Arg His Leu Asp Ile Leu Arg Lys His Ile Asp Leu Leu Glu Lys 20 25 30 Leu Lys Asp His Leu Ser Glu Glu Leu Lys Glu Arg Val Asp Arg Ser 35 40 45

Ile Lys Lys Leu Glu Glu Ser Ile Lys Arg Leu Glu Arg Ile Ile Glu 50 55 60 Glu Leu Gln Glu Leu Ala Glu Tyr Ser Leu 65 70 <210> SEQ ID NO 400 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 400 Asp Ala Tyr Asp Leu Asp Arg Ile Val Lys Glu His Arg Arg Leu Val 1 5 10 15 Glu Glu Gln Arg Glu Leu Val Glu Glu Leu Glu Lys Leu Val Arg Arg 20 25 30 Gln Glu Asp His Arg Val Asp Lys Lys Glu Ser His Glu Ile Leu Glu 35 40 45 Arg Leu Glu Arg Ile Ile Arg Arg Ser Thr Arg Ile Leu Thr Glu Leu 50 55 60 Glu Lys Leu Thr Asp Glu Phe Glu Arg Arg Thr Arg 65 70 75 <210> SEQ ID NO 401 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 401 Asp Met Glu Tyr Glu Leu Lys Lys Ser Ala Glu Glu Leu Arg Lys Ser 1 5 10 15 Leu Glu Glu Leu Lys Arg Ile Leu Asp Glu Leu His Lys Ser Leu Arg 20 25 30 Glu Leu Arg Arg His Gly Asp Asp Glu Glu Tyr Val Gln Thr Val Glu 35 40 45 Glu Leu Arg Lys Glu Leu Glu Glu His Ala Lys Lys Leu Glu Glu His 50 55 60 Leu Lys Glu Leu Glu Arg Val Ala Thr 65 70 <210> SEQ ID NO 402 <211> LENGTH: 69 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 402 Asp Arg Gln Arg Ile Leu Asp Arg Leu Asp Lys Ile Leu Glu Lys Leu 1 5 10 15 Asp Asp Ile Leu Lys Lys Leu Lys Asp Ile Leu Glu Thr Leu Ser Lys 20 25 30 Asp Asp Val Ser Asp Arg Arg His Lys Asp Leu Val Glu Lys Phe Arg 35 40 45 Glu Leu Val Asp Thr His His Lys Leu Val Glu Arg Tyr Arg Glu Leu 50 55 60 Val Tyr Gln Asn Arg 65 <210> SEQ ID NO 403 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 403 Arg Glu Lys Asp Glu Ser Lys Glu Leu Asn Asp Glu Tyr Lys Lys Leu 1 5 10 15 Leu Glu Glu Tyr Glu Arg Leu Leu Arg Arg Ser Glu Glu Leu Val Lys 20 25 30 Arg Ala Lys Gly Pro Arg Asp Glu Lys Glu Leu Lys Arg Ile Leu Glu 35 40 45 Glu Asn Glu Asp Ile Leu Arg Arg Thr Lys Glu Ile Leu Glu Arg Thr 50 55 60 Lys Glu Ile Ser Glu Glu Gln Lys Tyr Arg Arg Arg 65 70 75 <210> SEQ ID NO 404 <211> LENGTH: 105 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 404 Asp Pro Gln Arg Ala Ala Asp Arg Leu Asp Lys Ile Leu Glu Lys Leu 1 5 10 15 Asp Asp Ile Leu Lys Lys Leu Lys Asp Ile Leu Glu Thr Leu Ser Lys 20 25 30 Asp Asp Val Lys Asp Arg Arg Ala Lys Asp Leu Val Glu Lys Phe Arg 35 40 45 Glu Leu Val Asp Thr His His Lys Leu Val Glu Arg Tyr Arg Glu Leu 50 55 60 Val Tyr Thr Ala Thr Ala Gly Ser Asp Leu Ala Arg Glu Leu Ile Arg 65 70 75 80 Arg Val Glu Glu His Thr Lys Arg Leu Arg His Ile Leu Lys Arg Leu 85 90 95 Arg Glu His Glu Glu Lys Leu Arg Arg 100 105 <210> SEQ ID NO 405 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 405 Glu Asn Lys Tyr Ile Leu Lys Glu Ile Leu Lys Leu Leu Arg Glu Asn 1 5 10 15 Leu Lys Leu Leu His Asp Ile Leu Arg Leu Leu Asp Glu Asn Leu Glu 20 25 30 Glu Leu Glu Lys His Gly Ala Lys Asp Leu Asp Asp Tyr Arg Arg Lys 35 40 45 Ile Glu Glu Ile Arg Lys Lys Val Glu Asp Tyr Arg Glu Lys Ile Glu 50 55 60 Glu Ile Glu Lys Lys Val Glu Arg Asp Arg 65 70 <210> SEQ ID NO 406 <211> LENGTH: 68 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 406 Asp Lys Glu Tyr Leu Val Thr Glu His Glu Lys Leu Val Arg Glu His 1 5 10 15 Glu Lys Ile Val Ser Glu Ile Glu Lys Leu Val Lys Lys His Glu Ala 20 25 30 Gly Val Asp Glu Ser Glu Leu Glu Glu Ile Leu Lys Lys Val Glu Lys 35 40 45 Leu Leu Arg Lys Leu Asp Glu Ile Leu Glu Gln Leu Thr Gln Leu Leu 50 55 60 Arg Lys Thr Glu 65 <210> SEQ ID NO 407 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 407 Asp Glu Glu Glu Ala Asn Tyr Val Ser Asp Lys Ala Val Lys Ile Ala 1 5 10 15 Glu Asp Val Gln Glu Leu Leu Lys Glu Leu Leu Glu Leu Ser Glu Val 20 25 30 Val Arg Arg Gly Glu Val Asp Glu Asp Glu Tyr Asp Arg Val Leu Arg 35 40 45 Lys Leu Gln Glu Val Met Lys Glu Tyr Glu Glu Val Leu Lys Glu Tyr 50 55 60 Glu Glu Val Ser Arg Lys His Glu 65 70 <210> SEQ ID NO 408 <211> LENGTH: 112 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 408 Asp Ala Glu Tyr Leu Val Thr Glu His Glu Lys Leu Val Arg Glu His 1 5 10 15 Glu Lys Ile Val Ser Glu Ile Glu Lys Leu Val Lys Lys His Glu Lys 20 25 30 Gly Val Asp Glu Ser Glu Leu Glu Glu Ile Leu Lys Lys Val Glu Lys 35 40 45 Leu Leu Arg Lys Leu Asp Glu Ile Leu Glu Gln Leu Thr Gln Leu Leu 50 55 60 Arg Lys Ala Glu Lys His Ile Asp Lys His Ser Lys Ala Ala Asp Gln 65 70 75 80 Leu Ala Thr Ser Ile Lys Lys Leu Glu Asp Ser Ile Asp Gln Leu Ile 85 90 95 Lys Ile Val Arg Lys Phe Glu Glu Ser Val Lys Lys Leu Gln Lys His 100 105 110 <210> SEQ ID NO 409 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 409 Asp Glu Glu Tyr Glu Leu Glu Arg Ile Ser Arg Glu Ser Lys Glu Leu 1 5 10 15 Leu Glu Arg Tyr Lys Arg Leu Leu Arg Glu Tyr Gln Glu Leu Leu Lys 20 25 30 Glu Leu Arg His Val Lys Asp Leu Asp Arg Ala Val Lys Ile Ile His 35 40 45 Glu Leu Met Arg Val Ser Lys Glu Leu Val Glu Ile Ser His Arg Leu 50 55 60 Leu Glu Leu His Glu Arg Leu Val Arg Arg Arg Lys 65 70 75 <210> SEQ ID NO 410 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 410 Arg Asp Lys Tyr Leu Leu Glu Arg Leu Asn Asp Ile Leu Lys Lys Leu 1 5 10 15 Asp Glu Ile Val Asp Lys Leu Ser Asp Ile Leu Lys Arg Leu Lys Asp 20 25 30 Val Arg His Asp Asp Arg Leu Gln Glu Leu Val Glu Arg Tyr Lys Glu 35 40 45 Ile Val Lys Glu Tyr Lys Arg Ile Val Glu Glu Tyr Glu Lys Leu Val 50 55 60 Arg Glu Phe Glu Glu Gln Gln Arg 65 70 <210> SEQ ID NO 411 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 411 Pro His Glu Glu Val Val Glu Leu His Glu Arg Val Met Glu Ile Ser 1 5 10 15 Glu Arg Ala Val Glu Leu Ile Gln Arg Ile Ile Asp Ile Ile Arg Arg 20 25 30 Ile Arg Glu Asp Asp Lys Asp Ile Glu Lys Leu Val Lys Thr Ile Arg 35 40 45 Asp Leu Val Arg Glu Tyr Glu Glu Leu His Arg Glu Leu Glu Glu Ile 50 55 60 Asp Glu Glu Ile Tyr Lys Lys Ser Glu 65 70 <210> SEQ ID NO 412 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 412 Asp Ala Glu Tyr Lys Val Arg Glu Ser Val Lys Arg Ser Lys Glu Ser 1 5 10 15 Val Lys His Ser Glu Asp Val Val Asp Lys Leu Asn Lys Ser Val Lys 20 25 30 Leu Ser Glu Ser Gly His Ser Asp Ala Glu Lys Ala Ser Arg Glu Leu 35 40 45 Val Lys Leu Val Arg Glu Val Val Glu Leu Ser Arg Glu Val Ile Lys 50 55 60 Leu Ser Glu Lys Val Leu Arg Val Ile Ser 65 70 <210> SEQ ID NO 413 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 413 Arg Ala Arg Glu Val Val Lys Arg Ala Lys Arg Ile Ile Glu Glu Trp 1 5 10 15 Gln Lys Ile Leu Glu Glu Trp Arg Arg Ile Leu Glu Glu Trp Arg Arg 20 25 30 Leu Leu Glu Asp Glu Arg Val Asp Asp Arg Asp Asn Glu Arg Ile Ile 35 40 45 Arg Glu Asn Glu Arg Val Ile Arg Glu Asn Glu Lys Ile Ile Arg Asp 50 55 60 Val Ile Arg Leu Leu Glu Glu Leu Leu Tyr Glu Arg Arg 65 70 75 <210> SEQ ID NO 414 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 414 Asp Trp Glu Glu Leu Leu Arg Arg Leu Glu Lys Val Leu Gln Glu Tyr 1 5 10 15 Glu Glu Ile Val Lys Glu Leu Ile Asp Leu Ile Glu Arg Leu Ile Lys 20 25 30 Val Ser Glu Asp Lys Ser Lys Asp Ala Ser Glu Tyr Lys Lys Leu Val 35 40 45 Thr Glu Leu Glu Lys Leu Ile Ser Lys Leu Glu Glu Ile Ser Lys Lys 50 55 60 Leu Glu Glu Leu Val Lys Glu Tyr Glu Tyr Lys Thr Glu 65 70 75 <210> SEQ ID NO 415 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 415 Pro Lys Glu Glu Ile Val Lys Leu His Asp Glu Ser Ala Glu Leu His 1 5 10 15 Arg Arg Ser Val Glu Val Ala Asp Glu Ile Leu Lys Met His Glu Arg 20 25 30 Ser Lys Asp Val Asp Asp Glu Arg Glu Ser Arg Glu Leu Ser Lys Glu 35 40 45 Ile Glu Arg Leu Ile Arg Glu Val Glu Glu Val Ser Lys Arg Ile Lys 50 55 60 Arg Leu Ser Glu Glu Val Glu Tyr Leu Val Arg 65 70 75 <210> SEQ ID NO 416 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 416 Asp Lys Glu Arg Ala Ala Arg Ala Thr Glu Glu Met Val Lys Leu Thr 1 5 10 15 Lys Lys Leu Leu Lys Ala Val Glu Asp Leu Val Arg Asp Val Arg Arg 20 25 30 Leu Leu Lys Glu Gly Leu Ile Ser Glu Lys His Ala Arg Ile Ala Glu 35 40 45 Thr Ile Leu Glu Val Phe Lys Lys His Ala Lys Ile Ile Lys Lys His 50 55 60 Val Asp Ile Val Lys Tyr Asp Glu Ser 65 70 <210> SEQ ID NO 417 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 417 Pro Glu Asp Glu His Val Tyr Val Val Arg Glu Ile Tyr Glu Val Leu 1 5 10 15 Arg Glu His Ala Glu Val Leu Glu Glu Asn Arg Glu Val Ile Glu Arg 20 25 30 Leu Leu Glu Ala Lys Lys Arg Gly Asp Lys Ser Glu Glu Leu Val Lys 35 40 45 Glu Leu Lys Lys Ser Ile Asp Lys Leu Lys Glu Ile Ser Arg Lys Leu 50 55 60 Glu Glu Ile Val Lys Glu Leu Glu Lys Val Ser Glu Lys Leu Lys 65 70 75 <210> SEQ ID NO 418 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 418 Asn Asp Glu Glu Leu Lys Lys Ile Leu Glu Thr Leu Asp Arg Ile Leu 1 5 10 15 Lys Lys Leu Asp Lys Ile Leu Thr Arg Leu Asp Glu Val Leu Lys Lys 20 25 30 Ser Glu Asp Pro Asn Leu Asp Asp Lys Asp Tyr Thr Glu Leu Val Lys 35 40 45 Gln Tyr Ile Glu Leu Val Lys Lys Tyr Glu Glu Val Val Lys Glu Tyr 50 55 60 Glu Glu Val Val Arg Gln Leu Ile Arg Leu Phe Ser 65 70 75 <210> SEQ ID NO 419 <211> LENGTH: 72 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 419 Thr Gln Glu Glu Ile Asn Arg Ile Gln His Glu Val Leu Arg Ile Gln 1 5 10 15 Glu Glu Ile Asp Glu Ile Leu Arg Asp Ile Val Glu Lys Leu Lys Ala 20 25 30 Ile Ser Arg Gly Glu Leu Asp His Glu Val Val Lys Asp Val Glu Asp 35 40 45 Lys Val Arg Glu Ala Leu Glu Lys Ser Glu Glu Leu Leu Asp Lys Ser 50 55 60 Arg Lys Val Glu Tyr Lys Ser Glu 65 70 <210> SEQ ID NO 420 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 420 Glu Glu Asp Glu Arg Ile Arg Tyr Asp Leu Asp Arg Ile Arg Lys Asp 1 5 10 15 Val Arg Arg Lys Leu Glu Glu Ile Arg Gln Arg Val Arg Glu Leu Glu 20 25 30 Lys Lys Leu Arg Asp Ala Gly His Arg Arg Asp Glu Lys Glu Leu Leu 35 40 45 Arg Glu Leu Ile Glu Thr Ser Lys Asp Ile Leu Arg Leu Val Glu Glu 50 55 60 Leu Leu Lys Lys Ile Ile Asp Lys Ser Glu Asp Leu Leu Arg Lys Thr 65 70 75 80 Glu <210> SEQ ID NO 421 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 421 Asp Glu Lys Asp Arg Val Tyr Glu Ile Leu Lys Glu Val Gln Arg Leu 1 5 10 15 Val Lys Glu Tyr Arg Asp Ile Ser Lys Glu Ile Glu Asp Leu Val Lys 20 25 30 His Tyr Glu His Ile Thr Asp Asp Glu Ala Gln Glu Val Ser Lys Glu 35 40 45 Leu Ile Asp Lys Ser Leu Arg Ala Ser Glu Ile Val Arg Glu Leu Ile 50 55 60 Arg Leu Ile Lys Glu Leu Leu Asp Glu Leu Glu 65 70 75 <210> SEQ ID NO 422 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 422 Asp Glu Glu Glu Tyr Tyr Lys Glu Lys Leu His Lys Leu Leu Arg Glu 1 5 10 15 Ile Glu Glu Leu Leu Lys His Tyr Arg Glu Leu Val Arg Arg Leu Glu 20 25 30 Glu Leu Val Lys Arg Gly Glu Leu Asp Lys Asp Thr Ala Ala His Ile 35 40 45 Leu Glu Arg Leu Ser Glu Leu Leu Glu Arg Ile Ile Arg Arg Val Ala 50 55 60 His Thr Leu Arg Arg Leu Ser Glu Glu Arg Arg 65 70 75 <210> SEQ ID NO 423 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 423 Gly Ser Glu Gly Ser 1 5 <210> SEQ ID NO 424 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 424 Asp Ile Val Glu Leu Val Asp His Leu Leu Lys Arg Ser Leu Lys Leu 1 5 10 15 Leu Glu Glu Leu Ala Glu Leu Val Arg Arg Leu Leu Glu Lys Ser Thr 20 25 30 Glu Leu Leu Lys Arg Arg Thr Glu Glu His Lys Glu Glu Val Val Glu 35 40 45 Glu Ser Glu Tyr Met Val Arg Glu Leu Glu Glu Arg Leu Arg Arg Val 50 55 60 Val Asp Glu Ser Glu Lys Leu Val Arg Asp Ala Asp Lys His Ile Arg 65 70 75 80 <210> SEQ ID NO 425 <211> LENGTH: 4 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 425 Gly Gly Gly Ser 1 <210> SEQ ID NO 426 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 426 Pro Glu Val Asp Val Leu Arg Arg Ile Val Arg Glu Ile Leu Lys Ala 1 5 10 15 Ser Glu Glu Leu Leu Arg Leu Leu Arg Lys Leu Ile Asp Glu Ala Leu 20 25 30 Lys Leu Ser Glu Arg Lys Arg Asp Ser Gln Glu Tyr Arg Glu Val Val 35 40 45 Asp Arg Val Lys Lys Glu Leu Glu Arg Leu Leu Asp Glu Tyr Arg Lys 50 55 60 Leu Val Glu Glu Leu Lys Glu Lys Leu Arg Tyr Asp Thr Arg 65 70 75 <210> SEQ ID NO 427 <211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 427 Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Ser 1 5 10 <210> SEQ ID NO 428 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 428 Pro Arg Glu Tyr His Ser Lys Asp Ile Leu Arg Lys Val Asp Glu Ile 1 5 10 15 Leu Glu Arg Ile Arg Arg His Ala Asp Arg Val Lys Lys Lys Ser Glu 20 25 30 Arg Leu Lys Arg Glu Asn Val Asp Val Asn Glu His Ser Lys Asp Val 35 40 45 Lys Arg Val Ile Arg Glu Leu Leu Glu Leu Val Lys Glu Leu Leu Arg 50 55 60 Leu Ala Lys Lys His Ser Asp Asp Gln Gln Glu 65 70 75 <210> SEQ ID NO 429 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 429 Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser 1 5 10 <210> SEQ ID NO 430 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 430 Pro Lys Leu Asp Lys Leu Arg Glu Leu Leu Glu Arg Asn Leu Glu Lys 1 5 10 15 Leu Arg Glu Ile Leu Glu Glu Val Leu Lys Ile Leu Arg Thr Asn Leu 20 25 30 Glu Arg Val Arg Glu Asp Ile Arg Asp Glu Asp Val Leu Gln Glu Tyr 35 40 45 Glu Arg Leu Ile Arg Lys Ala Glu Glu Asp Leu Arg Arg Val Leu Lys 50 55 60 Glu Tyr Asp Asp Leu Leu Lys Lys Leu Val Tyr Glu Leu Arg 65 70 75 <210> SEQ ID NO 431 <211> LENGTH: 94 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence

<220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 431 His His His His His His Gly Ser Gly Ser Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Ser Thr Glu Lys Arg Leu Leu Glu Glu Ala Glu Arg Ala His Arg 20 25 30 Glu Gln Lys Glu Ile Ile Lys Lys Ala Gln Glu Leu His Arg Arg Leu 35 40 45 Glu Glu Ile Val Arg Gln Ser Gly Ser Ser Glu Glu Ala Lys Lys Glu 50 55 60 Ala Lys Lys Ile Leu Glu Glu Ile Arg Glu Leu Ser Lys Arg Ser Leu 65 70 75 80 Glu Leu Leu Arg Glu Ile Leu Tyr Leu Ser Gln Glu Gln Lys 85 90 <210> SEQ ID NO 432 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 432 Pro Asn Gln Glu Leu Leu Asp Arg Val Arg Lys Ile Leu Glu Asp Leu 1 5 10 15 Leu Arg Leu Asn Glu Glu Leu Val Arg Leu Asn Lys Glu Leu Leu Lys 20 25 30 Arg Ala Leu Glu Met Arg Arg Lys Asn Arg Asp Ser Glu Glu Val Leu 35 40 45 Glu Arg Leu Ala Glu Glu Tyr Arg Lys Arg Leu Glu Glu Tyr Arg Arg 50 55 60 Glu Leu Glu Lys Leu Leu Glu Glu Leu Glu Glu Thr Ile Tyr Arg Tyr 65 70 75 80 Lys Arg <210> SEQ ID NO 433 <211> LENGTH: 91 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 433 His His His His His His Gly Ser Gly Ser Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys 20 25 30 Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu 35 40 45 Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr 50 55 60 Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu 65 70 75 80 Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 85 90 <210> SEQ ID NO 434 <211> LENGTH: 81 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 434 Asp Glu Glu Glu Leu Val Glu Thr Val Lys Arg Ile Gln Lys Glu Ile 1 5 10 15 Leu Asp Arg Leu Thr Glu Leu Ala Lys Leu Leu Val Glu Ile Gln Arg 20 25 30 Glu Ile Lys Lys Leu Lys Asp Glu Gly Glu Asp Asp Lys Glu Leu Lys 35 40 45 Arg Leu Ser Asp Glu Leu Glu Glu Lys Val Arg Gln Val Val Glu Glu 50 55 60 Ile Lys Arg Leu Ser Asp Glu Leu Glu Glu Thr Val Glu Tyr Val Ser 65 70 75 80 Arg <210> SEQ ID NO 435 <211> LENGTH: 90 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 435 Ser His His His His His His Ser Ser Gly Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Ser Asp Ser Asp Glu His Leu Lys Lys Leu Lys Thr Phe Leu Glu 20 25 30 Asn Leu Arg Arg His Leu Asp Arg Leu Asp Lys His Ile Lys Gln Leu 35 40 45 Arg Asp Ile Leu Ser Glu Asn Pro Glu Asp Glu Arg Val Lys Asp Val 50 55 60 Ile Asp Leu Ser Glu Arg Ser Val Arg Ile Val Lys Thr Val Ile Lys 65 70 75 80 Ile Phe Glu Asp Ser Val Arg Lys Lys Glu 85 90 <210> SEQ ID NO 436 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 436 Ser Lys Glu Glu Ile Leu Lys Glu Leu Glu Asp Leu Gln Arg Arg Leu 1 5 10 15 Ile Glu Glu Leu Lys Lys Leu Gln Glu Arg Val Val Glu Leu Leu Glu 20 25 30 Glu Leu Ile Lys Arg Leu Arg Asp Arg Gly Arg Asp Asp Lys His Leu 35 40 45 Lys Arg Leu Val Lys Glu Val Arg Arg Leu Ser Glu Glu Val Leu Arg 50 55 60 Ser Ile Lys Glu Val Ser Asp Arg Val Arg Tyr Gln Leu Arg 65 70 75 <210> SEQ ID NO 437 <211> LENGTH: 91 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 437 Ser His His His His His His Ser Ser Gly Glu Asn Leu Tyr Phe Gln 1 5 10 15 Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys 20 25 30 Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu 35 40 45 Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr 50 55 60 Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu 65 70 75 80 Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 85 90 <210> SEQ ID NO 438 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 438 Asp Leu His Glu Val Val Tyr Glu Thr Lys Glu Leu Leu Lys Arg Ile 1 5 10 15 Glu Glu Val Val Glu Glu Leu Arg Lys Lys Ser Glu Asp Ile Ile Arg 20 25 30 Lys Ala Glu Arg Gly Glu Ile Ser Glu Asp Glu Leu Lys Arg Leu Gln 35 40 45 Glu Glu Ile Ala Arg Glu Ala Lys Lys Leu Leu Asp Glu Ile Lys Arg 50 55 60 Val Leu Glu Arg His Leu Glu Gln Thr Leu 65 70 <210> SEQ ID NO 439 <211> LENGTH: 150 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 439 Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu Ser 1 5 10 15 Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys Lys 20 25 30 Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile Lys Glu 35 40 45 Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg Ile Ala 50 55 60 Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Ala Ala Asp Asp Lys 65 70 75 80 Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala 85 90 95 Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg 100 105 110 Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu 115 120 125 Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr 130 135 140 His Ala Lys Lys Val Glu 145 150

<210> SEQ ID NO 440 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 440 Pro Glu Gln Glu Ile Ala Asp Arg Ile Leu Thr Glu Ile Arg Glu Ser 1 5 10 15 Gln Lys Glu Leu Glu Arg Leu Ala Arg Lys Ile Leu Lys Leu Leu Asp 20 25 30 Glu Ser Gln Glu Lys Ala Lys Arg Gly Arg Leu Ser Glu Glu Glu Ser 35 40 45 Asp Glu Leu Leu Glu Arg Ile Lys Lys Glu Leu Asp Glu Leu Leu Glu 50 55 60 Arg Ser Lys Glu Leu Leu Lys Lys Ile Glu Tyr Glu Leu Arg 65 70 75 <210> SEQ ID NO 441 <211> LENGTH: 154 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 441 Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu Ser 1 5 10 15 Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys Lys 20 25 30 Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile Lys Glu 35 40 45 Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg Ile Ala 50 55 60 Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Gly Ser Gly Ser 65 70 75 80 Pro Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile 85 90 95 Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu 100 105 110 Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr 115 120 125 Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu 130 135 140 Ile Ala Lys Thr His Ala Lys Lys Val Glu 145 150 <210> SEQ ID NO 442 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 442 Pro Glu Asp Asp Val Leu Arg Arg Leu Glu Glu Val Ser Glu Lys Ile 1 5 10 15 Leu Arg Val Ala Glu Asp Val Ala Arg Gln Leu Arg Glu Val Ser Glu 20 25 30 Lys Ile Thr Gln Gly Lys Val Asp Arg Lys Glu Trp Glu Glu Asp Ile 35 40 45 Lys Arg Leu Lys Arg Glu Leu Glu Glu Leu Leu Arg Glu Trp Lys Glu 50 55 60 Glu Ile Glu Arg Leu Thr Tyr Glu Leu Arg 65 70 <210> SEQ ID NO 443 <211> LENGTH: 160 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 443 Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu Ser 1 5 10 15 Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys Lys 20 25 30 Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile Lys Glu 35 40 45 Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg Ile Ala 50 55 60 Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Gly Ser Gly Ser 65 70 75 80 Pro Gly Gly Ser Gly Ser Pro Asp Asp Lys Glu Leu Asp Lys Leu Leu 85 90 95 Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp 100 105 110 Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro 115 120 125 Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala 130 135 140 Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 145 150 155 160 <210> SEQ ID NO 444 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 444 Asp Glu Lys Glu Asp Asn Arg Arg Leu Gln His Lys Ile Glu Arg Ile 1 5 10 15 Leu Glu Lys Asn Glu Asp Leu Gln Arg Lys Leu Glu Glu Ile Leu Glu 20 25 30 Leu Leu Glu Arg Gly Glu Ala Asp Glu Glu Lys Ile Asp Arg Leu Arg 35 40 45 Lys Ala Val Glu Asp Tyr Arg Arg Val Val Glu Glu Ile Lys Glu Asp 50 55 60 Val Lys Arg His Lys Tyr Thr Val Arg 65 70 <210> SEQ ID NO 445 <211> LENGTH: 172 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 445 Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu Ser 1 5 10 15 Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys Lys 20 25 30 Leu Leu Asp Asp Pro Asp Ser Glu Asp Ile Ala Arg Glu Ile Lys Glu 35 40 45 Leu Leu Arg Arg Leu Lys Glu Ile Ile Glu Arg Asn Gln Arg Ile Ala 50 55 60 Lys Glu His Glu Tyr Ile Ala Arg Glu Arg Ser Gly Gly Ser Gly Ser 65 70 75 80 Pro Gly Gly Ser Gly Ser Pro Gly Gly Ser Gly Ser Pro Gly Gly Ser 85 90 95 Gly Ser Pro Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu 100 105 110 Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu 115 120 125 Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu 130 135 140 Thr Tyr Val Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu 145 150 155 160 Leu Glu Ile Ala Lys Thr His Ala Lys Lys Val Glu 165 170 <210> SEQ ID NO 446 <211> LENGTH: 82 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 446 Asp Glu Lys Lys Leu Ile Asn Glu Val Val Glu Thr Gln Lys Arg Leu 1 5 10 15 Ile Lys Glu Ala Ala Lys Arg Leu Ser Glu Val Val Arg His Gln Thr 20 25 30 Glu Leu Ile Arg Glu Leu Arg Glu Lys Asn Val Asp Asp Lys Asp Val 35 40 45 Glu Lys Leu Leu Lys Glu Ser Leu Asp Leu Ala Glu Glu Ile Val Arg 50 55 60 Arg Ile Lys Glu Leu Leu Asp Glu Ser Lys Lys Leu Val Glu Tyr Val 65 70 75 80 Ser Asn <210> SEQ ID NO 447 <211> LENGTH: 161 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 447 Asp Ala Tyr Asp Leu Asp Arg Ile Val Lys Glu His Arg Arg Leu Val 1 5 10 15 Glu Glu Gln Arg Glu Leu Val Glu Glu Leu Glu Lys Leu Val Arg Arg 20 25 30 Gln Glu Asp His Arg Val Asp Lys Lys Glu Ser His Glu Ile Leu Glu 35 40 45 Arg Leu Glu Arg Ile Ile Arg Arg Ser Thr Arg Ile Leu Thr Glu Leu 50 55 60 Glu Lys Leu Thr Asp Glu Phe Glu Arg Arg Thr Arg Gly Ser Glu Gly 65 70 75 80 Ser Gly Ser Glu Gly Ser Gly Ser Asp Asp Lys Glu Leu Asp Lys Leu

85 90 95 Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile Asp 100 105 110 Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys Asp 115 120 125 Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu Lys 130 135 140 Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys Val 145 150 155 160 Glu <210> SEQ ID NO 448 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 448 Asp Glu Arg Tyr Ala Thr Arg Glu Ile Val Glu Arg Ile Glu Arg Ile 1 5 10 15 Ala Arg Glu Ile Leu Lys Arg Thr Glu Glu Ile Val Arg Glu Val Arg 20 25 30 Glu Val Leu Ser Arg Asp Val Asp Gln Glu Glu Val Val Arg Arg Leu 35 40 45 Ala Asp Leu Leu Arg Glu Ser Val Glu Leu Val Gln His Leu Val Arg 50 55 60 Arg Val Glu Glu Leu Leu Gln Glu Ser Val Glu Arg Lys Lys 65 70 75 <210> SEQ ID NO 449 <211> LENGTH: 163 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 449 Asp Glu Asp Asp Glu Leu Glu Arg Leu Leu Arg Glu Tyr His Arg Val 1 5 10 15 Leu Arg Glu Tyr Glu Lys Leu Leu Glu Glu Leu Arg Arg Leu Tyr Glu 20 25 30 Glu Tyr Lys Arg Gly Glu Val Ser Glu Glu Glu Ser Asp Arg Ile Leu 35 40 45 Arg Glu Ile Lys Glu Ile Leu Asp Lys Ser Glu Arg Leu Trp Asp Leu 50 55 60 Ser Glu Glu Val Trp Arg Thr Leu Leu Tyr Gln Ala Glu Gly Ser Glu 65 70 75 80 Gly Ser Gly Ser Glu Gly Ser Asp Glu Lys Asp Tyr His Arg Arg Leu 85 90 95 Ile Glu His Leu Glu Asp Leu Val Arg Arg His Glu Glu Leu Ile Lys 100 105 110 Arg Gln Lys Lys Val Val Glu Glu Leu Glu Arg Arg Gly Leu Asp Glu 115 120 125 Arg Leu Arg Arg Val Val Asp Arg Phe Arg Arg Ser Ser Glu Arg Trp 130 135 140 Glu Glu Val Ile Glu Arg Phe Arg Gln Val Val Asp Lys Leu Arg Lys 145 150 155 160 Ser Val Glu <210> SEQ ID NO 450 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 450 Pro Ala Arg Glu Ile Leu Glu Glu Val Val Lys Lys His Leu Glu Val 1 5 10 15 Val Glu Asp Ala Ala Arg Ile Leu Glu Glu Ile Ile Arg Glu His Glu 20 25 30 Lys Ala Val Arg Glu Asp Arg Asp Lys Lys Glu Leu Glu Glu Ile Ser 35 40 45 Arg Asp Leu Leu Arg Lys Ala Arg Glu Ala Leu Lys Lys Val Lys Asp 50 55 60 Ile Ser Asp Asp Leu Ser Arg Glu Ile Glu Tyr Val Ala Ser 65 70 75 <210> SEQ ID NO 451 <211> LENGTH: 166 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 451 Thr Glu Arg Lys Leu Leu Glu Arg Ser Arg Arg Leu Gln Glu Glu Ser 1 5 10 15 Lys Arg Leu Leu Asp Glu Met Ala Glu Ile Met Arg Arg Ile Lys Lys 20 25 30 Leu Leu Lys Lys Ala Arg Gly Ala Asp Glu Lys Val Leu Asp Glu Leu 35 40 45 Arg Lys Ile Ile Glu Arg Ile Arg Glu Leu Leu Asp Arg Ser Arg Lys 50 55 60 Ile His Glu Arg Ser Glu Glu Ile Ala Tyr Lys Glu Glu Gly Ser Glu 65 70 75 80 Gly Ser Gly Ser Glu Gly Ser Gly Ser Asp Glu Ser Asp Arg Ile Arg 85 90 95 Lys Ile Val Glu Glu Ser Asp Glu Ile Val Lys Glu Ser Arg Lys Leu 100 105 110 Ala Glu Arg Ala Arg Glu Leu Ile Lys Glu Ser Glu Asp Lys Arg Val 115 120 125 Ser Glu Glu Arg Asn Glu Arg Leu Leu Glu Glu Leu Leu Arg Ile Leu 130 135 140 Asp Glu Asn Ala Glu Leu Leu Lys Arg Asn Leu Glu Leu Leu Lys Glu 145 150 155 160 Val Leu Tyr Arg Thr Arg 165 <210> SEQ ID NO 452 <211> LENGTH: 79 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 452 Asp Ser Asp Glu Lys Ala Glu Tyr Leu Leu Lys Glu Met Glu Arg Val 1 5 10 15 Val Arg Glu Ser Asp Glu Val Val Lys Lys Ile Leu Arg Asp Leu Glu 20 25 30 Glu Val Leu Glu Arg Leu Arg Arg Gly Glu Ile Ser Glu Asp Asp Val 35 40 45 Thr Glu Ile Leu Lys Glu Leu Ala Glu Arg His Ile Arg Ala Ile Glu 50 55 60 Glu Leu Val Arg Arg Leu Arg Glu Leu Leu Glu Arg His Lys Arg 65 70 75 <210> SEQ ID NO 453 <211> LENGTH: 162 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 453 Asp Glu Asp Asp Glu Leu Glu Arg Leu Leu Arg Glu Tyr His Arg Val 1 5 10 15 Leu Arg Glu Tyr Glu Lys Leu Leu Glu Glu Leu Arg Arg Leu Tyr Glu 20 25 30 Glu Tyr Lys Arg Gly Glu Val Ser Glu Glu Glu Ser Asp Arg Ile Leu 35 40 45 Arg Glu Ile Lys Glu Ile Leu Asp Lys Ser Glu Arg Leu Trp Asp Leu 50 55 60 Ser Glu Glu Val Trp Arg Thr Leu Leu Tyr Gln Ala Glu Gly Ser Glu 65 70 75 80 Gly Ser Gly Ser Glu Gly Ser Gly Ser Asp Asp Lys Glu Leu Asp Lys 85 90 95 Leu Leu Asp Thr Leu Glu Lys Ile Leu Gln Thr Ala Thr Lys Ile Ile 100 105 110 Asp Asp Ala Asn Lys Leu Leu Glu Lys Leu Arg Arg Ser Glu Arg Lys 115 120 125 Asp Pro Lys Val Val Glu Thr Tyr Val Glu Leu Leu Lys Arg His Glu 130 135 140 Lys Ala Val Lys Glu Leu Leu Glu Ile Ala Lys Thr His Ala Lys Lys 145 150 155 160 Val Glu <210> SEQ ID NO 454 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 454 Pro Lys Glu Asp Ile Leu Arg Glu Val Leu Arg Arg His Lys Glu Ile 1 5 10 15 Val Arg Glu Ile Val Arg Leu Val Arg Glu Ala Val Glu Thr His Leu 20 25 30 Glu Leu Val Lys Arg Asn Ser Asp Asp Arg Asp Ala Gln Asp Val Ile 35 40 45 Arg Lys Leu Glu Glu Asp Leu Glu Arg Leu Val Arg His Ala Gln Glu 50 55 60 Val Ile Glu Glu Ile Phe Tyr Arg Leu His 65 70 <210> SEQ ID NO 455 <211> LENGTH: 158 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide

<400> SEQUENCE: 455 Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu 1 5 10 15 Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val 35 40 45 Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile 50 55 60 Ala Lys Thr His Ala Lys Lys Val Glu Gly Ser Glu Gly Ser Gly Ser 65 70 75 80 Glu Gly Ser Pro Thr Asp Glu Val Ile Glu Val Leu Lys Glu Leu Leu 85 90 95 Arg Ile His Arg Glu Asn Leu Arg Val Asn Glu Glu Ile Val Glu Val 100 105 110 Asn Glu Arg Ala Ser Arg Val Thr Asp Arg Glu Glu Leu Glu Arg Leu 115 120 125 Leu Arg Arg Ser Asn Glu Leu Ile Lys Arg Ser Arg Glu Leu Asn Glu 130 135 140 Glu Ser Lys Lys Leu Ile Glu Lys Leu Glu Arg Leu Ala Thr 145 150 155 <210> SEQ ID NO 456 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 456 Asp Arg Glu Tyr Ile Ile Lys Asp Ile Leu Asp Ser Gln Glu His Leu 1 5 10 15 Leu Arg Leu Ile Glu Glu Leu Leu Glu Thr Gln Lys Glu Leu Leu Glu 20 25 30 Ile Leu Lys Arg Arg Pro Asp Ser Val Glu Arg Val Arg Glu Leu Val 35 40 45 Arg Arg Ser Lys Glu Ile Ala Asp Glu Ile Arg Arg Gln Ser Asp Arg 50 55 60 Asn Val Arg Leu Leu Glu Glu Val Ser Lys 65 70 <210> SEQ ID NO 457 <211> LENGTH: 160 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 457 Asp Asp Lys Glu Leu Asp Lys Leu Leu Asp Thr Leu Glu Lys Ile Leu 1 5 10 15 Gln Thr Ala Thr Lys Ile Ile Asp Asp Ala Asn Lys Leu Leu Glu Lys 20 25 30 Leu Arg Arg Ser Glu Arg Lys Asp Pro Lys Val Val Glu Thr Tyr Val 35 40 45 Glu Leu Leu Lys Arg His Glu Lys Ala Val Lys Glu Leu Leu Glu Ile 50 55 60 Ala Lys Thr His Ala Lys Lys Val Glu Gly Ser Glu Gly Ser Gly Ser 65 70 75 80 Glu Gly Ser Gly Thr Lys Glu Asp Ile Leu Glu Arg Gln Arg Lys Ile 85 90 95 Ile Glu Arg Ala Gln Glu Ile His Arg Arg Gln Gln Glu Ile Leu Glu 100 105 110 Glu Leu Glu Arg Ile Ile Arg Lys Pro Gly Ser Ser Glu Glu Ala Met 115 120 125 Lys Arg Met Leu Lys Leu Leu Glu Glu Ser Leu Arg Leu Leu Lys Glu 130 135 140 Leu Leu Glu Leu Ser Glu Glu Ser Ala Gln Leu Leu Tyr Glu Gln Arg 145 150 155 160 <210> SEQ ID NO 458 <211> LENGTH: 74 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 458 Glu Ser Glu Asp Arg Ile Lys Glu Leu Leu Lys Arg His Ile Glu Leu 1 5 10 15 Val Glu Arg His Glu Glu Leu Leu His Glu Ile Lys Lys Leu Ile Asp 20 25 30 Leu Glu Glu Lys Asp Asp Lys Asp Arg Glu Glu Ala Val Lys Arg Ile 35 40 45 Asp Asp Ala Ile Lys Glu Ser Glu Glu Met Leu Glu Glu Ser Lys Glu 50 55 60 Ile Leu Glu Glu Ile Glu Tyr Leu Asn Arg 65 70 <210> SEQ ID NO 459 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 459 Pro Leu Lys Glu Arg Leu Leu Glu Ile Gln Arg Asp Leu Asp Arg Val 1 5 10 15 Leu Glu Glu Val Val Glu Arg Leu Leu Arg Ile Gln Glu Arg Leu Asp 20 25 30 Ser Val Val Glu Arg Lys Pro Pro Asp Val His Glu Glu Tyr Lys Tyr 35 40 45 Ile Val Asp Glu Ile Arg Glu Ile Val Glu Arg Val Val Arg Glu Tyr 50 55 60 Glu Glu Ile Val Lys Arg Ile Asp Glu Glu Val Arg 65 70 75 <210> SEQ ID NO 460 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 460 His Glu Lys Asp Ile Val Tyr Lys Val Glu Asp Leu Val Arg Lys Ser 1 5 10 15 Asp Arg Ile Ala Glu Arg Ala Arg Glu Ile Val Lys Arg Ser Arg Asp 20 25 30 Ile Met Arg Glu Ile Arg Lys Asp Lys Asp Asn Lys Lys Leu Ser Asp 35 40 45 Asp Leu Leu Lys Val Thr Arg Asp Leu Gln Arg Val Val Asp Glu Leu 50 55 60 Glu Glu Leu Ser Arg Glu Leu Leu Arg Val Ala Glu Glu Ser Arg Lys 65 70 75 80 <210> SEQ ID NO 461 <211> LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 461 Gly Ser Glu Gly Ser Gly Ser Glu Gly Ser Gly Gly Ser 1 5 10 <210> SEQ ID NO 462 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 462 Asp Glu Glu Glu Ile Glu Glu Leu Leu Arg Glu Leu Glu Lys Leu Leu 1 5 10 15 Lys Lys Ser Glu Glu Ala Leu Glu Glu Ser Lys Lys Leu Ile Asp Glu 20 25 30 Ser Glu Glu Leu Leu Arg Arg Asp Arg Leu Asp Lys Glu Lys His Val 35 40 45 Arg Ala Ser Glu Glu His Val Lys Leu Ser Glu Glu His Leu Arg Ile 50 55 60 Ser Arg Glu Ile Val Lys Ile Leu Glu Lys Ala Val Tyr Ser Thr Arg 65 70 75 80 <210> SEQ ID NO 463 <400> SEQUENCE: 463 000 <210> SEQ ID NO 464 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 464 Asp Glu Asp Asp Glu Leu Glu Arg Leu Leu Arg Glu Tyr His Arg Val 1 5 10 15 Leu Arg Glu Tyr Glu Lys Leu Leu Glu Glu Leu Arg Arg Leu Tyr Glu 20 25 30 Glu Tyr Lys Arg Gly Glu Val Ser Glu Glu Glu Ser Asp Arg Ile Leu 35 40 45 Arg Glu Ile Lys Glu Ile Leu Asp Lys Ser Glu Arg Leu Trp Asp Leu 50 55 60 Ser Glu Glu Val Trp Arg Thr Leu Leu Tyr Gln Ala Glu 65 70 75 <210> SEQ ID NO 465 <400> SEQUENCE: 465 000 <210> SEQ ID NO 466

<211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 466 Asp Asp Glu Glu Glu Asp Lys Arg Leu Leu Glu Glu Val Lys Arg Ser 1 5 10 15 Leu Asp Thr Asp Glu Arg Ile Leu Glu Lys Leu Arg His Ser Leu Glu 20 25 30 Arg Gln Leu Glu Asp Val Asp Lys Asp Glu Asp Ser Arg Arg Val Leu 35 40 45 Arg Glu Leu Asp Glu Ile Thr Lys Arg Ser Arg Glu Val Val Lys Arg 50 55 60 Leu Arg Lys Leu Ala Tyr Glu Ser Lys 65 70 <210> SEQ ID NO 467 <400> SEQUENCE: 467 000 <210> SEQ ID NO 468 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 468 Pro Ser Lys Glu Tyr Gln Glu Lys Ser Ala Glu Arg Gln Lys Glu Leu 1 5 10 15 Leu His Glu Tyr Glu Lys Leu Val Arg His Leu Arg Glu Leu Val Glu 20 25 30 Lys Leu Gln Arg Arg Glu Leu Asp Lys Glu Glu Val Leu Arg Arg Leu 35 40 45 Val Glu Ile Leu Glu Arg Leu Lys Asp Leu His Lys Lys Ile Glu Asp 50 55 60 Ala His Arg Lys Asn Glu Glu Ala His Lys Glu Asn Lys 65 70 75 <210> SEQ ID NO 469 <400> SEQUENCE: 469 000 <210> SEQ ID NO 470 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 470 Pro Lys Glu Glu Ser Val Glu Glu Leu Lys Arg Val Ile Asp Lys His 1 5 10 15 Glu Glu Ile Leu Arg Glu Leu Lys Arg Val Leu Glu Glu His Glu Arg 20 25 30 Val Ser His Asp Glu Asp Glu Asn Glu Leu Arg Arg Ser Leu Glu Arg 35 40 45 Leu Lys His Ile Leu Asp Arg Leu His Glu Ser Leu Lys Glu Leu His 50 55 60 Glu Leu Leu Lys Lys Asn Glu Tyr Thr Glu Arg 65 70 75 <210> SEQ ID NO 471 <400> SEQUENCE: 471 000 <210> SEQ ID NO 472 <211> LENGTH: 70 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 472 Asp Glu Glu Tyr Val Thr Arg Ser Gln Arg Arg Leu Lys Arg Leu Leu 1 5 10 15 Glu Glu Tyr Ile Lys Val Val Glu Glu His Ala Arg Leu Val Glu Arg 20 25 30 Asn Glu Arg Asp Asp Lys Glu Leu Lys Arg Ser Ile Asp Glu Leu Asp 35 40 45 Lys Leu Thr Lys Glu Leu Leu Glu Leu Val Lys Arg Tyr Lys Glu Leu 50 55 60 Val Asp Lys Thr Glu Thr 65 70 <210> SEQ ID NO 473 <400> SEQUENCE: 473 000 <210> SEQ ID NO 474 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 474 Arg Glu Glu Glu Leu Lys Glu Ser Ala Glu Glu Leu Glu Arg Ser Val 1 5 10 15 Arg Glu Leu Lys Lys Glu Ala Asp Lys Tyr Lys Glu Glu Val Asp Arg 20 25 30 Leu His Tyr Arg Gly Lys Val Asp Lys Asp Trp Val Arg Val Val Glu 35 40 45 Lys Leu Ile Lys Leu Val Glu Glu His Leu Glu Leu Ile Arg Glu His 50 55 60 Leu Glu Leu Leu Lys Glu Glu Arg Arg 65 70 <210> SEQ ID NO 475 <400> SEQUENCE: 475 000 <210> SEQ ID NO 476 <211> LENGTH: 76 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 476 Asp Lys Asp Glu Arg Gln Glu Arg Leu Asn Glu Glu Ser Asp Lys Ser 1 5 10 15 Asn Glu Glu Ser Glu Arg Ser Asn Arg Glu Ser Glu Glu Leu Asn Arg 20 25 30 Arg Ala Arg Gly Pro Asn Asp Glu Lys Glu Leu Gln Glu Ile Leu Asp 35 40 45 Arg His Leu Glu Leu Leu Glu Arg Asn Gln Arg Leu Leu Asp Glu Asn 50 55 60 Lys Glu Ile Leu Arg Glu Ser Gln Tyr Leu Asn Asp 65 70 75 <210> SEQ ID NO 477 <400> SEQUENCE: 477 000 <210> SEQ ID NO 478 <211> LENGTH: 73 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 478 Glu Ser Glu Tyr Thr Gln Glu Glu Ile Leu Glu Leu Leu Lys Glu Ser 1 5 10 15 Ile Lys Leu Leu Arg Glu Ile Leu Arg Leu Leu Glu Glu Ser Glu Glu 20 25 30 Leu Trp Arg Arg Glu Asn Thr Lys Ser Glu Arg Ser Glu Glu Ile Lys 35 40 45 Glu Arg Ala Lys Glu Ala Ile Lys Arg Ser Glu Glu Ile Leu Glu Arg 50 55 60 Val Lys Arg Leu Ser Asp His Ser Arg 65 70 <210> SEQ ID NO 479 <400> SEQUENCE: 479 000 <210> SEQ ID NO 480 <211> LENGTH: 78 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 480 Pro Glu Lys Tyr Leu Ile Lys Thr Gln Glu Glu Leu Leu Arg Arg His 1 5 10 15 Ala Glu Ile Leu Glu Asp Leu Ile Arg Lys Val Glu Arg Gln Val Asp 20 25 30 Leu Arg Arg Lys Val Asp Glu Arg Asp Glu Asp Leu Lys Arg Glu Leu 35 40 45 Glu Arg Ser Leu Arg Glu Leu Glu Arg Leu Val Arg Glu Ser Ser Arg 50 55 60 Leu Val Glu Glu Ile Arg Glu Leu Ser Lys Glu Ile Lys Arg 65 70 75 <210> SEQ ID NO 481 <400> SEQUENCE: 481

000 <210> SEQ ID NO 482 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 482 Glu Lys Glu Tyr Ile Glu Lys Leu Ser Arg Lys Ile Glu Glu Asp Ile 1 5 10 15 Arg Arg Ser Glu Glu Arg Ala Lys Asp Ser Glu Arg Leu Val Arg Arg 20 25 30 Leu Glu Glu Leu Ala Lys Arg Lys Arg Leu Asp Leu Asp Asp Val Leu 35 40 45 Arg Val Ala Glu Glu Asn Leu Glu Ile Leu Glu Asp Asn Leu Arg Ile 50 55 60 Leu Glu Glu Ile Leu Lys Glu Gln Asp Lys Ser Asn Arg 65 70 75 <210> SEQ ID NO 483 <400> SEQUENCE: 483 000 <210> SEQ ID NO 484 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 484 Asp His Glu Asp Val Val Arg Leu His Glu Asp Leu Val Arg Lys Gln 1 5 10 15 Glu Asp Ala Arg Arg Val Leu Glu Glu Ile Val Arg Leu Ala Glu Glu 20 25 30 Ile Val Glu Val Ile Lys Lys Asp Glu Lys Asp Lys Asp Arg Val Thr 35 40 45 Arg Leu Val Glu Glu Ile Glu Lys Leu Val Glu Glu Tyr Lys Lys Lys 50 55 60 Val Asp Glu Met Arg Lys Ile Ser Asp Glu Ile Lys Tyr Arg Ser Arg 65 70 75 80 <210> SEQ ID NO 485 <400> SEQUENCE: 485 000 <210> SEQ ID NO 486 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 486 Arg Glu Asp Glu Glu Leu Glu Glu Glu Ile Asp Arg Ile Arg Gln Met 1 5 10 15 Val Glu Glu Tyr Glu Glu Leu Val Lys Glu Tyr Glu Glu Leu Thr Glu 20 25 30 Lys Tyr Lys Gln Gly Lys Val Asp Lys Glu Glu Ser Lys Lys Ile Ile 35 40 45 Glu Lys Ser Glu Arg Leu Leu Asp Leu Ser Gln Asp Ala Val Arg Lys 50 55 60 Val Lys Glu Ile Ile Arg Arg Ile Leu Tyr Thr Asn Arg 65 70 75 <210> SEQ ID NO 487 <400> SEQUENCE: 487 000 <210> SEQ ID NO 488 <211> LENGTH: 75 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 488 Pro Leu Glu Glu Ile Leu Lys Ile Gln Arg Arg Ile Asn Lys Ile Gln 1 5 10 15 Asp Asp Ile Asn Lys Ile Leu His Glu Ile Leu Arg Met Gln Glu Lys 20 25 30 Leu Asn Arg Ser Ser Asp Lys Asp Glu Val Glu Glu Ser Leu Arg Arg 35 40 45 Ile Arg Glu Leu Ile Lys Arg Ile Lys Asp Leu Ser Lys Glu Ile Glu 50 55 60 Asp Leu Ser Arg Glu Val Lys Tyr Arg Thr Thr 65 70 75 <210> SEQ ID NO 489 <400> SEQUENCE: 489 000 <210> SEQ ID NO 490 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 490 Asp Glu Asp Glu Thr Ser Tyr Arg Ile Leu Glu Leu Leu Arg Glu Ile 1 5 10 15 Val Arg Ala Ser Arg Glu Leu Ile Arg Leu Ser Glu Glu Leu Leu Glu 20 25 30 Val Ala Arg Arg Asp Asp Lys Asp Glu Thr Val Leu Glu Thr Leu Ile 35 40 45 Arg Glu Tyr Lys Glu Leu Leu Asp Arg Tyr Arg Arg Leu Ile Glu Glu 50 55 60 Leu Thr Arg Leu Val Glu Glu Tyr Glu Glu Arg Ser Arg 65 70 75 <210> SEQ ID NO 491 <400> SEQUENCE: 491 000 <210> SEQ ID NO 492 <211> LENGTH: 80 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 492 Asp Glu Glu Glu Leu Asn Arg Glu Leu Leu Glu Lys Ser Lys Arg Leu 1 5 10 15 Val Asp Ile Asn Arg Asp Ile Ile Arg Thr Ala Gln Glu Leu Ile Glu 20 25 30 Met Leu Lys Asp Ser Lys Asp Gly Arg Val Asp Glu Asp Thr Lys Arg 35 40 45 Glu Leu Arg Asp Lys Leu Arg Lys Leu Glu Glu Lys Leu Glu Arg Val 50 55 60 Arg Glu Glu Leu Arg Lys Tyr Glu Glu Leu Leu Arg Tyr Val Gln Arg 65 70 75 80 <210> SEQ ID NO 493 <400> SEQUENCE: 493 000 <210> SEQ ID NO 494 <211> LENGTH: 77 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Synthetic peptide <400> SEQUENCE: 494 Asp Glu Glu Asp Val Leu Tyr His Leu Arg Glu Leu Leu Glu Glu Leu 1 5 10 15 Lys Arg Val Ser Asp Asp Tyr Glu Arg Leu Val Arg Glu Ile Lys Glu 20 25 30 Thr Ser Glu Arg Lys Asp Arg Asp Thr Lys Glu Asn Lys Asp Met Leu 35 40 45 Asp Glu Leu Val Lys Ala His Arg Glu Gln Glu Lys Leu Leu Glu Arg 50 55 60 Leu Val Arg Leu Leu Glu Glu Leu Phe Glu Arg Lys Arg 65 70 75

Claims

1-116. (canceled)

117. A designed heterodimer protein, comprising a monomer A polypeptide and a monomer B polypeptide, wherein: (a) the monomer A polypeptide and the monomer B polypeptide together comprise 4 alpha helices that interact to form the designed heterodimer protein; and (b) central repeat units of each of the monomer A polypeptide and the monomer B polypeptide comprise a buried, asymmetric hydrogen bond network connecting all four alpha helices; wherein: (i) the monomer A polypeptide is a non-naturally occurring polypeptide comprising 2 alpha helices connected by an amino acid linker, and the monomer B polypeptide is a non-naturally occurring polypeptide comprising 2 alpha helices connected by an amino acid linker; or (ii) the monomer A polypeptide is a non-naturally occurring polypeptide comprising 1 alpha helix, and the monomer B polypeptide is a non-naturally occurring polypeptide comprising 3 alpha helices connected by amino acid linkers.

118. The designed heterodimer protein of claim 117 wherein the monomer A polypeptide is a non-naturally occurring polypeptide comprising 2 alpha helices connected by an amino acid linker, and the monomer B polypeptide is a non-naturally occurring polypeptide comprising 2 alpha helices connected by an amino acid linker.

119. The designed heterodimer protein of claim 117 wherein the monomer A polypeptide is a non-naturally occurring polypeptide comprising 1 alpha helix, and the monomer B polypeptide is a non-naturally occurring polypeptide comprising 3 alpha helices connected by amino acid linkers.

120. The designed heterodimer protein of claim 117 wherein the monomer A polypeptide and the monomer B polypeptide have an interaction specificity determined by four hydrogen bond networks.

121. The designed heterodimer protein of claim 117 wherein the monomer A polypeptide and the monomer B polypeptide each comprise an effector polypeptide domain.

122. The designed heterodimer protein of claim 121 wherein each of the effector polypeptide domains is independently selected from the group consisting of a nucleic acid binding protein, a transcription factor, a receptor binding protein, a split enzyme, and an effector of membrane receptors.

123. The designed heterodimer protein of claim 117 wherein the monomer A polypeptide comprises a region that binds to a target A and the monomer B polypeptide comprises a region that binds to a target B.

124. The designed heterodimer protein of claim 123 wherein a binding affinity of the monomer A polypeptide for target A is approximately equal to a binding affinity of the monomer B polypeptide for target B.

125. The designed heterodimer protein of claim 123 wherein a binding affinity of the monomer A polypeptide for target A and a binding affinity of the monomer B polypeptide for target B are greater than a binding affinity of target A for target B.

126. A cell comprising the designed heterodimer protein of claim 117.

127. The cell of claim 126 wherein assembly of the designed heterodimer protein regulates a biological function of the cell.

128. The cell of claim 126 wherein the monomer A polypeptide and the monomer B polypeptide selectively form a cognate pair and avoid binding to other non-cognate monomers of the cell.

129. A biological cell comprising a protein logic gate comprising the designed heterodimer protein of claim 117 as a component of the protein logic gate.

130. The protein logic gate of claim 129 provided as an AND, OR, NOT, XOR, NAND, NOR or XNOR logic gate.

131. A transcriptional network comprising the designed heterodimer protein of claim 117 as a component of the transcriptional network.